0001493152-22-006240.txt : 20220308 0001493152-22-006240.hdr.sgml : 20220308 20220308071539 ACCESSION NUMBER: 0001493152-22-006240 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 93 CONFORMED PERIOD OF REPORT: 20211231 FILED AS OF DATE: 20220308 DATE AS OF CHANGE: 20220308 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Xtant Medical Holdings, Inc. CENTRAL INDEX KEY: 0001453593 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 205313323 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34951 FILM NUMBER: 22720321 BUSINESS ADDRESS: STREET 1: 664 CRUISER LANE CITY: BELGRADE STATE: MT ZIP: 59714 BUSINESS PHONE: 406-388-0480 MAIL ADDRESS: STREET 1: 664 CRUISER LANE CITY: BELGRADE STATE: MT ZIP: 59714 FORMER COMPANY: FORMER CONFORMED NAME: Bacterin International Holdings, Inc. DATE OF NAME CHANGE: 20100615 FORMER COMPANY: FORMER CONFORMED NAME: K KITZ INC DATE OF NAME CHANGE: 20090108 10-K 1 form10-k.htm
0001453593 false FY 0001453593 2021-01-01 2021-12-31 0001453593 2021-06-30 0001453593 2022-03-08 0001453593 2020-01-01 2020-12-31 0001453593 2021-12-31 0001453593 2020-12-31 0001453593 us-gaap:CommonStockMember 2019-12-31 0001453593 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001453593 us-gaap:RetainedEarningsMember 2019-12-31 0001453593 2019-12-31 0001453593 us-gaap:CommonStockMember 2020-12-31 0001453593 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001453593 us-gaap:RetainedEarningsMember 2020-12-31 0001453593 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001453593 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001453593 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001453593 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001453593 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001453593 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001453593 us-gaap:CommonStockMember 2021-12-31 0001453593 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001453593 us-gaap:RetainedEarningsMember 2021-12-31 0001453593 XTNT:InvestorRightsAgreementMember 2021-01-01 2021-12-31 0001453593 us-gaap:SalesRevenueNetMember XTNT:NoCustomerMember XTNT:ConcentrationCreditRiskMember 2020-01-01 2020-12-31 0001453593 us-gaap:SalesRevenueNetMember XTNT:NoCustomerMember XTNT:ConcentrationCreditRiskMember 2021-01-01 2021-12-31 0001453593 us-gaap:AccountingStandardsUpdate201613Member 2019-12-30 2020-01-02 0001453593 XTNT:ComputersAndEquipmentMember 2021-01-01 2021-12-31 0001453593 XTNT:SurgicalInstrumentsMember 2021-01-01 2021-12-31 0001453593 XTNT:OrthobiologicsMember 2021-01-01 2021-12-31 0001453593 XTNT:OrthobiologicsMember 2020-01-01 2020-12-31 0001453593 XTNT:SpinalImplantMember 2021-01-01 2021-12-31 0001453593 XTNT:SpinalImplantMember 2020-01-01 2020-12-31 0001453593 XTNT:OtherRevenueMember 2021-01-01 2021-12-31 0001453593 XTNT:OtherRevenueMember 2020-01-01 2020-12-31 0001453593 us-gaap:EquipmentMember 2021-12-31 0001453593 us-gaap:EquipmentMember 2020-12-31 0001453593 us-gaap:ComputerEquipmentMember 2021-12-31 0001453593 us-gaap:ComputerEquipmentMember 2020-12-31 0001453593 XTNT:ComputerSoftwaresMember 2021-12-31 0001453593 XTNT:ComputerSoftwaresMember 2020-12-31 0001453593 us-gaap:FurnitureAndFixturesMember 2021-12-31 0001453593 us-gaap:FurnitureAndFixturesMember 2020-12-31 0001453593 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001453593 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001453593 XTNT:OtherPropertiesMember 2021-12-31 0001453593 XTNT:OtherPropertiesMember 2020-12-31 0001453593 XTNT:SurgicalInstrumentsMember 2021-12-31 0001453593 XTNT:SurgicalInstrumentsMember 2020-12-31 0001453593 XTNT:TermLoanCommitmentMember 2021-05-06 0001453593 XTNT:TermLoanCommitmentMember XTNT:AgentAndLendersMember 2021-05-06 0001453593 XTNT:RevolvingLoanCommitmentMember 2021-05-06 0001453593 XTNT:TermLoanCommitmentMember XTNT:AgentAndLendersMember 2021-12-31 0001453593 2021-05-05 2021-05-06 0001453593 XTNT:SecondAAndRCreditAgreementMember 2021-05-05 2021-05-06 0001453593 us-gaap:LondonInterbankOfferedRateLIBORMember 2021-05-06 0001453593 us-gaap:RevolvingCreditFacilityMember 2021-05-05 2021-05-06 0001453593 XTNT:RevolvingLoanCommitmentMember us-gaap:LondonInterbankOfferedRateLIBORMember 2021-05-05 2021-05-06 0001453593 XTNT:CreditAgreementsMember 2021-01-01 2021-12-31 0001453593 XTNT:CreditAgreementsMember 2021-12-31 0001453593 XTNT:CreditAgreementsMember 2021-05-05 2021-05-06 0001453593 2022-03-06 2022-03-07 0001453593 XTNT:SecondAAndRCreditAgreementsMember 2021-12-31 0001453593 XTNT:SecondAAndRCreditAgreementsMember 2021-01-01 2021-12-31 0001453593 XTNT:TwoThousandTwentyWarrantsMember XTNT:ROSAndRoyaltyOpportunitiesMember 2020-05-06 0001453593 2020-10-01 2020-10-02 0001453593 2020-10-02 0001453593 us-gaap:LondonInterbankOfferedRateLIBORMember 2020-10-02 0001453593 srt:MinimumMember 2020-08-07 0001453593 srt:MaximumMember 2020-08-07 0001453593 XTNT:RestructuringAgreementMember XTNT:RoyaltyOpportunitiesandROSMember 2020-10-01 2020-10-02 0001453593 srt:MaximumMember 2020-11-05 2020-11-06 0001453593 2020-11-06 0001453593 2020-11-05 2020-11-06 0001453593 XTNT:ROSAndRoyaltyOpportunitiesMember 2020-11-15 2020-11-17 0001453593 us-gaap:InvestorMember us-gaap:PrivatePlacementMember 2021-02-23 2021-02-24 0001453593 us-gaap:InvestorMember us-gaap:PrivatePlacementMember 2021-02-24 0001453593 XTNT:InvestorWarrantMember us-gaap:PrivatePlacementMember 2021-02-24 0001453593 us-gaap:InvestorMember us-gaap:PrivatePlacementMember XTNT:PlacementAgentAgreementMember 2021-02-24 0001453593 us-gaap:InvestorMember us-gaap:PrivatePlacementMember XTNT:PlacementAgentAgreementMember 2021-02-23 2021-02-24 0001453593 us-gaap:InvestorMember XTNT:PrivatePlacementWarrantMember XTNT:PlacementAgentAgreementMember 2021-02-24 0001453593 us-gaap:InvestorMember XTNT:PrivatePlacementWarrantMember XTNT:PlacementAgentAgreementMember 2021-02-23 2021-02-24 0001453593 XTNT:TwoThousandAndEighteenEquityIncentivePlanMember srt:MaximumMember 2018-08-01 0001453593 XTNT:TwoThousandAndEighteenEquityIncentivePlanMember srt:MaximumMember 2018-10-27 0001453593 XTNT:TwoThousandAndEighteenEquityIncentivePlanMember 2018-07-28 2018-08-01 0001453593 XTNT:TwoThousandAndEighteenEquityIncentivePlanMember 2021-12-31 0001453593 XTNT:EmployeesAndDirectorsMember 2021-01-01 2021-12-31 0001453593 XTNT:EmployeesAndDirectorsMember 2020-01-01 2020-12-31 0001453593 us-gaap:EmployeeStockOptionMember 2021-12-31 0001453593 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001453593 us-gaap:RestrictedStockMember 2021-12-31 0001453593 us-gaap:RestrictedStockMember 2021-01-01 2021-12-31 0001453593 us-gaap:StockOptionMember XTNT:TwoThousandAndEighteenEquityIncentivePlanMember 2020-12-31 0001453593 us-gaap:StockOptionMember XTNT:TwoThousandAndEighteenEquityIncentivePlanMember 2019-12-31 0001453593 us-gaap:StockOptionMember XTNT:TwoThousandAndEighteenEquityIncentivePlanMember 2021-01-01 2021-12-31 0001453593 us-gaap:StockOptionMember XTNT:TwoThousandAndEighteenEquityIncentivePlanMember 2020-01-01 2020-12-31 0001453593 us-gaap:StockOptionMember XTNT:TwoThousandAndEighteenEquityIncentivePlanMember 2021-12-31 0001453593 us-gaap:RestrictedStockUnitsRSUMember XTNT:TwoThousandAndEighteenEquityIncentivePlanMember 2020-12-31 0001453593 us-gaap:RestrictedStockUnitsRSUMember XTNT:TwoThousandAndEighteenEquityIncentivePlanMember 2019-12-31 0001453593 us-gaap:RestrictedStockUnitsRSUMember XTNT:TwoThousandAndEighteenEquityIncentivePlanMember 2021-01-01 2021-12-31 0001453593 us-gaap:RestrictedStockUnitsRSUMember XTNT:TwoThousandAndEighteenEquityIncentivePlanMember 2020-01-01 2020-12-31 0001453593 us-gaap:RestrictedStockUnitsRSUMember XTNT:TwoThousandAndEighteenEquityIncentivePlanMember 2021-12-31 0001453593 us-gaap:MeasurementInputExpectedTermMember 2021-12-31 0001453593 us-gaap:MeasurementInputPriceVolatilityMember 2021-12-31 0001453593 XTNT:TwoThousandTwentyWarrantMember 2020-05-06 0001453593 XTNT:TwoThousandTwentyWarrantMember 2020-05-05 2020-05-06 0001453593 XTNT:SettlementAgreementMember 2021-07-02 0001453593 country:US 2021-01-01 2021-12-31 0001453593 country:US 2020-01-01 2020-12-31 0001453593 XTNT:SoleholdersMember 2021-12-31 0001453593 XTNT:SubleaseAgreementMember XTNT:CardialenIncMember 2021-01-01 2021-12-31 0001453593 XTNT:ConcentrationCreditRiskMember us-gaap:SalesRevenueNetMember XTNT:OneCustomerMember 2021-01-01 2021-12-31 0001453593 XTNT:ConcentrationCreditRiskMember us-gaap:SalesRevenueNetMember XTNT:TwoCustomerMember 2020-01-01 2020-12-31 0001453593 XTNT:RestOfWorldMember 2021-01-01 2021-12-31 0001453593 XTNT:RestOfWorldMember 2020-01-01 2020-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-K

 

(Mark One)

 

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended December 31, 2021

 

or

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from __________ to __________

Commission file number: 001-34951

 

Xtant Medical Holdings, Inc.
(Exact Name of Registrant as Specified in Its Charter)
 
Delaware   20-5313323

(State or other jurisdiction of

incorporation or organization)

   (IRS Employer
Identification No.)
     

664 Cruiser Lane

Belgrade, Montana

   59714
(Address of Principal Executive Offices)   (Zip Code)
     
(406) 388-0480
(Registrant’s Telephone Number, Including Area Code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading symbol(s)   Name of each exchange on which registered
Common stock, par value $.000001 per share   XTNT   NYSE American LLC

 

Securities registered pursuant to Section 12(g) of the Act: None

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.:

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer ☒ Smaller reporting company ☒
    Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒

 

The aggregate market value of the common stock held by non-affiliates as of June 30, 2021 was $22.0 million (based on the closing price of the Company’s common stock on the last business day of the Company’s most recently completed second fiscal quarter, as reported on the NYSE American).

 

The number of shares of the Company’s common stock, $0.000001 par value, outstanding as of March 8, 2022 was 87,313,701.

 

DOCUMENTS INCORPORATED BY REFERENCE

 

None.

 

 

 

 

 

 

TABLE OF CONTENTS

 

  Page
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS 2
     
PART I 3
Item 1. Business 3
Item 1A. Risk Factors 16
Item 1B. Unresolved Staff Comments 54
Item 2. Properties 54
Item 3. Legal Proceedings 54
Item 4. Mine Safety Disclosures 54
     
PART II 55
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 55
Item 6. Reserved 55
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations 56
Item 7A. Quantitative and Qualitative Disclosures About Market Risk 63
Item 8. Financial Statements and Supplementary Data 64
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 88
Item 9A. Controls and Procedures 88
Item 9B. Other Information 88
     
PART III 89
Item 10. Directors, Executive Officers and Corporate Governance 89
Item 11. Executive Compensation 95
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 102
Item 13. Certain Relationships and Related Transactions, and Director Independence 104
Item 14. Principal Accounting Fees and Services 109
     
PART IV 110
Item 15. Exhibit and Financial Statement Schedules 110
Item 16. Form 10-K Summary 113
     
SIGNATURES 114

 

 

 

This Annual Report on Form 10-K contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”), and are subject to the safe harbor created by those sections. For more information, see “Cautionary Statement Regarding Forward-Looking Statements.”

 

As used in this report, the terms “we,” “us,” “our,” “Xtant,” “Xtant Medical,” and the “Company” mean Xtant Medical Holdings, Inc. and our consolidated wholly-owned subsidiaries, unless the context indicates another meaning.

 

We own various unregistered trademarks and service marks, including our corporate logo. Solely for convenience, the trademarks and trade names in this report are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the owner of such trademarks and trade names will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend the use or display of other companies’ trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies. We include our website address throughout this report for reference only.

 

The information contained on or connected to our website is not incorporated by reference into this report.

 

We are a “smaller reporting company” as that term is defined in Rule 12b-2 promulgated under the Exchange Act. Accordingly, this report reflects the scaled reporting requirements of smaller reporting companies as set forth in Regulation S-K, promulgated under the Exchange Act.

 

1
 

 

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

 

The statements contained in this Annual Report on Form 10-K that are not purely historical are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Our forward-looking statements include, but are not limited to, statements regarding our “expectations,” “hopes,” “beliefs,” “intentions,” or “strategies” regarding the future. In addition, any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should” and “would,” as well as similar expressions, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward looking.

 

A forward-looking statement is neither a prediction nor a guarantee of future events or circumstances and those future events or circumstances may not occur. You should not place undue reliance on forward-looking statements, which speak only as of the date of this Form 10-K. The forward-looking statements contained in this Form 10-K are based on currently available operating, financial and competitive information and our current expectations and beliefs concerning future developments and their potential effects on us. These forward-looking statements involve a number of risks, uncertainties, or assumptions, many of which are beyond our control, which may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in the “Part I. Item 1.A. Risk Factors” section of this Form 10-K. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We are including this cautionary statement to make applicable and take advantage of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities laws.

 

2
 

 

PART I

 

Item 1. Business

 

Overview

 

Xtant Medical Holdings, Inc. is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant fixation systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures. Our products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine.

 

We promote and sell our products in the United States through independent distributors and stocking agents, supported by direct employees. We have an extensive distribution channel of commissioned independent agents and stocking agents in the United States representing some or all of our products. We also maintain a national accounts program to enable our agents to gain access to independent health delivery network hospitals and through group purchasing organizations (“GPOs”). We have biologics contracts with major GPOs, as well as extensive access to integrated delivery networks (“IDNs”) across the United States for both our biologics and spine hardware products. We promote and sell our products internationally through distribution partners in Canada, Mexico, South America, Australia, and certain Pacific region countries.

 

We have focused and intend to continue to focus primarily on four key growth initiatives: (1) introduce new products; (2) expand our distribution network; (3) penetrate adjacent markets; and (4) leverage our growth platform with technology and strategic acquisitions. During 2021, we launched four new products, including most recently, a bone marrow aspirate concentrate offering, which was introduced in November 2021. We expanded our distribution network by bringing on over 40 new agents during 2021. In furtherance of our goal to penetrate adjacent markets, we added new sales personnel to leverage certain adjacent non-spine markets, such as the foot and ankle, cranio-maxilofacial, oncology, joint reconstruction and trauma markets and we made progress towards this goal during 2021 by expanding our private label and original equipment manufacturer (“OEM”) sales into these adjacent markets. Finally, one of our key growth initiatives is to add depth to our product offering through targeted strategic acquisitions. While the intent of these four key growth initiatives is to increase our future revenues, no assurance can be provided that we will be successful in implementing these growth initiatives or increasing our future revenues.

 

Industry and Market Overview

 

The orthopedic biomaterials market consists of materials that are organic, inorganic or synthetic in nature. These materials are implanted or applied in or near the indicated bone to aid in healing, encourage bone tissue augmentation, compensate in areas where bone tissue is depleted, and restore structure to allow for repair. These materials are often used as substitutes to autograft materials, which are taken from a harvest site in the patient to patch or repair the wounded or unhealthy site.

 

Fixation is often instrumental in allowing the body to heal and regenerate tissue. Fixation provides the constructive support necessary for reestablishing stability, by immobilizing the regenerative site, and relieving stress. Fixation also can help hold the biomaterial in place in order to achieve a better outcome. Examples of fixation products can include, but are not limited to, plates, screws, pins, rods, spacers, and staples. Fixation products may be made from various metals and polymer materials.

 

Our Orthobiologics Products

 

Our biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, and our line of 3Demin products, as described below, as well as other allografts:

 

●OsteoSponge is a form of demineralized bone matrix (“DBM”) made from 100% human bone. Derived from trabecular (cancellous) bone, OsteoSponge is designed to provide a natural scaffold for cellular in-growth and expose bone-forming proteins to the healing environment. The malleable properties of OsteoSponge enable it to conform to, and fill, most defects. Upon compressing the allograft, OsteoSponge springs back to fill the void. OsteoSponge’s unique mechanical and osteoconductive properties in tandem with its osteoconductive potential make OsteoSponge an ideal bone graft for use in various orthopedic practices including spine, neurology, cranial/maxillofacial, trauma, plastic/reconstruction and general procedures where new bone growth is needed.

 

3
 

 

●OsteoSponge SC is a form of OsteoSponge designed to fill bony defects in the subchondral region of joints.

 

●OsteoSelect DBM Putty is designed to be easily molded into any shape and compressed into bony voids. We have validated a low-dose, low-temperature gamma sterilization process designed to provide maximum osteoinductive potential while still affording device level sterility.

 

●OsteoSelect PLUS DBM Putty combines the exceptional cohesive characteristics of OsteoSelect DBM Putty with demineralized cortical chunks. OsteoSelect PLUS is designed to deliver differentiated handling properties and ensure patient safety through validated, terminal sterilization. Each lot of OsteoSelect PLUS DBM is tested for osteoinductivity in vivo prior to being released. OsteoSelect PLUS is indicated as a bone void filler and bone graft substitute in the pelvis, extremities, and posterolateral spine.

 

●3Demin is a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone. They consist of 100% demineralized cortical bone with excellent, malleable handling characteristics, and are distributed as a sterile allograft. Our 3Demin products are easily hydrated with any biocompatible liquid, making them an ideal option for various bone grafting applications. They are most commonly used in spinal fusion procedures.

 

●OsteoFactor is a uniquely processed allograft that contains retained growth factors found within the endosteum layer of allograft bone. Unlike the various growth factor-based products on the market today, OsteoFactor is not limited to a single growth factor but contains a wide array of naturally occurring proteins and peptides that support bone formation and remodeling.

 

●OsteoVive Plus is a growth factor enriched cellular bone matrix created through a proprietary processing method. The combination of viable cells, growth factors and DBM fibers results in an allograft containing higher concentrations of growth factors than other cellular allografts.

 

We also process and distribute (i) sports allografts which are processed specifically for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction and meniscal repair, (ii) milled spinal allografts which are comprised of cortical bone milled to desired shapes and dimensions, and (iii) traditional allografts for multi-disciplinary applications including orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary and plastic/reconstructive.

 

Our Spinal Implant Products

 

We offer a comprehensive line of products that are used to treat a variety of spinal and sacroiliac conditions, including trauma, degeneration, deformity and tumor, including use of minimally invasive surgery techniques. Some of our key spinal implant product lines include:

 

Cervical Products

 

●The Certex Spinal Fixation System consists of screws, hooks, rods, and cross connectors. Various sizes of these implants are available so that adaptations can be made to take into account pathology and individual patient anatomy. It is intended to promote fusion of the subaxial cervical spine and cervico-thoracic junction (C3 − T3 inclusive).

 

●The Spider Cervical Plating System consists of simple, single step locking with 3 forms of locking feedback providing confidence in Spider System construct and performance. Self-drilling screws preserve cancellous bone for secure screw purchase. If drilling is desired, instruments offer optional drill guides and drill bits. A full sweep of 15° angulation can be achieved with Spider System variable screws.

 

4
 

 

Thoracolumbar Products

 

●The Axle Interspinous Fusion System is a fully modular interspinous device matched to the patient’s individual anatomy and available in multiple implantable configurations.

 

●The Silex Sacroiliac Joint Fusion System is a sacroiliac fixation system which actively compresses across the SI joint. Sacroiliac dysfunction is increasingly recognized as a frequent contributor to chronic low back pain.

 

●The Xpress Minimally Invasive Pedicle Screw System combines minimally invasive functionality to the most common lumbar fixation procedures — pedicle screw fixation.

 

●The Fortex Pedicle Screw System consists of titanium alloy bone screws, rods, cross-connectors and associated instruments. The system is indicated for attachment to the pedicles of the thoracic, lumbar, and sacral spine.

 

Interbody Products

 

●Calix is a family of PEEK interbody spacers and precision instruments for both cervical and thoracolumbar applications. Calix PC is a frictional titanium plasma-coated PEEK implant that provides additional biomechanical performance and end-plate visualization.

 

●The Axle-X Interspinous Fusion System is an internal fixation device for spinal surgery in the non-cervical spine (T1 − S1 inclusive). It is a minimally invasive, modular interspinous fusion system with angled spikes that allows for adequate L5 − S1 engagement and other variations in patient anatomy. The Axle-X Interspinous Fusion System is designed to provide spinal stability for lumbar fusion procedures, including the treatment of degenerative disc disease, spinal tumors and trauma.

 

●The Irix-C Cervical Integrated Fusion System consists of an integrated titanium ring, surrounded by an outer PEEK ring and two screws. It is intended for spinal fusion procedures at one level (C3 − T1 inclusive) in skeletally mature patients for the treatment of degenerative disc disease.

 

●The Irix-A Lumbar Integrated Fusion System consists of an integrated titanium ring, surrounded by an outer PEEK ring and three screws. It is intended for spinal fusion procedures at one or two contiguous levels of the lumbosacral spine (L2 − S1 inclusive) in skeletally mature patients for the treatment of degenerative disc disease.

 

Sales and Marketing

 

We distribute our products in the United States through an extensive distribution network of commissioned independent sales agents and stocking agents. As of December 31, 2021, we had over 300 independent sales agents and stocking agents. We also maintain a national accounts program to enable our agents to gain access to IDN hospitals and through GPOs. We have biologics contracts with major GPOs, including Vizient, Premier, and HealthTrust Purchasing Group, as well as extensive access to IDNs across the United States for both biologics and spine hardware systems.

 

Our international footprint includes distribution partners in Canada, Mexico, South America, Australia, and certain Pacific region countries. We do not have any operations in or sales to Europe.

 

5
 

 

Donor Procurement

 

Xtant’s mission with respect to donor procurement is: “Honoring the gift of donation, by helping our patients live as full, and complete a life as possible.”

 

In furtherance of our mission, we have agreements with multiple recovery agencies, and we continue to explore options to expand our network for access to donor tissue in anticipation of increased demand for our biologics products. We expect to be able to continue to build our network for donor tissue as our processing capabilities and sales increase.

 

Competition

 

There are various public and private organizations that offer both fixation and orthobiologics to their customers. The market is dominated by large competitors, including Medtronic plc, Johnson and Johnson, Zimmer Biomet Holdings, Inc., Stryker Corporation, Nuvasive, Inc., and Globus Medical, Inc. Together, we believe these large competitors have approximately 80% market share. We compete with these larger competitors and several others, including Surgalign Holdings, Inc., SeaSpine Holdings Corporation, OrthoFix Medical Inc., Alphatec Holdings, Inc., as well as dozens of privately-owned companies. We also compete with tissue banks that do not offer spinal fixation products, such as AlloSource International, Inc., LifeNet Health, and MTF Biologics.

 

Intellectual Property

 

We rely upon patents, trademarks, trade secrets and other proprietary rights to maintain and improve our competitive position. We review third-party proprietary rights, including patents and patent applications, as available, to develop an effective intellectual property strategy, avoid infringement of third-party proprietary rights, identify licensing opportunities and monitor the intellectual property owned by others.

 

We protect our proprietary rights through a variety of methods. As a condition of employment, we generally require employees to execute an agreement relating to the confidential nature of and company ownership of proprietary information and assigning intellectual property rights to us. We generally require confidentiality agreements with vendors, consultants, and others who may have access to proprietary information. We generally limit access to our facilities and review the release of company information in advance of public disclosure. There can be no assurances, however, that confidentiality agreements with employees, vendors, and consultants will not be breached, adequate remedies for any breach would be available, or competitors will not discover or independently develop our trade secrets. Litigation also may be necessary to protect trade secrets or techniques we own.

 

Patents

 

Although we believe that, in the aggregate, our patents are valuable, and patent protection is beneficial to our business and competitive positioning, our patent protection will not necessarily deter or prevent competitors from attempting to develop similar products. There can be no assurances that our patents will provide competitive advantages for our products or that competitors will not challenge or circumvent these rights. In addition, there can be no assurances that the United States Patent and Trademark Office (“USPTO”) or foreign patent offices will issue any of our pending patent applications. The USPTO and foreign patent offices may deny or require a significant narrowing of the claims in our pending patent applications and the patents issuing from such applications. Any patents issuing from the pending patent applications may not provide us with significant commercial protection. We could incur substantial costs in proceedings before the USPTO or foreign patent offices, including opposition and other post-grant proceedings. These proceedings could result in adverse decisions as to the patentability, priority of our inventions, and the narrowing or invalidation of claims in issued patents. Additionally, the laws of some of the countries in which our products are or may be sold may not protect our intellectual property to the same extent as the laws in the United States or at all.

 

Our policy is to file patent applications in the United States and other countries when we believe it is commercially advantageous to do so. We do not consider our business to be materially dependent upon any individual patent. As of December 31, 2021, our fixation patent portfolio includes 60 issued patents globally, and our biologics patent portfolio includes 19 issued patents globally and 7 patent applications pending. We expect that additional patent applications will be filed and prosecuted as inventions are discovered, technological improvements and processes are developed, and specific applications are identified. There can be no assurance that we will be able to obtain final approval of any patents.

 

6
 

 

Trademarks

 

We have registered, and continue to seek registration, of trademarks and continuously monitor and aggressively pursue users of names and marks that potentially infringe upon our registered trademarks. We currently own the following registered trademarks: OsteoSponge®, OsteoVive®, OsteoWrap®, OsteoLock®, BacFast®, OsteoSelect®, Elutia®, OsteoSTX®, hMatrix®, 3Demin®, BACTERINSE®, and Circle of Life®. Under the X-spine name, we own the following registered trademarks: SILEX®, X-SPINE®, IRIX®, CAPLESS®, CERTEX®, CALIX®, H-GRAFT®, SPIDER, X90®, HYDRAGRAFT®, BUTREX®, FORTEX®, AXLE®, FIXCET®, XTANT®, Capless® and X-spine’s square design logo.

 

Trade Secrets and Other Proprietary Rights

 

To safeguard our proprietary knowledge and technology, we rely upon trade secret protection and non-disclosure/confidentiality agreements with employees, consultants and third-party collaboration partners with access to our confidential information. Although we believe our proprietary technology has value, because of rapid technological changes in the medical industry, we also believe that proprietary protection is of less significance than factors such as the intrinsic knowledge and experience of our management, advisory board, consultants and personnel and their ability to identify unmet market needs and to create, invent, develop and market innovative and differentiated products.

 

Government Regulation

 

We are registered with the U.S Food and Drug Administration (“FDA”) as a manufacturer of human cellular and tissue products (“HCT/Ps”) as well as medical devices, and we are an accredited member in good standing of the American Association of Tissue Banks (“AATB”). We meet all licensing requirements for the distribution of HCT/Ps in states with licensing requirements, including Florida, California, Delaware, Illinois, Louisiana, Maryland, Oregon, and New York. Our industry is highly regulated, and we cannot predict the impact of future regulations on either us or our customers.

 

Our fixation products and instrumentation systems are regulated as medical devices and therefore are subject to extensive regulation by the FDA, as well as by other domestic and international regulatory bodies. These regulations govern multiple activities that Xtant and our suppliers, licensors and partners perform and will continue to perform. These regulated activities include product design and development, testing, manufacturing, labeling, storage, safety, premarket clearance, advertising and promotion, product marketing, sales and distribution, post-market surveillance and post-market adverse event reporting. All products currently marketed by Xtant are regulated as HCT/Ps and/or have received 510(k) clearances.

 

Human Tissue

 

Human tissue product regulations are designed to ensure that sound, high quality practices are followed to prevent the introduction, transmission or spread of communicable disease. Among other things, the regulations require that companies that recover, process, store, label, package or distribute HCT/Ps register with the FDA. In addition, regulations provide criteria that must be met for donors to be eligible to donate tissues and is referred to as the “Donor Eligibility” rule. Regulations also govern the processing and distribution of the tissues and are often referred to as the “Current Good Tissue Practices” (“cGTP”) regulations.

 

7
 

 

An HCT/P is regulated solely under section 361 of the Public Health Service Act (“PHSA”) and 21 CFR Part 1271 if it meets the following four criteria:

 

1) The HCT/P is minimally manipulated;

 

2) The HCT/P is intended for homologous use only;

 

3) The manufacture of the HCT/P does not involve the combination of the cells or tissues with another article (with limited exceptions); and

 

4) The HCT/P does not have a systemic effect and is not dependent upon the metabolic activity of living cells for its primary function; or the HCT/P has a systemic effect or is dependent upon the metabolic activity of living cells for its primary function and: is for autologous use; is for allogeneic use in a first-degree or second-degree blood relative; or is for reproductive use.

 

Several of our products, including OsteoSponge and OsteoWrap, are regulated as HCT/Ps and are therefore subject to the following regulatory requirements under section 361 of the PHSA and 21 CFR Part 1271:

 

●Registration and Listing: Establishments that engage in the manufacture of HCT/Ps are required to register annually with the FDA and list their HCT/Ps. New establishments are required to register and list their HCT/Ps within 5 days after beginning operations.

 

●Donor Eligibility: HCT/P establishments must screen donors for risk factors for, and clinical evidence of, relevant communicable disease agents and diseases and communicable disease risks associated with xenotransplantation, as well as test donors for relevant communicable disease agents.

 

●Good Tissue Practices: HCT/P establishments must comport with the regulatory requirements for preventing the introduction, transmission, or spread of communicable disease. These regulations cover facilities, environmental control, equipment, supplies and reagents, recovery, processing and process controls, labeling controls, storage, receipt, predistribution shipment, and distribution of HCT/Ps.

 

●Adverse Reaction Reporting: Establishments are required to investigate any adverse reaction involving a communicable disease related to an HCT/P that the manufacturer made available for distribution. The regulatory criteria call for reporting such adverse reactions involving a communicable disease if it is fatal, life-threatening, results in permanent impairment of a body function or permanent damage to a body structure, or necessitates medical or surgical intervention, including hospitalization.

 

●Inspections: The FDA has broad post-market and regulatory enforcement powers. HCT/P manufacturers are subject to unannounced inspections by the FDA and other state, local and foreign regulatory authorities to assess compliance with the cGTP regulations.

 

●Violative Product: Upon an FDA finding that there are reasonable grounds to believe that an HCT/P is a violative HCT/P because it was manufactured in violation of applicable regulations; the HCT/P is infected or contaminated so as to be a source of dangerous infection to humans; or an establishment is in violation of applicable regulations, the FDA may issue an order that the HCT/Ps be recalled, destroyed or retained, take possession of and/or destroy the violative HCT/Ps, or serve upon the establishment an order to cease manufacturing.

 

Failure to comply with applicable regulatory requirements can result in enforcement action by the FDA, which may include sanctions such as warning or untitled letters, injunctions, or other action.

 

There are many HCT/P products that must undergo regulatory review and licensure by the FDA. The approval process for a Biologics License Application (“BLA”) includes a rigorous review of the safety and efficacy of the biological product. Successful applications typically require testing and validation through a series of clinical and non-clinical studies taking place over multiple years of product development. We refer to all of our HCT/P products as biologics.

 

8
 

 

Medical Devices

 

The Center for Devices and Radiological Health regulates the clearance and approval of conventional medical devices, such as our spinal hardware, as well as some of the HCT/Ps that are also regulated as medical devices, such as our OsteoSelect DBM putty. In the United States, medical devices are subject to extensive regulation by the FDA under the Federal Food, Drug, and Cosmetic Act (“FDCA”) and its implementing regulations, and certain other federal and state statutes and regulations. The laws and regulations govern, among other things, the design, manufacture, storage, recordkeeping, approval, labeling, promotion, post-approval monitoring and reporting, distribution and import and export of medical devices. Failure to comply with applicable requirements may subject a device and/or its manufacturer to a variety of administrative sanctions, such as FDA refusal to approve pending pre-market approval applications (“PMAs”), issuance of warning letters, mandatory product recalls, import detentions, civil monetary penalties, and/or judicial sanctions, such as product seizures, injunctions, and criminal prosecution.

 

Under the FDCA, medical devices are classified into one of three classes based on the risk associated with the device and the level of control necessary to provide a reasonable assurance of safety and effectiveness. Class I devices are deemed to be low risk and are subject to the fewest regulatory controls. Class III devices are generally the highest risk devices and are subject to the highest level of regulatory control to provide reasonable assurance of safety and effectiveness. Class III devices must typically be approved by the FDA before they are marketed.

 

Most Class I devices and a minority of Class II devices are completely exempt from premarket review by the FDA. Most Class II devices and a minority of Class I devices require 510(k) clearance. Devices that pose the highest risk, including life sustaining, life-supporting or implantable devices, or devices deemed not substantially equivalent to a previously 510(k)-cleared device or a “pre-amendment” Class III device in commercial distribution before May 28, 1976 for which PMA applications are not required, are placed in Class III requiring PMA approval. A novel device is placed in Class III by default, but it may be eligible to be placed in Class I or Class II via “de novo” classification if it can be shown to pose only low to moderate risk with appropriate regulatory controls.

 

The PMA approval pathway requires proof of the safety and effectiveness of the device to the FDA’s satisfaction. The 510(k) clearance pathway is much less burdensome and time-consuming than the PMA approval pathway. The de novo pathway has an enhanced burden compared to the 510(k) clearance pathway, but is much less burdensome than a PMA approval process.

 

Under the 510(k) clearance pathway, the applicant must submit to the FDA a premarket notification demonstrating that the medical device is substantially equivalent to a legally marketed predicate device. A predicate device may be a previously 510(k) cleared device, Class II de novo device, or a pre-amendment device (unless the FDA has issued a regulation calling for PMA applications for this device type). To be substantially equivalent, the proposed device must have the same intended use as the predicate device, and either have the same technological characteristics as the predicate device or have different technological characteristics and be shown to be equally safe and effective and not raise different questions of safety and effectiveness than the predicate device.

 

After the FDA accepts the 510(k) premarket notification, it begins a substantive review. By statute, the FDA is required to complete its review within 90 days of receiving the 510(k) notification. As a practical matter, clearance often takes longer, typically ranging from three to nine months or more, and clearance is never assured. The FDA’s 510(k) review generally compares a proposed device to a predicate device with respect to intended use and technology. The information necessary to show substantial equivalence will depend on the differences between the proposed device and the predicate device, which may include bench, animal, and/or clinical studies. The discussion of what data is needed is sometimes conducted in a voluntary process called the pre-submission process whereby companies meet with the FDA to discuss the data needed for clearance.

 

If the FDA finds the applicant’s device is substantially equivalent to the predicate device, it will send a letter to the applicant stating that fact. This allows the applicant’s device to be commercially distributed in the United States. Otherwise, the applicant must fulfill the much more rigorous premarketing requirements of the PMA approval process or seek reclassification of the device through the de novo process.

 

9
 

 

After a device receives 510(k) clearance, any modification that could significantly affect its safety or effectiveness, or that would constitute a major change in its intended use, requires a new 510(k) clearance or could require reclassification through the de novo process or a PMA approval. The FDA requires each manufacturer to make this determination in the first instance, but the FDA can review any such decision. If the FDA disagrees with a manufacturer’s decision not to seek a new 510(k) clearance, the agency may require the manufacturer to seek 510(k) clearance, de novo classification, or PMA approval. The FDA can also require a manufacturer to cease marketing and/or recall the modified device until 510(k) clearance, de novo classification, or PMA approval is obtained.

 

Another procedure for obtaining marketing authorization for a medical device is the “de novo classification” procedure. Devices of a new type that the FDA has not previously classified based on risk are automatically classified into Class III, regardless of the level of risk they pose. Additionally, in response to a 510(k) premarket notification, if the FDA determines that the device is “not substantially equivalent” to a previously cleared device, the device is automatically designated as a Class III device. The device sponsor must then fulfill more rigorous PMA requirements or can request a risk-based classification determination for the device in accordance with the de novo process, which is a route to market for novel medical devices that are low to moderate risk and are not substantially equivalent to a predicate device.

 

The advantage of the de novo classification is that it generally requires less data than a PMA. The disadvantage is that it may require more data than a 510(k) and most often will include human clinical data. A request for de novo classification also has a longer review time. If the de novo application is denied, the device remains in Class III and PMA approval may be required before the device may be legally marketed in the United States. The FDA is increasingly moving devices with slightly different proposed indication statements or different technological features off the 510(k) path and onto the de novo path, resulting in more time and expense for the company.

 

A device not eligible for 510(k) clearance or de novo classification must follow the PMA approval pathway, which requires proof of the safety and effectiveness of the device to the FDA’s satisfaction. The cost of preparing and submitting a PMA is substantial and a PMA application must provide extensive preclinical and clinical trial data and also detailed information about the device and its components regarding, among other things, device design, manufacturing and labeling. Under federal law, the submission of most PMAs is additionally subject to a substantial annually adjusted application user fee. Satisfaction of FDA PMA requirements typically takes years, and the actual time required may vary substantially based upon the type, complexity, and novelty of the device or disease. In the future, Xtant may decide to strategically commercialize products in the United States that would require a PMA, but there are no plans to do so at the present time.

 

After a medical device enters commercial distribution, numerous regulatory requirements continue to apply. These include:

 

●The FDA’s Quality System Regulation (“QSR”) requirements, which require manufacturers, including third-party manufacturers, to follow stringent design, testing, production, control, supplier/contractor selection, complaint handling, documentation and other quality assurance procedures during all aspects of the manufacturing process;

 

●Labeling regulations, unique device identification requirements and FDA prohibitions against the promotion of devices for uncleared, unapproved or off-label uses;

 

●Advertising and promotion requirements;

 

●Restrictions on sale, distribution or use of a device;

 

●The potential for new 510(k) clearances for certain modifications to previously 510(k) cleared devices;

 

●Medical device reporting regulations, which require that manufacturers report to the FDA if their device may have caused or contributed to a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if the malfunction were to recur;

 

●Medical device correction and removal reporting regulations, which require that manufacturers report to the FDA their field corrections and product recalls or removals if undertaken to reduce a risk to health posed by the device or to remedy a violation of the FDCA;

 

10
 

 

●Recall requirements, including a mandatory recall, if there is a reasonable probability that the device would cause serious adverse health consequences or death;

 

●An order of repair, replacement or refund;

 

●Device tracking requirements; and

 

●Post-market surveillance regulations, which apply when necessary to protect the public health or to provide additional safety and effectiveness data for the device.

 

The FDA has broad post-market and regulatory enforcement powers. Medical device manufacturers are subject to unannounced inspections by the FDA and other state, local and foreign regulatory authorities to assess compliance with the QSR and other applicable regulations, and these inspections may include the manufacturing facilities of any suppliers. Failure to comply with applicable regulatory requirements can result in enforcement action by the FDA, which may include sanctions such as: warning letters, fines, injunctions, consent decrees and civil penalties; unanticipated expenditures, repair, replacement, refunds, recall or seizure of our devices; operating restrictions, partial suspension or total shutdown of manufacturing; the FDA’s refusal of our requests for 510(k) clearances, de novo classification, or premarket approvals of new devices, new intended uses or modifications to existing devices; the FDA’s refusal to issue certificates to foreign governments needed to export devices for sale in other countries; and withdrawing 510(k) clearances, de novo marketing authorization, or premarket approvals that have already been granted; and criminal prosecution.

 

International Regulation

 

Many foreign countries have regulatory bodies and restrictions similar to the FDA. International sales are subject to foreign government regulation, the requirements of which vary substantially from country to country. The time required to obtain approval in a foreign country or to obtain a CE Certificate of Conformity may be longer or shorter than that required for FDA approval and the related requirements may differ. Some third-world countries accept CE Certificates of Conformity or FDA clearance or approval as part of applications of approval for marketing of medical devices in their territory. Other countries, including Brazil, Canada, Australia and Japan, require separate regulatory filings. In light of extensive new legislation in Europe, specifically the new European Medical Device Regulation, we ceased selling products in the European Union (“EU”) during the third quarter of 2020 after concluding that the cost to maintain our regulatory approvals and sell our products in the EU, especially in light of this extensive new legislation, exceeded the benefits of doing business there for Xtant.

 

Healthcare Fraud and Abuse

 

Healthcare fraud and abuse laws apply to Xtant’s business when a customer submits a claim for an item or service that is reimbursed under Medicare, Medicaid or most other federally-funded healthcare programs. The Federal Anti-Kickback Statute prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, items or services for which payment may be made, in whole or in part, under federal health care programs, such as by Medicare or Medicaid. The concerns that the Anti-Kickback Statute addresses are multiple, but primary among them are, first, that the federal government pays/reimburses health care providers for the true acquisition cost of goods and services provided to patients served by government programs. The government does not want, for example, health care providers obtaining manufacturer discounts which are not disclosed to the government on cost report forms submitted for reimbursement to the government. The government wants to be the beneficiary of such discounts. Second, for that reason, the government wants transparency in the billing process which discloses such discounts to the government. Third, the government does not want purchasing, prescription or referral decisions for medical devices biased by economics unrelated to the best choices for a patient.

 

11
 

 

The Federal Anti-Kickback Statute is subject to evolving interpretations and has been applied by government enforcement officials to a number of common business arrangements in the medical device industry. Remunerative relationships with physicians in which manufacturers give health care providers gifts or pay for entertainment, sporting events, trips or other perquisites, may be viewed as an attempt to buy loyalty to the manufacturer’s products. A number of states also have anti-kickback laws that establish similar prohibitions that may apply to items or services reimbursed by government programs as well as any third-party payors, including commercial insurers. Further, federal legislation, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively “PPACA”), among other things, clarified the intent requirements of the Federal Anti-Kickback Statute and the federal criminal statutes governing healthcare fraud. Specifically, a person or entity can be found to have violated the statutes without actual knowledge of these statutes or specific intent to violate them. In addition, the PPACA amended the Social Security Act to provide that the government may assert that a claim including items or services resulting from a violation of the Federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the Federal False Claims Act or federal civil money penalties statute. Amendments to the Federal False Claims Act provide that a violation of the Federal Anti-Kickback Statute is also a violation of the Federal False Claims Act, subjecting healthcare entities to treble damages and mandatory penalties for each false claim or statement.

 

Additionally, the civil Federal False Claims Act prohibits, among other things, knowingly presenting or causing the presentation of a false, fictitious or fraudulent claim for payment of federal funds, or knowingly making, or causing to be made, a false record or statement material to a false or fraudulent claim to avoid, decrease or conceal an obligation to pay money to the federal government. The purpose of the Federal False Claims Act is to prevent manufacturers from causing or inducing inappropriate prescriptions leading to an inappropriate government reimbursement. It often comes into play where a manufacturer suggests or assists a health care provider to bill for an off-label, uncovered use. It also can occur when the reimbursement advice given by a manufacturer results in inappropriate reimbursement claims from “upcoding,” miscoding, “stretched” coding, the use of inappropriate modifiers or inappropriate care settings. These behaviors can result in the government paying for products or procedures that should not be reimbursed by the federal government. The manufacturer must be truthful and not misleading in the reimbursement advice it gives to customers.

 

Actions under the Federal False Claims Act may be brought by the Attorney General or as a qui tam action by a private individual in the name of the government. Violations of the Federal False Claims Act can result in very significant monetary penalties and treble damages. The federal government is using the Federal False Claims Act, and the accompanying threat of significant liability, in its investigations of healthcare companies throughout the country for a wide variety of Medicare billing practices, as well as federal Anti-Kickback Statute violations and certain marketing practices, including off-label promotion, and has obtained multi-million and multi-billion dollar settlements under the Federal False Claims Act in addition to individual criminal convictions under applicable criminal statutes. Given the significant size of actual and potential settlements, it is expected that the government will continue to devote substantial resources to investigating healthcare providers’ and suppliers’ compliance with the healthcare reimbursement rules and fraud and abuse laws.

 

The Federal Physician Payments Sunshine Act imposes annual reporting requirements on device manufacturers for payments and other transfers of value provided by them, directly or indirectly, to physicians (including physician family members) and teaching hospitals, as well as ownership and investment interests held by physicians. Device manufactures are also required to collect information on payments or transfers of value to physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists, and certified nurse midwives for reporting to the Centers for Medicare & Medicaid Services (“CMS”). A manufacturer’s failure to submit timely, accurately and completely the required information for all payments, transfers of value or ownership or investment interests may result in civil monetary penalties. Certain states also mandate implementation of commercial compliance programs, impose restrictions on device manufacturer marketing practices and require tracking and reporting of gifts, compensation and other remuneration to healthcare professionals and entities.

 

Our operations are also subject to the U.S. Foreign Corrupt Practices Act (“FCPA”). We are required to comply with the FCPA, which generally prohibits covered entities and their intermediaries from engaging in bribery or making other prohibited payments to foreign officials for the purpose of obtaining or retaining business or other benefits. In addition, the FCPA imposes accounting standards and requirements on publicly traded United States corporations and their foreign affiliates, which are intended to prevent the diversion of corporate funds to the payment of bribes and other improper payments, and to prevent the establishment of “off books” slush funds from which such improper payments can be made. We also are subject to similar anticorruption legislation implemented in certain foreign jurisdictions.

 

12
 

 

Coverage and Reimbursement

 

Xtant’s currently approved products are commonly treated as general supplies utilized in spinal and orthopedic surgery and if covered by third-party payors, are paid for as part of the surgical procedure. Accordingly, healthcare providers in the United States generally rely on third-party payors, principally private insurers and governmental payors such as Medicare and Medicaid, to cover and reimburse all or part of the cost of a spine surgery in which Xtant products are used. Sales volumes and fees for Xtant products will continue to depend in large part on the availability of coverage and reimbursement from such third-party payors. Third-party payors perform analyses on new technologies to determine if they are medically necessary before providing coverage for them. These third-party payors may still deny reimbursement on covered technologies if they determine that a device used in a procedure was not used in accordance with the payor’s coverage policy. Particularly in the United States, third-party payors continue to carefully review, and increasingly challenge, the prices charged for procedures and medical products.

 

In the United States, a large percentage of insured individuals receive their medical care through managed care programs, which monitor and often require pre-approval of the services that a member will receive. Some managed care programs pay their providers on a per capita basis, which puts the providers at financial risk for the services provided to their patients by paying these providers a predetermined payment per member per month and, consequently, may limit the willingness of these providers to use Xtant products.

 

The overall escalating cost of medical products and services has led to, and will likely continue to lead to, increased pressures on the healthcare industry to reduce the costs of products and services. Government or private third-party payors cannot be guaranteed to cover and reimburse the procedures using Xtant products in whole or in part in the future or that payment rates will be adequate. In addition, it is possible that future legislation, regulation or coverage and reimbursement policies of third-party payors will adversely affect the demand for Xtant products or the ability to sell them on a profitable basis.

 

Internationally, reimbursement and healthcare payment systems vary substantially from country to country and include single-payor, government-managed systems as well as systems in which private payors and government managed systems exist side-by-side. Xtant’s ability to achieve market acceptance or significant sales volume in international markets will be dependent in large part on the availability of reimbursement for procedures performed using company products under the healthcare payment systems in such markets. A number of countries may require Xtant to gather additional clinical data before recognizing coverage and reimbursement for its products.

 

ISO Certification

 

Xtant is an International Organization for Standardization (“ISO”) certified organization. To obtain ISO 13485:2016 certification, an organization must demonstrate its ability to provide medical devices that consistently meet applicable customer and regulatory requirements. The primary objective of ISO 13485:2016 is to facilitate harmonized medical device regulatory requirements for quality management systems. All requirements of ISO 13485:2016 are specific to organizations providing medical devices, regardless of the type or size of the organization. The certification assures our customers and partners of our commitment to quality, and in the quality of our innovative products and processes. Additionally, we believe that our ISO 13485:2016 certification may offer new markets and business opportunities for our products in the global marketplace.

 

13
 

 

Human Capital

 

Mission, Quality Policy and Core Values

 

Our Mission is to “honor the gift of donation, by allowing our patients to live as full, and complete a life, as possible.” Our quality policy and core values, which we strive to achieve and which govern how we and our employees conduct business, prioritize, make decisions, and work with one another to achieve our Mission, are:

 

●Quality. Quality is first in everything we do. Our products and services will meet regulatory requirements through our effective quality system.

 

●Integrity and Compliance. We do the right thing. We know and follow procedures and regulations.

 

●Accountability & Ownership. We make and meet our commitments.

 

●Teamwork & Continuous Improvement. We work together and strive to get better at everything we do.

 

●Respect the Gift of Donation. We serve as stewards of the safety and use of donated human tissue.

 

We recognize that our employees are key to our ability to achieve our Mission and live out our quality policy and core values.

 

Employees

 

As of December 31, 2021, Xtant had 118 employees, 116 of whom were full time employees, and of whom 54 were in operations, 20 were in sales and marketing, 4 in research and development and engineering, 11 in regulatory and quality affairs, and 29 were in administrative functions. In addition, we utilize various outsourced services to manage normal business cycles. None of our employees are covered by a collective bargaining agreement and management considers its relations with employees and service partners to be good.

 

Code of Conduct

 

Each employee agrees to follow our Code of Conduct, which is on our corporate website, and covers a wide range of business practices and procedures. Recognizing that our Code of Conduct may not address every situation our employees may encounter, other resources exist to assist our employees in their decision-making, including our management team, training and a hotline pursuant to which employees can ask questions or report issues on an anonymous basis.

 

Employee Safety, Health and Wellness

 

We are committed to maintaining a safe workplace and promoting the health and wellness of our employees. We have an employee Health & Safety Committee that is comprised of employees and recommends improvements in furtherance of employee health and safety. We also have implemented multiple safety programs and regularly perform safety hazard evaluations within our manufacturing facility. We publish a quarterly Safety Standard newsletter that reiterates our commitment to safety, highlights actions we have taken and intend to take to improve employee safety, and provides practical advice to employees to keep them and their families safe. Throughout the COVID-19 pandemic, our employees have been our first and foremost focus as we implemented a number of measures to provide a safe work environment, including social distancing and remote work schedules.

 

With respect to health and wellness, we provide our employees a variety of flexible and convenient health and wellness programs designed to support their physical and mental health. These include, among others, medical, dental and vision coverage, health savings and flexible spending accounts, flexible work schedules, family leave and care resources, and an employee assistance program. With respect to the COVID-19 pandemic, we have encouraged our employees to get a COVID-19 vaccine by sharing information on the vaccines and where to obtain one.

 

14
 

 

Compensation and Benefits

 

We provide competitive compensation and benefits to attract and retain superior talent and to give our employees the tools to succeed both on and off the job. In addition to salaries, our compensation and benefits, typically include annual bonuses; commission programs; a 401(k) plan with employee matching opportunities; tuition assistance; and company-sponsored short-term and long-term disability, life and accidental death and dismemberment insurance, among others.

 

Employee Engagement

 

We provide all employees with the opportunity to anonymously share their opinions and feedback directly with senior management and human resources. Submissions are analyzed to enhance the employee experience, promote retention, drive change, and leverage the overall success of our organization.

 

Employee Development and Training

 

We recognize that successful execution of our strategy is dependent on attracting, developing and retaining top talent in all areas of the business. We have a robust learning management system platform that includes several modules for employee development and training. In addition, we have a professional development policy intended to promote professional development opportunities and provide support to employees who want to increase the effectiveness of their performance in their current position. We encourage employees to obtain skills, knowledge and abilities which may improve their opportunities for career advancement within our Company and the purpose of our professional development policy is to provide our employees with the requirements for approval, time off, and reimbursement for employee training and professional development activities.

 

Diversity, Equity and Inclusion

 

We strive to create a diverse workplace in which all employees feel respected, valued and empowered to reach their full potential. We define diversity as the range of human differences, including but not limited to race, ethnicity, gender, gender identity, sexual orientation, age, social class, physical ability or attributes, religious or ethical values system, national origin, and political beliefs.

 

Community Engagement

 

Throughout the year, we encourage our employees to engage in community outreach programs and we sponsor various community organizations in the Belgrade, Montana area. As a company, we work closely with the Donate Life Community to support our industry and promote the gift of donation. We have been an active sponsor for the Donate Life Rose Parade event since 2012 and sponsor a donor family and select employees to attend that event each year.

 

Corporate Information

 

We began operations in 1998 as a spin out of the Center for Biofilm Engineering at Montana State University, or the CBE, and incorporated as “Bacterin, Inc.” in the state of Montana in January 2000. Through a series of transactions and corporate events, we eventually became Bacterin International Holdings, Inc., a Delaware corporation (“Bacterin”). Bacterin’s common stock traded on the NYSE Amex, now known as the NYSE American, under the ticker symbol “BONE.” On July 31, 2015, we acquired all of the outstanding capital stock of X-spine Systems, Inc. (“X-spine”) for approximately $60 million in cash, repayment of approximately $13 million of X-spine debt, and approximately 4.24 million shares (0.4 million shares post reverse split) of Xtant common stock. As a result of this transaction, X-spine became a wholly owned subsidiary of Bacterin International Holdings, Inc. and we immediately then changed our corporate name to “Xtant Medical Holdings, Inc.” Soon thereafter, we formed a new wholly owned subsidiary, Xtant Medical, Inc., to facilitate the integration of Bacterin and X-spine. On October 15, 2015, our common stock began trading on the NYSE MKT, now known as the NYSE American, under the ticker symbol “XTNT.”

 

Controlled Company Status

 

As a result of debt restructuring transactions completed in 2018 and 2020, OrbiMed Royalty Opportunities II, LP (“Royalty Opportunities”) and ROS Acquisition Offshore LP (“ROS”), which are funds affiliated with OrbiMed Advisors LLC (“OrbiMed”), collectively own approximately 83.7% of our outstanding common stock as of December 31, 2021. Because more than 50% of the combined voting power of all of our outstanding common stock is beneficially owned by OrbiMed, we are a “controlled company” as defined in section 801(a) of the NYSE American Company Guide. As such, we are exempt from certain NYSE American rules requiring our Board of Directors to have a majority of independent members, a compensation committee composed entirely of independent directors and a nominating committee composed entirely of independent directors.

 

Available Information

 

We make available, free of charge and through our Internet website, our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and any amendments to any such reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, as soon as reasonably practicable after we electronically file such material with, or furnish it to, the Securities and Exchange Commission (“SEC”). Reports filed with the SEC also may be viewed at www.sec.gov. We include our website throughout this report for reference only. The information contained on or connected to our website is not incorporated by reference into this report.

 

15
 

 

Item 1A. Risk Factors

 

Our business and an investment in our common stock are subject to a variety of risks. The following risk factors describe some of the material factors that could have a material adverse effect upon our business, financial condition, results of operations, and the market price for our common stock. Many of these events are outside of our control. If any of these risks actually occur, our business, financial condition or results of operations may be materially adversely affected. In such case, the market price of our common stock could decline and investors in our common stock could lose all or part of their investment.

 

Risk Factors Summary

 

This summary is not complete and should be read in conjunction with the risk factors set forth below.

 

Risks Related to Our Business

 

●The COVID-19 pandemic has adversely affected our business, operating results and financial condition.

 

●Prolonged inflation and supply chain disruptions could result in delayed product launches, lost revenue, higher costs and decreased profit margins.

 

●We may not be able to compete successfully because we are smaller and have fewer financial resources and less ability to invest in the development of new products.

 

●If we are unable to innovate, develop, introduce and market new products and technologies, our business may be negatively affected.

 

●We have completed business combinations in the past which involve risks and may do so in the future.

 

●Our private label and OEM business involves risks and may be subject to significant fluctuation.

 

●Our growth and inventory reduction initiatives may involve risks.

 

●Our biologics business is dependent on the availability of human donors and negative publicity could reduce demand for our biologics products and impact the supply of available donor tissue.

 

●We are highly dependent on the continued availability of our facilities.

 

●We may be subject to product liability litigation that could be expensive.

 

●Our quarterly operating results are subject to substantial fluctuations.

 

●We operate in some markets outside the United States that expose us to additional risks.

 

●Our ability to deduct interest is limited.

 

Risks Related to Governmental Regulation

 

●Our business is subject to extensive governmental regulation, including product approvals and clearances and healthcare fraud and abuse laws, false claims laws, and physician payment transparency laws.

 

●Governmental regulation could restrict the use of our tissue products or our procurement of tissue.

 

●Outside of the United States, our medical devices must comply with the laws and regulations of the foreign countries in which they are marketed, and compliance may be costly and time-consuming.

 

16
 

 

●Modifications to our products may require new regulatory clearances or approvals or may require us to recall or cease marketing our products until clearances or approvals are obtained.

 

●Our manufacturing operations are required to comply with the FDA’s and other governmental authorities’ laws and regulations regarding the manufacture and production of medical devices.

 

●Even if our products are cleared or approved by regulatory authorities, they could be subject to restrictions or withdrawal from the market.

 

●The use, misuse or off-label use of our products may harm our image in the marketplace or result in injuries that lead to product liability suits.

 

●If our products cause or contribute to a death or serious injury, or malfunction in certain ways, we will be subject to medical device reporting regulations and likely litigation.

 

●Any future product recall or voluntary market withdrawal of a product due to defects, enhancements and modifications or other reasons could adversely affect our business and operating results.

 

●If we or our suppliers fail to comply with regulations pertaining to human cells, tissues, and cellular and tissue-based products or are deemed to be biological products requiring approval of a BLA prior to being marketed, these products could be subject to withdrawal from the market or other enforcement action.

 

●Loss of AATB accreditation would have a material adverse effect on us.

 

●Federal regulatory reforms may adversely affect our ability to sell our products and our business.

 

●Product pricing is subject to regulatory control, which could impact our revenue and other operating results.

 

●Our revenues depend upon prompt and adequate coverage and reimbursement from public and private insurers and national health systems.

 

●We may not receive regulatory approvals, or may experience delays in receiving regulatory approvals, from governmental authorities.

 

Risks Related to Our Reliance on Third Parties

 

●Substantially all of our revenue is conducted through independent distributors and sales agents who we do not control.

 

●We depend on third-party suppliers for products, components and raw materials.

 

Risks Related to Human Capital Management

 

●We have limited staffing and are dependent upon key employees and qualified personnel, and competition for such talent is intense, especially around Belgrade, Montana.

 

17
 

 

Risks Related to Our Outstanding Indebtedness, Need for Additional Financing and Financial Condition

 

●We have incurred significant losses, expect to continue to incur losses and may need additional financing to satisfy our anticipated future liquidity requirements.

 

●We have indebtedness that we may be unable to refinance or extend the maturity date of and which may substantially limit our ability to conduct and invest in our business and the anticipated replacement of the LIBOR benchmark interest rate could affect our interest rates.

 

Risks Related to Intellectual Property

 

●We could be required to pay damages or prevented from selling our products due to intellectual property lawsuits.

 

●We may not be able to obtain or protect our proprietary rights relating to our products and if our patents and other intellectual property rights do not adequately protect our products, we may lose market share to our competitors and be unable to operate our business profitably.

 

Risks Related to Our Information Technology, Cybersecurity and Data Protection

 

●We are dependent on various information technology systems, which are outdated and in need of significant upgrades or conversion to a new enterprise resource planning system.

 

Risks Related to Our Controlled Company Status

 

●We are a “controlled company” within the meaning of the NYSE American rules since OrbiMed funds own a significant percentage of our common stock. As such, they have the right to designate a majority of our Board of Directors, and are able to exert significant control over our Company and management.

 

Risks Related to Our Common Stock

 

●Shares of our common stock are equity securities and subordinate to our outstanding indebtedness.

 

●The market price of our common stock is extremely volatile.

 

●We may issue additional common stock resulting in dilution, and the sale or availability for sale of substantial amounts of our common stock or other equity securities could adversely affect the market price of our common stock.

 

●Our common stock may be delisted if we do not comply with the NYSE American continued listing requirements.

 

●Anti-takeover provisions may discourage or prevent a change in control.

 

●Our Amended and Restated Certificate of Incorporation (“Charter”) authorizes us to issue and designate shares of our preferred stock without stockholder approval and designates the Court of Chancery of the State of Delaware as the exclusive forum for certain litigation that may be initiated by our stockholders.

 

●We have never paid dividends and do not expect to do so in the foreseeable future.

 

18
 

 

General Risk Factors

 

●We are subject to several other general risk factors, including risk regarding worldwide economic instability and social unrest; climate change; changes in accounting standards; public company requirements; securities litigation and increased environmental, social and governance practices scrutiny.

 

Risks Related to Our Business

 

Our business, operating results and financial condition have been and will likely continue to be materially adversely affected by the COVID-19 pandemic.

 

Since March 2020, the COVID-19 pandemic has caused business closures, severe travel restrictions and the implementation of social distancing measures. In addition, the pandemic has resulted in a nationwide shortage of nurses and other healthcare and medical support personnel as well as a more general labor shortage. At the onset of the COVID-19 pandemic and subsequently as a result of surges in cases and hospitalizations caused by the Delta and Omicron variants, hospitals and other medical facilities have cancelled or deferred elective procedures, diverted resources to patients suffering from infections and limited access for non-patients, including our direct and indirect sales representatives. Because of these circumstances, surgeons and their patients have been, and may continue to be, required, or are choosing, to defer procedures in which our products otherwise would be used. In addition, many facilities that specialize in procedures in which our products are used have experienced staffing shortages, temporary closures and/or reduced operating hours. These circumstances have negatively impacted, and may continue to negatively impact, the number of elective procedures being conducted and the ability of our employees, independent sales representatives and distributors to effectively market and sell our products, which has had and will likely continue to have a material adverse effect on our revenues.

 

The resurgence in cases and hospitalizations during the second half of 2021 caused our revenues to decline as compared to the prior year periods and the second quarter of 2021. Throughout the second half of 2021, and most acutely starting in August 2021, spine and other surgery procedure volumes were negatively impacted in many of our key markets, due to cancellations and/or postponements of procedures as a result of increased hospitalizations, restrictions on elective procedures, and staffing shortages, which negatively impacted our second half 2021 revenues. This reduction in elective procedures and staffing issues have continued into the beginning of 2022, thereby continuing to negatively impact our revenues. Additionally, it is possible that restrictions could be reinstated if there is a resurgence of cases and hospitalizations or staffing shortages could continue to persist or worsen, which would continue to adversely impact our revenues.

 

The COVID-19 pandemic has also caused adverse effects on general commercial activity and the global economy, which has led to an economic slowdown and could cause other unpredictable events in the future, any of which could adversely affect our business, operating results or financial condition. The adverse effect of the pandemic on the broader economy has also negatively affected demand for procedures using our products and may continue to negatively affect demand both in the near- and long-term. The pandemic also has disrupted the global supply chain, impacting our ability to obtain raw materials, components and products. The pandemic has also adversely affected, and may continue to adversely affect, our distributors, independent sales representatives, customers, contract manufacturers and suppliers and their respective businesses, which, in turn, have adversely affected and may continue to adversely affect, our business and operations. As a result of this negative effect of the pandemic on the economy, one or more of our distributors, independent sales representatives, customers, contract manufacturers and suppliers may experience financial distress, cancel, postpone or delay orders, be unable to perform under a contract, file for bankruptcy protection, go out of business, or suffer disruptions in their business or we may need to offer special payment terms or relief to our distributors, independent sales representatives and customers. Accordingly, we believe we are exposed to heightened credit risk as a result of the pandemic. This could adversely impact our ability to manufacture and provide products and otherwise operate our business, as well as increase our costs and expenses.

 

The COVID-19 pandemic has also led to and could continue to lead to severe disruption and volatility in the global capital markets, which could increase our cost of future capital and adversely affect our ability to access the capital markets in the future. The decline in our revenues and adverse impact of the pandemic on our other operating results may impact our ability to comply with our debt covenants under our credit agreements with MidCap Financial Trust (“MidCap”) and our ability to access funding thereunder or refinance that debt or extend its maturity date. We may need to borrow funds from alternative sources, such as other lenders and institutions or government agencies. There can be no guarantee that such borrowing will be available or available on favorable terms or without restrictions that may otherwise impair our operating flexibility.

 

19
 

 

The foregoing and other continued disruptions to our business as a result of COVID-19 have resulted, and could continue to result, in a material adverse effect on our business, operating results, financial condition, prospects and the trading price of our common stock throughout 2022. Although we continue to monitor the impact of the COVID-19 pandemic on our business, operations and financial results, the full extent to which the COVID-19 pandemic will continue to impact our business will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning COVID-19, new variants of COVID-19 that may emerge, such as Delta and Omicron, the availability, effectiveness and acceptance of vaccines, the need for and availability of boosters, actions that federal, state and local governmental or regulatory agencies take in response to COVID-19, the actions to contain it or treat its impact, future resurgences of the virus and its variants, the speed at which government restrictions are lifted, patient capacity at hospitals and healthcare systems, and the willingness and ability of patients to seek care and treatment due to safety concerns or financial hardship.

 

No assurance can be provided that our revenues will ever return to pre-COVID-19 levels. If our revenues continue to decline and do not recover to pre-COVID-19 pandemic levels, we may be required to incur impairment charges to our long-lived assets and goodwill, and we could experience an increase in the amount of excess inventory quantities on hand and be required to recognize inventory write-downs, each or all of which could adversely affect our future results of operations.

 

The COVID-19 pandemic also heightens the risks in certain of the other risk factors described in this Form 10-K.

 

Prolonged inflation and supply chain disruptions could result in delayed product launches, lost revenue, higher costs and decreased profit margins.

 

A majority of our products are manufactured and sold inside of the United States, which increases our exposure to domestic inflation and fuel price increases. Recent inflationary pressures stemming from supply chain disruptions and increased demand have resulted in increased fuel, raw material and other costs which, if they continue for a prolonged period, may adversely affect our results of operations. We have begun to experience shortages in certain raw materials, suppliers have been unable to meet delivery schedules due to excess demand and labor shortages, and lead times have lengthened throughout our supply chain. Our efforts to mitigate supply chain weaknesses may not be successful or may have unfavorable effects. For example, efforts to purchase raw materials in advance for product manufacturing may result in increased storage costs or excess supply. If our costs rise due to continuing significant inflationary pressures or supply chain disruptions, we may not be able to fully offset such higher costs through price increases. In addition, delays in obtaining materials from our suppliers could delay product launches or result in lost opportunities to sell our products due to their availability. Increased costs and decreased product availability due to supply chain issues could adversely impact our revenue and/or gross margin, and could thereby harm our business, financial condition, and results of operations.

 

Many competitive products exist, and we expect more will be developed. Our operating results have suffered during the past few years due to intense competition and we may not be able to compete successfully because we are smaller and have fewer financial resources and less ability to invest in the development of new products.

 

The markets for our products are highly competitive and subject to rapid and profound technological change. Our success depends, in part, on our ability to maintain a competitive position in the development of technologies and products for use by our customers. Many of the companies developing or marketing competitive products enjoy several competitive advantages over us, including greater financial and human resources for product development and sales and marketing; greater name recognition; established relationships with surgeons, hospitals and third-party payors; broader product lines and the ability to offer rebates or bundle products to offer greater discounts or incentives to gain a competitive advantage; and established sales and marketing and distribution networks. Our competitors may develop and patent processes or products earlier than us, obtain regulatory clearances or approvals for competing products more rapidly than us, develop more effective or less expensive products or technologies that render our technology or products obsolete or non-competitive or acquire technologies and technology licenses complementary to our products or advantageous to our business, which could adversely affect our business and operating results. Not all of our sales and other personnel have non-compete agreements. We also compete with other organizations in recruiting and retaining qualified sales and management personnel. If our competitors are more successful than us in these matters, we may be unable to compete successfully against our existing or future competitors. Our industry has been subject to increasing consolidation. Consolidation in our industry not involving our Company could result in existing competitors increasing their market share through business combinations and result in stronger competitors, which could have a material adverse effect on our business, financial condition, and operating results. We may be unable to compete successfully in an increasingly consolidated industry and cannot predict with certainty how industry consolidation will affect our competitors or us.

 

20
 

 

If we are unable to innovate, develop, introduce and market new products and technologies, we may experience a decrease in market share or revenue if our products become obsolete, and our business and operating results would suffer.

 

Due to lack of funding, our research and development efforts and ability to develop new products have suffered during the past several years. We may be unable to compete effectively with our competitors unless we can keep up with existing or new products and technologies in the markets in which we compete. If we do not continue to innovate, develop, introduce and market new products and technologies, or if those products and technologies are not accepted, we may not be successful. Moreover, research and development efforts require a substantial investment of time and resources before we are adequately able to determine the commercial viability of a new product, technology, material, or innovation and our current and recent annual operating plans have not provided for any significant investment in new products. Demand for our products also could change in ways we may not anticipate due to evolving customer needs, changing demographics, slow industry growth rates, declines in our markets, the introduction of new products and technologies, evolving surgical philosophies, and evolving industry standards, among others. Additionally, our competitors’ new products and technologies may beat our products to market, may be more effective or less expensive than our products, or may render our products obsolete. It is also important that we carefully manage our introduction of new and enhanced products and technologies. If potential customers delay purchases until new or enhanced products are available, it could negatively impact our revenue. Our new products and technologies also could reduce demand for or render our existing products obsolete and thus adversely affect sales of our existing products and lead to increased expense for excess and obsolete inventory.

 

We have completed acquisitions and business combinations in the past and our current business strategy includes targeted strategic acquisitions in the future. Acquisitions and business combinations are risky and may harm our business, reputation, operating results and financial condition.

 

We have completed acquisitions and business combinations in the past, including the acquisition of X-spine Systems, Inc. in 2015, and may complete acquisitions and business combinations in the future, especially since one of our key growth initiatives is to add depth to our product offerings through targeted strategic acquisitions. Our ability to complete acquisitions and business combinations will depend, in part, on the availability of suitable candidates at acceptable prices, terms, and conditions; our ability to compete effectively for acquisition candidates; and the availability of capital and personnel to complete such acquisitions and run the acquired business effectively. Any acquisition or business combination could impair our business, reputation, operating results and financial condition. The benefits of an acquisition or business combination may take more time than expected to develop or integrate into our operations, and we cannot guarantee that previous or future acquisitions or business combinations will, in fact, produce any benefits. Acquisitions and business combinations may involve a number of risks, the occurrence of which could adversely affect our business, reputation, operating results and financial condition, including:

 

●diversion of management’s attention;

 

●disruption to our existing operations and plans;

 

●inability to effectively manage our expanded operations;

 

21
 

 

●difficulties or delays in integrating and assimilating information and financial systems, operations, manufacturing processes and products of an acquired business or other business venture or in realizing projected efficiencies, growth prospects, cost savings, and synergies;

 

●inability to successfully integrate or develop a distribution channel for acquired product lines;

 

●potential loss of key employees, customers, distributors, or sales representatives of the acquired businesses or adverse effects on existing business relationships with suppliers, customers, distributors, and sales representatives;

 

●adverse impact on overall profitability if our expanded operations do not achieve the financial results projected in our valuation models;

 

●reallocation of amounts of capital from other operating initiatives and/or an increase in our leverage and debt service requirements to pay acquisition purchase prices or other business venture investment costs, which could in turn restrict our ability to access additional capital when needed or pursue other important elements of our business strategy;

 

●infringement by acquired businesses or other business ventures of intellectual property rights of others;

 

●violation of confidentiality, intellectual property and non-compete obligations or agreements by employees of an acquired business or lack of or inadequate formal intellectual property protection mechanisms in place at an acquired business;

 

●inaccurate assessment of additional post-acquisition investments, undisclosed, contingent or other liabilities or problems, unanticipated costs associated with an acquisition, and an inability to recover or manage such liabilities and costs;

 

●incorrect estimates made in the accounting for acquisitions and incurrence of non-recurring charges; and

 

●write-off of significant amounts of goodwill or other assets as a result of deterioration in the performance of an acquired business or product line, adverse market conditions, changes in the competitive landscape, changes in laws or regulations that restrict activities of an acquired business or product line, or as a result of a variety of other circumstances.

 

In addition, effective internal controls are necessary for us to provide reliable and accurate financial reports and to effectively prevent fraud. The integration of acquired businesses may result in our systems and controls becoming increasingly complex and more difficult to manage. We devote significant resources and time to comply with the internal control over financial reporting requirements of the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”). However, we cannot be certain that these measures will ensure that we design, implement, and maintain adequate control over our financial processes and reporting in the future, especially in the context of acquisitions of other businesses. Any difficulties in the assimilation of acquired businesses into our control system could harm our operating results or cause us to fail to meet our financial reporting obligations. Also, some acquisitions may require the consent of the lenders under our credit agreements with MidCap and /or the consent of Royalty Opportunities and ROS under the Investor Rights Agreement. We cannot predict whether such approvals would be forthcoming or the terms on which the lenders or these investors would approve such acquisitions. These risks, among others, could be heightened if we complete a large acquisition or other business combination or multiple transactions within a relatively short period of time.

 

22
 

 

Our private label and OEM business, which we expect to account for an increasing percentage of our revenue, involves risks and may be subject to significant fluctuation on a product to product basis from period to period since our customers could decide to use other OEMs.

 

We expect an increasing portion of our future revenues to be derived from our private label and original equipment manufacturer, or OEM, business. This expectation is based on our plan to focus on expanding this business. We may not be successful, however, in retaining or expanding our private label and OEM business. Our private label and OEM business, although not subject to commissions, involves lower gross margins which, if this business increases as a percentage of our revenue, will put pressure on our future gross margins. In addition, our private label and OEM business involves other additional risks. For example, we generally do not have long-term supply agreements covering this business so our customers could periodically decide to use other OEMs based on cost, quality, delivery time, production capacities, competitive and regulatory considerations or other factors. Thus, revenues from our private label and OEM customers and the products we provide them are subject to significant fluctuation on a product to product basis from period to period. The success of our private label and OEM business is dependent upon the success of our private label and OEM customers in creating demand for and selling the products that we manufacture for them. If our private label and OEM business significantly increases, we may experience difficulties in staffing our manufacturing facility and meeting demand.

 

Our growth initiatives designed to increase our revenue and scale may not be successful and involve risks.

 

During 2021, we focused primarily on and during 2022 we intend to continue to focus primarily on four key growth initiatives: (1) introduce new products; (2) expand our distribution network; (3) penetrate adjacent markets; and (4) leverage our growth platform with technology and strategic acquisitions. While the intent of these four key growth initiatives is to increase our future revenues, no assurance can be provided that we will be successful in implementing these growth initiatives or increasing our future revenues. Also our key growth initiatives involve risks, including effects on our product sales mix, which may adversely affect our gross margins and operating results. For example, a decrease in sales of our hardware products typically reduces our gross margins. In addition, margins vary among our biologics products, so the current trend towards our fiber-based products as opposed to our cancellous-based products may also reduce our future gross margins.

 

Our inventory reduction initiatives designed to improve our working capital may adversely affect our ability to fulfill demand in the future, which may harm our business and operating results.

 

During 2021, we focused on inventory reduction initiatives designed to improve our working capital. While we intend to continue these initiatives in 2022, our ability to fulfill demand may be adversely affected as a result. These initiatives may have other adverse effects on our business and operating results, including adverse effects on our cost of sales and margins. No assurance can be provided that we will be successful in implementing our inventory reduction initiatives or that they will improve our working capital.

 

Our biologics business is highly dependent on the availability of human donors. Any disruptions could cause our customers to seek alternative providers or technologies and harm our business and operating results.

 

Our mission is, “honoring the gift of donation, by allowing our patients to live as full, and complete a life as possible.” Accordingly, our biologics business is highly dependent on our ability to obtain donor cadavers as the raw material for many of our biologics products. The availability of acceptable donors is relatively limited, and we compete with many other companies for this limited availability. The availability of donors is also impacted by regulatory changes, general public opinion of the donor process and our reputation for our handling of the donor process. In addition, due to seasonal changes in the mortality rates, some scarce tissues are at times in short supply. A disruption in the supply of this crucial raw material could have significant consequences for our revenue, operating results and continued operations.

 

Negative publicity concerning methods of tissue recovery and screening of donor tissue in our industry could reduce demand for our biologics products and impact the supply of available donor tissue.

 

Media reports or other negative publicity concerning both alleged improper methods of tissue recovery from donors and disease transmission from donated tissue could limit widespread acceptance of some of our biologics products. Unfavorable reports of improper or illegal tissue recovery practices, both in the United States and internationally, as well as incidents of improperly processed tissue leading to the transmission of disease, may broadly affect the rate of future tissue donation and market acceptance of technologies incorporating human tissue. In addition, such negative publicity could cause the families of potential donors to become reluctant to agree to donate tissue to for-profit tissue processors.

 

23
 

 

We are highly dependent on the continued availability of our facilities and would be harmed if they were unavailable for any prolonged period of time.

 

Any failure in the physical infrastructure of our facilities or services could lead to significant costs and disruptions that could reduce our revenues and harm our business, reputation and financial results. We are highly reliant on our Belgrade, Montana facilities. Any natural or man-made event that impacts our ability to utilize these facilities could have a significant impact on our operating results, reputation and ability to continue operations. The regulatory process for approval of facilities is time-consuming and our ability to rebuild facilities would take a considerable amount of time and expense and cause a significant disruption in service to our customers. Further, the FDA or some other regulatory agency could identify deficiencies in future inspections of our facilities or our supplies that could disrupt our business and harm our operating results.

 

We may be party to product liability litigation that could be expensive, and our insurance coverage may not be adequate in a catastrophic situation.

 

The manufacture and sale of medical devices and biologics expose us to significant risk of product liability claims, which are made against us from time to time. We may incur material liabilities relating to product liability claims, including product liability claims arising out of the use of our products, if the liabilities exceed or are not covered under our insurance program. No assurance can be provided that any amounts that we may be required to pay to resolve such matters in the future will be within our insurance limits.

 

We also could experience a material design or manufacturing failure in our products, a quality system failure, other safety issues, or heightened regulatory scrutiny that would warrant a recall of some of our products. Product liability lawsuits and claims, safety alerts and product recalls, regardless of their ultimate outcome, could result in decreased demand for our products, injury to our reputation, significant litigation and other costs, substantial monetary awards to or costly settlements with patients, product recalls, loss of revenue, increased regulatory scrutiny, and the inability to commercialize new products or product candidates, and otherwise have a material adverse effect on our business and reputation and on our ability to attract and retain customers. We currently carry product liability insurance; however, our insurance coverage may not be adequate, and our business could suffer material adverse consequences due to product liability claims.

 

Our quarterly operating results are subject to substantial fluctuations, and you should not rely on them as an indication of our annual or future results.

 

Our quarterly revenue and operating results have varied and in the future may vary significantly, and period-to-period comparisons of our results of operations are not necessarily meaningful and should not be relied upon as indications of our annual results or future performance. Any shortfalls in revenue or earnings from levels expected by industry analysts or investors, as a result of such quarterly fluctuations or otherwise, could have an immediate and significant adverse effect on the market price of our common stock in any given period. Our quarterly operating results may vary significantly due to a combination of factors, many of which are beyond our control. These factors include, among others:

 

●demand for our products;

 

●the impact of COVID-19 on the number of elective procedures and our business and operating results;

 

●the level of competition;

 

●the number, timing, and significance of new products and product introductions and enhancements by us and our competitors;

 

●our ability to develop, introduce, and market new and enhanced versions of our products on a timely basis;

 

●the timing of or failure to obtain regulatory clearances or approvals for our products;

 

24
 

 

●changes in pricing policies by us and our competitors;

 

●changes in the treatment practices of our customers;

 

●changes in independent sales representative or distributor relationships and sales force size and composition;

 

●the timing of material expense- or income-generating events and the related recognition of their associated financial impact;

 

●the number and mix of products sold in the quarter and the geographies in which they are sold;

 

●the number of selling days;

 

●the availability and cost of components and materials;

 

●the timing of orders and shipments;

 

●ability to obtain reimbursement for our products and the timing of patients’ use of their calendar year medical insurance deductibles;

 

●work stoppages or strikes in our industry;

 

●changes in FDA and foreign governmental regulatory policies, requirements, and enforcement practices;

 

●changes in accounting standards, policies, estimates, and treatments;

 

●restructuring, impairment, and other special charges;

 

●costs associated with pending and any future litigation;

 

●variations in cost of sales due to the amount and timing of excess and obsolete inventory charges and manufacturing variances;

 

●income tax fluctuations and changes in tax rules;

 

●general economic, social and other external factors, such as the COVID-19 pandemic, supply chain disruptions and labor shortages; and

 

●increases of interest rates, which can increase the cost of borrowings under our credit agreements, and generally affect the level of economic activity.

 

Although our international business is not substantial, we do operate in some markets outside the United States that are subject to political, economic, and social instability and expose us to additional risks.

 

Although our revenue from outside the United States comprised only 1% of our total revenue for the year ended December 31, 2021 after we ceased selling products in the EU after concluding that the cost to maintain our regulatory approvals and sell our products in the EU, especially in light of extensive new legislation, exceeded the benefits of doing business there for Xtant, our international sales operations nevertheless expose us and our representatives, agents, and distributors to the following risks inherent in operating in foreign jurisdictions:

 

●the imposition of additional U.S. and foreign governmental controls or regulations on orthopedic implants and biologic products;

 

25
 

 

●withdrawal from or revision to international trade policies or agreements and the imposition or increases in import and export licensing and other compliance requirements, customs duties and tariffs, import and export quotas and other trade restrictions, license obligations, and other non-tariff barriers to trade;

 

●economic instability, including economic instability caused by the COVID-19 pandemic and currency risk between the U.S. dollar and foreign currencies, in our markets;

 

●a shortage of high-quality international salespeople and distributors;

 

●loss of any key personnel who possess proprietary knowledge or are otherwise important to our success in international markets;

 

●changes in third-party reimbursement policy that may require some of the patients who receive our products to directly absorb medical costs or that may necessitate our reducing selling prices for our products;

 

●transportation delays and interruptions, including due to recent supply chain and shipping disruptions; and

 

●exposure to different legal and political standards.

 

Our ability to deduct interest is limited.

 

Our ability to deduct interest on indebtedness properly allocable to our trade or business (which excludes investment interest) is limited to an amount equal to the sum of (i) our business interest income during the taxable year and (ii) 30% of our adjusted taxable income for such taxable year. For taxable years beginning after 2021, our adjusted taxable income for purposes of computing the 30% limitation will be reduced by depreciation, amortization and depletion deductions thereby causing a more restrictive limitation than that which existing for taxable years beginning prior to 2022. Disallowed interest deductions may be carried forward indefinitely and treated as business interest paid or accrued in the succeeding taxable year.

 

A shift in performing more procedures in ambulatory surgical centers from hospitals as a result of the COVID-19 pandemic or otherwise would likely put pressure on the prices of our products and margins.

 

To protect health care professionals involved in surgical care and their patients, we anticipate that more outpatient eligible procedures may be performed in ambulatory surgery centers during the COVID-19 pandemic, and as its acuity declines and the healthcare system returns to a more normalized state. We anticipate that this trend will nevertheless continue as a cost control measure with the healthcare system. Because ambulatory surgery center facility fee reimbursement is typically less than facility fee reimbursement for hospitals and due to surgeons’ potential ownership interests in ambulatory surgery centers, we typically experience more pressure on the pricing of our products by ambulatory surgery centers than by hospitals, and the average price for which we sell our products to ambulatory surgery centers is less than the average prices we charge to hospitals. In addition, some surgeons may choose to use fewer implants due to their interest in the profitability of the ambulatory surgery center. An accelerated shift of procedures using our products to ambulatory surgery centers as a result of the COVID-19 pandemic could adversely impact the average selling prices of our products and our revenues could suffer as a result.

 

26
 

 

Risks Related to Governmental Regulation

 

Our business is subject to extensive regulation, including requirements for regulatory clearances or approvals prior to commercial distribution of our products. If we fail to maintain regulatory clearances and approvals, or are unable to obtain, or experience significant delays in obtaining, FDA clearances or approvals for our future products or product enhancements, our ability to commercially distribute and market these products could suffer.

 

Our medical device products and operations are subject to extensive regulation by the FDA and various other federal, state and foreign governmental authorities. Government regulation of medical devices is meant to assure their safety and effectiveness, and includes regulation of, among other things:

 

●design, development and manufacturing;

 

●testing, labeling, packaging, content and language of instructions for use, and storage;

 

●clinical trials;

 

●product safety;

 

●premarket clearance and approval;

 

●marketing, sales and distribution (including making product claims);

 

●advertising and promotion;

 

●product modifications;

 

●recordkeeping procedures;

 

●reports of corrections, removals, enhancements, recalls and field corrective actions;

 

●post-market surveillance, including reporting of deaths or serious injuries and malfunctions that, if they were to recur, could lead to death or serious injury;

 

●complying with the federal law and regulations requiring Unique Device Identifiers (“UDI”) on devices and their labeling and also requiring the submission of certain information about each device to FDA’s Global Unique Device Identification Database (“GUDID”); and

 

●product import and export

 

Before a new medical device, or a new use of, or claim for, an existing product can be marketed in the United States, it must first receive either premarket clearance under Section 510(k) of the FDCA, a de novo classification or a PMA, from the FDA, unless an exemption applies. The process of obtaining regulatory clearances or approvals to market a medical device can be costly and time-consuming, and we may not be able to obtain these clearances or approvals on a timely basis, if at all.

 

Most of our currently commercialized products have received premarket clearances under Section 510(k) of the FDCA. In the future, the FDA may determine that our products will require the more costly, lengthy and uncertain de novo or PMA processes. If the FDA requires us to go through a lengthier, more rigorous examination for future products or modifications to existing products than we had expected, our product introductions or modifications could be delayed or canceled, which could adversely affect our revenue. Although we do not currently market any devices under PMA and have not gone through the de novo classification process for marketing authorization, we cannot assure you that the FDA will not demand that we obtain a PMA or de novo classification prior to marketing or that we will be able to obtain 510(k) clearances with respect to future products.

 

27
 

 

The FDA can delay, limit or deny clearance or approval of a device for many reasons, including:

 

●we may not be able to demonstrate to the FDA’s satisfaction that our products meet the standard of “substantial equivalence” for a 510(k) or meet the standard for the FDA to grant a petition for de novo classification;

 

●we may not be able to demonstrate to the FDA’s satisfaction that our products are safe and effective for their intended uses;

 

●the data from our pre-clinical studies (bench and/or animal) and clinical trials may be insufficient to support clearance or approval in general or for specific, commercially desirable indications, where required;

 

●the manufacturing process or facilities we use may not meet applicable requirements; and

 

●changes in FDA clearance or approval policies or the adoption of new regulations may require additional data.

 

In addition, even if we do obtain clearance or approval, the FDA may not approve or clear these products for the indications that are necessary or desirable for successful commercialization. Any delay in, or failure to receive or maintain, clearances or approvals for our products under development could prevent us from generating revenue from these products or achieving profitability.

 

We are subject, directly and indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, and physician payment transparency laws. Failure to comply with these laws may subject us to substantial penalties.

 

We are subject to federal and state healthcare laws and regulations pertaining to fraud and abuse, and physician payment transparency, including false claims laws, anti-kickback laws and physician self-referral laws. Many states require compliance with different types of pricing transparency requirements such as having a code of conduct, as well as reporting remuneration paid to health care professionals or entities in a position to influence prescribing behavior. Violations of these federal and state laws can result in criminal and/or civil punishment, including fines, imprisonment and, in the United States, exclusion from participation in government healthcare programs. Greater scrutiny of marketing practices in our industry has resulted in numerous government investigations, prosecutions and settlements by various government authorities and this industry-wide enforcement activity is expected to continue. If a governmental authority were to determine that we do not comply with these laws and regulations, the Company and our directors, officers and employees could be subject to criminal and civil penalties, including exclusion from participation in U.S. federal healthcare reimbursement programs.

 

Many of these healthcare laws inevitably influence company standards of conduct. Other laws tie into these standards as well, such as compliance with the advertising and promotion regulations under the FDCA, the U.S. Federal Anti-Kickback Statute, the Federal False Claims Act, the Federal Physician Payments Sunshine Act and other laws. We use many distributors and independent sales representatives in certain territories and thus rely upon their compliance with applicable laws and regulations, such as with the advertising and promotion regulations or similar laws under countries located outside the United States and other applicable federal, state or international laws. These laws include:

 

●the U.S. Federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual for, or the purchase, order or recommendation of, any good or service for which payment may be made under federal healthcare programs, such as the Medicare and Medicaid programs. A person or entity does not need to have actual knowledge of the Federal Anti-Kickback Statute or specific intent to violate it to have committed a violation. In addition, the government may assert that a claim including items or services resulting from a violation of the Federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the U.S. Federal False Claims Act; this may constrain our marketing practices and those of our independent sales agencies, educational programs, pricing, bundling and rebate policies, grants for physician-initiated trials and continuing medical education, and other remunerative relationships with healthcare providers;

 

28
 

 

●federal false claims laws (such as the U.S. Federal False Claims Act) which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims seeking payment from Medicare, Medicaid or other federal-funded third-party payors that are false or fraudulent; this may impact the reimbursement advice we give to our customers as it cannot be inaccurate and must relate to on-label uses of our products;

 

●federal criminal laws that prohibit executing a scheme to defraud any federal healthcare benefit program or making false statements relating to healthcare matters;

 

●the Federal Physician Payments Sunshine Act, which requires manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children’s Health Insurance Program (with certain exceptions) to report annually to CMS, information related to payments or other “transfers of value” made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, and requires applicable manufacturers and group purchasing organizations to report annually to CMS ownership and investment interests held by the physicians described above and their immediate family members and payments or other “transfers of value” to such physician owners. We are also required to collect information on payments or transfers of value to physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists, and certified nurse-midwives for reporting to CMS;

 

●analogous state and foreign law equivalents of each of the above federal laws, such as state anti-kickback prohibitions and false claims prohibitions which may apply to items or services reimbursed by any third-party payor, including commercial insurers; state laws that require device companies to comply with the industry’s voluntary compliance guidelines and the applicable compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws that require device manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other and federal law in significant ways and may not have the same effect, thus complicating compliance efforts; and

 

●the Federal Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), and its implementing regulations, which created federal criminal laws that prohibit executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters and which also imposes certain regulatory and contractual requirements regarding the privacy, security and transmission of individually identifiable health information.

 

Certain of these laws have exceptions and “safe harbors” which if met may protect certain arrangements from liability. For example, certain financial payments that might otherwise implicate the Federal Anti-Kickback Statute will be permitted under the state if they are structured to comply with one of various statutory exceptions or regulatory safe harbors established by the Office of Inspector General (“OIG”) of the U.S. Department of Health and Human Services. These safe harbors include, for example, the “Discount” safe harbor which allows manufacturers of goods covered by federal payor programs to provide discounts to their customers in the form of rebates, volume discounts and the like as long as those discounts meet the express requirements of the safe harbor. Other safe harbors under the Anti-Kickback Statute may also apply to consulting, teaching and other personal service arrangements we may have with physicians and marketing personnel. These safe harbors are technical in nature and failure to meet any element of a safe harbor will cause an arrangement to lose safe harbor protection. In addition, there may not be safe harbors or exceptions for every potential financial arrangement we may enter into and, and even if there are, no assurances can be given that any of our arrangements or relationships will meet an otherwise applicable safe harbor.

 

29
 

 

Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available under such laws, it is possible that some of our business activities, including our relationships with customers, marketing personnel, physicians and other healthcare providers, some of whom have or may have ownership interests in the Company and recommend and/or use our products, could be subject to challenge under one or more of such laws. We are also exposed to the risk that our employees, independent contractors, principal investigators, consultants, vendors, and distributors may engage in fraudulent or other illegal activity. Misconduct by these parties could include, among other infractions or violations, intentional, reckless and/or negligent conduct or unauthorized activity that violates FDA regulations, manufacturing standards, federal and state healthcare fraud and abuse laws and regulations, laws that require the true, complete and accurate reporting of financial information or data or other commercial or regulatory laws or requirements. It is not always possible to identify and deter misconduct by our employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations.

 

In addition, state and federal healthcare regulations are constantly evolving. Existing laws and regulations are subject to new and sometimes more restrictive interpretations on a regular basis so that arrangements we believe to be legally compliant could be deemed to be non-compliant under new interpretations. Similarly, new federal and state health care laws and regulations are being adopted on a regular basis. While we endeavor to identify and comply with these new laws and regulations, it is possible that we may be unaware of new legal requirements or interpretations which could result in our violation of these laws and/or regulations.

 

There is also an increasing trend toward more criminal prosecutions and compliance enforcement activities for noncompliance with the HIPAA and state data privacy laws as well as for data breaches involving protected health information (“PHI”). In the ordinary course of our business, we may receive PHI. If we are unable to comply with HIPAA or experience a data breach involving PHI, we could be subject to criminal and civil sanctions and incur substantial investigation, defense and remediation costs.

 

If our operations are found to violate any of the laws described above or any other laws and regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, the curtailment or restructuring of our operations, the exclusion from participation in federal and state healthcare programs and imprisonment, any of which could adversely affect our ability to market our products and materially adversely affect our business, results of operations and financial condition. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management’s attention from the operation of our business.

 

U.S. governmental regulation could restrict the use of our tissue products or our procurement of tissue.

 

In the United States, the procurement and transplantation of allograft bone tissue is subject to federal law pursuant to the National Organ Transplant Act (“NOTA”), a criminal statute which prohibits the purchase and sale of human organs used in human transplantation, including bone and related tissue, for “valuable consideration.” NOTA permits reasonable payments associated with the removal, transportation, processing, preservation, quality control, implantation and storage of human bone tissue. We provide services in all of these areas in the United States, with the exception of removal and implantation, and receive payments for all such services. We make payments to certain of our clients and tissue banks for their services related to recovering allograft bone tissue on our behalf. If NOTA is interpreted or enforced in a manner which prevents us from receiving payment for services we render, or which prevents us from paying tissue banks or certain of our clients for the services they render for us, our business could be materially and adversely affected.

 

We are engaged through our marketing employees, independent sales agents and sales representatives in ongoing efforts designed to educate the medical community as to the benefits of our products, and we intend to continue our educational activities. Although we believe that NOTA permits payments in connection with these educational efforts as reasonable payments associated with the processing, transportation and implantation of our products, payments in connection with such education efforts are not exempt from NOTA’s restrictions and our inability to make such payments in connection with our education efforts may prevent us from paying our sales representatives for their education efforts and could adversely affect our business and prospects. No federal agency or court has determined whether NOTA is, or will be, applicable to every allograft bone tissue-based material which our processing technologies may generate. Assuming that NOTA applies to our processing of allograft bone tissue, we believe that we comply with NOTA, but there can be no assurance that more restrictive interpretations of, or amendments to, NOTA will not be adopted in the future which would call into question one or more aspects of our method of operations.

 

30
 

 

Outside of the United States, our medical devices must comply with the laws and regulations of the foreign countries in which they are marketed, and compliance may be costly and time-consuming. Failure to obtain and maintain regulatory approvals in jurisdictions outside the United States will prevent us from marketing our products in such jurisdictions.

 

We currently market, and intend to continue to market, our products outside the United States, with the exception of the EU. To market and sell our product in countries outside the United States, we must seek and obtain regulatory approvals, certifications or registrations and comply with the laws and regulations of those countries. These laws and regulations, including the requirements for approvals, certifications or registrations and the time required for regulatory review, vary from country to country. We may not obtain regulatory approvals or certifications outside the United States on a timely basis, if at all. Clearance or approval by the FDA does not ensure approval or certification by regulatory authorities in other countries, and approval or certification by one foreign regulatory authority does not ensure approval by regulatory authorities in other countries or by the FDA. Obtaining and maintaining foreign regulatory approvals, certifications or registrations are expensive, and we cannot be certain that we will receive or maintain regulatory approvals, certifications or registrations in any foreign country in which we currently or plan to market our products. For example, during 2020, we ceased selling products in the EU since the cost to maintain our regulatory approvals in the EU exceeded the benefit of doing business there. In addition, the regulatory approval process outside the United States may include all of the risks associated with obtaining FDA clearance or approval in addition to other risks.

 

Modifications to our products may require new regulatory clearances or approvals or may require us to recall or cease marketing our products until clearances or approvals are obtained.

 

Any modification to a 510(k)-cleared device that could significantly affect its safety or effectiveness, including significant changes to a device’s design, materials, chemical composition, energy source, or manufacturing process, or that would constitute a major change in its intended use, may require a new 510(k) clearance, a de novo classification, or possibly a PMA. Modifications to our products that were implemented without obtaining clearance or approval and for which FDA subsequently concludes that clearance or approval was required, may require us to recall or cease marketing the modified devices until clearance or approval is obtained. The FDA requires device manufacturers to initially make and document a determination of whether or not a modification requires a new approval, supplement or clearance. To do that, a manufacturer must determine if a change/modification to labeling of the device is a “major” change to the intended use statement (previously cleared by the FDA) or if a physical change/modification to the device itself “could significantly affect safety or effectiveness.” If the labeling change is major and/or the physical change significantly affects safety and effectiveness, the manufacturer must file for an additional 510(k) clearance, de novo classification, or PMA for those changes before the modified device can be lawfully marketed. If the Company concludes in its own self-determination that the changes do not meet either of the thresholds of “major “or “significantly affects,” it may simply document those changes by way of an internal letter-to-file as part of the manufacturer’s quality system recording keeping. However, the FDA can review a manufacturer’s decision and may disagree. The FDA will normally review a decision made by a manufacturer in a letter-to-file during a routine plant inspection, which FDA targets to conduct every two years for high-risk (Class III) device manufacturers and certain low and moderate risk (Class I and II) device manufacturers. In such a review the FDA may determine that a new clearance or approval was required before the device was put into commercial distribution.

 

We have made modifications to our products in the past that we concluded did not require a new clearance or approval, and we may make additional modifications in the future that we believe do not or will not require additional clearances or approvals. No assurance can be given that the FDA would agree with any of our decisions not to seek 510(k) clearance, de novo classification, or PMA approval. The issue of whether a product modification requires clearance or approval, as opposed to a “letter-to-file” documenting the change, is not always clear and companies rely on FDA guidance to assist in making such decisions.

 

31
 

 

If the FDA requires us to cease marketing and recall a modified device until we obtain a new 510(k) clearance, de novo classification, or PMA, our business, financial condition, operating results and future growth prospects could be materially and adversely affected. Further, our products could be subject to recall if the FDA determines, for any reason, that our products are not safe or effective. Any recall or FDA requirement that we seek additional approvals or clearances could result in significant delays, fines, increased costs associated with modification of a product, loss of revenue and potential operating restrictions imposed by the FDA. Obtaining clearances and approvals can be a time-consuming process, and delays in obtaining required future clearances or approvals would adversely affect our ability to introduce new or enhanced products in a timely manner, which in turn would harm our future growth.

 

Our manufacturing operations are required to comply with the FDA’s and other governmental authorities’ laws and regulations regarding the manufacture and production of medical devices, which is costly and could subject us to enforcement action.

 

We and certain of our third-party manufacturers and suppliers are required to comply with the FDA’s current Good Manufacturing Practices (“cGMP”) requirements and Quality System Regulations (“QSR”), which cover, among other things, the methods of documentation of the design, testing, production, control, quality assurance, labeling, packaging, sterilization, storage and shipping of our products. We and certain of our suppliers also are subject to the regulations of foreign jurisdictions regarding the manufacturing process for our products marketed outside of the United States. The FDA enforces the QSR through periodic announced (routine) and unannounced (for cause or directed) inspections of manufacturing facilities. The failure by us or one of our third-party manufacturers or suppliers to comply with applicable statutes and regulations administered by the FDA and other regulatory bodies, or the failure to timely and adequately respond to any adverse inspectional observations or product safety issues, could result in, among other things, any of the following enforcement actions:

 

●untitled letters, warning letters, fines, injunctions, consent decrees, disgorgement of profits, criminal and civil penalties;

 

●customer notifications or repair, replacement, refunds, recall, detention or seizure of our products;

 

●operating restrictions or partial suspension or total shutdown of production;

 

●refusing or delaying our requests for 510(k) clearance, de novo classification, or PMA approval of new products or modified products;

 

●withdrawing 510(k) clearances, de novo classifications, or PMAs that have already been granted;

 

●refusal to grant export certificates for our products; or

 

●criminal prosecution.

 

Any of these actions could impair our ability to produce our products in a cost-effective and timely manner in order to meet our customers’ demands. We also may be required to bear other costs or take other actions that may have a negative impact on our future revenue and other operating results. Furthermore, our key component suppliers may not currently be or may not continue to be in compliance with all applicable regulatory requirements, which could result in our failure to produce our products on a timely basis and in the required quantities, if at all.

 

32
 

 

Even if our medical device products are cleared or approved by regulatory authorities, if we or our suppliers fail to comply with ongoing FDA or other foreign regulatory authority requirements, or if we experience unanticipated problems with our products, these products could be subject to restrictions or withdrawal from the market.

 

Any product that we market will be subject to continued regulatory review, oversight and periodic inspections by the FDA and other domestic and foreign regulatory bodies. Such oversight will cover, among other things, the product’s design and manufacturing processes, our quality system and compliance with reporting requirements, our compliance with post-approval clinical data requirements, and our promotional activities related to our products.

 

Even if regulatory clearance or approval of a product is granted, such clearance or approval may be subject to limitations on the intended uses for which the product may be marketed and reduce our potential to successfully commercialize the product and generate revenue from the product. If the FDA determines that our promotional materials, labeling, training or other marketing or educational activities constitute promotion of an unapproved use, it could request that we cease or modify our training or promotional materials or subject us to regulatory enforcement actions. It is also possible that other federal, state or foreign enforcement authorities might take action if they consider our training or other promotional materials to constitute promotion of an unapproved use, which could result in significant fines or penalties under other statutory authorities, such as laws prohibiting false claims for reimbursement.

 

In addition, we may be required to conduct costly post-market testing and surveillance to monitor the safety or effectiveness of our products. Later discovery of previously unknown problems with our products, including unanticipated adverse events or adverse events of unanticipated severity or frequency, manufacturing problems, or failure to comply with regulatory requirements such as QSR, may result in, among other things, changes to labeling, restrictions on such products or manufacturing processes, product corrections, removal of the products from the market, voluntary or mandatory recalls, a requirement to repair, replace or refund the cost of any medical device we manufacture or distribute, fines, withdrawal of regulatory clearance or approvals, delays in or refusals of new 510(k)s, de novo requests or PMA applications, untitled letters, warning letters, refusal to grant export certificates for our products, product seizures, injunctions or the imposition of civil or criminal penalties which would adversely affect our business, operating results and prospects.

 

The use, misuse or off-label use of our products may harm our image in the marketplace or result in injuries that lead to product liability suits, which could be costly to our business or result in FDA sanctions if we are deemed to have engaged in improper promotion of our products.

 

Our products currently marketed in the United States have been cleared through the FDA’s 510(k) process for use under specific circumstances. Our promotional materials and training methods must comply with FDA and other applicable laws and regulations, including the prohibition on the promotion of a medical device for a use that has not been cleared or approved by the FDA. We believe that the specific surgical procedures for which our products are marketed fall within the general intended use of the surgical applications that have been cleared by the FDA. However, the FDA could disagree and require us to stop promoting our products for those specific indications/procedures until we obtain FDA clearance or approval for them. Use of a device outside of its cleared or approved indication is known as “off-label” use. We cannot prevent a surgeon from using our products for off-label use, as the FDA does not restrict or regulate a physician’s choice of treatment within the practice of medicine. However, if the FDA determines that our promotional activities, reimbursement advice or training of sales representatives or physicians constitute promotion of an off-label use, the FDA could request that we modify our training or promotional or reimbursement materials or subject us to regulatory or enforcement actions, including, among other things, the issuance of an untitled letter, a warning letter, injunction, seizure, disgorgement of profits, a civil fines and criminal penalties. Other federal, state or foreign governmental authorities also might take action if they consider our promotion or training materials to constitute promotion of an uncleared or unapproved use, which could result in significant fines or penalties under other statutory authorities, such as laws prohibiting false claims for reimbursement. For example, the government may take the position that off-label promotion resulted in inappropriate reimbursement for an off-label use in violation of the Federal False Claims Act for which it might impose a civil fine and even pursue criminal action. In those possible events, our reputation could be damaged, and adoption of the products would be impaired. Although we train our sales force not to promote our products for off-label uses, and our instructions for use in all markets specify that our products are not intended for use outside of those indications cleared for use, the FDA or another regulatory agency could conclude that we have engaged in off-label promotion.

 

33
 

 

There may be increased risk of injury and product liability if surgeons attempt to use our products off-label, misuse our products or do not follow recommended user techniques and guidelines. Product liability claims are expensive to defend and could divert our management’s attention and result in substantial damage awards against us. Furthermore, the use of our products for indications other than those indications for which our products have been cleared by the FDA may not effectively treat such conditions, which could harm our reputation in the marketplace among surgeons and patients. Any of these events could harm our business and operating results.

 

If our products cause or contribute to a death or serious injury, or malfunction in certain ways, we will be subject to medical device reporting regulations, which can result in voluntary corrective actions or agency enforcement actions.

 

Under the FDA medical device reporting regulations, medical device manufacturers are required to report to the FDA information that a device has or may have caused or contributed to a death or serious injury or has malfunctioned in a way that would likely cause or contribute to a death or serious injury if the malfunction of the device or one of our similar devices were to recur. Under the FDA’s reporting regulations applicable to HCT/Ps, we are required to report all adverse reactions involving a communicable disease if it is fatal, life threatening, results in permanent impairment of a body function or permanent damage to body structure, or necessitates medical or surgical intervention, including hospitalization. If we fail to report these events to the FDA within the required timeframes, or at all, the FDA could take enforcement action against us. Any such adverse event involving our products also could result in future voluntary corrective actions, such as recalls or customer notifications, or agency action, such as mandatory recalls, destruction, cessation of manufacturing, inspection or other enforcement action. Any corrective action, whether voluntary or involuntary, as well as defending ourselves in a lawsuit, would require the dedication of our time and capital, distract management from operating our business, and may harm our reputation and financial results. We are currently subject to certain product liability litigation, which could harm our business, financial condition or results of operations, especially if this litigation requires payments in amounts that exceed our product liability insurance coverage.

 

Any future product recall or voluntary market withdrawal of a product due to defects, enhancements and modifications or other reasons would significantly increase our costs.

 

The FDA and similar foreign governmental authorities have the authority to require the recall of commercialized products. In addition, foreign governmental bodies have the authority to require the recall of our products in the event of material deficiencies or defects in design or manufacture. Manufacturers may, under their own initiative, recall a product if any material deficiency in a device is found or for other reasons. A government-mandated or voluntary recall by us or one of our distributors could occur as a result of component failures, manufacturing errors, design or labeling defects or other deficiencies and issues. Recalls of any of our products would divert managerial and financial resources and could have an adverse effect on our financial condition and results of operations. The FDA requires that certain recalls undertaken to reduce a risk to health be reported to the FDA within 10 working days after the recall is initiated. Companies are required to maintain certain records of recalls, even if they are not reportable to the FDA. We may initiate voluntary recalls involving our products in the future that we determine do not require notification of the FDA. If the FDA disagrees with our determinations, they could require us to report those actions as recalls. In addition, the FDA could take enforcement action for failing to report the recalls when they were conducted.

 

If we or our suppliers fail to comply with regulations pertaining to human cells, tissues, and cellular and tissue-based products, these products could be subject to withdrawal from the market or other enforcement action.

 

Certain of our products are regulated as HCT/Ps. Section 361 of the PHSA authorizes the FDA to issue regulations to prevent the introduction, transmission or spread of communicable disease. HCT/Ps regulated as “361” HCT/Ps are subject to requirements relating to registering facilities and listing products with the FDA; screening and testing for tissue donor eligibility; and current Good Tissue Practice (“cGTPs”), when processing, storing, labeling, and distributing HCT/Ps, including required labeling information, stringent record keeping, and adverse event reporting, among other applicable requirements and laws. The FDA regulations also have additional requirements that address sub-contracted tissue services, tracking, and donor records review. If a tissue-based product is considered human tissue, the FDA requirements focus on preventing the introduction, transmission and spread of communicable diseases. A product regulated solely as a 361 HCT/P is not required to undergo 510(k) premarket clearance, de novo classification or PMA.

 

34
 

 

The FDA may inspect facilities engaged in manufacturing 361 HCT/Ps and may issue untitled letters, warning letters, or otherwise authorize orders of retention, recall, destruction and cessation of manufacturing if the FDA has reasonable grounds to believe that an HCT/P or the facilities where it is manufactured are in violation of applicable regulations. There also are requirements relating to the import of HCT/Ps that allow the FDA to make a decision as to the HCT/Ps’ admissibility into the United States.

 

An HCT/P is eligible for regulation solely as a 361 HCT/P if it is: (i) minimally manipulated; (ii) intended for homologous use as reflected by labeling, advertising or other indications of the manufacturer’s objective intent; (iii) the manufacture does not involve the combination of the HCT/P with another article, except for water, crystalloids or a sterilizing, preserving, or storage agent (not raising new clinical safety concerns for the HCT/P); and (iv) it does not have a systemic effect and is not dependent upon the metabolic activity of living cells for its primary function or, if it has a systemic effect or is dependent upon the metabolic activity of living cells for its primary function, it is intended for autologous use or allogeneic use in a first or second degree relative or for reproductive use. If any of these requirements are not met, then the HCT/P is also subject to applicable biologic, device, or drug regulation under the FDCA or the PHSA. These biologic, device or drug HCT/Ps must comply with the requirements exclusively applicable to 361 HCT/Ps and, in addition, with requirements applicable to biologics under the PHSA, or devices or drugs under the FDCA, including licensure, clearance or approval, as the case may be.

 

Over the course of several years, the FDA issued regulations that address manufacturer activities associated with HCT/Ps. The first requires that companies that manufacture HCT/Ps register with the FDA. This set of regulations also includes the criteria that must be met in order for the HCT/P to be eligible for regulation solely under Section 361 of the PHSA and the regulations in 21 CFR Part 1271, rather than under the drug or device provisions of the FDCA or the biological product licensing provisions of the PHSA. The second set of regulations provides criteria that must be met for donors to be eligible to donate tissues and is referred to as the “Donor Eligibility” rule. The third rule governs the processing and distribution of the tissues and is often referred to as the cGTP rule. The cGTP rule covers all stages of allograft processing, from procurement of tissue to distribution of final allografts. Together these regulations are designed to ensure that sound, high quality practices are followed to reduce the risk of tissue contamination and of communicable disease transmission.

 

At the time they came into effect approximately 15 years ago, these regulations increased regulatory scrutiny within the industry in which we operate and have led to increased enforcement action which affects the conduct of our business. In addition, these regulations can increase the cost of tissue recovery activities. The FDA periodically inspects tissue processors to determine compliance with these requirements. Allegations of violations of applicable regulations noted by the FDA during facility inspections could adversely affect the continued marketing of our products. We believe we comply with all aspects of 21 CFR Part 1271 that we are required to comply with, although there can be no assurance that we will be deemed by FDA to be in compliance. Entities that provide us with allograft bone tissue are responsible for performing donor recovery, donor screening and donor testing and our compliance with those aspects of the cGTP regulations that regulate those functions are dependent upon the actions of these independent entities. If our suppliers fail to comply with applicable requirements, our products and our business could be negatively affected. If the FDA determines that we have failed to comply with applicable regulatory requirements, it can impose a variety of regulatory actions, or enforcement actions from public warning letters, fines, injunctions, consent decrees and civil penalties to suspension or delayed issuance of approvals, seizure of our products, total or partial shutdown of our production, withdrawal of approvals, and criminal prosecutions. If any of these events were to occur, it could materially adversely affect us.

 

In addition, the FDA could disagree with our conclusion that one or more of our HCT/Ps meet the criteria for marketing solely under Section 361 of the PHSA, and therefore that one or more of the HCT/Ps require licensure, approval or clearance of a marketing application. The FDA could conclude that the tissue is more than minimally manipulated, that the product is intended for a non-homologous use, that the product is combined with another article, or that the product has a systemic effect or is dependent on the metabolic activity of living cells for its primary function. The FDA could also determine that a modification to an HCT/P makes it ineligible for regulation solely as a 361 HCT/P. If the FDA were to draw these conclusions, it would likely require clinical studies conducted pursuant to an investigational new drug application (“IND”) and the submission and licensure, approval or clearance of a marketing application in order for us to continue to market the product. Such an action by the FDA could cause negative publicity, decreased or discontinued product sales, and significant expense in obtaining required marketing licensure, approval or clearance.

 

35
 

 

Procurement of certain human organs and tissue for transplantation, including allograft tissue we may use in future products, is subject to federal regulation under National Organ Transplant Act. NOTA prohibits the acquisition, receipt, or other transfer of certain human organs, including bone and other human tissue, for valuable consideration within the meaning of NOTA. NOTA permits the payment of reasonable expenses associated with the removal, transportation, implantation, processing, preservation, quality control and storage of human organs. For any future products implicating NOTA’s requirements, we would reimburse tissue banks for their expenses associated with the recovery, storage and transportation of donated human tissue that they would provide to us. NOTA payment allowances may be interpreted to limit the amount of costs and expenses that we may recover in our pricing for our services, thereby negatively impacting our future revenue and profitability. If we were to be found to have violated NOTA’s prohibition on the sale or transfer of human tissue for valuable consideration, we would potentially be subject to criminal enforcement sanctions, which could materially and adversely affect our operating results. Further, in the future, if NOTA is amended or reinterpreted, we may not be able to pass these expenses on to our customers and, as a result, our business could be adversely affected.

 

Other regulatory entities with authority over our products and operations include state agencies enforcing statutes and regulations covering tissue banking. Regulations issued by Florida, New York, California and Maryland are particularly relevant to our business. Most states do not currently have tissue banking regulations. It is possible that others may make allegations against us or against donor recovery groups or tissue banks about non-compliance with applicable FDA regulations or other relevant statutes or regulations. Allegations like these could cause regulators or other authorities to take investigative or other action or could cause negative publicity for our business and the industry in which we operate.

 

Loss of AATB accreditation would have a material adverse effect on us.

 

We are accredited with the American Association of Tissue Banks, a private non-profit organization that accredits tissue banks and sets industry standards. Although AATB accreditation is voluntary and not required by law, as a practical matter, many of our customers would not purchase our products if we failed to maintain our AATB accreditation. Although we make every effort to maintain our AATB accreditation, the accreditation process is somewhat subjective and lacks regulatory oversight. There can be no assurance that we will continue to remain accredited with the AATB and any loss of our AATB accreditation would adversely affect our business and operating results.

 

Federal regulatory reforms may adversely affect our ability to sell our products and our business.

 

From time to time, legislation is drafted and introduced in Congress that could significantly change the statutory provisions governing the regulatory approval, manufacture and marketing of regulated products or the reimbursement thereof. In addition, FDA regulations and guidance are often revised or reinterpreted by the FDA in ways that may significantly affect our business and our products. Any new regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of future products. In addition, FDA regulations and guidance are often revised or reinterpreted by the agency in ways that may significantly affect our business and our products. It is impossible to predict whether legislative changes will be enacted or FDA regulations, guidance or interpretations changed, and what the impact of such changes, if any, may be.

 

For example, the FDA may change its clearance and approval policies, adopt additional regulations or revise existing regulations, or take other actions which may prevent or delay approval or clearance of our products under development or impact our ability to modify our currently cleared products on a timely basis. Any change in the laws or regulations that govern the clearance and approval processes relating to our current and future products could make it more difficult and costly to obtain clearance or approval for new products, or to produce, market and distribute existing products. Significant delays in receiving clearance or approval or the failure to receive clearance or approval for our new products would have an adverse effect on our ability to sell our products and our business.

 

36
 

 

Product pricing is subject to regulatory control, which could impact our revenue and other operating results.

 

The pricing of our products may become subject to control by the government and other third-party payors. The continuing efforts of governmental and other third-party payors to contain or reduce the cost of healthcare through various means may adversely affect our ability to successfully commercialize our products. In most foreign markets, the pricing of certain diagnostics and prescription pharmaceuticals are subject to governmental control. In the United States, we expect that there will continue to be federal and state proposals to implement similar governmental control, though it is unclear which proposals will ultimately become law, if any. Changes in prices, including any mandated pricing, could impact our revenue and other operating results.

 

Our revenues depend upon prompt and adequate coverage and reimbursement from public and private insurers and national health systems.

 

Political, economic and regulatory influences are subjecting the healthcare industry, including the medical device industry, in the United States to fundamental change. The ability of healthcare providers to purchase our products depends in part on the extent to which reimbursement for the costs of such materials and related treatments is and will continue to be available from governmental health administration authorities, private health coverage insurers and other organizations. In the United States, healthcare providers who purchase our products generally rely on these third-party payors to pay for all or a portion of the cost of our products as a component of a single bundled payment amount for the procedures in which the products are used. Because there is often no separate third-party payor reimbursement to the provider for our products, the additional cost associated with purchasing our products can impact the provider’s profit margin for delivering the treatment that includes are product as a component. If third-party payor reimbursement to providers for procedures involving our products is eliminated or reduced, some of our target customers may be unwilling to purchase our products and may choose to instead purchase less expensive alternatives from our competitors. In addition, third-party payors for hospital services and hospital outpatient services, including Medicare, Medicaid and private healthcare insurers, typically revise their coverage and payment policies, methodologies and amounts on an annual basis, which can result in noncoverage, stricter standards for reimbursement of hospital charges for certain medical procedures or the elimination of or reduction in reimbursement. Further, Medicare, Medicaid and private healthcare insurer cutbacks could create downward price pressure on our products. Healthcare reform legislation at the federal and state levels could result in changes in coverage of and reimbursement for our products. Finally, our revenues also depend upon timely reimbursement data input from our independent agents. All of these factors could adversely affect our business.

 

Although the results of our clinical studies may support our product candidate claims, we may not receive regulatory approvals, or may experience delays in receiving regulatory approvals, from governmental authorities.

 

Our ongoing research and development, pre-clinical testing and clinical study activities are subject to extensive regulation and review by numerous governmental authorities. We are currently conducting post-market clinical studies of some of our products to gather information about these products’ performance or optimal use. Clinical studies must be conducted in compliance with FDA regulations and local regulations, and according to principles and standards collectively referred to as “Good Clinical Practices.” Non-compliance could result in regulatory and legal enforcement action and also could invalidate the data. Even if our clinical studies are completed as planned, and even if our clinical studies demonstrate our product claims and that our products are safe and effective for the proposed new indicated use, we cannot be certain that the FDA or foreign authorities and notified bodies will agree with our conclusions. It is possible that the FDA or foreign authorities and notified bodies may deny clearance or approval of a device for any of the following reasons:

 

●our inability to demonstrate to the satisfaction of the FDA or the applicable foreign authority or notified body that our products are safe or effective for their intended uses;

 

●the disagreement of the FDA or foreign authorities and notified bodies with the design or implementation of our clinical trials or the interpretation of data from pre-clinical studies or clinical trials;

 

●serious and unexpected adverse device effects experienced by participants in our clinical trials;

 

37
 

 

●the data from our pre-clinical studies and clinical trials may be insufficient to support clearance or approval, where required;

 

●our inability to demonstrate that the clinical and other benefits of the device outweigh the risks; or

 

●the manufacturing process or facilities we use may not meet applicable requirements.

 

Delays in obtaining regulatory clearances and approvals may:

 

●delay or prevent commercialization of products we develop;

 

●require us to perform costly tests or studies;

 

●diminish any competitive advantages that we might otherwise have obtained; and

 

●reduce our ability to collect revenue.

 

Any delay or termination of our clinical studies will delay the filing of our product submissions and, ultimately, our ability to commercialize our products and generate revenues. It is also possible that patient subjects enrolled in our clinical studies of our marketed products will experience adverse side effects that are not currently part of the product’s profile and, if so, these findings may result in lower market acceptance, which could have a material and adverse effect on our business, results of operations and financial condition.

 

Risks Related to our Reliance on Third Parties

 

Substantially all of our revenue is conducted through independent sales agents and distributors who we do not control.

 

Substantially all of our revenue is conducted through independent sales agents and distributors. Because the independent sales agent or distributor often controls the customer relationships within its territory (and, in certain countries outside the United States, the regulatory relationship), there is a risk that if our relationship with the independent sales agent or distributor ends, our relationship with the customer will be lost (and, in certain countries outside the United States, that we could experience delays in amending or transferring our product registrations). Also, because we do not control the independent sales agent or field sales agents of a distributor, there is a risk we will be unable to ensure that our sales processes, compliance, and other priorities will be consistently communicated and executed by the sales agent or distributor. If we fail to maintain relationships with our key independent sales agents and distributors or fail to ensure that our independent sales agent and distributors adhere to our sales processes, compliance, and other priorities, this could have an adverse effect on our operations. Changes to or turnover within our independent sales agent or distributor organization or transitions to direct selling models also could adversely affect our business if these transitions are not managed effectively. Further, independent sales agents and distributors of companies we have acquired may decide not to renew or may decide to seek to terminate, change and/or renegotiate their relationships with us. A loss of a significant number of our sales agent or distributors could have a material adverse effect on our business and results of operations.

 

One of our independent sales agents was associated with approximately 19% and 21% of our revenues during 2021 and 2020, respectively. In any one reporting period, this independent sales agent may contribute an even larger percentage of our revenues. We do not have a long-term agreement with this independent sales agent that requires this agent to continue selling our products on our behalf. While we anticipate that we would retain most of the sales associated with this independent sales agent in the event that we lose this independent sales agent, the loss of this independent sales agent and the agent’s strong relationships with customers could adversely affect our revenues and other operating results.

 

In addition, our success is partially dependent upon our ability to retain and motivate our independent sales agents and distributors, and their representatives to sell our products in certain territories. They may not be successful in implementing our marketing plans. Some of our independent sales agents and distributors do not sell our products exclusively and may offer similar products from other companies. Our independent sales agents and distributors may terminate their contracts with us, may devote insufficient sales efforts to our products, or may focus their sales efforts on other products that produce greater commissions or revenues for them, which could have an adverse effect on our operations and operating results.

 

38
 

 

We depend on a limited number of third-party suppliers for products, components and raw materials and losing any of these suppliers, or their inability to provide us with an adequate supply of materials that meet our quality and other requirements or our failure to order a sufficient supply of products, components and raw materials, could harm our business and operating results.

 

Outside suppliers, some of whom are sole-source suppliers, provide us with products and raw materials and components used in manufacturing our orthobiologics and spinal implant products. We strive to maintain sufficient inventory of products, raw materials and components so that our production will not be significantly disrupted if a particular product, raw material or component is not available to us for a period of time, including as a result of a supplier’s loss of its ISO or other certification, long required lead times, or other reasons, such as the supply chain and shipping disruptions experienced throughout 2021. Despite our efforts, we sometimes experience an insufficient inventory of products, raw materials and/or components. At the end of 2019 and beginning of 2020, we experienced a supply issue with certain of our biologics and hardware products. Although this supply issue subsequently resolved, if we fail to plan our procurement accordingly or are unable to obtain sufficient quantities of raw materials and components used in manufacturing our orthobiologics and spinal implant products that meet our quality and other requirements on a timely basis for any reason, we may not produce sufficient quantities of our products to meet market demand until a new or alternative supply source is identified and qualified and, as a result, we could lose customers, our reputation could be harmed, and our business could suffer. Furthermore, an uncorrected defect or supplier’s variation in a component or raw material that is incompatible with our manufacturing, unknown to us, could harm our ability to manufacture products.

 

Although we believe there are alternative supply sources, replacing our suppliers may be impractical or difficult in many instances. For example, we could have difficulty obtaining similar products from other suppliers that are acceptable to the FDA or other foreign regulatory authorities. In addition, if we are required to transition to new suppliers for certain components or raw materials of our products, the use of components or materials furnished by these alternative suppliers could require us to alter our operations, and if we are required to change the manufacturer of a critical component of our products, we will have to verify that the new manufacturer maintains facilities, procedures and operations that comply with our quality and applicable regulatory requirements, which could further impede our ability to manufacture our products in a timely manner. Transitioning to a new supplier could be time-consuming and expensive, may result in interruptions in our operations and product delivery, could affect the performance specifications of our products or could require that we modify the design of those systems.

 

Risks Related to Human Capital Management

 

We have limited staffing and are dependent upon key employees. In addition, our business is dependent upon a sufficient number of qualified workers and competition for such talent is intense, especially around Belgrade, Montana, where the population is small and the labor market is tight. If we cannot attract and retain qualified personnel or if we must increase substantially our labor costs to attract and retain qualified personnel, the growth and success of our business, as well as our operating results and financial condition, may be adversely affected.

 

Our success is dependent upon the efforts of a relatively small management team and staff. We have experienced a high level of employee turnover in past years, including members of our management team. Most recently, on January 3, 2022, we appointed a new Interim Chief Financial Officer. We have employment arrangements in place with our executive and other officers, but none of these executive and other officers are bound legally to remain employed with Xtant for any specific term. We do not have key person life insurance policies covering our executive and other officers or any of our other employees. If key individuals were to leave Xtant, our business could be affected adversely if suitable replacement personnel are not recruited quickly.

 

39
 

 

The population around Belgrade, Montana, where our headquarters and production facilities are located, is small, and as a result, there is a limited number of qualified personnel available in all functional areas, which has made it difficult for us to attract and retain the qualified personnel necessary for the development and growth of our business. We have been further impacted by the recent labor shortage, which arose, in part, as a result of the COVID-19 pandemic. Our ability to maintain our productivity at competitive levels and increase production in the future may be limited by our ability to employ, train and retain personnel necessary to meet our requirements. Companies in our industry, including us, are dependent upon an available labor pool of qualified employees. We compete for qualified personnel with other companies, academic institutions, governmental entities, and other organizations. A shortage in the labor pool of workers, which we believe currently exists in Belgrade, Montana, and which has worsened due to the recent labor shortage, has made it more difficult for us to attract and retain qualified personnel. We cannot be certain that we will be able to maintain an adequate qualified labor force necessary to operate efficiently and to support our growth strategy and operations. A tight labor market in the Belgrade, Montana area also has required us to enhance our wages and benefit packages to attract a sufficient number of workers, and it is possible that these increased labor costs may not be effective in recruiting and retaining a sufficient number of qualified personnel. There can be no assurance that we will be successful in retaining our current personnel or in hiring or retaining a sufficient number of qualified personnel in the future. If we cannot attract and retain qualified personnel or if we must increase substantially our labor costs to attract and retain qualified personnel, the growth and success of our business, as well as our operating results and financial condition, will be adversely affected.

 

Risks Related to Our Outstanding Indebtedness, Need for Additional Financing and Financial Condition

 

We have incurred significant losses, expect to continue to incur losses and may not achieve or sustain profitability.

 

We have a history of incurring net losses, and at December 31, 2021, we had an accumulated deficit of $235.3 million. During the year ended December 31, 2021, we incurred a net loss of $5.0 million. Our ability to achieve profitability will be influenced by many factors, including, among others, the level and timing of future revenues and expenditures; development, commercialization, market acceptance and availability and supply of our products; competing technologies and market developments; our ability to develop and introduce new products; regulatory requirements and delays; the strength of our relationships with our independent sales agents and distributors; and our ability to attract and retain key personnel. As a result, we may continue to incur operating losses for the foreseeable future. These losses will continue to have an adverse impact on our stockholders’ equity, and we may never achieve or sustain profitability.

 

We may need additional financing to satisfy our anticipated future liquidity requirements, which financing may not be available on favorable terms, or at all, at the time it is needed and which could reduce our operational and strategic flexibility.

 

Although it is difficult for us to predict our future liquidity requirements, we believe that our cash and cash equivalents and restricted cash balance of approximately $18.4 million as of December 31, 2021, together with existing credit availability under our Credit, Security and Guarantee Agreement (Term Loan) (the “Term Credit Agreement”) and Credit, Security and Guaranty Agreement (Revolving Loan) (the “Revolving Credit Agreement” and, together with the Term Credit Agreement, the “Credit Agreements”) with MidCap Financial Trust (“MidCap”), in its capacity as agent, will be sufficient to meet our anticipated cash requirements through at least the end of March 2023. Although we have availability under our Term Credit Agreement, our ability to obtain additional term loans under this agreement is in the sole and absolute discretion of MidCap and the lenders. Additionally, although we have availability under our Revolving Credit Agreement, the availability of such funds is determined based on a borrowing base equal to percentages of certain accounts receivable and inventory. These credit facilities have a maturity date of May 1, 2026, and all of our indebtedness thereunder matures on such date. We may require or we may seek additional funds to fund our future operations and business strategy prior to March 2023. Accordingly, there is no assurance that we will not need or seek additional funding at any time. We may elect to raise additional funds even before we need them if market conditions for raising additional capital are favorable. We may seek to raise additional funds through various sources, such as equity and debt financings, additional debt restructurings or refinancings, or through strategic collaborations, license agreements or acquisition transactions. We can give no assurances that we will be able to secure additional sources of funds to support our operations, or if such funds are available to us, that such additional financing will be sufficient to meet our needs or on terms acceptable to us. This is particularly true if economic and market conditions deteriorate. Any failure by us to raise additional funds on terms favorable to us, or at all, could result in our inability to pay our expenses as they come due, limit our ability to expand our business operations, and harm our overall business prospects. If adequate funds are not otherwise available, we could be required to curtail operations significantly, including reducing our sales and marketing expenses, which could negatively impact product sales, delaying new product initiatives, and we could even be required to cease operations, liquidate our assets and possibly seek bankruptcy protection.

 

40
 

 

To the extent we raise additional financing through the sale of equity or convertible debt securities or the restructuring or refinancing of our outstanding debt, the interests of our current stockholders may be diluted, and the terms may include discounted equity purchase prices, warrant coverage, or liquidation or other preferences that adversely affect the rights of our current stockholders. If we issue common stock, we may do so at purchase prices that represent a discount to our trading price and/or we may issue warrants to purchasers, which could dilute our current stockholders. If we issue preferred stock, it could affect the rights of our stockholders or reduce the value of our common stock. In particular, specific rights granted to future holders of preferred stock may include voting rights, preferences as to dividends and liquidation, conversion and redemption rights, sinking fund provisions, and restrictions on our ability to merge with or sell our assets to a third party. Additional debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. Prior to raising additional equity or debt financing, we must obtain the consent of MidCap and ROS and Royalty Opportunities, parties to an Investor Rights Agreement dated February 14, 2018 with the Company (the “Investor Rights Agreement”), and no assurance can be provided that MidCap, ROS or Royalty Opportunities would provide such consent, which could limit our ability to raise additional financing.

 

We have indebtedness which matures on May 1, 2026. We may not be able to extend the maturity date of or replace our Credit Agreements or generate enough cash flow from our operations to service our indebtedness, and we may incur additional indebtedness in the future, which could adversely affect our business, financial condition, and operating results.

 

As of December 31, 2021, we had $15.6 million of principal outstanding under our Credit Agreements, which such indebtedness matures on May 1, 2026. Although we believe that we will be able to pay off our outstanding indebtedness or extend the maturity date of that facility at the appropriate time, no assurance can be provided that we will do so on terms that are favorable to us or at all. Our ability to make payments on, and to refinance, our indebtedness, including amounts borrowed under our Credit Agreements, and our ability to fund planned capital expenditures, contractual cash obligations, known and unknown liabilities, research and development efforts, working capital, any future acquisitions and business combinations, and other general corporate purposes depends on our ability to generate cash in the future. This, to a certain extent, is subject to general economic, financial, competitive, legislative, regulatory, and other factors, some of which are beyond our control. If we do not generate sufficient cash flow from operations or if future borrowings are not available to us in an amount sufficient to pay our indebtedness or to fund our liquidity needs, we may be forced to refinance all or a portion of our indebtedness on or before the maturity dates thereof, sell assets, reduce or delay capital expenditures, seek to raise additional capital, or take other similar actions. We may not be able to execute any of these actions on commercially reasonable terms or at all. Our ability to refinance our indebtedness will depend on our financial condition at the time, the restrictions in the instruments governing our indebtedness, the consent of our lender, and other factors, including market conditions. Our inability to generate sufficient cash flow to satisfy our debt service obligations, or to refinance or restructure our obligations on commercially reasonable terms or at all, would likely have an adverse effect, which could be material, on our business, financial condition, and operating results.

 

In addition, our significant indebtedness, combined with our other financial obligations and contractual commitments, could have other important consequences. For example, it could:

 

●make us more vulnerable to adverse changes in general U.S. and worldwide economic, industry, and competitive conditions and adverse changes in government regulation;

 

●limit our flexibility in planning for, or reacting to, changes in our business and our industry;

 

●restrict our ability to make strategic acquisitions, business combinations or dispositions or to exploit business opportunities;

 

41
 

 

●place us at a competitive disadvantage compared to our competitors who have less debt; and

 

●limit our ability to borrow additional amounts or raise financing for working capital, capital expenditures, contractual obligations, research and development efforts, acquisitions or business combinations, debt service requirements, execution of our business strategy, or other purposes.

 

Any of these factors could materially and adversely affect our business, financial condition, and operating results. In addition, we may incur additional indebtedness, and if we do, the risks related to our business and our ability to service our indebtedness would increase.

 

A failure to comply with the covenants and other provisions of our Credit Agreements may cause suspension or termination of the Credit Agreements and/or require the immediate repayment of our outstanding indebtedness. If we are at any time unable to generate sufficient cash flows from operations to service our indebtedness when payment is due, we may be required to attempt to renegotiate the terms of the Credit Agreements, seek to refinance all or a portion of the indebtedness, or obtain additional financing. There can be no assurance that we will be able to successfully renegotiate such terms, that any such refinancing would be possible, or that any additional financing could be obtained on terms that are favorable or acceptable to us.

 

The terms of our Credit Agreements substantially limit our ability to conduct and invest in our business, take advantage of business opportunities, and respond to changing business, market, and economic conditions.

 

Our Credit Agreements include a number of significant financial and operating restrictions. For example, the agreements contain financial covenants that, among other things, require us to maintain a minimum liquidity covenant, as defined in the agreements, and contain provisions that restrict our ability, subject to specified exceptions, to, among other things:

 

●create, incur, assume, guarantee or otherwise become or remain directly or indirectly liable with respect to any debt, except for permitted debt;

 

●create, assume, incur or suffer to exist any contingent obligations, except for permitted contingent obligations;

 

●purchase, redeem, defease or prepay any principal of, premium, if any, interest or other amount payable in respect of any debt prior to its scheduled maturity;

 

●create, assume or suffer to exist any lien on our assets;

 

●declare, order, pay, make or set apart any sum for any distribution, except for permitted distributions;

 

●enter into or assume any agreement prohibiting the creation or assumption of any lien upon our properties or assets or create or otherwise cause or suffer to exist or become effective certain consensual encumbrances or restrictions of any kind;

 

●declare, pay, make or set aside any amount for payment in respect of subordinated debt;

 

●engage in mergers or consolidations;

 

●acquire, make, own, hold or otherwise consummate any investment, other than permitted investments;

 

●enter into certain transactions with affiliates;

 

●amend or otherwise modify any organizational documents; and

 

●make certain amendments or modifications to certain material contracts.

 

42
 

 

We may be unable to comply with these covenants, which could result in a default under the Credit Agreements. In addition, these provisions may limit our ability to conduct and invest in our business, take advantage of business opportunities, and respond to changing business, market, and economic conditions. In addition, they may place us at a competitive disadvantage relative to other companies that may be subject to fewer, if any, restrictions or may otherwise adversely affect our business. Transactions that we may view as important opportunities, such as significant acquisitions or business combinations, may be subject to the consent of the lenders, which consent may be withheld or granted subject to conditions specified at the time that may affect the attractiveness or viability of the transaction. In addition, our Investor Rights Agreement with ROS and Royalty Opportunities further substantially limits the operation of our business and the ability of our management to conduct and invest in our business.

 

Our Credit Agreements involve additional risks that may adversely affect our liquidity, results of operations, and financial condition.

 

Availability of additional term loans under the Term Credit Agreement is based solely on the discretion of MidCap and the lenders, and additional funds are for the purposes agreed to between us, the borrowers and the lenders in advance of the making of loans under this additional tranche. Availability of additional funds under the Revolving Credit Agreement is determined based on a borrowing base equal to percentages of certain accounts receivable and inventory of the borrowers in advance with a formula set forth in the Revolving Credit Agreement. As a result, our access to credit under the Credit Agreements is subject to the discretion of MidCap and the lenders as well as fluctuations to our accounts receivable and inventory. Our inability to borrow additional amounts under the Credit Agreements if and when we need them may adversely affect our liquidity, results of operations, and financial condition.

 

Our outstanding indebtedness under the Credit Agreements bears interest at variable rates, which subjects us to interest rate risk and could increase the cost of servicing our indebtedness. The impact of increases in interest rates could be more significant for us than it would be for some other companies because of the amount of our outstanding indebtedness, thereby affecting our profitability. Upon the occurrence and during the continuance of an event of default under the Credit Agreements, MidCap may terminate its commitments to lend additional money thereunder and declare all amounts outstanding thereunder to be immediately due and payable. Subject to certain exceptions, amounts outstanding under the Credit Agreements are secured by a senior first priority security interest in substantially all existing and after-acquired assets of our Company and each borrower. Accordingly, under certain circumstances, MidCap could seek to enforce security interests in our assets securing our indebtedness under the Credit Agreements, including restricting our access to collections on our accounts receivable. Any acceleration of amounts due under our Credit Agreements or the exercise by MidCap of its rights under the security documents, would have a material adverse effect on us.

 

We may be unable to meet financial or other covenant requirements in our Credit Agreements, and we may be unable to successfully negotiate waivers to cure any covenant violations.

 

Our Credit Agreements contain representations, warranties, fees, affirmative and negative covenants, including a minimum liquidity covenant and substantial operating covenants, and default provisions. A breach of any of these covenants could result in a default under the agreement. Upon the occurrence and during the continuance of an event of default under the Credit Agreements, MidCap could elect to declare all amounts outstanding under the credit facility to be immediately due and payable and suspend or terminate all commitments to extend further credit. If MidCap accelerates the repayment of borrowings, we may not have sufficient assets to repay our indebtedness. Also, should there be an event of default, or should we need to obtain waivers following an event of default, we may be subject to higher borrowing costs and/or more restrictive covenants in future periods. In addition, to secure the performance of our obligations under the Credit Agreements, we pledged substantially all of our assets, including our intellectual property, to MidCap and the lenders. Our failure to comply with the covenants under the Credit Agreements could result in an event of default, the acceleration of our debt and the loss of our assets.

 

43
 

 

The anticipated replacement of the LIBOR benchmark interest rate could affect interest rates under our Credit Agreements, which may adversely impact our business, operating results and financial condition.

 

In July 2017, the United Kingdom’s Financial Conduct Authority (“FCA”), which regulates the London Interbank Offered Rate (“LIBOR”), which is widely used as a reference for setting the interest rates on loans, announced its intention to phase out LIBOR by the end of 2021. On November 30, 2020 the ICE Benchmark Administration (“IBA”), with the support of the United States Federal Reserve and the FCA, announced its intention to extend publication of most U.S. dollar LIBOR tenors to June 30, 2023. On March 5, 2021, IBA confirmed it would cease publication of Overnight, 1, 3, 6 and 12 month U.S. dollar LIBOR tenors immediately following the LIBOR publication on June 30, 2023. IBA also ceased publishing 1 Week and 2 Month USD LIBOR settings immediately following the LIBOR publication on December 31, 2021. The U.S. Federal Reserve, in conjunction with the Alternative Reference Rates Committee, a steering committee comprised of large U.S. financial institutions, is considering replacing LIBOR with the Secured Overnight Financing Rate (“SOFR”), a new index calculated based on transactions in the market for short-term treasury securities.

 

If LIBOR ceases to exist before our Credit Agreements are terminated, MidCap may choose to replace LIBOR with a reasonably comparable index or source together with corresponding adjustments to the applicable margin or scale factor, spread adjustment or floor such that the new index preserves the current all-in yield as the basis of such margin, consistent with such determinations made by MidCap with respect to other arrangements in which it serves in a similar capacity. The result of this adjustment may cause us to attempt to renegotiate the Credit Agreements, since borrowings thereunder are indexed to LIBOR. Any such adjustment or renegotiation may increase or otherwise affect interest rates under our Credit Agreements. We are evaluating the potential impact of the eventual replacement of LIBOR, including the possibility of SOFR as the dominant replacement. However, we are not able to predict whether LIBOR will cease to be available after June 30, 2023, the effective of any replacement for LIBOR that may be chosen by MidCap, whether SOFR will become a widely accepted benchmark in place of LIBOR and if so, whether it will be chosen by MidCap as the replacement for LIBOR, or what the impact of a transition from LIBOR may be on our business, results of operations and financial condition.

 

Risks Related to Intellectual Property

 

If we lose any future intellectual property lawsuits, a court could require us to pay significant damages or prevent us from selling our products.

 

The medical device industry is litigious with respect to patents and other intellectual property rights. Companies in the medical device industry have used intellectual property litigation to gain a competitive advantage. Legal proceedings, regardless of the outcome, could drain our financial resources and divert the time and effort of our management. If we lose this litigation or any other similar legal proceedings of which we may become subject, a court could require us to pay significant damages to third parties, indemnify third parties from loss, require us to seek licenses from third parties, pay ongoing royalties, redesign our products, or prevent us from manufacturing, using, selling, offering for sale, or importing our products. While we do not believe that any of our products infringe any valid claims of patents or other proprietary rights held by others, we have been subject to patent infringement claims in the past. There can be no assurances that we do not infringe any patents or other proprietary rights. In addition to being costly, protracted litigation to defend or prosecute our intellectual property rights could result in our customers or potential customers deferring or limiting their purchase or use of the affected products until resolution of the litigation.

 

If our patents and other intellectual property rights do not adequately protect our products, we may lose market share to our competitors and be unable to operate our business profitably.

 

We rely on patents, trade secrets, copyrights, know-how, trademarks, license agreements, and contractual provisions to establish our intellectual property rights and protect our products. These legal means, however, afford only limited protection and may not completely protect our rights. For example, competitors may be able to design around some of our intellectual property rights to develop competing but non-infringing technologies. In addition, we cannot be assured that any of our pending patent applications will issue. The U.S. Patent and Trademark Office (or an applicable foreign intellectual property office) may deny or require a significant narrowing of the claims in its pending patent applications and the patents issuing from such applications. Any patents issuing from pending patent applications may not provide us with significant commercial protection or sufficient commercial protection to prevent competitors from utilizing similar but non-infringing technologies. We could incur substantial costs in proceedings before the U.S. Patent and Trademark Office. These proceedings could result in adverse decisions as to the priority of our inventions and the narrowing or invalidation of claims in issued patents. In addition, the laws of some of the countries in which our products are or may be sold may not protect our intellectual property to the same extent as U.S. laws or at all. We also may be unable to protect our rights in trade secrets and unpatented proprietary technology in these countries. Additionally, patents and certain other intellectual property rights are not perpetual, and third parties will be able to utilize the subject rights upon expiration.

 

44
 

 

In addition, we hold licenses from third parties that are necessary to utilize certain technologies used in the design and manufacturing of some of our products. The loss of such licenses could prevent us from manufacturing, marketing, and selling these products, which could harm our business. If we, or the other parties from whom we would license intellectual property, fail to obtain and maintain adequate patent or other intellectual property protection for intellectual property used in our products, or if any protection is reduced or eliminated, others could use the intellectual property used in our products, resulting in harm to our competitive business position.

 

We seek to protect our trade secrets, know-how, and other unpatented proprietary technology, in part, with confidentiality agreements with our employees, independent distributors, and consultants. We cannot be assured, however, that the agreements will not be breached, adequate remedies for any breach would be available, or our trade secrets, know-how, and other unpatented proprietary technology will not otherwise become known to or independently developed by our competitors.

 

We may not be able to obtain or protect our proprietary rights relating to our products without resorting to costly and time-consuming litigation.

 

We may not be able to obtain, maintain and protect certain proprietary rights necessary for the development and commercialization of our products or product candidates. Our commercial success will depend in part on obtaining and maintaining patent protection on our products, successfully asserting these patents against competitors employing infringing technology, and successfully defending these patents against third-party challenges. Even if our patents cover a competing technology, a competitor may not accede to our demands to cease and desist or license our patent rights, which will then require us to pursue costly and time-consuming litigation. Even if we were successful in any such litigation, a court may not issue an injunction, or the infringing competitor may alter its technology to no longer infringe. Our ability to commercialize our products will also depend in part on the patent positions of third parties, including those of our competitors. The patent positions of medical device and biotechnology companies can be highly uncertain and involve complex legal and factual questions. Accordingly, we cannot predict with certainty the scope and breadth of patent claims that may be afforded to other companies’ patents. We could incur substantial costs in litigation if we are required to defend against patent suits brought by third parties, or if we initiate suits to protect our patent rights. Such suits that we may need to defend extend beyond suits by our competitors and may include patent assertion entities, which acquire and assert patents as a means to generate income, due to the expensive nature of patent litigation. In the ordinary course of litigation, attorney fees are not recoverable.

 

In addition to the risks involved with patent protection, we also face the risk that our competitors will infringe on our trademarks. Any infringement could lead to a likelihood of confusion and could result in lost sales. Similarly, while we are cautious to avoid infringing the rights of third parties, we cannot control a third party asserting its trademarks against us. There can be no assurance that we will prevail in any claims we make to protect our intellectual property, or in defense of any claims brought against us.

 

Future protection for our proprietary rights is uncertain which may impact our ability to successfully compete in our industry. The degree of future protection for our proprietary rights is uncertain. We cannot ensure that:

 

●we were the first to make the inventions covered by each of our patent applications;

 

●we were the first to file patent applications for these inventions;

 

●others will not independently develop similar or alternative technologies or duplicate any of our technologies;

 

●any of our pending patent applications will result in issued patents;

 

●any of our issued patents or those of our licensors will be valid and enforceable;

 

45
 

 

●any patents issued to us or our collaborators will provide a basis for commercially viable products or will provide us with any competitive advantages or will not be challenged by third parties;

 

●any of our patent or other intellectual property rights in the U.S. and the technologies embodied therein will provide or be subject to similar or any protection in foreign markets;

 

●we will develop additional proprietary technologies that are patentable;

 

●the patents of others will not have a material adverse effect on our business rights; or

 

●the measures we rely on to protect the intellectual property underlying our products will be adequate to prevent third parties from using our technology, all of which could harm our ability to compete in the market.

 

Risks Related to Information Technology, Cybersecurity and Data Protection

 

We are dependent on various information technology (“IT”) systems, and failures of, interruptions to, or unauthorized tampering with those systems could have a material adverse effect on our business.

 

We rely extensively on IT systems to conduct business. Our reliance on IT systems increased as work from home arrangements were necessitated by the COVID-19 pandemic. These systems include, but are not limited to, ordering and managing materials from suppliers, converting materials to finished products, invoicing and shipping products to customers, processing transactions, summarizing and reporting results of operations, complying with regulatory, legal or tax requirements, and providing data security and other processes necessary to manage our business.

 

In addition, if our systems are damaged or cease to function properly due to any number of causes, ranging from catastrophic events to power outages to security breaches, and our business continuity plans do not effectively compensate for this on a timely basis, we may suffer interruptions in our ability to manage operations. Increased global cybersecurity vulnerabilities, threats and more sophisticated and targeted cybersecurity attacks pose a risk to the security of our systems and networks and those of our customers, suppliers, independent sales agents, distributors and third-party service providers, and the confidentiality, availability and integrity of any underlying information and data. Work from home arrangements may increase cybersecurity risks related to phishing, malware, and other similar cybersecurity attacks. We have programs, processes and technologies in place to prevent, detect, contain, respond to and mitigate security related threats and potential incidents. We undertake considerable ongoing improvements to our IT systems in order to minimize vulnerabilities, in accordance with industry and regulatory standards. Because the techniques used to obtain unauthorized access change frequently and can be difficult to detect, anticipating, identifying or preventing these intrusions or mitigating them if and when they occur may be challenging. During 2021, one of our employees was the victim of phishing scheme and as a result we paid three fraudulent invoices. Although the amount involved was immaterial, management brought the matter to the attention of the Audit Committee of the Board of Directors and immediately implemented a remediation plan in response thereto. Despite the remediation plan, no assurance can be provided that we will not become subject to another or similar attack, especially when our cybersecurity protection is dependent at least to some extent on the lack of human error.

 

Our IT systems require an ongoing commitment of significant resources to maintain, protect and enhance existing systems and develop new systems to keep pace with continuing changes in information processing technology, evolving systems and regulatory standards. We also outsource certain elements of our IT systems to third parties that, as a result of this outsourcing, could have access to certain confidential information and whose systems may also be vulnerable to these types of attacks or disruptions. There can be no assurance that our protective measures or those of these third parties will prevent or detect security breaches that could have a significant impact on our business, reputation, operating results and financial condition. The failure of these systems to operate or integrate effectively with other internal, customer, supplier or third-party service provider systems and to protect the underlying IT system and data integrity, including from cyber-attacks, intrusions or other breaches or unauthorized access of these systems, or any failure by us to remediate any such attacks or breaches, may also result in damage to our reputation or competitiveness, delays in product fulfillment and reduced efficiency of our operations, and could require significant capital investments to remediate any such failure, problem or breach, all of which could adversely affect our business, operating results and financial condition. We maintain cyber liability insurance; however, this insurance may not be sufficient to cover the financial, legal, business or reputational losses that may result from an interruption or breach of our systems.

 

46
 

 

Our current enterprise resource planning (“ERP”) system is outdated and in need of a, upgrade or conversion to a new ERP system.

 

Although we have made upgrades to our ERP system, it is still outdated and in need of significant additional upgrades or conversion to a new ERP system. Implementing new or upgraded systems carries substantial risk, including failure to operate as designed, failure to properly integrate with our systems, potential loss of data or information, cost overruns, implementation delays, and disruption of operations. Third-party vendors are also relied upon to design, program, maintain, and service the ERP system. Any failures of these vendors to properly deliver their services could have a material adverse effect on our business. In addition, any disruptions or malfunctions affecting our ERP system implementation plan could cause critical information upon which we rely to be delayed, defective, corrupted, inadequate, or inaccessible. We may experience difficulties in our business operations, or difficulties in operating our business under these systems, either of which could disrupt our operations, including our ability to timely invoice customers, ship and track product orders, project inventory requirements, manage our supply chain, effectively manage customer accounts receivable and pay suppliers within terms and otherwise adequately service our customers, and could lead to increased costs and other difficulties. In the event we experience significant disruptions as a result of the implementation or upgrade of new systems or otherwise, we may not be able to fix our systems in an efficient and timely manner. We may not realize the benefits we anticipate should all or part of the ERP system upgrade implementation process prove to be ineffective. Accordingly, such events may disrupt or reduce the efficiency of our entire operations and have a material adverse effect on our operating results and cash flows.

 

Risks Related to Our Controlled Company Status

 

Funds affiliated with OrbiMed own a significant percentage of our common stock, have the right to designate a majority of our Board of Directors, and are able to exert significant control over matters subject to stockholder approval, preventing other stockholders and new investors from influencing significant corporate decisions.

 

ROS and Royalty Opportunities collectively owned approximately 84% of our outstanding common stock as of December 31, 2021. We are party to an Investor Rights Agreement with ROS and Royalty Opportunities under which they are permitted to nominate a majority of the directors and designate the chairperson of our Board of Directors at subsequent annual meetings, as long as they maintain an ownership threshold in our Company of at least 40% of our then outstanding common stock. If ROS and Royalty Opportunities are unable to maintain this ownership threshold, the Investor Rights Agreement contemplates a reduction of nomination rights commensurate with their ownership interests. In addition, under the Investor Rights Agreement, for so long as the ownership threshold is met, we must obtain the approval of a majority of our common stock held by ROS and Royalty Opportunities to proceed with the following actions: (i) issue new securities; (ii) incur over $250,000 of debt in a fiscal year; (iii) sell or transfer over $250,000 of our assets or businesses or our subsidiaries in a fiscal year; (iv) acquire over $250,000 of assets or properties in a fiscal year; (v) make capital expenditures over $125,000 individually, or $1,500,000 in the aggregate during a fiscal year; (vi) approve our annual budget; (vii) hire or terminate our chief executive officer; (viii) appoint or remove the chairperson of our Board of Directors; and (ix) make loans to, investments in, or purchase, or permit any subsidiary to purchase, any stock or other securities in another entity in excess of $250,000 in a fiscal year. As long as the ownership threshold is met, we may not increase the size of our Board of Directors beyond seven directors without the approval of a majority of the directors nominated by ROS and Royalty Opportunities. The Investor Rights Agreement also grants ROS and Royalty Opportunities the right to purchase from us a pro rata amount of any new securities that we may propose to issue and sell.

 

47
 

 

Because of their significant share ownership and control, OrbiMed has the ability to exert substantial influence or actual control over our management and affairs and over substantially all matters requiring action by our stockholders and Board of Directors, including amendments to our Charter, Second Amended and Restated Bylaws (“Bylaws”), election and removal of directors, the appointment of management, future issuances of our common stock or other securities, payment of dividends, if any, on our common stock, the incurrence or modification of indebtedness by us, any proposed merger, consolidation or sale of all or substantially all of our assets and other corporate transactions, as well as certain day-to-day decisions involved in operating our business, such as annual operating plans, capital expenditures and other investments in our business. The interests of OrbiMed may not necessarily in all cases be aligned with management’s views on the operation of our business or the interests of our other stockholders. In addition, OrbiMed and their affiliates may have an interest in pursuing acquisitions, divestitures and other transactions or not pursuing such transactions that, in their judgment, could enhance or reduce their investment, even though such transactions might involve risks to our other stockholders. For example, OrbiMed could cause us to make acquisitions that increase our indebtedness or cause us to sell revenue-generating assets. In addition, OrbiMed and their affiliates are able to determine the outcome of all matters requiring stockholder approval and are able to cause or prevent a change of control of our Company or a change in the composition of our Board of Directors and could preclude any acquisition of our Company. This concentration of voting control could deprive our other stockholders of an opportunity to receive a premium for their shares of common stock as part of a sale of our Company and ultimately might affect the market price of our common stock.

 

We are a “controlled company” within the meaning of the NYSE American rules and rely on exemptions from various corporate governance requirements that provide protection to stockholders of other companies.

 

We are a “controlled company” as defined in section 801(a) of the NYSE American Company Guide because more than 50% of the combined voting power of all of our outstanding common stock is beneficially owned by OrbiMed Advisors LLC. As a “controlled company,” we are exempt from certain NYSE American rules requiring our Board of Directors to have a majority of independent members, a compensation committee composed entirely of independent directors and a nominating committee composed entirely of independent directors. These independence standards are intended to ensure that directors who meet those standards are free of any conflicting interest that could influence their actions as directors. We rely on NYSE American’s controlled company exemptions and do not have a majority of independent directors on the Board of Directors, an independent nomination and governance committee or an independent compensation committee. Accordingly, our stockholders do not have the same protections afforded to stockholders of companies that are subject to all of the corporate governance requirements of the NYSE American rules.

 

Risks Related to Our Common Stock

 

Shares of our common stock are equity securities and are subordinate to our outstanding indebtedness.

 

Shares of our common stock are common equity interests. This means that our common stock will rank junior to any outstanding shares of our preferred stock that we may issue in the future or to the indebtedness under our Credit Agreements and any future indebtedness we may incur and to all creditor claims and other non-equity claims against us and our assets available to satisfy claims on us, including claims in a bankruptcy or similar proceeding. Additionally, unlike indebtedness, where principal and interest customarily are payable on specified due dates, in the case of our common stock, (i) dividends are payable only when and if declared by our Board of Directors, and (ii) as a corporation, we are restricted to making dividend payments and redemption payments out of legally available assets. We have never paid a dividend on our common stock and have no current intention to pay dividends in the future. In addition, our Credit Agreements preclude us from paying dividends. Furthermore, our common stock places no restrictions on our business or operations or on our ability to incur indebtedness or engage in any transactions, subject only to the voting rights available to stockholders generally.

 

Our inability to comply with the continued listing requirements of the NYSE American could result in our common stock being delisted, which could affect its market price and liquidity and reduce our ability to raise capital.

 

We are required to meet certain qualitative and financial tests to maintain the listing of our common stock on the NYSE American. If we do not maintain compliance with the continued listing requirements for the NYSE American within specified periods and subject to permitted extensions, our common stock may be recommended for delisting (subject to any appeal we would file). On October 5, 2020, we regained compliance with these continued listing requirements as a result of the completion of our August 2020 debt restructuring. No assurance can be provided that we will continue to comply with these continued listing requirements, especially in light of the significant decrease in the value of our common stock during the past year. If our common stock were delisted, it could be more difficult to buy or sell our common stock and to obtain accurate quotations, and the price of our stock could suffer a material decline. Delisting would also impair our ability to raise capital.

 

48
 

 

The market price of our common stock is extremely volatile, which may affect our ability to raise capital in the future and may subject the value of the investment of our stockholders to sudden decreases.

 

The market price for securities of medical device and biotechnology companies, including ours, historically has been highly volatile, and the market from time to time has experienced significant price and volume fluctuations that are unrelated to the operating performance of such companies. The trading volume and prices of our common stock have been and may continue to be volatile and could fluctuate widely due to factors both within and beyond our control. During 2021, the sale price of our common stock ranged from $0.56 to $6.58 per share, and our daily trading volume ranged from 12.9 thousand to 218.8 million shares. Such volatility may be the result of broad market and industry factors. Future fluctuations in the trading price or liquidity of our common stock may harm the value of the investment of our stockholders in our common stock. Factors that may have a significant impact on the market price and marketability of our common stock include, among others:

 

●the terms of any potential future transaction(s) related to debt financing, debt restructuring or capital raising;

 

●our ability to make interest payments under our Credit Agreements;

 

●our observance of covenants under our Credit Agreements;

 

●announcements of technological innovations or new commercial products by us or our present or potential competitors;

 

●developments or disputes concerning patent or other proprietary rights;

 

●developments in our relationships with employees, suppliers, distributors, sales representatives and customers;

 

●acquisitions or divestitures;

 

●litigation and government proceedings;

 

●adverse legislation, including changes in governmental regulation;

 

●third-party reimbursement policies;

 

●additions or departures of key personnel;

 

●sales of our equity securities by our significant stockholders or management or sales of additional equity securities by our Company;

 

●changes in securities analysts’ recommendations;

 

●short selling;

 

●changes in health care policies and practices;

 

●the delisting of our common stock or halting or suspension of trading in our common stock by the NYSE American;

 

49
 

 

●economic, social and other external factors, such as the COVID-19 pandemic, supply chain disruptions, labor shortages and persistent inflation; and

 

●general market conditions.

 

In the past, following periods of volatility in the market price of a company’s securities, securities class action litigation has often been instituted. These lawsuits often seek unspecified damages, and as with any litigation proceeding, one cannot predict with certainty the eventual outcome of pending litigation. Furthermore, we may have to incur substantial expenses in connection with any such lawsuits and our management’s attention and resources could be diverted from operating our business as we respond to any such litigation. We maintain insurance to cover these risks for us and our directors and officers, but our insurance is subject to high deductibles to reduce premium expense, and there is no guarantee that the insurance will cover any specific claim that we currently face or may face in the future, or that it will be adequate to cover all potential liabilities and damages.

 

We may issue additional common stock resulting in stock ownership dilution.

 

Future dilution may occur due to additional future equity issuances and/or equity financing events by us, including any potential future restructuring of our outstanding indebtedness. In addition, we may raise additional capital through the sale of equity or convertible debt securities, which would further dilute the ownership interests of our stockholders. As of December 31, 2021, we had outstanding warrants to purchase approximately 7,111,112 shares of our common stock, stock options to purchase 3,188,355 shares of our common stock and restricted stock unit awards covering 2,970,104 shares of our common stock under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan, options to purchase 13,311 shares of our common stock under our prior equity compensation plan, and 1,246,080 shares available for issuance under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan. If these or any future warrants, options or restricted stock units are exercised or otherwise converted into shares of our common stock, our stockholders will experience additional dilution.

 

The sale or availability for sale of substantial amounts of our common stock or other equity securities could adversely affect the market price of our common stock.

 

Sales of substantial amounts of our common stock or a preferred stock in the public market, or the perception that these sales could occur, could adversely affect the market price of our common stock and could materially impair our ability to raise capital through equity offerings in the future. We cannot predict what effect, if any, market sales of securities beneficially owned by OrbiMed or any other stockholder or the availability of these securities for future sale will have on the market price of our common stock.

 

Anti-takeover provisions in our organizational documents and agreements may discourage or prevent a change in control, even if a sale of the Company could be beneficial to our stockholders, which could cause our stock price to decline and prevent attempts by our stockholders to replace or remove our current management.

 

Several provisions of our Charter and Bylaws and our Investor Rights Agreement could make it difficult for our stockholders to change the composition of our Board of Directors, preventing them from changing the composition of management. In addition, several provisions of our Charter and Bylaws may discourage, delay or prevent a merger or acquisition that our stockholders may consider favorable. These provisions include:

 

●We have shares of common stock and preferred stock available for issuance without stockholder approval. The existence of unissued and unreserved common stock and preferred stock may enable the Board of Directors to issue shares to persons friendly to current management or to issue preferred stock with terms that could render more difficult or discourage a third-party attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise, thereby protecting the continuity of our management.

 

●Shares of our common stock do not have cumulative voting rights in the election of directors, so our stockholders holding a majority of the shares of common stock outstanding will be able to elect all of our directors.

 

50
 

 

●Special meetings of the stockholders may be called only by the Board of Directors, the chairman of the Board of Directors or the chief executive officer.

 

●The Board of Directors may adopt, alter, amend or repeal our Bylaws without stockholder approval.

 

●Unless otherwise provided by law, any newly created directorship or any vacancy occurring on the Board of Directors for any cause may be filled by the affirmative vote of a majority of the remaining members of the Board of Directors even if such majority is less than a quorum, and any director so elected shall hold office until the expiration of the term of office of the director whom he or she has replaced or until his or her successor is elected and qualified.

 

●The affirmative vote of the holders of at least two-thirds of the voting power of the then outstanding shares of our capital stock entitled to vote generally in the election of directors, voting together as a single class, is required to amend or repeal the provisions of our Charter related to the amendment of our Bylaws, the Board of Directors and our stockholders as well as the general provisions of our Charter.

 

●Stockholders must follow advance notice procedures to submit nominations of candidates for election to the Board of Directors at an annual or special meeting of our stockholders and must follow advance notice procedures to submit other proposals for business to be brought before an annual meeting of our stockholders.

 

●Unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware will be the exclusive forum for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee to us or our stockholders, (iii) any action asserting a claim arising under any provision of the General Corporation Law of the State of Delaware, our Charter or our Bylaws, or (iv) any action asserting a claim governed by the internal-affairs doctrine.

 

●The Investor Rights Agreement includes director nomination rights, which provide that so long as the Ownership Threshold (as defined in the Investor Rights Agreement) is met, Royalty Opportunities and ROS are entitled to nominate such individuals to the Board of Directors constituting a majority of the directors. In addition, under the Investor Rights Agreement, so long as the Ownership Threshold is met, certain matters require the approval of Royalty Opportunities and ROS to proceed with such a transaction, including without limitation, the sale, transfer or other disposition of our assets or businesses or our subsidiaries with a value in excess of $250,000 in the aggregate during any fiscal year (other than sales of inventory or supplies in the ordinary course of business, sales of obsolete assets (excluding real estate), sale-leaseback transactions and accounts receivable factoring transactions).

 

These anti-takeover provisions could substantially impede the ability of our stockholders to benefit from a change in control and, as a result, could materially adversely affect the market price of our common stock and the ability of our stockholders to realize any potential change-in-control premium.

 

Our Board of Directors is authorized to issue and designate shares of our preferred stock without stockholder approval.

 

Our Charter authorizes our Board of Directors, without the approval of our stockholders, to issue up to 10 million shares of our preferred stock, subject to limitations prescribed by applicable law, rules and regulations and the provisions of our Charter, as shares of preferred stock in series, to establish from time to time the number of shares to be included in each such series and to fix the designation, powers, preferences and rights of the shares of each such series and the qualifications, limitations or restrictions thereof. The powers, preferences and rights of these series of preferred stock may be senior to or on parity with our common stock, which may reduce its value.

 

51
 

 

Our Charter designates the Court of Chancery of the State of Delaware as the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit the ability of our stockholders to obtain a favorable judicial forum for disputes with us.

 

Our Charter provides that the Court of Chancery of the State of Delaware will be the exclusive forum for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of a fiduciary duty owed to us or our stockholders by any of our directors, officers, or other employees, (iii) any action asserting a claim against us arising under the Delaware General Corporation Law (“DGCL”) or (iv) any action asserting a claim against us that is governed by the internal affairs doctrine. Stockholders in our Company will be deemed to have notice of and have consented to the provisions of our Charter related to choice of forum. The choice of forum provision in our Charter may limit the ability of our stockholders to obtain a favorable judicial forum for disputes with us.

 

Notwithstanding the foregoing, Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder and Section 22 of the Securities Act of 1933, as amended (the “Securities Act”), creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. As a result, the exclusive forum provision will not apply to suits brought to enforce any duty or liability created by the Exchange Act, the Securities Act, or any other claim for which the federal courts have exclusive jurisdiction.

 

We have never paid dividends and do not expect to do so in the foreseeable future.

 

We have not declared or paid any cash dividends on our common stock. The payment of dividends in the future will be dependent on our earnings and financial condition and on such other factors as our Board of Directors considers appropriate. Unless and until we pay dividends, stockholders may not receive a return on their shares of our common stock. There is no present intention by our Board of Directors to pay dividends on our common stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. In addition, the terms of our Credit Agreements preclude us from paying dividends. As a result, appreciation, if any, in the market price of our common stock will be the sole source of gain for our stockholders for the foreseeable future.

 

General Risk Factors

 

Worldwide economic and social instability could adversely affect our revenue, financial condition, or results of operations.

 

The health of the global economy, and the credit markets and the financial services industry in particular, as well as the stability of the social fabric of our society, affects our business and operating results. For example, the credit and financial markets may be adversely affected by the current conflict between Russia and Ukraine and measures taken in response thereto. If the credit markets are not favorable, we may be unable to raise additional financing when needed or on favorable terms. Our customers may experience financial difficulties or be unable to borrow money to fund their operations, which may adversely impact their ability to purchase our products or to pay for our products on a timely basis, if at all. In addition, adverse economic conditions, such as the recession caused by the COVID-19 pandemic, recent supply chain disruptions and labor shortages and persistent inflation, could also adversely impact our suppliers’ ability to provide us with materials and components, which may negatively impact our business. As with our customers and vendors, these economic conditions make it more difficult for us to accurately forecast and plan our future business activities.

 

Climate change, or legal, regulatory or market measures to address climate change, may materially adversely affect our financial condition and business operations.

 

Climate change resulting from increased concentrations of carbon dioxide and other greenhouse gases in the atmosphere could present risks to our future operations from natural disasters and extreme weather conditions, such as hurricanes, tornadoes, wildfires or flooding. Concern over climate change could result in new legal or regulatory requirements designed to reduce or mitigate the effects of greenhouse gases, as well as more stringent regulation of water rights. Inconsistency of regulations in the states in which we operate may affect the costs of compliance with such legal or regulatory requirements.

 

52
 

 

In addition, public company stockholders are increasingly sensitive to the climate change impacts and mitigation efforts of companies, are increasingly seeking enhanced disclosure on the risks, challenges, governance implications, and financial impacts of climate change faced by companies and are demanding that companies take a proactive approach to addressing perceived environmental risks, including risks associated with climate change, relating to their operations. Adverse publicity or climate-related litigation that impacts us could have a negative impact on our business.

 

Changes in accounting standards, policies, or assumptions utilized in determining accounting estimates could adversely affect our financial statements, including our operating results and financial condition.

 

In preparing our consolidated financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”), we must make decisions that impact our results of operations and/or financial condition. Such decisions include the selection of the appropriate accounting principles to be applied and the assumptions on which to base accounting estimates. In reaching such decisions, we apply judgments based on our understanding and analysis of the relevant circumstances, historical experience, and expert valuations, as appropriate. As a result, actual amounts could differ from those estimated at the time our consolidated financial statements are prepared. Our critical accounting estimates are described later in this report under Part II. Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations. In addition, various authoritative accounting or regulatory entities, including the Financial Accounting Standards Board (“FASB”), , and the SEC may amend, expand, and/or eliminate the financial accounting or reporting standards that govern the preparation of our consolidated financial statements or could reverse their previous interpretations or positions on how various financial accounting and/or reporting standards should be applied. We disclose the impact of accounting pronouncements that have been issued but not yet adopted within our Annual and Quarterly Reports on Form 10-K and Form 10-Q, respectively. However, we do not provide an assessment of proposed accounting pronouncements, as such proposals are subject to change through the exposure process and therefore, we cannot meaningfully assess their effects on our consolidated financial statements. Future changes to accounting standards could modify the accounting policies and procedures that are currently utilized in the preparation of our consolidated financial statements. Such changes may be difficult to predict and implement and could materially, or otherwise, impact how we prepare and report our consolidated financial statements, results of operations, and financial condition.

 

The requirements of being a public company, including compliance with the reporting requirements of the Exchange Act and the requirements of the Sarbanes-Oxley Act and the NYSE American, may strain our resources, increase our costs and divert management’s attention, and we may be unable to comply with these requirements in a timely or cost-effective manner.

 

As a public company, we are subject to the reporting requirements of the Exchange Act and the corporate governance standards of the Sarbanes-Oxley Act and the NYSE American. These requirements place a strain on our management, systems and resources and we will continue to incur significant legal, accounting, insurance and other expenses. The Exchange Act requires us to file annual, quarterly and current reports with respect to our business and financial condition within specified time periods and to prepare a proxy statement with respect to our annual meeting of stockholders. The Sarbanes-Oxley Act requires that we maintain effective disclosure controls and procedures and internal controls over financial reporting. The NYSE American requires that we comply with various corporate governance requirements. To maintain and improve the effectiveness of our disclosure controls and procedures and internal controls over financial reporting and comply with the Exchange Act and NYSE American requirements, significant resources and management oversight are required. This may divert management’s attention from other business concerns and lead to significant costs associated with compliance, which could have a material adverse effect on us and the market price of our common stock. Furthermore, as we grow our business both organically and through acquisitions, our disclosure controls and procedures and internal control over financial reporting will become more complex, and we may require significantly more resources to ensure that these controls and procedures remain effective.

 

53
 

 

These laws and regulations could also make it more difficult or costly for us to obtain certain types of insurance, including director and officer liability insurance, and we may be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. These laws and regulations could also make it more difficult for us to attract and retain qualified persons to serve on our Board of Directors or its committees or as our executive officers. Advocacy efforts by stockholders and third parties may also prompt even more changes in governance and reporting requirements. We cannot predict or estimate the amount of additional costs we may incur or the timing of these costs. Furthermore, if we are unable to satisfy our obligations as a public company, we could be subject to delisting of our common stock, fines, sanctions and other regulatory action and potentially civil litigation.

 

Increasing scrutiny and evolving expectations from customers, regulators, investors, and other stakeholders with respect to our environmental, social and governance practices may impose additional costs on us or expose us to new or additional risks.

 

Companies are facing increasing scrutiny from customers, regulators, investors, and other stakeholders related to their environmental, social and governance (“ESG”) practices and disclosure. Investor advocacy groups, investment funds and influential investors are also increasingly focused on these practices, especially as they relate to the environment, climate change, health and safety, supply chain management, diversity, labor conditions and human rights, both in our own operations and in our supply chain. Increased ESG-related compliance costs could result in material increases to our overall operational costs. Our ESG practices may not meet the standards of all of our stakeholders and advocacy groups may campaign for further changes. A failure, or perceived failure, to adapt to or comply with regulatory requirements or to respond to investor or stakeholder expectations and standards could negatively impact our business and reputation and have a negative impact on the trading price of our common stock.

 

Item 1B. Unresolved Staff Comments

 

None.

 

Item 2. Properties

 

Our headquarters and manufacturing facility are located at 664 Cruiser Lane, Belgrade, Montana 59714. We also have two other facilities on the Montana campus, located at 600 Cruiser Lane, Belgrade, Montana 59714, and at 732 Cruiser Lane, Belgrade, Montana 59714. All our properties are leased.

 

We lease an approximately 14,000 square foot facility at 664 Cruiser Lane, Belgrade, Montana, which runs through October 2025. This building is an FDA registered facility with a Class 10,000 (ISO 7) environmentally controlled area. The validated manufacturing areas and laboratory facilities located in this facility provide processing, final packaging and testing space to manufacture medical devices pursuant to FDA, GMP regulations, and ISO 13485:2003. The facility is registered with the FDA for device design, device manufacture, and contract manufacture, as well as for screening, testing, storing, and distributing biological tissues. We also lease approximately 17,700 square feet in a building located at 600 Cruiser Lane, Belgrade, Montana. This space includes six Class 100 (ISO 5) clean rooms, a fully equipped diagnostics laboratory, microbiology laboratory and testing laboratory. We lease the building under a ten-year operating lease which runs through August 2023 and has a ten-year renewal option. We also lease approximately 21,000 square feet in a building located at 732 Cruiser Lane, Belgrade, Montana, where one Class 1,000 (ISO 6) clean room is located, which runs through January 2024.

 

In addition to our facilities in Belgrade, Montana, we lease approximately 100 square feet of office space in Minnetonka, Minnesota.

 

Item 3. Legal Proceedings

 

Our legal proceedings are discussed in Note 11 – Commitments and Contingencies in the notes to our consolidated financial statements in this Form 10-K.

 

Item 4. Mine Safety Disclosures

 

Not applicable.

 

54
 

 

PART II

 

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

 

Market Information

 

Our common stock is listed on the NYSE American under the ticker symbol “XTNT.”

 

Holders of Record

 

As of March 8, 2022, we had 173 holders of record.

 

Dividends

 

We have not paid any cash dividends and do not expect to do so in the foreseeable future. In addition, our credit agreements with MidCap preclude us from paying dividends.

 

Recent Sales of Unregistered Securities

 

We did not sell any unregistered equity securities of our Company during the quarter ended December 31, 2021.

 

Purchases of Equity Securities by the Issuer and Affiliated Purchasers

 

We did not purchase any shares of our common stock or other equity securities of our Company during the quarter ended December 31, 2021.

 

Item 6. Reserved

 

55
 

 

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

This Management’s Discussion and Analysis provides material historical and prospective disclosures intended to enable investors and other users to assess our financial condition and results of operations. The following discussion should be read in conjunction with our consolidated financial statements and accompanying notes included in this Annual Report on Form 10-K. In addition to historical financial information, the following discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Some of the numbers included herein have been rounded for the convenience of presentation. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of many factors, including those discussed in the “Cautionary Statement Regarding Forward-Looking Statements” and under the heading “Part I. Item 1A. Risk Factors.”

 

Business Overview

 

We develop, manufacture and market regenerative medicine products and medical devices for domestic and international markets. Our products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease. We promote our products in the United States through independent distributors and stocking agents, supported by direct employees.

 

We have an extensive sales channel of independent commissioned agents and stocking distributors in the United States representing some or all of our products. We also maintain a national accounts program to enable our agents to gain access to integrated delivery network hospitals (“IDNs”) and through group purchasing organizations (“GPOs”). We have biologics contracts with major GPOs, as well as extensive access to IDNs across the United States for both biologics and spine hardware systems. While our focus is the United States market, we promote and sell our products internationally through stocking distribution partners in Canada, Mexico, South America, Australia, and certain Pacific region countries.

 

We have focused and intend to continue to focus primarily on four key growth initiatives: (1) introduce new products; (2) expand our distribution network; (3) penetrate adjacent markets; and (4) leverage our growth platform with technology and strategic acquisitions. During 2021, we launched four new products, including most recently, a bone marrow aspirate concentrate offering, which was introduced in November 2021. We expanded our distribution network by bringing on over 40 new agents during 2021. In furtherance of our goal to penetrate adjacent markets, we added new sales personnel to leverage certain adjacent non-spine markets, such as the foot and ankle, cranio-maxilofacial, oncology, joint reconstruction and trauma markets and we made progress towards this goal during 2021 by expanding our private label and original equipment manufacturer (“OEM”) sales into these adjacent markets. Finally, one of our key growth initiatives is to add depth to our product offering through targeted strategic acquisitions. While the intent of these four key growth initiatives is to increase our future revenues, no assurance can be provided that we will be successful in implementing these growth initiatives or increasing our future revenues.

 

Impact of the COVID-19 Pandemic

 

Since March 2020, the COVID-19 pandemic has caused business closures, severe travel restrictions and implementation of social distancing measures. At the onset of the COVID-19 pandemic and more recently as a result of the surge in cases and hospitalizations caused primarily by the Delta and Omicron variants, hospitals and other medical facilities have cancelled or deferred elective procedures, diverted resources to patients suffering from infections, and limited access for non-patients, including our direct and indirect sales representatives. Because of these circumstances, surgeons and their patients have, and may continue to, defer procedures in which our products otherwise would be used. In addition, many facilities that specialize in procedures in which our products are used have experienced staffing shortages, temporary closures, and/or reduced operating hours. These circumstances have negatively impacted, and may continue to negatively impact, the number of elective procedures being conducted and the ability of our employees, independent sales representatives and distributors to effectively market and sell our products, which has had and will likely continue to have a material adverse effect on our revenues.

 

56
 

 

While eased COVID-19 restrictions caused our revenues to improve in the year ended December 31, 2021 as compared to the prior year, the resurgence in cases and hospitalizations during the third and fourth quarters of 2021 caused our revenues to decline during the third and fourth quarters of 2021 as compared to the respective prior year periods and the second quarter of 2021. Throughout the third and fourth quarter of 2021, and most acutely starting in August 2021, spine and other surgery procedure volumes were negatively impacted in many of our key markets, due to cancellations and/or postponements of procedures as a result of increased hospitalizations, restrictions on elective procedures and staffing shortages, which negatively impacted our 2021 revenues. This reduction in elective procedures and staffing issues have continued into the beginning of first quarter 2022 and could continue to persist or worsen, which would continue to adversely impact our revenues. Additionally, it is possible that additional restrictions could be reinstated if there is another sustained resurgence of COVID-19 cases and hospitalizations.

 

The COVID-19 pandemic also has caused adverse effects on general commercial activity and the global economy and supply chain, disrupting our ability to obtain raw materials, components and products. The pandemic has also adversely affected, and may continue to adversely affect, our distributors, independent sales representatives, customers, contract manufacturers and suppliers and their respective businesses, which in turn, have adversely affected, and may continue to adversely affect, our business and operations.

 

Although we continue to monitor the impact of the COVID-19 pandemic on our business, operations and financial results, the full extent to which the COVID-19 pandemic will continue to impact our business during 2022 will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning COVID-19 variants, the actions to contain it or treat its impact, the availability, acceptance and effectiveness of vaccines, future resurgences of the virus and its variants, the speed at which government restrictions are lifted, patient capacity at hospitals and healthcare systems, and the willingness and ability of patients to seek care and treatment due to safety concerns or financial hardship. If our revenues continue to decline and do not recover to pre-COVID-19 pandemic levels, we may be required to incur impairment charges to our long-lived assets and goodwill and write-off excess inventory, which would likely adversely affect our future operating results.

 

Results of Operations

 

Comparison of Years Ended December 31, 2021 and December 31, 2020

 

The following table sets forth our results of operations for 2021 and 2020 (dollars in thousands):

 

   Year Ended December 31, 
   2021   2020 
       % of       % of 
   Amount   Revenue   Amount   Revenue 
Revenue                    
Orthopedic product sales  $55,146    99.8%  $53,188    99.7%
Other revenue   117    0.2%   149    0.3%
Total Revenue   55,263    100.0%   53,337    100.0%
                     
Cost of Sales   22,773    41.2%   18,945    35.5%
                     
Gross Profit   32,490    58.8%   34,392    64.5%
                     
Operating Expenses                    
General and administrative   14,449    26.1%   13,503    25.3%
Sales and marketing   21,025    38.0%   20,983    39.4%
Research and development   870    1.6%   657    1.2%
Total Operating Expenses   36,344    65.8%   35,143    65.9%
                     
Loss from Operations   (3,854)   (7.0)%   (751)   (1.4)%
                     
Other Expense                    
Interest expense   (995)   (1.8)%   (5,976)   (11.2)%
                     
Total Other Expense   (995)   (1.8)%   (5,976)   (11.2)%
                     
Net Loss from Operations Before Provision for Income Taxes   (4,849)   (8.8)%   (6,727)   (12.6)%
                     
Provision for Income Taxes                    
Current and Deferred   —    (0.0)%   (296)   (0.6)%
                     
Net Loss  $(4,849)   (8.8)%  $(7,023)   (13.2)%

 

57
 

 

Revenue

 

Total revenue for the year ended December 31, 2021 increased 3.6% to $55.3 million compared to $53.3 million for the prior year. The increase of $1.9 million is largely attributed to additional private label and OEM orthobiologics sales of $2.4 million, bringing total private label and OEM sales to $4.9 million, compared to $2.6 million for the prior year. This increase was partially offset by reduced implant sales of $1.0 million versus the prior year.

 

Cost of Sales

 

Cost of sales consists primarily of manufacturing cost, product purchase costs and depreciation of surgical instruments. Cost of sales also includes reserves for estimated excess inventory, inventory on consignment that may be missing and not returned, and reserves for estimated missing and damaged consigned surgical instruments. Cost of sales increased by 20.2%, or $3.8 million, to $22.8 million for the year ended December 31, 2021 from $18.9 million for the year ended December 31, 2020. This is primarily due to increased under-absorption of labor and overhead of $1.0 million driven by initiatives to reduce inventory, with the remaining increase resulting primarily from sales mix and sell through of product subject to greater production costs during prior periods.

 

Gross profit as a percentage of sales decreased to 58.8% for the year ended December 31, 2021 compared to 64.5% for the year ended December 31, 2020. Of the 5.7% decrease for the year ended December 31, 2021, 1.9% was due to increased under-absorption of labor and overhead, 1.3% was due to sales mix including greater sales of lower margin private label and OEM sales, and 2.6% was due to sell through of product subject to greater production costs during prior periods. We expect higher product costs to continue in future periods but otherwise expect gross profit to improve as the effect of COVID-19 on surgical procedures diminishes.

 

General and Administrative

 

General and administrative expenses consist primarily of personnel costs for corporate employees, cash-based and stock-based compensation related costs and corporate expenses for legal, accounting and other professional fees, as well as occupancy costs. General and administrative expenses increased 7.0%, or $0.9 million, to $14.4 million for the year ended December 31, 2021 compared to $13.5 million for the year ended December 31, 2020. This increase is primarily attributable to additional stock-based compensation expense of $1.1 million, additional legal settlement expenses of $0.5 million and increased salaries and wages of $0.5 million. These increases were partially offset by reduced expense of $0.8 million related to various employee compensation plans and reduced severance expense of $0.3 million.

 

58
 

 

Sales and Marketing

 

Sales and marketing expenses consist primarily of sales commissions, personnel costs for sales and marketing employees, costs for trade shows, sales conventions and meetings, travel expenses, advertising and other sales and marketing related costs. Sales and marketing expenses totaled $21.0 million for each of the years ended December 31, 2021 and 2020. The year-over-year comparison included reduced commissions expense of $0.3 million resulting from a greater mix of private label and OEM sales versus 2020, which offset additional expense of $0.3 million associated with tradeshows and related travel.

 

Research and Development

 

Research and development expenses consist primarily of internal costs for the development of new product technologies. Research and development expenses increased $0.2 million, or 32.4%, to $0.9 million for the year ended December 31, 2021 from $0.7 million for the year ended December 31, 2020. This increase was due primarily to an increase in research and development headcount in 2021 compared to 2020.

 

Interest Expense

 

Interest expense for the year ended December 31, 2021 decreased $5.0 million to $1.0 million as compared to $6.0 million for the year ended December 31, 2020. This decrease resulted from our October 1, 2020 debt restructuring which, among other things, reduced our outstanding principal and paid-in-kind interest by $61.7 million.

 

Income Tax Provision

 

Income tax provision for the year ended December 31, 2021 decreased $0.3 million to $0 as compared to $0.3 million for the year ended December 31, 2020. This decrease was due to certain states suspending the utilization of net operating losses as offsets to taxable income in the prior year.

 

Liquidity and Capital Resources

 

Working Capital

 

Since our inception, we have financed our operations through primarily operating cash flows, private placements of equity securities and convertible debt, debt facilities, common stock rights offerings, and other debt transactions. The following table summarizes our working capital as of December 31, 2021 and December 31, 2020 (in thousands):

 

   December 31, 
   2021   2020 
Cash and cash equivalents  $18,387   $2,341 
Accounts receivable, net   7,154    6,880 
Inventories   17,945    21,408 
Total current assets   44,330    31,365 
Accounts payable   2,615    2,947 
Accrued liabilities   4,349    5,462 
Line of credit   3,620    — 
Current portion of long-term debt   —    16,797 
Total current liabilities   11,077    25,649 
Net working capital   33,253    5,716 

 

Our increase in cash and cash equivalents is due primarily to the completion of a private placement of shares of common stock and warrants in February 2021. On February 24, 2021, we issued in a private placement to a single healthcare-focused institutional accredited investor 8,888,890 shares of our common stock at a purchase price of $2.25 per share, and a warrant to purchase up to 6,666,668 shares of our common stock. The warrant has an exercise price of $2.25 per share, subject to customary anti-dilution, but not price protection, adjustments, was immediately exercisable and expires on the five-year anniversary of the date of issuance. We received net proceeds of approximately $18.4 million, after deducting fees and other estimated offering expenses, from the private placement. We expect to use these net proceeds for working capital and other general corporate purposes. On May 6, 2021, we refinanced our outstanding debt due December 31, 2021 with a line of credit and $12.0 million term loan.

 

59
 

 

Cash Flows

 

Net cash provided by operating activities for the year ended December 31, 2021 was $0.4 million compared to $0.7 million used in operating activities for the year ended December 31, 2020. This increase was due primarily to greater generation of cash from initiatives to reduce inventory levels in response to reduced lead times, which was partially offset by the effect of collection of accounts receivable for the year ended December 31, 2020.

 

Net cash used in investing activities for the year ended December 31, 2021 was $1.9 million, primarily representing purchases of property and equipment of $2.1 million, partially offset by proceeds from sale of fixed assets of $0.2 million. Net cash used in investing activities for the year ended December 31, 2020 was $1.3 million, primarily representing purchases of property and equipment of $1.5 million, partially offset by proceeds from sale of fixed assets of $0.2 million.

 

Net cash provided by financing activities was $17.5 million for the year ended December 31, 2021, which was primarily attributable to $18.4 million of proceeds from our February 2021 private placement, net of issuance costs. Net cash used in financing activities was $0.9 million for the year ended December 31, 2020 consisting primarily of $1.0 million of costs associated with our debt restructuring.

 

Current and Prior Credit Facilities

 

On May 6, 2021, the Company, as guarantor, and our subsidiaries, as borrowers (collectively, the “Borrowers”), entered into a Credit, Security and Guaranty Agreement (Term Loan) (the “Term Credit Agreement”) and Credit, Security and Guaranty Agreement (Revolving Loan) (the “Revolving Credit Agreement” and, together with the Term Credit Agreement, the “Credit Agreements”) with MidCap Financial Trust, in its capacity as agent (“MidCap”).

 

The Term Credit Agreement provides for a secured term loan facility (the “Term Facility”) in an aggregate principal amount of $12.0 million (the “Term Loan Commitment”), which was funded to the Borrowers immediately, and an additional $5.0 million tranche available solely at the discretion of MidCap and the lenders, for the purposes agreed to between the Company, the Borrowers and the lenders in advance of the making of loans under such additional tranche. The Revolving Credit Agreement provides for a secured revolving credit facility (the “Revolving Facility,” and, together with the Term Facility, the “Facilities”) under which the Borrowers may borrow up to $8.0 million (such amount, the “Revolving Loan Commitment”) at any one time, the availability of which is determined based on a borrowing base equal to percentages of certain accounts receivable and inventory of the Borrowers in accordance with a formula set forth in the Revolving Credit Agreement. All borrowings under the Revolving Facility are subject to the satisfaction of customary conditions, including the absence of default, the accuracy of representations and warranties in all material respects and the delivery of an updated borrowing base certificate.

 

The Facilities have a maturity date of May 1, 2026. Each of the Borrowers, and the Company, as guarantor, are jointly and severally liable for all of the obligations under the Facilities on the terms set forth in the Credit Agreements. The Borrowers’ obligations, and the Company’s obligations as a guarantor, under the Credit Agreements are secured by first-priority liens on substantially all of their assets, including, without limitation, all inventory, equipment, accounts, intellectual property and other assets of the Company and the Borrowers.

 

The proceeds of the Term Facility were used to pay transaction fees in connection with the Facilities and to pay in full all outstanding indebtedness and accrued interest under the Company’s prior credit facility, which is described below. The proceeds of the Revolving Facility may be used to pay transaction fees in connection with the Facilities, to pay in full all outstanding indebtedness and accrued interest under the Company’s prior credit facility, and for working capital and general corporate purposes.

 

60
 

 

The loans and other obligations pursuant to the Credit Agreements bear interest at a per annum rate equal to the sum of the LIBOR rate, as such term is defined in the Credit Agreements, plus the applicable margin of 7.00% in the case of the Term Credit Agreement, and 4.50% in the case of the Revolving Credit Agreement, subject in each case to a LIBOR floor of 1.00%.

 

The Credit Agreements contain affirmative and negative covenants customarily applicable to senior secured credit facilities, including covenants that, among other things, limit or restrict the ability of the Borrowers, subject to negotiated exceptions, to incur additional indebtedness and additional liens on their assets, engage in mergers or acquisitions or dispose of assets, pay dividends or make other distributions, voluntarily prepay other indebtedness, enter into transactions with affiliated persons, make investments, and change the nature of their businesses. In addition, the Credit Agreements require the Borrowers and the Company to maintain net product revenue at or above minimum levels and to maintain a minimum adjusted EBITDA and a minimum liquidity, in each case at levels specified in the Credit Agreements. As of December 31, 2021, we were in compliance with all covenants under the Credit Agreements.

 

On March 7, 2022, the Credit Agreements were amended to, among other things, (i) provide for a waiver of compliance with respect to the Company’s minimum adjusted EBITDA requirement if and so long as the Company’s liquidity (as specifically defined in the Credit Agreements) is in excess of $14 million and there is not otherwise an event of default under the Credit Agreements, commencing with the next delivery of the compliance certificate required under the Credit Agreements, and (ii) re-set the date certain fees payable in connection with optional prepayments are determined to the date the amendment was executed and consequently extend such fees’ original expiration. In addition, the exit fees were increased by 25 basis points.

 

On May 6, 2021, contemporaneously with the execution and delivery of the Credit Agreements, that certain Second Amended and Restated Credit Agreement, dated March 29, 2019, among the Company, the Borrowers, OrbiMed Royalty Opportunities II, LP and ROS Acquisition Offshore LP, as subsequently amended (the “Second A&R Credit Agreement”), which was scheduled to mature on December 31, 2021, was terminated in accordance with the terms thereof and all outstanding amounts were repaid by the Borrowers to Royalty Opportunities in its role as sole lender thereunder.

 

Cash Requirements

 

We believe that our $18.2 million of cash and cash equivalents as of December 31, 2021, together with amounts available under the Facilities, will be sufficient to meet our anticipated cash requirements through at least March 2023. However, we may require or seek additional capital to fund our future operations and business strategy prior to March 2023. Accordingly, there is no assurance that we will not need or seek additional financing prior to such time.

 

We may elect to raise additional financing even before we need it if market conditions for raising additional capital are favorable. We may seek to raise additional financing through various sources, such as equity and debt financings, additional debt restructurings or refinancings, or through strategic collaborations and license agreements. We can give no assurances that we will be able to secure additional sources of funds to support our operations, or if such funds are available to us, that such additional financing will be sufficient to meet our needs or on terms acceptable to us. This is particularly true if economic and market conditions deteriorate.

 

To the extent that we raise additional capital through the sale of equity or convertible debt securities or the restructuring or refinancing of our debt, the interests of our current stockholders may be diluted, and the terms may include discounted equity purchase prices, warrant coverage, liquidation or other preferences that would adversely affect the rights of our current stockholders. If we issue common stock, we may do so at purchase prices that represent a discount to our trading price and/or we may issue warrants to the purchasers, which could dilute our current stockholders. If we issue preferred stock, it could adversely affect the rights of our stockholders or reduce the value of our common stock. In particular, specific rights granted to future holders of preferred stock may include voting rights, preferences as to dividends and liquidation, conversion and redemption rights, sinking fund provisions, and restrictions on our ability to merge with or sell our assets to a third party. Additional debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. Prior to raising additional equity or debt financing, we may be required to obtain the consent of the Agent under our Credit Agreements and/or ROS and Royalty Opportunities under our Investor Rights Agreement with them, and no assurance can be provided that they would provide such consent, which could limit our ability to raise additional financing and the terms thereof.

 

61
 

 

Recent Accounting Pronouncements

 

Information regarding recent accounting pronouncements is included in Note 1 to our consolidated financial statements in “Item 8. Financial Statements and Supplementary Data.”

 

Critical Accounting Estimates

 

All of our significant accounting policies and estimates are described in Note 1 to our consolidated financial statements in “Item 8. Financial Statements and Supplementary Data.” Certain of our more critical accounting estimates require the application of significant judgment by management in selecting the appropriate assumptions in determining the estimate. By their nature, these judgments are subject to an inherent degree of uncertainty. We develop these judgments based on our historical experience, terms of existing contracts, our observance of trends in the industry, information provided by our customers, and information available from other outside sources, as appropriate. Actual results may differ from these estimates under different assumption conditions.

 

We believe that the following financial estimates are both important to the portrayal of our financial condition and results of operations and require subjective or complex judgments. Further, we believe that the items discussed below are properly recorded in our consolidated financial statements for all periods presented. Our management has discussed the development, selection, and disclosure of our most critical financial estimates with the Audit Committee of the Board of Directors and with our independent registered public accounting firm. The judgments about those financial estimates are based on information available as of the date of our financial statements. Those financial estimates include:

 

Goodwill and Intangible Assets

 

Goodwill represents the excess of costs over fair value of assets of businesses acquired. Goodwill and intangible assets acquired in a purchase business combination and determined to have indefinite useful lives are not amortized, instead they are tested for impairment annually and whenever events or circumstances indicate the carrying amount of the asset may not be recoverable. We conduct our impairment test on an annual basis and review the analysis assumptions on a quarterly basis. We test goodwill for impairment at the reporting unit level, which is an operating segment or one level below an operating segment, referred to as a component. A component of an operating segment is a reporting unit if the component constitutes a business for which discrete financial information is available and segment management regularly reviews the operating results of that component.

 

We chose December 31 to assess our annual goodwill for any impairment in order to closely align with the timing of our annual planning process. In testing goodwill for impairment we perform a quantitative impairment test, including computing the fair value of the reporting unit and comparing that value to its carrying value. If the fair value is less than its carrying value, then the goodwill is determined to be impaired. In the event that goodwill is impaired, an impairment charge to earnings would become necessary. There was no impairment of goodwill recorded in 2021 or 2020.

 

We evaluate other intangible assets whenever current events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. Recoverability for assets to be held and used is based on our projection of the undiscounted future operating cash flows of the underlying assets. To the extent such projections indicate that future undiscounted cash flows are not sufficient to recover the carrying amounts of related assets, a charge might be required to reduce the carrying amount to equal estimated fair value. We did not have a triggering event in 2021 or 2020.

 

62
 

 

Inventory Valuation

 

Inventories are stated at the lower of cost or net realizable value. Cost is determined using the specific identification method and includes materials, labor and overhead. We calculate an inventory reserve for estimated obsolescence and excess inventory based on historical usage and sales, as well as assumptions about anticipated future demand for products. A significant sustained decrease in demand could result in an increase in the amount of excess inventory quantities on hand. Additionally, our industry is characterized by regular new product development and introductions that could result in an increase in the amount of obsolete inventory quantities on hand due to cannibalization of existing products. Our estimates for excess and obsolete inventory are reviewed and updated on a quarterly basis. Our estimates of anticipated future product demand may prove to be inaccurate in which case we may be required to incur charges for excess and obsolete inventory. Increases in our inventory reserves result in a corresponding expense, which is recorded to cost of sales. We believe the total reserve at December 31, 2021 of $10.3 million is adequate.

 

Accounts Receivable and Allowances

 

Accounts receivable represents amounts due from customers for which revenue has been recognized. Normal terms on trade accounts receivable are net 30 days, and some customers are offered discounts for early pay. We perform credit evaluations when considered necessary, but generally do not require collateral to extend credit.

 

The allowance for doubtful accounts is our best estimate of the amount of probable credit losses in our existing receivables. We determine the allowance based on factors such as historical collection experience, customers’ current creditworthiness, customer concentration, age of accounts receivable balance, general economic conditions that may affect a customer’s ability to pay, and management judgment. In addition, we include provision for current expected credit loss based on historical collection experience adjusted for current economic conditions affecting collectability. Actual customer collections could differ from our estimates. Account balances are charged to the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. Provisions to the allowance for doubtful accounts are charged to expense. We do not have any off-balance sheet credit exposure related to our customers.

 

Deterioration in the financial condition of any key customer or a significant slowdown in the economy could have a material negative impact on our ability to collect a portion or all of our accounts receivable. We believe that an analysis of historical trends and our current knowledge of potential collection issues provide us with sufficient information to establish a reasonable estimate for an allowance for doubtful accounts. However, since we cannot predict with certainty future changes in the financial stability of our customers, our actual future losses from uncollectible accounts may differ from our estimates. In the event we determined that a smaller or larger uncollectible accounts reserve is appropriate, we would record a credit or charge, as applicable, to bad debt expense in the period that we made such a determination. We believe our allowance for doubtful accounts at December 31, 2021 of $0.6 million is adequate.

 

Going Concern

 

The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business and do not include any adjustments relating to the recoverability or classification of assets or the amounts of liabilities that might result from the outcome of these uncertainties. Our ability to continue as a going concern, realize the carrying value of our assets and discharge our liabilities in the ordinary course of business is dependent upon a number of factors, including, the level and timing of future revenues and expenditures; development, commercialization and market acceptance of our products; competing technologies and market developments; regulatory requirements and delays; and ability to attract and retain key personnel.

 

Management’s evaluation of going concern was conducted as part of its discussions with and the review by the Board of Directors of our 2022 Annual Operating Plan. Management believes that our $18.4 million of cash and cash equivalents as of December 31, 2021, together with amounts available under the Facilities, will be sufficient to meet our anticipated cash requirements through at least March 2023.

 

Item 7A. Quantitative and Qualitative Disclosures About Market Risk

 

This Item 7A is inapplicable to Xtant as a smaller reporting company.

 

63
 

 

Item 8. Financial Statements and Supplementary Data

 

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

 

Report of Independent Registered Public Accounting Firm (PCAOB ID Number 166) 65
Consolidated Statements of Operations 67
Consolidated Balance Sheets 68
Consolidated Statements of Changes in Stockholders’ Equity (Deficit) 69
Consolidated Statements of Cash Flows 70
Notes to Consolidated Financial Statements 71

 

64
 

 

Report of Independent Registered Public Accounting Firm

 

To the Stockholders and Board of Directors of

Xtant Medical Holdings, Inc.

 

Opinion on the Financial Statements

 

We have audited the accompanying consolidated balance sheets of Xtant Medical Holdings, Inc. (the “Company”) as of December 31, 2021 and 2020 and the related consolidated statements of operations, stockholders’ equity, and cash flows for each of the years in the two-year period ended December 31, 2021; and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020 and the results of its operations and its cash flows for each of the years in the two-year period ended December 31, 2021 in conformity with accounting principles generally accepted in the United States of America.

 

Basis for Opinion

 

The Company’s management is responsible for these financial statements. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (the “PCAOB”) and are required to be independent with respect to the Company in accordance with U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

Critical Audit Matter

 

The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

 

65
 

 

Valuation of Inventory

 

Critical Audit Matter Description

 

As explained in Note 1 to the consolidated financial statements, the Company reviews the components of its inventory on a quarterly basis for estimated obsolescence and excess inventory adjusts inventory to its net realizable value as necessary. Net inventory at December 31, 2021 totaled $18 million.

 

Auditing management’s calculation of estimated excess and obsolete inventory involved a high degree of auditor judgment due to the sensitivity of significant assumptions. Such assumptions include product life cycle, sales forecasts, and timing of competitors introducing new or enhanced products.

 

The impact of competition and the continuing impact of the COVID-19 pandemic on the sales forecast further increased the difficulty in auditing the reasonableness of management’s estimates and assumptions and required a significant amount of audit effort.

 

How the Critical Audit Matter Was Addressed in the Audit

 

Our procedures related to management’s forecasts of product demand used to record the excess and obsolete inventories reserve included the following, among others:

 

●Gained an understanding of the Company’s internal control over developing its excess and obsolete inventories reserve to identify the types of potential misstatement, assessed the factors that affect the risks of material misstatement, and designed further audit procedures.

 

●Evaluated the appropriateness and consistency of management’s methods and assumptions used in developing their estimate of the excess and obsolete inventory reserve, which included consideration of reserve trends by product category and the impact of changes in inventory management processes on the estimate.

 

●Evaluated the appropriateness of specified inputs supporting management’s estimate, including the age of on-hand inventory items; historic inventory trends; historic write-off activity; and revenue forecasts, including the Company’s ability to forecast sales by comparing prior period sales forecasts to actual amounts, taking into consideration the COVID-19 pandemic impact on current and future demand through sensitivity analysis.

 

●Developed an independent expectation of the excess and obsolete inventory reserve using historical inventory activity and compared our independent expectation to the amount recorded in the financial statements.

 

/s/ Plante & Moran, PLLC  
   
We have served as the Company’s auditor since 2011.  
   
Denver, Colorado  
   
March 8, 2022  

 

66
 

 

XTANT MEDICAL HOLDINGS, INC.

Consolidated Statements of Operations

(In thousands, except number of shares and per share amounts)

 

         
   Year Ended December 31, 
   2021   2020 
Revenue          
Orthopedic product sales  $55,146   $53,188 
Other revenue   117    149 
Total Revenue   55,263    53,337 
           
Cost of Sales   22,773    18,945 
           
Gross Profit   32,490    34,392 
           
Operating Expenses          
General and administrative   

14,449

    13,503 
Sales and marketing   21,025    20,983 
Research and development   870    657 
Total Operating Expenses   36,344    35,143 
           
Loss from Operations   (3,854)   (751)
           
Other Expense          
Interest expense   (995)   (5,976)
Total Other Expense   (995)   (5,976)
           
Net Loss from Operations Before Provision for Income Taxes   (4,849)   (6,727)
           
Provision for Income Taxes Current and Deferred   —    (296)
           
Net Loss  $(4,849)  $(7,023)
           
Net loss per share:          
Basic  $(0.06)  $(0.25)
Dilutive  $(0.06)  $(0.25)
           
Shares used in the computation:          
Basic   85,456,175    28,499,847 
Dilutive   85,456,175    28,499,847 

 

See notes to audited consolidated financial statements.

 

67
 

 

XTANT MEDICAL HOLDINGS, INC.

Consolidated Balance Sheets

(In thousands, except number of shares and par value)

 

   As of   As of 
  

December 31,

2021

  

December 31,

2020

 
ASSETS          
Current Assets:          
Cash and cash-equivalents  $18,243   $2,341 
Restricted cash   144    — 
Trade accounts receivable, net of allowance for credit losses of $552 and $653, respectively   7,154    6,880 
Inventories   17,945    21,408 
Prepaid and other current assets   844    736 
Total current assets   44,330    31,365 
           
Property and equipment, net   5,212    4,347 
Right of use asset, net   1,258    1,690 
Other assets   287    402 
Intangible assets, net   400    457 
Goodwill   3,205    3,205 
           
Total Assets  $54,692   $41,466 
           
LIABILITIES & STOCKHOLDERS’ EQUITY          
Current Liabilities:          
Accounts payable  $2,615   $2,947 
Accrued liabilities   

4,349

    5,462 
Current portion of lease liability   462    423 
Current portion of finance lease obligations   31    20 
Line of credit   3,620    — 
Current portion of long-term debt   —    16,797 
Total current liabilities   11,077    25,649 
           
Long-term Liabilities:          
Lease liability, net   842    1,303 
Financing lease obligations, net   103    — 
Long-term debt, plus premium and less issuance costs   11,787    — 
Total Liabilities   23,809    26,952 
           
Commitments and Contingencies (note 11)   -     -  
Stockholders’ Equity:          
Preferred stock, $0.000001 par value; 10,000,000 shares authorized; no shares issued and outstanding   —    — 
Common stock, $0.000001 par value; 300,000,000 shares authorized; 87,068,980 share issued and outstanding as of December 31, 2021 and 300,000,000 shares authorized; 77,573,680 shares issued and outstanding as of December 31, 2020   —    — 
Additional paid-in capital   266,068    244,850 
Accumulated deficit   (235,185)   (230,336)
Total Stockholders’ Equity   30,883    14,514 
           
Total Liabilities & Stockholders’ Equity  $54,692   $41,466 

 

See notes to audited consolidated financial statements.

 

68
 

 

XTANT MEDICAL HOLDINGS, INC.

Consolidated Statements of Changes in Stockholders’ Equity (Deficit)

(In thousands, except number of shares)

 

                   Total 
   Common Stock  

Additional

Paid-In-

   Accumulated  

Stockholders’

Equity

 
   Shares   Amount   Capital   Deficit   (Deficit) 
                     
Balance at December 31, 2019   13,161,762   $—   $179,061   $(223,266)  $(44,205)
                          
ASU 2016-13 cumulative effect adjustment   —    —    —    (47)   (47)
Stock-based compensation   —    —    1,084    —    1,084 
Common stock issued on vesting of restricted stock units   144,878    —    —    —    — 
Issuance of warrant   —    —    1,862    —    1,862 
Debt exchange, net of exchange costs of $1,058   58,754,394    —    62,175    —    62,175 
Issuance of common shares, net of issuance costs of $143   712,646    —    620    —    620 
Exercise of warrants   4,800,000    —    48    —    48 
Net loss   —    —    —    (7,023)   (7,023)
Balance at December 31, 2020   77,573,680   $—   $244,850   $(230,336)  $14,514 
                          
Private placement of common stock, net of issuance costs of $1,926   8,888,890    —    12,831    —    12,831 
Warrants issued in connection with the private placement   —    —    5,243    —    5,243 
Warrants issued in connection with the private placement to placement agents   —    —    351    —    351 
Common stock issued on vesting of restricted stock units   782,596    —    —    —    — 
Gain on debt extinguishment   —    —    785    —    785 
Withholding of common stock upon vesting of restricted stock units   (176,186)   —    (201)   —    (201)
Stock-based compensation   —    —    2,209    —    2,209 
Net loss   —    —    —    (4,849)   (4,849)
Balance at December 31, 2021   87,068,980   $—   $266,068   $(235,185)  $30,883 

 

See notes to audited consolidated financial statements.

 

69
 

 

XTANT MEDICAL HOLDINGS, INC.

Consolidated Statements of Cash Flows

(In thousands)

 

         
   Year Ended December 31, 
   2021   2020 
Operating activities:          
Net loss  $(4,849)  $(7,023)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:          
Depreciation and amortization   1,332    2,079 
Non-cash interest   147    5,963 
Non-cash rent   9    16 
Gain on sale of fixed assets   (86)   (369)
Stock-based compensation   2,209    1,084 
Provision for reserve on accounts receivable   45    307 
Provision for excess and obsolete inventory   839    485 
           
Changes in operating assets and liabilities:          
Trade accounts receivable   (319)   2,890 
Inventories   2,624    (5,792)
Prepaid and other assets   (67)   40 
Accounts payable   (332)   101 
Accrued liabilities   (1,113)   (512)
Net cash provided by (used in) operating activities   439    (731)
           
Investing activities:          
Purchases of property and equipment   (2,115)   (1,545)
Proceeds from sale of fixed assets   225    241 
Net cash used in investing activities   (1,890)   (1,304)
           
Financing activities:          
Payment of taxes from withholding of common stock on vesting of restricted stock units   (201)   — 
Payments on financing leases   (50)   (156)
Costs associated with refinancing   (136)   (1,058)
Payments on long-term debt   (411)   (315)
Borrowings on line of credit   36,361    — 
Repayments on line of credit   (36,492)   — 
Proceeds from issuance of common stock, net of issuance costs   18,426    620 
Proceeds from exercise of common stock warrants   —    48 
Net cash provided by (used in) financing activities   17,497    (861)
           
Net change in cash and cash equivalents and restricted cash   16,046    (2,896)
           
Cash and cash equivalents and restricted cash at beginning of year   2,341    5,237 
Cash and cash equivalents and restricted cash at end of year  $18,387   $2,341 
Reconciliation of cash and cash equivalents and restricted cash reported in the consolidated balance sheets          
Cash and cash equivalents  $18,243   $2,341 
Restricted cash   144    — 
Total cash and cash equivalents and restricted cash reported in the consolidated balance sheets  $18,387   $2,341 

 

See notes to audited consolidated financial statements.

 

70
 

 

Notes to Consolidated Financial Statements

 

(1) Business Description and Summary of Significant Accounting Policies

 

Business Description

 

The accompanying consolidated financial statements include the accounts of Xtant Medical Holdings, Inc., formerly known as Bacterin International Holdings, Inc., a Delaware corporation, and its wholly owned subsidiaries, Xtant Medical, Inc., a Delaware corporation, Bacterin International, Inc., (“Bacterin”) a Nevada corporation, and X-Spine Systems, Inc. (“X-spine”), an Ohio corporation (Xtant Medical Inc., Bacterin and X-spine are jointly referred to herein as “Xtant” or the “Company”). The terms “we,” “us” and “our” also refer to Xtant.

 

All intercompany balances and transactions have been eliminated in consolidation.

 

Xtant products serve the combined specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders to promote healing following spine, cranial and foot surgeries and the development, manufacturing and sale of medical devices for use in orthopedic spinal surgeries.

 

Since March 2020, the COVID-19 pandemic has caused business closures, severe travel restrictions and implementation of social distancing measures. At the onset of the COVID-19 pandemic, hospitals and other medical facilities cancelled or deferred elective procedures, diverted resources to patients suffering from infections and limited access for non-patients, including our direct and indirect sales representatives. Because of the COVID-19 pandemic, surgeons and their patients have been, and may continue to be, required, or are choosing, to defer procedures in which our products otherwise would be used, and many facilities that specialize in the procedures in which our products otherwise would be used have experienced temporary closures or reduced operating hours. These circumstances have negatively impacted, and may continue to negatively impact, the ability of our employees, independent sales representatives and distributors to effectively market and sell our products, which has had and will likely continue to have a material adverse effect on our revenues.

 

At December 31, 2021, the Company had cash and cash equivalents of $18.2 million, and an accumulated deficit of $235.2 million and has incurred significant losses in the current and prior periods.

 

Management’s evaluation of going concern was conducted as part of its discussions with the Xtant Board of Directors’ review of the 2022 Annual Operating Plan. Management believes that our $18.2 million of cash and cash equivalents as of December 31, 2021, together with amounts available under our line of credit, will be sufficient to meet our anticipated cash requirements through at least March 2023.

 

Investor Rights Agreement

 

We are party to an Investor Rights Agreement with ROS Acquisition Offshore (“ROS”) and OrbiMed Royalty Opportunities II, LP (“Royalty Opportunities”), which are funds affiliated with OrbiMed Advisors LLC (“OrbiMed”). Under the Investor Rights Agreement, Royalty Opportunities and ROS are permitted to nominate a majority of the directors and designate the chairperson of our Board of Directors at subsequent annual meetings, as long as they maintain an ownership threshold in our Company of at least 40% of our then outstanding common stock (the “Ownership Threshold”). If Royalty Opportunities and ROS are unable to maintain the Ownership Threshold, the Investor Rights Agreement contemplates a reduction of nomination rights commensurate with our ownership interests. In addition, for so long as the Ownership Threshold is met, we must obtain the approval of a majority of our common stock held by Royalty Opportunities and ROS to proceed with the following actions: (i) issue new securities; (ii) incur over $250,000 of debt in a fiscal year; (iii) sell or transfer over $250,000 of our assets or businesses or our subsidiaries in a fiscal year; (iv) acquire over $250,000 of assets or properties in a fiscal year; (v) make capital expenditures over $125,000 individually, or $1.5 million in the aggregate during a fiscal year; (vi) approve our annual budget; (vii) hire or terminate our chief executive officer; (viii) appoint or remove the chairperson of our Board of Directors; and (ix) make, loans to, investments in, or purchase, or permit any subsidiary to purchase, any stock or other securities in another entity in excess of $250,000 in a fiscal year. As long as the Ownership Threshold is met, we may not increase the size of our Board or Directors beyond seven directors without the approval of a majority of the directors nominated by Royalty Opportunities and ROS.

 

71
 

 

The Investor Rights Agreement grants Royalty Opportunities and ROS the right to purchase from us a pro rata amount of any new securities that we may propose to issue and sell. The Investor Rights Agreement may be terminated (a) upon the mutual written agreement of all the parties, (b) upon our written notice, ROS or Royalty Opportunities if the ownership percentage of our then outstanding common stock of ROS and Royalty Opportunities is less than 10%, or (c) upon written notice of ROS and Royalty Opportunities.

 

Concentrations and Credit Risk

 

The Company’s accounts receivables are from a variety of health care organizations and distributors throughout the world. No single customer accounted for more than 10% of our revenue or accounts receivable in the fiscal years 2021 or 2020. Management believes that all significant credit risks have been identified at December 31, 2021.

 

Use of Estimates

 

The preparation of the financial statements requires management of the Company to make a number of estimates and assumptions relating to the reported amount of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the period. Significant estimates include the carrying amount of property and equipment, goodwill, and intangible assets and liabilities; valuation allowances for trade receivables, inventory and deferred income tax assets and liabilities; current and long-term lease obligations and corresponding right-of-use asset; and estimates for the fair value of long-term debt, stock option grants and other equity awards upon which the Company determines stock-based compensation expense. Actual results could differ from those estimates.

 

Cash, Cash Equivalents, and Restricted Cash

 

The Company considers all highly liquid investments purchased with an original maturity date of three months or less to be cash equivalents. Cash equivalents are recorded at cost, which approximates market value. At times, the Company maintains deposits in financial institutions in excess of federally insured limits.

 

Cash and cash equivalents classified as restricted cash on our condensed consolidated balance sheets are restricted as to withdrawal or use under the terms of certain credit agreements. The December 31, 2021 balance included lockbox deposits that are temporarily restricted due to timing at the period end. The lockbox deposits are applied against our line of credit the next business day.

 

Trade Accounts Receivable

 

Accounts receivable represents amounts due from customers for which revenue has been recognized. Normal terms on trade accounts receivable are net 30 days, and some customers are offered discounts for early pay. The Company performs credit evaluations when considered necessary, but generally does not require collateral to extend credit.

 

In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments–Credit Losses: Measurement of Credit Losses on Financial Instruments to change the impairment model for most financial assets and certain other instruments. For trade and other receivables, held to maturity debt securities, loans, and other instruments, entities are required to use a new forward-looking “expected loss” model that generally will result in the earlier recognition of allowances for losses. The Company adopted the guidance on January 1, 2020 and recognized a cumulative effect adjustment of $47,000 to retained earnings and accounts receivable, net as a result of adoption. The Company has included the additional disclosures required by ASU 2016-13 in Note 2, “Receivables.”

 

72
 

 

The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing receivables. The Company determines the allowance based on factors such as historical collection experience, customers’ current creditworthiness, customer concentration, age of accounts receivable balance, general economic conditions that may affect a customer’s ability to pay, and management judgment. In addition, we include provision for current expected credit loss based on historical collection experience adjusted for current economic conditions affecting collectability. Actual customer collections could differ from estimates. Account balances are charged to the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. Provisions to the allowance for doubtful accounts are charged to expense. The Company does not have any off-balance sheet credit exposure related to its customers.

 

Inventories

 

Inventories are stated at the lower of cost or net realizable value. Cost is determined using the specific identification method and includes materials, labor and overhead. The Company calculates an inventory reserve for estimated obsolescence and excess inventory based on historical usage and sales, as well as assumptions about future demand for its products. These estimates for excess and obsolete inventory are reviewed and updated on a quarterly basis. Increases in the inventory reserves result in a corresponding expense, which is recorded to cost of sales.

 

Property and Equipment

 

Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally three to seven years for computers and equipment and five years for surgical instruments. Leasehold improvements are depreciated over the shorter of their estimated useful life or the remaining term of the lease. Repairs and maintenance are expensed as incurred.

 

Intangible Assets

 

Intangible assets with estimable useful lives are amortized over their respective estimated useful lives to their estimated residual values and reviewed for impairment whenever events or circumstances indicate their carrying amount may not be recoverable. Intangible assets include trademarks and patents and include costs to acquire and protect Company patents. Intangible assets are carried at cost less accumulated amortization. The Company amortizes these assets on a straight-line basis over their estimated useful lives.

 

Other Assets

 

Other assets consist of the short-term and the long-term portion of prepaid expenses and security deposits.

 

Long-Lived Asset Impairment

 

Long-lived assets, including property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the estimated fair value of the assets.

 

Goodwill

 

Goodwill represents the excess of costs over fair value of assets of businesses acquired. Goodwill and intangible assets acquired in a business combination and determined to have indefinite useful lives are not amortized, instead they are tested for impairment at least annually and whenever events or circumstances indicate the carrying amount of the asset may not be recoverable. The Company conducts its impairment test on an annual basis and reviews the assumptions on a quarterly basis. We test goodwill for impairment at the reporting unit level, which is an operating segment or one level below an operating segment, referred to as a component. A component of an operating segment is a reporting unit if the component constitutes a business for which discrete financial information is available and segment management regularly reviews the operating results of that component.

 

73
 

 

Revenue Recognition

 

In the United States, we generate most of our revenue from independent commissioned sales agents. We consign our orthobiologics products to hospitals and consign or loan our spinal implant sets to the independent sales agents. The spinal implant sets typically contain the instruments, disposables, and spinal implants required to complete a surgery. Consigned sets are managed by the sales agent to service hospitals that are high volume users for multiple procedures. We ship replacement inventory to independent sales agents to replace the consigned inventory used in surgeries. Loaned sets are returned to the Company’s distribution center, replenished, and made available to sales agents for the next surgical procedure.

 

For each surgical procedure, the sales agent reports use of the product by the hospital and, as soon as practicable thereafter, ensures that the hospital provides a purchase order to the Company. Upon receipt of the hospital purchase order, the Company invoices the hospital, and revenue is recognized in the proper period.

 

Additionally, the Company sells product directly to domestic and international stocking resellers, original equipment manufacturer resellers and private label resellers. Upon receipt and acceptance of a purchase order from a stocking reseller, the Company ships product and invoices the reseller. The Company recognizes revenue when the products are shipped, and the transfer of title and risk of loss occurs. There is generally no customer acceptance or other condition that prevents the Company from recognizing revenue in accordance with the delivery terms for these sales transactions. In the normal course of business, the Company accepts returns of product that have not been implanted. Product returns are not material to the Company’s consolidated statements of operations. The Company accounts for shipping and handling activities as a fulfillment cost rather than a separate performance obligation. The Company’s policy is to record revenue net of any applicable sales, use, or excise taxes. Payment terms are generally net 30 days from invoice date and some customers are offered discounts for early pay.

 

Disaggregation of revenue

 

The Company operates in one reportable segment with its net revenue derived primarily from the sale of orthobiologics and spinal implant products across North America. Sales are reported net of returns. No rebates, group purchasing organization fees or other customer allowances are present, and so are not relevant to net revenue determination. The following table presents revenues from these product lines for the years ended December 31, 2021 and 2020 (dollars in thousands):

 

 Summary of Revenues from Product Lines

  

Year Ended

December 31, 2021

  

Percentage of

Total Revenue

  

Year Ended

December 31, 2020

  

Percentage of

Total Revenue

 
Orthobiologics  $42,259    77%  $39,308    74%
Spinal implant   12,887    23%   13,880    26%
Other revenue   117    0%   149    0%
Total revenue  $55,263    100%  $53,337    100%

 

Research and Development

 

Research and development costs, which are principally related to internal costs for the development of new products, are expensed as incurred.

 

Net Loss Per Share

 

Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding. Shares issued during the period and shares reacquired during the period are weighted for the portion of the period that they were outstanding. Diluted net loss per share is computed in a manner consistent with that of basic earnings per share while giving effect to all potentially dilutive shares of common stock outstanding during the period, which include the assumed exercise of stock options and warrants using the treasury stock method. Diluted net loss per share was the same as basic net loss per share for the years ended December 31, 2021 and 2020, as shares issuable upon the exercise of stock options and warrants and settlement of restricted stock units were anti-dilutive as a result of the net losses incurred for those periods. Diluted net loss per share is not reported as the effects of including 13,282,882 and 5,115,868 outstanding stock options, warrants and restricted stock units for the years ended December 31, 2021 and 2020, respectively, are anti-dilutive.

 

74
 

 

Fair Value of Financial Instruments

 

The carrying values of financial instruments, including trade accounts receivable, accounts payable, accrued liabilities and long-term debt, approximate their fair values based on terms and related interest rates.

 

The Company follows a framework for measuring fair value. The framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:

 

Level 1: Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets.

 

Level 2: Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.

 

Level 3: Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

 

A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. During the years ended December 31, 2021 and 2020, there was no reclassification in financial assets or liabilities between Level 1, 2 or 3 categories.

 

Reclassification

 

Certain prior year amounts have been reclassified to conform with current year presentation.

 

(2) Receivables

 

Concurrent with the adoption of ASU 2016-13, the Company’s allowance for doubtful accounts was expanded to include provision for current expected credit loss (“CECL”). The Company’s provision for CECL is determined based on historical collection experience adjusted for current economic conditions affecting collectability. Actual customer collections could differ from estimates. Account balances are charged to the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. Provisions to the allowance for credit losses are charged to expense. Activity within the allowance for credit losses was as follows for years ended December 31, 2021 and 2020 (in thousands):

 

  

December 31,

2021

  

December 31,

2020

 
         
Balance at January 1  $653   $547 
Provision for current expected credit losses   45    307 
Write-offs against allowance   (146)   (201)
   $552   $653 

 

75
 

 

(3) Inventories

 

Inventories consist of the following (in thousands):

 

  

December 31,

2021

  

December 31,

2020

 
Raw materials  $5,613   $3,757 
Work in process   571    1,733 
Finished goods   11,761    15,918 
 Total  $17,945   $21,408 

 

(4) Property and Equipment, Net

 

Property and equipment, net are as follows (in thousands):

 

  

December 31,

2021

  

December 31,

2020

 
Equipment  $5,541   $4,807 
Computer equipment   828    649 
Computer software   490    570 
Furniture and fixtures   94    133 
Leasehold improvements   3,994    3,987 
Other   10    10 
Surgical instruments   11,424    11,291 
Total cost   22,381    21,447 
Less: accumulated depreciation   (17,169)   (17,100)
 Total  $5,212   $4,347 

 

Depreciation expense related to property and equipment, including property under capital lease, for the years ended December 31, 2021 and 2020 was $1.3 million and $2.0 million, respectively.

 

(5) Goodwill and Intangible Assets

 

The results of the Company’s annual goodwill impairment tests for the years ended December 31, 2021 and 2020 indicated that no goodwill impairment existed as of the test date.

 

The following table sets forth information regarding intangible assets (in thousands):

 

  

December 31,

2021

  

December 31,

2020

 
Patents  $847   $847 
Accumulated amortization   (447)   (390)
Net carrying value  $400   $457 

 

76
 

 

Amortization expense was $0.1 million for both of the years ended December 31, 2021 and 2020. The following is a summary of estimated future amortization expense for intangible assets as of December 31, 2021 (in thousands):

 

      
2022  $54 
2023   53 
2024   52 
2025   52 
2026   49 
Thereafter   140 
Total  $400 

 

(6) Accrued Liabilities

 

Accrued liabilities consist of the following (in thousands):

 

  

December 31,

2021

  

December 31,

2020

 
Wages/commissions payable  $3,184   $4,057 
Other accrued liabilities   1,165    1,405 
Accrued liabilities  $4,349   $5,462 

 

(7) Debt

 

Long-term debt consists of the following (in thousands):

 

  

December 31,

2021

  

December 31,

2020

 
Amounts due under the Term Facility  $12,000   $— 
Accrued end-of-term payments   83    — 
Amounts due under the Second A&R Credit Agreement   —    15,556 
Premium related to Second Amendment   —    1,241 
Less: unamortized debt issuance costs   (296)   — 
Less: current maturities   —    (16,797)
Long-term debt, less issuance costs  $11,787   $— 

 

Current Credit Facilities

 

On May 6, 2021 (the “Closing Date”), the Company, as guarantor, and its subsidiaries, as borrowers (collectively, the “Borrowers”), entered into a (i) Credit, Security and Guaranty Agreement (Term Loan) (the “Term Credit Agreement”) with MidCap Financial Trust, in its capacity as agent (the “Agent”), and a lender and the additional lenders from time to time party thereto and (ii) Credit, Security and Guaranty Agreement (Revolving Loan) (the “Revolving Credit Agreement,” and, together with the Term Credit Agreement, the “Credit Agreements”), with the Agent and the lenders from time to time party thereto. Contemporaneously with the execution and delivery of the Credit Agreements, that certain Second Amended and Restated Credit Agreement, dated March 29, 2019, among the Company, the Borrowers, OrbiMed Royalty Opportunities II, LP (“Royalty Opportunities”) and ROS Acquisition Offshore LP (“ROS”), as subsequently amended (the “Second A&R Credit Agreement”), which was scheduled to mature on December 31, 2021, was terminated in accordance with the terms thereof and all outstanding amounts were repaid by the Borrowers to Royalty Opportunities in its role as sole lender thereunder.

 

The Term Credit Agreement provides for a secured term loan facility (the “Term Facility”) in an aggregate principal amount of $12.0 million (the “Term Loan Commitment”), which was funded to the Borrowers on the Closing Date, and an additional $5.0 million tranche available solely at the discretion of the Agent and the lenders, for the purposes agreed to between the Company, the Borrowers and the lenders in advance of the making of loans under such additional tranche. The Revolving Credit Agreement provides for a secured revolving credit facility (the “Revolving Facility,” and, together with the Term Facility, the “Facilities”) under which the Borrowers may borrow up to $8,000,000 (such amount, the “Revolving Loan Commitment”) at any one time, the availability of which is determined based on a borrowing base equal to percentages of certain accounts receivable and inventory of the Borrowers in accordance with a formula set forth in the Revolving Credit Agreement. As of December 31, 2021, the Company had $3.2 million available under the Revolving Credit Agreement. All borrowings under the Revolving Facility are subject to the satisfaction of customary conditions, including the absence of default, the accuracy of representations and warranties in all material respects and the delivery of an updated borrowing base certificate.

 

77
 

 

The Facilities have a maturity date of May 1, 2026. The proceeds of the Term Facility were used to pay transaction fees in connection with the Facilities and to pay in full all outstanding indebtedness and accrued interest under the Second A&R Credit Agreement. The proceeds of the Revolving Facility were used to pay transaction fees in connection with the Facilities, to pay in full all outstanding indebtedness and accrued interest under the Second A&R Credit Agreement, and for working capital and general corporate purposes. As a result of the refinancing, we recorded a gain on extinguishment totaling $0.8 million. The gain represents the difference between the carrying value of our outstanding loans under the Second A&R Credit Agreement prior to the extinguishment and $15.6 million, the reacquisition price. Because of the related party affiliation between the Company and ROS, this debt extinguishment resulted in an increase in additional paid-in capital rather than flowing through our consolidated statements of operations as a gain on extinguishment.

 

The loans and other obligations pursuant to the Credit Agreements bear interest at a per annum rate equal to the sum of the LIBOR rate, as such term is defined in the Credit Agreements, plus the applicable margin of 7.00% in the case of the Term Credit Agreement, and 4.50% in the case of the Revolving Credit Agreement, subject in each case to a LIBOR floor of 1.00%. The Company is also required to make a final payment in an amount equal to 3.75% of the principal amount borrowed under the Term Facility. The final payment is being accreted to interest expense over the term of the Term Facility using the effective interest method. The effective rate of the Term Facility, inclusive of amortization of debt issuance costs and accretion of the final payment, was 9.87% as of December 31, 2021. In addition to paying interest on the outstanding loans under the Facilities, the Borrowers are also required to pay an unused line fee equal to 0.50% per annum in respect of unutilized commitments under the Revolving Facility, a fee for failure to maintain a minimum balance under the Revolving Facility, a collateral management fee under the Revolving Facility equal to 0.50% of the amount outstanding under the Revolving Facility, an origination fee equal to 0.50% of the Revolving Loan Commitment and 0.50% of the Term Loan Commitment, and if activated, of any additional term loan tranche, and certain other customary fees related to the Agent’s administration of the Facilities.

 

The Credit Agreements contain affirmative and negative covenants customarily applicable to senior secured credit facilities, including covenants that, among other things, limit or restrict the ability of the Borrowers, subject to negotiated exceptions, to incur additional indebtedness and additional liens on their assets, engage in mergers or acquisitions or dispose of assets, pay dividends or make other distributions, voluntarily prepay other indebtedness, enter into transactions with affiliated persons, make investments, and change the nature of their businesses. In addition, the Credit Agreements require the Borrowers and the Company to maintain net product revenue at or above minimum levels and to maintain a minimum adjusted EBITDA and a minimum liquidity, in each case at levels specified in the Credit Agreements.

 

On March 7, 2022, the Credit Agreements were amended to, among other things, (i) provide for a waiver of compliance with respect to the Company’s minimum adjusted EBITDA requirement if and so long as the Company’s liquidity (as specifically defined in the Credit Agreements) is in excess of $14 million and there is not otherwise an event of default under the Credit Agreements, commencing with the next delivery of the compliance certificate required under the Credit Agreements, and (ii) re-set the date certain fees payable in connection with optional prepayments are determined to the date the amendment was executed and consequently extend such fees’ original expiration. In addition, the exit fees were increased by 25 basis points.

 

Prior Credit Facilities

 

Under the Second A&R Credit Agreement, we could make requests for term loans from ROS and Royalty Opportunities in their sole discretion in amounts equal to the remaining commitment for additional delayed draw loans, which was approximately $2.2 million as of the date of the Second A&R Credit Agreement, and could request additional term loans with ROS and Royalty Opportunities in their sole discretion in an aggregate amount of up to $10.0 million. No interest was scheduled to accrue on the Second A&R Credit Agreement through March 31, 2020.

 

78
 

 

On May 6, 2020, we entered into a First Amendment to the Second A&R Credit Agreement (the “First Amendment”) with ROS and Royalty Opportunities which, among other things, provided that:

 

●No interest would accrue on the Loans from and after March 31, 2020 until September 30, 2020;

 

●Beginning October 1, 2020 through the maturity date of the Second A&R Credit Agreement, interest payable in cash would accrue on the Loans under the Second A&R Credit Agreement at a rate per annum equal to the sum of (i) 10.00% plus (ii) the higher of (x) the LIBO Rate (as such term is defined in the Second A&R Credit Agreement) and (y) 2.3125%;

 

●The maturity date of the Loans was December 31, 2021.

 

On May 6, 2020, we issued warrants to purchase an aggregate of 2.4 million shares of our common stock to ROS and Royalty Opportunities, with an exercise price of $0.01 per share and an expiration date of May 6, 2030 (collectively, the “2020 Warrants”). The issuance of the 2020 Warrants was a condition to the effectiveness of the First Amendment. The First Amendment was accounted for as a debt modification whereby the recorded debt balance was discounted for the fair value of the 2020 Warrants issued and interest expense is accrued through the maturity date of the Loans at the post-amendment effective interest rate of 10.02%. These 2020 Warrants were exercised in full in November 2020.

 

On October 1, 2020, we entered into a Second Amendment to the Second A&R Credit Agreement (the “Second Amendment”) with ROS and Royalty Opportunities, which among other things, provided for:

 

●Extinguishment by ROS and Royalty Opportunities of approximately $61.9 million of principal and paid-in-kind interest outstanding on the Loans in exchange for approximately 57.8 million shares of our common stock and the addition of a principal amount equal to prepayment fees associated with the Loans not paid in cash or exchanged for shares of our common stock;

 

●Exchange of approximately $0.9 million of prepayment fees associated with the Loans for approximately 0.9 million shares of our common stock (the “Prepayment Fee Shares”);

 

●Elimination of the availability of additional draw loan advances and reduction of available additional term loans to $5.0 million, the availability of which is in the sole and absolute discretion of the lender;

 

●Accrual of interest payable in cash for the remaining term of the Second A&R Credit Agreement at a rate per annum equal to the sum of (i) 7.00% plus (ii) the higher of (x) the LIBO Rate (as such term is defined in the Second A&R Credit Agreement) and (y) 1.00%; and

 

●Elimination of certain financial covenants.

 

As a result of the debt restructuring, as previously described, we recorded a gain on restructuring totaling $15.1 million during the year ended December 31, 2020. The gain represents the excess of the carrying value of our outstanding loans under the Second A&R Credit Agreement prior to the extinguishment of such debt in the debt restructuring transaction, $80.3 million, over the sum of the fair value of the 57.8 million shares issued therewith, $48.2 million based on the closing price of our common stock on October 1, 2020, and $17.1 million of undiscounted future cash payments associated with the Second Amendment. Because of the related party affiliation between the Company and ROS and Royalty Opportunities, this debt extinguishment resulted in an increase in additional paid-in capital rather than flowing through our consolidated statements of operations as a gain on extinguishment.

 

The carrying value of loans outstanding under the Second A&R Credit Agreement was equal to the undiscounted future cash payments associated with the Second Amendment and principal associated with loans thereunder. Cash interest payments in connection with the Second A&R Credit Agreement reduced the carrying value of associated loans; and accordingly, no interest expense related to cash interest payments was recorded for the remaining duration of the Second A&R Credit Agreement.

 

79
 

 

(8) Equity

 

Charter Amendments

 

On August 7, 2020, the Company’s stockholders, upon recommendation of the Board, approved an amendment to the Company’s Charter to increase the number of authorized shares of common stock from 75 million to 300 million. This Charter amendment was effective upon the filing of a Certificate of Amendment with the Office of the Secretary of State of the State of Delaware on October 1, 2020.

 

Debt Restructuring

 

On October 1, 2020, we issued 58.7 million shares of our common stock in connection with our debt restructuring. See Note (7) Debt.

 

Rights Offering

 

On November 6, 2020, we distributed to holders of our common stock, at no charge, non-transferable subscription rights to purchase up to an aggregate of 14,018,690 shares of our common stock (the “Rights Offering”). In the Rights Offering, holders received 0.194539 subscription rights for each share of common stock held on the record date, November 5, 2020. Each whole subscription right entitled the holder to purchase one share of our common stock for $1.07 in cash. The Rights Offering was commenced on November 6, 2020 and expired on December 4, 2020, at which time the rights were no longer exercisable. We issued 712,646 shares of our common stock in the Rights Offering, resulting in $0.8 million in gross proceeds to us.

 

Warrant Exercises

 

On November 17, 2020, ROS and Royalty Opportunities exercised warrants representing an aggregate of 4.8 million shares of our common stock and in connection therewith we received aggregate proceeds of $48,000. See Note (10) Warrants.

 

Private Placement

 

On February 24, 2021, we issued in a private placement (the “Private Placement”) to a single healthcare-focused institutional accredited investor (the “Investor”) 8,888,890 shares of our common stock at a purchase price of $2.25 per share, and warrants to purchase up to 6,666,668 shares of our common stock (the “Investor Warrant”). We received net cash proceeds of approximately $18.4 million, after deducting fees and other estimated offering expenses, from the Private Placement.

 

The Investor Warrant, described in more detail in Note (10), Warrants, has an exercise price of $2.25 per share, subject to customary anti-dilution, but not price protection, adjustments, is immediately exercisable and expires on the five-year anniversary of the date of issuance.

 

In connection with the Private Placement, we entered into a placement agent agreement with a placement agent (the “Placement Agent”) pursuant to which the Placement Agent served as our exclusive placement agent in connection with the Private Placement (the “Placement Agent Agreement”). Pursuant to the Placement Agent Agreement, we agreed to pay the Placement Agent a fee equal to a certain percentage of the aggregate gross proceeds from the Private Placement. In addition to the cash fee, we agreed to issue to the Placement Agent a warrant to purchase up to 5.0% of the shares sold to the Investor in the Private Placement, or 444,444 shares of our common stock (the “Placement Agent Warrant”). The Placement Agent Warrant, described in more detail in Note 10, “Warrants”, has an exercise price of $2.8125 per share, subject to customary anti-dilution, but not price protection, adjustments, is immediately exercisable and expires on the five-year anniversary of the date of issuance.

 

80
 

 

(9) Stock-Based Compensation

 

Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan

 

On August 1, 2018, our stockholders approved the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan at the 2018 annual meeting of stockholders of Xtant and on October 30, 2019 at our 2019 annual meeting of stockholders, our stockholders approved an amendment to increase the number of shares of common stock available thereunder by 1,500,000 shares. On October 27, 2020, at our 2020 annual meeting of stockholders, our stockholders approved an amendment to further increase the number of shares of our common stock available for issuance under the 2018 Plan by an additional 5,550,308 shares (as amended, the “2018 Plan”). The 2018 Plan became effective immediately upon initial approval of the plan by our stockholders on August 1, 2018 and will expire on July 31, 2028, unless terminated earlier. The 2018 Plan replaced the Amended and Restated Xtant Medical Equity Incentive Plan (the “Prior Plan”) with respect to future grants of equity awards, although the Prior Plan continues to govern equity awards granted under the Prior Plan. The 2018 Plan permits the Board, or a committee thereof, to grant to eligible employees, non-employee directors, and consultants of the Company non-statutory and incentive stock options, stock appreciation rights, restricted stock awards, restricted stock units, deferred stock units, performance awards, non-employee director awards, and other stock-based awards. The Board may select 2018 Plan participants and determine the nature and amount of awards to be granted. Subject to adjustment as provided in the 2018 Plan, the number of shares of our common stock available for issuance under the 2018 Plan is 8,358,055 shares, of which 1,246,080 shares remained available for grant as of December 31, 2021. Under the 2018 Plan, shares of our common stock related to awards granted under the plan that terminate by expiration, forfeiture, cancellation, or otherwise without the issuance of the shares become available again for grant under the plan.

 

Stock options granted under the 2018 Plan may be either incentive stock options to employees, as defined in Section 422A of the Internal Revenue Code of 1986, or non-qualified stock options. The exercise price of all stock options granted under the 2018 Plan must be at least equal to the fair market value of the shares of common stock on the date of the grant. The 2018 Plan is administered by the Board. Stock options granted under the 2018 Plan are generally not transferable, vest in installments over the requisite service period, and are exercisable during the stated contractual term of the option only by the optionee.

 

Stock option activity, including options granted under the 2018 Plan and the Prior Plan was as follows:

 

   2021   2020 
           Weighted           Weighted 
       Weighted   Average
Fair		       Weighted   Average
Fair		 
       Average
Exercise		   Value at
Grant		       Average
Exercise		   Value at
Grant		 
   Shares   Price   Date   Shares   Price   Date 
Outstanding at January 1   2,190,892   $2.25   $1.65    602,966   $6.07   $3.99 
Granted   1,012,083    1.27    1.07    1,708,743    1.24    1.01 
Cancelled or expired   (1,309)   345.82    170.89    (120,817)   6.95    4.31 
Outstanding at December 31   3,201,666   $1.80   $1.40    2,190,892   $2.25   $1.65 
Exercisable at December 31   649,042   $3.36   $2.37    122,739   $14.74   $8.95 

 

The estimated fair value of stock options granted is determined using the Black-Scholes-Merton method applied to individual grants. Key assumptions used to estimate the fair value of stock awards are as follows:

 

   Year Ended 
   December 31, 
   2021   2020 
Risk free interest rate   0.97%   0.54%
Dividend yield   0%   0%
Expected term   6.3 years    6.3 years 
Expected volatility   113%   105%

 

81
 

 

Restricted stock unit activity for awards granted under the 2018 Plan was as follows:

 

   2021   2020 
   Shares  

Weighted

Average Fair

Value at Grant

Date Per

Share

   Shares  

Weighted

Average Fair

Value at Grant

Date Per Share

 
Outstanding at January 1   2,503,698   $1.54    499,914   $2.87 
Granted   1,249,002   $1.27    2,148,662   $1.29 
Vested   (782,596)  $1.72    (144,878)  $2.52 
Outstanding at December 31   2,970,104   $1.39    2,503,698   $1.54 

 

Total stock-based compensation expense recognized for employees and directors was $2.2 million and $1.1 million for the years ended December 31, 2021 and 2020, respectively, and was recognized as general and administrative expense. As of December 31, 2021, total compensation expense related to unvested employee stock options not yet recognized was $2.7 million, which is expected to be allocated to expenses over a weighted-average period of 3.1 years. Total compensation expense related to unvested restricted stock units not yet recognized was $3.4 million as of December 31, 2021, which is expected to be allocated to expenses over a weighted-average period of 2.8 years.

 

(10) Warrants

 

2021 Warrants

 

As noted in Note 8, “Equity,” on February 22, 2021, the Company issued the Investor Warrants and Placement Agent Warrants. The Investor and Placement Agent Warrants meet all the requirements to be classified as equity awards in accordance with Accounting Standards Codification (“ASC”) No. 815-40. The number of shares of Company common stock issuable upon exercise of the Investor Warrants and Placement Agent Warrants is subject to standard and customary anti-dilution provisions for stock splits, stock dividends, or similar transactions. In addition, the Investor Warrants include a buy-out right whereby the holders of such warrants may put the warrants back to the Company or its successor in the event of a purchase, tender or exchange offer accepted by 50% or more of the Company’s holders of common stock and not approved by the Company’s board of directors. The buy-out amount is equal to the Black-Scholes value of the warrants on the date the triggering transaction is consummated based on certain inputs as defined in the Investor Warrant agreement. The consideration to be paid if the buy-out provision is triggered shall be in the same type or form of consideration that is being offered and paid to the holders of Company common stock in connection with the triggering transaction.

 

While the Investor Warrants are classified as a component of equity, we were required to allocate the proceeds of the Private Placement between the shares of common stock and Investor Warrants issued based on their relative fair values. We utilized a lattice valuation model to determine the fair value of the Investor Warrants. The fair value of the Placement Agent Warrants issued in connection with the Private Placement was determined using a Black Scholes model. Significant assumptions in both models included contractual term (5 years) and the estimated volatility factor based on a weighted average of comparable published betas of peer companies (61%).

 

2020 Warrants

 

As noted in Note 7, “Debt,” on May 6, 2020, we issued warrants to purchase an aggregate 2.4 million shares of our common stock to ROS and Royalty Opportunities with an exercise price of $0.01 per share and an expiration date of May 6, 2030. The issuance of the 2020 Warrants was a condition to the effectiveness of the First Amendment. The fair value of the 2020 Warrants upon issuance was determined to be $1.9 million. The 2020 Warrants met all the requirements to be classified as equity awards in accordance with ASC No. 815-40. The number of shares of our common stock issuable upon exercise of the 2020 Warrants was subject to standard and customary anti-dilution provisions for stock splits, stock dividends, or similar transactions. The 2020 Warrants were exercised in full on November 17, 2020.

 

82
 

 

The following table summarizes our warrant activities for the years ended December 31, 2021 and 2020:

 

       Weighted 
   Common   Average 
   Stock   Exercise 
   Warrants   Price 
Outstanding as of January 1, 2020   2,908,874   $4.16 
Issued   2,400,000    0.01 
Exercised   (4,800,000)   0.01 
Expired   (87,596)   85.92 
Outstanding as of December 31, 2020   421,278   $10.80 
Issued   7,111,112    2.29 
Expired   (421,278)   10.80 
Outstanding at December 31, 2021   7,111,112   $2.29 

 

(11) Commitments and Contingencies

 

Operating Leases

 

We currently lease four office facilities. These leases are under non-cancelable operating lease agreements with expiration dates between 2023 and 2025. We have the option to extend certain leases to five or ten-year term(s) and we have the right of first refusal on any sale.

 

The Company records lease liabilities within current liabilities or long-term liabilities based upon the length of time associated with the lease payments. The Company records its long-term operating leases as right-of-use assets. Upon initial adoption, using the modified retrospective transition approach, no leases with terms less than 12 months have been capitalized to the consolidated balance sheet consistent with ASC 842. Instead, these leases are recognized in the consolidated statement of operations on a straight-line expense throughout the lives of the leases. No Company leases contain common area maintenance or security agreements.

 

We have made certain assumptions and judgments when applying ASC 842, the most significant of which is that we elected the package of practical expedients available for transition, which allow us to not reassess whether expired or existing contracts contain leases under the new definition of a lease, lease classification for expired or existing leases, and whether previously capitalized initial direct costs would qualify for capitalization under ASC 842. Additionally, we did not elect to use hindsight when considering judgments and estimates such as assessments of lessee options to extend or terminate a lease or purchase the underlying asset.

 

As of December 31, 2021, the weighted-average remaining lease term was 3 years. Lease expense related to operating leases was $0.6 million for both of the years ended December 31, 2021 and 2020. The Company’s lease agreements do not provide a readily determinable implicit rate nor is it available to the Company from its lessors. Instead, as of December 31, 2021, the Company estimates the weighted-average discount rate for its operating leases to be 5.2% to present value based on the incremental borrowing rate.

 

83
 

 

Future minimum payments as of December 31, 2021 under these long-term operating leases are as follows (in thousands):

 

      
2022  $521 
2023   489 
2024   224 
2025   180 
Total future minimum lease payments   1,414 
Less amount representing interest   (110)
Present value of obligations under operating leases   1,304 
Less current portion   (462)
Long-term operating lease obligations  $842 

 

Litigation

 

In November 2020, we received a letter from a third party’s legal counsel alleging that some of our hardware products allegedly infringe an expired patent and offering to discuss settlement terms. Without admitting any liability, in July 2021, we entered into a confidential settlement agreement and release that included, among other things, a full release of all asserted patent claims from the third party and otherwise settled the dispute in exchange for a one-time lump sum payment of $550,000, which was recorded as a special charge in general and administrative expense.

 

In addition, we may be subject to potential liabilities under government regulations and various claims and legal actions that are pending but we believe are immaterial at this time or may be asserted in the future from time to time.

 

These matters arise in the ordinary course and conduct of our business and may include, for example, commercial, product liability, intellectual property, and employment matters. We intend to continue to defend the Company vigorously in such matters and when warranted, take legal action against others. Furthermore, we regularly assess contingencies to determine the degree of probability and range of possible loss for potential accrual in our financial statements. An estimated loss contingency is accrued in our financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Based on our assessment, we have adequately accrued an amount for contingent liabilities currently in existence. We do not accrue amounts for liabilities that we do not believe are probable or that we consider immaterial to our overall financial position. Litigation is inherently unpredictable, and unfavorable resolutions could occur. As a result, assessing contingencies is highly subjective and requires judgment about future events. The amount of ultimate loss may exceed the Company’s current accruals, and it is possible that its cash flows or results of operations could be materially affected in any particular period by the unfavorable resolution of one or more of these contingencies.

 

Indemnifications

 

Our arrangements generally include limited warranties and certain provisions for indemnifying customers against liabilities if our products or services infringe a third-party’s intellectual property rights. To date, we have not incurred any material costs as a result of such warranties or indemnification provisions and have not accrued any liabilities related to such obligations in the accompanying consolidated financial statements.

 

We have also agreed to indemnify our directors and executive officers for costs associated with any fees, expenses, judgments, fines and settlement amounts incurred by any of these persons in any action or proceeding to which any of those persons is, or is threatened to be, made a party by reason of the person’s service as a director or officer, including any action by us, arising out of that person’s services as our director or officer or that person’s services provided to any other company or enterprise at our request.

 

84
 

 

(12) Income Taxes

 

The Company’s provision for income taxes differs from applying the statutory U.S. Federal income tax rate to income before taxes. The primary difference results from providing for state income taxes and from deducting certain expenses for financial statement purposes but not for federal income tax purposes.

 

The components of income (loss) before provision for income taxes consist of the following (in thousands):

 

         
   Year Ended December 31, 
   2021   2020 
United States  $(4,849)  $(6,727)
           
Total  $(4,849)  $(6,727)

 

The components of the income tax provision are as follows (in thousands):

 

         
   Year Ended December 31, 
   2021   2020 
Current:          
Federal  $(51)  $51 
State   51    245 
Total current   —    296 
           
Deferred:          
Federal   —    — 
State   —    — 
Total deferred   —    — 
           
Total provision for income taxes  $—   $296 

 

The reconciliation of income tax attributable to operations computed at the U.S. Federal statutory income tax rate of 21% to income tax expense is as follows (in thousands):

 

         
   Year Ended December 31, 
   2021   2020 
Statutory Federal tax rate  $(1,018)  $(1,413)
Valuation allowance   315    (10,968)
State income taxes, net of Federal benefit   (110)   619 
Attribute reduction related to Sec. 382   —    8,607 
Change in state income tax rate   (33)   (61)
Gain on extinguishment of debt   165    3,488 
Stock compensation adjustment and other reconciling items   557    14 
Nondeductible executive compensation   124    — 
Nondeductible meals and entertainment expense   —    10 
           
Total provision for income taxes  $—   $296 

 

85
 

 

Deferred tax components are as follows (in thousands):

 

         
   At December 31, 
   2021   2020 
Deferred tax assets:          
Accrued liability for vacation  $130   $123 
Accrued commissions and bonuses / compensation   284    565 
Accrued contingencies   52    42 
Amortization   27    32 
Bad debt reserve   148    174 
Charitable contributions carryforward   15    — 
Lease liability   350    459 
Interest expense   1,968    2,342 
Inventory reserve   2,777    2,975 
Net operating loss carryovers   13,164    12,114 
Stock option compensation   783    653 
Other   113    109 
Total deferred tax assets   19,811    19,588 
           
Deferred tax liabilities:          
Right of use asset   (338)   (450)
Prepaids   (83)   (73)
Depreciation   (111)   (100)
Total deferred tax liabilities   (532)   (623)
           
Valuation allowance   (19,279)   (18,965)
           
Net deferred tax assets  $—   $— 

 

The ultimate realization of deferred tax assets is dependent upon the existence, or generation, of taxable income in the periods when those temporary differences and net operating loss carryovers are deductible. Management considers the scheduled reversal of deferred tax liabilities, taxes paid in carryover years, projected future taxable income, available tax planning strategies, and other factors in making this assessment. Based on available evidence, management does not believe it is more likely than not that all of the deferred tax assets will be realized. Accordingly, the Company has established a valuation allowance equal to the net deferred tax assets. The valuation allowance increased by $0.3 million in 2021 and decreased by $11.0 million in 2020.

 

At December 31, 2021 and 2020, the Company had total domestic Federal and state net operating loss carryovers of approximately $101.8 million and $97.0 million, respectively. Federal net operating losses generated prior to 2018 and State net operating loss carryovers expire at various dates between 2024 and 2040. Federal net operating losses generated after 2017 have an indefinite carryforward and are only available to offset 80% of taxable income beginning in 2021.

 

On March 27, 2020 the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) was signed into law. The CARES Act provided for an increased interest deduction for tax years 2019 and 2020, as well as the deferral of the employer portion of social security taxes.

 

The Company has completed a study to assess whether an ownership change, as defined by Section 382 of the Internal Revenue Code, had occurred from the Company’s formation through December 31, 2019. Based upon this study, the Company determined that an ownership change occurred during 2018. Accordingly, the Company reduced its deferred tax assets related to the federal net operating loss carryforwards that are anticipated to expire unused as a result of these ownership changes. These tax attributes were excluded from deferred tax assets with a corresponding reduction of the valuation allowance with no net effect on income tax expense or the effective tax rate. Future ownership changes may further limit the Company’s ability to utilize its remaining tax attributes.

 

The 2018 through 2020 tax years remain open to examination by the Internal Revenue Service and various other state tax agencies. These taxing authorities have the authority to examine those tax years until the applicable statute of limitations expire.

 

The Company did not recognize any material interest or penalties related to income taxes for the years ended December 31, 2021 and 2020.

 

86
 

 

(13) Employee Benefit Plans

 

We have a 401(k) plan for our employees. The 401(k) plan is a defined contribution plan covering substantially all of our employees. Employees are eligible to participate in the plan on the first day of any month after starting employment. Employees are allowed to contribute a percentage of their wages to the 401(k) plan, subject to statutorily prescribed limits and are subject to a discretionary employer match of 100% of their wage deferrals not in excess of 4% of their wages. The 401(k) plan matching contributions by the Company were temporarily suspended at the onset of the COVID-19 pandemic, but future plan matching contributions were subsequently restored effective July 1, 2020. The Company contributed $0.3 million and $0.2 million as part of the employer match program for the years ended December 31, 2021 and 2020, respectively.

 

(14) Supplemental Disclosure of Cash Flow Information

 

Supplemental cash flow information is as follows (in thousands):

 

         
   Year Ended 
   December 31, 
   2021   2020 
Cash paid during the period for:          
Interest  $846   $13 
Non-cash activities:          
Gain on extinguishment of Second A&R Credit Agreement  $785   $— 
Extinguishment of Second A&R Credit Agreement financed by line of credit  $3,755   $— 
Prepaid debt issuance costs  $75   $— 
Fixed assets acquired under finance lease  $163   $— 
Warrants issued in connection with the Private Placement to placement agents  $351   $— 
ASU 2016-13 cumulative effect adjustment  $—   $47 
Recognition of 2020 Warrants  $—   $1,862 
Partial extinguishment of Second Amended and Restated Credit Agreement (including debt issuance costs)  $—   $63,233 

 

(15) Related Party Transactions

 

Royalty Opportunities, which owns approximately 20% of the Company’s outstanding common stock, was the sole holder of our outstanding long-term debt and a party to the Second A&R Credit Agreement, which was terminated in connection with our debt refinancing described under Note 8, “Debt”. In addition, as described in more detail under Note 1, “Business Description and Summary of Significant Accounting Policies,” we are party to an Investor Rights Agreement and Registration Rights Agreement with Royalty Opportunities and ROS. Transactions between the Company and Royalty Opportunities and ROS are conducted under the provisions of the Second A&R Credit Agreement, the Prior Credit Agreement, the Investor Rights Agreement, and the Registration Rights Agreement, as noted above.

 

The Company was party to a Sublease Agreement wherein the Company leased from Cardialen, Inc., a portion of Cardialen’s office space on a month-to-month. The rent was approximately $1,000 per month. The agreement was terminated effective September 30, 2021. Because Jeffrey Peters is both a member of our Board of Directors and the Chief Executive Officer, President, and a director of Cardialen, this transaction qualified as a related party transaction.

 

All related party transactions are reviewed and approved by the Audit Committee or the disinterested members of the full Board.

 

(16) Segment and Geographic Information

 

The Company’s management reviews our financial results and manages the business on an aggregate basis. Therefore, financial results are reported in a single operating segment: the development, manufacture and marketing of orthopedic medical products and devices.

 

The Company attributes revenues to geographic areas based on the location of the customer. Approximately 99% and 98% of revenue was in the United States for the years ended December 31, 2021 and 2020, respectively. Total revenue by major geographic area is as follows (in thousands):

 

   Year Ended
December 31,		 
   2021   2020 
United States  $54,570   $52,147 
Rest of World   693    1,190 
Total  $55,263   $53,337 

 

 

87
 

 

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

 

None.

 

Item 9A. Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

Our management with the participation of our Chief Executive Officer and Interim Chief Financial Officer evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) as of December 31, 2021. Based upon that evaluation, our Chief Executive Officer and Interim Chief Financial Officer concluded that as of December 31, 2021, our disclosure controls and procedures were effective.

 

Management’s Report on Internal Control over Financial Reporting

 

Management is responsible for establishing and maintaining adequate internal control over financial reporting as such term is defined in Rule 13a-15(f) under the Exchange Act. Under the supervision and with the participation of senior and executive management, we conducted an evaluation of our internal control over financial reporting based upon the framework Internal Control - Integrated Framework (2013) as outlined by COSO, the Committee of Sponsoring Organizations of the Treadway Commission. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of an evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate.

 

Based on our evaluation under the framework Internal Control - Integrated Framework (2013), management concluded that our internal control over financial reporting was effective as of December 31, 2021.

 

Changes in Internal Control over Financial Reporting

 

There were no changes in the Company’s internal control over financial reporting during the fourth quarter ended December 31, 2021 that have materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

Item 9B. Other Information

 

On March 7, 2022, Xtant Medical Holdings, Inc., as guarantor, and its subsidiaries, Bacterin International, Inc., Xtant Medical, Inc. and X-spine Systems, Inc., as borrowers (collectively, the “Borrowers”), entered into a (i) Amendment No. 1 (the “Term Loan Amendment”) to Credit, Security and Guaranty Agreement (Term Loan) (the “Term Credit Agreement”) with MidCap Financial Trust, in its capacity as agent (the “Agent”), and a lender and the additional lenders from time to time party thereto and (ii) Amendment No. 1 (the “Revolving Loan Amendment” and collectively, with the Term Loan Amendment, the “Amendments”) to Credit, Security and Guaranty Agreement (Revolving Loan) (the “Revolving Credit Agreement” and, together with the Term Credit Agreement, the “Credit Agreements”), with the Agent and the lenders from time to time party thereto.

 

The Amendments provide for a waiver of compliance with respect to the Company’s minimum adjusted EBITDA requirement if and so long as the Company’s liquidity (as specifically defined in the Credit Agreements) is in excess of $14 million and there is not otherwise an event of default under the Credit Agreements, commencing with the next delivery of the compliance certificate required under the Credit Agreements, and (ii) re-set the date certain fees payable in connection with optional prepayments are determined to the date the amendment was executed and consequently extend such fees’ original expiration. In addition, the exit fees were increased by 25 basis points.

 

The foregoing description of the Amendments is only a summary of their material terms and do not purport to be complete and is qualified in their entirety by reference to the full text of the Term Loan Amendment and the Revolving Loan Amendment, which are filed as Exhibit 10.19 and 10.20, respectively, to this Annual Report on Form 10-K and incorporated herein by reference.

 

88
 

 

PART III

 

Item 10. Directors, Executive Officers and Corporate Governance

 

Directors and Executive Officers

 

The table below sets forth certain information concerning our current directors and executive officers as of February 25, 2022. No family relationships exist among our directors or executive officers. We sometimes refer to the Board of Directors of Xtant as the “Board.”

 

Name   Age   Position   Director/ Officer Since
Jeffrey Peters   53   Chairman of the Board and Director   2018
Sean E. Browne   56   President and Chief Executive Officer and Director   2019
John Bakewell(1)   60   Director   2018
Michael Eggenberg(2)   52   Director   2018
Robert McNamara(1)(2)   65   Director   2018
Matthew Rizzo(2)   49   Director   2018
Kevin D. Brandt   56   Chief Commercial Officer   2018
Scott C. Neils   37   Interim Chief Financial Officer   2022

 

(1)Member of the Audit Committee
(2)Member of the Compensation Committee

 

The business experience of each director and executive officer is summarized below.

 

Jeffrey Peters has served as Chairman of the Board and a member of our Board since February 2018. Mr. Peters was initially elected to the Board in connection with our restructuring in February 2018. Mr. Peters has over 25 years of medical device experience. Mr. Peters is a designee of Royalty Opportunities and ROS under the Investor Rights Agreement. Since December 2017, Mr. Peters has served as the President and Chief Executive Officer of Cardialen, Inc., a private medical device company developing low-energy therapy for cardiac arrhythmias. Mr. Peters is also a Venture Partner for OrbiMed Advisors LLC, a private equity and venture capital firm, a position he has held since January 2018. Mr. Peters served as Executive Chairman of Neurovasc Technologies, Inc. an interventional neuroradiology ischemic stroke technology company, from December 2015 to May 2017, and served as Chief Executive Officer of Anulex Technologies Inc., a former privately held medical device manufacturer, from April 2011 until May 2016. From 2013 to December 2017, Mr. Peters also served as an independent medical device consultant. From 2001 to 2007, Mr. Peters served in various positions at ev3 Inc., an endovascular company now owned by Medtronic plc, and its predecessor companies, including Chief Technology Officer, Vice President, Research and Development, Cardio Peripheral Division and Vice President, Business Development. Mr. Peters’ financial roles include portfolio manager at Black River Asset Management LLC from 2007 to 2008, an entrepreneur-in-residence at Foundation Medical Partners from 2009 to 2011, and an equity research analyst at Dain Rauscher Wessels from 1997 to 2001. Mr. Peters previously served as a member of the board of directors of Children’s Minnesota from 2016 to 2019. Mr. Peters received his BS in Mechanical Engineering and MBA from the University of Minnesota. Mr. Peters brings substantial medical device experience, including having served in several executive roles with start-up and emerging medical device companies, and significant financial and operating experience to the Board.

 

Sean E. Browne was appointed our President and Chief Executive Officer in October 2019 and has served as a member of our Board since October 2019. Prior to this, Mr. Browne served as Chief Revenue Officer of CCS Medical, Inc., a provider of home delivery medical supplies, from September 2014 to June 2019. Prior to CCS Medical, Mr. Browne served as Chief Operating Officer of The Kini Group, an integrated cloud-based software analytics and advisory firm, from March 2013 to August 2014. From November 2007 to March 2016, Mr. Browne served as President and Chief Executive Officer and a director of Neuro Resource Group, a venture start-up medical device company that was sold to a strategic buyer. In other roles, Mr. Browne served as President, Miltex Surgical Instrument Division for Integra LifeSciences Holdings Corporation, a publicly held medical device company that acquired Miltex Holdings, Inc. Mr. Browne served as Vice President, Sales and Marketing of Esurg.com, an e-commerce company serving physician and ambulatory surgery markets. Prior to Esurg.com, Mr. Browne served as Senior Vice President, Health Systems Division of McKesson Corporation, a drug company, and prior to McKesson, served in various positions with increasing responsibility at Baxter Healthcare. Mr. Browne holds a Masters of Business Administration from the Kellogg School of Management at Northwestern University and a Bachelor of Science degree, with a major in Finance and minor in Statistics, from Boston University. We believe that Mr. Browne’s day-to-day operations experience as a result of his role as our President and Chief Executive Officer enable him to make valuable contributions to the Board of Directors. In addition, in his role as President and Chief Executive Officer, Mr. Browne provides unique insight into our business strategies, opportunities and challenges, and serves as the unifying element between the leadership and strategic direction provided by the Board of Directors and the implementation of our business strategies by management.

 

89
 

 

John Bakewell has served as a member of our Board since February 2018. Mr. Bakewell was initially elected to the Board in connection with our restructuring in February 2018. Mr. Bakewell is an independent board member and consultant to the medical technology industry. He also serves on the board of directors of Treace Medical Concepts, Inc. (TMCI) and Neuronetics, Inc. (STIM), both publicly held companies and Impulse Dynamics, N.V., a privately held medical device company. Mr. Bakewell served as the Chief Financial Officer of Exact Sciences Corporation, a molecular diagnostics company, from January 2016 to November 2016. Mr. Bakewell previously served as the Chief Financial Officer of Lantheus Holdings, Inc., a diagnostic medical imaging company, from June 2014 to December 2015, as the Chief Financial Officer of Interline Brands, Inc., a distributor and direct marketer of broad-line maintenance, repair and operations products, from June 2013 to May 2014, and as the Executive Vice President and Chief Financial Officer of RegionalCare Hospital Partners, an owner and operator of non-urban hospitals, from January 2010 to December 2011. In addition, Mr. Bakewell held the position of Chief Financial Officer with Wright Medical Group, Inc., an orthopaedic company, from 2000 to 2009, with Altra Energy Technologies, Inc. from 1998 to 2000, with Cyberonics, Inc. from 1993 to 1998 and with Zeos International, Ltd. from 1990 to 1993. Mr. Bakewell began his career in the public accounting profession, serving seven years, collectively, with Ernst & Young and KPMG Peat Marwick. Mr. Bakewell previously served on the board of directors of Entellus Medical, Inc., a public ENT-focused medical device company, until its acquisition by Stryker Corp.; ev3 Inc., a public endovascular medical device company, until its acquisition by Covidien plc; Keystone Dental, Inc., a private dental implant medical device company; and Corindus Vascular Robotics, Inc., a public cardiovascular robotics medical technology company and now a Siemens Healthineers company. Mr. Bakewell holds a Bachelor of Arts in Accounting from the University of Northern Iowa and is a certified public accountant (current status inactive). Mr. Bakewell’s extensive financial and managerial experience as a senior executive of several publicly traded medical technology companies, as well as his experience serving on the board of directors of other companies contributes valuable experience to our Board.

 

Michael Eggenberg has served as a member of our Board since February 2018. Mr. Eggenberg was initially elected to the Board in connection with our restructuring in February 2018. Mr. Eggenberg is a designee of Royalty Opportunities and ROS under the Investor Rights Agreement. Since December 2016, Mr. Eggenberg has been a Managing Director with OrbiMed Advisors LLC, a private equity and venture capital firm, focusing on healthcare royalty and structured finance investments. From May 2005 to December 2016, Mr. Eggenberg was with Fortress Investment Group LLC, a global investment manager, most recently as a Managing Director focused on special opportunities funds. Mr. Eggenberg previously held positions at CIT Group Inc., Wells Fargo Bank, N.A. and Bank of America, formerly NationsBank. Mr. Eggenberg received his BS in Finance and General Business from Drexel University. Mr. Eggenberg brings valuable experience in the life science industry and finance experience to the Board.

 

Robert McNamara has served as a member of our Board since February 2018. He has over 25 years experience in the medical device industry. Mr. McNamara was initially elected to the Board in connection with our restructuring in February 2018. He also serves as Audit Committee Chairman of Axonics, Inc. (AXNX) and as a board member of Alpha Teknova, Inc. (TKNO). From January 2013 to July 2016, Mr. McNamara served as Executive Vice President and from April 2012 to July 2016 as the Chief Financial Officer for LDR Holding Corporation, a publicly held medical device (spinal implants) company acquired by Zimmer Biomet Holdings, Inc. In addition, Mr. McNamara has previously served as the Senior Vice President and Chief Financial Officer for publicly traded medical device companies including Accuray Inc., a stereotactic radiation company focused on treating cancer using AI robotics, Somnus Medical Technologies Inc., a RF energy company focused on treating upper airway breathing disorders, and Target Therapeutics, Inc., a minimally invasive catheter and device company treating vascular diseases of the brain. Mr. McNamara has been a member of the board of directors of Northstar Neurosciences Inc. and is the former Mayor of Menlo Park, California. Mr. McNamara began his career in public accounting and is a certified public accountant (current status inactive). Mr. McNamara holds a Bachelor of Science in Accounting from the University of San Francisco and a Masters of Business Administration in Finance from The Wharton School at the University of Pennsylvania. Mr. McNamara brings valuable finance and accounting experience in the medical device industry to the Board.

 

90
 

 

Matthew Rizzo has served as a member of our Board since February 2018. Mr. Rizzo was initially elected to the Board in connection with our restructuring in February 2018. Mr. Rizzo is a designee of Royalty Opportunities and ROS under the Investor Rights Agreement. Since December 2021, Mr. Rizzo has served as a General Partner with OrbiMed Advisors LLC, a private equity and venture capital firm, and is focused on healthcare royalty and structured finance investments. From April 2010 to December 2021, Mr. Rizzo served as a Partner with OrbiMed Advisors LLC. From 2009 to 2010, Mr. Rizzo was a Senior Director in Business Development at Ikaria, a biotherapeutics company. From 2006 to 2009, Mr. Rizzo was Vice President at Fortress Investment Group LLC, a global investment manager, focused on healthcare investments in the Drawbridge Special Opportunities Funds. From 2001 to 2006, Mr. Rizzo was at GlaxoSmithKline, where he worked in business and commercial analysis. Mr. Rizzo received his MBA from Duke University and his BS from University at Buffalo. Mr. Rizzo brings valuable experience in the life science industry and finance experience to the Board.

 

Kevin D. Brandt was appointed our Chief Commercial Officer in July 2018. From January 2017 to June 2018, Mr. Brandt served as Executive Vice President, Chief Commercial Officer – Domestic Direct of RTI Surgical, Inc., a surgical implant company. Mr. Brandt joined RTI as Vice President and General Manager, Emerging Technologies Commercialization in June 2012 and assumed additional responsibilities in January 2013 as head of RTI’s direct spine business. Following the acquisition of Pioneer Surgical, from July 2013 to December 2016, Mr. Brandt assumed additional responsibility when he began overseeing all North American and Canadian spine hardware and spine biologics portfolios. Mr. Brandt has over 28 years of commercial leadership experience in the global orthopedic industry focusing on building sustainable growth and value. Mr. Brandt’s expertise includes experience in sales, marketing, business development, mergers and acquisitions and integration leadership. Prior to joining RTI, Mr. Brandt held various senior leadership roles over an 18-year period in the orthopedic and spinal divisions at Stryker Corporation. In his most recent position at Stryker, he was President of Osteokinetics Corp. from January 2002 to June 2012. From June 2000 to December 2001, Mr. Brandt was Senior Director, US Spinal Sales, in which he was responsible for divesting and subsequently leading the Stryker Spine US Sales organization. Prior to joining Stryker, Mr. Brandt was a sales leader at Zimmer in a flagship office piloting a direct sales model from January 1990 to April 1994. Mr. Brandt earned a master’s degree in business administration in corporate finance and investments with distinction from Adelphi University, a bachelor of science degree in business administration from New York Institute of Technology, and has taken executive education courses at the Wharton School of Business, US Naval Academy and the Gallup organization.

 

Scott C. Neils, was appointed our Interim Chief Financial Officer January 3, 2022. From August 2019 until January 2022, Mr. Neils served as our Controller. Mr. Neils’ has 15 years of experience focused on public accounting and corporate finance. In this role, Mr. Neils gained extensive experience managing our finance and accounting functions. Prior to joining Xtant, Mr. Neils served as Audit Senior Manager at Baker Tilly US, LLP (formerly Baker Tilly Virchow Krause, LLP), an advisory, tax and assurance firm, from November 2015 to August 2019. Prior to that position, Mr. Neils was at Grant Thornton LLP, an accounting and advisory organization, from September 2007 to November 2015, most recently as Audit Manager. Mr. Neils is a Certified Public Accountant. He holds a Bachelor of Science in Business in Accounting and a Master of Accountancy from the Carlson School of Management at the University of Minnesota.

 

Controlled Company Status

 

We are a “controlled company” as defined in section 801(a) of the NYSE American Company Guide, and as such, we are exempt from certain NYSE American rules requiring our Board of Directors to have a majority of independent members, a compensation committee composed entirely of independent directors and a nominating committee composed entirely of independent directors. While we have a compensation committee, it is not comprised of a majority of independent directors. Since we do not have a nominating committee, the Board of Directors performs the functions of a nominating committee.

 

91
 

 

Investor Rights Agreement

 

We are party to an Investor Rights Agreement with OrbiMed Royalty Opportunities II, LP and ROS Acquisition Offshore LP, which are funds affiliated with OrbiMed Advisors LLC. Under the Investor Rights Agreement, Royalty Opportunities and ROS are permitted to nominate a majority of the directors and designate the chairperson of our Board of Directors at subsequent annual meetings, as long as they maintain an ownership threshold in our Company of at least 40% of our then outstanding common stock. If Royalty Opportunities and ROS are unable to maintain the Ownership Threshold, as defined in the Investor Rights Agreement, the Investor Rights Agreement contemplates a reduction of nomination rights commensurate with our ownership interests. For so long as the Ownership Threshold is met, we must obtain the approval of a majority of our common stock held by Royalty Opportunities and ROS to proceed with the following actions: (i) issue new securities; (ii) incur over $250,000 of debt in a fiscal year; (iii) sell or transfer over $250,000 of our assets or businesses or our subsidiaries in a fiscal year; (iv) acquire over $250,000 of assets or properties in a fiscal year; (v) make capital expenditures over $125,000 individually, or $1,500,000 in the aggregate during a fiscal year; (vi) approve our annual budget; (vii) hire or terminate our chief executive officer; (viii) appoint or remove the chairperson of our Board of Directors; and (ix) make, loans to, investments in, or purchase, or permit any subsidiary to purchase, any stock or other securities in another entity in excess of $250,000 in a fiscal year. As long as the Ownership Threshold is met, we may not increase the size of our Board or Directors beyond seven directors without the approval of a majority of the directors nominated by Royalty Opportunities and ROS.

 

The Investor Rights Agreement grants Royalty Opportunities and ROS the right to purchase from us a pro rata amount of any new securities that we may propose to issue and sell. The Investor Rights Agreement may be terminated (a) upon the mutual written agreement of all the parties, (b) upon our written notice or the written notice of ROS or Royalty Opportunities if the ownership percentage of our then outstanding common stock of ROS and Royalty Opportunities is less than 10%, or (c) upon written notice of ROS and Royalty Opportunities.

 

Director Independence

 

The Board has affirmatively determined that John Bakewell and Robert McNamara are “independent directors,” as defined under the independence standards of the NYSE American.

 

Board Leadership Structure

 

Under the terms of the Investor Rights Agreement, Royalty Opportunities and ROS have the right to designate the Chairman of the Board and have so designated Jeffrey Peters. Accordingly, Mr. Peters serves as Chairman of the Board. Sean E. Browne serves as our President and Chief Executive Officer. We believe this leadership structure is in the best interests of the Company and our stockholders and strikes the appropriate balance between the Chief Executive Officer’s responsibility for the strategic direction, day-to day-leadership, and performance of the Company and the Chairman of the Board’s responsibility to guide the overall strategic direction of the Company, provide oversight of our corporate governance and guidance to our Chief Executive Officer, and to set the agenda for and preside over Board meetings. We recognize that different leadership structures may be appropriate for companies in different situations and believe that no one structure is suitable for all companies. We believe that we are currently well-served by this leadership structure.

 

Board Committees

 

We currently maintain two Board committees, an Audit Committee and a Compensation Committee. We are a controlled company and have elected not to comply with the NYSE American corporate governance requirements, which require an independent nomination and governance committee and an independent compensation committee. We currently do not maintain a nomination and governance committee. While we maintain a Compensation Committee, it is not independent according to NYSE American corporate governance requirements.

 

92
 

 

The table below summarizes the current membership of each of our two standing board committees as of February 25, 2022. We also currently have a Strategic Transactions Committee on which Mr. McNamara is Chair and Messrs. Eggenberg and Rizzo serve as members.

 

Director   Audit Committee   Compensation Committee
John Bakewell   Chair    
Sean Browne        
Michael Eggenberg       ●
Robert McNamara   ●   Chair
Jeffrey Peters        
Matthew Rizzo       ●

 

Audit Committee

 

The organization and primary responsibilities of the Audit Committee are set forth in its charter, posted on our website at www.xtantmedical.com (click “Investors” and “Corporate Governance”), and include various matters with respect to the oversight of our accounting and financial reporting process and audits of our financial statements. The primary purposes of the Audit Committee include:

 

●to oversee the accounting and financial reporting processes of the Company and audits of the financial statements of the Company;

 

●to provide assistance to the Board with respect to its oversight of the following:

 

○integrity of the Company’s financial statements and internal controls;

 

○the Company’s compliance with legal and regulatory requirements;

 

○the qualifications and independence of the Company’s independent registered public accounting firm; and

 

○the performance of the Company’s internal audit function, if any, and independent registered public accounting firm.

 

●to prepare the report required to be prepared by the Audit Committee pursuant to the rules of the Securities and Exchange Commission.

 

The Audit Committee currently consists of Mr. Bakewell (Chair) and Mr. McNamara. The Audit Committee met five times during fiscal 2021. Under the NYSE American listing standards, all Audit Committee members must be independent directors and meet heightened independence requirements under the federal securities laws. In addition, all Audit Committee members must be financially literate, and at least one member must be financially sophisticated. Further, under SEC rules, the Board must determine whether at least one member of the Audit Committee is an “audit committee financial expert,” as defined by the SEC’s rules. The Board has determined that both Mr. Bakewell and Mr. McNamara are independent, financially literate, and sophisticated and qualify as “audit committee financial experts” in accordance with the applicable rules and regulations of the SEC.

 

Compensation Committee

 

The organization and responsibilities of the Compensation Committee are set forth in its charter, which is posted on our website at www.xtantmedical.com (click “Investors” and “Corporate Governance”). The primary purposes of the Compensation Committee include:

 

●recommending to the Board all compensation for the Company’s Chief Executive Officer and other executive officers;

 

93
 

 

●administering the Company’s equity-based compensation plans;

 

●reviewing, assessing, and approving overall strategies for attracting, developing, retaining, and motivating Company management and employees;

 

●overseeing the development and implementation of succession plans for the Chief Executive Officer and other key executive officers and employees;

 

●reviewing, assessing, and approving overall compensation structure on an annual basis; and

 

●recommending and leading a process for the determination of non-employee director compensation.

 

The Compensation Committee consists of Mr. McNamara (Chair), Mr. Eggenberg and Mr. Rizzo. The Compensation Committee met six times during fiscal 2021.

 

Director Nomination Process

 

Since we are not required under the NYSE rules to maintain a nominating committee and we do not have a nominating committee, the Board oversees our director nomination process. In identifying and evaluating candidates for membership on the Board, the Board may take into account all factors it considers appropriate, which may include strength of character, mature judgment, career specialization, relevant technical skills, diversity (including, but not limited to, gender, race, ethnicity, age, experience, and skills), and the extent to which the candidate would fill a present need on the Board. We do not have a formal diversity policy for directors. The Board identifies director candidates based on input provided by a number of sources, including Board members, stockholders, management, and third parties. The Board does not distinguish between nominees recommended by our stockholders and those recommended by other parties. Any stockholder recommendation must be sent to our Corporate Secretary at Xtant Medical Holdings, Inc., 664 Cruiser Lane, Belgrade, Montana 59714, and must include certain information concerning the nominee as specified in the Company’s Second Amended and Restated Bylaws. During the fourth quarter of 2021, we made no material changes to the procedures by which stockholders may recommend nominees to the Board.

 

Code of Ethics and Code of Conduct

 

We have adopted a Code of Ethics for the CEO and Senior Financial Officers as well as a Code of Conduct that applies to all directors, officers, and employees. Our corporate governance materials, including our Code of Ethics for the CEO and Senior Financial Officers and Code of Conduct, are available on our website at www.xtantmedical.com (click “Investors” and “Corporate Governance”). We intend to disclose on our corporate website any amendment to, or waiver from, a provision of our Code of Ethics for the CEO and Senior Financial Officers that applies to directors and executive officers and that is required to be disclosed pursuant to the rules of the SEC and the NYSE American.

 

94
 

 

Item 11. Executive Compensation

 

Executive Compensation

 

Summary Compensation Table

 

The table below provides summary information concerning all compensation awarded to, earned by, or paid to the individuals that served as a principal executive officer of the Company during the year ended December 31, 2021, and the two most highly compensated executives for the year ended December 31, 2021.

 

Name and Principal Position  Year   Salary(1)   Bonus(2)  

Stock

Awards(3)

  

Option

Awards(4)

  

Non-Equity

Incentive Plan

Compensation(5)

  

All

Other

Compensation(6)

   Total 
Sean E. Browne  2021   $590,228   $—   $—   $—   $

201,900

   $39,362   $

831,490

 
President and Chief  2020    603,692    —    1,850,762    1,508,484     510,000    76,116     4,549,054 
Executive Officer                                         
Greg Jensen)(7)  2021    393,846    —    198,438    206,543    

100,200

    55,883    

954,910

 
Former Vice President,  2020    402,462    —    107,557    108,469     170,000    72,616     861,104 
Finance and Chief Financial Officer                                         
Kevin D. Brandt  2021    408,615    —    205,878    214,288    

85,243

    9,992     924,016 
Chief Commercial Officer  2020    417,554    —    107,557    108,469     176,375    11,400     821,355 

 

(1)All salaries for 2020 reflect a 20% temporary reduction during second quarter of 2020 as part of our cost-savings measures in response to the COVID-19 pandemic. Additional detail on these measures and their impact on executive compensation is below under “Impact of COVID-19 Pandemic.”

 

(2)We generally do not pay any discretionary bonuses or bonuses that are subjectively determined and did not pay any such bonuses to any named executive officers in 2021. Annual cash incentive bonus payouts based on performance against pre-established performance goals are reported in the “Non-equity incentive plan compensation” column.

 

(3)Amounts reported represent the aggregate grant date fair value for restricted stock unit (“RSU”) awards computed in accordance with FASB ASC Topic 718. The grant date fair value is determined based on the per share closing sale price of our common stock on the grant date for 2021 and 2020.

 

(4)Amounts reported represent the aggregate grant date fair value for option awards granted to each named executive officer computed in accordance with FASB ASC Topic 718. The grant date fair value is determined based on our Black-Scholes option pricing model. The table below sets forth the specific assumptions used in the valuation of each such option award:

 

Grant Date  Grant Date Fair Value Per Share   Risk Free Interest Rate  

Expected

Life

  Expected Volatility   Expected Dividend Yield 
08/15/2021  $1.27    0.97%  6.25 years   112.66%   — 
11/15/2020   1.03    0.56%  6.25 years   105.28%   — 
08/15/2020   0.90    0.43%  6.25 years   101.99%   — 

 

(5)Amounts reported represent payouts under our annual bonus plan and for each year reflect the amounts earned for that year but paid during the following year.

 

95
 

 

(6)The table below provides information concerning amounts reported in the “All Other Compensation” column of the Summary Compensation Table for 2021 with respect to each named executive officer. Additional detail on these amounts is provided in the table below.

 

Name  401(k) Match   Commuting Expenses   Total 
Sean E. Browne  $11,600   $27,762   $39,362 
Greg Jensen   11,600    44,283    55,883 
Kevin D. Brandt   9,992    —    9,992 

 

(8)Mr. Jensen’s status as Vice President, Finance and Chief Financial Officer terminated effective January 3, 2022. From August 2019 to January 2022, Mr. Jensen served as our Vice President, Finance and Chief Financial Officer. From February 2019 to August 2019, Mr. Jensen served as our Vice President, Finance and Interim Chief Financial Officer, and from March 18, 2019 until the appointment of Mr. Browne as President and Chief Executive Officer on October 7, 2019, Mr. Jensen served in the capacity as our principal executive officer.

 

Executive Employment and Other Agreements

 

Employment Agreements

 

Effective October 7, 2019, we entered into an employment agreement with Sean E. Browne, our President and Chief Executive Officer, which provides for an annual base salary $600,000 and a target annual bonus opportunity equal to 100% of his annual base salary. We agreed to reimburse his reasonable travel and business expenses. In addition, we agreed to grant him an option to purchase 329,044 shares of our common stock and an RSU unit award covering 329,044 shares of our common stock under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, as amended (the “2018 Plan”), effective as of October 15, 2019, consistent with our equity grant policy. The total number of shares subject to these equity awards represented 5% of our then outstanding common stock. We also agreed to grant Mr. Browne additional stock options and RSU awards, in the same proportionate split, in the event OrbiMed (including its affiliates) converts any of our outstanding indebtedness into equity of the Company within five years. Accordingly, in response to the completion of our October 2020 debt restructuring, on November 15, 2020, we granted Mr. Browne an additional option to purchase 1,468,859 shares of our common stock and an RSU award covering 1,468,859 shares of our common stock. The terms of these awards are described under “Outstanding Equity Awards at Fiscal Year-End.” Our agreement with Mr. Browne also contains standard confidentiality, non-competition, non-solicitation and assignment of intellectual property provisions, as well as standard severance and change in control provisions, which are described under “—Potential Payments upon Termination or Change in Control.”

 

We were a party to an employment agreement with Mr. Jensen, our former Vice President, Finance and Chief Financial Officer. This agreement provided for an annual base salary $400,000 and a target annual bonus opportunity equal to 50% of his annual base salary. This agreement also contained standard confidentiality, non-competition, non-solicitation and assignment of intellectual property provisions, as well as standard severance and change in control benefits, which are described under “—Potential Payments upon Termination or Change in Control.” In connection with Mr. Jensen’s departure on January 3, 2022, the Company and Mr. Jensen entered into a standard and customary resignation agreement and release pursuant to which the Company agreed to provide Mr. Jensen certain severance benefits, as provided in his employment agreement effective as of August 8, 2019 with the Company, conditioned upon his execution and non-revocation of a release of claims against the Company.

 

Effective July 9, 2018, we entered into an employment agreement with Kevin D. Brandt, our Chief Commercial Officer, which provided for an initial annual base salary of $400,000 (which was subsequently increased to $415,000 in April 2019) with a target annual bonus of 50% of his annual base salary, and a $90,000 signing bonus, which was required to be paid back if Mr. Brandt terminated his employment with Xtant prior to the one-year anniversary of his hire date. In addition, the agreement provided for the grant of an RSU award covering 40,000 shares of our common stock, which will vest in full on July 9, 2021, the three-year anniversary date of Mr. Brandt’s hire date, assuming continued employment. The agreement also provides that Mr. Brandt is eligible to receive an annual equity award, subject to the approval of the Board, provided that the grant value of such equity award shall not be less than 50% of his annual base salary. Accordingly, on August 15, 2020, Mr. Brandt was granted an option to purchase 119,942 shares of our common stock and an RSU award covering 95,183 shares of our common stock, which are described under “Outstanding Equity Awards at Fiscal Year-End.” This agreement contains standard confidentiality, non-competition, non-solicitation, and assignment of intellectual property provisions, as well as standard severance and change in control provisions, which are described under “—Potential Payments upon Termination or Change in Control.”

 

96
 

 

Indemnification Agreements

 

We have entered into indemnification agreements with our executive officers that require us to indemnify them against certain liabilities that may arise by reason of their status or service as directors or executive officers to the fullest extent not prohibited by Delaware law.

 

401(k) Retirement Plan

 

We have a 401(k) plan for our employees. The 401(k) plan is a defined contribution plan covering substantially all of our employees. Employees are eligible to participate in the plan on the first day of any month after starting employment. Employees are allowed to contribute a percentage of their wages to the 401(k) plan, subject to statutorily prescribed limits and are subject to a discretionary employer match of 100% of their wage deferrals not in excess of 4% of their wages.

 

Outstanding Equity Awards at Fiscal Year-End

 

The table below provides information regarding unexercised option awards and unvested stock awards held by each of our named executive officers that remained outstanding at our fiscal year-end, December 31, 2021. All of the outstanding equity awards described below were granted under the 2018 Plan.

 

   Option Awards   Stock Awards 
Name  Number of Securities Underlying Unexercised Options (#) Exercisable   Number of Securities Underlying Unexercised Options (#) Unexercisable  

Option Exercise

Price

   Option Expiration Date(1)   Number of Shares or Units of Stock that Have Not Vested   Market Value of Shares or Units of Stock that Have Not Vested(2) 
Sean E. Browne   131,618    197,426(3)  $2.70   10/15/2029    197,426(4)  $110,559 
    367,215    1,101,644(5)   1.26   11/15/2030    1,101,644(6)   616,921 
Greg Jensen   19,530    19,533(7)   2.76   08/15/2029    16,950(8)   9,492 
    29,985    89,957(9)   1.13   08/15/2030    71,387(10)   39,977 
    —    192,308(11)   1.27   08/15/2031    156,250(12)   87,500 
Kevin D. Brandt   23,077    7,693(13)   6.20   08/15/2028    —    — 
    20,263    20,264(7)   2.76   08/15/2029    17,585(8)   9,848 
    29,985    89,957(9)   1.13   08/15/2030    71,387(10)   39,977 
    —    199,519(11)   1.27   08/15/2031    162,109(12)   90,781 

 

(1)All options awards have a 10-year term, but may terminate earlier if the recipient’s employment or service relationship with the Company terminates. All of Mr. Jensen’s options that were unvested as of his termination date were cancelled and his options that were vested as of his termination date will expire on April 4, 2022.

 

(2)Based on the closing price of our common stock on December 31, 2021 ($0.56), as reported by the NYSE American.

 

97
 

 

(3)This stock option vests in nearly equal installments annually over a five-year period beginning on October 15, 2020. In addition, this option will vest in full immediately in the event that it is discontinued upon a change in control or up to one year following a change in control and a pro rata percentage will vest immediately if Mr. Browne dies.

 

(4)This RSU award vests in nearly equal installments annually over a five-year period beginning on October 15, 2020. In addition, this RSU award will vest in full immediately in the event that it is discontinued upon a change in control or up to one year following a change in control and a pro rata percentage will vest immediately if Mr. Browne dies.

 

(5)This stock option vests in nearly equal installments annually over a four-year period beginning on October 15, 2021. In addition, this option will vest in full immediately in the event that it is discontinued upon a change in control or up to one year following a change in control and a pro rata percentage will vest immediately if Mr. Browne dies.

 

(6)This RSU award vests in nearly equal installments annually over a four-year period beginning on October 15, 2021. In addition, this RSU award will vest in full immediately in the event that it is discontinued upon a change in control or up to one year following a change in control and a pro rata percentage will vest immediately if Mr. Browne dies.

 

(7)This stock option vests in nearly equal installments annually over a four-year period beginning on August 15, 2020. In addition, this option will vest in full immediately in the event that it is discontinued upon a change in control or up to one year following a change in control and a pro rata percentage will vest immediately if the executive dies.

 

(8)This RSU award vests in nearly equal installments annually over a four-year period beginning on August 15, 2020. In addition, this RSU award will vest in full immediately in the event that it is discontinued upon a change in control or up to 12 months following a change in control and a pro rata percentage will vest immediately if the executive dies.

 

(9)This stock option vests with respect to 25% of the shares on August 15, 2021 and with respect to the remaining 75% of such shares over the three-year period thereafter in 12 as nearly equal as possible quarterly installments. In addition, this option will vest in full immediately in the event that it is discontinued upon a change in control or up to one year following a change in control and a pro rata percentage will vest immediately if the executive dies.

 

(10)This RSU award vests in nearly equal installments annually over a four-year period beginning on August 15, 2021. In addition, this RSU award will vest in full immediately in the event that it is discontinued upon a change in control or up to 12 months following a change in control and a pro rata percentage will vest immediately if the executive dies.

 

(11)This stock option vests with respect to 25% of the shares on August 15, 2022 and with respect to the remaining 75% of such shares over the three-year period thereafter in 12 as nearly equal as possible quarterly installments. In addition, this option will vest in full immediately in the event that it is discontinued upon a change in control or up to one year following a change in control and a pro rata percentage will vest immediately if the executive dies.

 

(12)This RSU award vests in nearly equal installments annually over a four-year period beginning on August 15, 2022. In addition, this RSU award will vest in full immediately in the event that it is discontinued upon a change in control or up to 12 months following a change in control and a pro rata percentage will vest immediately if the executive dies.

 

(13)This stock option vests in equal installments annually over a four-year period beginning on August 15, 2019. In addition, this option will vest in full immediately in the event that it is discontinued upon a change in control or up to one year following a change in control and a pro rata percentage will vest immediately if Mr. Brandt dies.

 

98
 

 

Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan

 

In 2020, the Board approved and the Company’s stockholders approved and adopted the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan (the “2018 Plan”). The purpose of the 2018 Plan is to advance the interests of the Company and our stockholders by enabling us to attract and retain qualified individuals to perform services, provide incentive compensation for such individuals in a form that is linked to the growth and profitability of our company and increases in stockholder value, and provide opportunities for equity participation that align the interests of participants with those of our stockholders.

 

The 2018 Plan replaced the Amended and Restated Xtant Medical Equity Incentive Plan (the “Prior Plan”). However, the terms of the Prior Plan, as applicable, continue to govern awards outstanding under the Prior Plan until exercised, expired, paid, or otherwise terminated or canceled.

 

The 2018 Plan permits the Board, or a committee or subcommittee thereof, to grant to eligible employees, non-employee directors, and consultants of the Company non-statutory and incentive stock options, stock appreciation rights, restricted stock awards, RSUs, deferred stock units, performance awards, non-employee director awards, and other stock-based awards. Subject to adjustment, the maximum number of shares of our common stock authorized for issuance under the 2018 Plan is 8,358,055 shares. To date, the Company has granted stock options, restricted stock and RSUs under the 2018 Plan. As of December 31, 2021, 1,246,080 shares of Xtant common stock remained available for issuance under the 2018 Plan.

 

Potential Payments upon Termination or Change in Control

 

Executive Employment Agreements

 

Under the terms of the employment agreements we have entered into with our named executive officers, if the executive’s employment is terminated by the Company without “cause” (as defined in the agreement), the executive will be entitled to receive a severance payment equal to 12 months of his annual base salary, payable as salary continuation, reimbursement of COBRA payments for up to 12 months, and the prorated amount of any unpaid bonus for the calendar year in which his termination of employment occurs, if earned pursuant to the terms thereof. If the executive’s employment is terminated by the Company without “cause” or by the executive for “good reason” in connection with or within 12 months after a “change in control” (as such terms are defined in the agreement), the executive’s severance payment, as previously described, will be paid in one lump sum, and in the case of Mr. Brandt, will equal two times his base salary. To be eligible to receive these payments, the executive will be required to execute and not revoke a release of claims against the Company.

 

In connection with Mr. Jensen’s departure on January 3, 2022, the Company and Mr. Jensen entered into a standard and customary resignation agreement and release pursuant to which the Company agreed to provide Mr. Jensen certain severance benefits, as provided in his employment agreement effective as of August 8, 2019 with the Company conditioned upon his execution and non-revocation of a release of claims against the Company.

 

Equity Award Agreements

 

All equity awards held by our named executive officers have been granted under 2018 Plan. Under the terms of the 2018 Plan and the award agreements governing these awards, if an executive’s employment or other service with the Company is terminated for cause, then all outstanding awards held by such executive will be terminated and forfeited. In the event an executive’s employment or other service with the Company is terminated by reason of death, then:

 

●All outstanding stock options will vest and become exercisable immediately as to a pro rata percentage of the unvested portion of the option scheduled to vest on the next applicable vesting date, and the vested portion of the options will remain exercisable for a period of one year after the date of such termination (but in no event after the expiration date).

 

99
 

 

●The outstanding unvested RSU awards will vest and become immediately issuable as to a pro rata percentage of the unvested portion of the RSU awards scheduled to vest on the next applicable vesting date and the unvested portion of the RSU awards will terminate.

 

In the event an executive’s employment or other service with the Company is terminated by reason of disability, then:

 

●All outstanding stock options will remain exercisable to the extent exercisable on the termination date for a period of one year after the date of such termination (but in no event after the expiration date).

 

●All outstanding unvested RSU awards will terminate.

 

In the event an executive’s employment or other service with the Company is terminated for any other reason, then:

 

●All outstanding stock options will remain exercisable to the extent exercisable on the termination date for a period of 90 days after the date of such termination (but in no event after the expiration date).

 

●All outstanding unvested RSU awards will terminate.

 

In addition, the equity award agreements governing the equity awards held by our named executive officers contain “change in control” provisions. Under the award agreements, without limiting the authority of the Compensation Committee to adjust awards, if a “change in control” of the Company (as defined in the 2018 Plan) occurs, then, unless otherwise provided in the award or other agreement, if an award is continued, assumed, or substituted by the successor entity, the award will not vest or lapse solely as a result of the change in control but will instead remain outstanding under the terms pursuant to which it has been continued, assumed, or substituted and will continue to vest or lapse pursuant to such terms. If the award is continued, assumed, or substituted by the successor entity and within one year following the change in control, the executive is either terminated by the successor entity without “cause” or, if the executive resigns for “good reason,” each as defined in the award agreement, then the outstanding option will vest and become immediately exercisable as of the termination or resignation and will remain exercisable until the earlier of the expiration of its full specified term or the first anniversary of the date of such termination or resignation, and the outstanding RSU award will be fully vested and will be converted into shares of our common stock immediately thereafter. If an award is not continued, assumed, or substituted by the successor entity, then the outstanding option will be fully vested and exercisable, and the Compensation Committee will either give the executive a reasonable opportunity to exercise the option prior to the change in control transaction or will pay the difference between the exercise price of the option and the per share consideration paid to similarly situated stockholders. Under these conditions, the outstanding RSU award will be fully vested and will be converted into shares of our common stock immediately thereafter.

 

100
 

 

Director Compensation

 

Director Compensation Program

 

Our director cash compensation consists of an annual cash retainer paid to each non-employee director and an additional annual cash retainer paid to the Chairman of the Board, the Audit Committee Chair, and the Compensation Committee Chair and annual RSU equity grants.

 

The table below sets forth the annual cash retainers for 2021:

 

Description  Annual Cash Retainer 
Non-Employee Director  $50,000 
Chairman of the Board Premium   32,500 
Audit Committee Chair Premium   32,500 
Compensation Committee Chair Premium   32,500 

 

In addition, during a portion of 2021, we maintained a Strategic Transactions Committee on which Mr. McNamara served as Chair and received a pro rata portion of an annual cash retainer of $25,000.

 

In 2021, we revised our non-employee director compensation program to provide for annual RSU equity grants, and accordingly, on August 15, 2021, each of our non-employee directors received an RSU award valued at $165,000 for 85,337 shares of our common stock. All of these RSU awards will vest on the one-year anniversary of the date of grant, August 15, 2022.

 

Director Compensation Table for Fiscal 2021

 

The table below describes the compensation earned by our directors during fiscal 2021, other than Sean E. Browne, our President and Chief Executive Officer. Mr. Browne is not compensated separately for his service as a director, and his compensation is discussed under “Executive Compensation.”

 

Name  Fees Earned or Paid in Cash   Stock Awards(1)(2)   Option Awards   All Other Compensation   Total 
John Bakewell  $82,500   $108,378   $—   $—   $190,878 
Michael Eggenberg   50,000    108,378    —    —    158,378 
Robert McNamara   95,000    108,378    —    —    203,378 
Jeffrey Peters   82,500    108,378    —    —    190,878 
Matthew Rizzo   50,000    108,378    —    —    158,378 

 

(1)The amount reported in the “Stock Awards” column represents the aggregate grant date fair value for the RSU awards granted to our non-employee directors in 2021. The grant date fair value for the RSU awards was determined based on the closing sale price of our common stock on the grant date.

 

(2)As of December 31, 2021, each non-employee director held the following number of unvested stock awards (all of which are in the form of RSU awards): Mr. Bakewell (143,436); Mr. Eggenberg (120,549); Mr. McNamara (143,436); Mr. Peters (143,146); and Mr. Rizzo (120,549).

 

101
 

 

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

 

Significant Beneficial Owners

 

The table below sets forth information as to beneficial owners that have reported to the SEC or have otherwise advised us that they are a beneficial owner, as defined by the SEC’s rules and regulations, of more than 5% of our outstanding common stock.

 

Title of Class  Name and Address of Beneficial Owner  Amount and Nature of Beneficial Ownership   Percent of Class(1) 
Common Stock 

OrbiMed Advisors LLC(2)

601 Lexington Avenue, 54th Floor

New York, NY 10022

   72,943,918    83.5%
Common Stock 

Altium Capital Management, LP(3)

152 West 57th Street, Floor 20

New York, NY 10019

   12,744,209(4)   7.2%(4)

 

(1)Percent of class is based on 87,313,701 shares of our common stock outstanding as of February 25, 2022.

 

(2)Based in-part on information contained in a Schedule 13D/A filed with the SEC on February 14, 2022. Includes 55,874,240 shares of common stock held of record by ROS Acquisition Offshore LP. OrbiMed Advisors LLC, a registered adviser under the Investment Advisors Act of 1940, as amended, is the investment manager of ROS. OrbiMed is also the investment manager of Royalty Opportunities S.àr.l., of which ROS is a wholly-owned subsidiary. By virtue of such relationships, OrbiMed may be deemed to have voting and investment power with respect to the securities held by ROS noted above and as a result may be deemed to have beneficial ownership over such securities. OrbiMed exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by ROS.

 

Also includes 17,069,678 shares of common stock held of record by OrbiMed Royalty Opportunities II, LP. OrbiMed ROF II LLC (“ROF II”) is the sole general partner of Royalty Opportunities, and OrbiMed is the sole managing member of ROF II. By virtue of such relationships, OrbiMed may be deemed to have voting and investment power with respect to the securities held by Royalty Opportunities noted above and as a result may be deemed to have beneficial ownership over such securities. OrbiMed exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by Royalty Opportunities.

 

(3)Based on information contained in a Schedule 13G filed with the SEC on March 8, 2021 and other information known to the Company. Altium Growth Fund, LP (the “Fund”), Altium Capital Management, LLC, and Altium Growth GP, LLC each have shared dispositive power and voting power over the shares. The Fund is the record and direct beneficial owner of the shares. Altium Capital Management, LP is the investment adviser of, and may be deemed to beneficially own the shares owned by the Fund. Altium Growth GP, LLC is the general partner of, and may be deemed to beneficially own the shares owned by the Fund. The number of shares consists of 6,246,291 shares of our common stock and 6,497,918 shares of our common stock issuable upon exercise of a warrant (the “Investor Warrant”).

 

(4)While the total number of shares of our common stock issuable upon exercise of the Investor Warrant is reflected in this table, the Fund is not permitted to exercise such Investor Warrant to the extent that such exercise would result in the Fund and its affiliates beneficially owning more than 9.99% of the number of shares of our common stock outstanding immediately after giving effect to the issuance of shares of common stock issuable upon exercise of such warrants. The Fund has the right to increase this beneficial ownership limitation in its discretion on 61 days’ prior written notice to us.

 

102
 

 

Security Ownership of Management

 

The table below sets forth information relating to the beneficial ownership of our common stock as of February 25, 2022, by:

 

●each of our directors;
●each of our named executive officers; and
●all directors and executive officers as a group.

 

The number of shares beneficially owned by each person is determined in accordance with the SEC’s rules and regulations, and the information is not necessarily indicative of beneficial ownership for any other purpose. Under the SEC’s rules and regulations, beneficial ownership includes any shares over which the individual has sole or shared voting power or investment power as well as any shares that the individual has the right to acquire within 60 days of February 25, 2022, through the exercise of any stock option, warrants, or other rights or the vesting of any RSU awards. Except as otherwise indicated, and subject to applicable community property laws, the persons named in the table have sole voting and investment power with respect to all shares of common stock held by that person.

 

The percentage of shares beneficially owned is computed on the basis of 87,313,701 shares of our common stock outstanding as of February 25, 2022. Shares of our common stock that a person has the right to acquire within 60 days of February 25, 2022, are deemed outstanding for purposes of computing the percentage ownership of the person holding such rights, but are not deemed outstanding for purposes of computing the percentage ownership of any other person.

 

Title of Class  Name of Beneficial Owner  Amount and Nature of Beneficial Ownership (1)   Percent of Class 
Common Stock  John Bakewell   147,794    * 
Common Stock  Sean E. Browne   837,447    1.0%
Common Stock  Michael Eggenberg   —    — 
Common Stock  Robert McNamara   146,057    * 
Common Stock  Jeffrey Peters   147,794    * 
Common Stock  Matthew Rizzo   —    — 
Common Stock  Greg Jensen   90,259    * 
Common Stock  Kevin D. Brandt   138,737    * 
Common Stock  All executive officers and directors as a group (8 persons)   1,428,083    1.6%

 

*Less than 1% of outstanding shares of common stock.

 

(1)Includes for the persons listed below the following shares subject to options and RSUs held by that person that are currently exercisable or become exercisable within 60 days of February 25, 2022:

 

Name  Options   RSUs 
Sean E. Browne   498,833    — 
Greg Jensen   49,515    — 
Kevin D. Brandt   73,326    — 
All directors and executive officers as a group (8 persons)   582,413    — 

 

103
 

 

Securities Authorized for Issuance under Equity Compensation Plans

 

The table below provides information about our common stock that may be issued under our equity compensation plans as of December 31, 2021.

 

Plan Category 

Number of Securities to Be Issued upon Exercise of Outstanding Options, Warrants and Rights

(a)

  

Weighted Average Exercise Price of Outstanding Options, Warrants and Rights

(b)

  

Number of Securities Remaining Available for Future Issuance under Equity Compensation Plans (Excluding Securities Reflected in Column (a))

(c)

 
Equity compensation plans approved by security holders   6,171,771   $1.80    1,246,080 
Equity compensation plans not approved by security holders   —    —    — 
Total   6,171,771   $1.80    1,246,080 

 

(1)Amount includes 3,188,355 shares of our common stock issuable upon the exercise of stock options granted under the 2018 Plan, 13,311 shares of our common stock issuable upon the exercise of stock options granted under the Prior Plan and 3,970,105 shares of our common stock issuable upon the vesting of RSU awards granted under the 2018 Plan.

 

(2)Not included in the weighted-average exercise price calculation are 3,970,105 RSU awards.

 

(3)Amount includes 1,246,080 shares of our common stock remaining available for future issuance under the 2018 Plan. No shares remain available for grant under the Prior Plan since such plan has been terminated with respect to future grants.

 

Item 13. Certain Relationships and Related Transactions, and Director Independence

 

Policies and Procedures for Review and Approval of Related Party Transactions

 

Pursuant to its charter, the Audit Committee reviews and approves all related party transactions and makes recommendations to the full Board regarding approval of such transactions, unless the Board specifically delegates this responsibility to the Compensation Committee. The Audit Committee reviewed the transactions described below and determined that they were fair, just, and reasonable to the Company and in the best interests of the Company and its stockholders.

 

In addition, because of its significance, the debt restructuring described below was also approved by a Special Restructuring Committee composed solely of the two Audit Committee members and prior to approving the transaction the Special Restructuring Committee received a written opinion dated August 7, 2020 from its advisor, Duff & Phelps, LLC, that, as of the date of such opinion, the exchange price of the debt restructuring was fair, from a financial point of view, to the stockholders of the Company unaffiliated with Royalty Opportunities and ROS, without giving effect to any impact of the proposed transaction on any particular stockholder other than in its capacity as a stockholder.

 

104
 

 

Related Party Transactions

 

Below is a description of transactions that have occurred during the past two fiscal years, or any currently proposed transactions, to which we were or are a participant and in which:

 

●the amounts involved exceeded or will exceed the lesser of: $120,000 or one percent (1%) of the average of our total assets at year end for the last two completed fiscal years; and

 

●a related person (including any director, director nominee, executive officer, holder of more than 5% of our common shares or any member of their immediate family) had or will have a direct or indirect material interest.

 

Investor Rights Agreement

 

We are party to an Investor Rights Agreement with OrbiMed Royalty Opportunities II, LP (“Royalty Opportunities”) and ROS Acquisition Offshore LP (“ROS”) pursuant to which Royalty Opportunities and ROS are permitted to nominate a majority of the directors and designate the chairperson of our Board of Directors at subsequent annual meetings, as long as they maintain an ownership threshold in our Company of at least 40% of our then outstanding common stock. If Royalty Opportunities and ROS are unable to maintain the Ownership Threshold, as defined in the Investor Rights Agreement, the Investor Rights Agreement contemplates a reduction of nomination rights commensurate with our ownership interests. For so long as the Ownership Threshold is met, we must obtain the approval of a majority of our common stock held by Royalty Opportunities and ROS to proceed with the following actions: (i) issue new securities; (ii) incur over $250,000 of debt in a fiscal year; (iii) sell or transfer over $250,000 of our assets or businesses or our subsidiaries in a fiscal year; (iv) acquire over $250,000 of assets or properties in a fiscal year; (v) make capital expenditures over $125,000 individually, or $1,500,000 in the aggregate during a fiscal year; (vi) approve our annual budget; (vii) hire or terminate our chief executive officer; (viii) appoint or remove the chairperson of our Board of Directors; and (ix) make loans to, investments in, or purchase, or permit any subsidiary to purchase, any stock or other securities in another entity in excess of $250,000 in a fiscal year. As long as the Ownership Threshold is met, we may not increase the size of our Board or Directors beyond seven directors without the approval of a majority of the directors nominated by Royalty Opportunities and ROS.

 

The Investor Rights Agreement grants Royalty Opportunities and ROS the right to purchase from us a pro rata amount of any new securities that we may propose to issue and sell. The Investor Rights Agreement may be terminated (a) upon the mutual written agreement of all the parties, (b) upon our written notice or the written notice of ROS or Royalty Opportunities if the ownership percentage of our then outstanding common stock of ROS and Royalty Opportunities is less than 10%, or (c) upon written notice of ROS and Royalty Opportunities.

 

Debt Restructuring

 

On August 7, 2020, we entered into a Restructuring and Exchange Agreement (the “Restructuring Agreement”) with Royalty Opportunities and ROS, pursuant to which the parties thereto agreed, subject to the terms and conditions set forth therein, to take certain actions as set forth therein and as described below (collectively, the “Restructuring Transactions”) in furtherance of a restructuring of our outstanding indebtedness under that certain Second A&R Credit Agreement, as defined below under “—Second Amended and Restated Credit Agreement and Warrant Issuance”. The primary purpose of the Restructuring Transactions was to improve our capital structure by reducing the amount of our indebtedness and cost to service our debt, which should make it easier for us to refinance or replace this debt in the future, as well as facilitate easier access to capital markets for investment in our growth initiatives. The Restructuring Transactions also allowed us to regain compliance with the NYSE American continued listing standards, which we achieved on October 5, 2020. The Restructuring Transactions included, among others:

 

●an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended (the “Charter”), to increase the number of authorized shares of our common stock from 75 million to 300 million (the “Charter Amendment”);

 

105
 

 

●the exchange by the Company of shares of our common stock for approximately $40.8 million of the aggregate outstanding principal amount of loans outstanding held by the Royalty Opportunities and ROS under the Second A&R Credit Agreement, as well as, without duplication, approximately $21.1 million of the outstanding amount of PIK Interest (as defined in the Second A&R Credit Agreement) (such loans and PIK Interest, the “Exchanging Loans”), plus all other accrued and unpaid interest on the Exchanging Loans outstanding as of the closing date, at an exchange price of $1.07 per share, representing the average closing price of our common stock over the 10 trading days immediately prior to the parties entering into the Restructuring Agreement, and resulting in the issuance of approximately 57.8 million shares of our common stock (the “Share Issuance”);

 

●the execution of an amendment to the Second A&R Credit Agreement by the parties thereto to change certain provisions therein, including extinguishing loans in an aggregate principal amount equal to the Exchanging Loans outstanding thereunder together with all accrued and unpaid interest thereon, paying a portion of the prepayment fee payable thereunder in respect of the Exchanging Loans with proceeds of additional loans under the Second A&R Credit Agreement, with the remaining portion of the prepayment fee exchanged for an additional 0.9 million shares of our common stock, reducing the amount of credit availability thereunder, decreasing the interest rate and eliminating certain financial covenants; and

 

●the launch by the Company of a rights offering to allow stockholders of the Company to purchase up to an aggregate of $15 million of our common stock at the same price per share as the $1.07 per share exchange price used to exchange the Exchanging Loans into our common stock as part of the Share Issuance (the “Rights Offering”).

 

Immediately after the execution of the Restructuring Agreement by the parties thereto, we solicited and obtained the written consent of Royalty Opportunities and ROS, the holders of an aggregate of 9,248,678 shares of our common stock as of August 7, 2020 (the “Consenting Majority Stockholders”), representing a majority of the outstanding shares of our common stock as of such date, for the approval of the Charter Amendment and the Share Issuance, in accordance with applicable provisions of the Delaware General Corporation Law and the Company’s Second Amended and Restated Bylaws. The written consent of the Consenting Majority Stockholders was sufficient to approve the Charter Amendment and the Share Issuance. Therefore, no proxies or additional consents were solicited by us in connection with the Charter Amendment and the Share Issuance. Pursuant to Section 14(c) of the Exchange Act, and the rules and regulations promulgated thereunder, on September 10, 2020, we sent a definitive information statement to all holders of our common stock as of August 7, 2020 for the purpose of informing such stockholders of the written actions taken by the Consenting Majority Stockholders. In accordance with Exchange Act Rule 14c-2, the stockholder consent of the Consenting Majority Stockholders could not become effective until at least 20 calendar days following the mailing of the information statement.

 

On October 1, 2020, the closing of the Restructuring Transactions, other than the Rights Offering, occurred, and in connection therewith, the following actions took place:

 

●the Charter Amendment was filed with the Office of the Secretary of State of the State of Delaware;

 

●the Share Issuance occurred;

 

●an amendment to the Second A&R Credit Agreement was executed by the parties thereto, and in connection therewith, the Company issued an additional 0.9 million shares of our common stock in exchange for a portion of the prepayment fee payable under the Second A&R Credit Agreement in respect of the Exchanging Loans; and

 

●the Registration Rights Agreement, as described in more detail below, was executed by the parties thereto.

 

Pursuant to the terms of the Restructuring Agreement, we commenced the Rights Offering to allow our stockholders as of the November 5, 2020 record date to purchase up to an aggregate of 14,018,690 shares of our common stock at a subscription price of $1.07 per share, the same price per share as the $1.07 per share exchange price used in the Share Issuance. The Rights Offering expired on December 4, 2020. We issued 712,646 shares of common stock in the Rights Offering and received $762,531 in gross proceeds.

 

As a result of the completion of these Restructuring Transactions, Royalty Opportunities and ROS owned immediately thereafter, in the aggregate, approximately 93.9% of our outstanding common stock.

 

106
 

 

2020 Registration Rights Agreement

 

Effective October 1, 2020, we entered into a Registration Rights Agreement with Royalty Opportunities and ROS, which required us, among other things, to file with the SEC a shelf registration statement covering the resale, from time to time, of our common stock that was issued pursuant to the Share Issuance no later than December 30, 2020 and use our best efforts to cause the shelf registration statement to become effective under the Securities Act no later than March 30, 2021. This registration statement was filed on December 18, 2020 and was declared effective by the SEC on December 23, 2020.

 

Second Amended and Restated Credit Agreement and Warrant Issuance

 

On March 29, 2019, the Company and our subsidiaries, Bacterin International, Inc., Xtant Medical, Inc. and X-spine Systems, Inc., entered into a Second Amended and Restated Credit Agreement with Royalty Opportunities and ROS (the “Second A&R Credit Agreement”). On April 1, 2019, we issued warrants to purchase an aggregate of 1.2 million shares of our common stock to Royalty Opportunities and ROS with an exercise price of $0.01 per share and an expiration date of April 1, 2029. The issuance of these warrants occurred on April 1, 2019 and was a condition to the effectiveness of the Second A&R Credit Agreement. These warrants were exercised in full in November 2020. The Second A&R Credit Agreement, as subsequently amended, has been terminated, as described below.

 

First Amendment to Second A&R Credit Agreement and Warrant Issuance

 

On May 6, 2020, the Company and our subsidiaries, Bacterin International, Inc., Xtant Medical, Inc. and X-spine Systems, Inc., entered into a First Amendment to the Second Amended and Restated Credit Agreement with Royalty Opportunities and ROS, which among other things, provided that:

 

●No interest would accrue on outstanding loans thereunder from and after March 31, 2020 until September 30, 2020;

 

●Beginning October 1, 2020 through the maturity date, interest payable in cash would accrue on the loans thereunder at a rate per annum equal to the sum of (i) 10.00% plus (ii) the higher of (x) the LIBO Rate (as such term is defined in the Second A&R Credit Agreement) and (y) 2.3125%;

 

●The maturity date of the loans thereunder was extended to December 31, 2021;

 

●The Revenue Base (as such term is defined in the Second A&R Credit Agreement) financial covenant was revised through December 31, 2021; and

 

●The key person event default provision was revised to refer specifically to Sean Browne in lieu of a former executive.

 

In conjunction therewith, we issued warrants to purchase an aggregate of 2.4 million shares of our common stock to Royalty Opportunities and ROS, with an exercise price of $0.01 per share and an expiration date of May 6, 2030. The issuance of these warrants was a condition to the effectiveness of this amendment. These warrants were exercised in full in November 2020.

 

107
 

 

Second Amendment to Second A&R Credit Agreement

 

On October 1, 2020, pursuant to the Restructuring Transactions discussed above, the Company and our subsidiaries, Bacterin International, Inc., Xtant Medical, Inc. and X-spine Systems, Inc., entered into a Second Amendment to the Second A&R Credit Agreement with Royalty Opportunities and ROS, which among other things, provided for:

 

●Extinguishment by Royalty Opportunities and ROS of approximately $61.9 million of principal and paid-in-kind interest outstanding on the loans under the Second A&R Credit Agreement in exchange for approximately 57.8 million shares of our common stock and the addition of a principal amount equal to prepayment fees associated with the loans thereunder not paid in cash or exchanged for shares of our common stock;

 

●Exchange of approximately $0.9 million of prepayment fees associated with the loans thereunder for approximately 0.9 million shares of our common stock;

 

●Elimination of the availability of additional draw loan advances and reduction of available additional term loans to $5.0 million, the availability of which is in the sole and absolute discretion of the lender;

 

●Accrual of interest payable in cash for the remaining term of the Second A&R Credit Agreement at a rate per annum equal to the sum of (i) 7.00% plus (ii) the higher of (x) the LIBO Rate (as such term is defined in the Second A&R Credit Agreement) and (y) 1.00%; and

 

●Elimination of the base revenue financial covenant.

 

After execution of the Second Amendment to the Second A&R Credit Agreement, Royalty Opportunities was the sole holder of our outstanding long-term debt and the sole lender under the Second A&R Credit Agreement, as amended.

 

On May 6, 2021, contemporaneously with the execution and delivery of the new Credit Agreements, the Second A&R Credit Agreement, as amended, was terminated in accordance with the terms thereof and all outstanding amounts were repaid by the borrowers to Royalty Opportunities in its role as sole lender thereunder.

 

During the year ended December 31, 2021, the largest amount of principal outstanding under this credit facility was $15.6 million, and as of December 31, 2021, the amount of principal outstanding was $0.00. The Company paid $1.2 million in interest under the credit facility and $15.6 million in principal amount during the year ended December 31, 2021.

 

During the year ended December 31, 2020, the largest amount of principal outstanding under this credit facility was $55.8 million. Other than principal and interest paid in Xtant common stock as part of the debt restructuring transaction described above under ““—Debt Restructuring,” the Company paid $0.3 million in interest under the credit facility and no principal amount during the year ended December 31, 2020.

 

Warrant Exercises

 

On November 17, 2020, ROS and Royalty Opportunities exercised warrants representing an aggregate of 4.8 million shares of Xtant common stock and in connection therewith the Company received aggregate proceeds of $48,000.

 

Termination of Second A&R Credit Agreement

 

On May 6, 2021, contemporaneously with the execution and delivery of the new Credit Agreements, the Second A&R Credit Agreement, as amended, was terminated in accordance with the terms thereof and all outstanding amounts were repaid by the borrowers to Royalty Opportunities in its role as sole lender thereunder.

 

Lock-Up Agreements

 

On February 24, 2021, we entered into Lock-Up Agreements with each of our directors and executive officers, pursuant to the Securities Purchase Agreement, dated as of February 22, 2021, between us and the purchasers signatory thereto. Pursuant to the Lock-Up Agreements, our directors and executive officers, among other things, agreed not to offer, sell, contract to sell, hypothecate, pledge or otherwise dispose of (or enter into any transaction which is designated to, or might reasonably be expected to, result in the disposition (whether by actual disposition or effective economic disposition due to cash settlement or otherwise) by the undersigned or any affiliate or any person in privity), directly or indirectly, or establish or increase a put equivalent position or liquidate or decrease a call equivalent position within the meaning of Section 16 of the Exchange Act with respect to any shares of our common stock, or securities convertible, exchangeable or exercisable into, our common stock beneficially owned, held or acquired by each of our executive officers or directors. The lock-up period has a 90-day duration and expired on May 25, 2021.

 

108
 

 

Sublease Agreement

 

We were party to a Sublease Agreement with Cardialen, Inc., under which we leased a portion of Cardialen’s office space in Brooklyn Center, Minnesota. The Sublease Agreement was amended several times to change the amount of office space and monthly rent. Under the amended Sublease Agreement, we agreed to pay rent ranging from $500 to $1,350 per month for 2020, $950 per month for 2021, $975 per month for 2022 and $1,000 per month thereafter through the expiration date of January 31, 2024. During fiscal 2021 and 2020, we paid a total of $7,600 and $11,215, respectively, to Cardialen under this lease agreement. This lease agreement has been terminated. Because Jeffrey Peters is both a member of our Board and the Chief Executive Officer, President, and a director of Cardialen, this transaction qualified as a related party transaction.

 

Director Independence

 

The Board has affirmatively determined that John Bakewell and Robert McNamara are “independent directors,” as defined under the independence standards of the NYSE American.

 

Item 14. Principal Accounting Fees and Services

 

Audit and Non-Audit Fees

 

Plante & Moran, PLLC (“Plante Moran”) served as the independent registered public accounting firm to audit our books and accounts for the fiscal years ended December 31, 2021 and 2020.

 

The table below presents the aggregate fees billed for professional services rendered by Plante Moran for the years ended December 31, 2021 and December 31, 2020.

 

   2021   2020 
Audit fees  $284,317   $262,116 
Audit-related fees   —    — 
Tax fees   —    — 
All other fees   8,000    18,500 
Total fees  $292,317   $280,616 

 

In the above table, “audit fees” are fees billed for services provided related to the audit of our annual financial statements, quarterly reviews of our interim financial statements, and services normally provided by the independent accountant in connection with statutory and regulatory filings or engagements for those fiscal periods. “Audit-related fees” are fees not included in audit fees that are billed by the independent accountant for assurance and related services that are reasonably related to the performance of the audit or review of our financial statements. These audit-related fees also consist of the review of our registration statements filed with the SEC and related services normally provided in connection with statutory and regulatory filings or engagements. “Tax fees” are fees billed by the independent accountant for professional services rendered for tax compliance, tax advice, and tax planning. “All other fees” are fees billed by the independent accountant for products and services not included in the foregoing categories.

 

Pre-Approval Policy

 

It is the Audit Committee’s policy to approve in advance the types and amounts of audit, audit-related, tax, and any other services to be provided by our independent registered public accounting firm. In situations where it is not practicable to obtain full Audit Committee approval, the Audit Committee has delegated authority to the Chair of the Audit Committee to grant pre-approval of auditing, audit-related, tax, and all other services up to $20,000. Any pre-approved decisions by the Chair are required to be reviewed with the Audit Committee at its next scheduled meeting. The Audit Committee approved 100% of all services provided by Plante Moran during 2021 and 2020.

 

109
 

 

PART IV

 

Item 15. Exhibit and Financial Statement Schedules

 

Financial Statements

 

Our consolidated financial statements are included in “Part II, Item 8. Financial Statements and Supplementary Data.”

 

Financial Statement Schedules

 

All financial statement schedules are omitted because they are inapplicable since we are a smaller reporting company.

 

Exhibits

 

The exhibits being filed or furnished with this report are listed below, along with an indication as to each management contract or compensatory plan or arrangement.

 

A copy of any exhibits listed or referred to herein will be furnished at a reasonable cost to any person who is a stockholder upon receipt from any such person of a written request for any such exhibit. Such request should be sent to: Scott Neils, Interim Chief Financial Officer, Xtant Medical Holdings, Inc., 664 Cruiser Lane, Belgrade, MT 59714, Attn: Stockholder Information.

 

Exhibit No.   Description
3.1   Amended and Restated Certificate of Incorporation of Xtant Medical Holdings, Inc. (filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on February 13, 2018 (SEC File No. 001-34951) and incorporated by reference herein)
     
3.2   Certificate of Amendment of the Amended and Restated Certificate of Incorporation of Xtant Medical Holdings, Inc. (filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on October 31, 2019 (SEC File No. 001-34951) and incorporated by reference herein)
     
3.3   Certificate of Amendment of the Amended and Restated Certificate of Incorporation of Xtant Medical Holdings, Inc., as amended (filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on October 1, 2020 (SEC File No. 001-34951) and incorporated by reference herein)
     
3.4   Second Amended and Restated Bylaws of Xtant Medical Holdings, Inc. (filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on February 16, 2018 (SEC File No. 001-34951) and incorporated by reference herein)
     
4.1*   Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934
     
4.2*   Form of Common Stock Certificate
     
4.3   Investor Rights Agreement dated February 14, 2018 among Xtant Medical Holdings, Inc., OrbiMed Royalty Opportunities II, LP, ROS Acquisition Offshore LP, Park West Partners International, Limited and Park West Investors Master Fund, Limited (filed as Exhibit 10.3 to the Registrant’s Current Report on Form 8-K filed with the SEC on February 16, 2018 (SEC File No. 001-34951) and incorporated by reference herein)
     
4.4   Registration Rights Agreement (for Common Stock underlying the Indenture Notes) dated January 17, 2017 among Xtant Medical Holdings, Inc., ROS Acquisition Offshore LP and OrbiMed Royalty Opportunities II, LP. (filed as Exhibit 10.9 to the Registrant’s Current Report on Form 8-K filed with the SEC on January 20, 2017 (SEC File No. 001-34951) and incorporated by reference herein)

 

110
 

 

Exhibit No.   Description
4.5   Registration Rights Agreement (for Common Stock underlying the PIK Notes) dated January 17, 2017 among Xtant Medical Holdings, Inc., ROS Acquisition Offshore LP and OrbiMed Royalty Opportunities II, LP. (filed as Exhibit 10.13 to the Registrant’s Current Report on Form 8-K filed with the SEC on January 20, 2017 (SEC File No. 001-34951) and incorporated by reference herein)
     
4.6   Registration Rights Agreement (for Common Stock issued upon the exchange of the Notes and pursuant to the Private Placement) dated as of February 14, 2018 among Xtant Medical Holdings, Inc., OrbiMed Royalty Opportunities II, LP, ROS Acquisition Offshore LP, Telemetry Securities, L.L.C., Bruce Fund, Inc., Park West Investors Master Fund, Limited, and Park West Partners International, Limited (filed as Exhibit 10.4 to the Registrant’s Current Report on Form 8-K filed with the SEC on February 16, 2018 (SEC File No. 001-34951) and incorporated by reference herein)
     
4.7   Registration Rights Agreement dated October 1, 2020 among Xtant Medical Holdings, Inc., OrbiMed Royalty Opportunities II, LP, and ROS Acquisition Offshore LP (filed as Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed with the SEC on October 1, 2020 (SEC File No. 001-34951) and incorporated by reference herein)
     
4.8   Registration Rights Agreement, dated February 24, 2021, by and between Xtant Medical Holdings, Inc. and the investor party thereto (filed as Exhibit 4.4 to the Registrant’s Registration Statement on Form S-3 filed with the SEC on April 6, 2021 (Sec File No. 333-255074) and incorporated by reference herein).
     
4.9   Form of Investor Warrant (filed as Exhibit 4.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on February 22, 2021 (SEC File No. 001-34951) and incorporated by reference herein)
     
4.10   Form of Placement Agent Warrant (filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed with the SEC on February 22, 2021 (SEC File No. 001-34951) and incorporated by reference herein)
     
10.1●   Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan (filed as Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on October 28, 2020 (SEC File No. 001-34951) and incorporated by reference herein)
     
10.2●   Form of Employee Stock Option Award Agreement for use with the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan (filed as Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed with the SEC on August 3, 2018 (SEC File No. 001-34951) and incorporated by reference herein)
     
10.3●   Form of Employee Restricted Stock Unit Award Agreement for use with the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan (filed as Exhibit 10.3 to the Registrant’s Current Report on Form 8-K filed with the SEC on August 3, 2018 (SEC File No. 001-34951) and incorporated by reference herein)
     
10.4●   Form of Non-Employee Director Restricted Stock Unit Award Agreement for use with the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan (filed as Exhibit 10.2 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 (SEC File No. 001-34951) and incorporated by reference herein)
     
10.5●   Amended and Restated Xtant Medical Equity Incentive Plan (filed as Exhibit 10.8 to the Registrant’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2015 (SEC File No. 001-34951) and incorporated by reference herein)
     
10.6●   Form of Indemnification Agreement for Directors and Officers (filed as Exhibit 10.6 to the Registrant’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2017 (SEC File No. 001-34951) and incorporated by reference herein)

 

111
 

 

Exhibit No.   Description
10.7●   Employment Agreement dated as of October 7, 2019 between Xtant Medical Holdings, Inc. and Sean E. Browne (filed as Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on October 7, 2019 (SEC File No. 001-34951) and incorporated by reference herein)
     
10.8●   Employment Agreement effective as of July 9, 2018 between Xtant Medical Holdings, Inc. and Kevin D. Brandt (filed as Exhibit 10.18 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2018 (SEC File No. 001-34951) and incorporated by reference herein)
     
10.9●   Amended and Restated Employment Agreement effective as of August 8, 2019 between Xtant Medical Holdings, Inc. and Greg Jensen (filed as Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2019 (SEC File No. 001-34951) and incorporated by reference herein)
     
10.10●*   Resignation Agreement and Release effective as of January 3, 2022 between Xtant Medical Holdings, Inc. and Greg Jensen
     
10.11●   Offer Letter dated as of January 3, 2022 between Xtant Medical Holdings, Inc. and Scott Neils (filed as Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on January 3, 2021 (SEC File No. 001-34951) and incorporated by reference herein)
     
10.12   Restructuring and Exchange Agreement dated as of January 11, 2018 among Xtant Medical Holdings, Inc., OrbiMed Royalty Opportunities II, LP, ROS Acquisition Offshore LP, Bruce Fund, Inc., Park West Partners International, Limited, Park West Investors Master Fund, Limited, and Telemetry Securities, L.L.C. (filed as Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on January 12, 2018 (SEC File No. 001-34951) and incorporated by reference herein)
     
10.13   Restructuring and Exchange Agreement, dated as of August 7, 2020, by and among Xtant Medical Holdings, Inc., OrbiMed Royalty Opportunities II, LP and ROS Acquisition Offshore LP (filed as Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on August 10, 2020 (SEC File No. 001-34951) and incorporated by reference herein)
     
10.14   Securities Purchase Agreement dated as of February 14, 2018 among Xtant Medical Holdings, Inc., OrbiMed Royalty Opportunities II, LP and ROS Acquisition Offshore LP. (filed as Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed with the SEC on February 16, 2018 (SEC File No. 001-34951) and incorporated by reference herein)
     
10.15   Securities Purchase Agreement, dated February 22, 2021, by and between Xtant Medical Holdings, Inc. and the investor party thereto (filed as Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on February 22, 2021 (SEC File No. 001-34951) and incorporated by reference herein)
     
10.16   Placement Agent Agreement, dated February 22, 2021, by and between Xtant Medical Holdings, Inc. and A.G.P./Alliance Global Partners (filed as Exhibit 10.3 to the Registrant’s Current Report on Form 8-K filed with the SEC on February 22, 2021 (SEC File No. 001-34951) and incorporated by reference herein)
     
10.17   Credit, Security and Guaranty Agreement (Term Loan), dated as of May 6, 2021, by and among Xtant Medical, Inc., Bacterin International, Inc., X-spine Systems, Inc., and any additional borrower that hereafter becomes party thereto, Xtant Medical Holdings, Inc., and any additional guarantor that hereafter becomes party thereto, and MidCap Financial Trust, as agent, and the lenders from time to time party thereto (filed as Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on May 6, 2021 (SEC File No. 001-34951) and incorporated by reference herein)

 

112
 

 

Exhibit No.   Description
10.18   Credit, Security and Guaranty Agreement (Revolving Loan), dated as of May 6, 2021, by and among Xtant Medical, Inc., Bacterin International, Inc., X-spine Systems, Inc., and any additional borrower that hereafter becomes party thereto, Xtant Medical Holdings, Inc., and any additional guarantor that hereafter becomes party thereto, and MidCap Financial Trust, as agent, and the lenders from time to time party thereto (filed as Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed with the SEC on May 6, 2021 (SEC File No. 001-34951) and incorporated by reference herein)
     
10.19*   Amendment No. 1 to Credit, Security and Guaranty Agreement (Term Loan), dated as of March 7, 2022, by and among Xtant Medical, Inc., Bacterin International, Inc., X-spine Systems, Inc., and any additional borrower that hereafter becomes party thereto, Xtant Medical Holdings, Inc., and any additional guarantor that hereafter becomes party thereto, and MidCap Financial Trust, as agent, and the lenders from time to time party thereto
     
10.20*   Amendment No. 1 to Credit, Security and Guaranty Agreement (Revolving Loan), dated as of March 7, 2022, by and among Xtant Medical, Inc., Bacterin International, Inc., X-spine Systems, Inc., and any additional borrower that hereafter becomes party thereto, Xtant Medical Holdings, Inc., and any additional guarantor that hereafter becomes party thereto, and MidCap Financial Trust, as agent, and the lenders from time to time party thereto
     
21.1   Subsidiaries of the Registrant (filed as Exhibit 21.1 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2020 (SEC File No. 001-34951) and incorporated by reference herein)
     
23.1*   Consent of Independent Registered Public Accounting Firm, Plante & Moran, PLLC
     
31.1*   Certification of Chief Executive Officer Pursuant to SEC Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
     
31.2*   Certification of Chief Financial Officer Pursuant to SEC Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
     
32.1**   Certification of Chief Executive Officer Pursuant to Rule 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
     
32.2**   Certification of Chief Financial Officer Pursuant to Rule 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
     
101.INS*   Inline XBRL INSTANCE DOCUMENT (the instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document)
     
101.SCH*   Inline XBRL TAXONOMY EXTENSION SCHEMA
     
101.CAL*   Inline XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
     
101.DEF*   Inline XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
     
101.LAB*   Inline XBRL TAXONOMY EXTENSION LABEL LINKBASE
     
101.PRE*   Inline XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
     
104   Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)

 

 

● Indicates a management contract or compensatory plan
* Filed herewith
** Furnished herewith

 

Item 16. Form 10-K Summary

 

Optional disclosure, not included in this Annual Report on Form 10-K.

 

113
 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  XTANT MEDICAL HOLDINGS, INC.
     
March 8, 2022 By: /s/ Sean E. Browne
  Name: Sean E. Browne
  Title: President and Chief Executive Officer
(principal executive officer)
     
  By: /s/ Scott Neils
  Name: Scott Neils
  Title: Interim Chief Financial Officer
(principal financial and accounting officer)

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities indicated on March 8, 2022.

 

Signature   Title
     
/s/ Sean E. Browne   President and Chief Executive Officer
Sean E. Browne   (principal executive officer)
     
/s/ Scott Neils   Interim Chief Financial Officer
Scott Neils   (principal financial and accounting officer)
     
/s/ John Bakewell   Director
John Bakewell    
     
/s/ Michael Eggenberg   Director
Michael Eggenberg    
     
/s/ Robert McNamara   Director
Robert McNamara    
     
/s/ Jeffrey Peters   Director
Jeffrey Peters    
     
/s/ Matthew Rizzo   Director
Matthew Rizzo    

 

114

 

 EX-4.1 2 ex4-1.htm

 


Exhibit 4.1

 

XTANT MEDICAL HOLDINGS, INC.

 

DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934

 

Xtant Medical Holdings, Inc., a Delaware corporation (Xtant, we, us and our), has only one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (Exchange Act): our common stock, par value $0.000001 (common stock).

 

The following description summarizes the material terms and provisions of our common stock and does not purport to be complete. It is subject to and qualified in its entirety by reference to the provisions of our Amended and Restated Certificate of Incorporation, as amended (Certificate of Incorporation), our Second Amended and Restated Bylaws (Bylaws) and the Investor Rights Agreement dated as of February 14, 2018, by and among Xtant and certain stockholders (Investor Rights Agreement), which are filed as exhibits to our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and are incorporated by reference herein. We encourage you to read our Certificate of Incorporation, our Bylaws, the Investor Rights Agreement and the applicable provisions of the General Corporation Law of the State of Delaware for additional information.

 

Authorized Shares

 

Our Certificate of Incorporation provides that we have authority to issue 300,000,000 shares of common stock and 10,000,000 shares of preferred stock, par value $0.000001 per share (preferred stock).

 

Our preferred stock may be issued from time to time in one or more series. The Board of Directors of Xtant (the Board) is authorized, by resolution or resolutions, to fix the number of shares of any series of preferred stock and to determine the designation, powers, rights, preferences, qualifications, limitations, privileges and restrictions, if any, of any wholly unissued series of preferred stock, including without limitation, authority to fix by resolution or resolutions the dividend rights, dividend rate, conversion rights, voting rights, rights and terms of redemption (including sinking fund provisions), redemption price or prices and liquidation preferences of any such series, and the number of shares constituting any such series and the designation thereof, or any of the foregoing.

 

We may amend from time to time our Certificate of Incorporation to increase the number of authorized shares of common stock or preferred stock. Any such amendment would require the approval of the holders of a majority of the voting power of the shares entitled to vote thereon. In addition, pursuant to our Certificate of Incorporation, the Board is authorized to increase (but not above the total number of authorized shares of the class) or decrease (but not below the number of shares of any such series then outstanding) the number of shares of any series (including a series of preferred stock), the number of which was fixed by it, subsequent to the issuance of shares of such series then outstanding, subject to certain limitations, without the vote of our stockholders.

 

Voting Rights

 

Each holder of our common stock is entitled to one vote per share on each matter submitted to a vote at a meeting of stockholders, including in all elections for directors. Stockholders are not entitled to cumulative voting in the election of directors. Subject to applicable law and the rights, if any, of the holders of outstanding shares of any series of preferred stock we may designate and issue in the future, holders of our common stock are entitled to vote on all matters on which stockholders are generally entitled to vote.

 

Our stockholders may vote either in person or by proxy. At all meetings of stockholders for the election of directors at which a quorum is present, a plurality of the votes cast shall be sufficient to elect. All other elections and questions presented to the stockholders at a meeting at which a quorum is present shall, unless otherwise provided by our Certificate of Incorporation, our Bylaws, the rules or regulations of any stock exchange applicable to us or applicable law or pursuant to any regulation applicable to us or our securities, be decided by the affirmative vote of the holders of a majority in voting power of the shares of our stock that are present in person or by proxy and entitled to vote thereon.

 

 

 

 

Dividends

 

The Board may authorize, and we may make, distributions to our stockholders, subject to any restriction in our Certificate of Incorporation and to those limitations prescribed by law and contractual restrictions. Subject to preferences that may apply to any shares of preferred stock outstanding at the time, the holders of our common stock will be entitled to share equally, identically and ratably in any dividends that the Board may determine to issue from time to time.

 

Liquidation Rights

 

Upon liquidation, dissolution or winding up, all holders of our common stock are entitled to participate pro rata in our assets available for distribution, subject to applicable law and the rights, if any, of the holders of any class of preferred stock then outstanding.

 

Other Rights and Preferences

 

Under the terms of our Certificate of Incorporation and Bylaws, holders of our common stock have no preemptive rights, conversion rights or subscription rights, and there are no redemption or sinking fund provisions applicable to our common stock. The rights, preferences and privileges of the holders of our common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of preferred stock that the Board may designate and issue in the future. Our Certificate of Incorporation and Bylaws do not restrict the ability of a holder of our common stock to transfer his, her or its shares of common stock. All shares of our common stock currently outstanding are fully paid and non-assessable.

 

Transfer Agent

 

The transfer agent for our common stock is Broadridge Corporate Issuer Solutions, Inc.

 

Exchange Listing

 

Our common stock is listed on NYSE American under the symbol “XTNT.”

 

Anti-Takeover Effects of Certain Provisions of our Certificate of Incorporation, Bylaws and Investor Rights Agreement and Our Status as a Controlled Company

 

Anti-takeover provisions in our Certificate of Incorporation, Bylaws and Investor Rights Agreement and our status as a controlled company may discourage or prevent a change in control, even if such a sale could be beneficial to our stockholders.

 

Certificate of Incorporation and Bylaws

 

Our Certificate of Incorporation and Bylaws contain the following anti-takeover provisions that may have an anti-takeover effect of delaying, deferring or preventing a change in control of Xtant:

 

●We have shares of common stock and preferred stock available for issuance without stockholder approval. The existence of unissued and unreserved common stock and preferred stock may enable the Board to issue shares to persons friendly to current management or to issue preferred stock with terms that could render more difficult or discourage a third-party attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise, thereby protecting the continuity of our management.

 

●Shares of our common stock do not have cumulative voting rights in the election of directors, so our stockholders holding a majority of the shares of common stock outstanding will be able to elect all of our directors.

 

 

 

 

●Special meetings of the stockholders may be called only by the Board, the chairman of the Board or the chief executive officer.

 

●The Board may adopt, alter, amend or repeal our Bylaws without stockholder approval.

 

●Unless otherwise provided by law, any newly created directorship or any vacancy occurring on the Board for any cause may be filled by the affirmative vote of a majority of the remaining members of the Board, even if such majority is less than a quorum, and any director so elected shall hold office until the expiration of the term of office of the director whom he or she has replaced or until his or her successor is elected and qualified.

 

●The affirmative vote of the holders of at least two-thirds of the voting power of the then outstanding shares of our capital stock entitled to vote generally in the election of directors, voting together as a single class, is required to amend or repeal the provisions of our Certificate of Incorporation related to the amendment of our Bylaws, the Board and our stockholders as well as the general provisions of our Certificate of Incorporation.

 

●Stockholders must follow advance notice procedures to submit nominations of candidates for election to the Board at an annual or special meeting of our stockholders and must follow advance notice procedures to submit other proposals for business to be brought before an annual meeting of our stockholders.

 

●Unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware will be the exclusive forum for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of Xtant to us or our stockholders, (iii) any action asserting a claim arising under any provision of the General Corporation Law of the State of Delaware, our Certificate of Incorporation or our Bylaws, or (iv) any action asserting a claim governed by the internal-affairs doctrine. Notwithstanding the foregoing, Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder and Section 22 of the Securities Act of 1933, as amended (Securities Act), creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. As a result, the exclusive forum provision will not apply to suits brought to enforce any duty or liability created by the Exchange Act, the Securities Act, or any other claim for which the federal courts have exclusive jurisdiction.

 

Investor Rights Agreement

 

We are party to an Investor Rights Agreement, which includes certain provisions that may have an anti-takeover effect of delaying, deferring or preventing a change in control of Xtant. The Investor Rights Agreement includes director nomination rights, which provide that so long as the Ownership Threshold (as defined in the Investor Rights Agreement) is met, OrbiMed Royalty Opportunities II, LP and ROS Acquisition Offshore LP (collectively, the Investors) are entitled to nominate such individuals to the Board constituting a majority of the directors. In addition, under the Investor Rights Agreement, so long as the Ownership Threshold is met, certain matters require the approval of the Investors to proceed with such a transaction, including without limitation, the sale, transfer or other disposition of assets or businesses of the Company or its subsidiaries with a value in excess of $250,000 in the aggregate during any fiscal year (other than sales of inventory or supplies in the ordinary course of business, sales of obsolete assets (excluding real estate), sale-leaseback transactions and accounts receivable factoring transactions).

 

Controlled Company Status

 

We are a “controlled company” as defined in section 801(a) of the NYSE American Company Guide because more than 50% of the combined voting power of all of our outstanding common stock is beneficially owned by OrbiMed Advisors LLC. Our status as a controlled company may have an anti-takeover effect of delaying, deferring or preventing a change in control of Xtant.

 

 

 

 EX-4.2 3 ex4-2.htm

 

Exhibit 4.2

 

 

   

 

 

 

   

 

 EX-10.10 4 ex10-10.htm

 

Exhibit 10.10

 

RESIGNATION AGREEMENT AND RELEASE

 

This Resignation Agreement (“Agreement”) and the Release, which is attached and incorporated by reference as Exhibit A (“Release”), are made by and between Greg Jensen (“Employee”), and Xtant Medical Holdings, Inc., its affiliates, related or predecessor corporations, subsidiaries, successors and assigns (“Employer”).

 

Employer and Employee (collectively, “Parties”) wish to end their employment relationship in an honorable, dignified and orderly fashion. Toward that end, the Parties have agreed to separate according to the following terms.

 

IN CONSIDERATION OF THIS AGREEMENT, THE PARTIES AGREE AS FOLLOWS:

 

1. Resignation. Employee’s employment shall end effective as of January 3, 2022 and be considered by the Parties as a resignation by Employee (“Resignation Date”).

 

2. Accrued Obligations. Employer will pay to Employee his accrued by unpaid base salary and any unreimbursed business expenses through Employee’s Resignation Date (“Accrued Obligations”) as set forth in Section 12.A. of Employee’s Employment Agreement. Employer will pay the Accrued Amounts to Employee in a lump sum payment on the first regularly scheduled payday following Employee’s Resignation Date, subject to payroll deductions and withholdings as reasonably determined by the Employer to be required by applicable law.

 

3. Consideration. Employer shall, (1) after receipt of a fully executed Agreement and Release; (2) after expiration of all applicable rescission periods; and (3) provided Employee complies with his obligations under this Agreement, provide Employee with separation benefits (“Consideration”) set forth in Section 12.B. of Employee’s Employment Agreement (“Exhibit B”) as follows:

 

  A. Severance. Employer will pay to Employee severance in the total gross amount of Four-Hundred Thousand Dollars ($400,000), less required payroll deductions and withholdings, (“Severance”), payable in substantially equal installments for a period of eighteen (18) months pursuant to Employer’s standard payroll process. The Severance payments will commence with the first payroll period in July 2022 but only after the expiration of the rescission periods described in the Release have expired.
     
  B. 2021 Bonus. Employee will continue to be eligible for his bonus for 2021 subject to the terms thereof, which will be determined and paid in the same manner and at the same time as the Board of Directors, in its sole discretion, determines for the other executive officers of Employer, but no later than March 15, 2022.
     
  C. COBRA Continuation. Group health benefits end as of the month in which Employee’s Resignation Date occurs. If Employee timely elects continuation coverage under Employer’s group medical and dental plans pursuant to section 4980B of the Internal Revenue Code of 1986, as amended (“COBRA”), in accordance with ordinary plan practices, and so long as Employee remains eligible for such coverage, for the “Premium Subsidy Period,” Employer shall pay, or reimburse Employee, for such coverage of Employee (and his dependents, as applicable) at the same rate it pays for active employees enrolled under the Employer’s plans as of the Resignation Date. For purposes of the preceding sentence, the “Premium Subsidy Period” is the twelve (12) month period commencing with the month following the end of the month in which the Employee’s Resignation Date occurs.

 

 

 

 

Employee will receive the necessary enrollment forms and further information about rights and responsibilities from the Employer’s COBRA administrator shortly after Employee’s Resignation Date. In order to receive these benefits, Employee must enroll in the COBRA program.

 

4. Equity Awards. Employer and Employee acknowledge and agree that Employee holds options to purchase an aggregate of 351,313 shares of Common Stock of Employer, 49,515 shares of which are vested as of the Resignation Date and 301,798 shares of which are unvested as of the Resignation Date. Such vested options shall remain exercisable by Employee through April 4, 2022, at which time such options shall expire if not exercised. Such unvested options are terminated as of the Resignation Date. Employer and Employee further acknowledge and agree that Employee holds 285,331 Restricted Stock Units of Employer, 244,587 of which are unvested as of the Resignation Date. Such unvested Restricted Stock Units will be terminated and forfeited as of the Resignation Date.

 

5. Termination of Benefits. Except as otherwise provided by this Agreement, Employee’s participation in Employer’s employee benefits, bonus, and all other compensation or commission plans, will terminate on the Resignation Date, unless otherwise provided by law, or benefit plan. Employee shall receive no compensation or benefits under such plans, except as specifically provided in Section 3 of this Agreement.

 

6. Execution of Agreement and Release of all Claims. Employee agrees to execute the Release on or after Employee’s Resignation Date, but not earlier. Employee agrees to fully execute this Agreement, and the Release attached as Exhibit A, releasing any and all actual or potential claims which may have arisen at any time during his employment with or separation from employment with Employer. Employee’s failure to execute this Agreement and/or Release, or any attempt to rescind this Agreement or that Release, shall terminate this Agreement, and the Parties’ respective rights and obligations under this Agreement.

 

7. Satisfactory Performance and Cooperation During Transition. Employee shall fully cooperate with Employer in responding to questions, providing assistance and information, and defending against claims of any type, and will otherwise assist Employer as Employer may request through Employee’s Resignation Date (“Transition Period”). More specifically:

 

(a) During the Transition Period, Employee shall reasonably cooperate with Employer as it meets and otherwise communicates/works, with Employer’s employees, customers, strategic relationships, consultants, and vendors on the transition of Employee’s duties to other individuals. Employee shall be available, upon reasonable notice, during business hours to respond to Employer’s questions and electronic communications. Employer shall reimburse Employee for Employee’s reasonable out-of-pocket expenses (such reimbursement shall not include compensation for any such time or Employee’s attorney’s fees) incurred in accordance with this paragraph upon submission of receipts to Employer for such expenses.

 

2

 

 

(b) Employee shall not, absent Employer’s specific approval, initiate any form of communication with Employer’s employees, customers or strategic partners regarding Employer, Employer’s products or Employees, and shall communicate with such persons in the above capacity only in conjunction with person(s) who Employer has designated to participate in such communications.

 

8. Stipulation of No Charges. Employee affirmatively represents that he has not filed nor caused to be filed any charges, claims, complaints, or actions against Employer before any federal, state, or local administrative agency, court, or other forum. Except as expressly provided in this Agreement or required by law, Employee acknowledges and agrees that he has been paid all wages, bonuses, compensation, benefits and other amounts that are due, with the exception of any vested right under the terms of a written ERISA-qualified benefit plan. Employee waives any right to any form of recovery or compensation from any legal action, excluding any action claiming this Agreement and Release violate the Age Discrimination in Employment Act (“ADEA”) and/or the Older Workers Benefit Protection Act (“OWBPA”), filed or threatened to be filed by Employee or on Employee’s behalf based on Employee’s employment, terms of employment, or resignation or separation from, Employer. Employee understands that any Consideration paid to Employee pursuant to this Agreement may be deducted from any monetary award he may receive as a result of a successful ADEA and/or OWBPA claim or challenge to this Agreement and Release. This does not preclude Employee from eligibility for unemployment benefits, and does not preclude or obstruct Employee’s right to file a Charge with the Equal Employment Opportunity Commission (“EEOC”).

 

9. Return of Property. Employee shall return, on or before the Resignation Date, all Employer property in Employee’s possession or control, including but not limited to any drawings, orders, files, documents, notes, computers, laptop computers, fax machines, cell phones, smart devices, access cards, fobs, keys, reports, manuals, records, product samples, correspondence and/or other documents or materials related to Employer’s business that Employee has compiled, generated or received while working for Employer, including all electronically stored information, copies, samples, computer data, disks, or records of such materials. Employee must return to Employer, and Employee shall not retain, any Employer property as previously defined in this section.

 

10. Agreement Not to Seek Future Employment. Employee agrees that he will never knowingly seek nor accept employment or a consulting/independent contractor relationship with Employer, nor any other entity owned by Xtant Medical Holdings, Inc., either directly or through a consulting firm.

 

11. Withholding For Amounts Owed to Employer. Execution of this Agreement shall constitute Employee’s authorization for Employer to make deductions from Employee’s Consideration, for Employee’s indebtedness to Employer, or to repay Employer for unaccrued Paid Time Off already taken, employee purchases, wage or benefit overpayment, or other Employer claims against Employee, to the extent permitted by applicable law.

 

3

 

 

12. Non-Disparagement. Employee agrees that, unless it is in the context of an EEOC or other civil rights or other government enforcement agency investigation or proceeding, Employee will make no critical, disparaging or defamatory comments regarding Employer or any Released Party, as defined in the Release, in any respect or make any comments concerning the conduct or events which precipitated Employee’s resignation. Furthermore, Employee agrees not to assist or encourage in any way any individual or group of individuals to bring or pursue a lawsuit, charge, complaint, or grievance, or make any other demands against Employer or any Released Party. This provision does not prohibit Employee from participating in an EEOC or other civil rights or other government enforcement agency charge, investigation or proceeding, or from providing testimony or documents pursuant to a lawful subpoena or as otherwise required by law. Employer also agrees that it will make no critical, disparaging or defamatory comments regarding Employee.

 

13. Compliance with Employment Agreement and Protection of Confidential Information. Employee agrees to comply with the provisions of and the restrictions set forth in his Employment Agreement (Exhibit B). Employee agrees to never divulge or use any trade secrets, confidential information, or other proprietary information of Employer which Employee obtained or to which Employee had access during his employment with Employer. For purposes of this latter obligation, “Confidential Information” means information that is not generally known and that is proprietary to Employer or that Employer is obligated to treat as proprietary. It includes, but is not limited to, information or data of Employer concerning its business, financial statements, patient contact information and data, products, plans, ideas, drawings, designs, concepts, inventions, discoveries, improvements, patent applications, know-how, trade secrets, prototypes, processes, techniques and other proprietary information. It does not include information that Employee can establish: (i) is already lawfully in the possession of Employee through independent means at the time of disclosure thereof; (ii) is or later becomes part of the public domain through no fault of Employee; (iii) is lawfully received by Employee from a third party having no obligations of confidentiality to Employer; or (iv) is required to be disclosed by order of a governmental agency or by a court of competent jurisdiction. Any information that Employee knows or should reasonably know is Confidential Information, or that Employer treats as Confidential Information, will be presumed to be Confidential Information.

 

14. Confidentiality. It is the intent of Employer and Employee that the terms of this Agreement be treated as Confidential, except to the extent this Agreement is required to be disclosed under applicable federal securities laws, as determined by Employer. Employee warrants that he has not and agrees that he will not in the future disclose the terms of this Agreement, or the terms of the Consideration to be paid by Employer to Employee as part of this Agreement, to any person other than his attorney, tax advisor, spouse, or representatives of any state or federal regulatory agency, who shall be bound by the same prohibitions against disclosure as bind Employee, and Employee shall be responsible for advising those individuals or agencies of this confidentiality provision. Employee shall not provide or allow to be provided to any person this Agreement, or any copies thereof, nor shall Employee now or in the future disclose the terms of this Agreement to any person, with the sole exception of communications with Employee’s spouse, attorney and tax advisor, unless otherwise ordered to do so by a court or agency of competent jurisdiction.

 

4

 

 

15. Invalidity. In case any one or more of the provisions of this Agreement or Release shall be held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained in this Agreement and Release will not in any way be affected or impaired thereby.

 

16. Non-Admissions. The Parties expressly deny any and all liability or wrongdoing and agree that nothing in this Agreement or the Release shall be deemed to represent any concession or admission of such liability or wrongdoing or any waiver of any defense.

 

17. Governing Law. This Agreement shall be governed by and construed in accordance with the laws of Minnesota, without reference to its choice of law rules. Any action for breach of this Agreement shall be brought in the federal or state court, as appropriate, located in Minnesota.

 

18. Voluntary and Knowing Action. Employee acknowledges that he has had sufficient opportunity to review the terms of this Agreement and attached Release, and that he has voluntarily and knowingly entered into this Agreement. Employer shall not be obligated to provide any Consideration to Employee pursuant to this Agreement in the event Employee elects to rescind/revoke the Release. The Release becomes final and binding on the Parties upon expiration of the rescission/revocation period, provided Employee has not exercised his option to rescind/revoke the Release. Any attempt by Employee to rescind any part of the Release obligates Employee to immediately return all Consideration under this Agreement to counsel for Employer.

 

19. Legal Counsel and Fees. Except as otherwise provided in this Agreement and the Release, the Parties agree to bear their own costs and attorneys’ fees, if any. Employee acknowledges that Employer, by this Agreement, has advised his that he may consult with an attorney of his choice prior to executing this Agreement and the Release. Employee acknowledges that he has had the opportunity to be represented by legal counsel during the negotiation and execution of this Agreement and the Release, and that he understands he will be fully bound by this Agreement and the Release.

 

20. Modification. This Agreement may be modified or amended only by a writing signed by both Employer and Employee.

 

21. Successors and Assigns. This Agreement is binding on and inures to the benefit of the Parties’ respective successors and assigns.

 

22. Notices. Any notice, request or demand required or desired to be given hereunder shall be in writing and shall be addressed as follows:

 

5

 

 

  If to Employer: Xtant Medical Holdings, Inc.
    664 Cruiser Lane
    Belgrade, MT 59714
    Attention: Chief Executive Officer
     
  With a copy to: Thomas A. Letscher
    Fox Rothschild LLP
    Two22 Building - Suite 2000
    222 South Ninth Street
    Minneapolis, MN 55402-3338
     
  If to Employee: Greg Jensen
    1308 Summit Oaks Drive
    Burnsville, MN 55337

 

Either party may change its address by giving the other Party written notice of its new address.

 

23. Waivers. No failure or delay by either Party in exercising any right or remedy under this Agreement will waive any provision of this Agreement.

 

24. Miscellaneous. This Agreement may be executed simultaneously in counterparts, each of which shall be an original, but all of which shall constitute but one and the same agreement.

 

25. Entire Agreement. Except for any continuing, post-employment, obligations under Exhibit B, or employment related Employer policy, or as otherwise provided in this Agreement, this Agreement, the attached Release, and Exhibit B are the entire Agreement between Employer and Employee relating to his employment and his resignation. Employee understands that this Agreement and the Release cannot be changed unless it is done in writing and signed by both Employer and Employee.

 

  EMPLOYEE
     
  /s/ Greg Jensen
  Greg Jensen
  Dated:  01/27/22
     
  XTANT MEDICAL HOLDINGS, INC.
     
  By: /s/ Sean E. Browne
     
  Its: President, CEO
     
  Dated:  01/28/22

 

6

 

 

EXHIBIT A

RELEASE

 

I.Definitions. I, Greg Jensen, intend all words used in this release (“Release”) to have their plain meanings in ordinary English. Technical legal words are not needed to describe what I mean. Specific terms I use in this Release have the following meanings:

 

  A. “I,” “Me,” and “My” individually and collectively mean Greg Jensen and anyone who has or obtains or asserts any legal rights or claims through Me or on My behalf.
     
  B. “Employer” as used in this Release, shall at all times mean Xtant Medical Holdings, Inc. and any affiliates, related or predecessor corporations, parent corporations or subsidiaries, successors and assigns.
     
  C. “Released Party” or “Released Parties” as used in this Release, shall at all times mean Xtant Medical Holdings, Inc. and its affiliates, related or predecessor corporations, subsidiaries, successors and assigns, present or former officers, directors, shareholders, agents, employees, representatives and attorneys, whether in their individual or official capacities, and its affiliates, related or predecessor corporations, parent corporations or subsidiaries, successors and assigns, present or former officers, directors, shareholders, agents, employees, representatives and attorneys, whether in their individual or official capacities, benefit plans and plan administrators, and insurers, insurers’ counsel, whether in their individual or official capacities, and the current and former trustees or administrators of any pension, 401(k), or other benefit plan applicable to the employees or former employees of Employer, in their official and individual capacities.
     
  D. “My Claims” mean any and all of the actual or potential claims of any kind whatsoever I may have had, or currently may have against Employer or any Released Party, whether known or unknown, that are in any way related to My employment with or separation from employment with Employer, including, but not limited to any claims for: invasion of privacy; breach of written or oral, express or implied, contract; fraud; misrepresentation; violation of the Age Discrimination in Employment Act of 1967 (“ADEA”), 29 U.S.C. § 626, as amended; the Genetic Information Nondiscrimination Act of 2008 (“GINA”), 42 U.S.C. § 2000, et seq., the Older Workers Benefit Protection Act of 1990 (“OWBPA”), 29 U.S.C. § 626(f), Title VII of the Civil Rights Act of 1964 (“Title VII”), 42 U.S.C. § 2000e, et seq., the Americans with Disabilities Act (“ADA”), 29 U.S.C. § 2101, et seq., and as amended (“ADAAA”), the Employee Retirement Income Security Act of 1974 (“ERISA”), as amended, 29 U.S.C. § 1001, et seq., Equal Pay Act (“EPA”), 29 U.S.C. § 206(d), the Worker Adjustment and Retraining Notification Act (“WARN”), 29 U.S.C. § 2101, et seq., the Family and Medical Leave Act (“FMLA”), 29 U.S.C. § 2601, et seq.; National Labor Relations Act, 29 U.S.C. § 141, et seq., the False Claims Act, 31 U.S.C. § 3729, et seq., Anti-Kickback Statute, 42 U.S.C. § 1320a, et seq., the Minnesota Human Rights Act, Minn. Stat. § 363A.01, et seq., Minn. Stat. § 181, et seq., the Minnesota Whistleblower Act, Minn. Stat. § 181.931, et seq., the Montana Human Rights Act, Mont. Code Ann. § 49-1-101, et seq., the Montana Wrongful Discharge for Employment Act, Mont. Code Ann. § 39-2-901, et seq., the Montana Wage Payment Act, Mont. Code Ann. § 39-3-201, et. seq., or any and all other Minnesota, Montana, and other state human rights or fair employment practices statutes, administrative regulations, or local ordinances, and any other Minnesota, Montana, or other federal, state, local or foreign statute, law, rule, regulation, ordinance or order, all as amended. This includes, but is not limited to, claims for violation of any civil rights laws based on protected class status; claims for assault, battery, defamation, intentional or negligent infliction of emotional distress, breach of the covenant of good faith and fair dealing; promissory estoppel; negligence; negligent hiring; retention or supervision; retaliation; constructive discharge; violation of whistleblower protection laws; unjust enrichment; violation of public policy; and, all other claims for unlawful employment practices, and all other common law or statutory claims.

 

Ex. A-1

 

 

II. Agreement to Release My Claims. Except as stated in Section V of this Release, I agree to release all My Claims and waive any rights to My Claims. I also agree to withdraw any and all of My charges and lawsuits against Employer; except that I may, but am not required to, withdraw or dismiss, or attempt to withdraw or dismiss, any charges that I may have pending against Employer with the Employment Opportunity Commission (“EEOC”) or other civil rights enforcement agency. In exchange for My agreement to release My Claims, I am receiving satisfactory Consideration from Employer to which I am not otherwise entitled by law, contract, or under any Employer policy. The Consideration I am receiving is a full and fair consideration for the release of all My Claims. Employer does not owe Me anything in addition to what I will be receiving according to the Separation Agreement which I have signed.
   
III. Unknown Claims. In waiving and releasing any and all actual, potential, or threatened claims against Employer, whether or not now known to me, I understand that this means that if I later discover facts different from or in addition to those facts currently known by me, or believed by me to be true, the waivers and releases of this Release will remain effective in all respects – despite such different or additional facts and my later discovery of such facts, even if I would not have agreed to the Separation Agreement and this Release if I had prior knowledge of such facts.
   
IV. Confirmation of No Claims, Etc. I am not aware of any other facts, evidence, allegations, claims, liabilities, or demands relating to alleged or potential violations of law that may give rise to any claim or liability on the part of any Released Party under the Securities Exchange Act of 1934, the Sarbanes–Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the False Claims Act, the Anti-kickback Statute. I understand that nothing in this Release interferes with My right to file a complaint, charge or report with any law enforcement agency, with the Securities and Exchange Commission (“SEC”) or other regulatory body, or to participate in any manner in an SEC or other governmental investigation or proceeding under any such law, statute or regulation, or to require notification or prior approval by Employer of any such a complaint, charge or report. I understand and agree, however, that I waive My right to recover any whistleblower award under the Securities Exchange Act of 1934, the Sarbanes–Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act, or other individual relief in any administrative or legal action whether brought by the SEC or other governmental or law enforcement agency, Me, or any other party, unless and to the extent that such waiver is contrary to law. I agree that the Released Parties reserve any and all defenses which they might have against any such allegations or claims brought by Me or on My behalf. I understand that Employer is relying on My representations in this Release and related Separation Agreement.

 

Ex. A-2

 

 

V.Exclusions from Release.

 

  A. The term “Claims” does not include My rights, if any, to claim the following: unemployment insurance benefits; workers compensation benefits; claims for My vested post-termination benefits under any 401(k) or similar retirement benefit plan; My rights to group medical or group dental insurance coverage pursuant to section 4980B of the Internal Revenue Code of 1986, as amended (“COBRA”); My rights to enforce the terms of this Release; or My rights to assert claims that are based on events occurring after this Release becomes effective.
     
  B. Nothing in this Release interferes with My right to file or maintain a charge with the Equal Employment Opportunity Commission or other local civil rights enforcement agency, or participate in any manner in an EEOC or other such agency investigation or proceeding. I, however, understand that I am waiving My right to recover individual relief including, but not limited to, back pay, front pay, reinstatement, attorneys’ fees, and/or punitive damages, in any administrative or legal action whether brought by the EEOC or other civil rights enforcement agency, Me, or any other party.
     
  C. Nothing in this Release interferes with My right to challenge the knowing and voluntary nature of this Release under the ADEA and/or OWBPA.
     
  D. I agree that Employer reserves any and all defenses, which it has or might have against any claims brought by Me. This includes, but is not limited to, Employer’s right to seek available costs and attorneys’ fees as allowed by law, and to have any monetary award granted to Me, if any, reduced by the amount of money that I received in consideration for this Release.

 

VI.Older Workers Benefit Protection Act. The Older Workers Benefit Protection Act applies to individuals age 40 and older and sets forth certain criteria for such individuals to waive their rights under the Age Discrimination in Employment Act in connection with an exit incentive program or other employment termination program. I understand and have been advised that, if applicable, the above release of My Claims is subject to the terms of the OWBPA. The OWBPA provides that a covered individual cannot waive a right or claim under the ADEA unless the waiver is knowing and voluntary. If I am a covered individual, I acknowledge that I have been advised of this law, and I agree that I am signing this Release voluntarily, and with full knowledge of its consequences. I understand that Employer is giving Me twenty-one (21) days from the date I received a copy of this Release to decide whether I want to sign it. I acknowledge that I have been advised to use this time to consult with an attorney about the effect of this Release. If I sign this Release before the end of the twenty-one (21) day period it will be My personal, voluntary decision to do so, and will be done with full knowledge of My legal rights. I agree that material and/or immaterial changes to the Separation Agreement or this Release will not restart the running of this consideration period. I also acknowledge that the Separation Agreement, this Release and any other attachments or exhibits have each been written in a way that I understand.

 

Ex. A-3

 

 

VII.Right to Rescind and/or Revoke. I understand that insofar as this Release relates to My rights under the Age Discrimination in Employment Act (“ADEA”) I have the right to revoke the Release until seven (7) days after I sign it, and insofar as it relates to My rights under the Minnesota Human Rights Act (“MHRA”), I have the right to rescind the Release until fifteen (15) days after I sign it. Any such revocation or rescission must be in writing and hand-delivered to Employer or, if sent by mail, postmarked within the applicable time period, sent by certified mail, return receipt requested, and addressed as follows:

 

  A. post-marked within the applicable seven (7) or fifteen (15) day period;
     
  B. properly addressed to:
     
    Xtant Medical Holdings, Inc.
    664 Cruiser Lane
    Belgrade, MT 59714
    Attn: Chief Executive Officer
     
    and
     
  C. sent by certified mail, return receipt requested.

 

I understand that the Consideration I am receiving for settling and releasing My Claims is contingent upon My agreement to be bound by the terms of this Release. Accordingly, if I decide to rescind or revoke this Release, I understand that I am not entitled to the Consideration described in the Separation Agreement. I further understand that if I attempt to rescind or revoke My release of any claim, I must immediately return to Employer all Consideration I have received under My Agreement.

 

[Remainder of page intentionally left blank; signature page follows]

 

Ex. A-4

 

 

VIII.I Understand the Terms of this Release. I have had the opportunity to read this Release carefully and understand all its terms. I have had the opportunity to review this Release with My own attorney. In agreeing to sign this Release, I have not relied on any oral statements or explanations made by Employer, including its employees or attorneys. I understand and agree that this Release and the attached Agreement contain all the agreements between Employer and Me. We have no other written or oral agreements.

 

    /s/ Greg Jensen
    Greg Jensen
     
  Dated:  01/28/22

 

Ex. A-5

 

 

EXHIBIT B

 

EMPLOYMENT AGREEMENT

 

 

 

 

 EX-10.19 5 ex10-19.htm

 

Exhibit 10.19

 

amendment No. 1 to CREDIT, SECURITY AND GUARANTY AGREEMENT (TERM LOAN)

 

This AMENDMENT NO. 1 TO CREDIT, SECURITY AND GUARANTY AGREEMENT (TERM LOAN) (this “Agreement”) is made as of March 7, 2022, by and among XTANT MEDICAL HOLDINGS, INC., a Delaware corporation (“Holdings”) as a Guarantor, each of Holdings’ direct and indirect Subsidiaries set forth on the signature pages hereto as a “Borrower” (collectively, the “Borrowers” and each individually, a “Borrower”), MidCap Financial Trust, a Delaware statutory trust, as Agent (in such capacity, together with its successors and assigns, “Agent”) and the other financial institutions or other entities from time to time parties to the Credit Agreement referenced below, each as a Lender.

 

RECITALS

 

A. Agent, Lenders, and the Credit Parties have entered into that certain Credit, Security and Guaranty Agreement, dated as of May 6, 2021 (Term Loan) (the “Original Credit Agreement” and as amended hereby and as it may be further amended, modified, supplemented and restated from time to time, the “Credit Agreement”), pursuant to which the Lenders have agreed to make certain advances of money and to extend certain financial accommodations to Borrowers in the amounts and manner set forth in the Credit Agreement.

 

B. The Credit Parties have requested, and Agent and all Lenders have agreed, to amend certain provisions of the Original Credit Agreement, all in accordance with the terms and subject to the conditions set forth herein.

 

AGREEMENT

 

NOW, THEREFORE, in consideration of the foregoing, the terms and conditions set forth in this Agreement, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Agent, Lenders and the Credit Parties hereby agree as follows:

 

1. Recitals. This Agreement shall constitute a Financing Document and the Recitals and each reference to the Credit Agreement, unless otherwise expressly noted, will be deemed to reference the Credit Agreement as amended hereby. The Recitals set forth above shall be construed as part of this Agreement as if set forth fully in the body of this Agreement and capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the Credit Agreement (including those capitalized terms used in the Recitals hereto).

 

2. Amendments to Original Credit Agreement. Subject to the terms and conditions of this Agreement, including, without limitation, the conditions to effectiveness set forth in Section 4 below, the Original Credit Agreement is hereby amended as follows:

 

(a) Section 1.1 of the Original Credit Agreement is hereby amended by adding the following definitions in alphabetical order:

 

“First Amendment” shall mean that certain Amendment No. 1 to Credit, Security and Guaranty Agreement (Term Loan), dated as of the First Amendment Effective Date, by and among Holdings, as Guarantor, each of direct and indirect Subsidiaries of Holdings set forth on the signature pages thereto as a Borrower, Agent and Lenders.

 

“First Amendment Effective Date” shall mean March 7, 2022.

 

 
 

 

“Liquidity Threshold” means $14,000,000.

 

“Minimum EBITDA Covenant Waiver Period” means the period (x) beginning on the date upon which the Credit Parties deliver to Agent a Compliance Certificate in accordance with Section 4.1(i) evidencing that the Liquidity of the Credit Parties as of such date is greater than the Liquidity Threshold and (y) ending on the earlier to occur of (i) the occurrence of any Default or Event of Default or (ii) the date upon which the Credit Parties deliver to Agent a Compliance Certificate in accordance with Section 4.1(i) evidencing that the Liquidity of the Credit Parties as of such date is equal to or less than the Liquidity Threshold; provided that the financial covenant described in Section 6.3 shall be tested on any date upon which the Minimum EBITDA Covenant Waiver Period is terminated by operation of clause (y)(ii) of this definition.

 

(b) Section 2.2(h) of the Original Credit Agreement is hereby amended by replacing each occurrence of the words “Closing Date” with the words “First Amendment Effective Date”.

 

(c) Section 6.3 of the Original Credit Agreement is hereby amended and restated in its entirety as follows:

 

“Minimum EBITDA. Credit Parties will not permit the consolidated EBITDA of the Credit Parties for any Defined Period, as tested quarterly on the last day of the applicable Defined Period (other than any Defined Period ending during a Minimum EBITDA Covenant Waiver Period that has not been terminated on such date of determination as a result of the Credit Parties’ failure to maintain Liquidity in excess of the Liquidity Threshold), to be less than $500,000.

 

3. Representations and Warranties; Reaffirmation of Security Interest. Each Credit Party hereby confirms that all of the representations and warranties set forth in the Credit Agreement are true and correct in all material respects (without duplication of any materiality qualifier in the text of such representation or warranty) with respect to such Credit Party as of the date hereof except to the extent that any such representation or warranty relates to a specific date in which case such representation or warranty shall be true and correct as of such earlier date. Nothing herein is intended to impair or limit the validity, priority or extent of Agent’s security interests in and Liens on the Collateral. Each Credit Party acknowledges and agrees that the Credit Agreement, the other Financing Documents and this Agreement constitute the legal, valid and binding obligation of such Credit Party, and are enforceable against such Credit Party in accordance with its terms, except as the enforceability thereof may be limited by bankruptcy, insolvency or other similar laws relating to the enforcement of creditors’ rights generally and by general equitable principles.

 

4. Conditions to Effectiveness. This Agreement shall become effective as of the date on which each of the following conditions have been satisfied, as determined by Agent in its sole discretion:

 

(d) Each Credit Party shall have delivered to Agent this Agreement and the Amended and Restated Fee Letter, in each case, executed by an authorized officer of such Credit Party;

 

(e) all representations and warranties of Credit Parties contained herein shall be true and correct in all material respects (without duplication of any materiality qualifier in the text of such representation or warranty) as of the date hereof except to the extent that any such representation or warranty relates to a specific date in which case such representation or warranty shall be true and correct as of such earlier date (and such parties’ delivery of their respective signatures hereto shall be deemed to be its certification thereof); and

 

2
 

 

(f) prior to and after giving effect to the agreements set forth herein, no Default or Event of Default shall exist under any of the Financing Documents.

 

5. Release. In consideration of the agreements of Agent and Lenders contained herein and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Credit Party, voluntarily, knowingly, unconditionally and irrevocably, with specific and express intent, for and on behalf of itself and all of its respective parents, subsidiaries, affiliates, members, managers, predecessors, successors, and assigns, and each of their respective current and former directors, officers, shareholders, agents, and employees, and each of their respective predecessors, successors, heirs, and assigns (individually and collectively, the “Releasing Parties”) does hereby fully and completely release, acquit and forever discharge each of Agent, Lenders, and each their respective parents, subsidiaries, affiliates, members, managers, shareholders, directors, officers and employees, and each of their respective predecessors, successors, heirs, and assigns (individually and collectively, the “Released Parties”), of and from any and all actions, causes of action, suits, debts, disputes, damages, claims, obligations, liabilities, costs, expenses and demands of any kind whatsoever, at law or in equity, whether matured or unmatured, liquidated or unliquidated, vested or contingent, choate or inchoate, known or unknown that the Releasing Parties (or any of them) has against the Released Parties or any of them (whether directly or indirectly). Each Credit Party acknowledges that the foregoing release is a material inducement to Agent’s and each Lender’s decision to enter into this Agreement and agree to the modifications contemplated hereunder, and has been relied upon by Agent and Lenders in connection therewith.

 

6. No Waiver or Novation. The execution, delivery and effectiveness of this Agreement shall not, except as expressly provided in this Agreement, operate as a waiver of any right, power or remedy of Agent, nor constitute a waiver of any provision of the Credit Agreement, the Financing Documents or any other documents, instruments and agreements executed or delivered in connection with any of the foregoing. Nothing herein is intended or shall be construed as a waiver of any existing Defaults or Events of Default under the Credit Agreement or the other Financing Documents or any of Agent’s rights and remedies in respect of such Defaults or Events of Default. This Agreement (together with any other document executed in connection herewith) is not intended to be, nor shall it be construed as, a novation of the Credit Agreement.

 

7. Affirmation. Except as specifically amended pursuant to the terms hereof, each Credit Party hereby acknowledges and agrees that the Credit Agreement and all other Financing Documents (and all covenants, terms, conditions and agreements therein) shall remain in full force and effect, and are hereby ratified and confirmed in all respects by such Credit Party. Each Credit Party covenants and agrees to comply with all of the terms, covenants and conditions of the Credit Agreement and the Financing Documents, notwithstanding any prior course of conduct, waivers, releases or other actions or inactions on Agent’s or any Lender’s part which might otherwise constitute or be construed as a waiver of or amendment to such terms, covenants and conditions.

 

8. Miscellaneous.

 

(a) Reference to the Effect on the Credit Agreement. Upon the effectiveness of this Agreement, each reference in the Credit Agreement to “this Agreement,” “hereunder,” “hereof,” “herein,” or words of similar import shall mean and be a reference to the Credit Agreement, as amended by this Agreement. Except as specifically amended above, the Credit Agreement, and all other Financing Documents (and all covenants, terms, conditions and agreements therein), shall remain in full force and effect, and are hereby ratified and confirmed in all respects by each Credit Party.

 

3
 

 

(b) Governing Law. THIS AGREEMENT AND ALL DISPUTES AND OTHER MATTERS RELATING HERETO OR ARISING THEREFROM (WHETHER SOUNDING IN CONTRACT LAW, TORT LAW OR OTHERWISE), SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO CONFLICTS OF LAWS PRINCIPLES

 

(c) Incorporation of Credit Agreement Provisions. The provisions contained in Section 11.6 (Indemnification), Section 13.8(b) (Submission to Jurisdiction) and Section 13.9 (Waiver of Jury Trial) of the Credit Agreement are incorporated herein by reference to the same extent as if reproduced herein in their entirety.

 

(d) Headings. Section headings in this Agreement are included for convenience of reference only and shall not constitute a part of this Agreement for any other purpose.

 

(e) Counterparts. This Agreement may be signed in any number of counterparts, each of which shall be deemed an original and all of which when taken together shall constitute one and the same instrument. Signatures by facsimile or by electronic mail delivery of an electronic version of any executed signature page shall bind the parties hereto.

 

(f) Entire Agreement. This Agreement constitutes the entire agreement and understanding among the parties hereto and supersedes any and all prior agreements and understandings, oral or written, relating to the subject matter hereof.

 

(g) Severability. In case any provision of or obligation under this Agreement shall be invalid, illegal or unenforceable in any applicable jurisdiction, the validity, legality and enforceability of the remaining provisions or obligations, or of such provision or obligation in any other jurisdiction, shall not in any way be affected or impaired thereby.

 

(h) Successors/Assigns. This Agreement shall bind, and the rights hereunder shall inure to, the respective successors and assigns of the parties hereto, subject to the provisions of the Credit Agreement and the other Financing Documents.

 

[SIGNATURES APPEAR ON FOLLOWING PAGES]

 

4
 

 

IN WITNESS WHEREOF, intending to be legally bound, and intending that this document constitute an agreement executed under seal, the undersigned have executed this Agreement under seal as of the day and year first hereinabove set forth.

 

AGENT: MIDCAP FINANCIAL TRUST,
  as Agent

 

  By: Apollo Capital Management, L.P.,
    its investment manager
     
  By: Apollo Capital Management GP, LLC,
    its general partner

 

  By: /s/ Maurice Amsellem
  Name: Maurice Amsellem
  Title: Authorized Signatory

 

[Signatures Continue on Following Page]

 

5
 

 

LENDERS: ELM 2020-3 TRUST

 

  By: MidCap Financial Services Capital Management,
    LLC, as Servicer

 

  By: /s/ John O’Dea
  Name: John O’Dea
  Title: Authorized Signatory

 

  ELM 2020-4 TRUST

 

  By: MidCap Financial Services Capital Management,
    LLC, as Servicer

 

  By: /s/ John O’Dea
  Name: John O’Dea
  Title: Authorized Signatory

 

[Signatures Continue on Following Page]

 

6
 

 

BORROWERS:

 

  XTANT MEDICAL, INC.

 

  By: /s/ Sean E. Browne
  Name Sean E. Browne
  Title: President, CEO

 

  BACTERIN INTERNATIONAL, INC.

 

  By: /s/ Sean E. Browne
  Name Sean E. Browne
  Title: President, CEO

 

  X-SPINE SYSTEMS, INC.

 

  By: /s/ Sean E. Browne
  Name Sean E. Browne
  Title: President, CEO

 

GUARANTOR:

 

  XTANT MEDICAL HOLDINGS, LLC

 

  By: /s/ Sean E. Browne
  Name Sean E. Browne
  Title: President, CEO

 

7

 

 EX-10.20 6 ex10-20.htm

 

Exhibit 10.20

 

amendment No. 1 to CREDIT, SECURITY AND GUARANTY AGREEMENT (REVOLVING LOAN)

 

This AMENDMENT NO. 1 TO CREDIT, SECURITY AND GUARANTY AGREEMENT (REVOLVING LOAN) (this “Agreement”) is made as of March 7, 2022, by and among XTANT MEDICAL HOLDINGS, INC., a Delaware corporation (“Holdings”) as a Guarantor, each of Holdings’ direct and indirect Subsidiaries set forth on the signature pages hereto as a “Borrower” (collectively, the “Borrowers” and each individually, a “Borrower”), MidCap Funding IV Trust, a Delaware statutory trust, individually as a Lender and as Agent (in such capacity, together with its successors and assigns, “Agent”) and the other financial institutions or other entities from time to time parties to the Credit Agreement referenced below, each as a Lender.

 

RECITALS

 

A. Agent, Lenders, and the Credit Parties have entered into that certain Credit, Security and Guaranty Agreement, dated as of May 6, 2021 (Revolving Loan) (the “Original Credit Agreement” and as amended hereby and as it may be further amended, modified, supplemented and restated from time to time, the “Credit Agreement”), pursuant to which the Lenders have agreed to make certain advances of money and to extend certain financial accommodations to Borrowers in the amounts and manner set forth in the Credit Agreement.

 

B. The Credit Parties have requested, and Agent and all Lenders have agreed, to amend certain provisions of the Original Credit Agreement, all in accordance with the terms and subject to the conditions set forth herein.

 

AGREEMENT

 

NOW, THEREFORE, in consideration of the foregoing, the terms and conditions set forth in this Agreement, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Agent, Lenders and the Credit Parties hereby agree as follows:

 

1. Recitals. This Agreement shall constitute a Financing Document and the Recitals and each reference to the Credit Agreement, unless otherwise expressly noted, will be deemed to reference the Credit Agreement as amended hereby. The Recitals set forth above shall be construed as part of this Agreement as if set forth fully in the body of this Agreement and capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the Credit Agreement (including those capitalized terms used in the Recitals hereto).

 

2. Amendments to Original Credit Agreement. Subject to the terms and conditions of this Agreement, including, without limitation, the conditions to effectiveness set forth in Section 4 below, the Original Credit Agreement is hereby amended as follows:

 

(a) Section 1.1 of the Original Credit Agreement is hereby amended by adding the following definitions in alphabetical order:

 

“First Amendment” shall mean that certain Amendment No. 1 to Credit, Security and Guaranty Agreement (Revolving Loan), dated as of the First Amendment Effective Date, by and among Holdings, as Guarantor, each of direct and indirect Subsidiaries of Holdings set forth on the signature pages thereto as a Borrower, Agent and Lenders.

 

“First Amendment Effective Date” shall mean March 7, 2022.

 

 
 

 

“Liquidity Threshold” means $14,000,000.

 

“Minimum EBITDA Covenant Waiver Period” means the period (x) beginning on the date upon which the Credit Parties deliver to Agent a Compliance Certificate in accordance with Section 4.1(i) evidencing that the Liquidity of the Credit Parties as of such date is greater than the Liquidity Threshold and (y) ending on the earlier to occur of (i) the occurrence of any Default or Event of Default or (ii) the date upon which the Credit Parties deliver to Agent a Compliance Certificate in accordance with Section 4.1(i) evidencing that the Liquidity of the Credit Parties as of such date is equal to or less than the Liquidity Threshold; provided that the financial covenant described in Section 6.3 shall be tested on any date upon which the Minimum EBITDA Covenant Waiver Period is terminated by operation of clause (y)(ii) of this definition.

 

(b) Section 2.2(g) of the Original Credit Agreement is hereby amended by replacing each occurrence of the words “Closing Date” with the words “First Amendment Effective Date”.

 

(c) Section 6.3 of the Original Credit Agreement is hereby amended and restated in its entirety as follows:

 

“Minimum EBITDA. Credit Parties will not permit the consolidated EBITDA of the Credit Parties for any Defined Period, as tested quarterly on the last day of the applicable Defined Period (other than any Defined Period ending during a Minimum EBITDA Covenant Waiver Period that has not been terminated on such date of determination as a result of the Credit Parties’ failure to maintain Liquidity in excess of the Liquidity Threshold), to be less than $500,000.

 

3. Representations and Warranties; Reaffirmation of Security Interest. Each Credit Party hereby confirms that all of the representations and warranties set forth in the Credit Agreement are true and correct in all material respects (without duplication of any materiality qualifier in the text of such representation or warranty) with respect to such Credit Party as of the date hereof except to the extent that any such representation or warranty relates to a specific date in which case such representation or warranty shall be true and correct as of such earlier date. Nothing herein is intended to impair or limit the validity, priority or extent of Agent’s security interests in and Liens on the Collateral. Each Credit Party acknowledges and agrees that the Credit Agreement, the other Financing Documents and this Agreement constitute the legal, valid and binding obligation of such Credit Party, and are enforceable against such Credit Party in accordance with its terms, except as the enforceability thereof may be limited by bankruptcy, insolvency or other similar laws relating to the enforcement of creditors’ rights generally and by general equitable principles.

 

4. Conditions to Effectiveness. This Agreement shall become effective as of the date on which each of the following conditions have been satisfied, as determined by Agent in its sole discretion:

 

(d) Each Credit Party shall have delivered to Agent this Agreement and the Amended and Restated Fee Letter, in each case, executed by an authorized officer of such Credit Party;

 

(e) all representations and warranties of Credit Parties contained herein shall be true and correct in all material respects (without duplication of any materiality qualifier in the text of such representation or warranty) as of the date hereof except to the extent that any such representation or warranty relates to a specific date in which case such representation or warranty shall be true and correct as of such earlier date (and such parties’ delivery of their respective signatures hereto shall be deemed to be its certification thereof); and

 

2
 

 

(f) prior to and after giving effect to the agreements set forth herein, no Default or Event of Default shall exist under any of the Financing Documents.

 

5. Release. In consideration of the agreements of Agent and Lenders contained herein and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Credit Party, voluntarily, knowingly, unconditionally and irrevocably, with specific and express intent, for and on behalf of itself and all of its respective parents, subsidiaries, affiliates, members, managers, predecessors, successors, and assigns, and each of their respective current and former directors, officers, shareholders, agents, and employees, and each of their respective predecessors, successors, heirs, and assigns (individually and collectively, the “Releasing Parties”) does hereby fully and completely release, acquit and forever discharge each of Agent, Lenders, and each their respective parents, subsidiaries, affiliates, members, managers, shareholders, directors, officers and employees, and each of their respective predecessors, successors, heirs, and assigns (individually and collectively, the “Released Parties”), of and from any and all actions, causes of action, suits, debts, disputes, damages, claims, obligations, liabilities, costs, expenses and demands of any kind whatsoever, at law or in equity, whether matured or unmatured, liquidated or unliquidated, vested or contingent, choate or inchoate, known or unknown that the Releasing Parties (or any of them) has against the Released Parties or any of them (whether directly or indirectly). Each Credit Party acknowledges that the foregoing release is a material inducement to Agent’s and each Lender’s decision to enter into this Agreement and agree to the modifications contemplated hereunder, and has been relied upon by Agent and Lenders in connection therewith.

 

6. No Waiver or Novation. The execution, delivery and effectiveness of this Agreement shall not, except as expressly provided in this Agreement, operate as a waiver of any right, power or remedy of Agent, nor constitute a waiver of any provision of the Credit Agreement, the Financing Documents or any other documents, instruments and agreements executed or delivered in connection with any of the foregoing. Nothing herein is intended or shall be construed as a waiver of any existing Defaults or Events of Default under the Credit Agreement or the other Financing Documents or any of Agent’s rights and remedies in respect of such Defaults or Events of Default. This Agreement (together with any other document executed in connection herewith) is not intended to be, nor shall it be construed as, a novation of the Credit Agreement.

 

7. Affirmation. Except as specifically amended pursuant to the terms hereof, each Credit Party hereby acknowledges and agrees that the Credit Agreement and all other Financing Documents (and all covenants, terms, conditions and agreements therein) shall remain in full force and effect, and are hereby ratified and confirmed in all respects by such Credit Party. Each Credit Party covenants and agrees to comply with all of the terms, covenants and conditions of the Credit Agreement and the Financing Documents, notwithstanding any prior course of conduct, waivers, releases or other actions or inactions on Agent’s or any Lender’s part which might otherwise constitute or be construed as a waiver of or amendment to such terms, covenants and conditions.

 

8. Miscellaneous.

 

(a) Reference to the Effect on the Credit Agreement. Upon the effectiveness of this Agreement, each reference in the Credit Agreement to “this Agreement,” “hereunder,” “hereof,” “herein,” or words of similar import shall mean and be a reference to the Credit Agreement, as amended by this Agreement. Except as specifically amended above, the Credit Agreement, and all other Financing Documents (and all covenants, terms, conditions and agreements therein), shall remain in full force and effect, and are hereby ratified and confirmed in all respects by each Credit Party.

 

3
 

 

(b) Governing Law. THIS AGREEMENT AND ALL DISPUTES AND OTHER MATTERS RELATING HERETO OR ARISING THEREFROM (WHETHER SOUNDING IN CONTRACT LAW, TORT LAW OR OTHERWISE), SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO CONFLICTS OF LAWS PRINCIPLES

 

(c) Incorporation of Credit Agreement Provisions. The provisions contained in Section 11.6 (Indemnification), Section 13.8(b) (Submission to Jurisdiction) and Section 13.9 (Waiver of Jury Trial) of the Credit Agreement are incorporated herein by reference to the same extent as if reproduced herein in their entirety.

 

(d) Headings. Section headings in this Agreement are included for convenience of reference only and shall not constitute a part of this Agreement for any other purpose.

 

(e) Counterparts. This Agreement may be signed in any number of counterparts, each of which shall be deemed an original and all of which when taken together shall constitute one and the same instrument. Signatures by facsimile or by electronic mail delivery of an electronic version of any executed signature page shall bind the parties hereto.

 

(f) Entire Agreement. This Agreement constitutes the entire agreement and understanding among the parties hereto and supersedes any and all prior agreements and understandings, oral or written, relating to the subject matter hereof.

 

(g) Severability. In case any provision of or obligation under this Agreement shall be invalid, illegal or unenforceable in any applicable jurisdiction, the validity, legality and enforceability of the remaining provisions or obligations, or of such provision or obligation in any other jurisdiction, shall not in any way be affected or impaired thereby.

 

(h) Successors/Assigns. This Agreement shall bind, and the rights hereunder shall inure to, the respective successors and assigns of the parties hereto, subject to the provisions of the Credit Agreement and the other Financing Documents.

 

[SIGNATURES APPEAR ON FOLLOWING PAGES]

 

4
 

 

IN WITNESS WHEREOF, intending to be legally bound, and intending that this document constitute an agreement executed under seal, the undersigned have executed this Agreement under seal as of the day and year first hereinabove set forth.

 

AGENT: MIDCAP FUNDING IV TRUST,
  as Agent

 

  By: Apollo Capital Management, L.P.,
    its investment manager

 

  By: Apollo Capital Management GP, LLC,
    its general partner

 

  By: /s/ Maurice Amsellem
  Name: Maurice Amsellem
  Title: Authorized Signatory

 

LENDER: MIDCAP FUNDING IV TRUST,
  as a Lender

 

  By: Apollo Capital Management, L.P.,
    its investment manager

 

  By: Apollo Capital Management GP, LLC,
    its general partner

 

  By: /s/ Maurice Amsellem
  Name: Maurice Amsellem
  Title: Authorized Signatory

 

[Signatures Continue on Following Page]

 

5
 

 

BORROWERS:

 

  XTANT MEDICAL, INC.

 

  By: /s/ Sean E. Browne
  Name Sean E. Browne
  Title: President, CEO

 

  BACTERIN INTERNATIONAL, INC.

 

  By: /s/ Sean E. Browne
  Name Sean E. Browne
  Title: President, CEO

 

  X-SPINE SYSTEMS, INC.

 

  By: /s/ Sean E. Browne
  Name Sean E. Browne
  Title: President, CEO

 

GUARANTOR:

 

  XTANT MEDICAL HOLDINGS, LLC

 

  By: /s/ Sean E. Browne
  Name Sean E. Browne
  Title: President, CEO

 

6

 

 EX-23.1 7 ex23-1.htm

 

Exhibit 23.1

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We consent to the incorporation by reference in Xtant Medical Holdings, Inc.’s Registration Statements on Form S-3 (File Nos. 333-255988 and 333-255074), Form S-1 (File Nos. 333-224940 and 333-251515) and on Form S-8 (File Nos. 333-172891, 333-187563, 333-191248, 333-212510, 333-226588, 333-234595 and 333-249762) of our report dated March 8, 2022, relating to the December 31, 2021 and 2020 consolidated financial statements which appears in this Annual Report on Form 10-K.

 

/s/ Plante & Moran, PLLC

 

Denver, Colorado

March 8, 2022

 

 


 

 EX-31.1 8 ex31-1.htm

 

Exhibit 31.1

 

Certification of Chief Executive Officer
pursuant to Exchange Act Rules 13a-14(a)/15d-14(a), as adopted pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002

 

I, Sean E. Browne, certify that:

 

1. I have reviewed this annual report on Form 10-K of Xtant Medical Holdings, Inc.;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
   
  (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
   
  (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
   
  (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
   
  (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
   
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
   
  (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
   
  (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: March 8, 2022    
  By: /s/ Sean E. Browne
    Sean E. Browne
    President and Chief Executive Officer
    (Principal Executive Officer)

 

 

 

 EX-31.2 9 ex31-2.htm

 

Exhibit 31.2

 

Certification of Chief FINANCIAL Officer
pursuant to Exchange Act Rules 13a-14(a)/15d-14(a), as adopted pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002

 

I, Scott Neils, certify that:

 

1. I have reviewed this annual report on Form 10-K of Xtant Medical Holdings, Inc.;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
   
  (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
   
  (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
   
  (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
   
  (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
   
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
   
  (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
   
  (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: March 8, 2022    
  By: /s/ Scott Neils
    Scott Neils
    Interim Chief Financial Officer
    (Principal Financial Officer)

 

 

 

 EX-32.1 10 ex32-1.htm

 

Exhibit 32.1

 

CERTIFICATION of Chief Executive Officer PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report on Form 10-K for the year ended December 31, 2021 of Xtant Medical Holdings, Inc. (the “Company”), as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Sean E. Browne, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:

 

  (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
     
  (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

March 8, 2022 /s/ Sean E. Browne
  Sean E. Browne
  President and Chief Executive Officer
  (Principal Executive Officer)

 

 

 

 EX-32.2 11 ex32-2.htm

 

Exhibit 32.2

 

CERTIFICATION of Chief FINANCIAL Officer PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report on Form 10-K for the year ended December 31, 2021 of Xtant Medical Holdings, Inc. (the “Company”), as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Scott Neils, Interim Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:

 

  (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
     
  (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

March 8, 2022 /s/ Scott Neils
  Scott Neils
  Interim Chief Financial Officer
  (Principal Financial Officer)

 

 

 

 GRAPHIC 12 ex4-2_001.jpg begin 644 ex4-2_001.jpg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

  •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᫦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�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

    NT8_&JGQ#U G4O"UYHNVYU"/55C(A.2(V4[P3Z<4 =KJ'B M&VL-0CT\137%VZ>8(XE!PN3UR1CH:ETC6H-9MI98(Y8VBD,4D R!2.#T&23^==1>3P:1H^N:S!(CJT; MW99#D?)$!_[)F@"6]\00VTSPV]O/=R1DB180#L(&>S27[?)<"X+\B0+&"%(],\XK4\>V=MX?\%P:9I,::?#J&I06TA@&P*LCC>1C MID*10!OW'C.QM]LSVUT;$G'VP(#'Z9'.<>^*WOM,7D&QZ:78 M_/Y)9B3Z_<4B@#J+WXHZ3:2;TLM0N;%6V27D,(,8/08RP)YSV[4?"^_@U33- M>O[8L8;C6[J1-PP<$J1^E=9;Z=:6M@MC#:PI:(-JQ+&-H /ITKEOAO;1V,'B M2UB18XHM=NA&BC 5?EQ0!V]<3XB(7XE^#&<'8$OR&]_*7K^%=M7!^+[87WQ! M\&6KM(L3?;68HV-P$0^7B@":#XI^&YM;&F;[J-WD\N.:2+;&[=,*<\_E79M( M$C+N0H49))X'%<)\4M%L)/A_>7"VT*2Z8JW-LRKCRF0CICH,9XJ]X^OFB\"3 M,)C ;QH+>NI:M!IL:F1))97_U<,0!=_ID@5P7@CP9::CX%\/7NHHLNH)';W,$YY:%4 M<2(JGL,?SI^D:U'>?%OQ,;^Z1(M*@B@MTD; 4.-SL/AS4VO>/]+\-:A]CU*&Z5GVB%D0$3 M,1G:O/7H*YOXQ:;;6/@M==M((X+[2[F&6*:% K %U4C([1L$CJJ@L@VY.1GM2Z#KD' MB#3A?VL4J6[G]VT@ WCU'-4/&C/-X+U"&W;]Y>1"VB(YRTI"#_T*MG3[./3] M.MK*!0L5O$L: = %&/Z4 6'8(C.Q 51DD]JXZY^)FAVET(YDNQ 6VBZ$0\K\ M\Y_2NIU&U%_I=W9;RGVB!XMPZC&H-#35GEG\B2=X(E"#?(5." M0,].1U-:OA15U7P'HK7T<P ]:SK+Q5;W.JQ:;/:75 MIK/C+ M44NV\/MHTR7%[%J\) CY(0AA(3[;2<_A0!W@Y%96LZ_::)%$;C<\LS^7##&, MO(V,X ^E:@Z5Y7XYUI=#^+7A*\U#CZSKDFDZ=,UQ-%#YTCJOR*-V M,GO4]NNG:Q>V^K6US%.,6 MFP1@#@HQ./09[4D!OZEXWT32]7M]*GG=KZ>XCMTB1"?F<@+DG QSD\US/QI* MKX3TPDX!UBVRWIRU7_B!;P"[\*RK;1>8WB"T!EV@, -QZ]>PK,^.<1F\$V$* MD@R:K;J".V=U,#2UOXK^'=!U-K&9+ZX,;A)9K>$-%&W<%B1TZG'K70:MXGTO M2-$&L3RO)9N!M:%2Y;/(Q2OX>TTZ#+I)LX3;21%&5HP=Q(P6/J>^>M)_#]KK-M%)%!=;V1) V Q49P3Z5 M#<^)DC#R6EE<7L$61)+ %PI&01R1DC'-%=*@^V1(3;1E]VUA:>/4;.+S'7)V&0 C/7&">*[>TTJQT]Y'L;."W:7: M)/*C"[@.F<>@)_.@"XS!$+,<*!DFO+O#?C#P]I6I>+;V>Y"B75/E94R7&Q , M?\"W5Z@Z*\;(P!5A@CVKS[PCX,';^[1L#/N2: .P MU+7+73/LXE6222X;$4<2Y9O?Z5EP>,H(]7M]+U6UEL+BZ8K;&3!24CJ 0>#] M:R='O6U3XN>(HV8F+1[*WMX4[*9?G/K*SO/!>K->0HXBLY65F4$H0N*-'O-'T72+6Z#W? M]G1OY84\!5 .3ZYK-TC7;/P]/XQO+LLP&ME5BB7C7MO8V\5P^GPYFCB56.44G) YYK#\&:;;S^+O&-_)'ND75#$N[HN(TR1^?6 M@#6\+^/M,\57UWI]M%<07ULN]X)T"G;G&>":WM1U.#3(%DF#,78)'&G+2,>@ M KD[_3[?3_BWH6H6Z".;4;.ZAGVC&_8$8$^II-5N;=OBMI<5[<>5#8Z9+@QD?0UZ1"SM$A<88J"?K0!Q_Q8R/AAKI4_ M,(5Q_P!_%K?&HVVD>'(KV^F6*W@MT:21NPVBL#XLJS?"[7E7[QA7'_?:UIWN MB0>(/#-E97)/E?Z-*P[,$9'P1Z';C\: ,0_%'3X=4LK>]TW4+.TO6*V]W-&H M1SD =&)&21U%;OB?Q*?#%A_:$]C-/91Y:XEB(/E+QS@D9Y/\ZY#XM:MI3^#; MBWAF26^MYH98/+4N(V5QSD# X!'XUV?BNQ_M+PCJ]GY?F--9RJ$'\1VG'ZT M/\.Z_%XCTF+5+>VF@M9P&@,P 9UQUP"<O MJC@G(^I!/XT =CI/BN/5];O],AT^[C>P(6XDE"A0Q 90"&.O89#'*EFX1UZ MJS#:"/?)H 67Q//N#]*MZ-XEL-;TV6]MW*" ME9TD&&B8=00,],&F^%M+BTGPMIMA$"5CMTW,3RS$98GU)))KDM!L%TCXP^)+ M%8P+74[)+[R^J[MP5N/

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a]G9:M9Z1:1DZK$P65R<^D1SN!'YT^[\5:='&(I[$6OB-$-G-(3P$4[&(XZE:W-'L+[Q/)'9Q!K M;1+>-2,\M*1@ $_04I:RMZ$6Z$7A'2+G7KN?QAXDG:.&(LL4;'"F,.>]9VN6]U;_&%M/L;J1([I!(T0^ZI9<9Q^=9FG:5;V=O>74$\L^K M:G.UO-"__+,^9R?RJ]XE\07FB?%:XU:.P-Q91VRV9=><-MSG\#Q1*]@;U.FT M6'2+OP/=Z=J+1S7-L9UD#X#*P+8K:^'_ (Q6V+F>W1F=N2 >>*X MK1OAE-X@\O7+R^GMAJ.Z:>%!V).!^HKV*UMTM;6*WC&$B0(H]@,?TJZ:VN5% M7=R84M(*6M30**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M81N# ]#7/:MX0TS4([UOLJ">YB*%PO1CT/YXKH^](Y"C)/>D)Q3W/+M)\1:= M'80VWBVW:/4M.'E;RN3(!W'M7-:\E_XE\4P>)9+5X-#LGBA1&'+KGYCCTYKL M=2\11:O?N=,\/IJ0@)1[AXUQD=0,U$GCK3+S0]1TO4;!K6]@CYM'C #Y.%VX MXK&5K6(O?YZK(GOGN,50\'07?@_P 4PV.LD3-JBE;>?=N\MASL)/2MWQ]=07J1:);6 M<=YJMQ_JE*C]QWW9[#BFG?<5M+HH'X2^&6NEOGNF\D$-L)&, YQUK)\3>-M+ MEUW2XHHC_96FL9?,4<-(I "C]:H)\*O%SZ>))]?D#C)-K]H?:1G)7CCFH/$_ MB#1O["AT&31A:7\,Q\Q/*"_*!R<]P34R\@GO&M+D\-6UF[L)"MO<<849'^?Q-"E9W95[,[K6H[[ M^P(H;&:-9X)9[?,YQE0I&?VO->-R;B>29P;8,2%(.WICN*ZV_@CDE\/W,$;J$DBB8N -RR1,N#]. M,_6I7]?>2[JZ1QCZG#J'A6[\.SJSSSWSR;SC*@_,"/? /YUT6F^'AI^KZ%)' MND2.R$%J&/W @5F)^I-<)-I$TOBN6VLFQ?S*AC#=1@ $Y^F:]H:-Y=9TM('# M+9)(EQZY*+MJ5>4F@BWNSA]7T&'PI=:AJ:3J+6.*XNHP1C!D4C;^#<_B*E\$ M:==VUIH@GF7YI&E([ "'( _%@?PJ;XKQ6VL>$VGM+A));6Z6%E4]22 4-.\. MVD]IJFB6A9G6.VN)RI/"](U'Y#]:=35V^8UH]#*US7;2+QVFF2V4CW3ZG9-Y MR@8P5ZY^M>PCI7D&IZ_9P>-AI9LW-V^IV>)2@VQK@ +G_/6O7QTK>/QL<-@H MHHK0L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@#RV_T+[;\9R /L4@&?7::Z-(UC#;%"EF+''@"SH,Z3^'].D1@5:VC.1_NBN%^,LJ)IGAXM*J;=9MSR M>N":[C2-'MM%MC:VA<6_\$9;*QCT'IUK&U[P%I/B.\:XU)IY1N#I&9#M1@,; M@,\&@#K 01D&N,NI(O\ A<.G*95#C1Y<)W_U@_P/Y5T^G69L+00&>2< G#2$ MD@>F36)<^"K*ZUY==>>X_M) 528.050\[!STH Z8\C [UXA%!/X1^(=IX4(W M65]JRZE:-V12&#+^>/SKV]!M4#J0,9]:P=>\*6.NZGI>HS[DN].F$L,B\'@@ MD?2@#-^*;)_PK76E9U7=$J@GU+KBNATV>%M)M#YL9!A0_>&#\HJIXD\,6'BF MR2SU$R&W#;BB.0&^H'6L1OAAH;)&JSZBJ1C:JK>2* /INH LZEJYD3Q6+:Z) M^PZ<&78W"/LE)/UX%=#IVHVU_I-O?0SJ\$L2N'W=B,\UBZ%X'TC0+/4K6V26 M2/4ABY\V0L7&TKC)/H36)#\*-/MY1#;ZMJD6E=]-2Z<0MZY ;'Z4 6?!ENU] MKWBGQ"L@,&H7*V]JX[I$NTL/8MG\JZ#POJ46I>%].NUG$NZW3>^?X@ #G\:O M6=G:Z?:Q6=I!'!;PKM2.-=JJ/8"N0'PRLK>9ET[5M3L+%V)DL[>Y=8WSU& W M&: ':';C5?B-K/B&*026D-K'80LO0L#N?'Y@5W!JEIFFV>D6*6=C;I! G15& M.>Y/O5T]* /.-=OH+'XY>'_.D6,3:7+&"W&27.!^E.^,4D>3SUH ZM"/+7G/ KSGX3HMW\,6ME8'=<747X&1A_6N\L[%;/ M3TM!)-(JKMW.Y+8],DYK,\-^%;#PM!);Z:9%@D8N8VE6V& M9PWC7QE%N!VW-N0!_P!<%']*ZZ1=\;*&*Y!&1U%>V?TH YOPC=!N565I I8+FN?\2^"M.\23QW]N M;VXE78TUPY9MOIR3ZT +9])*^6\##DQXQLSUQCBK^N^$=/U[18= M&N&EBT^-0A@B8JK@8P#@]L4 1>'I!_PK737=A@Z5'D]O]4*C^&LBR?#G0L,# MBU"G'L2*>O@^"/P]#HD=_=QV<)"J%D(.P#&S@]*ET?PI!H.BRZ3I]Y<16[$> M7\Q)B]=ISQF@#.\!RH^I>+U5]Q&M2$_0QI_A4=NY_P"%SWP8@#^QEVCU_>#/ M\ZO>'_!-GX>WOUC$6^) MRN4!R5.#R#B@# U:>*/XXZ"C<2-I,X4_\"SC]*N^/2!J/A']XJ$:W%@'O\CU M)>> K6]\11Z]+?WAU"!O]'D\QL1(<_(!GIR?SI^O^!+3Q#J,=[>W]Z7@*M;* MDK*L#C'SJ >OO[T 8?Q0O6T+5?"7B AC:V5^T<^TX^21<9^@P:[PZK8K9_;# M=1"WV;_,W<8JK=>'[/4O#XT?5%^VP%-C&7EF[9R>A]ZY/1_A'HVDW$1-Y>7- MI$P=+*:5FA!!R,J3@]NHH ]"1E=%=3E6&0?452N+[R=5M+/ _P!(21@3ZKMX M_)C5V-0J!1T' P,5A>(?#IUN>PN8K^XLKFP=I(I(3UW#!!&>1@4 ",79O)6D8#GRU3)/ZX_&J]CJ,.@?&W6;"X]O$B,,1=<"-2XC$DQVQKGECCM7"^$=0CD^('CAKMPDT,T"JS\'R@K$?@* MV/#W@73]!N1=&>YO;A1B*2Y@P.*9-X*M9_$$>N/=W/VZ-0JN'/"\<=>AQ0! MU->>>*HX]'^)WAGQ!.VRVFCFT^5_[I8$IG\ ="D7@&RB&/H,?TKI*Q/#GAZ+PW9BRM;F5[2-0L4+G(C [ M"MN@#A-+O8;?XN^)+:1U5IK*VD3<<9V@Y_G4OCBXC36?!X+#YM74C_OAJE\0 M_#[3O$'B*WUN2XN+>YA3RV\AROF+Z$@CM4NK^"+76KNVFN+RY7[&RM:HK$"( M@8SUY- &GXJ/_%'ZW@X/V"?GT_=M7&RV[ZI^S]$D?SR?V3'(NWN4 8?^@UW5 MYIRW^ASZ7<2NRSVY@D?H2"N":I^'O#D'A[23IL<\D]H!B..4[A&N/NC.>* ( MO!OB"V\0>$]-OEE4R20)YJ9Y5\8(/X@UN6]Q%FVFDV,5E91".&-< =?<^IH L3PBX@E MA;[LB%3]",5YCX$U ^$_$E]X+U!PD2R/-8R/P&4G)'ZUZG7/^*/!^D^*[3R= M0@_>*62C:;>2X<;AZ$[LD5UT&B:;;Z(-&AM(ET\1^7 MY&T;=IZ\?CF@"W8WL.H6%O>6[AH9XUD0^H(R*X_X>6K!?$.KNA5=3U6:://_ M #S7Y1_Z":MV/A2\TRT&FV.M2Q:9EO+A\L%HU)SM5NH S6W!!#.,QRWMNCCU!<4K =A#;E=W'VS\5O%^'!7RK3CW M\NJ/Q2EA74_!<=WC[&VLJ9=W3A3C]:U;'P)'INO7.M6^J7?VRZ(^T%W)$@!X M!Y["K_C#PC9>,=(2PO&:,QRB6*1>&1AW!H Y/XR:C%'X=T^T ,COJ-LS;3]U M0W]:T/C+S\+-8(/01G_Q\5;N_AWIEYX>;2;B>XDW2K*URSDR$KTYSG'M6M-X M<@O/#$NAZA(UW#*C([R_,S%])EB=65[.(C![;!7)?";9< M>$=456!#ZK=J<>[_ .!K3\/> X_#FFS6EKJ5TV]!'$S2-^Z7T SQ5OPKX.M? M",<\-A/*UO,QE>-^?G/5O\^E &!\(0UAX2OYU[.@224_W1T4>@&: .8OG4?&[2T_B.BR@_]_/_ *QIGQDF M\GP().RW]L3_ -_!6G-X(CF\4Q^(FU*Y%_&IC1P.!&23LQGIS6CXI\,VGBW1 MCIEZ\B0F19,QG!RO2@#;0Y4X>X,:X$D@Y([4S6=*M=;TFYTV]0/;7$91U(SQ_D4 <9X_U&PL/A%>+! ML\N:R$<$02Y(_0U9T]@/COK /_0$A_\ 1E3:'\,=-T'79=0L[NYCC>9I MA:HY6,.F*Y/HD@QFNF\5>$K+Q9'8QWLLR"SG%Q$8V M*D..AX/:KE_H-OK'AU](U3%U')'MD9ADL?7ZT 7/[0M/L8O#%9RGPKTN>'@C24=?;]W6GXDT"+Q)ISZ=K6BKMDN&NE*]P6&1_,5U6B?#C3]%OI) MDNKB:W.XQVTC$QQDGJ%SCBKGA7P7;>$VF6RNYG@F)9XG8X+D_>QGKC _"BP% M+X5ZI'??#[2XVP$^0R](P M1C YH Q_BPX1/"A/;7;?^=;/Q,VGX:>(0QP/L3_RI/$O@:T\4W=K-?WUS_HA M$D*(Q"I(!P^,XS4^M^%V\0:,NE7^ISM;&/9/M7:9>0><&@#0\,L&\*:.0<_Z M%#_Z *YSX2J8_A[:!B"?/N#QVS*]='H6D'0],6Q%W)LO1O M!L/A_2KO3=,OKB"VN"S]#63_ M (6KXZ7>-WFVYV]_]6.:V_#O@I/"]MW3WMSG[6[N2)_J">,=OI0!SWPPO(M.U'Q-X=N9=ES!JDL\4;\9 MC<\%?;(->D"[M_M2VWFKYS#<$'7'K7)>*?ASI/B74(=3#RV.IQ !;JU)1C]< M$9/N>E:?ASPI:^'B\WVFXO+R4!9+JYV_B"RNTFA5 MHX;J:V=&Y'R,5_48K9/-R/PJY\*AM^&6B(3EA$^?KYC5IQ^&+ M:W\,MHEK<2PQR ^9,I.]]YRQSZD]:KZ'H%CX$T6Y6.[G.GPJ9-DK$B(#DD!H-X"L%498CODDUZ+:1P06Z0VZ1I%& H2/[JCT% M>5^'/AIINN6MQK\\EW9_VI<2744,$K1[(V)*YVGJ0<_C3=(LK_P5\6]/T"+4 M[N[TK4;5YECGE9]C*#ZD^E &]HV/^%V^)&'1M,MN_H357XNHC-X2=G"E-_S"MRU\#PV7B*37;>^N!?S@).Q8D.@Z+U[8%6O%G@^Q\6I8K>221FRF\^% MHR1A^QH Q_%>M5+OX>:1>Z996=R9I)+683BX M+'S&DZ;BI]ZSO"_A*U\+1-'#N0".O-:[>#]/&OVNL6K26UQ!$L.(3M# MQJ<[2!U!H S-=DC_ .%L>%$+#?\ 9[HC_O@UM>,]+.M^#-7TY/O7%JZK[G'% M4M1\%0:CKT6MRZA=)>6^X6[*2!$#V !KI+6%X;2.*60S,JX9V_BH YGX>^(; M77/!>FR1R 300)!.A/*.J[3G\JUM7UB*PTUKN'9*L=Q%$^&X7+JK?D&KF;KX M6Z6VJ37VG7M[IAGI^#;]YX$:>*/,#$<[\X _$FNLM(VAM((FY9$52?H*YP^ M%KRZ^RQZGK,US;VTBR"+;MWLIR-Q'4?6NJI@<%\56N+3PYI^KVZDOIFHP7+ M?W<[6_1J[2WO(;FRCO(I T,D8D5ATP1G^5+?6EO?64MM=QK+;R+AT89##T([ MUSMGX5N+*W-A;:K*FEY.RW"8*(>J!NH'M0!F?#&"1['7-9E0H=5U66Y3/>/@ M+_*E^$TBR^&+Z16!#:I%=3?:5'<:.=.MI7L80NU3;_)M4=AC':LKPUX M,M/"Y*Z=^3^= %3QS<16GB+P=//($C&I,I)Z0>U49_ =BWAZWTN"YN(G@N1=I<[R7,RY^8G.3UHL!!\0-#M-1@TJX\J,7R: ME;>2^.3F09'TQS^%=KCC%<\GAZ6;5;>]U&_>Z^RN7@0KM"MTR<=:Z+M0!YKX M_P!3_P"$9\=^%==DS]DE\VPG/90V&!/Y9_"M3X@:]8Q^!-5\B=)I;FSD$*H< M[@5Y/X#FNAU[P_I_B/36L=2@6:(G<,C)4^H]*YW1?ACH.BV5[:HKSK=1-$6F M.XQHU &C\/&0_#KP^4^[]AB_]!KFOA)J=M_9VNZ>[A)[75KAI QQP MS$@_H:Z_PYX0".M &-INK6VH_'N=H7!C71U2-^TGS$DC_ #VKH?%UQ%%XN\&QNP#/ M?2XS_P!<7%3W7@'1YM=L]8A5K6ZM8UA7R?E!0'.TXI=6\$6.M:U#JEW<7)G@ M.8,.0(3_ +/- '27=NMW93VS\I-&R-GT(Q7E?PRCFO9;33+A&QX8,\)<]&D= MB!^2Y_.O5XT,<"(7+E5P6/4FL#PC;P(-9N[=%5+S4II0P&-V,)G\U/YT =$* MXKXJ7;V?@:Z=1E&FB63_ '"PW?IFNVJCJVEVNLZ5H)+>X0HZGT- '&?% M#5[.'X8ZHD$@D%Q:;85BY^7CGZ8-6]6 N?@Y*L7S[](4#'_7,5/9?#[1[+PU M>P% % M'PKK5E-X&TF]-Q&(ULHM_P W0A0"/SK*^&U\-0_X2:XVE&DUJ5_+;JH*1_X4 MFG?"S0]-NQ)&]RT"R"1+;S"(E.<_=S@]NU;%EX1LM/\ $,^L6@U>Y\Z.ZC3RRT+E"Z^A((I^M^!=+\0&U-ZT[):JOD1K*P M"%>C 9Z].:5@-W5FVZ+?'.,6\G7_ '37)?#ZW34/A'IUJ"I6:TDCR/\PLR1LA=R5C]=H)X MR>:+ 8OPJU9;[P5#8."EUI+FPG0]0T? /XC%+)9'4_B\EYM!BTK3MFX]I)&/ M3\*TI_"D::M+J6EW;Z=<3C_25@7Y)C_>8="WOUK3L=+BL+-X$DD:23)DF8DR M2,1C<3U^E,#D/#<\;_&'Q@BD96VM0?R/^-:WQ)*?\*[UP2$!3:L.?PIEKX T MNTOI-1MY[N._GQ]HNEN'#S#.?F.>>E7_ !%X7L_$\$=M?R3&U3EX%U5;CX=:#?6-E9WT?&T;ZMJ1B8%63[2^ M"IX(Z^E ')>+]1GU'X;Z9XH6W9IM/O([PJ.NQ9"#CZC%=UIGB+3-4T6'58;J M(6TL8DR6'R\9P:GATBRAT9-*6!6LUB\GRF&1MQTYKD8?A-X<@O7DC2<6SG)M M1*1'G.>F<=: *GQ6CE?P_I/B.P;<-,NH[H[?XHSC./P_G70GQII4_A]=2L+A M;DS)F*%#\S,>WZ_I6[/86US8/92P(]J\?EF(@;=N,8Q7.:!\._#_ (73HF MA69F>2(-\K,3DG'KFML=* . \$21Z-XL\3>')/E_AX2YCX;'H2.HJSI MVEBS_>33-<7+##2N><>WI0!Q_P 09XT\3^!E+A6.K#KZ;:ZCQ;(D?@_6&=@% M^QRCG_=-5]7\':5K=_'>W\;RSPD-"2YQ$WJH[5+>>&[?4=&73+VYN+B 'YB\ MC$OSG#<\CZT 4OAS)&_PX\/LA&W[%'T[<5B?#V2&\UGQW$KAM^L.#CT* ?T- M=5I/ANST2Q^PV+2Q6HC,:1B0X0=<2M_>8 M=SR>: .5^&%W!HMWK7@^=Q''X)4M]\DLS M;IIY6+R2'_:8\F@#D?A%XKM-0\(P:3<.(+_2Q]FEBD;!(7H1[=OPKOK:_M;Q MYEMYDD,+;)"IX4XSBN8U?X9^&-9U%;^:Q$-QG+M;$Q;_ *[<9K7A\,Z=::.V MF6:/;0.VYFA.:3Q.J2JX_MRY8 'H"1BNG6^']OOI[%1_ MHR3(O<_,P8_^@_G6;I7@S1]#N?M&G)-;,SF214E8+*Q&,N,X;\:=K'A>WU36 M;;5EN+FUOK:)H4EMY"N4)R5(!&>>>:+ 8TME;/\ &6VN($ E329&N"!URX"Y M_7\JTO"_C?3O%>I:M962R!],F$4A8#YLD@$?BI_*KNB>'H-'DN)_.EN;RXP) M;J=BSN!T&23@#THT/PQI/A^ZO[C3K1(9;Z4RSL!]YLD_^S&@#;HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H/2BB@#PRUU&[E\8G3 MMCK:C5[@K>$\9"]/YUJ^)[3?>:Y:MO9)H(V>,'DGRV'/MQ67;ZCJK>-X],_L M]7MHM8G!EX"L^P?_ %ZZ#Q,[?\)'/N8+#/:)MQ]X['VG/_?0%O<2AGG3SXP>D:%BFW M\JXGX>:E#X5\/^*=OUIVC*-G_5AV1YC>:U-:6?\ PA%S"T3&]_UW8*'W$5V_AP6C7VE6 M\19'ATN209'#*[C'\L_A7)^(M,"^(+/4=2G(_P!)N_-CQ][;D@C\ !^-=;H% MW(_B&XMBH5+/2[:)L#')^;C\2 ?I4N*YK@GK8YJTMH)M6U6&+4VN9YH9H"N3 MA=\H#8_#-8&N>$/%EM]KU0#_ $2 D)$K'E%.T'\AFNDLB]MK>I>=I26_D(\C MSH1\Q64'Z\\BO4YIH+_1))$7S(I8&<#'W@0>**25Y)B6JNSS'PAK27)L[Z0! M$EB:*0$]"5((]^5%8<6J^*?^$W%U"C7$VG1.)3V>+.57]35[X?:2YDBDD*O% M;.;A$<_>R#Z]<[OTK,CN?%6F>,)T08NM9O)$CC8G&S(PWT&:4+V?J#;9W2>* M/!^I1>;J<*0WH7=*LB E6[_K40\23^*+K^QO#:&&TVXGNFXP!@<8JK%\,-%& MZX\0WDH@O<.PZ1CKD>HP:S=)\96?@NSE@C5Y-.\H3V@7\F&/ MSI.W,@5KFC;^)9C*-OAJ1=4. 9 !MW>N?K78^#] DTS05CU%4EO)97FF/7YF M/^&*YJVE\;7]BFJPI;0%U\U8#@,5ZC/'I79>%M=37]%6\\HQ2*[12QL.5=>M M4G&X1BKFRJA4"@ =J=VH-+6IJ(*6BB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBD)Q0!2N]4LK%U2ZNXH6:ZW\2=3T]VN1ICO MI,L[VT-P!G+#@-]":T[[PI:>,-=UNZN[F97MY5M;=4DQY>(U8M^)>N+U[6HX M?AKHVDPF*22VOQ;SDG[IB?);\1FLG)[F3;9V$)N= M;;0;"XBMQ#9?:[F>3' MS.QX!)[DAJYSQ'9S^*[+0];MX8QJBW$D4I0@"01MG'H>AKI/%.D6^L76K6L] MXML;^SMWMIMX4'86W '\>GO6'(=*TIK#1+75 8]'M7FDDCD#%IV.0">^>>/> MH:NALP[RRU]K>RM2TKZE-K?VFVWMEXX\')/H,E>*]$5+?P=8F64?;]=NCM&? MF=R21@>@K.T:T3PIH;^*?$MUYFH20[U60@;,C.U1Z]*H^$]=M];UF/4=79HK M[/[GS!M4(">@/U_6FEJNXEIH-O\ 7?'G]LO%;P1.+>-9)X8]AV9.0I/KCFG^ M+%L/$7AO0_%3VD9>"XC6Z&WG:6"LI^AKG$N_$EX]F^A;UN;MY+^9BN?-03>4 M%^F,'Z5TEOYTO@7QG"5'E1ZE.(5 Z?,.GX]*%J-ZIF_K>@[ULK;38%C\@;8@ M6'EPJ Z-H3Q-]KL="L8-)2!PC%6$^T[!Y9!3GN!S6SJUS'%HD4LDP86S6.%S@D@>F<\'%*VKMV#O[Y.!GO\K9_ 5O># M;^\NO$'B1KHQO";D20,A&0F"H!Q[**X+Q4]U_9VGWUM+);W+_9[H'< 5W+Y< M@Y[@KS]:ZCX7VFQ[JXQ)F:WA+,S;@_WN?3/-3%VFEY_H)7O8S=3TU=.\':G= MVJ"6'4;^"[CRQ( WY. >/:QJR MP>-WTO[$X:?5;%S<[#@#:,J#Z<6D<[?[>30!;AECGC66)U=&Y5E.EG6O#FH:8K;3=6[Q M YQ@D5J4A&: .4\%:U:2^%;*UEG2*[L8%M[B*0[61D&T\'J..M5;"R.O?$#_ M (2)2&L+"W-K:MMQO=N7/K@ XKI'T#2Y+E[EK-/.<89@2,_7%7HH(H$"0H$0 M=%48% $E%%% !1BBB@ HHHH **** "BBB@ HHHH **** "C%%% !1BBB@ HH MHH **** #%%%% !1110 4444 %%%% '$^)O'L&CZRV@0VMQ/J4L :W"1DJS, M2 ,]!CK74:1IZ:7I=O9Q_=B3!/J3R?US4CZ=9R7J7CV\;7*#"RE?F JR!B@! M:*** #%%,,@4H#_$<"GT %%%% !BBBB@ Q1110 8%%%% !@>E%%% !1110 4 M8%%% !1110 8%%%% !1110 4444 &*,444 %%%% !1BBB@ HP/2BB@!,#TI: M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D(R* M6FN2%)'6@#Q6*^NCXS2R\J:+3UUB4BXVY9SC./7O^0KJ?%%D+K58'C0[RL\3 MM@\G:'4#_OG-K_\)W]G:");!-7G5;UE^4-M/4].#Q717?B73]0BMFL[ MA3):ZC&9=>++%;769 )W4W$8ADVM]X! M@O/Y$_2O2/B+ K36$"6X8?8+HI(0?W9"#'\JS>SMV_%V!62;*OQ,DAN]:TRT M4QA4C:?>H&6:1U51^(S6MXN^(=/ M>^/VB&)EW2D_PQ(3@_\ B*['1M9TK1[:U@EN=LU_=/.$]%E8[2?QQ3^TY/8 M%O=&;H-LA\:7X-Z9K>2.<&WF^8HPD&/U.>?2MX7=UH-JMDFI6X5&V/',0-A/ M7'?'-+-6NI+)8EUN;5RUY(WG+9";:1% M@'H.X!!K7TB^U/PI<)'/,^HZ!<;8XY3\QC!]>^/K5*ST9T\6:%XBT^_,L-_+ M$@M@^0L9B^?CVP*;IVL&;3=2TJWE0[3)"TTI&Q>6VX[9HUO=B;*VI^%;3PSX M]TO78USH=VC13#.5AW@C@=ADUD3>&+*W\4:)92:BMS%YOEI&IRNQBSG/2HO&&GVOA/PS:^79O]HL9UFBN,,VY0_ )^ MAHEKKU"W5%UO%ES>:KKG]GW2!M'<#[,!C?$IPQK*\2:OKVG>,6T/PR0JZS&E MXN /W9*_,?;.W]:?92>&II=:U+0YO/U+6+8Q^4#DH7!SP/ M7DZJ=+TV"T",1DN_^ HD].9C;L=/X<\<67]E6UIK=]%%K$9,,\;<'>.GMS7< M Y&17D\'A32]?TK5_$ERB>']0BU#0[*>.9)"T"% MBISSM&2W]AH%C-]GEOED=YL?<1 "<5UQKA_'NFZBM_I?B'38_ M/ETWS%>W''F+( #4R3:T)D[(X_4+#6OAY>R:G9W[7T-R5$T,B_>)P"V1["K< M?A/2M:\&WRLQ$P0Y+@C8?UK)[F:T=C:-_P"'=1@_L'5IMK6T:^1* M6VL4(P"#^%+!8>"O#>^[C9)))I,*&<,SN>@QWK*O]&T68?\ "4>*(_)1D$=K M:@<^6H^7^AI^FZ#X.\5V:2Z%*(=0C8.,\LA!&\#?90<;516Z_7 JKXYL9(/&NF6<3)'8ZA:O$@48*.H.,?I5UKN33/%FD+J MDK)<->"/<>DA:-UR/;)_6J7Q&NYV\:Z4EK 6BTJ![J9_KSC^7YTHRM=]K"?P MW*'@YT?0[72TU5+36;%&V2O@@Q.^[;^!P*U/%6H0:3H%CX?T=QNQ3]XUJ^(-)MO#>FQZGX9*_ M8]<9+*Y=C]P.W7Z\L*2>E_ZZ@]M#9\?1(^F7*+.)T>T>6%>N[F1P/IP!^%7? MAEK=G_PK6Q>XGBA^QJT4F3@+AN#_ "-&OVXTR/2[B)-]C'%]@EWC&!GAL_4$ M?C7"7'@K28-1DFEN)8]-D'F,IX SG/U)XX],5*=G;%M*VGNMW-#? M7&(<_(%9&8GZBI);.YB\46MXT,C?9C:&&1^ (F^0J?Q)S^%4M5TRRL?!FEPR MW#6$TYDN&D RP+1N0M=EJ*YTNPB-P7#36( [MB0'/T./TJENUY?J)ILY/Q!I MD=[X=EAAD\MK*>XM)-WLQD4^W _6MSX;7#'PS;[K0P(MK'NDW9W$ @C\,5G: MC"RZ_JVG^<'-U:IJD3*O62(A'7\5 'XFJG@#4VL_#/B"PFSY6F/^O4:T=V<9X%*Q:O=3[#Y5O-+>.X.1Y<0+8S_ +S(/PKK-.\-W&LO M+!<7#H\3VLDR=RK+YC_FS?I5+P9H7V;P'?&213/?1I"OHOF/S^8"M79:8CVO MQ"U16G1UOK."?:!SF,;"![1S6K:T(/'$^F):M,9M0L2 M)V7_ %0&T[?K_C7L Z5Y+K.K/'XWETDZ<6\S4+&07(/4 #KQZBO6AT%=$/B9 M4-@HHHK4L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHI"<,!ZT +1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 A4'&1T.12T44 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2'H:6@]* M/"_M&KW7C,Z7+8+]C;6;A0R$X+&,]3V]FX_AN4C_@5>A>+YDN/A MW8> M"I%F&C0R.9&2[:#:IYV!&Z_F:EF\1FS\;:AX@",+.*;^SY[?NZ@<-^!:I_!& MD)8R17+J_P"Y!*$C[]QSP/UK1@TC3]2\::[J]P-D.FQHTL7\)D\LEC^@JE3: MOYL2=TC$F\6^'=!OX]0TVTN%NI2$5'/RQAS@XXK$L[&+4[KPQI"R/!#>W,UVL5V^N1V\&HZ9#:VE^ ]G.!DHP&]0?KBN"LY+N9- ,G[F[TJ]>2 M(OT="V32G?FOZC6YZCXJTV+_ (2CPTX4?.TMN?4*JY!K.G\=V6FW$NB:Y:BX MC23RE;U ZTS5_$<&J?$[3+#3@;A+>%F+)T#N=IS]!6I,?#_ (3A8:FOVF\P MTSG:#GO5M>]?S_0&M=#FO^$M\+^'!(^F:5Y=Y,-J.YXR?P]ZT;+1M*UZSUV> M^3S;F>2.*27N-T8VX_.K]GKGAOQ2WV&ZTLP+,JB)G4?,3T ]ZJ0>)]+T/Q-? M>';NW*7+3QLKCHP55"G\ *&[Z]!)=S!LK74#JUUX2&IB+3BH17(P0HXP*V?[ M!O/A]J&BS:=>R7%I-V]K9> +#5P0=1UAH()68?>+2;FY_2O6]7T/3=7C'V MZSCG*9VEER1]*\?UKP!XED%U%)=%]'T\O>6B!AP1DJH'7C%93CV,W=:'5^*- M9L[.37+_ %2S^UQ:1Y$<46T-@NN2W/U_2N>TH:(GBZPUJU1K&UUFP\V)PN"D MB,FPQ3V>MV*B4/SMD56"GGV(_*N,\3,OAG5_"&CV_E M7-W80X,;#*[F.,<\9(8X_"HE>UOZZ =7)<6'Q*TBZL2GV?5]/4EA'R^:N/F1@>_.1FGOH@.1:\U M;P_9^']1TZU-]LMYK%E88$/].^<066J(84!^Z3("0/ M;-#>,?$L&JR6EOX;9C<[I/)=%Q'(3C/IT&:U-2T%]*T73-++!M2\0:C'+?N3 MUP?,?GVZ4*R5_P"M-!=#NI7BN;>1-1AC6*9,30N<@)\VTX]ZXW3+3PX-32XD M2[^S;B;<7"YB5@>,')QT':M/QU0!\R,/8J#^=5%):"6L? MQ,'6M/:OKMV/%"VT5KY]K=W>G MDSD9$1(4\^_/ZU[ OW1]*N#O.3+@[H6BBBM2PHHHH **** "BBB@ HHHH ** M** "BBB@ HHHH *8[*B$LP"@@K@Y]4D\9WTUO;WBVOA MV%FBGFW;'N6'4)WV]L\=Z -*]\;V[7(L=#M9M5OAZ58?9-,NHK2!1P(Y M\Y_QI66S8-C5']_WQ_QH RBWCO("QZ3[_O6_^(H!\>?+E-)Z\XE;I_WQ6MML M]NT:H_O^^/\ C1BS^9?[4DY'_/8_XT 9>[QL?,PFF#!PO[QNG_?%1L_CS> J M:7C_ *Z-_P#$5KF&S&W.J2_+_P!-B?ZT@AL]P_XFDN>O,Q_QH RD;QR&PR:; M@]][^YO\ XBM9Q9.V?[2E&.PE/^-*L5NAS_:)/&P'S1:;GV=O_B:U=ML/^8G(,_\ 30T@A@9MW]J3 M8'HYH R&F\% &.EQXVP";/3?IY[?_$4AN_&X)Q8::?; MSV_^(K7>.,NK?VLPX& &'- 14(+:PQQP/VI^/\ R'6NT438;^WF MQ[2+3@MOC(UW/_;5?\: ,C[5X^!?=IVCE?X<73__ !NA;WQX7^;2]* ]KI__ M (BM?%N3C^V^?^NB_P"-*88MVX:T<#DCS!0!E&]\ M_F"@#'6_\;A<-I>GD^UPW_Q%2"]\9DL3IME[?OC_ /$UJ"*#&3JS>A/F#_&A M4@"#_B:MP<9,HZ_G0!D-?^- X TNR(P>?//_ ,33UOO&13)TVR4_]=C_ /$U MK".+_H*L?^!BD$*,[;=5<^VX<4 9 OO&1'.F68]A,?\ XFAM3\8B3"Z/;%<= M?._^M6PD2*3G57/U84IBC Q_:CCG^\* ,9=3\8[9"VCVP(^Z/.Z_I3_[1\79 M'_$HMO\ O]_]:M6.(;\C56(!Z9%,2VV$EM78\^HH S3J/BX8QI%L>?\ GN?\ M*0ZAXQ8972K00VD6.W_KX/\ \36PUNSJT@@.XK_;39'^[0!D?VEXT M" _V+9$G/ N#Q_X[31J?C8D#^Q+(#OFY/_Q-;*0D+AM98D'KE:5HFZ#6L?79 M0!CC4O&VXYT6PQ_U]-_\139-3\;C&S1-//UNF_\ B*UDBD)YU[/'HE/$3$;/ M[QCKADYH R#J'CDC(T;3![?:W_ /B*4ZCXX4Y.BZ<1CM=-_P#$ M5K>6N/\ D/?^/)2B/).W7,XX/*4 9']I^-B/^0+89_Z^F_\ B*0ZCXX[:-IW M_@2W_P 16T$0$G^VNW]Y*:$3/_(9S[;EH R([_QQCY])T[/M* ,?^T?&&,_V1 M9Y_Z[G_XFFG4?&.#C2+//_7<_P#Q-;&U&R5U0X'^VM*L0Z_VH2.QW"@#'74? M& 7YM(M,^@G/_P 32KJ7BXGG2+?'_7;_ .M6OY8VD_VGCWW"G+'P?^)F3_P( M4 8O]I>+_P#H$6__ '^_^M2?VGXOW@?V-;X[_OO_ *U;6W!V_P!I\_[PH$1W M9_M0\#!Y'6@#&;4O%X( TBV//_/;_P"M2?VGXOPQ_L:WR.@\[K^E;/D,,@ZH M>OJM."' _P")GGWRM &-)JGBU)0%T:W=,=?.[_E4)U;QEN.-"ML'UN/_ *U; MB1.TC$ZMD=-OR\4J1$;O^)J2/^ \4 8QU3Q@,YT2U/TN3_\ $T-JWBY0W_$B MMSQQBX_^M6O]EDSC^V7R>>BTJ6THP?[98G_=2@#&&J^,L9.A6O3M<'_XFF-K M/C,=/#MN?^WG']*W/*ER/^)R<^FU*:\,IQC6RO/]U* ,5_$/BJV"F?PN95[^ M1< D?GBK>D^--.U*\:PN$N-/OD^]!=*%_)@2#^=7VBEW?\AP@=P52LS6O#FF M^(;,6NJZ@LP0AE=66-U(]&7!'YT =2ISCZ4ZN!L]9N/!MW;Z=K-\;W3;F3RK M._/S,C?W),<]/XC^)KO0-I60!8XE MZR.3A5'U- &K17G0\5>*- U&PE\36MN-.U.Y6WC,!!-L[_<#?7IGFN@\6^(Y MM&BM;'3HA/K&HN8;*$],CEF;T '- '2T5Q.F:_XAT_Q#;:3XD@M_+O=XMKR MC;O4$[&]#@$]*T]&\13ZEXQ\1:+)"JQ:6+8I(#RWF(6.?IB@#HZ*QSJ\G_"8 M-HP0>6+ 7>\^ID*X_2L_P=XOA\4)J4?RI=:?>26TL8[ $[3^(H ZBBN$M?%. MO:L-?ATFRAEN=-U5K11(P4&,+G/YX_.JG_"2>.I]0U&QM]%M?/LQ&S9E7!#@ MD8Y]J /1J*\[E\4>+KKQ5JFDZ7I=O(FGQ0M([N!\SH&QR?K6UI.H>)TL]5GU MZSMX1#"'MO*<-N(4EL_B!0!U5%>;6'B;QW?:%;:Q'HUJ]O+#]H$:R#>RD9 Q MFMB^\<>3\.X?$MO:L\URD:P6YZF5VV!3_P "XH [&BN&M=>\1:1K>FVGB-+= MH-3@VUK%I2.R0R7! :?:=I..H&0<=*T8O&9N? >HZ[#$HNK".83 MV[?\LYH@=RG\1^M '7T5SC>)A=^ I_$FF;9?] >YB1N!N52<'\1BL6X\4^(9 M]$\*3Z79V\MYJ]N)9T=@ G[H.KZ99P6.T[Y(I0S M9QQQFLJ+Q-XWU*>]FTO1[*2RM[J6!3), S^6Q!XS[4 >BT5C^&]<_M_1DO3 MUO,'>*>"08,4BL593^5:X.10 M%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4'I12-G'% 'B<<^M-XV?RG7[$FMS M8F8\#Y#_ /JKH-2&N7OBK6)M#,*)#&D3S2''S!<[1@'US7*W%SJUGXPF-Q;# M^Q(]:GDDVL,-^Z)_H#726FNW%EX;L'@@3^T-6\R[Q*0HQ@L3SQP%4?C7.VMG M_6YC899?9]2&K1*X^T7D*W)A;^&YA.U^/<@?A7"'P_=/XAF33-HM0/.MG!QM M:?$8/USG/TKI4/V;Q ^M::G,5Q:WR)^#\_A[UFES)\O\ 7],'IJB/4#<:;KT4&DXDN--M8[.UMU'W M7;!=SVP%V_G4VFPZ[IGC6UCUR:%H[FS:!9HF)WNI# #('J?UK(L-- M,_:)2 K_ $/)[FLBQ:UL/%&I-#:31WB17(VGE2S.H4]<<]?PK U+_A,8%DGM MM(\NWLF$2QDC!5,C<>??)-1%[I=17:T1ZSINJV&KV21)!Y%Q;$!H64#9(< . M,=L]ZY:WBN&TKXD0R(1<"Y+,%_C0QY_7YJ9X6U:WO+G3K[;M^UQ^5)M'(#+N MR?HP%7$\6:+#\2Y;6"=9;+6+413N?N"6/*]_52!^%7%W*N9!L]3GU.PU,7*- MH:PPW2,&X&V, *!ZYXH,=I;>&+6+5H%N;^9B+*-%RZ,>>?3K5B\\ >(XKQK7 M1M0SI:-O@MV<;$3)PO/IBMNUT:R\)"?6]>NUGO&P8U;YMAR.%'KQVH2UV^8M MBOI>EV/PV\-(RIY^KW2YW8RS-@9'YBLBVL+O4KBRMM5A476I3R-<3D[MJ9=M MG]*SM6N=>OO'^F3:FC00W>GSFQAW?=D,?&1ZY ZUFZ7K.I>&?$OA]M9EE>(+ MOGR=VQGW+D_GFE)/8'V-=/%TVHVVM6S:>([.RA:6TGV@$.C[4 ^M7=:MK6\^ M.=E,642I9)*4?[L@&>/KC^=:,/A,^7'&]Y =(,PN6D5A\R [E4]\. M=4$@E4&WCVJ[.4F)M]#-MO'7_".RZEI2:9*\<5U,+-HE!R M&)/_ +,:]3\(V,VG>$]+L[@YFBMD5_KBHM#\+V>E:='#-%%<3@EGE= Q+$]> M:Z <5I&-M2XWO=@*6BBK+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** $_"HWC4H489#9!!Z>YM]%U.&*RE#/&MQ@[#[9[#-5)/APK6%UJT]\UWK321W"3L05 M5HR", ?3%48[!==L5\0>*]3EM([Q<6=K&X3:AR0>>3D#-8^L:CJW@XP0Z??_ M &W1M6Q'#+(.O$=AFU6WLM(+W1AQ@R3.2 M<>@Z_C6MK6BS^"I[CQ#X> 6U/SWMDQ^1NGS#/0\=JY7^W--TC5].UC2B(HK; M5FTF]!/#QG=AOKD$_2NKDAN?B'?K,)I;;P];G& ,&Z/'.3_#QVI128^GF93? M&70YK4O!82->G& 8^I_WL>OO6%XIT7Q3+9-XLGN_W[?+:VR.-L"NHP1[]J[9 MD\!6B_V%]3LYK/3[?4I)=*O)?+MG+?ZER#A2>^>,4 M23>C#4Z/7;'SK"TMKH^=?&P \PG)+ NK8'^\ZC\:Y7P?\0+_ ,-Z4?#D^E33 M:A#,X2,(3U^8C]<5W.H6%Y_8NFW"1R?VC FSR\=QN,F?9BH(]P*Y\7-Y>:RE MS::9+_:2@(&GB*H#N ))P,D>E9^\M4)MIC]5N[>[TY;Z73P[2ZC,1;HQ+,$1 MU+=>FX&I&2XD\!ZJ_P!IADN9]2A#E1\H"F/"8^B@?C3-=TJ;2]#TG3UOMMP' M=OM6"CLR'H,Y/ZU82"[M?#6OV\,21W5KJ,%Q#&PR!N\E@#ZYR:2OU[?Y MC$\*#4!::9/=7B-+=ZE-;^Q?%E\T&^.UO[N33VQDC M(8.5_$M^0I]]=:S!)/K%WI$U2 CDM:$+ MG'?ACGW%8_PXMKN+Q7=QWZ7.;G3VC=9%(!$;*O.1U XK=M]*O+>SGTQ(1/J& MG7GVRS9CC<@*[0?8C*Y]JKZ!KE_<^.M?U'4+4VUKIVEJQB(QY1/SL"?4X)_" MBSYE<+>\C%;5[N+5K'35TR1K2>?3)&N%7.W[O)/;.W%>VCH*\5DU35+/5K33 MS9C[/--I:W%SM/[LX3Y/;M_WU7M0Z#/6KI%0V%HHHK-2?)@Z8R.A;D#Z5J0SZ39VR6T6F3+%&NU4%FW _[YK'\*G6C%P.3[UT1O-5!8#2T..G[X<_I2 KM?:68P?[,F(/; M["W_ ,32F\TU$3&FS8QT^QMQ_P".U82[U7R@S:6@;T\\?X4?:]5\O)TQ,^GG M#_"@"+[5IS ?\2Z0?]NC?_$TINM.7_F'R<_].S?X5(+K5-N?[,CZ?\]Q_A1] MLU/_ *!B?]_1_A0 Q;G3RA<6$G_@,W^%,6XTYMS&P<'I_P >[?X5+]LU,D Z M8N/^NM*MUJ.1G3T SS^\H B2YT]R +"7)_Z=V']*2:YL%E5&T^1O?R&_PJ5K MS45&!I@/_;3_ .M2->:EO'_$M&#U.^@",SZ:B1SIPZXY:G&YU#<0+!?\ OJ@"$7-@?^7&3_OTW^%2"YLE&!:2 M $_\\3_A4C7%\!\MBN.FZ@"'S]/9CBS?)_Z9FA9=/'/V.3 MI_SR;_"I_M%Z 3]B7/89IOVJ_+@?8 !C^]0!&+JQ&0+20?2$_P"%)]HL0I/V M67!8?\LF_P *E%U>Y_X\!_WU0;J^! _L\8/^U0!$TNGA-QLY""<8\IO\*7S] M/(YM'YX_U)_PIYN[W!QI_3G[U(;R^P/^)=_X]0 GVBP4#_1'XP/^/=O\*:UU MIS9W6DI&>GV=O\*=I93>;*3!'_/JW^%2_;;XXVZ9GU^?_P"M0M]J!4YTSH> 9/\ MZU $'VG2L\6#]/\ GU;_ IHN-(C7(T^0=O^/1_\*L_:[_>1_98P!U\T?X4@ MO-2(/_$I''K*/\* *WVK2 -O]GS;?7[&_P#\32^?HZ@@:=+Q_P!.3_\ Q-3- M?ZF(MPT<%LXQYP_PJ3[=J&T?\2KD]1YP_P * *GGZ,9#_P 2^0$#J+-O\*<; MO2>?]!FY_P"G1_\ "I_MNH"/?_9(R3@CS1_A2B^O^O,34#^R<<6Q]<>4QJ07EZ7.=,.#QGS!_A M2I=WC9SINW'^WU_2@"$R:5N_X]SG'_/)A3MVF*W%NV2.NQJD:ZN5.!II)_WO M_K4GVR[W8_LUO^^O_K4 0M+I6<>0W_?#4IETI< PDY)_@;K4WVNXP3_9S$CM M_D4+=W!)W::P_P _2@".*73"6"PD=^4:C=IA) @)_P" M4OVNXS@:Y)'3T_2@"OYFELPQ;N3TR$>C.E!]WV9]V>IC>IOM=T Q.GG(Z8J1K MFX$1;[ 2Q[9_^M0!3:32"0OV=SNY^6-OZ4@ET=AS;OU[Q-_A5@WMR&P--?(. M,_Y%(;V[!&W2F(_WL?TH @:?1T?LC],_ZA_\*F^WWX4'^R&Y.,"4?X4W^T+XM_R"'[#_ M %@_PH B^T:.S;?LKG_M@_\ A3A)I ;BU;)_Z8-_A4QO;T,,:22/7S1_A3A= MWA7)TPC_ +:#_"@"(OI84K]G;"Y/^I;_ J$7.CE3FWD /7,+_X5:-Y=_P#0 M,;_OL?X4\W-P!QII_P"^A_A0!42;2"/E@.&X/[IJ>)-+P$$#X'_3)JG:[N5! MQIA/'9A_A1'=W+#YM.9?Q_\ K4 5A+I!R# PQS]QJD#Z4!@1$?\ 6J87,WF M,IL&QZ_Y%!NYQC_B7,?Q_P#K4 5C_9&<^2Q/^ZU*LFDE\!&SG/W6J<7=. M<'AJ2/^QF0,(B!_P*K'VR7W_UJ (%?2!C"8YQT:FLVC*Q7;@GKPU63=28S_9S]?3_Z MU(;N7.?[-8_A_P#6H A\W2!ABASTZ-2?:=' R4/_ 'RU3&\F"D_V:YP.!C_Z MU-%],0/^)6XSU!&/Z4 ,5](9?,V''^ZU-9]& +&,_P#?+5,M[.,C^RG S_GM M2F]F/32WQW_SB@"N9=$8_-$^N M %QI#G)Y]OTH IWAT*ZL)+6:%FCE4J?W#$C(QD<<'WJMX0U5HC<>'KZ9WO;# MB.24;6N(?X7YZ]P?I6K]ON20!I$GY_\ UJYOQ8+FUDL/$T.FR+-I;DS8?E[< MCYP1CMP1]* .[!R**9%(DD2.CAU90P8'J#WI], HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BC(HH **,T9% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 'I7-^*8H[FZ M\/6LPRDFJJVWL=D4KC]5!KI*Y/QU=KIFG:9JLJDPV&I0RS,/X4(:,GV W\T M;FI:39:Q:+;W\ EA6190N2,,IRIX[U@7%LES\5+.68!C9:3))&3_ M)(%./ MP4_G5GQGXC;0/#RW-J8WO+F:*WM$)SYCNP P._&3]!5'6KQ](^)>@W$BC['J M5M+I[/V64,)$Y]\,!0 GQ*(@\.6M]G;+:ZG9R(P[$RJI_,,13/#,:K\4_'#J M!\R6 ./41-3_ !\4O_[%T%'3[1?:E!(4SR(HF\QFQZ?+C\:31D-G\6?$J.=J MWUE:319_B\L.C8]>H_.@"ZQ8?%,#JIT3)'N)_P#Z]((W\N# M5+V\L;W)^4N9Y#&Q]#E=N?<5V,'ES_$:\G1U86VEQ0O@YVLTLC$'WPH_.L2V MT)/$WPRNM,9GC=[J\:)UZI(MU(5/U!% $OP^B"ZQXU?&&;6Y,_@J_P!"*U=( MR?'7B==Q($=G@>GRO7+?!G4[C5+;Q+AL+N[$J63$P1EMF(B.P]ZZ6R\3Q^(]#U@QV%W M:_9[=@?M,3)NW(3QD"L[P]-;+\4_'$K7/PCL M+-8O*UBV,=\L6./-67S=F/KQ4EKH:ZS\%]+AMH8Q>'3()[<[>1,JJZ_J/UJQ MJ/C:XM? >D^)E@58WN(1?J?^62%MDGTPWK2 -*\5Z/XIU.TT_4[.:RU2W<3P MQ7"LG[Q.ZD\$\GBH;Z\ET_5/B!=P<30Z9!+&?1A%)C]<4?$:. R^%;FT95OS MK=MY+)C+HV0^?4;?Z596UCU7Q?XUTPL/](T^VB;G^^DH_E0!H^&;BST7X>Z) M-=3I% +* M+(0!N908R_-GDX.,& MK7@X6FK^![+2-12.66QC6SNX#_"\6%Y'4=,UR%G]AA\*?$LZ='&+%+ITC\LY M4XA0'!^N:8&K&+?0M(\9>$E.U(;2:ZLD8]89(FR!ZX<-^=16VHG2O#WPYO6M MYIU6S"-'"A9N;7T SCBI?B]ITUOHG_"46&?M6GP303#J)()4*'/T+*WYU;TL MK';_ Z4E=GV)E'/?[,/\#0!LZ%XRCUW5#9)I6H6Q$1D\RX@9%X.,9('-)X' M.;#5AQQK%X/_ "*U=$LML'54>,.W0#&37*>!;F&'3=;,L\0$>LWVYBPX E.< MT 5-)ANKS5_&^EV=Z895O89$D R(R\2,V/KS^==X@(4 G)[GUKD/!#07$OB' M7$9?L]_J)\J7/RO'&BQJP/<':>:[ $'I0 M%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4AZ&EI&^Z: /!?$S:F; MC6BG_(+.H70)Z-O$9!Q^.!]*T?'.D7&J6WAN*U$PGCTW>! <' V9 ^N>?:J> ML6&NWOB74X5:+^RCJTWS-QY;/ 0._3I^-:\QU&\\/>#=5M;B*&[C1K&7>?D. M5VL/K\A/6N::U?H8]&7-/M+,W&L64S,9(+*ULYC'T!$9.#^!)/X5:MKVXU;X M>:5]HFAM;MSP?)WX!_'@?\ C5/R[V*YBTJTFAGGU*YCFU%U',:%26_ M/9M'MFG3ZR=9O)=/MD\O1;M3I]I*HX6>/+!L],9&!]!4\JV>FG]?Y@M$9WB+ M2I+[4=4TNQ#%)+*&2'^^WE3-N /; /%4_!.CW^F>&?&=MJ7S2N@E\L]B58G^ MGZUM1MJ=_'%1U P0:HZ;9W-OX:\53W^H>;6X3]PD-S+"V.7V21L2?7'( M'UKUW%M>6&&$;P3HVXY^5E;KS^->8:/'83>.+Z.:X,B[9UD52-O$B!0OU'6N M@TV\U32K'^S_ "(KB)"(V#MAHL]5//. >*5*\="E:QPO@&X22WTR&VCRBSRW M#9'S/$JDE1]&P*J:7IGA35/&>MB]F:T@MY&:W0R%<9&3[^_XUWV@Z-:Z=$L@ M9/W*O#"B\"-BV57/?.<'Z5S&O>!],N/BG86L#R1K/$;V\&X=R1CITXIQA971 M%M"M8>*/%ML9+?1X)KZRC4".=TR6'..?P/YU?\-2MKFNQKXND>.Z63-O;S?* MKD$$?7G%6K_XEV/A^_\ [+TS3A-!$XC\P*2O1>A'7O6JD^B_$:WFMU1[/5(( ME="/E=&/< ]LBM%9*Q6^C+?Q(L[;^R(=20[=0LI0;(*?F9\CY0._ICWK$\'Z M?8Z[I>IQ^(HP-3EF5;B.3Y3$F %(]!DUS*:OKE]\3- TC7U"SZ>))-F"%E<* MQ1O<<"LK4-=U75M0LGL$*:AJ %K.0I )+-SCV"TI-7%I<[)] T*SN/L4OB=E MM01F,3\8# 8S^'ZUZCI=G866GV]OIZQK;1K^["'(P>^>]<3!HOA+285T^Z(G ME \F:5VR5? _(Y-+HGB2R\'66IZ3JMUA=.D#PNYY>%^5_+FJC)B\XI: MJ:=J5MJFGP7MI(LD$Z;T8'.15O-:&E[BT444P"BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **0U0U;5K71;)[R\D*Q(.@Y)/M0#=CE?%'C'5-+U M"6WTS2C=QVY"SR[ONL5#8QCT(_.O.O$5BEQX TWQ&+AUO[ZX+2H#U61\,OX< M5V7@_P =Z;J.O:S%*KVHO+I9X/.& X$:1G_T$?G7"ZQ8:U>^%R;2#S+*RU2X M:(K_ Q[CN ]MQ_2L)2=C)MG?^*_L]CJ&H:C)9BX72K"V6VM@< F25E)_# K MEK%K2;PKHVG:G82-'(=Q6RDEB%O%(W2)-K$XX[DBENKC2UU,71O#>A^ M)[JTTW2'D:PL;PWU[/(.)7R J_\ H5=5KMY<:E>IH.CI]GTZ '[1/%[#<$7Z MX(JIXBU!/"?A^WT#PS"K7L["%G0?GMH)L@U"Q\&BZNO[55ELOMAMH &&\L@"LW_?1J^C23?#'6;2ZD\RZ M\/7C"*0=2(R"A_*L&PT^QU+0])U/5U9;>2.XAD91N\N7[4) ?Q!K7><6G@7Q M7J@01+X@OC!90LNT[3^[&?J-QHBVU=CW;.VUS5X[*".ZC*_Z6(@X8XV1G<("FU9?+D/3DXSM![TOC622+2WT^:%)2UHW MG3IT"_,2!] F*TOAC+!%\/\ 38%F!^SJTMV"UV[F'XWN=*GT M.RGDBDN8+BY:5HU;YDE,+D<8Z#))^E7WBB.H/HT\SQ6^N:0D*7&.1*BD _7: M<_\ 16?J\&I"%K73)H+9[?4;KRQ-T=7A=QC\R/QK>UV.$^%8)=0.94@@:%H MN7$W0E?S&/QJ'\7R!;7*5GHMUH(BU[Q3JYNOL%N8XT"X4ME@&QD_-@@?C7'V ME]J>DKJEKNJU^YT9];L4U&-9;B')&%RJ$L/+#>V>?PIR5UH)ZZF78VVI: MQ8&R^TBV\3Z,GD+,_(F0@88CCKS4^I:1J47A:[M+F5#K&N7,<_3%5O!TMVNNW,'B-I_P"V$4R1 ML_(,8!!V^]$^T1WUL4=;O]3M?&CZ5;V22::UYIR&4GE-N#S^*BO8!TKQ_P 0 MWFJP^,Y[:ULPUC+J&FM=2@\@Y4<>W"U[ .@K2&[L5$****U*"BBB@ HHHH * M*** "BBB@ HHHH **** "N;\;17-]H(TBSE\F?5)DM/,QG;&V3*ND- M/-&L)G(,%I<7G!X!RL8/Y,_ZT :R6NHQQI'%>P*B*%4>0> /^!4T MV^LE\KJ%J%_Z]R?_ &>JYM-'5V9[MRGSFFBST?=M^TODC. M-YH LI!J^3NOX,=L0'_XJAH-6"\7]OG/>$G_ -FJM';:*@ 6"!6X]O)/_Q5 BU@;P;NVR3\O[H__%5";/32Y8WTQ_[;&E-IITLP;[;- ME!C'G'I0!*L.K#K>6^?^N)_^*I1#J^XDWEMCM^Y)_P#9JA^RZ9C!O')(_P"> MII/LFFN%Q>28'I,: )3'K)'RWEMT_P">!_\ BJ!#K7R_Z=:].1]G/_Q51"TT MPCB]D.!C_7&FG3M.RW^G3@GKB>0/-- $@CUC<28/_34U*;;3PJ_Z2V >/GH FV:IA3]H MM\_Q?NC_ (TH74=A'G0%NWR'_&J\EOI\@56NF&#G[YI$L[$*?]+D;ZN: )"F MKEO]?;@8Y^0_XT\IJ9(_TB#'?Y#_ (U!]CL0V?M+G(XRYIS06+H%^TL,>CF@ M"0)JN>9K:C-I8KDF\<#_ 'S0 M!8(U7@Z5"MM8'D7+D?[YH-K9.,?:Y.!VOF4C65CT-Y,#[2F@"PPU,]&@ ^A_QH9=3VG:\. M?<&JXL[( #[;-E?^FQI[6UE@YO9NO_/8T .VZN6&)+<#'/RG_&G!=4VG,D!. M?[I_QJN+*Q(S]OG]?]<12M8V+'/V^<8_Z>#0!,!JV/OVX_X"?\:8RZR00LUJ M/^ '_&HQ86(/&H3\#'_'P:46=GD@:E<$X_Y^#0!(%UC:R:KNRMQ;X_ZY'_&JXL[ ,,7LF!U'FFG_ &?3RV1= M/_W\H ?LUC\?/;[TW'_ $M\YZ;Z %7^ MU=W)M\9/K^%*G]J;?F\@GZFF"WM5;<;Q\9_OTBVMK@XO9#GG[_2@"5CJF#Q; M_7)H_P")H67F #//6H#8VKG<;V7'7B2GM;V;Q[1>RC!Z^<: )"=4W+Q!C//6 ME;^T_P"#R/QS4$EI:.%_T^9<<<3&E:UM=NTW\PX_Y[&@"1O[5V#;Y&[\:5O[ M4P,"W)[YS5?[):;L_P!HSY'!'GFE:SM<ATYYA+ M-I[O:.V/[C$+^:[3^-;]<5HIM]+^(NL:9%*\@O[2+4?F;=\ZDQL?T0UVM, H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH ***0].* %HK%TWQ/I>J3WD-I7C\: MZS1M9L-;A[8E!GDX M(/\ 0UQ$=AKUGXNTC2447MO#I\=U:SR\&-DWJ W7C,B_E3 ]B4Y7KFEKC_AM MJFHZMX6DGU2837,=[<0[QT*JY Q[5USNL:,[D!5&23V% #J*H76K6-C+:QW- MU'&URVV $_ZP\=/S%7A0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 5#=VT%[:26US&LD$J[75NA%3 M44 <=I?P]TK2]3AO5EN9S;G-O',X9(3[#'I6[K.B66N::;&]C+Q$A@5X9".A M!]:U*,4 ZA M&I$]XL:R^X0''_H1J_1@4 =MO(?)D$C9^7!Z?G738HQ0!2TS3H-)TNUTZV!6"VC6) >R@8'\JK M+X?TY=+NM--N&M+EW>2,],N:< MB,$8X_"MJ#2K6VUB\U1(_P#2KM(TE;U"9Q_,UHT8% '(:M\/]*U74)K\SW-M M-/\ ZYH&"AZU%\,Z7'X>FT.* )9S1E'5>K \$GWK;HI@4M1TZVU33;C3KM-] MM<1F.1?53Q61J/@S1]3L--LKB"0PZ7%U-!.TD\S32 /PS,7&=N &##]16Q& J;5Z"G8![44 %%(>AI,]@>10 ZBF MD_6EYQ0 M%-S@]:7- "T4F32'\: '44T,,XSFCG_ ": '44W)[4A//4_2@!] M%(#UYHS0 M%-!SZCZT'CGM0 ZBFYST/2G'I0 44F?>DS0 ZBFY-+0 M%-SSP M>*,X/)_^O0 ZBFY.>_\ A1G/TH =130>O7CM1DB@!U%)GI2=Z '44F>,]*3) M[G\: '44G>@=3UH 6BF[N]&I% #J*2DS]<4 .HII., M\]* M #Z*;GWHR<]?PH =14?F+ MD#<,^A/6GJ6F#@;'.2%]U.[\ZYF6+5_^$^NIX[T)I0UME<-DMO,:X*C MT!;'X5N>+U&L:I;:/IT174Q&UPLWW?LZ#@G(_O$YQ6$G;?H9(DN["U\,K%H? MAX-)JNIR(DTS?,4A!PS'Z _K7-6L=W)H=MX2MI%MY;.\=4;.75T=G#8] "GZ MUL>&K*7POJ2Z7JRF*YNPJ17N=RSG=EESU&1_Z#6JFI:*WC7[.(VDU+RQ;&Y* MC:7P6//7VJ)=P>J*<&FV?B@?:I+IM-UN'_1KM0>65>2<=P00:Y/Z5DZ_H,_B[7YX=&"HT2"*?42<;LGYE&.3MSBM;P=' M+I^H3Z'?6KQZBD D>7JMPHXX/?J"/BYM#!;Q"^9 M.>6!9#SQVK*U>XMII(9]5OG:YNXVD$2MM6,!B%_&K<"PMXKU">WU:664+.AC M8$+AI$!/_?)-6-2^#\-U%J5W]KWWTK.\)89 /.!_+\JB%Y-H+Z%K0+TZ?*;) M_,D@F^>$G^"7.,GVP,U0O;M;:;X@7TT@C27^Z"N3C]/RK)\'7S7FG: M8]XY,<-TUJTS'!<*A& /H?\ QT5O2?V5/XP\0>&]Q\O6=-A 8#A91&W'M\I! MJHOFT\Q]"'3M4TM=7TWPD=/7[+-;QH;G^)9C'N']:?+;Q7EM_;-K,+/4+$89 MNTVUB=O]*GMHM1CN["QU.R6*&PGCFGO5/#K%'A<=\G-\ MO)C;P@]MP)/YY'XT:JS?41V%_/9^,]%M/$^CJ@UC32)43OE>2I_#=6'<-(KJWC@B2_1IHAU7)9>?QQ^=7KO1[CPEXST:ZTI1%;WMNZ75M_"TB("Q], M\FMOQ%X?B\;>&IVTRZ2&[G0AE;@;L@G(]-]-U"$ MRV4D,][%,?X6.<8_"H-2T.#7/B?H\.I)2O'Y!JPM8O-3N?%7B+Q#86BO;QVBVENS?>;!YQ['YJRF^ MOK^@WJ@L]=\0:1J6JZ7X:LA<:;I,C2%&)^93\Q4<=B37L]E7>$/%V@Z1X7N&DWG4B5DN8MGS.\F<#WZFKO@GQZ)+>PTK5;*>RD8) M!;O(!A\ #_&M(.UF.+/3:*1>G-+6YH%%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 &N!\=7<=IXI\+_;TSI3R3K<,PRBMM&S'->UP$*6MBC+)<.6*1.@)ZG MID&N+N]-N;K3?$'B+3)'LK*Y14@6/Y?,3(1:1AB/RJQJ^H^/H+(/':VS1%EWO P9MIZX!'7FI[C3;N/2DT' M3M0^Q1VUHC7=TS?,KD]"3_NFLWP]-X@T7Q@VF7-Z=1M/LWGKR#OCR!E3W((- M.+LDBK:DVG26)O\ 0(XO^7B\>21YAF5R$D*@GKUV\5!\0X8O^%C^"GC57GGF MEA<8R?+..OM\S=:M^+]#1X[#Q)H#;SI]VMS+%$<[E'# #U]O>LN]N-*\2ZI_ MPD&FRW$^JA/L]I&N=L#[6.?3./UQ4V:O\A7LK&%X%;Q0BRVUI;6E[IJ/*'2X M(\OS%DP&&1Z 5J^*I=1N98[?Q'!':06R^=IP@^8/+NPHXXX7&/J:J:5&FC^' M]%T?5-0:SLY(;F[N)8V(+RA]H0D<\%AQ[59U.5]6\(ZO97ER9KWPQJ$WC6"[B\N\ADZ1R.2Q)]LEA^-< G@ZZTU MREKK\]II$CJTJ&0@@_Q' ZY&2,>U>O:@T*B)K.R M\C5$M9VO"9I"P*QR"!OW?H/_ -55K20ZCX0U1H]R-=:A:6ZR$8( \E2QSZ8) MJ);_ "_S%U+NIWVH-9PQ^*K&V;2KN0(TD1W-:R'E<^P]>M8T>CW1OM<@O[DQ M268#)M.?M<9B8(3GMO.<>M6H=-MX]0ELYM0NM5TC6K1G4LV\+*K $KCD<<_\ M!JS8V2Z\FGS7-RT-WH,GV?41N_UR(,C=[':'_&J>J_K^OZ8N4?923Z/)%<3P M#4/%&JQQS&)ONP*.,;OX5&>WI4FHZC>:GI]_T@:;X[N(%U$WUG> MZ88_G?=^\0@,,_0_K2O_ "[%MZF?J5UK/_"3W-U:NBZ=-=:8TJD?,H(7 4>F M2/UKUT=*\1DBUO4-7@N;:9%L(9-,^T+E>65L?H,_I7MPZ5=/=A!!1116Q844 M44 %%%% !1110 4444 %%%% !1110 &N*LLW7Q!\1W#V/VE;6"VLXV^4D?*T MC#D]]Z_D*[1N5(]:XS1[?43XE\57-G)"L7Q)9[O<-3=NNG_EI9?DU @ A(;_B1DX_V M(^?UIR+%(NPZ.RJ.F5CX_6O+?B?8>-+2\DURVU@V^DI"D;I X4*Y;;G!YZL* MY[PQI7C_ ,6Q7ES9^*)8;>"0(I9P=_R@YZ4 >ZL88P!_99/H-B?XT((67)TK M:3U!1/\ &O%[#X@^,?!WB :)XI$_\ SS6G&.V S]@'_?"TT+JO.9(<^PH"ZKGF2';]* '^1:*>+%2#C_GD*%MK)4*BR3!Z_NQ49&L M'O *4+JNWF2'/TH$/$5D%"?8T*^GE"E-K9'&;&+\8EI -3W23S M0!)]AT]<_P#$O@_[\K2_8[%6^73X>>XA6H_^)QG&;3'ONI#_ &R$&!:$]^M M#O[/L,9_LR#C_IDE*;"QCX73(2,=HDJ(#7,\_8NOHU.!UK?RMD%Q_M4 .6PL M5SC2H>3D_NDH^R61;!TN+)_Z9)3)!K?.S[#^(:@G6P2-MD??YN*!DPM+0 _\ M2V,;N#B-*9'8V"#RQIL8'O&M"_VSCDV?_CU-8ZR.@M#],T" VUBLNS^S4)QU M\I<5(;:U8!CIJG_?M:CD MALG8!M.!YS_JUIY&J<E@1G_8%/4ZF1 M\RP TX_VGQ@0?K0,A/V,';]A./\ KF*!]BY'V#\XQ4I.HY&!$!WYII?5<\)# MCZT"&$V6"/L)Q[1"FYL00OV$\_\ 3,5+NU7(PL.,4X'4S_#".E $1CT[^*Q7 M'O"#3673&PQLTZ_\\/\ ZU3[M3!/R0XH#:IP=D/N,T 5 =*:0_Z !SR?(_\ MK4GGZ0'*_8.<_P#/M_\ 6JX[:ED82$\>M1@ZQ@_);9[9)H A,FD=#8KT_P"? M;_ZU1M+H@;YM-C)]?LG_ -:KBG5R/F2U!]B:0G5QT6V/YT 4=^@ X_LZ//\ MUY__ &-+YGA^([A81@GCBS/_ ,35TMJ^T%5MBV3G.::'UOO%:?@3_C0!4$V@ M'_EQCXY_X\S_ /$TS[9H#EU^P# '/^AG'_H-7@VM%_N687WS3@=8&5LP?\ @5 %83Z*_(L1Q_TZG_"E,^C+M;[$IR<#_1C_ (594ZUSE+,?]]4A M&LX;BTQVSF@17:71RX0V )QU%M_]:G!M)C8 6*CC/_'O_P#6JP#JP/W;3'XT MA;5_-_U5KC'J?\: (3-I18D6G/\ UP_^M0+G3512+,]> (>GZ5)C6-Y.RT _ M&E#ZN.L-J3VY_P#KT 1IM-']I]X(/TH A,FE%>;48S_ ,\?_K4JOI0!(M!P/^>'_P!:I7.J M ?);P?F*4-J@(/DP8[C- %59]'92PM>#P1Y!_P *0/HH&!9C&<_\>Y_PJT?[ M4SD06X'I2!M6W#,%N!W.: *YDT1P?]%7C_IW/^%(9M#=L&U&>G_'L?\ "K@_ MM'/*6XH8ZF'7;!;E>_/>@92WZ V3]C3)Y/\ HI_^)I'DT KEK%""/^?0_P#Q M-7=VJA>+>WS]?_KTUY-7^4+;V^._S?\ UZ!%-9/#^P8LD"GM]C;_ .)H+>'5 M7=]CB&<_\N;?_$U;,NM ';;6WL-Q_P :0R:T?^7:T(],G_&@91DG\.;?FL48 M9Z?8S_\ $T+_ ,(UM$GV&,#_ *\V_P#B:O%M;*Y$-GD'H<_XTH;6LD&"S"XX MP3_C0(R'33_^$HT.ZLH4C,@F@W+#L)79OP3@'JG3VKK:YR]>]&IZ(;F.)%%\ M1^[YSFWF'\R*Z.@ HHHI@%%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 A.*-WM2,??%:TEU;2P6NFQ/(+ANDVP@. M%]<$J/QH ZP-R<@BN=\9>))O#.F6MQ!I\E]+P74M&T<;9=7ENEN+2'<1@H&^8^V 1@]: //K M)9]:GUWPYI-G)IUTEF4NY" K.N^1UP>Y)<#\37JWAF]EDT#3HKUX4U#[.@EB M64,58*,UQNJ7FJ6OQ#T>&XM8+)=5MF@N9XL$G:0P&><'G&?>JVF:?I5UXCGU MG3(KZSDTZZCMD\R5RESODV,V&)R."!]?I0!K^)?$1U'Q=;^#+:U#+*AEN;F1 M,QQ@(7"\]SQ^=,FO-7'Q&FTM8+>!Y]*4QW(8V74_2JGB:.VTG4[7QO?+-> M1V]_<6TEM]Y4C!= P7IP$S^-=!H/A:+1IETR*6%;<.MRT8;YY"A&QCWQP,UH M:AHVD3S/IEUY%LSXWG^+&>QSTI ?Q6=QSW:9X6'T\O(Q70:-::3>7;65M>1W/\ 9,L>1&>C!"H#$?>( ]^E M '&WDEZ?&FEZUK&L2IX>U)GBBA5V4*[%EC4@>PS^-;MOJFK'XB:AH]NMO*UI MID>R=SC +9^;CKTX^E:E_P"$K?5E@TRYDA>PLYA-'$I/F1G)8=.G/Z51MK#- MK%?6ZLNIZS8W#/-GD,RAU]ACY5';BF >'O$\.E^*%\&7%I!!,T37-N]OCRY MG.OV\VY\M%?#\D D?AFN?T;0+6VN-.N+"WN)#I?GF M6\O0WF8VOMC&[DC+G\!6%_9\+>*O#FNZIJ%]._B"U$9B4GRXI7"X.!Q@%B,& MD E]%+IFN:/H6OO]J-K''-I]SC_V9 M9:)-I=D\JSV\[OKRS0:+?2V[!9DMY&C+= P4D9_&O(-'U;XM:OX=M]:M9]/>WG@,T<91=Y M'8?=[_6O7M9XT/4,]/LTG_H)KQSP=J_Q'B\!6-OH_AFUFM!;D6UPURBL1N., M@N/3TH W=;\<:S<_"[1O$6C.D%_=W,4#*Z@C>7*$=.FX54NM8^)?AL6VJ:V; M&?2TFB6X6 *&"L0I/0="16?K<]I'\"-$_LIO.:VN;0, -I$ZL&<<]]^?SJQK M_BO7/%&KVW@:ZT6:5\8AB&!NY]S6/INM>*_!?BS3M&\3W2:C9:I)L@O%/W7/&TY -:^DG M?\<-<$BD&+285B)Z;2P)Q^-0_%^.,Z3H%R #3;))IQN(W'8F/<#7/73V M,OQ6O8[ZZ@2*/08X/+D<*,RRN6QGV1?SJKX-U./4/@[-$LZRR6-G/:.0?^>: MD+_X[MH Y?3M;^)USX=@\31RVEQ9-")S;@@,R '/;KQ6UXS\<:G_ ,*\T#7] M!812ZA%S^M<;XBUSQ%XTU*T\&76CMI4EQ*MS))(X.848$ MX()%=#;*H_:%NF/#?\(^H ]O.Q_2F!BVUQ\1];GU:72[ZW%M:ZA/:QK(V"VQ ML>E=9X5\;G5/!-_J^HQ^3K_9B8S-%IQ)P8 MQDXZ=2*O^)O'FK+\']*\36&ZWOIIXHYE8=\LK#Z$BN]UW7;;PYI]LQM)[B&0 M^6L=O$7PH4GL.G&/QKS3XE:QIVN_!6.^TJ PVLEZJQQ;-I#*S#&.WS#]:8&U MIFG?$Q=1T^2^U*UDLUG5KA5(R8]P)'3TS7I<\L<$$DTK!8XU+,3V Y->'X8K&22-)90P.U2.3][MBNP\8"0^"M<$)(D-A.%(ZYV&@#SN. M/Q]XUAN-;TG6H],L&DD%E >LB*Q4,<#O@UJVOQ!NO^%43Z]+ ?[6MLVIB=<; M[C<%&/4$D&M[X;LK_#K0'7: UFC<>_7]1$,LFEAN N/IC(%7_&/C35+CP'X5U?0IQ; MW.KWL,7MEU8$'_@0_2O4Y!&T;)( 4(.X$<$=\U\_:O+/!\(O!4]I%YS6_B#, M,8_B"RS;0/R% '3W%S\1/!\UKJ&LZG:W^F?:8TN G!1&8+GE1ZBK/C2_\7W/ MQ,M-!\-ZG%:1S:9]I(E' (=@3T/;%8^J>)/$'C?7M.\'WVCG2+>ZD6XF,_!E MCC8-A3GDY4<#UJ[XRUJY\/\ QITV^L]+N=2D.C,C06RY8 RGG'H.* -GP1K/ MBB#Q;J/AKQ3*=?\57VE3Z;#_9!L[6*=2K_>+YP?\\UM_!L6Z_"O M1A"J@%9"^/[WF-G- $?AG7];NM \0Z9J\BIK^D;E++C#!H]T;_CS^5)U\0>!;/7IAL+ MPL\H]"I(/\JX/X3^,]:UWQ+?6VL7#20W5I]KL@_9%E9./\]A6KJ6E/X ^!=_ MIT=R#<06KIYN>KR-CC/^]5+38-*T7Q5X!_L^_M9$%C+IT@CD#$Y3S%)QZL/U MH Q_%J?$GPZT=V=?C:WO=1%I!&&YC#D[">/;'&:WM2@\9^&/ FOW6HZXMS>> M9;?99E/^K!D56[#L:T/BZI.BZ$R_PZY:']35WXN%E^%VLE%+.!$5QZ^:E &' M!X8^)/VNWDF\3Q-"LB&6+)Y4'YAT_"O2=3=XM*O)(V*ND#LK#L0IKSNQU'XG M_P!K6"W>FV8L'FC\]E=-RH6&[C/I7H.K<:)?_P#7O)_Z": /+[3Q)K1^"VAW M'VMCJVK3I:+#/$^C?:M9N=8TN]F^SW"N/-6T#2M6DTJWT>./MVWPS\(W-AJ#PZCJ$]G&\^>29(B3G\:V-*POP'@ MST_X1[_V@:YGQ\91\'_![^7Q0!MZ9X6\>V^N6ES?>*4N+-) MU>:$%AN4'D=*R73QIKWC[Q-8:5KPL[2QECV*Q/&Y0<#@^AK6TF]^);^(+)-4 MLK1--,H$[)LSMYST/L/SKDW\0Z[X?^)OC>YT726U*(>2]P/^>9"<8Y&>,]* M.R^'VK^(1XDUOPWXAF6XGT]8Y(YP<[T8G!_2M#XCZI>V>EV&G:=<_9;O5;Z* MS6XSCR@QY8'UP*R?A9;WNJ3:EXTU*=3/JVV-(%/^IC1F 4^ASZUO^/\ PT_B MGP\;2VE$-]#(L]K-G!20>GU&10!RVEZ?XN\)^-]'@O=8N=4T>^$DD:'K#Z9I.E;8;F6)BK22D9*C'I5;PKXN\7Z/XFT_PS MXQL0R7+>5!?;0=S ,>2O&3P/PK6^%#&1O&#OGSCXAN0_'/;% $?@S5]9T;QG M>>#/$-\;Q_)%S873G+21\Y&?48/Y5O\ @2XO+FWUPWER\YBUJZBB+'.U%; ' MX5SGBC,?QV\&M$HW-:7*OCKMVM6_\/V'D>(ESR-?O0?;Y_\ Z] &;\3=4U'3 M=4\'I87;P+=:Q'#,%. Z$C(/ZUI^.[Z[LIO#7V6Y>$SZU;P2*K$!T8G(./I6 M%\6BO]I^"MV<#6XOSXQ6M\1 ?,\)G/(\06H_4_TS^= CDOB/IOC32+76O$=E MXFDATZ)TDBM4=LJIVKZ>IHU"Q\8>'? NJ:I?^)I+J26*W-OM=LQDR+GMZ-C\ M*ZKXPY7X4ZZ1C_5IP?3S$JK\2 [?"%]C;6VV?)/7]['0,/B%KVK-K.E>$- G M,&HZH"\MR#CR(1U8'KG@]/2L2,:]\-- DX61VD56_-0/QK4DU&\_X7;#IHNW^QC0FN&M\ MG;N\[;NQTK-\3Z0NN>)-=A^SJ]W'H-O-92X^9)5DF9<>^Y15/PQKL/B;XLZ; MJ\("K<>%R60CYE87.&!^A'2@"G!H7B#QQ=:QKEKXCNK%HKR6"UMHI"NWRVP, MX['%>B>"KW4K[PE82ZQ$T>H!"DX;J64D9_'&?QKSK6_#'C3PCK.I:OX2N1O0O!/B5/%?A>VU4)Y:Y4X*1(#DY]2>*Y77;9/#>C>-?#Z';;SK#J5C%Z(TBJX'_ AT]ZZ M.8D_M"6V\':- ;83TSYO('X4@*>GZ;X@\#^,=*MWU"\U72]1#Q2[V+>5)G.X MY/3!->I"H'E@26..61!(Y.P-C)QC./S%3@\4P%HHHH **** "BBB@ I",@TM M(>AH \6:SU:3XAMG(S[BM6*2^@\*W6J65Q&-6UB_*1 MRN>$3>0H![ *IKG=I.%T#Q+/',TPWZ?J"MG$PS MU(Y!]/QKG;#3YVT#^T4F:/7KF\-F82WS+.96)(/LASGT%;%IITTUEJ&CR3O+ M=V=Q%<6U6-KN](P"S \9ZY)P2?0U$=6N;S1-.U?SV M%YI-^;.\=>KIG:Q^GW356&"[U&XLM-U2X,%Q_)(Z^E6]>O;6'5EEMK>26X((O/LQ91O!YR>F<# MI2I26LOZU%%V5F9W@71Q)8:6+B-%-I=37DX8YS(P"*O/<[B?PK)OK*_E\4WG MA_38C'?74ZW4=YWBB/(R>Q RN*[W3=0TN]TJ".Q0)MVF2,J0ZW *E-W?&<^U M8YN[JUN?'.KQ!/MFGVZ11/QC=Y08_P#CP%5&"BO5CM)#ITT2:]]J- MMAY[97^9ACT]JYJRODLX/!%R\I>"VU*>WE8]AYBXR/Q/Y5U.G7%C9Z]IT<,T M\^L9MOM1=B5G6=27&#QP.?PK(T[PE(?$>H7GA^\N= N$@L[ M6;[-:[<;I7Q@!0>V[:/I1:\N8;U]X@\1>%?%]U9L4UI[I8_F>%7.67)X_&M? M24C,6N3A-EO%Y'DQ$_="QC=Q]2?SK,L1J_AW-[7,8A]SE2O/L2#^55+74(IHK&^T^Q^)G]H_84DM)] MBDM& B,J[2?3(.:ZWQW<6&LMH5IILL<]ZFHPRQ^5_ JG+?A@TWP[I%EK/A:] MTG4A&UW;74L4ASAXVW'GCG'2K?PS\*Z=9Z)8:RJM+=S0 >8[$XYP<9^E)1;6 MO4$KZ'H*Y[TZD48%+70:A1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% 'G_C3P#)XBU-;VSOY;5Y$$-RJGB2,9Q_.O.-7\8/!X;B\(QVDR3Z M;L3O"Q?&V.7[Q(]CD M_E6O+##X%UJ.XBB4Z'?2AY'"_P"H?LV>PZ?G7-:SX3@N;+2O#5I*@MSI]PQ6VNG& 5[*WZ54;M:ANKF7J5GX3OB MFG:KJD:&UN3=P2B48DB=M^W_ +ZXJE?RW-OX2\3ZXL"A]>U".VM5 ZPABJL/ MJ Q_&NEF^'/A"*^34Y9LP@?*C.-N.3_6N6\;>,M-N=3TB*UB+:3IDSSN!TD9 M!\@'T8&IDK,%='<>,#/;:#<(\_"12RM(1@#:?D'T&2?PH^']K%JOPVT]=0(N MOM"NTN\8Y+DD>V#_ $JCKMM::U9(8?,+7U@\D"%N"SY'/T+@_A7'Z!\37\(Z M.VB7VE337MJ28U0XRN!P>.U3!^_@7/M2WGGV_@#Q)%;W)62*:";S%3.U72$G'T!--U=I+VPDU*V)M;VXO2 M6:4_*G^C[6Q]",5T-E%9_P!I'1;Z-476-*C)7/WF0;'4?@5-+XI)>7ZL-T8O M@ZW:RTNSBFNHQ+:ZFZ&7(VD-;EV5>V!G/X5LZ,+*WT]VNWV7?B:267DXX((4 M?@A45SNNZ?!IK6WAW158FVC"?.4DC'F%OSV+^%$5RO5[/\ 1C+L%W=)I&@65WN^W:=J$ML5"X#%()"I^G ( MK*^&RWL/C/RKF0/$FFFX#CD*7VY'UX!KH=9U"WMM:M;]4S;WOV>^!_NE&*/_ M ..N/^^35G6M-L/"WA?4;K2]QN=2988I'.?]:P "^P!I62^7Y"5VSG7T^_6: MT>R8'3S/8-/&#RV2#N_4?E7LPZ5XWJ^E:G%XH;[->F/3K6;3H9(@.6P0 /\ M/K7L@Z5K2O=W'#8****V+"BBB@ HHHH **** "BBB@ HHHH **** $/2N/T2 M.UDU3Q+YUWY9_M4\"0+@^1%78&N.T:XLX-6\2B2W>!^ MZH 88-%9@6U!?_ D?XTC6VB,Q_XF:CV%T/\ &G"]TTDD6,QQZ14OVO3B0?L$ M_P#WZH Y7XC0V$'PWU00WIE :)O]8&_Y:IQ6+\&X[%O#>IQS7FTFY 93*%*_ M* *W?B-=63_#G5A';LA#1<.NWGS4KG?@Y+:V^B:Q+/;.Y-VI+*F025Z?A0,K M_&W2[&YTK1]2M;A6FAN?):17#84C//OD#CWK?^&-W;ZQX(1KW47\^WE,4A:4 M#;W'Z''X5:^(+Z=?> =5*VDJM JS*3'@;@PQ_.N.^#>HP1ZGK6F3Q;D,$=P MO. #L_J* /66@TK*DZ@.AQ_I H2WTECN6_\ NGM/7&?$KQ-/X8M=+U'3+1)( MFE>.19%('W21^HKJ=/U6QN=+T^[ELY ]U DN5CX4L@)H$61#I+$D:D< X_X^ M!3V33%4(VH#DX&)A7CMM\3-?FTG4M3M?#EO+I5E.5EN"3P,@?IQ2ZC\4]=BT M"'49O#<"6/]7\-ZQ%%_8D$MGL>,#]Z*9]EL6)(U!L=_P!\*X67Q7J7_"N='UW3-&6\NIOW MT\2DA8UPVX_^.@5B:'X\\4:]9S7^G^%+>6VB?:[;VSG&?3T(H ]8\FSQ@7[' MC_GLM(T%D",Z@RYX_P!XT;S,-#DMQG% $PM+-1G^T M),'UE6G?9[,*4_M!OF[^:N:KLVC.2#;@[>M)Y^C#Y_LY!_W: )7L;(CYM3E' M_;9?\*%M+./KJ;_C,M1M/HS#FW+<9X6D\_1MRC[,>>GRG_&@"22ULW<9U20> MWFJ,_I2?8K%FXU23CMYR_P"%#3Z2GWK<\#/W/_KU&USHKIO:W.#URA_QH F^ MR6)X&IR?-T_?+_A37L;$D[M4D!QS^^7_ J%+W1(PH6 \],(?\:D:[T:4<@0-U MY^2E$^EY_P!0X[F/=Z21\T+8_P!S_P"O0(E6TM2V1J#G_MJM2FVML@_;W_[^+_A4 FTI M$)$''^[2?:-)8F/Y5#))H0)618AQW/\ ]>HQ/X?7Y0L>#]>?UH M_8;<#']I2_\ M?Q?\*:]E!N+'59ESC/[Q/\*JM<:!@DPC@>A_QJ99M%QD1CYQZ4 3"UMQC_B9 MR'GKYB_X4V6TM70'^TY ,[L^8O\ A3#XQ3UN])*< M>F* )1;6YS_Q,'_"1?\ "F?9(1@?VC)DGO(O^%,\_20!\G4<<4TW.C[P"F"/ M:@"?[-#MP-0?K_ST7_"D-K"3QJ3_ /?Q?\*B,VD'@Q@^]'F:.HSY8^7B@"5K M2+^'490?]]?\*<+.,( VH2D_[Z_X57^TZ,6 *BG[](*-\HP!DT +]@B+D_VG M/]!(G^%/2RC4_P#(2G/U=/\ "H1+HOS,%3@<_P" MH F&G D'^U;@@'^^G_Q-'V!2_&L7/TWQ_P#Q-5U/A^/C]USZM_\ 7I@_X1M3 MNQ#DG^\?\: +8TX"+8-8NL>N^/\ ^)H6P"KC^V+D\=2\?_Q-4Q+X; ; CQW^ M;_Z]*LGASY0!%CM\W_UZ &ZA;>5=:.5O99L:@#ARIS^Z<$< =CFNEKE+TZ9] MIT8V?EACJ"[<'_8?/Z5U= !1113 **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BF]2:1&5ONMD?6@#GO'7B"Y\+^$KS6+6W2>6WV MX1\XP6 )/MS7'Z;:ZMK.M63:U;VR:1>VLM^?*;Y0=T3%"GZUU?Q#URQ\ M/^#KR\U"W%S V(A"6QO9C@#^OX5R6L6^LVFE>&IOMD$=G)>06\EO%&?EAE&" MN<].U# @L/%$G@>TTC1;/1[N]T^:60?;-K88;R21@= I%:.NZ-:^(=7U#6+& M95U>UMX);&;=PD3*#;.;5;:222PL%5PIPQ 7E?UQ2 H65K<:EI%DFH2&6\31C)%,1@[]X( M?_QU/SJIIDNG1W'A;??2>5JF;V*UXQO(#DDXR54G\"*FL?B'X9OK_2;ZVN1' M%+;R6C(^ 4RH=?P'EL/QKSOPY>2^([33-2TJVF;5-'46=C$/]6R'=O+'Z,!^ M% 'J/B_Q_IVB:7]ML?L]_<1O$6C3#$([%0PQ[\5SUYXPT6SO/$5ZMQ$$O[:S MF:$L-RR;S&V1Z@;#^%5- ^#-P\5C)K.HE9;:/RV$(_UF)#(,Y/8G%=SI_P . M?#MG<37,EFMQ<3$F1Y.A.<]*8'E[>*=1_MK6?%%H)I[B_M9(=-A6,L(A'(J@ M$#^\ 35N(ZGK>N+;:I;:A#%;W,]S!J*(0S%U&Q>F-N>U>SQV5C9*6C@BC7'. M%[5!)K.CP1;Y+VV5!W9A0!XY';>-$TVWM_["G\V/59M0,A4[6X<9(_O$5ZM_P );H!_YBUK^$@JS'K& MDR@;+RV;=V##F@#PCP[XGU?3=6C\47T\Y2.V@M=0M94(,K$[=RCU'!S]:[&+ MQYIZ:=H8TQUO-3726CM[1#EFF81*H('/&UR?;->DS:=IUZF)+:*1<#JO%8=Q M\/M!:\@O;>V^RW<#F2&2(XVMC^5 &1\/?%4VHZ59V6N31'5[R.6Y,0 7:@DV M;2/7-+J$%II.BSZK'=1WECI,SM:08!,4P;:$)'4!\<=>*P[OX67VF_;KO3KT MW=Q.%(,@VLF)?,(7![G-B60BNXHR0H\T(6 'L"^X#WIPUNX;QZ=8%U( M=(CLF26SV8V. H /JQ8L*L^'[77[+P>99?(N8IUE>XM74K(H.[*AL]0!CIVH M ZKP7KTOB?PK9:S-;"V>Y#GRAG@!BHZ^PK?K!\&WFE7WA73YM$^73_*VQ(>J M@'!!^AS6V[!67)&3P,G_ #_D4P'T4SN!G]>M/H **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"AK;^7H&HOM+;;64[0, MD_*>*\=\(?% :%X,L=,E\/ZK+<6\;*K"!\,=Q(_AZ M2,KEU.0 2/;]:]F,:&/857;C&W'%1P6T-LI6&)(P3DA1B@#SI/!VD>-?$VO: MMJ4=R);6^^Q0E)"GR1Q)GZ_,S53\*:0GA>7QWX=@BE-G%$+BU#9)=7B.0#WY MXKU4*JYVJ!DY.!U--$4?F,^P;V&"<=: /#O"OC[5-+\ 6&AVOAO47U-;9H8) M#"^S.6VYX^E3^,M%OM$^%G@ZPDBDENK?5();D*,G<1(S$_B:]K$48QB-1CI@ M4/&DHVNH8 YY&: ///BMI>H-8Z;XBT=7-]I,ZR.D8RTD1(RN!U&<&H+(2W7Q MW34XX)?LE>F%0RD$ @^M(L:*J_K6SX4\(WEUX!\11:K&T=]XAEGN)$ M88,9=<*/P->D^5&3GRUS]*?VH \WDAD ,(_$7@.UN?"_P#PCUQ??978:=/&C%9$9BP!(ZXS MBKD7@?48_@_+8[I&UIY%U)%.]'B/P]=Z/X!\ Z5%#)++:ZO:27&Q22I. MYG)QVW-7L'DQ"7S!&N_UQS3RJMC*@XY&10!P7Q.TV=;/3?$MA!)-?Z)=).L< M0RTL18!TP.O!S^%5@T][\9]+U*&UF%E)H!_?%3C+R%@.G7 'YUZ,0",$ CWH M"*""% (&!QVH 9(BR1,C#*L,$>U>,:)KM_\ "J34M!U32KJ[L3/)<:=-!&Q# M*3RI(!]J]KIKQQR8WHK8]1F@#S?P?9:G?:?XC\3ZQ8R6FH:LI2.#805A5,)P M><\FKFC:*^L?!BRTJ\@99Y-+$6QEPRR!, X/0@UWV!C&.*0 8 P* /#?MFL M^+?"OA/PYJ^F7DHL\3*?*B[MQP"6'_ 'S6EX]^'^F^'/"C:QX[NOAUJEO8VTES5LBC4EB1*AX _.NP*J1@@$>X MI2 >M 'E,_Q/\0Q*8E\&WYE51\QA?:3W/3VKTC4RS:-=LJY8V[X3U.TX'YU< MV+_='Y4[% 'BFG:1K\7P1\/36$%S%JFE7'V@VNTAI5$K_*1UQ@@U8OM=U+XC M7>AZ.FBWEE%#>QW-].\;*$V#.%)'0DU[$% & !Z4BHBG*JH/L* /)M1O=9\ M!?$/4M2:RO-2T?5D5E6)2_DR ]. <=ZE\):;J7BO3/&M]J5F]C_;RB""-EVD M(L;*#S_O5ZJRJP^90?J* H48 'M0!X6OB'Q#;^ /^$&BT&Z.K1P?8/-\MBA M7[N[.,?=KI/B%I.I0_#OPW8Z9:/=W-C=VA,:*2?W2')X]Q7I_EINW;%W>N.: M4@'J!0!YG:?$?7KC5;&VF\(WD4-SQ?[HX]J H!R ?I0!YOX.TK4/#/Q%\1Z9Y,QT> M] O;60@[$A&: /,/!EAJ7B M;QM<>.-9LIK*..W%OI]O(I!5#GR\3>+/"VH^(H8/!]Y>VL^KW5Q# M,L+X92V!C YZ"O9P !@ >@HP/2@#RKQ5#K?C#X>Z=K<>DR6^KZ;?K>I9LIW M,(V;C'7D8JE_;NN?$#Q9X>C7P]>Z=I6FW27ES-<1,N74' !(''^->Q8 &,<4 M!57HH'T% '&?%6UN;[X;ZO:VD$D\TJHHCB4LQ^=>@'TJC\0+2ZN_A.;:VLYY M[@QVQ$*J=X(9"XR?SK$EN-6^*VKZ3;7&AW6G:'92BZN6N$93+( 0$&0/6O8B 1@BD" MJHPH 'L* .6MK>X'Q,U"X-O(+5M)@192IVEA)*2 ?7#5R/AOPG=:)\:=8GBL MYETF6Q9+>8 [$WNKLH/3.[=7K%&* /&[?Q%XN\%7VJ:-+H=YJT37#R6%R$9M MP8Y ./K^E6[%=9^'WPA6[CM\ZG+=?:;J.0<1^8_/'; Q7K!52U8_B31 M/^$@T]+%YS% 9D>8 9WJISM_$@4 :[G;&QP3@9P.]>+ZGHFK/\ (=,.GRM?Q MW18V^TY*_:68E 'F?Q:\,7NL:18ZAI<,DE];.LNL\+:EK=]J.NQ:M9BWAMKQH[-MA7S(\G M#<]>U=-1B@ HHHH **** "BBB@ I&Z&EH/2@#PS7M.^T>(-8N#=[(3J;I]D' M/FOY*KN]?XCT]*NZW%;:MX9\*S>:L41C^RR.3\J<=.?>/'Y47.C.WC:ZU-+L M-.FM#;$WW4_=@#([_>_6M[2X=&C&I^%M2*-'#<-<1[SC$;X?\,,3^%<\HMRL M8]T4- G?2K2*^OW4^7X?BDDF[G]X2F?P!Y]Z;#Y&C^$1IEP";ID36+I,_*RF M8%U7VP"?I56^<:YKD2(Q33;Z:"WMPHQ_HT*L\A/LQP/I2-J"ZEXQ@294*SQH M'7/2&8E GX Y_"LVUHK[?U<+ZH9XIEDEUK59X)]J2:7; $CGRUN2&;\.*J^' M8CIOAKQ=++=+)9/ML;69^/.;)! ]>6P*U;!8M+O;.[U$YBM#+H]\Y^Z(F.^( MGZ90$_[5:6NS:9=76B^';".&6$W7GR+&V<)$ NKY%]IQX1X94W9 X((ZTX)\7&J2(Q/\ %^?*_@JC\:B9_$;^-4:U5IK MG30TH4@_-'DL%_*I@VT_4$]A)-9_L>5+.\TR=?$%LOV<72QG:P1-BOTQG:,_ MC73:#8ZGK++IMJ9K+08XPTCD8:7.1@,?I^M7U\=>'9G4ZW;);WT7$J/U4XY_ M7-4_^$DNO&ETVF^%]L%AM"S70YVK@@X'XUK97N)1TN4M?\66MGJ,/A/0F5+! M()'GE4YSL)9P#ZX%8OAW5M.OM=\,Z*7CUKPXHCBTY%BL\GJ5.3^N:)*S ML&MR"+3WAEUJ6629]8OI)[-(B>,,^%./I4_B>\U&S^)L&K6ED;Q-.MH[68JI M;Y^3QCTW9K8MM5\0(WV:301)J !4S '@\X/YXKM_"F@/I&FR?;F$]_=3-W4CFO3=.T^#3- M.MK&V7;#;QB-!["K( 48 P*45HE8T2L*****H84444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 E,.& YJEJ&N:;I^3^E+)#<^'GTOP]ILZV42V[ MW-[=D_Q'@>Y)85@:W8R^*] TB[)B.L0:@UNLHX$VP$YS^50Y67,07?"\+>"O M$UJETPGCU;]RL@_Y9/NX7]:Z#QUJ(NX$\.6MH+O4+U2!W6$?WC^=>DZZ+ M2VM'N#_:]UKJSQ1[R3$BASGV&2/RKTE8;3P7&%4/?:UJ,F$[M(W /)Z**B#= MK,$_=.)@^#.JI8)NU@^Q(_2JOB?Q(++0T\-W>B".Y9MH(^[M_B(X] M!6K?WWC[4=8:WTVXC%Q"A:6#>0@.0-N<=<&M#7YX?$WA'3O$36F+K2[L&[B* MC. =LBGVP(?#FCWEC;O$8XP(83_ *%(.3[CH?45B;)=0U& M2.+3)'OPV$\U7DV[%)]R Q_*O.IK2_UR74+J%4 TA/MLBXY9F17+):QW-AY\2L?WIZ@X].U>N#H*WI_$PBK!1 M116I84444 %%%% !1110 4444 %%%% !1110 A[5R.CW-]#J?B40VBR@:E\I MW[<_N8_8UUS=,UR>B6\W]J^)V2^,8.I @8SM_<14F!M"[U+:3]@C^GG'_P") MI!>ZF0?^)?'_ -_C_P#$U$UC>]3K# _[@Q_.G"QO,@G6'/'38/\ &@8_[9J@ MS_Q+HO\ O^?_ (FFF]U0$?\ $L0_2;_[&FO87K*-FL.O/]P?XTC6%\=N-:;' MO&/\:!'+_$BZU&;X?ZBLU@D:EHLGS-V!YJ>PK$^#,UU'H>JF&!9!]K VE\8^ M7GM6]\2K*0_#[5#<:@[H#&6 &,_O$XXK ^#,;R:'JQBN#"WVI1TSP%H&=/X_ MGOI? &N+)9J@^S$YWY[CVKS'X1W,B^-IGM8D?=:NDBYP3]UA^HKTSX@6\J?# MW6_/U([3 ><8[CBO+?A!%)<>/[IHF6$169)QQN[9_P#'A^5 (Z/XOSW^JP16 M"6ZQK8VQU";+YRI(C Z>I:NK\!:U9>DK'I\5E#S]W">:?_'L5%\%5>\\#WMB;]F6.X*L#_"KH#C]30!': M6=Q8?L_7"S1+&;J W;L#GB20-_(U/HFFS^)?@:^G-;QLSI.49FSAQ(Q!Z5N^ M--):Q^%6KZ?%<[XXK()&#Q@*1@?IBJGPLM)9?AI8QI<^6&:4,N>GS$$?G0". M,^*-Z\ND^#;E]RF2Q:10O=BD?^?QKV6^+7MDUA<0I_ID)3EOO$KSV[9KQ[XR MZ>MB_A6W27,%K#-&@!Z*-@'Y "MZXUV/6?BWX6T^RU=IK>"SEF?R\[2QC.,_ M@,T ;'A"*\T[X:W6ER0AI+ WEIDGCY6;!_6L7X'W,G_"&7DMO:;E-\1@MCC: MH)Z5W]_8M%HNI(MT )(IF],%@?\ &N ^!T3GP3=>7$1P2V+1CG)+*S'^H MJ:[#VW[2*R^?ND:: ,<_PM;*"/Y&O5?$/@W3_$[0_P!IR"3R&W19 .WU% &5 M\.(]0TKP+IUM)9.YP\@.?X6DG_ (ELB_5NM*M]>G&=-+G_ (F. M?JHI#:7Q'&I =O\ 5B@!3?W@*XTV0YZ_-TICZA? 973')S_>I/L>H @_VJ.! M_P \Q2BRU$,Q.J=>@\L4 2+>WK,P.G,,=#OZ_I1]MO=G_(/;/^__ /6J(6>I MD@_VJI'_ %R%3"UOPO\ R$A_WZ% "?;;SC.G-_WW_P#6I#?7PC)&G,3CIO\ M_K5&;/4RQVZL/IY0H^PZKM(_M@=?^>*T .&H7Y)_XEK#GJ9/_K4\7=Z'V_V? MQZ^9_P#6IGV+4?,8_P!J94K@#RQP:>;2^R/^)ET_Z9B@!HOK[YO^):V7[9SI MP'IF3_ZU->\O\X_LT$=OWG_UJ5+74%;+:B&!Z904&VOBP/\ : _W!0 IO+_ M (QIXYZ_O/\ ZU*+R\+8-@1[[_\ ZU(;6^('_$P ^B"FK:Z@O74 ?^ B@![W M=XN M@6]?G_^M2&]O1P-/)_X'_\ 6I/L]_G_ (_UQZ[:)C_=% #'U" MZ4$C3)CQZBG1W]TQ&=.E48'4BA;>_ .;U">W%*MO>X.Z]4D^BT -;4+H2X&F M3'_:R*=]ON2/^0=+^8H:WO2H5;U0JPW7X;CIL% +^Z+;3ILH' MU%(U_;%)]DU($G^TE_[\BG?9-1/_,2'_?D4 O;MCSIS#_@7_UJ;)J% MXNT+IKMZ_-TI/L>J8(_M0?\ ?D4OV34-H_XF0!'4^6.: ')>794-_9Y! _O_ M /UJ47UWMYT]_P#OJF+::C_T$5/_ &S I7MM0+'&H*!Z>6* %^VWA/\ R#C_ M -]__6I1>7G_ #X$?\#_ /K4"VOL?\?X_P"^!3?LNH!3_P 3 9[?+0 IOKL MYL&X]&IOVV[(&--;'^]_]:E^RW^/^/\ &?\ =IZV]\H/^F*3[B@!/MMV%)^P M-QVW4T7MTQS_ &<^?=O_ *U.,%\2/],4>N!0+>^'6\!_"@!/MEQGG3VR/]JD M^W7&/^0;-^E/,%Z<8O%]_EI&M[X@;;Q?^^: &O>7!*@:;*@IQM=5W$C4$QC_G MF*;]DU4NW_$R3!' \H<&@8XZGIQ7<4VCFXNA(?[ M00$!< _(]=)0(****8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !2$TM-8$GCC@B@#SCQCJ&J:3XPM=3%^$T^)8DAM@W^M9GV29]QNC(_ M&JGAB1OAC9ZI_P )1J@D@GFCFADV_P 3@[U'/087GCO67#X8T\Z7JMQK]U=' M4=-OFN(IIY25)4[EV*3T.!V]*U==G37_ S+K2:>FK)JLT=K80RJ#LBW8)YX M!.&/X"D!LZN^C>/=.T,EA,75A@.XA(1)& CK$N2,="/EY'O7):W MXGL?#TVK^%H]%O'C$#2RWB@,3E?]823DX)'OQ0!N^.KZ?3/">N/;1^9?Q*BV M.!\P\TA1M^AW?E7!ZAXH\1:_<6=CHEP9KF"SM9S"0<-/RDJO^>>_2MJUF\0? M$/6-(U"T$FG:9;K')<2/\K22+NX4#J/FKT#3-(TKPKI\L@,<669YKF0 ,Y)) M))[T '5$TN7Q!%"?L$"QQP1+@;AC+$]\X].]=?+/H_ARS)D:"R@'.. M *\ZUOXJW>K7C:3X(T^2^N?NO^-]7DNY >+=) M&*#'J#@4P+^J_&:P$[V>@:=YN+A5S\K=\C'K7J6#@\T8H \V7X'^#PP)MG..V16?)\!-"9W:&_NH M,] G0'\Z]9Q]?SHQUH \SX!!%!!]: /*]'^->ES7*VNM6,^F3@X)?E0?KQ7H&=)\16!P M8+RUE'/<'_\ 53=8\+Z+KL+QZCIUM.'&"SQ M^?6O.+[X5ZQX?N'O_!NLRVY M4Y%K)(VS'< ,+&73KH81;C'[MVS MCM_A7<:IHFF>);-+A1 UPN&M[Q%!>-E(((;KU XI 86C:R?$B>%Q>1A;ADFN M;F(_PR1?NSD?[SY_"LO7=(_M76-'CDU5[#8?MD*YP'!G+./KL('XUS^N-XF\ M!ZOJ.J7VR]LKU7A2>$',)D9"21CC.T],\G\:W=,U2Z\6^(%T_6?#<,&BVMLD MJ2W14NI;A,=>NW!YH T-!U/P_P"!O"U\T$TK:N"?I0!N> [ MW4M2U.\U*347N["^@6Y5&&!;NSL!&.?[@%=_7D=_HTFA2^$=/\*ZA=K&]RJ7 M1A=C&R*./%$_ANUT\VD/G3W%RJL@ M'(B7YI&_!12^-?$TOAB#2+M=OV:;48X+@GDB-@V2/IC-,#JLTFX]N:Q[W4Y( MM;T2V@(:WO3,7;/98]PQ^-*+WQ=%IOAYK-+5].2]+W60 MD6BR2:?)J=WJ:6T94G9Y;*3SE>N0>U 'H>>:0M@=#]*X[3T\;07[S:MSOU0JMS DP7N R@X_6L;2?$4NH>+]8TUDVVUN$6W8_QLO^ MMQ]"5% '2;CGM1D]ZY'6M:U>ZU]]"\/PPK<6\*S7%Q/]Q V=JC@Y)QGI67)X MNU>W\/>*+>ZB1-:T6W$GF*/WAYHR:XG3;;QR;^QEO-0L&LMP M>=8U(8J>O0>E M(#M!R**1>% -+3 **** "BBB@ I#T-+2,,J0.* /&+[0[>?QQ>:K*S/*-96) M+56P'!C49/US^E;>O^';+6?&]J+FV^6YM&BW \AHR&7_ -F!K#NM$M[CX@7. MKQWLB20ZVB"(,< ^6N3CUP3^M=]J&(]0TBY"LT@OW09X.&A?^9&:YYNZU_K4 MS6S.6U.]MUO;N*.)+:TM+6/3X=G1'E8%@/H@-6\VH&RV9^Y M&5PCCZ''_?5=1XAD31? S7,_SS7\\UPK=2'DRB_D'_2I'T:UMO@A:RX'VS[' MYJ.>"QW!V/UP@_*LK\[VZ?U^2$M=37TF=;[5Q'>*?L^IVBETZAIHCL<'W8 ? ME4ND:3I&F^,Q9Z=!L^QV)E=O[K.^ ?P"G\ZR=)U6U_X1JPU9W(%G?+(Y7^%) M0 S>^')K?LK^VM_%^MK3]:=.44N6W]?TAKS,*& M,3>-KI+K2(K6TS<(95;+/D)QT_O 5TMK<:CHMI]B:VCFMHR8U4289 S' /'0 M"N7M;JT3X@W4K:E)-'&UR7MW!X(1I96:X,<40;:C[K+UX]#Q6!JGAP>*(DU:XU'.H7B&>WL2YRL9.57T^[S6KI M,MYX2%O>":2\TB[VHT3'+0D$Y.#Z#QIIO@R:;^SP9=-NT>2")?\ GJK;=H^O-6/$/ANVT?QCHWC. MP16TU9L7*H.$##:S8Z>EMI<"2VFOP80P^559BWY\TY-+W@M([DL&VG M< 0Q./8"DYM6^?Z G9GM=**\ZT+QW;Z5;1Z3XCN6&IVTS03/U#'J#FO1%<,H M(.0>AK6,DS2]QU%%%4 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !2,P5220![TIKC_ !I?3O=Z7X?M9V@EU5I TJCE$1=Q(_E2;LKB;L9MQX;T MOQ=XGUQ]1?SWM6BAA57/[I3&&)&/=C7G^O:\MAX"M=$2196LM2-M,-O)122& MK?O]%U#P%(^LV6HRW+2@O.).1)C_ .L*N67AO3M2\+WTVHVJM)<;[OS(SROR M[B*P>NADR_XHM[35KV>"[N1;0:EI\36]SG #(Q9AGZ$&LAKOP_I]SINCVUT\ MEMI9DN)'CR6DE=2!@]3][]*U4UKPS-9VF@:QL2-;.-X9)7VDJP['\*(CJFO#5=>AEMII)#]E,@.V.+C*CTSZU>UW2+SQ'JFDC5G*QO?1O%; M*W*@8V,!P<]>X_*A/3T%JC!O+G7[]K< MZ',Z32S7-W*4.#-LEV ;OH1Q[5N6K3?\(S\1+A5"VSO((E[%Q'A\?5JP?"EU M8'1(M%GU036QX@U*QL/"LGA_0)5OYMXGOWC;?M3 M<"[-CUYJ%HD_7]1FGXH,::6OFAFOSI3(@QD+E><_@K#\:TOA/=KV>0/K7FT_A;7]"CN;#3=6 M*:4PSA7 (SQENZGCVIK25PORL[+Q+]CAL[JVOGG^QP:JVSR]RD%HBXQCDX)Q M4=N=NN1AVECF^S6"YK@$+,=,6(RD#<3%'21Q7A M.>+1?'5[8,R#;=L Z\X1'Y_$*>/J:Z7Q-%;HA'VB2U*M<6BRQ9^0B7S4''X" MN*DM+RW\3PZW/'Y=GJMY*L! QD'(_7!_.O3M$\JYOKZUGMEEWB"[C67!^8Q@ M-^JG/O1]I]A4T^4Y_4[+5+WQ-'=PW[6\-L=-:YA>,[C4;:[86L-S8N]L",.,XR>_:O71T%;4]V:1V"BBBMB@HHHH **** M"BBB@ HHHH **** "BBB@!&^Z:X[3(]-DUGQ-]HF9&%^N\>:R_\ +&/T-=BW MW:X[3+NW@U?Q,)+*69AJ*Y9(2^088\= >E)@:K0:+(.;EL?]?#_XTT0Z(,#[ M4_'_ $W?_&IH[RU=?^09. >>;5A_2D6]M&!;^RYP0?\ GU;_ H&0&/0E #7 M;@=!_I$@Z_C0L6A,H(NG(7G/VA_\:D:^LV4%M(G.#T^RM_A3EN[55 &DS@?] M>K?X4 ]<_\'8[3^QM6^V3;2;A"2LK#^'V- M=#\1+V)OA]J8CT^13F,'?"5Q\ZC/05S_ ,%_W6B:SYUKYZB[7:53<2-O]*!& MQ\39M+MOA]>K',TI>6-44NS98L..?:N=^"UA;-%=#T#5?"^FZA>:"99[[==L^Q^6=B0>/8UQ'A*2+PY\8 M=0T\VA$,DLL*1;3]UL,* /1?'3::OPZUZ2&9G#6S
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end GRAPHIC 13 ex4-2_002.jpg begin 644 ex4-2_002.jpg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

    %!X,\.+I0N7NV\V2:28KMW,QSTS]*A\5>"8O%>KZ->7 M-Y)%#IEP)_(51B5@01D_A7649% "#K2T44 %%%% !11FB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &NJNA5@"IX( M(R"/2O-KCX5W6G:I<:AX0\3W>A-SZC=&ZED:/9@D=.ISU/4FNENK=+NTFMG^Y*C(W&>",5-10!Y MMX+^$-CX-\0#5X]3GNG2%HHXWB50H;'/'?K70>)/!L7B37=$U&XNG2/2IC.L M"H")&[9-=310!B^*-!'B70;C29)C%%/@.=N[(],?YZ5>TK3XM*TJTT^#/E6T M2Q+D8X Q5RB@ HHHH 0]*X_Q5\.M)\47T>I-+6K[6'U'>NQHH \ MZG^'GB"[A>WNO'^KO;NFTJD2(?KN'(K;\+^ -"\)W$EW80S/?2KMEN[B4R2. M#C.2?<5U5% ',>(_!\?B35])O;B]ECBTZ83"!4!61@0>3U%2>,_"R^,- &D2 M7E+10!SWC+PNGC#PY+HTMY+:1 M3.K.\0R2 '+31;:1Y8K92H=Q@L2223CZT_Q'H-MXFT"ZTB[=TAN 7 MCX92"#D?E6M10!R?@OP%IO@G[:UE-<327C*TCSD$\9X&/K75GI2T4 >)9KNZO=0N$\I6N2I$*?W5P!CT_P#UUU/Y_6EHH YCQCX-M_%\&GQS M7<]JUC''+#L:Z3!*[><<=>XI]% 'GU[\*K)+\W_ (>U:_T&Y9R\GV,Y MCNQ>*]%HH BAACMXDAAC5( MD 5448"CT%9GB?0_^$D\.WFD&ZDMENDV-+&/F SGC\JV** ,[0=(AT'0['2K M=G:*TA6)6;JV.YK1HHH **** "FR*6C90Q4D$!AV]Z=10!SGA#PN_A;3[FVD MU*ZU!Y[@S&6X.2 0!M'MQ^M/B\-,OC"7Q ]_.^Z+REMNB+P!G^==!10!S?B[ MPL?%-I:P?VE=V2V\XE/VA76FQ74EJTT7E"9.64<BCP]H%KI:W$US]G7'FS'+.SSI>6<^IK.\->$SX?U/5KZ35+ MN^DU";S"L[96,9)PH[#FNCDE2&-Y)'5$0;F9C@*/4FDCEBGA6:*1)(W&Y75@ M5(]0: .=UCPI)JOBK2M:_M6ZACL,DV:'$*]&73X]3N+#$JR& M2 X+8_A/MS^E7)?%7AZWO!:3:YIL=P3CRVND#9],9K75E=0RL&4C((.010!6 M^S,MA]F25U81[%DZD<8S]>]8O@_PLWA/2I+-]1N-2EEF:5KBX^]R ,=>G%=) M1D&@#EK?PE-'X]F\32ZMA!H Y;3_ A/9^-[[Q+/K%UM7%G;6,OF26T0.)^0<$Y]O0UU%% &5X@TRYUG0KO3[6_DL)IT"BY MC!+1\]L$=N.O>ET#2Y=&\/V6FRW>?R[ M5MT4 Q:DES<:?JL2[8[NW/('H1WK(_X03QC&O">E^%+(V^GQ,7*>/AXV ZJ:WZ* //1X. M\9S0+IUUXV1CU+'N M:W** .#UGP#>OXGE\2>&]:?2M1G4+.C0B2&8 8RR^O?ZU1\0?"Z[\6:=$-;\ M0S37Z,")(X@D:KGHJ X!]Z]*HH X_P 7^"F\4:3I^F#4'M;2TD5W41[S*%Q@ M')]JVM:T"SUW0)]&O%86LR"-MAP1C&"/3I6M10!YS8^"?&6GVL>F0>-F72XL M(@^Q*9U3T$A[XXS5OPW\.8?#'B^YUFTO998;B(HTO?I6KXFT>77_#M[I45V;5KJ/RS*$W M;02,\>XR/QK6HH PM$\/MH7A&UT*UNFS;VQA2?;@YQ][ ]S47A#PY=>&](:T MO=5N-3G>1I&GFZ\]@"3Q7144 J:!=V%C?R6 M%S-$8TNE!9H^G(YST]Z9X:TJYT/P_9Z==7TM_/ FU[F4DM(?7DD_J:V** .8 M\.>'=2T?5M5O+[69K^.\DW0Q/NQ"N2<#)/J*;K7AK5-3\5:5J<.NW%MI]F29 MK! =LY]2<_TKJ:* .=\8Z'J7B'0_L.FZM+IDQD5FFC)#;1U4$5KK;2II@M4G M?S5B\M9FY;.W&[ZYYJP)8VD,8D0N%#;0W.#WQZ4H=6. P./0T 8'A+0;W0-* MDMK_ %2;4KAYFD::4GH>PJ"'PYJ:^.9M2P,7EQ:>"P1#C!)&<'O749I MB2QR9\N16QUVG.* .>\7:#JFO6MI%INKOIQBG$DI0?ZQ1_#6O>VLTNES6MM< M-#.T+)'-C)1B,!OSJVKHXRC*PZ9!S3J ,'PEHM]H&A)8ZAJ4FI7/F.[W$@P3 MD\#\!4%CH.K6_C*_UBYUAYK":()#8[>(\=ZZ7(]:* .8\0:%K>I^(=(N['67 ML]/M)-]S;*O,PR#C-:7B&QO]3T&[L]-OS87LR;8KG;N\LYZUJTF0!DGB@#/T M2PN--T6SL[NY:ZN(8PLDYZR-W;\:R_#.@ZKH]]JL^I:Q)J"W4^^W1A@0I_=K MI%=74,K!@>00.RXN,$X //3UK?HH I6-K/::5;VLMPTT\<*QM,QY9@,%JRO"NC: MOH]K=IJ^K-J4LLY>-SD;%P/EKHJ* .:CT/6?^$[?69-:U=)10!'&I154DG:,9/?CK4E%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 54O?]6GUJW52^^XOUH MM4444 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !59M1LDD:-KRW5UX*F501^&:LFN%U'X2># MM5U&XO[[37FN;A]\CF=QD_0' % '8?VGI_\ S_6W_?Y?\:1-4T^21(TO[5I' M.%43*2Q]AGFO#_"?PY\-ZK\1O%-F;25M)T]DBBC$[8$G<9SD]Z])TOX6^#]$ MU.#4M/T<17-N2T;><[8.,="<=Z .JEO[."0QS7<$;CJKR $?@34+:UI2G#:G M9@^AG7_&O(-(\+Z/X\^*OBN[U2U6[LK)TABQ(P4MT/ -=>WP:\"$EO[$7G_I MJ_'ZT =E!JNGW5QY%O?6TLVTMLCE5C@=3@'I4DE_9Q3B"2[@28X C:0!CGIQ MUKGO#_P_\,^&-2:_TC35MKEHS&7#L&S'W2#]?UH ^D3BJM[J=CIPB-[=PV_FML3S'"[F]!GJ:I>&-:B\0^&=/ MU:%MRW,*L<=CW'YUY]\0A#K?Q/\ "&@R'='%(UW(.>0.1_*@#U@$, 000>10 M2%!). .II%&W ' ' Z5E^)[^/3?"VJWDC +#:R-GWVG'ZT 2GQ!HP.#JUB# MTYN$_P :0^(-% R=7L!_V\I_C7EGPS^&GAS5O MAJ>M:5'VN([FV MBN(CF.5!(I]01FO+K #7?V@K^Y^_#HU@(QG^&1N#_6@#T6ZU_1[.#/#>M?&?4]/&EP_V9IED@, !"F1NN>: /5X_%7A^5D6+6;"1G<(BI M<(23Z8!K7KE;?X;>#[.XAN+70;6&6%Q(C(#D$?C75#B@!:*** "BC/.** "B M@]*HZIJ]AHMFUWJ5W';6ZG!DD. #Z4 7J*XRQ^*G@O49_)AUN%7W[/WT;("? MJ0!^M=BK!EW*01ZB@!U%7;]2H.*U/#WBO0 M_%4#3Z)J,5VB??"@AE^H(!% &W36=44LS *.22:4G SG%>9?&?Q-9Z;X/N-( M^VB+4;\I$B?-D(6R6XX&,4 >D6]S!=P+-;RI)$WW64Y!_&ILBN5\"Z[H>J^' M+>#1KQ;B*QACAD.UAL;;R"6'L:@U+XG>%=.O'LVOVN9XCB1;2)IMAZQ![U7U'Q=HFE:Y!H]]>I!>3(9$5@<; M0"FN1)>32Q@X,T%N[QC_@0&*ZVQOK;4K*&\LY4FMIE M#QR(22WV,FVM87F<#U(4' ^M/\/>//#_B: M[>TL+LB[C&6MID,<@_X">: .GHS61KWB+2_#-@+S5+A8(6<(K$9RQK)U/XB^ M'=-:.,W,MW*Y $=G"TK+D9^8#I^- '6U7O+ZUL8A)=W$4*%@H,C 9). !67X M>\5Z1XHLIKK2[CS%A8I,C*5>-O=>M>1>//&^B:O\0?#4(FN)M-L)'FND2)LE MATPHY/2@#W@'(!'2EK D\6Z/%X;@UVXN#!8S@&,S1E&.>@VGG-8:_%GPRLD8 MN#?VT4C;5GN+5DC]OFZ4 =W0>E10317,*3PR))'(-R.AR&'K4IX&: ,G4/$. MDZ9J=GIUY>)%>79Q!"*"258@RH6PQX&?2M6.19(ED4Y1E# ^U $E%9$'B/3+CQ'/H,,Q>_MXQ) M*BH2J ],MT!K7H ANKJ"SM9+BYFCBAC&7=S@ 4V*ZAGM5NHY 863>'[%>N:\ M>^,?C+29[>U\,(\[77VZ/S@$8#8.N#WZUWG_ E&F7/@74-3T\RI:6L#QJ98 MS&1M7 Z]N10!K:%XCTCQ)!-/I%V+J*&4Q.X5@ XZ@$]?PK7KQWX>^)]#\'?# MG31,UQ>7UX6NIK>QB,T@+,>6 Z #'6N_\,>,M'\71SMIDL@DMVVSPSQ^7)&? M=3S0!T=%<_XC\8:-X65!J5SB:09CMH5WS.,XR%')K,T3XE^'M8U--,!N[&^D M&8X+^V,+2#_9SUH [.B@4'I0 9HKEO$/C[P]X;4'QMLK5#+,?^ C MI^.*9H?Q!T+7-5_LQ#=6>H[=PM;Z PN1[ \'\#0!UE&:R]?UZP\-Z-/JNI2& M.VA&6902?3 K#F^)'A]+2WGMI+F^:= Z06D#22*#SEA_#^- '89JK?:A::= M;B:[N(X8V8(I=@,DG ]36'X9\;Z-XL:[CT^65+BS.)[>XC*2)[D9Z5Y=XU\ M,K^M:FL:YI'@[P\M[=JUK80[45(H\[<]!@4 ;M&0.]<->?%3P]###+9B M\U!) "S6L#,(\] Y_A-:7B#QWH7AI8EU"Y<74RAH[.%"\Q!_V!S0!T]%<1I? MQ/T34-1AL+J"_P!,N9_]2M_!Y0D^ASUK0\:^+;'PKHTLMW]IW21NL9@A+[3C MJ3VH V;/5K'4)[F"TN8YY+9MLPC.=A]#CO5)/%6CMXI;PVMSG5$B\UH@IP%Q MGK7G'P3URS&CII7V&^%]=3S7$MR]NPCD&/\ 1/#EVEC,\MUJ$OW+2TC,DA^H'3\: MBTCXA:3J.IQ:7<07>FW\W^J@O(MGF'&<*>A- '7T5!=W4%G9RW5Q*D<$2EW= MCPH'4UPS?%33Y(Y+JRT;6+RQB^_=Q6QV8]1ZB@#T"BLGP_XATSQ/IJ:AI5TL M\!.#@X9#Z,.QK6H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ I#TI:1B%4L> !DT <-K-P_BKQ>/#$#XTR MP19]48?QL>4BS^IJIXE>]\1>*X/!6F2RV6FP0";4Y[8['"'A(E/;(_3-6/A: M/MFC:IK4C%YM2U*>1G/]U6V*/P I_A9U7XD>+XI\_:V-NZ$]XMI ^A_G0!? MA^'/A""Q%F/#M@T6,,7A#,W;ECSFJW@OP_J'A,ZII\LJOH43<\:$99 M3GHH[5V,LB11/)(P5$&YB>@ ZFN"UKQU9:C\,M;URP$B1(LMM$TRX\QON@CV MYZT =-X;\06_BC15U2TBECA=W2/SEP6VDC?$'33X$ MD\36$-Y/ P=0(X+/AO:/<:%>?VYH$ ,DFG7(Q+"O+ M'RV[XSG!J_XQU2#5OA="^D6_EQZ])#!&H 0J96RQ/OP: &?">]75O!;V%SIV MI1.ZL\\]XIQ<-)DL58]1R*U_A?/,_@N&UG*L]C<36F5.Y)%;!Z$^E<'X MV8W_ (R\(:+O'DO=27<\97AUB7TZ;0] O-;U=E?6+F)KJ\D) MR$P,A!V 4<5Y_P#"2UOM*\:WAU)FD?6K!;Z%MQ.$+D\_G7H'Q,NGMO .I"+/ MFSA;=,<\>^%+FYF$%NFFRV32'A254$ ^G>@#8\<:OD[3-/+-*H)+HA*\<\_= M.*KV]VUQIOB?Q_?@B-H);738R"-L(^52/=F-3^)T.@_!BSTFWW+/>1P6483J M'D(+?7J: -O2M7\,>%? UOK$!EMM'N&68-*&+[I#G)SS3+KXI>';:XMA_ILM MK.P5;U+9O(!/3+D?RK+\=:;#J%]X,\(#FWDN1)-$!UBA3/Y9Q5_XG($\&P:5 M9QJHO;N"U2-!C"E@3@>P'\J .NU/5;'2-+EU&^N%AM8UW,Y/7TQZD^EG/;\:@U^TBU;XE^'M$N0SZ?9VCWQC+85W4 MA5SZ@=:O?%$VR?#C5?M"K@1J(,C_ ):;AMQ[YH Z+7=''5 MC)J-W;K+ST6-=SYKT2VMH;.V2""-8X44!548 % ')?#.6=/#MSIER3YNEWTU MIRV[Y0V5Y[\&NTKA?AF$EL]>Z@A?RKNJ "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *IW_P#JD^M7 M*J7O^J3ZT 6J*** %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ J"]N!:V%Q<-C$4;.?P&:G-< M;\4M2&F?#G6)0S!WA\I".N6('\LT 8'P-MF;PMJ&KR?ZW4M0EF;//0X'/YUZ M5>W*VEC<7+ [O1]'\"Z+8G5K+,=JI.Z= FQWO@O5K^Z!< MZS>SO(&'5<[1_6NB^(^N6MI\,]6OHKE'CEM]D4D;@ABQ &#T[U>\ Z7_ &/X M$T:R PR6J,WNS#/]: .,^$-Y-I.H:[X,NAM.FW#20$M_RS8],4_1!_;?QYUN MZ91Y>DVRP)GGD@9_G5/Q\P\#?$?3/&J)FUNHVM;Q <;CC@X[GI5[X+1"[M-= MUYD._4+YF5V.25'2@#U+I_.O._C1>O;_ ]N+.$YGOI8[9$_O9(XKT1N%.?2 MO)?BM=VUUXP\'Z-<7*01?;/M$CNP"@#U]N* $T2T^+>F:1:6,%MH*001!$#N MVX#'<#O5]S\8"I4+X?4G@,">*[<>)=")_P"0SI_XW"#^M'_"3:%YJ1C6;!G= M@JJMRA)).!WH R?&&I7.C?#C4KRYEC^UI9D.PX5G(VG _&L#PUX1\_X'QZ&X MVSW=F\K''_+1LL#_ "IOQINM_ABPTA/F?4[^*$ '^'(S7HMG;K:6=O:I]V*) M8P/H * .$^$.O-J7@=;:\9$NM*D>TGYZ!>A.?;^54OA#$;^\\5>)'5?^)AJ3 M)$P.*-0;X9^-O$3H@^QZ]9&2%0V LG0\?G7H_PGTP:7\.-)C*%' MF0SNI[%SF@#M6(5220 .I/:O+OA!$VHWWBGQ++\SW^HM%')ZHE=IXTU$Z5X+ MUB^5@&BM7*G/?&!_.L3X1:8=+^&NE(W^LN%-P^>N7.: .YHHHH *0]*6@]* M.:OO'WA33KM[2[UZRAN(VV-&S\@^F!6EHVO:7K\#SZ7>1W44;;&9.QK+N?A[ MX1O+F2YN/#MC+-*VYY'BR2?4UJZ/H.E^'[5K72;&*S@9MQ2(8!/K0!HDX!-> M>^,]-\/'Q18:OXH\200V5JO[K3+@J%9_[^,Y_2O0F^Z:\9\ 6N@W_BSQ'<^( M6L[K7/MC%1=JI, =1MK*[M[RZ*;;?R(6;8^0>&" MX' ->B^&H[@^"],BEV&F^&=,GMW%Q?1B=H M%#+&H.,#'&?:NU\>>(-0\&>'+&XTV&&2*.1(9GD4DK& !D =Z .*\$^(M/\ MA[=7FC^+;*;3[Z6X>0:I-&62X0M\HW@9X]Z[K3/!NF_\)P?&>F7_ .ZN;?8T M$&WRI2?X\CK5S^VO"WB70!+=W>FW%G-'F19I$(7CD$'H17&?!E(TO/$JZ3+( M_AY;S%D3]WWVY[4 >LGI7G?Q&CM]2\0>$-%:**22?4/M#@@$B.($GKV)->B' MH:\SO]0M_P#A?-HMY/!#%9:0_EF1ROSNPSC/'3- "_J\+^"'M;-1;2:@W MV1::#KYA:YM--OTDN$0;@T;<$X[]JZ)O%OA!-$&K)?::;9H\J%9-QXSMV^O: M@#A_"6M:;*]?9_,:\U( MJKXQ\J\"@#HOB MGIGPVUI!! D"VKA8MH"D]ACUIGPYMS9_"[1HIV$!%GN9F M.-FXD@Y/UK"^-][CPO8Z2N/,U*]CAQGMGGBKGQ2M+FT^%%Q:::LF($BC;RQS MY8(!_2@#+\.:UX#\#M>(NOC5-1N9V>>X2,ROU^[E0>!63=ZQ8^)OCKX:?2$E MC:VAD>X:2(QF5<'Z9KL/"^N>!=*\*6<^GWNEV\8A7(1E$A? R,=2_O09%Z8CXR?T->CZ M-HFGZ#I\=GI]LD,2@ D 9;''1].+ 9Z2-_\ KKN_%&J1 MZ)X6U34I"0MO;._'KCC]<4 >>_"%1=Z[XRU*% MM+J.R/ [@')!J7PU'#K'Q MJ\2WZPQ+!IUO':(5 (+GDGZUH_"&U_LSX7VMW*,O<^9>2''+;B3_ "%9/P8U M#37T_5)VO8CJ6HZE+(\!8;PH/''7I0!I_%/0M5U&VTB^TJT^VKIUSYTEB#_K M1D=!T/&:=;>)O"GQ$TNZ\.W6;*Z=3&]E=($DC/JN>N/:JFF_$*ZT[XB:OH/B MJ6*RMBRG3I7CV*X[_-TYK'^,-SX?U"TL!IZ1;^)/B/XI\77""1(;MK6U#X-6/%%RGQ)\8Z7X=T=Q-I>FSBZU&\B.8]R_=C!Z&@#=^*=L^H_"6^D5?W MD4,5PH(Z$$'^M:<_BRUT7X<6VNR.LG^AQ^4H/^MD*C 'KS6SX@L4O_#>HV93 M*R6SJ%'TX_D*\7^&T.J>-Y=.LM4C3^QO#K,!'@_O9<_*#]* /1_AKX?N=)T- M]1U0[M6U5_M5P3R5WM?'K0K-1N&EV+ MW,W (#'A?YCK6A\8[[[%\/KBUB($E_/':JHX)W,,X^F*Q/">KZ5_PMWQ7J%_ MJ%O!<2-':6TO0=*N_$21-6\>>#_#Y*,@NOM4Z]]H'I^% '7^#_ M O8^%O#UI8VL 65(P99&^^SDX @DCD5U?P]\=>'+7PC::5J6H6VFZAIL7E7%M=GRBI'\0#8 MSU[5=T7QGJ?B[Q=M\/QVS^&+92+B\GB<-,_I'SC&<^/K78^&/#5AX5T2WTZP@1?+C >4+AI&'4D]>O:N,\5R'6/C M#X6T971H[-)+V:-N?FP=IKT74;H6.F75V2 ((GDR>.@)H \V\!YO_BQXUU&$ M*;9&2W#JO!<')_&I/"SMK7QE\5:BZ1^5811V,9'.3W)R/;M2_!B%H?!-[K4Z ML9M0NY;E_4@9Q^E4?@WK6DFWU1)M2A_M?4=1EE-NS_O, X''4\4 3?$)1K/Q M-\&:!A2D4K7LJ]<*O\ONU+\:I);K3-$T*!P)=1U"-. #@ ]B,FM_'[7 M+U&.S2;);4 C.6)YQ2ZULUWX]:'98#1Z1:/%O#1M[2 M&-+>UA9VXQN(&237B_P^\::0NL:OXJ\06MY-J=S-LBF@M'E2.,?W2!QZ<5[O MJ=D-0TJ[LBQ7[1"\18=L@C^M>8_#3Q1I?AGPTWAS7KJ+3;W3I9$(G_=B5-W# M9- &3\3O%VD^*/#"0:7IVISZA#<1R0NUBZE,').X_A73_$O5)[?X2?+N%W?Q M0VZAA\VYP,\5+!XRU3Q5XLM[/PD8)-%MB3?WTJ';)_LQYZ_6LOXM7L'_ D' MA*PO91!I[7PN)YW7Y0%Y )[=* .YL$3P[X)@#@)]BL1NSZJF3^M<5\)])/<#.W^5:7Q)\3V2_"W4KZRN5FCND^SPR1G[S,<<5HZ7X>V? M"FWT&%R';31&K ?Q%,_S- 'FOPV\7Z78P7VO:O8:I=:I?W#-YT=F\H$>> & MQ5OXD>*[;Q'8:9)I&DZPU[:7J3"1K-XR@!&1GO6]\._&>EZ1X7MM!UVX33=1 MTU?)D2XRF\ G##CFM33?%>K>*O&*IX?\L>'+12+J[EC.9Y/[J<=!QS2 VO%F MDW/B/P/?Z=!)Y=S=6VU">/FX(!_$8KC_ YX\3PQ8Z?X>\8:3/H\T:>2EQY> MZWEP,9W#IFKOCSQ1K7A/Q7HEZ!(WAM\K?".+<4)XR?;D5)XG\:^"=4\,7EO) MJ%IJ!EA/E6T7S.[$?*% Y%,#=\*^$]%\/2WM[H[R.FHR>:9;WZM',0SB-CDQJ3PISZ"NTH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I& *D$9&.E+2' MI0!PWPPC^P^'[_2)"IFL-3N(F'L7W _CN_2KWB+P6-7U2'6=-OY=+UF%#&+J M-=WF)_=<="*Z"UTRRLKNZN;:V2*:Z8/.Z]9"!U-7* //9?!OBS6[8V?B/Q;O MLBWSQZ=;"%I5[JS>GTK=-X-\;3V#:3<^,HGTTH8V=;$"=XSQM+9 ''&15SQ# MX$FN?#VCZ;X?U :<^D2I);M)$)5.T<9!Z]Z[FD;E3_2@#@_$UUJDND6/A%+A M;G7=2AV75Q$-BQQ\"27 Z9Z 5V.EV$6EZ9:V$ Q%;Q+$O&,@#%-M-*LK*^N; MR"#;H **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ /2N'\ M4,++XA>$+UUS'*\]INQ]UF7(_/%=P>E9^IZ/9:M]F-Y$9#;3":(@X*N.AH R M_%7AV7Q'_9< G2.VM[Y+JX1ESY@3G;^?\JS/B%X$E\<1:1#]M%O%:7/FS@@Y MD0C! Q]*[4#!S^&:=0!S7B/PR^J>';?1;!XK:WCDBW*R\&-"#MX^E&O^'9]9 MU/09$EB2TTZY%Q)&ZDE\#Y0.W6NEHH YI_#<\WC^#Q'-<(8;:Q:U@AVG<&9@ M68G\,4NN^'9]9\1:%>F2,6FG2O.\; EFZ3K3SH+'3X)56#')D?C/Y4>-M5N+'0VLM.!?5-0_T>V4= M03U?Z 9.?:NF/0UG)HUHNMR:L49[IXQ&&8Y"*.P';ZT -\.Z/%X?T"RTJ$EE MMH@A8_Q-U+?B2:U*04M !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %5+W_ %2?6K=4[_\ U2?6@"W1110 M%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 !Z5C^(/#>F>)K$6>JPM-;AP^P' R/7UK8HH CCB2*)(HUVHB MA54= .U9VN>'].\1V0L]3@::WW;M@"/^$=@_P"_DG_Q5=Q10!@W?@_0[SPY#H$]BK:9#M*0 G V].:V M8H5@B2*) L:+M51T '2I:,B@#+UKP_I7B*V6VU:RCNX4;(KY;S5]*@NYE7:&DST^E=#FB@#C? M^%5>!LY_X1JS)SZ-_C4D'PQ\%VUS%<0>'K2.:)@Z.H;((.0>M==10!E:EX>T MO5[NSNM0M$GFLWWP,V?D/TK3^@Z4ZB@#&UGPMHFOR12:KIL%X\2E4,HSM!K3 MM[:&TMX[>WC$<,8"HBC 4"IJ* *&KZ18ZYITEAJ5NMQ:R_?C;.#SG^E6+2UA ML;2*UMHQ%!$@2-!T51T%3T4 %%%% !1110 4444 !KF]8\!>%]>O/MFHZ+;S M7)ZR\JQ^I!KI** ,-O"'A]K&WLCHMF;:W;=%&8@=A]16I+:P3VYMY8(Y(6&# M&R KCZ58HH X]_A=X)>\^UGPW9^=G/&[;]=NPM(K:'.[9&H )]?K5VC(]: *=WIEC?30RW=G#.\+;HF M= 2A]0:LR1I+&T;H&1N&5AD'\*?10!S]MX'\+V=\;VWT"P2Y)SO$*G!]?:M- M-*L8M2?4$LXEO'4*\X0!V'H35VB@"G!I=C;7LUY!:11W,W^ME50&?ZFIKJV@ MO+62VN8DEAD&UT<9##WJ:C- $,%M#:VR6\$2QPH-JQJ, #TQ67!X4T&UU7^T M[?2;6*]Y'G+'AN>M;5% %#4-'T[5HA'J%C!&-$T0NVFZ5:VK M,E 'F/BKXDJ]Y?\ A?P_ MIMW=:XV;=',6(D+#EBWH.>:ZSP3X9A\)^&+334 ,ZKNN).[RGECGZUNK#&KE MUC0,WWF"\GZU(* %I#R*6C- &-<^%=!N[]+^XT:QEO$8,L[P*7!]A%-MK6"SMTM[6! M(84X6.-0JJ/I4]% &7J?A[1]:*?VGI5G>;>AG@5\?F*N6EC:6$*PV=M#;Q#H MD,80?D.*L44 %(P)7BEHH S+[P]HNISK<7^D6%U,O1Y[9'/YD&K=O:PVENL- MK!'!$.B1(%4?@!5C(HH J)I]F+XWPM(!=E=AG$0\PCT+8SBIYX8YX7BEC62- MQAD89!'N*DR** ((+2"TMEM[>&.*%1A8XU 4?A5.'0-)M[Y;Z#3;:*Z7.)4B M"MSUZ5IT4 5+;3K2TEFEM[2"&28[I&CC"ESZDCK3DL;5+QKM;:%;AAM:4(-Y M'IFK).!D]** "LV_T32]4=6O]-M;EUZ-+$'(_$UI44 06MG;6<(BM;>*",?P MQH%'Y"FW=A:7\7EW=M#.G]V5 P%6:* *8TRQ%HMI]C@^S+R(O+!4?A5H*%7 M '0#I3J3(QG(Q0!1O-'T^_.-7"[?>G^*?%&I:#):I8>&-0UEYE+/]F.!%[$X MQ7*^+,ZU\:O"FEQD%+&*2]E!Z=#C^E>I<_UH \MU'XN:GI#6XU'P)JUN;AMD M*O*OSMZ#CK5R7XB>*-C&+X;ZRQ R,R@#/Y9JKXUE.K_%KPCH4?*VQ>^F&>H M/^%>H@8/6@"O8337-A;SW$!MYG0,\1ZH2.16+XJ\0ZEH$=L=.\.WNL/*Q#+: MG'ECU-='0>E 'E>I?%C5]'@CGU+P)J-K!+((T,LRC+'@#\ZOQ_$#Q-*K$?#S M5AA3M)E4@G'TJA\4IFU+Q5X.\.1G!N+T7,A[;$/.:]3^F: .(U_QW/X:\&V. MM:AHLRWMTZ1"QW@,KMV)K/3QYXP9-W_"O;_D9&)EK/\ BI<077B_P=I%U-#% M;/=&YD>1MHP.!R>*](_MS20>=4LAQT-PG^- '#GQWXS"9'P[O\_]?"UU6M>( M)-#\'W&MW5H1+! )7M]W(8XRN?QK036=+EF2&+4K-Y7^ZBSJ6;Z#-E#=YFJ7L<"[>N,@GCZ4 :_P^\?Q>.(KMC:BTN+=AF/?NW*>_YUVK, I. M>G->.7>G6OPV^)>B75JODZ7J48M)0#P9.Q_/%>F>*+]=*\+:G>NV!#;.V?>N^H **** "BBB@ HHHH **,CUHH *,BD;I7$^+/'4FDZU;>'-#LUU M#7[H;Q"Q*I$G]]SZ8!H [>C->8ZOK/Q'\+:?-K.J)X?OM/@PTT=OYB2(F<'! M/!ZUW]AJ<%_HT&J(2L$L(F!;C (S0!?R/6BO+=.\3>-?'0EO_#/]EZ5I,*TTDY4\D SMH=2A3S8;FU)\J=.N<'H<=J ._/2 ML'Q?J>L:3X=FN]"TS^TM05E5+< \Y.">/3K^%;Q.!7(>-?$=_HEUH-GIJV[W M.HWZVY$R,WR=6(Q["@#I-+ENYM,M9+^-8KMHE:9%Z*Q'(JY7*>-?&<7A*Q@$ M=L]]J=X_E6EI%]Z1NY^@[UC+#\49+-[TWVAPR,N\67D,2/\ 9+>M 'H9Z5RL MFK>)O^$_CTR+2$_L'R-[WY)SOP?EZ^M)X%\6OXKT>>6YMEMKZSF-O=0*1_9FGW/V:WV+@E@3G/K0!W@QZTN[@LV"1.S%50]V=NX]A3/%>N^//!%C'KM[?:9?6(G1)K2"W*D*W& M%8\]: /56("DYZGBV?57MK22*SLKDVT('IFJ/CK5==L_ M!1UK0I;.W\J#SIUND+L4(^ZN._-8?PFTCQ/8Z%93S7E@-*NB]RT*QGS=S\YW M=.M 'J1Z&N7\<>,(O!NC)=M"UQ//*L%O$O&YS73G'I7B/CVW\4Z[\1-)\/M= M:?Y2S&\M5"'Y%'>3^]^% 'M5L\CVT33J$F*@NH_A..14UP2$G !_6J%E!\2]:MTU*34],TH,"T5B+?SC@X(#L>A^E M'H]%<5X"\67VO-J>F:S;1V^K:7-Y4RH?E<'HP'I6%KOCWQ!9?%'_ (1O2+*& M^@%LKF-1A@Y!ZGL!UH ]2HR/6O,O$T_Q!T30[KQ!_:FF8ME\UK!+?(VY&1OZ MDXKL=)U]+WPA;:]=QF%9+87$B+SMXR<8H W*,CUKS+3=5\9^.T?4M'NH-$T? M>5M_.@\R6;'\1ST%3^'?$?B73_'8\)>)WMKQY[8W%K>6Z; 0.H*_A0!Z-17F MWQ'\<:MX8U[0-.TF%)I+Z0^9$5W.ZY PM:-]:>.[^VDN[?4['22JEDM5MQ,2 M/]ICW^E ';L0!R<5S%[XM$7C>R\,6MJTL\L1GGE)PL2 ''U)_K6;\/\ Q3JO MB[P1+>S+;QZG'))!YF#Y;,IQNP.U<-X;M?&6O^.M'-&^S-J^J':;JX0^7&%QE]OE2:Y#-5U#3)4CO+6W:6-G3<..3Q],T =!D#O17,^&_$GVSX?6/B M'4I%!>S$\[ ;1G&37-?#'QSJ_BS4-7M]5A\L6^V2 &+RV,;9VY'T% 'I1(KE MO$E[XJMM7TR#P]I]I/9RN/MLTXYC7/;YEYQ[&L_7?$>JR?$'3/#.B3PQ_NS< M7[O'O*1YX ]"?ZU';>)M7OOB]<>';>2$Z39V0EG'EY?>> "W;K0!I^-O& \( M:=9R+:/=7=[<+;6\2\98^O<_A6UJ%\^G:)U>0^+K?Q M?K'Q,TK06U/3@$WWML8XB!$%Z>8#R>E=-X_U#5="^$6IG6[N&YOYE\CS+>/8 MOSG X/MF@#;^'/B#5?%'A*#5]6B@BEG=O+6$$ )GC.3UKKJ\O\(Z?XRN_!.E M6EG);>';:&V549H_/F?CJ0>%!_/FM'X?^)-9O]9U[0-=ECN+S2I@@NHT"B12 M.X'0]* ._HS0>E>>_%3QAJ7A/3]-.D[&NKNZ$91H]^Y?0?6@#T$D8]?:N6M[ MGQ8_CV:":UM4\-I$=DV1YCN1QWK+2S^(6IBUU"75[#2D#JSV*0;\1]]SGG=[ M=*C^&/B76_$T.LWNK3PO;0W;0VPCC"C:I.3GO0!Z%1FO-(?$GB;QKK%W;^&7 M@L-%M7,3:C*F\S.."$'L>]9WBSQ1XS^'>BR->26^L02C9;WPC$3Q2'H'3ICT M(H ]8GF6&WDE+ !%+$_09KB_AEXEU?Q9H]YJNI&W^S-=O'9^4NT[%..:74M5 MU'3OA%$-=URV\?:OX M2UB__M-+>)9XKIHU1@#V('!KF/$NG^)]<^+FG:(==MP]LC:A"PM_EB4'@$=S M0![;%O\ +3S""^/F(Z9[U)6=HMM?VFF11:I>K>W@R7G6/8#D^E3:GJ-KI.FW M-_>2B.WMXS)(Q[ 4 6Z,CUKR_2YO&GCR'^U;?5%\/Z/(3]FB2W#S2KV8D] : MDL-?\1^%_'EGX;\07T6I6.HJQM+P1[) X_A8#B@#N/$6L1:!X=U#59062TA: M4J.Y'0?G7GWA*_\ B;XB&GZQH_C1+K,.G6L$ M&J6\=AJ%Q':&T,67=F/)S_2NO\'>'];T&W6WU/75U"WCA6."%;98O*Q[CKQQ M0!U '.:=110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !13)!( M0!&0#GDM3A0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %&1ZTAZ5P?Q,\3:IH,&C6NCNJ7NI7RP*SKD =^* .]HJ*,,+=!*P M9PHWMV)QR:X;X<>)M3\4S>(+F]E1[.WOC;V@5 /E'?/>@#OJ,UY)H?C?Q9XA M\6^(-.TJ"UEM;6<10RS#;'"!U)QR3[5+XIU#QCX'73]9FUJ+4K::[6"XM6@$ M8^<\;3[8H ]6R*0_=/?CM6!XH\4VGA;PS+K-X#A0%CB[O(WW5_.N:TBT\?:W M:IJ][K<&EO*F^'3X[82!1V#L: +GCGQ7J6B:[X=TK2DBDGU*Y*2*PR0@ZD5V MX_"O%+'4=1\4?'+3[/5;:.*30H) YB8E7<\AO:NP\8>,-1MM>MO"WAJWBFUJ MYB\QGEY2V3^\1^= '>T9 [UYMJEIX\\-:))JZZ_%JDULGF3VC6RJK@==AZCC M-=?H>O0:SX7M]:"^7')!YKH#G9QDB@#:R/6C/.*\?\&>*O&WC5K];2ZM+>U2 MY8"[:WSL0'A57/)]S7H?AC3]:T^PDBUW4QJ%R9W9)0@4!#T& !0!NFN%\%^+ M=1\2^*?$=NZ0C3-.F$$#HI#$]\UUFLWT>G:)>WLD@C2"!Y"Y[8%<-\%;-X_ MW]HS(XFU*YEN27ZL"?E_0&@#T9LX..M<-I_BO4]1^*VI>'83;_V986JR2G8? M,WGMG..]=RS!5+,0 .2:\N^$Q_M+6/%VOM&!]KU$QQOZJO'!]* /4?$_6_#VE6<-Y;6J!8]Z[4@;^\[=2#Z"CQ??>//!FC_\ "17'B/3[ MN&&11/8?85C3!.-J/]X_C0!ZO(2$; W'' ]:Y?P=J/BC4C?OXDTJ#3PDVVU2 M,Y9DYY8[C3O$?B.32?A]=Z^@2&=+,31J_P P#D9 ]^365IFH^*=5^&EEJL5_ M8Q:M+']HDEGA_=JG)( '0XH Q=:\;>,M4\87^A>"]-M)4L /.N+H$+O_ +N< M@5Z)H+ZL^C6SZXD$6H%J7(AMO)DC!.-PQU'-=/XY\4RZ!X#FUO3VA#E8S$\O*@. M1@D#KP: .NHR/6O-=-O_ (A^*=$@OK1].TA2JE3-$7>X]6QR$'>J$7CWQ5-X M]U#PW86-K?O:1JC':459#U8MV'7C% 'K.:*\C\4^)O&O@(VNKZM?:??V-Q.( MY+2* IY?'\+&ND\[QGXAMEO-/EM-%MI%#PQ3Q^9,P/=\<#/M0!W%%<-\,_%. MI^)]-U$:L(3=V%VULTD(PKX[XKN3TH BN;F&TM9;F>58X8D+N[' 51WKS=?' MWB+Q1=2Q>"] 66TC8K_:-\^R-B/[@[TWXK75UJ-]H/@^SFZ?:Z58P65G"L-O FQ$48 '^10!YY>^)?B'X7@;4-:T>PU#3U&9?L M+$21CUQWKNM URT\1Z';:K9,?)G7(#=5]B/6M"XA2YMY8)!E)$*,/4$8-9'A MGPOIOA337L-,$HMV*-;\47/B5W> 6]I<-;V64Q\P' M4^HKC;&W\9:_\4;Z6+4--34M'A,!E,9:,;O0>N#0!UTGB[Q+X8\)7.I>+;"V M^VM,D-G!9-G>S=-Q^M=[:/+);0O.BI,R@R*O0-CI7B?C>U\::GXH\/>&[S5- M/EFFD^U+Y$!6-=AZN#U%>B7NL:SX3\$ZAJFNS6M_>P M&+=#&K'HHP: .PHK MS;3T^)>JZ-!JJ:SI5O+/$)4LFMMP&>0"];/P_P#%MWXHTZZ34K3[-J-A,8+@ M+]QF'=: .O/3UKGO&/BJ#PEHGVZ6%YY))5@AA7@O(W09KHCTKQ#XD+XIU3Q] MH7AT3V/DS3&ZM3L)";.A<4 >SV(]4 M\(>&1/K\EI?ZM//Y5K#:@QK*3C:!GGBL^.T^*%];_;?[7T>Q=_WB60MBV!_= M9CWH ]%H/%<=X \7W'B>SO;?4;=+;5=.G,%U"F<9[,,]C78T <]XU\02^&/" M=[JT$4Z=:P"&WN])0QJO0E?\ ]5 ' MK!Z<5X]XC^,M]8>+9=&TC3;2ZB6X2V2>24C,AZ].HKL/B5XE?P[X6D6T^;4; MX_9;1 >2[<9'TS7GVG^%X=,\;>#O#0BC>ZMX&U'4I/O;I>V3]: /4?%.IZQI MNF6TFC:6-0NY)TC=/X40GYF/? K?4G"[L;L&/%VAZ386@NA> M-$B;I&&<*%Y 'JE45YY MJK_$=M/GU2UFT:P6%6E6Q=&E9E'.&D/ ;'91CWK<\$^*3XI\'VVM7$*VSL&$ MRALJ"O4@^E '3TF1ZUYM!XH\4>-;R<^$$LK/2;:0QF_O4+^>1P0BCM[T1>*_ M$WACQ5IVC^+%L[NSU)BEOJ-JIC"R?W64T >E9%%<9\2/%UUX.\.1WUE!%/<2 M7"1A)!G*G[V!D9/I5 7GQ$UJTM+_ $^'2M.A9D8PW.YI9$.,D@C"\9Z&@#T+ M(]:*\ZN/%OB+7O&%]H'A>"SB33&"7EY>@D;R.BJ.>M(OC'7O#?BC3=$\4Q6L MZ:D=L%Y9JRJ&]&!H ]&HIH.3GZTZ@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *IW_^J3ZU;/0U5O\ MF)?][^E %JBBB@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH J7^IV&EV_VC4+VWM8=P7S)Y51 M7^&,ZY\W\Z]$H *#137.U&."V!G [T >70,=<_:!G?;YL&CZ>$&1]QW MZUZESVKSKX;:+?P:YXFUS5+*XM[B_N_W?GK@F,=,>U>BMPI.,XH \?O-)L?' M/QPO;74D^U:?I%@H$)Z>8QYS^>:ZG_A4?@4N7_X1VWY[;WQ^6:X[1F\<:!XD M\1:M!X.^V'4KG=O:4(V%X'X8["N@7QKX[V@M\/YV.[!Q<@8H W=)^''A'0]1 MCU#3M%@@NH^4<,QV\8XR?>N7\:EM9^+_ (/T9=KQ6F^^F4CIC./Y"NI\,:[X MCU>[F36/#+Z5 BY2228.7.>F!6+HVBZKO["6&RBLUMK.5R,/SSC]: M +GQ6\/OKW@:Z:!S73M'LK%%"BW@2/ [845>I!VSUZ\TM !1110 4444 %(>E+10!YUJ'B#X MCI?7,>G>%K.6V60K$TLNTLOK]X5T'@^]\3W]K<3>)]+MM.F\S$4,,F\[<=2< MFNEHH 0\BO,[CQ?J^N>)KNU\'>&[&[GLE>1Z7; M>+/A]K6L0V_AR;7-,O[DW,4UM*BNC'L0: */Q)N/'UMX$D.KW>AHMRZ6\EO8 M1/NE#'D;G/'X5ZEID-GI_AFQM9FCB@6V2/$C@#!4 KFO-/&.A^/O%PTF[N-' ML(K6&[60Z<)]TB+_ 'G;(4G'85UOQ"\'W7BK08(]/DCAU"S<2P&3H3CH32 Y MY_!'BKP1<377@?4([FPDD,KZ3>?=Y.3L;M72>!/%]KXR@N9I--^Q:M9N(;N" M1061O8]<5C6WBKX@VEK'8W7@)Y[Y!L%Q#?)Y+GH&.%KT M8]*\K\+*=9^-_B?5F(:.P@2SB8=#W-, 4+K'[0LBW#!XM+TT-#&W(#,1R/?F MO4V(526. >:\^\5>%-MSIOPWFU>X3]_>2S7LK?WNI!_*KVO^#[ZR^%MQX9\-0QRW,R"-C*^S.2-[ M9/?BK=[X?U.R^%7_ C^DQ!K\60MU'F!0&(P3G\Z ,;X+V:R>';_ %Z0YGU. M]EEW'KL#<"JWQFN6OV\-^&(FP^I:@CR+_P!,UZ_SKM_!.BS>'O!FE:5=!1<6 MT 23:<@MU//>N>UKPMJFL?%K1=9DMU&DZ7 Q63S!EI#_ +- %?XQ3-:^ 8]* MM7*RWUQ#9QK_ +)//Z8KO=*LUT[2K.R4!1!"D>![ "N*^)&A:YJ=UH5_I-E% M??V;<&X:VD?;N;& <_B:Z[0KN_OM,CN-2L/L-PQ(,&[=M Z4 :1X!KR_0P=: M^.>O7^"8M*M4M$/7#GK^/->HFO*_#.F>,/#'BO4U;1;>[L]4OC,]YYPW(G;( MH S?BK8ZEKWQ$\*Z+9R1Q!E>=6E.4RISDKWZ5U?]F_$E8]H\0:(2?XC9/_CZ M5+X]\):AKIT_5="N([?6],D,EN\OW7']P^QK.N;OXC:S9OI9T:RTPRKYN*Z_1O"\7A'PA-INBQM)<^4S;WG-4/ACX:U'PO MX2:UU=(QJ$US+/-Y;;@=QSU% &;\;+V6#X>SVD&3/>S) B@]02,UIZOKEM\/ M?A]9NUJT[Q1Q6T-OG!DD( _.JOCSPMJWBCQ%X:2&&$Z3978NKIV?#9'0 =^ M*TOB#X7N?%7ADVME*L=[!*EQ S]"Z\@'TH RK"'XDZG%!CZ-"P#?98X# M,X!&<$G ':N>\*0ZG=_'757U#4%U"33;(1&98A&%W?P@#W-=)9ZA\1KP1V<^ MC:=8-MQ)>M/Y@'NJCK57X?\ @O7?#'B?Q!?:I-'=1WA#13JWS2'W':@"G%$/ M$/[0%Q(^V2WT2Q50IY"R/_6NY\7ZG_8O@_5M1 R8+5V ]R./U-<_X%\+ZEI. MO^)-:U:&*.?4[K=&L;[B(QTR:M?$S1-9\1^$9=(T98_-N7596D?: @/- &?\ M*H/[#^%%I=3C:7BDO'!XQG+'/X"J_P %[=SX1N=6E!$FJ7LMQSZ;L+^E=3>Z M'.? ".6'4MFH:ASFEM_"?B_P-KNH7?A6*RU/3+^4SRV=S)Y;HY[JQJU= M^'O%?C?4]-?Q)966EZ98S+I' % 'I28(!7H>E9_B"U%[X;U.U M9=PEM)4Q]5-:(&/PI'&488SD=/6@#QO0C<:O\)O"WATG]_>W AE5#RL$;EGS MZ8 /UQ716\MKHGQ6UR21XX+3^QHI=N0H^0D'],?G6?\./AK?^&?$NH:OJIA M8L76T5)"QC#-ECZ6ACBL!%Y5Y*'PY&[.,=Q@8_&@#1^& M^FSW/]I>+M20"^UF8O$/^>=N.$7V]:S/A6O]I>(?&'B&3):XU V\;'^ZG;^5 M>@W-M+9Z#+:Z5"OFQP&.WC)P,XP.>U<]\-?#%[X4\(1V&HF,WLDSSS>7R S' MIGO0!@^&5;6/C9XHU9H_W.G6Z6".>S=3^F:7XM1MJU]X5\/*V5O=2#S+ZH@S MS[4GA30_&'A3Q-J41TRSO-.U._,\M_\ :,.JGU7K6MJ7AC4]5^*FE:W-"G]E M:=;L(V\WYC(V>JT =F[):6C-C;%"A.!V '_UJ\V^#,,US9Z[KMQ\TFHZ@[*Q M')53@?S'Y5W7B:VOKWPSJ5IIJHUY-;O'$)#A=S CDUG^ /#TOA?P5INDW"(M MQ#&?/"'(+DY)SWH Z4G KROQ5#_;WQL\,Z8N^(]22'[/<1+#9[9-S*H/.?2@#H?%=_\ V7X1U>]).8K20C'K@@?S M%RQ16JVZVTA9@BGY=IZ^M &#\*+6WM?AGHGV?'[Z#S7 M;NSL223^-8OQ@=-0@\/^'@N^34=2B. ,D*O/Z\TW0_"7C;P@9-,\/ZGIEUHC MEGM_MJ,&ASSCY>HK&TO2=1OOCLO]IZI_:$FFV@ED>*,+'$QZ(!VQ^= &W\:9 M@G@RQT: E6U"^AMD"_W0\7>$M7O+1[>QN]-O+U[B2\\S$@!SCB@#THG MY37F_P ;I6'P_, DV1W%Y#%(0<90M_*O1\'-8OBOPU;>*_#MUI%RS(LJ@I(H MY1QT84 7]+@CMM(LX(L"..!%7;T("BO.O&[G4_BOX,TVU59);.1[J< \HG'6 MKMK;_$G2+%=)BCTK4(XU$<6H2R%6 X +)WQ6CX/\#2:%J%YK6KWHU'6[SB2< M)M6-?[J#L* ,+QYNUGXG>#M"11(D$K7\P(Z!1@?R)KU ]_4UQ%AX4U0_%6] M\47\D/V06@MK2.-B3CN2/SKN* "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ /2O+?$I;6OC?X;TO/[G3K=[Q@>A?M7J1KSKQ!X8\16WQ M$@\7>'HK.Z9K7[+/;W#[,KZJ?6@#K/%6I1Z1X5U74)#Q;VKOUQS@X_6N2^%T M/]A_"*WOI2-\D,M\Y(P>,?#LL=U=VUK.Y7RK")CY2 '^-O MXC71:YX?U!OAI+X?TI(A=O9BV&7*J,C#'/YT 8WP6TS[/X(.IRIBZU6XDN9" M>I!8X_2J7Q7;^UO$?@_PTC-NN;X7$F.FQ.]=YX6TAM \+:9I38+VMND;%22, M@<_K7/3^%]6O/BY;>(YS#_95G9&&!=V7+MG)QVH QOB7"-1\=^"-)N(RUE+= MM)( V 2/NY'YUZAD#&, 5QWQ!\)WWB.VL;S1YXK?5]-F\ZVDE!P3Z&JHB^(. MM6!L;R+3])W1E9+F*8R.YQ_"!PN3^E &/X CCU#XJ^-]8A97A61+:-O]H#)Y MK!\-Z/XDUKX@^*]:T;6[73I8KHV[B2W\TE>H&#T'%=Y\,O!]YX.T*YMK\Q-> M3W#2.\;$[QV)/K5*^\*^(]!\7:AXD\,26MRM^%^T:?=$H,@=58=Z (]5T'QR M^E7,>H>-]+BM9(BDCO8+'@$8^]GBG"SD^'OPKF$?-+&(B?0$\UN>#K*/3?!NCVD9!2*TCY'3D M _U-7=_P"'6O/M(TKXD^#K<:7IZ:9K>FP_+;O< MS&*1%SP#]!0!V7C?6X_#_@W5-0_-8GPPTP^'/AC8_:.)&B M>[ESZMEOY5DR>"O%7C34+6?QM=6MOIMK*)$TVR)99".F]J[3Q187USX1U#3] M(BC^TRVYAA4MM5<\?RH XKX*VWVK2=8\12_-/J=](0YZ[%. *;\;)C>:3HOA MV(;I=5U&--H_NJ1G^==CX%T&;PUX*TS2;D)]IMXL2E.A8G)K$\0^%M6UGXG^ M']7$4*Z7I<;.9"_S-(>VW\N: ,[XR2QVW@6TT6('=?W4-I&H_P _2M7QU/:,]:0%CPE:2^'OA19)L5+B#3C,PZ?, M5+<^_2LGX*6@'@-=2=E>ZU"YDN)Y%SECNP <^E>@K;(+,6I!,8C\KZKC%>:Z M7H_C/X?"ZMM(TVWU_299VEBA%R()80QZ9;@BF!J_%^^AL_ASJ%O)S)>;;>%< M9)8D=!WK%\86#W'PV\+^&9 INK^XM+=5[?+AF_( U>'A7Q%XPUZRU/Q8EK96 M-D_F0:;!(7W-_>=NGZ5LZWHE_J?C_P .7@MA_9FFI-+)+N7(D( 4 =?7\Z . MI58;.T"J D,*#"@?=4#_ .M7F?P9M!))H2%7SD[%/ _6N\\31: MC/X9U*#24#W\L#QPAF"C<1C)/XUF_#SP_/X8\#Z;I=U&L=W$A,ZJVX;R3G![ M]J .3^)L9UOQUX-\.DGR7N3=RX]$/'\J]"UR\33= O[MG$:P6[N#V! .*Y5? M#6KW'QC/B*XC1=*@L?(@^?)+D\G':M/XA:3JNN^#+W2](V_:;D*A+-M^3//- M &#\$;%X/A]%>S(%FU"XDN7;^]EN#7I!Z>E9/AC2O[$\,Z;IA&&MK=48>^.? MU-:U 'EGB=X[3X[>$[BX!:*6TEB0GHK\X->BZMI_]JZ5=6)GE@$\90R1'#)G MN#ZU@^.O!D?C#3(DCG-KJ-J_FVMTH.48=C[&L"WU7XH:7!%:7/AS3]4=1M^U M1W?E[L<98&@#G_&W@:+P?X-OM6M_$VNM/ JK$LESN#/P ,>^:[C22_AKX413 MW4\SR6VFM-(\S9;<5W ;O1=#ACDGGC6 "1MH5.,\_04 9?P?M/[-^&MM=W VR7;27XJYXT\%ZQ>>+=,\5^'983J-F-DEO,_AO9M+IUZNN^'[9<_9)EQ/$@]&'6N^\+ZW8^(]!M=7TY D-R-Q&.0W<'' M>N2O-0^(FMZ3)I\?ANSTZ6XC:.6YFN@ZIG@E5^E=3X.\.)X4\+V&C(PD:W3] MY(!@.YY)H WCTKRVPSK?[0&HW0.Z'1M/6$ _PN_7\:]2/2O+]!TOQ9X:\<:Q M.VB0WUIK%T)#>)<5ZKD 9 M/3OFN'\:^%-5O=6T[Q'X;>!=8L>F>M %7X;.FI?$+QOK%HH^PR7*0JP/#NHY->I5S_@WP MM;>#_#MMI-NWF&/+23$8,CGJQ]*Z ]* /*_$ZKK?QO\ #&F[\KIUN]Y*AZ$] MC3/',BZ/\7?"&KRLD-M+'+;332'"*.O7L<9ZULZ3X8U8?%K6/$NH1(EF]LMO M9LL@)('7([57^+OA#5O%^B6%OH]O#+<0W&]C*X7"XQQF@#)TF(?$3XI3:]YG MF:'H8\FT'!62;)RWTZ_I5WP7(GB#XI^+->"AXK4II\+^FWKC]:ZKP]X>7PEX M-BTW3KFYCDU#I$:>(?CWK5\\7[O1;1+=-PR"[=Q^M:_ MP^\/:QI6H>)=3UJU$4^HWIE@02JQ\L=,[>!1\-?#6K:)-X@O]:@$=WJ=\TR# M7&.21ZUT.M^'K;6_#%SH M4P/V>6#R5/\ =P!M/X$4 1>#-,AT?P=I-E!C;';)R!C)(!/UZ]:XGXNG[5JO M@_3K?<]T^J)*%3J$'4_2K6D7?C_PSI::/<^'8=8,";+:\M[I8E8#[H=3R.@J M[X=\)ZS<>*I/%7BIK4WWE!+6UMR66U'?GH3[T 9?Q$1M8^(7A#0-H:(R->2Y MYPJ__JKTUWBMX&>1TBB1>68X517$6_AO5)_C!<>([N 1Z?;V/V>T82 EV)^8 MD=N]=)XIT1?$GAC4-(9@GVJ$H&.?E/8\>XH Y35/ UZNOW/BCPCK(L[V] :: M)QO@N,#C/U]:D\*>-'UK7W\/^(M'2R\06:>9QAT)?+2:6U;S0@&![9%;?@_P9#X6 M%W<27DVH:E?2>9U=110 4444 %%(S*BEF("CDDG@4N1ZT %%% M% !1110 4449'K0 449'K10 4449'K0 44W>H8+N&X\@9Y-.H **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HIKR1Q(7D=45>K,< 4R"Y@NH_,MYHY4 MR1NC<,,CJ,B@"6BBB@ HHI-R@@;AD]!GK0 M%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 'I56^_U*_[W]*M'I56^_U*_P"]_2@"S1110 M%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !4%S>VMFH:ZN88%/0RR!1^M3'D8KPW3#H'B/X MFZ[#XZXOH9?+T^SNV(A$73*]!DT >WPW$-S$)8)HY8ST>-@P/XBEDFBBV^9( MB;CA=S 9/H*\V@^']UX9\?6&I^$E2UT:6-EU&U,QV=^-_AW2F M0^7I]NUU(3P#UQT- 'K&1ZU'%<0SAO*FCDVG#;&!P?0UF^)+Y=,\,ZI?.&*P M6LC\=>%-#?B)X8U'2;**S6]>:SD1,[6+(2#UZ\8H ]1JLUW:S MV\^R[B*H"LCI(#Y?'?TKF_B#XG/A;PK/-;LIU*Y(M[&/&2TS<#CT&NZ' M'X$^!NH6LS;[^^0?:IB/51-%?7!E:YN)E( M8GLISBNN!! (.0:\Q\5^'8+;X$S6")S9V*W"$=G&&)]>I-=AX7U*&?P1I6H/ M*JP_88WDD/ &%&XG\C0!LO=V\4Z027$22R?)]2\=7X LH6:VT[<,@1KUD'U&>:H:'IZ?%CQ/>Z[JQF M?P]92&"RLRY"2L#RYQU^GO0!Z?IWB'1M6E,>GZI9W4B]5BF5C^AK29U4$LP M'))->4_$SP5I.G>$Y]=T6SATZ^TPBX66V_=[PI'RG'6MGQ'XH4_!JYUUSM>Y MT\8XZLX _K0!V%QK.F6UG]KFU"U2WW;?-:5=I/IG/6E75=/;3EU 7D'V-AD3 M%P$/X]*\Q^&OPUL#X3M+OQ# +Z>=?,BAF)V0J>F%SC)&.?>L[XBVFFZ/XB\* MZ=J=C(G@RV1E=4#&,29_BQVZ=?>@#UBQ\1Z+J4ICL]5LYY <;$F4G/IC-6-5 MO$L-(O;MR L$#R')[ $UY]X@\#^'O&?AV&Z\(OI]M?Q.C6M]:X^7:>A*^U7/ MB-?7.B_":ZCNY5GO);=+1I%& SMA2?I0!E?" VFA^ /[5U6YBMI-0N7D+S28 MW+GY0,FO2K'4[#5(#+87<-S&#@F)PV#Z<5P7@/X=:?9>&M.DU>/[;=F$,$FR M8X0PZ*O^>M9O@.VL[+XQ>+[32(#;Z;##&K1*3L$W&<#MWH Z[Q'X=TGQ#XDT MIKS5'BN[,F2*UCF"F3ODKU(KI7N[:.YCMGN(DG<92)G 9A[#J>]>8:'#'K'Q M^UW4)-#?4&LEU6R-TIPT?G+N!].M:N1G&:\O^(G@+P[!X&O[ZSTZ*SNK"$SPW$ MVR+MZ@MG)KK/ 6I2ZOX'T:]F;<\MLN23R<9&3[\"@#I*@N[RVL;=KB[N(H(4 M^])*X51^)J<].:\]\3>%'UOQC#=^(=6M?^$;MHMR:?))LW2?WFSP1]: .IL_ M%?A_4+E;>TUBRFF;[J+.,GZ#/-:TDL<,;22R*B*,LS' ]S7C?Q17P3#X0DE MTBYTN'6('5K-K!T,@;(R/EYQC-=1XMU*6R^"UQ=73$7$FF1H^Y@"S.JJ1GU. M: .PEUO2H=/:_?4K1;,':9S,NS/IG.,TS2]>TG6M_P#9FHV]WL^^(I Q7ZBO M/OAU\.-/B\*Z7=Z]%]ON?)WI'/S'$K9(PO0\'J:KVMG;6/[0P@TVU2W@73-] MPL("H6QQ\H'7D4 >L2RQPQ-))(B(HRS,< #W-9EAXET/5+MK2QU>RN;A1N,< M4ZLV/7 ->>>)A+X_^):>$Q<31Z-I4(GU'RGVF5S]U/<=*Z'Q)X(\/V_A/4/[ M/TZVTV>WMI)(;FTB$OKFO3#TH KG4+(7WV'[7;_;-N[[ M/YJ^9CUVYSC@UFOXN\.1:B+"37M-6ZSM\IKE V?3KU]J\NCT.3QG\;M8F^U7 M%O8Z:JQ2>22AD.T#:&';K^&:VOB3X4\*:-\-M3EBT.RCDC0&&1(@)?,+ [_ M +VCP.&'Z5P?Q<\5PZ3X2FL[+5(H-0N)H[ MB,1N)Y^4;<\GUK,AL;?P5\9K.TTL^1I^M6Q+V4:X1'!/S $X'([ 56\>M;-9^E:/I^BVYM]-LXK6 MN*1K@9]:OMG:<$9[9H S]4UW2M%5&U/4+:T M$G">=(%W?3/6H]*\2:)KG_(+U6TNSW6*8,?RKB;#P]IEAXDU#7/&VLZ5>ZA+ M(1;1S3#R[>+T"/T-<]XED\.?\+.\(MX7EM1?-=E+O[ 0$\OC[VW@\&@#VF26 M.*-I)'5449+$X %<\/'OA1KD6P\0:>92'6#RWAV!9XGQ@DY^;(/.: /2$=) M%5D8,IY!!X-/-@+IVI7RWCI(Q1QV4\XY]\UTQZ=,T >2?$_P 6 MV$^HZ%HMKKR0))?+]O\ *<$! <8;TYKU"PO[*^L5NK*XBFMCD+(C KQP>:\H MCT31]:^.]Y!%IUK);:?9[[A3'E3,W.2/7YJE^*.K6>FQ:1X(L)XM+BOY 9Y$ M.Q8H@P[CN: .ZN?'GA:UO/LLVO62S@X*B3.#]>E;\,T4\22PR))&XW*Z'(8= MB*X+3Q\,[/26TZ&YT0P>7M=F=-[@<$ECR?PK)^#6JQS/XETNVN#-865\?L9! MR!&2<;<]N* /25UC3GOY[%;Z W4"[Y8O,&Y!ZD=JS4\<>&)-26P37+-KIFVB M,29R?8]*\N\&^'8/&OQ"\4Z[>!Q8171MDB1L"7:W\7J. :U_C-H^D:?X%ADL M].M8;H7D*6[11!6SGG! ST% 'K)QWZUS^J>-_#.CW(M[_6[2&8G&S>6(/OMZ M5-?V^H7/@Y[>TO187[V@5;AQGRFVC)ZBN/\ #UMX#\':>+*^U;2KK4F8M=W4 M[*SRR'DGG.!SC% '?:9JVGZQ:BYTZ\ANH3_'$X;'U]*;?:SINF300WM[!;R7 M#;84D< NO.,?2@"3P)XLTG4/'/B74 MKS6$+37:6FGQRR'[GH@]R!7I>L:]I6@6HN-5OH+6,D &1L9)]!U/X5PGP@\* MZ9!X!TK4+C3K5[R?-P)7B#,N2=N#C@X'ZUC^)+FQT3XOOJ?BZSEDT>6V1;&Y M="\,3CKD#C/)H ]+T?Q9H&OS>5I>KVMU* 6\M7^?'KM/.*VZ\[U?P;I/B^YT M?Q!X:U&TLKBTF#_:K- 1*G=#M(Q_]>O0ESCD@GN0,4 .HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ I">*4UB>*O$$'AKPY>:G.V/+0B,?WGQP* .'\;O+XX\76W@6 MS=TLH%^U:I/&3\@ ^1,CN<]/I3O@@PM]!UC2OG!L=3ECPW/RD\?RK3^%NAR: M;X?;5]1G2?5M8[\K2O"^FW#PW^N7 A,L;89( MA]XCT],UMZ9X#\,Z7I']F0:/:R0D8=IHP[OQ@EF/.3SS0!OF^M%L_MANH!;8 MW>=Y@V8]=W2O+/#_ (KT_5?B[K5W=:RBV-G"D%@DLP5&8X#%1GDYR*UO"_@Z M7PMH.OV6M-;7>B-+)<6UK@MY<8R<'/X5C_!WPEHUWX236;O1[=KBYN9)(6EC MW$1AOEQGWS0!ZZ"#CG/>EIJC P!@=AZ4Z@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH #TJI??ZI?][^E6ZJ7_\ JD^M %JBBB@!:*** "BBB@ HHHH M**** "BBB@ HHHH ***1CM0G!..<"@!:*XJT\1^)M8UC[-:>&7LK)'Q)=Z@V M-P!_A4=X@EGCA S'$,L)( MLCLW7(KHK^PMM3L)K.[B$EO,NUU/<5P4'PG732\>B^+/$&F6;_\ +M#< JOT MSTH S?A^VH^'/B'K'@R34)=0TRW@6XM6E?>T()'RD_CC%3>#@VI_&3Q;J4J- M_HR):Q,6[?2NQ\,^#-*\*K*UDLLUU.GZ MKJ>D74XQXBM!+!=//;2B4W+3%I9FSG,C'[ MW(Z=/:N@\4>&++Q;HYTO4)+E+9G#L+>383CU/I0!D_"[2QI'PYT> @B22$3/ MN[L_/\L5!\4)4T_0M/UIP,:;J=O<%O12X4C\=U=E:6T=G9P6L0/EPQB-,G)P MHP*H>)/#UEXIT2?2-1\T6TQ7=Y3;6X(88/U H \^T*1/B-\1+C6G21]"T3]S M8HX^22?^)\=\9J?XM2'4;SPKX=C<%K_4DDD3U5>_TS7>Z)H=EX>TN+3]/1D@ MCR1N.6)/*['Q%18E@3EA'GDD=:SOB?9?8? M!/ACPG!_R]W<%LP')(0#-=KH/P_T'P_>&_@MI+B_/6[NY#++^9Z59U7PAI>M M:_INL7JS/V MVIV]WIT4;V=P87M9P')4=R#ZUV@Z\UQFJ_##P[J6K/JD:7=C?2',DUC.8BY] M3ZT <1XIT&V\ ^-?#U_X69[9]1O!#<:=')\DBGDL%K9^+K?VA<^$] 5ANU#4 ME9T'.47K^&372Z1\/-#TG5$U39<7FH)]RYO)3(ZGV]*OZAX3TS4_$>G:[=I* M][I^?L^'^5F MW=JEY:36TA8),AC8J<'!&#@_C6-I7A'2]%\,-X>L$FBL&5E/[P[_ )NIS0!R M'P:5K[3_ !!XBE.Y]4U*5E;'.Q>!_.LSX2:S;ZCXT\92RNGVNYO"T1)&6121 M@>O0&NTFL-,^'GP[U&/3%>*UL[:61 S%CN(/?ZXKE?A]X!TC5/AGI$M_#(;R M?==BYC&-)_ ML'PUINE#'^BVZQMCNP SC\._#OP_IOCAM4U_Q'(-6O1>20B"9LQP*#P G3OWKV0]*XR] M^&.@7>K3ZE#]ML9[@YF%E'+==PU#4(82!UV)U_I723_ U\+W$%G&^G8-K( M)8Y%D8/N]2V[TXDVY$A"@YZE(22\23_ &2(MU7;UQ[<5ZLZ;T96_B&#BLCP M_P"%]*\,6T\&E6[11W$QFEWNSEG/4Y)H X;P@T>G_&CQE:W#!+J[6.> ,>73 M';UK5^+/BNU\.^";^'[2B7]W'Y-O&""QW<$XZXQFM?Q+X$T/Q/#].:9\ M9GGO=,T+0+>I)-0:C MX6T[5==L-9NUF>ZL,F!1(0@).YXH X3XR6\5EHWAJZ:/=8Z?J41E]$4#: M"?H:]/BNK>6T^U)/&UNR^9YH8;=O7.?3%)>6-MJ-I):7L"7%O*NQXY%RK#Z5 MQW_"I_#89HT.I)8L;!/]:]#TW2;#1[5;73K.*U@7D)$H S M7.:E\-M U'7&U@K>6]X\BRR-;7!C$A7IN'0T =CUKFOB#?7>F^ M:N[%F6XC MMFV,O5<\$CW )-=(!WIEQ!%\NQYA=CR=V[(&*Q8GTO5_C]I\6G6]J++3+)R&MD509><].#U'Y M5UB?"7PO%.[11WL<#G+VJ7+"$_\ ?2MJS\%Z%I^NIK-G8+;WBQF,-&2!C&, M$4 98\<^3\1Y/"M[;Q6T9A\R"X:7F4X'&.E8'Q:\*:(GAN^\1PA-/U>U4/#< MP-Y;2-D84^N:[7Q#X.T/Q0J#5;%)9(^8YAE9$/LPK)M?A;X:MY_.GBO+[!!" M7ERTJJ0>H!H V_"=W>7_ (5TNZU"/R[N6V1I5]R*V6.%)/04BJ% "J%4< < M#Z4IZ4 >6?"A5U#Q!XQ\1,!NN]2:&-L\[%[?R_*J_BJTT^W^-^BWFMPPR6%U M9-%$9URBRC/7/%=?8_#GP[INOG6;*WG@N&D,C)',PC9NN2O2MG6_#^F>(;%K M/5+1+B'.1N'*GKD&@#G?$6G>"?#.C7&JWVC:7M1-RH($W2MT"J.^214>C7MI M:^ +WQ"F@Q:'(]I)*80JJ655.TG [\58L?ACX7LKR.Y^Q2W#Q$&);F9I%0CN M >E=%J^CV>MZ5/IM]$9+6Z=O4LWK MWZ?K61\2Z@([J59/+^ M7'0GTYKIH= \'>%-,-XMAI]O;A1F9HP2^?<]2:VM:T+3/$&GM8ZK9QW5NQSL M<=#Z@]C6'I?PW\-:1,DL-G+,T?"?:;AY0OT#''2@#C_@Y)!JNN>*_$,*HB75 MT%C2,8"KR<8_#]:N>!MNK_%CQIK8D65(#'90MG. .3@_A7=Z/X:TC0#=G2K& M.U%VP>81Y 9AQGVZT:%X9TGPW'<)I-FML+A_,FVDDNWJ2?K0!SGQ=U7^R_AM MJI0D2W"BVCP<'E^([ M>W@U6U^T102K-&I)&&'\Z=K>@:=XBT:;2-2MA-9R@!D#%>A!&".1C H IPC_ M (1SP.L=A"EP^G6(V0JV-[*F<9]\9K-\&>)[+X@^%1/=VUJ92S)D^%;26UTJ&5(IFW2>;*TA..,98FLK4OA;X1U*[>[;2_L\\A MR[VLSPE_KM(S0!Q]C86WA?XUV>G>%K@?8KZVDFO]/23,<)&?FQV[<5[%CFL7 M0?".A^&EQI6G1P/MVF0DO(1Z%F)/ZUMT %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M (>!7D^L*GQ-^(#:'',S:!H\9:Z:)N))R>%R/2O5Y$62-HV&58$$>U9FA>'- M*\.6\L&E6:6T);3PKX?N-3N'3* M*?)B9\&5^RBKNKZ+IVO:>]EJ=K'ZM?69L+R\M=B0 DE2^ .OUKJ/ ^G)I'@G1=/1 MMWE6<9)SU+#)_4FK^L:)8:[I4NFZC;K-:2XW1G(!(QCZ=*H^&/!^E>$HYXM+ M%P(YMN5FF:3;CH!GH* .@/2J=QJEA:7<-I<7<$=S-_JHF^.YH T;V_M-.M'NKVXCM[=,;I)6"JOU)I\4\%Q M;K<12I)"R[UD4Y!'J#Z51UW0-.\2Z4^FZM;^?:NP8H6(R0<@\5:BL+:#3ET^ M*(+:K'Y0C'0)C&/RH ;8ZI8:I&\MC=PW*(VUFB<, ?3(IW]I6/\ :'V#[;!] MLV[OL_F#?CKG;UQ5'P_X:TOPOIW]GZ/:BWM2YD*;BWS'&3DD^E,A\*:-!XGF M\1I9C^U9D\MYRQ)VX QCIT% &A?ZG8:7 );^\@MHV;:&FD"@GT&>IJ MXC,4BJ=N5(P1[<4 +9:C9:E;FXL;N&YA#%3)#('4$=1D=Z9#JNGW%_+817UN M]Y",R0+*I=?JN3R35>P\*:1IGB" M_P!=M+9DU"_7%Q+O8A^G8G Z"@#0O]6T_2_)^W7UO:^<^R+SI53>WHN3R?85 M-E9.N^%-(\1W%C/J=J9Y+&42P'<5VMD?GT MJQKN@V'B31Y]*U*-I+6?!D56*DX((Y_ 4 7;2\MK^UCNK.XCGMY!E)(F#*P] M01P:BM=5T^]NI[:UO;>>>W.)HXI58QGT8 \?C2:7I=IHVEV^G6,7E6MNH2-, MYP*SM"\(Z1X=OM1O-.MV2?4)C-<,SELMDGCTZT :D^HV-M=0VT]W!'/-_JHW MD 9_H">:DN;JWLX'GNIXH(4&6DE<*J_4GI6-?>$=)U'Q-8^(+F&1K^R7;$P< MA0,^E3>)?#6G^*]$ETG4UE:VD9681/M.05+6YAF,+;9!&X;8?0XZ&BUL8;+3HK& $0Q1") 3_ @8ZUE^&?"6 ME^$X;J+2TD"W4YGE,C[B6/OCI0!JKJ%HUZ]DMU";I%W-"'&\#U(ZXY'YTEUJ M%E920I=74,+SMLB61PI=O09ZGZ5D67@S2-/\5WWB6WBE_M.\39([R$KCCH.W MW13M9\(Z5KNM:9JM\DKW.FL7M]KD+DD')'?I0!M33Q6\#332K'$@W,[' 4>] M);W$-U"D\$JRQ.,JZ$$'\:J:UHUIKVCW&F7RN;:X7:X1MIZYX-2:3IEOHVE6 M^G6@86\";$#')QUY/XT 20W]I<74MM# M(-.UN]AD>\T\'[.0Y"KSGD=Z -FXN(;6%YKB5(HD&6=V"@#W)IT4L<\2RQ.K MQN,JRG((]C69XA\/6'BC19](U)9&M9B"XC8J>#D<_6K6G:?;Z7IMOI]LA6WM MXQ&@)R<#UH ?;:A9WK2+:W4,QB.)!'(&VGT..E*U]:I>+:-R^;,9)"V3[9Z#FG)X3TQ/%C^) DW]H-'Y62Y* = M.!0!KW-Y:V2![JYA@0G:&E<*"?3FI&D1$,C.JJ 6+$X 'K]*Q?$GA/2_%D5I M%JL,(Y4;AZ^HK2O+"#4+">QN$)MYXFB< X^4C!% $MO=VUW%YMM<1 M31Y(WQ.&&1UY%-6^M'O&LUN8C'/#FG>%M'CTK2XGCM48 ML%=BQR>O)J*S\*:78>)+S7X(Y/M]VA65F]222QQ0O+(ZI&BEF=C@ #N3Z5B>(?"6E>)I["74XI9#8R^="$D* MC=[^M:.IZ;;ZMI=SI]TK-;W,9CD"DJ<$=B* )[6ZM[VW6>VFCFB?[KQL&!^A M%-AO;6XEDBAN(GDB.'17!*GIR.U5=$T6S\/:1!I>G1M':P K&K.6/7/4_6JN MB^%=)\/W>HW6GP/'-J$AEN'+D[F))X].M &I-?V=O<16\]W!%/-_JXWD"L_T M!Y-.NKNVL;=[BZGC@A3[TDC!5'U)K%N_".EWWBRU\23K,=0M8O*C_>'8!DG[ MOKR?TJQXC\-V'BG2SIVHB4VY<.1&^TDC^E &K%+'-"DT4BO&Z[E=3D$>H/I4 M-IJ-CJ"NUE>6]RJ-M#2064-OIZ6,2%8(XA$HSR% QU^E9GACPG MI?A&RFL])CD2&:4S/YDA8EB/4_2@#5;4+);T6;7=N+IAD0&0;R/7;G-.N;RU MLHO-NKF&"/(&^5PHR>@R:QD\'Z0GBY_$XAJ+*T$,RS*L;E,>N?2H[>ZM[R+S;:XBGCR1OB M<,,^F15:_P!*MM0T>;2IU86LT/DLJ'!"8QP:K^'?#NG^%]'ATO34=+:+.W>= MSG_ZD*^%ZYR1 MCG\Z -V:>*WB:6:5(XU&6=V 'N32Q317$2RPR))&XRKHP((]B*RO$GARP\5 M:)-I&I+(;64@L(W*G(.1S]:MV&FV^F:5!IULI%O!$(D4GG 'K0!-!>VMTTBV M]S#,8CMD$<@;8?0XZ4K7=LERENUQ$L[CTB, MMS/%#&."\CA1^9I_F(8_,WKLQNW9XQZYK$\3^%=.\6V$-EJ@G,$4JS!8I-F6 M'3/J*T+G38+O2)-,<.MO)#Y)VG!"XQP?6@"Q!#M,TKQ M/J?B" 3&\U$ 2[W)50/0=J -V6XAAV^;-''N.%WL!D^U.9U1"[,%51DL3@ > MM<_XC\':=XHNM.N-0:<-82^;$LE:.LZ3#KFBW>EW#R)#=1F-VB; M:P'L: +L4\4\0EAE22,]&1@0?Q%"7$#S/"DT;2IRR!@67ZCM6?H&A6GAO1;? M2; /]FMU(7><\G\:HZ-X.T[0]?U36;9[A[O42#*9')"^RB@#=DN((F19) MHT9SA S %C[>M++/%!&9)I4CC'5G8 #\36%K'A#3]:\1:7K5TTXGTXDQ(KD( MV?45)XJ\+VGB[1FTN^EGCA+ART+[3D=OI0!N*RNH96!4C((/45'# M*78=K;'#;3Z''0U%;V,5MIL=BFXQ1Q")23DX Q^=9/A;PCIWA*UN8-/\TBXG M,\C2MN)8T ;9N(!.L!FC$S#<(RPW$>N.M+)/%"F^65$7^\S "L&3P=I\OC6+ MQ2TEQ]NCA\D)O_=X]<4[Q=X2LO&.DIIM_+<1P+*LO[E@-Q'0'@\4 ;X((!!! M!Z>],BN(9PQAFCD"G:VQ@<'T.*@-C'_9OV!"T<7DF$%<9 QC\ZS/"OA2Q\(Z M6;"Q>:1&D,A>9MS$GWH VOM$/G>3YT?FXSLW#=CZ5)7/6_A&PA\8S>)O-N6O M98O+VM)^[48 X%=#0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M5+__ %2?6K=4[_\ U2?6@"W1110 M%%% !1110 4444 %%%% !1110 4444 M%%%% "8I:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*#TKED\<::_CS_A$(XYWU!(C+(P4>6@VANO7N/SH ZFBD!!Y!!I@D#J: "BC(]:* "BC M(]:* ,_6-'LM>TV73]1A\ZUE&'3.,C-6+*S@T^SAL[6,16\*!(T7HJCI5C(] M:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B@]*SFUJQ76HM(\W M-[)$9A&HSA/5B.GXT :-%P;!H Z6C-5+_ %*STV))+R=(EDD6)-QQN=C@*/4G MTJR#]/PH =1156\O[6P6-KJ=(Q*ZQIN/WF)P /4T 6J*0=C2YH **SKW6;'3 MKZRL[J<1S7KF.!2/OM@G&?7 K0'/O0 M%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4[__ %2?6KE4[_\ MU2?6@"W1110 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% "'I7(>$_%]IXKUO6H[3 M3&A739OLSW3L"9'R00.^/E%=+JEZFG:3>7LF-EO"\K9Z84$_TKS/X/)_9/PQ MOM?NES)>S3W\ASC*CI_Z"?SH T;3XN:==:GJ&G+I.HM=VTK0PP1+YDER0<$J M!T7ISTI)?B==Z3J^GV?B'PM>:9;7\@B@N&F64;ST4A1UY'>J7P0T58/"EQK\ M\>+W6+AYG?C[FXA<>F3D_EZ5#\6)'U'Q;X)T&-/FFO?M+2=EVX _]F/X4 >L M#&>U*:0<]N*Y3XDZQ+HGP^UBZ@W?:# T<6T9P6^7/X9S0!G7'Q%GU#4KO3?" M.@3ZW-:L8YK@2+%;HXZC>>I]A4F@>/YKOQ0OAC7=$GTG5GB,L0,@DCF !)*, M/0 U?^'>A1^'O NE6:JHD:%9I6'\;O\ ,2?>KNIZ#ISZW;>)IH7:^TV"182K MD#!!R"._!- &1XF^(,&BZS%H6F:=/K&MRKO%I;$+L7&%#86%PX07$%VL_EL>!N '') _&J?P5LFN]+U7Q5>*/[1U6\D+,>J1@\+G MTSG\JW_BP;=?AAKIG"_ZC]WGKYA8;<>^: .AUC6H=)\-7FM;6GAM[9KD*IY< M!B?#:EJ*;ACG:N/Z ML* .]\1>)(M!\(W6OM"TD4$*S"/.")]*LY_#OAN>ZDE!,K M2RB*&+!QC>>I^E4?C=(8_!&GZ';AM^HWL-JF#V'//Y"O0M(TVUT+1K>PMD6. M"VB PHZX')- '$:#\5H[^>_TO4M)N+77[/C[!%^\:9O12/PSGI46N?$3Q'X7 M:QN];\+QP:7=3)"9$N@[QENF[''0'\JS_A#"-21 M^:T_XRF75=5\(^&HLD7VH"1QGLI S^ )H ]&UO7M/\/:+-JNI3&*VB4$DCYB M>P ]?:N/L_%OC?68Q?:9X.ACTU_FB-[QV=L^]4?'RMX@^)/A7PP^TV M2%K^Y0\>8JYP/?[AKT]56-0H "J , >U ',^#/&UMXOAO46UEL]0L9/*N MK28_,C?7T.#67K7Q+M]$\=CP[+82RCR _FQ\L7(R%"UC>$I5F^//B]K;:MO' M:11R[1@&3*\GW^]^M0^ +:+7_BIXM\1R1!DM9_LD!?G:PX)'X C\: -;6_&W MBW1=,FUN?PG$FD0*K.KW8\]5S@DJ.!UKN]*U&'5M+M-0@!$5S$LJ!NN",UQ/ MQHU!K/X:7D,?^MOI([95/4[FR1^0-=;X9T\Z5X6TFP;.^VM(HVSUW!1G]: - M6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH ***#TH RO$FN6_AWP]>ZK,L%S]YNBC\3BLKP9HT]AI3:CJ9WZQJ7^D7 MV-U'@!8_E75ZOXAU^VNM.TS3M"^U:A<0>;/*S[;>W/3EN_/:J>E+_: M?Q;UZ_\ ,#Q:990V,8!SM=\R-^/051^W>(_&/B37+#3-972-,TJ<6K-#&'F= M\9+ GH.: +FG^+/$5CXJLM#\3Z3:Q_V@'^RW5DY9"R@DJP;D<#]:Y_QS?>)K M_P").AZ3IVE6LPLF?4(%FFVB4*NWQTMY/C/8P2:S: -7XJM]D\,V6JJ2LNGZE;3HPZ\R!2 M/R:N[[UP?Q-=;VSTCPTBAYM7U"-=O]V.,B1V_# _.N[ Y[\#% #J*** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH *IW_^J3ZU"RB5@PP0VT9X]< MYKBE@N]9_: 6XDLYOL.D6#+'*ZG9O;C@],_,WY5ZE0!SWH 3!QTKG/'OAR7Q M7X+U+1X6"S3H#$6.!N5@P_E72TAZ4 >7Z/\ $M=+T*VTW5M UI-;MH%C>U2T M+&0J ,JPXP<5>\$Z)X@NK[6=?\17,\2ZHNVWT\RL5@C^AZ'V^M>@XYZ4IH \ M>\*:E??"Z"X\/:]I5_+IJW+R66H6D/FHR'& P'*G^M+JRZO\6+JRL(M,N]-\ M-02K+/+=+M:YY[*?0?JWM7KY&:,=.* /,/B1I4^KZOX1T.QTZ66S@O%FF:-# MLB1>%!/;C/Z5Z!KEU-8Z!J%S;Q22SQ6[M''&N69MOR@#ZXK0QSD]:4]* /._ M@QHEQHO@"%;RWD@N[FX>:5)E(<$X'.>>@_6LW7-,U+7?CMH,ILIO[*TJ%I'G M93L+E6(P>F<[?RKU7'MC\*,*RF?3K*1KJXFV$QAN MPSTS\OZUVGBJXN+;PIJDEK#)-<"V=8DC!+%B,#'XFMGOTH/2@#AOA'HDN@?# MFPMKB%XKJ1Y)9D<8.XN1W]@*S+K2K_5_CO97TUK,-+TFQ812-'\AD8$'!]?F M'Y5Z9BC'/2@#SGQYH.L0>*]&\9:#:M>W-BOV>YM%.#) 22=N>_S&G7WQ&U&Z M@:ST'PIK$VIN"H%Q#Y20MZLQZCZ5Z*>E(!S_ )YH X+P7X9O/!?A74+^_5KO M7;K?=78A&XN_)5%]>,5#\'-%O=(\$F34[5[>_O;N6XE25<,"3@9[]L_C7HE) MTZ"@#S/XEZ7?^(/$_A'2H+&XEL8[T75U.L>40+T!/;O^=>F#J?3I1WI: "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH *#THHH X3XJ0O'H&GZQ$A:32-3M[ MS&.JAMK?HU=L1'<1%6"O'(F"I&001S^AITL:2Q,DB*Z$@^E=)10!RL/@33K7QA-XEMKF]AN9VWS0I,?*D;:5RR]S@_G5?6/ASI6KZU M)JR7.H6%U. +C['<&-9@/[PZ$^]=E10!S.@^!M#\.:M/J>F02Q7,\0AD+2,P M8 YSSWIEGX&L=/\ %ESXAM;J^2:YE=310!RGB#P'IFOZG' MJIFNK/4XX_*6[M)#&Y7G@XZ]:71_".B^%!<:F7DFNMA::^O9-\FT#GD_=%=5 M37570JRAE(P01G(H XGPU:S^)?$;>,+^!HH$1K?28)%*LL1/S2D'HSY_("NW M[TBJ% X &*=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 53O_P#5)]:N'H:J7_\ J5_WOZ4 6J** M* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M*J7_ /JD^M6ZIW_^J3ZT 6Z*** %HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &2 E#CKVI5SQD_I0!:HHHH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ I,CU%!/!Q7#1_$[29?&Z^&8K6Z>1IC"MT #"SA= MQ /?TX[T =U12#K2F@ HS7.^(/%,6@:GHM@UK)<3:K<_9X]C ;<#))_"M]3D M]: 'T9K,\0ZS%X>\/WVK31M)':0M*47JV.U9QS0!T]%8&I^)[70_#*:UJ<>(S"' 6,-C<20 ,_CG\* -[(HJKI]P] MYI]O010 N:*YKPKXK'B>ZU98K4Q06%TU MJLN_=YA4G)]N@_.ND/2@!CLGGFU!6D+JV/*1@!U%'2C- !11D'O1F@ HHS2'IUH 7(]:*Y[6->U#3]>TO3;30K MJ]ANSF:ZC;;';*.I8X_2MY3SV]3QB@!]%)D>M97B37[/PSH5SJM[N,4(&$09 M+L3A5'N3@4 :N1ZBEK*O]6DL_#LNJQV-Q<2);^M !1110 444F1ZT M+11FDR/6@!:**3(]10 M%%&1ZT %%&1ZT9H ***,B@ HR*ANKA+6SGN'^Y#& MSM@]@,FL/P5XI7QEX>CUF*SEM89)'2-9&!+!21G\Q0!T5%&1ZT4 %%%&E^+[:S\;67A=+.>:[NH#<>8F-B(,CGOV_E0!TU%)D9ZT9 [B@!:**, MB@ HHHH **** "BBB@ HHR*0$'H10 M&0>](>E+5N?'UUX7CLI2UK:K< M2W&[Y5W=!B@#IJ,CUI#TK%O?$EE8>)=-T%]SWU^DKHJC(144DLWIGH* -O(] M:*YKQ#XKCT'6M#TQ;1[F?5KAH4V,%V!0"6.>H -=&.&Q_DT .HHHS0 449 H MH ***,T %%&1ZUB>+O$4?A7PM?:T\7G"U0,(MVW>20,9_&@#;HJEI=X][IEG M=30^1+/"LC1;L["1G'X9J[0 4449'K0 449'K1D4 %%%07EW!96,]W<.%@@C M:21O15&3_*@">BLCPWKD7B/0[;5H(7B@N-QB#]60,0&]LXZ5KGI0 9HKG],U MZ]U#Q/J>FR:+7?2G"7!/4*/0>M=!D>M !112$X4F@!")!\SNQIWB;78_#7AF^UF>%IEM8M[1*>6Z# /XT ;.115' M2+YM2TBSO7@>W:XA67RGZID9P:NY'J.* %HHR/6B@ HHHS0 449K%\5^(8O" MWAB]UJ6(S+;(&$08 N20 ,_C0!M454TVZ:\TVUNGA,+31+(8R<[-PSC-6\B@ M HHR** "BC(]:* "BC(]:,B@ HHS4%[=)96%Q=R?ZN"-I'P>RC)_E0!/1D'O M7+:#XP&O>"V\2)IMPL>V1XH%^=Y0I., >N*T_#FK3:WH=OJ-SIUQITDH):VN M>'3GOZ>M &M11D#O4-U#5;2.1+:?<8O,&"R@X!QV!QFM6@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH *J7O^J3ZU;/2JM]_J5_WOZ4 6 M:*** %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHIKLJ(S,0 HR2>PH Y/X@:_-HGA\6U@"^JZDWV.S13\V]N"P'?:#G M\*XOQ;X;M_!WASP;=6Q83Z3J4(FD4\RF3_6%B>N2#^=17Q>]!P[#[\@ [R:YQET2SEDEC5]T;NW =?\ 9((Q70:CXMU[6_$USH7@ MZ"U*V)"WVHW63%&__/-!_$WK57P[:Y%M6M;:1M7FC@BO MK($(077*E3R#7:^+-1VA65"V(E R1CVJAXX:+4?B#X M)T=$,DL=U)>R ,,(B+D$_B*CU9!K'QRT6VVDQZ/827;D-GYW^5(/%GA?X?6]UENX[<>5 M&?*^=CC@GDXHN_\ B:?':QBQNBTC2GE;T$DC8'XX/Z5%X^235OB#X(T38)(! M,;[19M/T32K$:AXBOUS'#G;&BC[SL?08-9FI7' MQ&T+3SK$[Z5J,4 \RXL882I5!][:W<@<_A3/#I-W\7O+B(GS&_V$].G)]#6-K<-W MI/P!T7164K=7OV>U93P0'?=_]:O6].M(]-TJVLXPJQV\*Q@8P.!2 Y#P+XAU MN]UC7- \0-!<7NENH%U FQ)%8<9'K4>I>(O$NN>)KG0_"T,-K%8D?:M0O82R M9/\ "@[UF?#F[9-)\7^+KI-XN=0GE4#J8H@0 /R-.T)/&_C?3(M:E\0KH=E= M9DMK6VME>18\XRSGN13 LV_B+Q1X=\9:1H/B"6TU"UU0.(;N!#&RN 201TQ2 M_%@-J,?AK0$"YU+5H@X/7RT!9OTK+M=*D/QJL;:[UJ[U4V%@]P1, !"Y^48Q M[-5^_P#^)S\>].MF1FAT?36G/<"1S@'\C^E 'I("H@"C"@8 %<]XR\3OX8TJ M.>WL9KV[N)1!!%&I(WGIN/85T7;GTK@]?U[Q!J7C0>%?#4EO9R6\ N;R]N$W M[5/ "KZ\C\Z *EW'\3+33IM8EU71PT4+32:>MJ2, $[0_7.!71Z!XI_M7P#! MXDGA6WWVK7#H#D#:#G'Y5P_C?1-;T'P-J^H7_CG49R("J1%$C5V8[=O'7K4_ MB4?\(O\ L^BS#E9?L$4"E!W<@G]-U &3\-[7QO>>%W;2I;'2;.>YDGCN9X?, M>O2@#.U.?6 M[WXZ72Z!;VTTUEIBQ/-QU;QCX?\;:3I7B*]LM0T_51*D= MQ;V_E&.55+;2/3CK3/A*T5^/$NL,V^ZO-4EWEOO!!]T>PZ\59\5W$=]\4?!N MEPEGN+5Y[V8+_P LX_+*C/U/\Z $\>>--7\/^)-"TG1K6"[N+XL7@;@L.<<] MAD=?K3KK5O$OA6VO?$?BK4;$Z9'!\MA:1([6"2=_B-J<<,:EI&DM8SM4#)Y[5/\,M$L]/T_4=2L/$,FMQZI<> MN"/SJMJOBK5)_ MB-8>%M!6!O*C^TZG-*A81QYX48_B/3\:YG1];M/ 6J_$&.^F1%2Z%];0.=ID M\Q3]W/4$A1D5TOPST.>ST:;7=33_ (G.LR?:KEF&"JG[J>P H L:;XBU/4/B MAK&AKY']DZ=:Q.Q*'>97 .-V<8QG\JHZCXF\0:WXGO?#_AB&"W^Q)_I&H7T3 M%58]-@Z-5+X=7>^#QAXMGC'EW-_*R;.6\J(=/YU#I,?CWQSIXUA/$47AZPG< MR6<%O9K-(8\X!0\3A23E1P M1Q5#XOP>(M3N-'T6PFLEM-0NT2-&R',BC=EL\%1Z5772-27XSZ#I]YXBO-66 MQM9+R4S(JJC$%0,+@<\'G-;NMXU;XT^'K$MNBTNREO74'[KM\JF@!GB/6O%O MA3P)!)=WFFS:Y<7\5M"\4)$(#G &#U. :UO&'BZZT$V6E:7:"^U[4,BWA/RH MN/O2.W9?\#69XU0:Q\1?!NB%=ZP2OJN: "^C^)6D:.VK/J6F7\T$9DGL5MMH(QE@K=M,T@@I?:D8[8*>"#-)NZ?0T ;7A77?'WB_P .6L\::?IJ."6OY(]_ MFCMY,=CQ77Z18Q:7I% MG80HB);P)&%3H !_C7 ?#:XBD?QAXKNV6&&ZU%U$A.0(XAC/ZF@"W=:_K_B M'QE?Z#X>OK;3XM,4?:9IHO,=V8<;1Z#UI-+\1>*=*\=P>'/$*17UK=P&6WO[ M:$H%(!R''0=*?J7A+3_%CP^*_#6LSZ;J$L?RWML?EF R!O4]:=X1\4:V_BFZ M\)>)H;9M1MK<3QW=O]V=,XR1V/>@#O3G'T]*X'QYXNU?1/$&@:3H<,%Q=WTC MF6"3C,8X!SVP>?PKOZ\VL(SJWQYU.Y9BT6CZ9% BD.O" M6FP:_>7NGR6JW,:2Z?#!D[6.,!CWK5U*[\=WNCW&KV4EAH\,<#3);7$?G2, M,_,>@_"HOB4G]K:UX.\/J[$76IBXFC'\4<2ECGVK6^)VJC1OAQK5V'VNUOY2 M'U+G:/\ T+]* )/ GB6Y\1^!+/6]0B\N=T,KZ*.;5O&L]O.R_O(;"W144]L$^G3WH D\'>(M>N/$^L^&O$*VTEWIT:2 MI=0#:)4?I\O8U)X5\2:IJ'CKQ5H6H>68M-DB:U*H%;RW!.#Z]!S6!\*8!<>* MO&.K-?3WQ^U)9I%?C'?:C>SQ16E]HBR-N."\D;[0!ZD MCC\: -[Q/XCO;7Q%HOA[13$VH7DN^=G&X16ZC+$^A/0?6NN%>=?#?3+C4]0U M'QQJBN+S4F:.UB<8$-L&^4 'UQUKT*W@\IHPQP"I[\\?C4T.K>*O M&_B'48=#OHM&T;3Y3;-<-"LLLSCKMST%<[X_\/ZM$_A[2[[Q5?:K)J.I1(;= MXT1=@.2=JC/:@#T/XAZK_9/PYUJ]C8*XM&2//JXVC_T*L@:BWPW^$NELEF;F MYCABA2)3M#2R=R>PW'FJWQA7[;I>@^'HU9FU/5(8RB M'_$UO-X2U"X4RRQB3R8GQ)&!T8>AH Y74=1^)?A_2)-=N_[%OH8T\R>PAC97 M1>^U_P"(UT=YX[TZP\$6WB6>&8+O\0_Q[=*L^,9H=3^)'P_M),"RD,MRD9 VL=@(R/RQ]30 M!>CN_B?>Z>-3BMM!MMR>9'I\_F-)@\@%AT./UK<\!>+CXPT(W5K> MZ@SG9(/Z5TLKK%$[R,JJBEBQX KSOX0;KRT\1ZR"K6^HZO-+;LHP-@.!0!Z M37BS:GJ]S\=-8?0=(AOKBWLH[)I[B;RTM>Y9L DY/8=:]FE=8XG=N%4%B?I7 MG'P:BCN= U36]QDN-2U.>21VZD!L*/P':@":Q\6>)M&\867A[Q5;6$B:B#]C MOK+GI6KXO\9/X>N;+2],TY]3UK4"?LUHKA .KNQZ+Q6'XT*Z MG\4O!.E6Y!GM)9;V;'_+.,+CGTSC%8MQI&M>(_C-K-UI.MII5QID$<0+P";A MEZA6XQU_.@#6U#6?B/X7THZWJT6C7]K&0US;6P9'B0GDACP2,_EDUZ-I][%J M.GVU[ &-*.A^&M-TMKA;@VL"Q>:!@.0.HH V#TKC/ WB>^\37GB"280_8+*_:ULV MC4C>%'S$^O5:Z76;O^S]#U"\'6"VDE'..BDUR7P@L#9?#73)),^=>;[N4GNS ML3G\MM %G5O$NH1?$O1O#5DMLUO/:R75TT@)=57@8QTYJOXF\3:TWBNV\*>& MUMDOY(C(_%^I)XC3PQX:L8KO5?+$L\L[[8K9#T+=R?0=ZSM#\3 M>)M(\86?A7Q;%;3M=1N]IJ5O\HFV\X9?X3C-(/&G@XYQ MS74>,O%UMX0T47CHUS=7#B&SMDY::5ONCZ>M";&\G+6MM;331JV ))E7 )'KP#0!>M7^)7 MV4:E<#2.5#_V6D9W+ZC?ZXK*^$MR^O>(_%WB2>!H9;BZ2V$9.=BH.1GZUZ7? MWL&GZ?<7EU($@AC,DC$]@"3CWKC/A! X\#+?RIM?4KJ:\_X"SD#] * .]/2O M%8QXOU?XV7,D$NF;](@6-\Y9%BD;.!Z/BO:STKSGX9(;W5?&&O$96]U5HHFQ M_!&,#'_?7Z4 97B?5-1D^->FVVE:>+VYL-.E76I-I=UIU]>+;-;VZ,&B+],,>N*L_#N--4\7>,?$>]G66^^Q0Y.0%B'./ MJ=M)XV?^UOB3X,T()O$,SZE,,\80$+G\: -_QCXM_P"$;CM+6TM3>ZK?R&.U MME/4CDL?]D#O6)>'XF6&G/J;7.D7)B0R2:>D)!(')4/W.*BCC^U?'V9[E@5M M-( M0W/S,PW$>_.*[C7=3M]&T"_U&Z8+#;PL[Y[X'3\>E %'PYXFMO$/A&WU MY%\J-X6>1#_ 5^\I^F#5#X=>(=1\4^&FU;4%B3S;B00",$9C4X!/UKBM'^U> M&/V<)[AE(GFM9)D3'*^:QQ^C5Z%X*T\:-X%T>SE9 8;1"[=!DC)/ZT 9Z^(] M1N/BJWAV$1_V?;:=]HN#M.=['"C/;M6==>*M=\3ZW>Z/X/6W@BL9/+N=4NEW MHKXY5%[GI5#P([:KJ_CCQ+;[BTUPUM;/U^6->,?B15WX,+ ?A]%.CB2YGNIY M+E\ $R;CU_ "@#)\7^+?&O@;35AN?L6HS7DBQ6=]''LVOD<.G3\JD^,>H7,/ MA31-*:V%W?W]] )(8_XRAW,!]6P*L_$1K?6O''@WP\K;Y!?&\G1><1QC=SZ= M*-:4:U\=M#L>&CTBQ>\D&TD!F.%_]EH =XFN/B#8:#>:Z-2TK3HK2(S&R2$R M$J.Q<]\8Z5V7A35Y=>\*Z7JLR*DEW;K*RKT&17-?&&_:S^'MU:0D>?J,L=E& M,\DN>?T%=CI%BFF:/96* !;>!(ACI\J@4 6;B9+>VEFD("1J78GT')KRWPAX MK\;>--)N6L8]/M8EN)%CU2:,E2@/ 2,=6'J3BNL^).IG2_AWK=PF[S&MFB3; MUR_R_P!:M^#-)&A^#='T[&##:1J^!C+8R<^^30!S?A?6O$MEXZN_"OB&^M]4 M_P!$^UPWD$ B8#(!5E7@=?Y4_7/%6MZIXLD\+^$4M1=6J![^^NEW);9Z*%_B M-5O!8?5?BCXTUIB3' \>G0D]/DY;]0*3X0M%-:^);QW)O9M:G,ZL?F4<;0>^ M,9P* (=+ M]4U;X?ZEXCU5K8[))S;"-"%,:<+N]FA@=U[. MA(E/8QH.W3DUGZK;3Z#^SYI^DQH$O+Z&"W S@^9*:]1T?3X]+T2RT^)% M1+>!(@%Z<* : .1\#>)-:O?$6N>'=>:WFO-+\MAE>=? M"P+J-UXJ\1@ C4=5=8V_Z9QC 'ZFO13TH \>\=P^*]6^)>AZ;8?V?Y4!:_M/ M-!PNW@E_7GH!5SXIWFHVWP^TW3K_ ,JZU:^NHHI(K=2%F(.XJH//H/K5_1MN MJ_&[Q#>#F6$5FC;L@._S,,>O%'B&'^VOC/X;LLLT6F6LM]*H(*AC\JY'K MG!H C\0:IX\TOPU=:^ITFR@M(O-_L_89&*#&07Z XSTKH[OQC;:9X"MO$]^A M59;:*7R4ZEW"X09]SBL_XLRL?A]>647^OU"6*SC&<'+R#^@-] &O!)\2M7L_[2BETK2E>/?#82QF5SW 9NV1 M6YX)\33^)=.N?MMJ+74;"Y>UNH1T#KW'L:QY?"_BRW$D\OC^9($!:1FLHP$5 M>IZ_K4WPUT2STZSU+4;'Q =;BU2Y\]KDJ!\X!#=* .Y/2N$U[Q+K][XCE\-^ M%;6%;JWA$MS?7BGRHP>@4#[QKN9I%AA>5_N(I8_0WT M71C(4A5(!-+(%R"Q)Z4 +/XB\7^$_$>B67B";3]1LM5N!;">WA,31R'IQGD5 M#\;;V=/#VF:5:VZW,U_J$:^0W_+0+SC'IDBLS4M'U%OBWX4TNZ\0SZJMOOOI M8I8U41E0<'CIGCBMK5?L^J?'31+:4[AINGRS!>WF-QG\!0 W7-3^(>@:5)KS MQ:2UE:H'GTV%262,=2'/7 ]*ZJ?QAIMKX)3Q3.Y2Q:W6?'4G=C"CWR<55^). MJIH_P[UJX;&^2V:"-<9+/)\H'_CU<-XFTV>U\!^ /#UZP6*:[M8;L_P@ <@^ MV3B@#H[*Y^(7B"T74K:73M'MYAN@M[F$R2%3TW8Z<5>\%>+;_7+G5M'U>TBM M-9TR0+((R2DBD?+(/8UV("HNT8"CH!T KSGP3*=7^)/C#7;=0+$^39QRCI(R M#DB@#:\"^);WQ!#K$>HI EWI]_):E8@1\H^Z3GUJ#Q#XLO8?&FD^%]$C@FNY MP;B\:3GR(!W^I[5@6FKVO@[XA^-WOIHXK-[>+4$1F"EWVX('J:T/AEIUQ>0W M_C35$']H:TV^,,.88!]Q?IP#0 _6_&6L7_B>?PQX.MK>:^ME#7UY=$B.WST& M!R358^(/%WA+7M,M_%$VG7^EZE,MN+NVC,1@D;ID>A]37-^!/#_B36%U?6M, M\6C36N[^02Q?9%F8;6P,EB".,<5IZQX3U6_U/2](USX@PS3"X2\@LFLU5I?+ M.<\-[&D!ZUT-<=\4]4&D_#C6)L$N\/DH <BV6YU&9TMXHQD1F5^!DYX&?>L'X@Q?VIXU\$Z%&/E^V-=R*JY M&R,9'\JZ3Q-:>'_%<4_A._NT^U/&)Q#&^)8P#\K@?4T ^,OAC:F;4IT\1^&$*H\TAVW%NI..?[PY'/-:7Q+<:Q%X2T6%!Y6J: MG%(=QQM1 &(Q]#TH U?AQIGBC1]!M]-U\:_I5H]*JWW^J7_>_I0!9HHHH 6BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ]*Q/%&EZCK M6A3Z?IU^MA+.-CSF/>54]<#W&1^-;=% &9H.C6WA_1;32[-0(+:,(IQ@L>[' MW)IVOZ8=9T"_TU616N86B#.FX D=2.]:-% ')Q>"8'^'MOX4U" O$&A7]R/"_B-++3;F8S-;7%N)O*9CD[,\ M=:]%HH X/1/AR=+\:KXFNM8N=0N_LS1.;A1RQQRO]T8SQ6GH_A*33?&NM>(Y MKXW#Z@D<4<13'DHO;-=310!P=UX+UV#QU-XCT77(H$O!''=P7%N'S&AZ*W:M M3_A%'D^(8\4S7I=8[/[+!;>7@("L+$(6 MF"!TE3/1U/6L]?A_J.MW-M<>,M<;4UMI!+'9P1>3!N!X+ =?I7H-% '+>)?" M/_"1ZCHDSWAAM=,N/M#6ZID2D8QSVQBM^_MWO-.N;:.0Q/-$R!Q_#D$9JU10 M!SGA[PG;Z%X07PZ9&G@V.CN1@MO)+']37.Z;X \1Z+'_ &;IGC&>+1QD1Q-; MJTL2GLK5Z+10!Q7AWX?1^'O%MUKT>IW-U)=6_DRB< LQ!!W%NYXK2TKPO_9W MC#6/$$EV\\NHJD:H1Q$B= #71T4 (>AKB?$G@:ZU'Q#'XAT369M+U58Q$[;- MZ2KZ,M=O10!YOK'PON_%.FR1^(O$MY<7A(:)H$$<,9'_ $S'7\:VO%'@E/%6 MD:;I=Y>R+9VKH]PJK@W&T 8]N_YUUU% ' R^!-;BMVTO3?%=U:Z._'DF,-+& MO0HK]ABNBL/#-IHWAAM#TD&VB,3(LG5@6'+GU.>:W** /-],^%T_AK343PUX MANK"_(_TF9HEDCN#SR4/ Z]JWO"W@N+P_KW0 FO+CKMZ[5'\*Y M[5U5% ',>&/"*^'=3UN_:[-U/JESY[,8PNP8X7CK5KQ5X7LO%FD?8+MI8F60 M20SQ'#Q.#D,*W:* /.I_A]XAU>U_LW7_ !I=7FE9 :&&U2%YE'\+N#DC^==U MI^GVNE6$%C90"&VMT$<4:]%45;HH X'7OA?9>(?&D7B"]NLQIY>ZT\D$2!.Q M;TKL[NU,VGS6L#"$O$T:,$R$XQTJW10!S7A?PG'X=\)1Z!)!P!S7.6/P^\3:*HL-#\:2V>D9RL+V:221CGA6;I_GBO2** .'T'X=0^'_ M !A-X@@U2[GEN(/*G6X^.1TQ3=6\$:U/XT;Q%H_B5K!I42*>!K59 M T:GD GIFNZHH YN/PNW_"<-XFFOI99%M/LL5OM 5 2"3^)'ZU5\4>"?[=U* MVUC3M4N=(UBU0QQ7<*!MRGLRG[PKKJ* //U^'5_JU];W'B[Q'/K$5LX>*T2! M8(=P_B8+UK9\2^$$\27^B327C00:9=+=>0D8Q(R].>U=/10!6O;>2YL9X(Y/ M*>6-D$F,E<]_PK$\+>$;3PUX1A\/[OM,05Q+(RX,I2$V=LT$-KM&U2W5LT>-/":^,=)ATR6[>" 7"32A5SY@7^&NEHH Q MO$?AVU\1^'Y])G+Q(P&QXS\T; Y4CWXKFK3P/X@,"V.I>,+RXT]%VA(XPDCC MMN?K^5=]10!R?@WP?:^ ]/O[>&^DEM)I_M :X(!CX ()_K7%>,["P^(/Q(TC M1;-UN%TZ-I=0GC.5C0GA,C^(UZIJ^EVFM:5<:;?1F2UN%VR(&()&<]1]*H^& M_">B^$[1K71K);=&.7;DLWU8\F@#6AB6&-8XTVQH JKZ <5(>E+10!YU/\/] MBH#A/PKT6B@#EM4\*3ZIXTT?7'OE6UTU'VVOE9)=AC.<^E9WBWP#-K6MV_ MB#1=5DTG6[=/+6<)O61?1AGTKNJ* /.;WP-XJ\20+:>)_%$+:<)%>2VTZS\L MS@'.&8G/;L*W?%O@V'Q)IEI#!NIHH \VO/!7C M;7H#I^M^+H$TUCB5;"T\N28>C-VY]*[O2-*M-$TNVTVQA$5K;H$1?IZ^N:O4 M4 4-;LI]2T.^L;:=8)KB%HED9:#LN:KZ_X M,U"X\2IXD\.ZL--U(PB"=9(1)%.G7##KD>M=M10!Y[#X U76M5M=0\::U'J: MV;[[:PMH!% C=F)ZM^->@*,=!@=/2G44 5-4T^+5=*NM/F)$=S$T3$=0",5P M.B^ _%=GIT6C7?BXKHUN-D*6MLJ3%.<*SGZ@5Z310!QO@3P)'X)LM1MEO#=B M]N3,6:/:0-H&#R<]^?>LT?#O4M"O;B?P=KBZ9!=2&2>SG@$L98C&1GGM7HE% M '&:-X+O8?$$2PRD#J5/0UW-% '%:'X$FMM:77O$&JRZSJ\:E8'D0)%;Y_N(.A] MZO>+_""^)XK2:&]EL-3L9#+9WD0RT;$<@CN#73T4 >=:I\/M;\4:-)IWB+Q5 M+*C* %M+98DW#N1W^E=GH.E)H6@V&EQ-N2T@2(-C&[ QG'N:TJ* &N-R,,D9 M&,KU%<-X4\%ZYX6U"[A3Q +C1I3*\=N]N/,61SG);T%=W10!S?@KPP?"7AT: M<]Q]HG::2>6;;C>[L3_A^5-@\*;/'UUXHGNC*7M5M8(-O$0SDG/O7344 VT+9%E:0 M"&*3W?N?I7H=% &'XD\.6WB+PSZ7IM\WF2PVY4QD\@D _<->G2(LD;(RAE88 M(/0CTKBKSX4>$+RZ:X.F- 6;]C6)4";1&B]LYYZ5KZ7I M-CHUHMKIUK';0#G:BXS[GWJ]0!S'BGPBOBB\T>2>[>*WTV[6Z,(0'S67ISVK MI>??FG44 V>,>U9&I?#ZZ&M7>L^&?$5SH M5W>?-=*L"SQRMZ[7Z&N[HH XK0OAZECK$>MZWJ]YKNKQ9\J>Z 6.'/\ SSC' M"GW%2^+_ 9=>(K_ $O4M.UJ72[_ $\MY4JQ"12",'*FNPHH IZ=!-/"S^,/#YTC[?)9Q22H\S(@8NH.=N,BNEHH Y;7 M_"7]ORZ$#>-#::7<+<-!Y>?.VCY03GC'T-=%4KM+LQ))Q^-;9&12T4 <-9>#M:K8 MZ]&--O[@3W=I+;!F;&>%;Z5J:=X7:R\9:KXCFO&GDO84A2'R\"%5[ ]\UTM% M &#K_AW^W=0T::2Y:.'3;K[480,B5@/ES]#S3/%WA6T\7Z+_ &?=22PNKK+# M<1_?B<>3^ _$FKVYT_6_&5Q<:85"O';VZPR2@=F8>O>NVTO2[/1 MM.@T^PA6&UMTV1QJ. /ZFKM% #9$62-D8 JPP0>XKSK2_ 7B7PZTEIH7BA8- M*DE,GDS6H=H@QR0AKT>B@#AM,^'B:9XRA\2?VM>75P+=X9Q<_,7W#J#_ ]. M@J/4/AN-1\57WB)M8NHK^3:+5HN!!M&!]1ZUWM% ' V_@/5-2U2TO/%FN_VJ MEE(7M[6*W$,1/9G ^\PKH?%/AFT\5Z')IEXTD2LPD2:+AXG'*LM;M% ' #PC MXQF@.GW?C+.G[0F^&T"W#*!C!>NH\/>'K#PQH\6EZ;$4@CR26.6=CR68]S6O M10!Y_P",OA?;>,O$UEJMU>M'#;H$D@6,9D&<\MZ$<5W4,$=M!'!#&$BC4(BK MP% Z"IJ* //I_ &L:9KE[J7A/Q$=,COG,ES:S6ZS1EO[R#L:T] \$1Z;KL_B M#5+Q]3UN=!&;AT"K&H_A11T%==10 TC^>:YG5/"DFI^-M(U^2[40:;%($MO* MR6=@1NW9XKJ** .9_P"$7ED\?+XEGO%=(K7[/!;^5S'GJ=V:SO$G@!M5\0)X MCT;5KC2-;CC$0G10Z.OHRGJ*[>B@#SFZ\!^)_$4,=GXI\4QW&G)('>WL;01& M?!SM=B>G X JYXQ\$ZGK.JZ-JVAZLFGW>E!EA2:+S(\$<\>N.*[JB@#E=7T7 MQ+J/AZQM(-?2RU)&0W=U#!_K@,Y '8'-=-&A1$5F+E5"ECWXZU)10 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ! MZ&JU[_JE_P!ZK-5+W_5I]: +5%%% "T444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% $A MJM>_ZH?[U %BBBB@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "JUY]Q?K5D]*K7G^J'^]_2@"Q1110 M%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% >E5KS_ %8_WOZ59JO= M_P"K7ZT 3T444 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 'I5:\_U0_P![^E63TJM>?ZH?[W]* +%%%% "T444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 !Z56O/]4/\ >_I5 MD]*K7G^J'^]_2@"Q1110 M%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%&1G&:* "BBB@ MHHHH **** "BBB@ HHHH **** "BBC- !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 449HH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **,CUHS0 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%)D9QF@!:*** "BBB@ H MHHH **** "BBB@ HHHH **** "BDR/6EH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** ]#5:]_U0_P![^E63TJM>?ZH? M[W]* +%%%% "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 &BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH *BN+B&UMY+BXE6.&,;G=C@*/GYTU_'?A6 M-"SZ_IX ]9A_C7/>'_A1X.AT2P\_08)+DP(9))"Q9F*@G//J:T)/A3X&D7YO M#EKGU!;_ !H ZVVN8;NWCN+>1989%W(Z'(8>HJ:J]K:P6%G%:VZ"*"%0B(.@ M %]=#!*EQ#'-&28W4.I(QD$>] #;V[@L+*:[NI1%!"I>1SG M"@=^*KZ3JUAKFGQ:AIMRES:R9V2J#@XX.,U-J%JM]IUU:. 5GB:,@^XQ_6O/ M?@C<@^"[C3F;]Y87\T!3^Z-V1_.@#TH]*Q[GQ-H]KKD.C37T8U*9=Z6RY+%? M7';I5[4]0MM+TNZO[IPL%O$TDASV KS3X7V4_B/6-3\?ZG %EOG,5@I_Y9PC MCCZ_XT >J@\]:6N5U[XA^%O#=T;74]6CCN5&3 @+N!]!2Z#\1/"_B2[6TTW5 M(WN6&5A<%'(^AH Z@\#-9.B>)M)\1&Z_LN[6X%K*8I2H(VL.HJ;7KY--\/:C M>NX18+:23=Z84FN*^"EA]D^'5M=NH,M_+)C9HK%TCQ3I&NWU M[9Z=<^=+9/LGPI 5O3)[U9UO6[#P_I=0\;,"N0>G!KG]>^(WA?PY(T-_J:&=3AH85,C@^F!0!U= M%E>&[:.YU>\CM8)' M\M6<'EJUCP#7E/Q41-:\7>#O#+HKI<7;7$H(R"J\"8\;O$%J, M\=&_PJ:T^)?@V_N!;VWB"T>4]%)(S^8JZO@SPR,@:#IY'O IJIJO@+PI=:5/ M#+H]E GEMF6.((R#'7<* .FBECFB66*1'C89#(<@CV-29KS3X'SR3> &4RM) M!%>S1V[,%6V:KJ<<<^,B!,LY_ 4 =-17)^'?B-X8\3 M7GV33[_%T1N$,Z&-B/8-UKJSR./YT +17'Z[\3?"?AZ[DM+S4U>ZC_UD-NID M93Z$#I5SPUXYT#Q8Q32[S?,HW-#(NQP/H>: .DHJM>W]II]G)=WES%!;QC<\ MDCA5 ^M<(_QI\%I*0M]/(BL%::*W)0$^IH ]$/2LC7?$6E>&[2.YU6Z2".20 M1QY4L6;T ')JYI^HV>K6$=[87,5Q;2C*21,"#6#XFU'PPVKZ5HFN6Z75Y=R@ MV<#P&3YNF[T 'K0!TL,JS1I(F2K*",Y!Y]JDK$F\3Z3:^)+;P]+,RZC/"988 MO+;!4>C=.U;1.1Q0 M&16%8>*](U+7[O1+.=IKRTYG"QML0^A;&,^U5/$7C_ M ,->%YS;ZEJ(%UMW?9XE:20#U(7I^- '445RGA_XB>&/$MV+6PU$"Z896">- MHG;Z;OO?A75$\4 +FH;NZALK.:ZN)!'#"A=W/\*@9)KEO$'Q*\+^&KUK'4-0 M)NE78XD!9V M^@%8=C\7/#5W>0VTXO[!ICB.2]MC$C'ZYQ0!WU%,4AE!!!!Z$=#[URI^(WAE M7U-9=0$8TU]DYD!'SYQM4=2<]A0!UM)D>HKE/"GC[2_%TUY'96U_"MH TDEW M!Y:X/0@DGWZXK-U'XM^&+/49;"W-[J-S%G>MA;F8#\//F6MPFR5/J/\*D\?ZD-*\!ZS=[U4BV9% M)YP6^7^N?PH G\*^*=/\7Z6=3TL7'V7S#&&FBV%B.N/;FMW(QGM7CO@SQWX7 M\(>!='TV*6>_N_*\RXBL(C*R,W)+\@#MQFN]\)^-]#\902R:1<.9(3B6&9"L MB?4&@#I:*P/$7B_2_"\VGQZFTJ"_G$$3I&64,>F3VK='\^M #LT5S][XPTJP M\3V?AV1IGU*[0ND<41;:OJQ'3@'K6\.O- #J*IZGJECH]A+>ZC=16UM$,O)( M< 5P_P#PN?PDS94ZDT//[\63[#[YQTZ?F* /0\C&B:]IGB*P6_TJ[2X M@;@LIY4^A'8_6HM?\3Z-X8M!]M$F;$GS=/SKO05(R"",=NGUH QO^$KTK_A+?^$8$KG4Q M#YQ0(2JKC/+=J76/%6EZ%J>G:??2R"[U!_+MTCC+%C7"^ @-7^+'C76RRR10 M.EE$>N,=<'\*DUH_VS\>=#L=N8]*L7NG.,X9NG]* /4!U(I:0=:6@ HH-9&N M^)-)\-6OVG5+N.W0_=!Y9OH.] &O17 1_&/P@TH1[FZ@4\"6:V9$_P"^CQ7< MV]Q#=6Z7%O*LD4BAD=3D$4 39HKF]?\ '&@>&IOL^H7P%UMWBWB!>3'KM%9N MF_%3POJ>H06"W%S;W,P!1+FV:/.>G)% ';45&[I$C2.P15&6). !ZUPU[\7_ M ?97;VZ7D]TR-AFMH'D53WYQB@#O&Z5C^(?$NE>%[%;W59S#"[[%VJ6);TX MJ#PUXRT/Q;!)+HUXLOEG]Y&RE'7W(/-5O$VL>&HM3TO1-=+F".>/\ U14U5;J[M=-LWGNI8[>VA7+.Y"JHKB MX_B]X-EN%1-1D,;ML$Y@81_GU_'I0!WV1ZT5@MXMT5?$-KH0NQ)J%S%YT<<: MEALZ@DCBGZ]XHTKPT;/^U)WA%Y.((B(RX+GH#CI0!MYHS7$Z_P#%3PCX;N/L M]YJ@DFW8:.V0R%?KBN@T#Q#I7B;3Q?Z1>)=6Y."RY!4^A4\@T :U%%(2,4 + M17&:I\4O"&D7;VMQJZR31G:Z0(TNT^A*@C-:/A[QMX>\43/#I6HQS3H-SPD% M74>X/6@#HJ3(]:K:AJ%KI>GSWUY*(K:!"\CGHJCO6'=^/O#5CH4.LS:I$+29 M/,BQG?(.GRKU- '345B>'_%6B^)X'FTB]2X6/&]<%67/J#S6E?ZA9Z99R7=] MWBQWM\<6\.TEG_*L.Q^*7A#4KU+ M.WU50\K^7&\B%49O9CP:YF8KKO[1$";!)#HUADG^Y(P)Q^HH ]8''7&:"0 < MT8_.LS7-?TSPYIS7^JW2V]LIQO/\J +,6I6DVH26,=PCW,2AY(U.2H/3/I5O M(KQ3X2^*=!BGU:XO-30:IK&IL8XW!#.I^YCVP:]6N=>TRSU>#2[F[2.\FC:9 M(V/\ ZMGTZT :M&,O#]Q837RZI MM!)Y3O(VWYO09ZFJ>C?$;PMKVH_8;+4 MU^TEBJI*I3>?]G/6@#JZ,BD9@JEB0 .22>E<=J7Q2\(:9=-;RZM')(OW_(!D M"_4CB@#LJKWM[;Z?937EW*L5O"A>1V. H'6L_0O$^B^)8&FT?48+M4^^(VY7 MZBO,?C!X[T.X\,OH=IJJOSUW2X-2L)#);3C(18\C C:H[GTH M9'K17/W/C7PY9Z/#JESJ]K%:3#,;N^"_..%ZG\ MJ?H7B[0?$I<:/J<5TR#+HN591[@@&@#<8@*22,#KFH+2\M[Z!9[:9)8B2%=# MD''!P:X3XL^*+/2_"&HZ6FH+#JUU"%@C5L/@L,GCGIFM'X?ZUX?GT*QT;2+^ M*>>ULXWFCC))7<,DG\2: .RHK"USQ?X?\-D#5]6MK5B,B-VR_P"0R?TJ+0_& M_AOQ&RKI>KVT\AZ1EMKGZ*<&@#HJ*** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH #T-5KW_5+ M_O59/0U6O?\ 5+_O4 6**** %HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $/2O'OC?=32W'AK2; M.U:\NY+HSBU49,H4PD;^OS#\J )G\>^. M0B&+X=79R.09!P>F *GT_P :^-[[4;6UF\!S6L4L@66:63Y8U[FO2<8/>@CO M0!YM\4-9U&2XTSP?HTX@OM;1^T5I+WN]8)=*=+4R'*F3+9V^AQ7J9X#'./4T >0?8 M8O ?QHTBTTB/R]-URW=)+1>%B*Y.1[9QQ4OQI,NI2>'?#UJ[BZO;O(V]0HXR M/I3;6?\ X33X[B\MV2;2_#EL8U<'(:9@==7*!Y)6 ZYQP/I74HH4!5&% P!C&* M4#FEH 0]#@X->5_#>9=.^)/CK0QPOVE;N,#T.<_^A"O5"<#->0:_J4'@SXUR M:Q=D):7NC.2!QO:/)Q]3M% %WXG:A-X@U73O &ENWG7T@:^D7_EC .3GW(S7 MH"Z6;/P^-,TQUMC';^5"^S(0XP#CBN$^%&CW-TM_XTU6,#4M7D+1@C&R'MCT MS_(5;^+NLWNE^%X+>QN3;/J%PMLUPN0R!NI!^F: &>'O#'A?P?'(^N:EIUYK M$[$SW=X4W$^@#9P*Y/XCW?AN[\3>%I/#4]E)K0U&,.UD1N:+WV]17::5\(_! MUE:1_:-,CU&YP"]S=LTC.<=>3BN0N]/T6[^.6@:5HUA;00:7&\TS0 %QR!Q MZ8_6@#L/C#?M8_#748X_OWA2T7/^V<'],UO:+;1^&O UG % 6QL 6!X^94R? MUS7%?%C&J^(/!?AWS"HN]1\Z50.JICK^9K?^*NH'3OAKK#CAY8A GL6./Y9H M Q?@E:N_AF_UN9-LNK7TEP1C^'.!^N:3XXW1_P"$0L](C;;/JE]' GYUUG@7 M3DT7P'HUD7RL5HC%B>.?F/\ .N"\0ZG!XJ^-OAO0[9UEATG?=3G.5+ 9X_(4 M =#\1/$7_"!?#D+:.JW1C6TM>@P=N"?P )K,\!:?X.T#1H[VYU;3;K5+I1/< M7,TRDY.#W/';]:C^-D$$D'AF2]C9[!-347('3:1CGVKI%^&7@::%73P[8/&R MY5E4X(/(P.?I7E< M%GX!'CL>&-.\*P2W<*"22YA'RP]^3G.:]448X]* %/(Q7B/B.[U^_P#CFTWA MNQM[^?2;)4*3/M5-_7GL>:]N;I7EGPE']I:_XR\0N,M=ZB8D/HJYX_44 -O/ M%/Q3T^WDFN/"%C+&$))@N"Y7WP*R[*Y\??%/1 RW%CHNCS$I(8COE;'52.U> MTMRIKRBS+^!_C-+IXWKH_B*/S8LGY8IQU ';)S_WU0!OZO+8_"[X93?8L*MG M#LAW#_62MP"?Q.:YGX

    $]-TV/7=9UFPNM>OU\RXFN95)B)_@4$\8K6^-\7 MF^ 4WH7MUOX#.%Z[,G/ZXK4L?A[X%N].MY8/#]A-"\2E79-Q(P.I]: ..^*^ MH>&9]!M-=TK4+ ZO97D302V\BE\9^8': 8I; [-1U7RX+ M%+;PC:75Y=+OF,,8(A7U:CXJI!I^H^"[J:$ M+IUIJ $G94& #V[8H ZCP?X(T_POI<0,*SZE(H>[NY!NDED/)Y],YK,\0^ M[B\\=Z'XET22WLY+9V^V94_ODXP,#OC<*[W>&3>C KC((/!%<=X?\>#Q#XTU M;1;.P,EGIV5>^5P49ACY1B@#A_'.I:?XJ^)EGX:U34X[/0M/'G78>0(LT@Z* M3QCJ!^-=U%KW@"TTQ=.CU+0X[,*$\D2QE0.GK^M<7H'A_P /:M\6/&%GX@L( M+N]DE6:W6XYS'ST'?^'\JZW6O!OP_P!$TBYU._\ #NE1V\$99F,(&?0?4]* M.=^$MW:VWBCQ9HFE2QR:1#.)[1HWW* W7'MFI$?^W?VAG93NAT73R&##A7;C M^M;_ ,.4T*\T4:]H_AN/14N@5Q@*TB \-QVK ^%.S5O%'C/Q)L.+N^\F)CW1 M<\?RH L>/K9K7XF^ ]70_>NWLG '4-T_K73>//%(\*>&Y;N$"2^F/D6@!^FV?\ PJSX67VL7B[M$-.LH];UGQ!IUQXAU(":=[RX0/%D_="D_**V?C=#)-\.I2L+S1QW4+S(N> M4#<_ADBM+3_ '@74M+MKF#P_ITL,L09'V;N"/[W?O0!QWQ8UKPM<:1::QI>K M:8^MV5U')$]O,C28SA@VTYQCUKL?&_BV30_AO)K%L"UW=0HEL$[22 8(^F2? MPKGM4T_P!8>,[#PS;>#K.]N[D$RM;QIBV7U!?!=GX=T2*2XA$^JW2^;>74PW2.Y'(R>@YZ5P_QG\*Z?+>: M%;_!.V=O"NH:O)G?J=_+/N/<9X/\Z M.C\;_P!FZ3\/-9:6VC%I%:.H15 )&U<>^2*S_AENTGX2:5/>+CRK5IV'?;D ML.O?%9WQMNL^"X-(0GS=4O8K= ._S!B/TKI?$>E2#X=7^E66/,CTYHH@,@': MF,<>N* /+? ?B/PI>*O%6L6PU6>>06T-TV?(BSC@=*ZCQOXP\">(_!FK M6?\ ;-E<2BVM>!--G_ +'TV>[@3RKD2P*SI("< M@[@34WBZ?P?X9NK2QMO"NF:CJEVX1;**"-6VD\L?E- &Y\/=5EO/AII6H7KA MF6V.]AW"$C)]\+7!?"#PM:ZU)J7B[4[8!L(4GY@OXUV?CJ6W\-_ M"K5_L<"6"BU*)';X 1I#MP,<=6K2^'VFC2/ &AVFS:5M$=@1R"PW'/OS0!RG MQI\0R:1X/KC\:F\*^*/AIX2T6'3M,U[3T11E MY"2&D;NQ/7M5+XGQ6$'Q!\&W^LV\0S#,8=L8W \?Y]J[D^$_"8@\T M^'M%$0&[>;.+:!ZYVT >8ZMXG\.7OQ@\)ZGX=U"WFN)WDM+QX5X96P!D]_O' M\JW/CC#K:ZN$CM;0^?(&8X5F8@$XZ=.] 'HWA7PQI_ MA318+"QMXHR$!ED4"T:ZFFCCMU3>TC-\H7US7EO@R3_A,_BMJOB^.-AIEE!]BLI&Z2'H6'MU MY'K0!>^-\"CP/!J&/GL+Z"92!T&[!_G7:W^O6NE^%Y==O6VV\-L)W./;.![D MX'XUF_$?3O[4^'6NVH3&-.^UQV5I;I+JS MLN-Q0 8SW!(_,T =E\+=(N-2FOO'6KQL+_5V_<1L.(8!PH'ID ?Y->FFHK>" M.U@BMX4"11*$10. ./TJ4]* /.?C'IVHZCX4MC8V3W\5M=QSW5J@RTD8]!W MJSX7^)?A/Q'&NG+*EA=8"-87:"/!Q]T<8/2K&G>/!=_$O4?"5S:"U^S1>9!+ M(YS.?ES@=,+O GA[Q/93/J5K%#,J$_;$ 1TQSDL.N/>@"/PWX'L/". ML:SJEG=2"VU ^8;0*%CBQR2M>9^&M:\,^)O&^I^)O%NIP1/;2[-/M+J4*B(. M-P!/-=/\*KZ_U?X6W]O--+.T+W%M;3RMS(@7Y>:SOA%X<\)ZUX)BCO-'LI]3 MM)9([D3(&D5MQZYYQC% &]XR\8^"-7\&ZM8MK6FW#M:2>5&LH)#[?DQZ'.*O M?#[7&F^%.GZI"S=G8^B9ZG\*I>+X/!?@^RBE/AFQNKVX=8+>SAB022DG M''%6/B+):>'/A-JT5M!'9));^1'$A"A6D.,?J: *GP3ML>!I-2DC"S:E>S7# MM_>!; _K5;X?L=9^*7C77R^Z.*5=/B![!>N/Q7]:ZOPU;IX:^'-A%)\HL]/$ MDG;!";C^N:Y_X)VK)X&;495Q-J5Y-<%CU8%L _SH ](HIJR1NS*KJS+PP!R1 M]:=0 AX!K@M:\/>'X?&J^(?$6LP.%C"6]G=LH2,_WADY/Y5W%W*\%E/-&F]X MXV95_O$#(%>1?#;POHWC'3;GQ/XBA74M4N;F0NEPVY8%!X4+T'>@#HO$GC3P M%=>'M0LY]4TRX#6[@0+ALX!(&!TZ4?!>*6+X7Z6TISYAD9.2?EWD#^59'Q9/ MAWPWX(NM/LK#3K?4+[;!"D<2JX!(W'@9QC-=))J"^!/A5!>06IN18643&)3C M).,G\R30!P:ZP/ WQ4UJ_P#%.F2FVU!U^QZBL6]8U]-W:NZUW3-"^)_AM$L= M5C^619(;RW 9XR#SUZ>E;&A:E9>,/"UI?20P30W40:2$X<*3U!KRWQGX=T_P M!XP\.ZKX7,EI<7EX()+&%OD=3U.WMUH ]!\5Z-J+?#.^T?3)I+B^6R\J-FP' MD('/XD5R'PY\?^&=/T:T\.ZC"NAZG HBD@N(O+5W_O9QW]ZZ;Q%\0(_#OCK1 M_#US:J(=0&?M32;0G4 >_3]16SKOA#0/$L$B:IIMO.SKM\W9AQZ$,.: ,JW\ M":"VP(YB1U..#UKG;D#7?VB+9"%DBT73=WKMD8]?_'Q^ M51_"=9M*\4^)_#<%[)>:382J+>1FW!2>2N?4#^52?#$_VIX\\:Z]N4QR7(MX MBH[*3D9_ 4 )XF:7QU\2XO"'G.NBZ?"+J_2/CS6_A5O;.*]$.A:6=)_LS^SK M;["$*"W$2[ ,=AZUYSH=Q;Z%\>O$5M?LD,FJVT,\'CVKT/Q# MK^G^&])FO[^YBB5%)178 R-V51W))'3UH \H^%_AN/3/BMXI$9WV^F_Z/"[' M)4,<[?P&:O?$C3V\7_$SPSX569UMX8WO+D*> ,X'X_*1^-:?P8@DF\/ZIKMP M#]HU?4)+AP3G [#/UW56\'@ZY\:O%VLN=\6GK'80G^[Q\WZAOSH [[3]"TG1 M-.:WM+&WAMPF)#L +KW+''/XUY_\#Q'+8>(KRWBV6EQJDC0X7"X]OPQ7:^.] M9CT+P/K&H.5_=V[* 3C+-\H_4UE_"723I'PUTB%D*231FXD&, ME9/B+3KK5]#NK&TU%M/DF4J;A%#%!WP,CMD5JGD5YA\5;BYO=4\,^'#=O9Z= MJ=T1=SH^QB%QA,]LY.: -'PY:^!_!.EQV']JZ0;D9^T7,TT?F2OW+$DFN0U. M[T'4/C7X5F\+R6LDQWO>36APK)@CYL<-7>V7PR\%:9"H3P_8MY:\RW$8D)[Y M);(KB_"*Z1K'QPU>]T:WMHK+2[(0)]G4*K.3@D <>OY4 =%\9]1EL?AS=0V[ M'SKZ9+5 #@MN.@K#^(ZC6_B M%X,\/F,R0K<-=W '8+P,_D:]-NKA+2RFN9#B.*-I&/H ,T >5_#Z.%_B]XVF ML(%2Q3RXB4X7S >>/P-+?1I\1OB?/I%PTDFA:"H,\(;"SS'H#Z@'^56/@?;O M-X7U#6YA^^U2^DFYZE02!^NZD^%H2Q\8>.=/EPMT=1\X*3DLASR#W'- '=W7 MAG1KS3GL)-,MA;L-N(X@I'H01R#[UY=\$='^R^(O%ETT[S&WNC8K([;B55B? MO'D]!7J7B/7[+PUH=UJ=[,J1PQLR@GEF X ' MO (KB=3T9/'WQRO+=I)4L=*A6.=D;!)P/E^A)Q7LMI;QZ;ID%OO_ '=M"J;C MZ*,?R%><_!R(WR>(?$4J@R7^HR*C^J*?_KC\J .]MM$TZPMHXK"QMK9HE(A9 M8AE#C&?7-<=X<\*:!X6O+V[US5[*_P!9NYF>2XO'0,H)Z $\=?UJ_P#%37+O M0O %[<6,ABN)2L"R@ F/><%N?Y]LU1\/?"GPG#IEKH>)M170_!VIW[N1 M]EM'(;ON"D _GBO+?%&FZ#??%?PGX>T>QLD%HS7=UY"@8 Y"G'^Z3^-=-\:] M0-OX!?3XV_?:G=0V@ Z\L&/Z"@#,^$W@2R'A:RUC5;=)KBZ7SHXF)*1@G(./ M4CFE^)4-E'XW\$6UI;QQWDE\7/E*%)0 <''7G^5>FZ58KINCVEC$ %MX$B7' M3Y5 KS/!U_\ :+S@2VVBZ?G/4)(W]?FH [CQQ!?W7@C6(-+W&^:V<1!>I/H/ MPK@/AEXI\%0Z!9Z)<0VNFZK&@CN(+J'8TDG2.?R'YU:\1^!/#?BJ,C5=,BDDZ><@V2#'HPH SK/X?VFF^/1XGT MNZ%G!)!LGLX8QLE./O9_&N7\4:7I^I?&[PWI<=I;A(+>2\ND$ "R=<%O7I4_ MPIEN],\2>)/"AOI+_3]-D4V\\AW,,]5)_I[5-X4)UKXU^*]68!XM/ACLH7Z@ M'J'"_".D1Q M?VCI-S=2Y>:]FFC+S-SDY)]S6)\6K*TN/&?@S^UXC)I,MPT$JMG:6)7&<5U! M^%G@5R7'ANSY]"P'Z'VH Y'5;O1-(^,GAV_T&\M'?5 ;2\AM95*G)^5B%.,\ M_I72_#I/P]NQ&@DEO)$M44GKN/./P%9'AVP^'VH>-;K2=&\,(+C27$C7R M*-BN",8;=D\^E+\3Q_:WC/P5X> ;RYKLW4VWNB8_^O0!J_#_ .'>E^'-'@FN MK5;K4IHP99;A0YC!YV+D<#FNZA@BMXUBAC6.-!A548 IX["G4 9OB#4(M*\. MZC?RG"06[N?P''ZUQGP6TQK#X=6LTT6V:[DDN&SR2"2!_+]:D^,MX\'PXN[> M/:'OI8[8%C@#<<_TKK=!L4TGPYIUBI4+;6T<9(Z<*,G^= ''_$MXK[5/"FA. M=XO-321XUZE$(.3[ U/\7=3>P^'=['"4\Z]:.UC#'CYV&?TKFTU*V\8?'NR: MR=+BRT.UD#2(+/!7A[)8RWQNI0/[B#J?UH U?!/ MPYTO1=(L9M1A_M#4Q$"9;OY_*R,[4!^Z*P[6RLXOVARFFVT4"0:66N?(&U2Y M/&0*]8XZ8KRKX8 ZMXT\9>)7 "O=FSBQS\J$YY_ 4 )\7-/L-1U;POI?V*WD MU"_OT4RLGS"-.2,]<S9#;21*T6PY&W'&*\S^,FI_VA;Z;X+T] MQ)J&J7*>8BG_ %42\DGZ\?D: /2M(O#J&D65X0 ;B!)2!V+ ''ZU=JKI]J++ M3[6U'_+&%(_^^1BK5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 !Z&JU[_ *I?]ZK)Z&JM]_J5 M_P![^E %FBBB@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@!#G''6N2\*^#IM!\0:YK%U?"[FU2 M;S!B/;Y:_P!WK]*ZZB@ H/2BB@#E?&?@:Q\96L/FS36M]:MNM;R'[\1R#^(X MKGKCP-XXU"W6QO\ QZWV';LD$%BJR.OH6S^M>ET4 87ACPKI7A'25T[2;;RD M'WW/+2'U8]ZS_#?@Z31/$VM:W^L+FZNY8#: C"(#O!(R">U=M10!#;6\=I:Q6T*;8HE"*H' M0#BLOQ1X:L/%F@S:3J*.T,F"&3&Y&'1A6U10!YG!\-/$$4*V+^/M4?3 -IA$ M*ABO3&[K5_1_A;I7A_Q?!KVEW$\/EQ-&]NWS"3<.6)ZYKO:* .4O/!:7WC^Q M\43WTC?8H#%#:;!M4G.6SUSS6IXE\/6?BG0KC2;XN()Q@E#@@CH16O10!YMI M_P ++VV@6PN_&.KW&D)A5LDQ&"H_A+#DBM?1/AWINA^,;KQ#;2ONFA\F.W" M)$O'0]2>.IKLJ* ,W7="T_Q%I,^FZG;B>VF^\IZ@]B/>N&'PKOX(!96/C;6+ M731P+90#@>F[K7I=% '/>%?!FD^$+62+3HG,LIW37$K;I)#[FNAHHH AO(3< MV,R(5WIU7(ZBL+P7X1MO!>A#2K:>2X7S6E:60 ,S-US^5='10 'I7+> M,O!5KXQM[*.:ZN;.>SF$T-S;G#J>A'XUU-% %*ZTZWU#37L+Z);B"2/RY$D& M0X[Y]ZX6/X5S:<)8-"\6:OIFGR'_ (\T(=4_W2>17H]% '+^%O NC^$_-ELT MEFO)^)KNX;?(_P"/85K:WH=AXATF?3=2@$UO,,$'J#V(/8BM*B@#S1/A3=Q6 MW]GQ>,]:72<8%J7!('H&ZXKL?#?A?2O"FEKI^E6_E1?>=FY=SZL>YK:HH Y' MQ)\/-'\2:E%JKMJQ+MCO+1]CCZ^M8L?PD@O;J*?Q)XAU;7%B(*17$FV/C ML5'7]*](HH K-9QBQ>TA_<1^7Y:", ;!C'%8_@[PE:>#-"_LJRFFFC,K2M), M2TLGWI&/5F]ZVZ* *U_8VVI6,UG>0B:"9=KH>A%>>#X1M8(]OH/B[7-+ MT^0DM:1R!E&>H4\$?K7IE% '*^$O .B^#4E;3TFFNYO]==W3[Y9/J>!^E;6L MZ-8Z_I4^FZE )K688=3D?B"*T** /-+?X2-;Q_85\6:VNC X%@DH5=O]W<.< M=NU;&@_#C1_#?B-M7T]IXQY11;IR><]:[.B@#SWQWIEOKWBKPQ9)>3" MZM[KSY;:%R!Y0P2SXZ#Y0!GU-=7KNOVWA^S2YN+:]G1W"!;2W:5AGN0.@]ZN M1V%K%>RWD=K&ES* KS!0&<#H"?2K)&>O_P"J@#CF^)WAJW.V\EN[-_[D]G(K M$?3%1GXM>#=Q5=3D9AV%M)G_ -!KLI+>&4@RPQR'IED!--%I;H7#9[+: MR$_RKL#9VQZV\7_? _PI1;0CI#'_ -\B@#C%^+?A)A_Q]70^MI(/Z5*/BGX5 M)(^UW'';[+)_A77FVA(P8D(_W11]FA!SY29_W10!QQ^*WA,'!N[@'_KUD_PI M@^+7A(G NKG_ ,!9/\*[3R(O^>4?_?(H\B/_ )YI_P!\T <6?BWX24\W5U_X M"R?X4H^+7A)NEU=?^ DG^%=F+>('/DQY_P!T4OE1_P#/-?RH XP?%CPJ>%N+ ML_2SD_PIG_"W/"GF%?-OL_\ 7E+_ (5VXC0=$4?A2A0#G:/KB@#B#\6O"H&3 M+?8_Z\I?\*:/B]X2()^T7F!_TY2?X5W6*-H':@#A&^,'A!5+&YO,#_ISD_PI MR_%SPBT7F?:[D#OFUDS_ "KN,#T'Y4;%_NB@#A$^,/@]SM6ZN\_]>LY1_[+ M43_&3P;&V/MEV3[6,O\ \37?%0>U&T'L/RH X3_A;WA#9/\ TYR?X5V8C0'. MQ<_2CRDSG8N?I0!Q1^*_A99-C2WP/8FSDQ_*GO\ %3PM&,O<78'_ %Z2?X5V M1C5N2JG\*/+7^ZI_"@#C$^*WA23E;FZX];23_"F?\+;\)Y(^TW?'I:2?X5VW ME)@C8OY4T6\0Z1)_WR* .+'Q:\)D\7%Y_P" $5;:;B\S_UYR?X5 MW'DQ_P#/-?RH\J/_ )YK^5 '%CXL^$CC_3+CG_IUD_PH/Q8\)CDW=QQ_TZR? MX5VGDQ_\\U_*CR(O^>:?]\T <2OQ;\'NI*W\Q Z_Z/)Q^E))\7_!,+A)-693 M[V\G^%=MY,?_ #R3\%I&MX7^]#&?J@H X^/XL^!Y!E= R MVT>(82?:&3_XFNO^QVX&!!$/^ "F_8+3_GU@_P"_8_PH Y7_ (6OX'"[O[?A M _ZXR?\ Q--_X6WX%_Z&&'_OU)_\376_8+3&/LL&/^N:_P"%)_9]G_SZ0?\ M?I?\* .27XN> WZ>(H/QBD_^)I3\6O J\?\ "0P?A%)_\375_P!G67_/G;_] M^E_PH_L^R XLX/\ OTO^% '*CXL>!6&5\16Q _V'_P#B:C_X6_X"_P"ACM_^ M_4G_ ,376-IEBW+65LWUB7_"@:7IX4A;&V /;RE_PH Y4_%SP&!D^)+8C_KG M)_\ $T+\7/ ;\+XCMC[>7)_\376?V;98 ^QV^!V\I!PB;'80R?_ !-.7XL>"64L-:7 Z_N) M/_B:ZS^S[(\& M;2?[2DW?W?LLF?\ T&D'Q>\'E@OV^<$^MK(/Z5V8LK4'/V:'/KY8_P *7[+! MG)@B_P"^!_A0!Q@^+G@YI"GVZXR._P!EEQ_*E/Q:\'ABOVZX('4BUE_PKLQ; M0@G$$>?]T?X4?9X?^>$?/^R/\* .,'Q;\'$9%_/UQS:R?X5))\5?"41&Z_F. M>F+:3_"NO^RP8QY$7'^R/\*#;0MPT$9'NH_PH X\?%;PB3Q?R_\ @._^%"?% M;P@[8_M"51W9K=\#]*Z_[%:_\^\7_?L?X4?8K7!'V>'!_P"F8_PH Y%_BOX+ M1BIUI3CN(G_^)IT?Q3\'RH735@5'?R7_ ,*ZK^S[/_GSM_\ OV/\*46-H!@6 ML 'H(Q_A0!R/_"U_"&]4_M-@6/\ SP?'\JV?#GBW1_%23R:3<-,L#[)"R,O/ MMFM4V-I_SZP?]^Q_A4D<4<(Q&BJ">=JXS^5 %;5].35](NM.DEEBCN8S&SQ' M# 'KBJWA[0[;PWH%GI%GO,%M&50R=3SGG\ZUJ* .G^'],33],M5 MMK=!PB@\^Y).2?QK'D\ :+<>*+_7KM)KN>]@^SR13ONB"8 ("X&.G.O:N[TO2;'1=/BL-.MDMK6(8 M2*,<#WJ]377>A4YP1CB@#F?'WB*T\->#M0N[DQEY(7A@A8$^=(PP%X]<_ES6 M/\)?"/\ PC7A6&>Y1?[2OE669@.BXRJ>@QGM3-,^#_A^RU<:E=SZAJ4JR&2- M+R;@@8/'\J '4&BB@#E_%?@'0_&"I)?Q217D0Q%>6[;)8_P > M]*?$%_:# ^SR76$;GOUR/;BO2J* *>FZ99Z1I\-CI]LEO:PC M:D:C@"N1UGX8:7J&LOK&FWM]HNHR?ZR:PDV;_5/^R.W6M;Q7X4L_%^GPV-_).EO%.LQ6(XWE>S>V:Z"B@#,U MO1XM;T*ZTF622&&YB,3-$<, ?2DT?3++PSX?MM.@;R[.RBVAY3T4)M5M+B>>ROKX?9WE*UAC@@B6*&-=J(HP% [ #M4U "'H<5Y[QBU>;4=$U?4 MM&DG8M*EG)A6)] >G?\ .O0Z* //;GX0>'KO3GAN'NY[UW#M?S2;Y<]>IZ"N MX2QA&FI8RJ)H5B$3"09W #'-6J* /.)/A%96MXT^@:[K.AJ^2\5I-\F3Z ]* MU-#^'.FZ5J2:I>7=[J^HQ_ZNYOY=Y3W4= :[.B@#$\1^%M(\56 LM7M!-&K; MHV!PT;>JDE>&=,DLM M*A: R#][.#F21L8W$GJ:@\'>#K3P7I6^U7 M5I]MO9R:A$..H'_P"N@#<\':0^B>#]+TQS^\A@ ,/"L/C'0'TBXNI MK>%W5V:/J<'('TK;M;=+6VAMX@1'$@1 ?0# J:B@ K \5^$]/\7:2;&^#*RG M=%,G#Q-GJ#6_10!YK;_"BX98K?5O&6MZEIZ8'V1Y-BD#L3G)%;?AGX?Z9X2U MW4-2TMI$CO(PAMNJIC!X/US^==?10!RH\&1M\0!XLFOYGE2#R([8( B@C&<] MSUK;UK3O[7T.^TWSC#]J@>'S N2H88SC\:OT4 9'AK08/#/ARRT:V=Y(;2/8 MKN!ECDDGCW-<_P")/AO9ZWJQUFQO[G2M590K7-M_$ <\CI7;T4 >=77PIM]5 MTZYBUS6M0U6[FCV+/.^!%[JHXS78^'=&A\/:!8Z3!(\D5K$(U=_O-W)/XFM2 MB@!#TKF/&_@V#QEID%L]U+:3VTXG@GBZHX[UU%% ',:1X:O['0;_ $^]UV[O MY[LN!&+?PAX=M]'MII)TB+$RN,%R3G) K?HH H:QI-G MKNDW&FW\(EMITV.I'ZBN!T_X6ZMIELNG6WC;5$TK!!MU ! ST5NHXXKTVB@# M@K/X5:-I?B;2];TV6XMYK$%74G?YX((^9CSWK4\3>#8O$VK:->W-[/'%IDQF M%NH&V5N.374T4 -YKF/#G@V'P_K>MZN;R:ZN=4F\QS(H'EC)PHQVY_05U-% M'/>*_!VD^,;!+74XFW1-OAFB.UXV]0:YN/X>>(8X5M1X\U3[( 4V[%W;<8QF MO1:* .>\+>#]+\(V4D&G(YDF;?//(=SRMZDU7\'>#8O"0U-ENY+J74+HW$KN MH&"<\?2NIHH Q_$OAG2_%>D2:;JL'FP-R".&0^JGL:XE/A?K2VZ:JDWA"*X\? M6OBJ6]F,EK;-;Q6I4;%SG)S^-=-10 @I:** ,#Q?X5L_&/A^72;UY(T9@Z21 M_>1AT(KFK+X::@?L\&M>,=4U+3X.EHJ^2L@'0.0Q)'3TSBO1** ./\+^ [;P MOKNJ:G;W&Y;TA8[:.+RXK=!S@#)R<]Z?+X*^T?$6V\6SZA(YMH&@AM/+&U00 M03GKWKK:* (+N*2>SFBBD\N1T(5R,[21UQ6#X)\)IX.T'^S$N#?>*?AUJ&I>)6\0Z!XAGTG498?(F(3>KIV^E==)I$5[H/]E: MD3=QO (IF?\ Y:<:?X7N)K^6XFU/5IR?,O[L9?'H/2NQHH 3O2T44 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 55OO]2/][^E6JJ7_ /J1_O?TH M4444 +1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 55OO\ 4C_>_I5JJE__ *D?[_\ M2@"U1110 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !52_\ ]2/][^E6ST-5KW_5+_O4 6**** %HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ I.]+10 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%&1ZT %%%)D>HH 6BC-% !11D49H **,CUHH **,T4 %%% M% !2-D*2.M+D>M&: &J25&1@XIU% H **,T4 %%&:* "BC(]:,CUH **,CUH MH **,CUHS0 449!Z&C(]: "BBB@ HHS10 449HS0 449HR/6@ HHHH **,BC M(]: "BC(HH **** "BBC- !111F@ HHR/6C(]: "BC-% !129'K2T %%)D8S MFC(]10 M%)D>M+0 449HZ4 %%&1G&:,T %%%% !11D49H ***,CUH **,T9% M !11D>M% !11FB@ HHS10 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% >AJK??ZE?\ >_I5JJM]_J1_O?TH LT444 +1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%!H **8N_>V=NSMCK3Z M"BBB@ HHHH **** "BBB@ HHHH Q/&&N2>&_">HZQ%;K<26L8<1.VT-R!R>W M6N/LO%WQ%U+3;>]M? ]D8KA4D1FU1/F1AG./I6W\5$+_ O\0A>OV4G\B#7- M>'/BKX:L_"^DVCP:H&@M(8\"Q=AE4 RIQSTH Z+PMXXGUG7;K0=6TF32M6MX M5F,+RAUD0G!*D=0*GTKQ5<7WQ$UKPT]M&L.GV\4J3*Q)?> <'\_TKG/#2ZAX MJ^)\OBY]-N-/TNULC9V_VE-KW!+$[\=0.3^E3>&I _QR\8A6SBSM0>V/E% ' MI!Z5Y]J/C+Q.WCG4O#NAZ#:WBV4$E>7D;O]/R0.YQ7>ACLR_'& M6YZ<5P]MXY\0W%[9POX#U6WBGE1))I)5VQ*6 +$#L,YJS\3M=ET#P+>S6\J1 MW5QMM87<[0&#WZ5Z M6>A'%>0>+K32=)^&FD3:3JEF]]X=\F:U9)U)D;@,.#SNSG\Z]2TN_AU;2K74 M("##& ./YB@#@O^$Q\5>*M0O8_!FG6:Z;:2F$ZC?,=LL@ZA%'4#UJ M>P\;:YI7BRR\-^+-/MXY+X8M;ZT8F.1L'@@]#Q5&VT'QCX!GO(_#4-GJVAS3 MF=;2>0I-"6QD*>A'M6GI/Q T_5-=MM(UW1[G2M8WC[/'=Q95F]4;U]J )O&O MB[6-!U_1=)T73K>\N-2+@"9R@3;CG(^M0MJ'Q-\QR-$T;9M) %T3SZ5E?$F\ MN+#X@^"+JSLGO;E99U2!#@D%1GGZ9-:DOC;Q4L;[/A_J)=2=H^TK@CUI =+X M9GUZXTYG\16EM:WOFL%BMY-Z[!T.:O:O=266BWUW$BO)!;R2HK="54D#]*CT M.\N]1T:TN[^Q:QNY8PTELYR8SZ9HU_GPYJ8];27_ - -,#"\.^);[6_AK#XB M>&)+R2UDFV $KN4M@?CBLOX7_$4>.;&XCNDBAU.V.9(H^FPG@BHO C(GP&M2 M[$J-,G)V]+5KLP2ENJ@;>1^=7/&?BJ/PEHJW(MGNKF>06]K;KQYDC< $ M]A7&^+M5M]:\2_#+4[0EK>ZOGD0GT*KP:Z_QSX4_X2S0TMXKG[-?6TJW%K-C M(213D9'IQ0!@RR?%$VJWPCT.,JF]K!@6;(ZJ'''XUM^$/%P\5^'9;W[/]GO[ M.3'.X=+?B1XJT3^U-,T_0Q TKHAN'=6(5B#D# MITKH;&3XE2:C:+J$&@QV1<"X,+N7"]]N>]<-\.=>\6Z7X/CM-&\)MJEFEU.$ MNVNUCW@N?X3R*] T'Q%XLU#68[;5/"#Z?:,I+7)NE< CIP* */C+Q3XCTSQC MHFA>'K2RGEU&*1S]J+ #8">H[8%,EN_BI%$9CIWAV4("6A263WN MH6?Q7\(3:78C4+M;:YV6YD"!@1C.X\#@G\JFUKXA>+]-:TM+CP?'8W-](8H) MYKU'B5NG/\3&UFV.I0Z#'IWF?OA;N[/LQ MVSWSBNYZ?2E[T'IVH \[U#Q-XF\0>)[_ $+P@MG;1Z:1'>:A>H6"R$9"HHZ\ M"JUUX@\9^"]1T\^(Y['5M)NI%ADN+:!HY86/&<#@C)%6M3\'>(M*\17NO^#= M3MXWOF$EYI]X"8IG'&01RIZU"OQ$U?1KZ"T\:>&7TZ.XD"17EM*)X"?0^E ' M5>*O$]EX5T%]3N4EG+%8X8(AEYI&^ZH'N37+0Q_%'6+5;Y;O2-&W*'CLI83* MP!YVNW;WQ3?'Y%Q\0/ -E)\T#WDTI&!\Q5!@Y_SUKTGJ#W/I0!QO@_Q??:G? M76A>(+*.PUZS :2*)LI*AX$B^Q]*3Q9XMO+35K?PWX=@BNM?N8_."S'Y((\X M+O\ X5C^(F:U^.7A.2UV^; MHCVGI[<#- $VII\2]"T^YU5=5TK5%ACWR67V4Q[@/O;2/;/7TKJ?#'B6'Q1X M4M]8M5$;2Q'E '#>)_$VK2^*;?PGX;,$>I M/%]HGN+ALPZU;0;3<6;6VUF3N5([UM^+/!4^K MZM!KNA:J=+UVV3RQ-MW)(G]QU[CK61=^*?''A*WEN?$FAVNI:=$-TMYI\FU@ MO0DH>U &[XL\47-A\,KKQ)I:B.<6T<\2S+]W@#I= LO%EMJ4KZ[JEE=VGD 1I;P>61)GDG/;%8NJ>*= M;USQ//X>\(M;QRV!!O[VX3>D?^P!W:M_PQ<>*)UNO^$DL+"U8./(^QREPR^^ M:Y?X/*OV+Q%-*5-Y)K,XF]1C&W^M("#7;OQUX$L?[9GU.WUW38G7[5 ;41R( MI."RD=>M=)XI\3/;?#>^\1:1(I<6HGMV8<#)'7Z9KJY%5T*NH93U##BN-^*& MP?"W7_+V[/LA QT'(I@;WAN[N+_PSI5Y=,&N)[2*21E P6903C\ZYW7-?U2S M^*?AO1;>5%T^^@G>="F6)121@_7%;WA#CP9H8X_Y!\'3_KF*X_Q(0?CIX.&2 M,65T?_'6H F\:ZSXEA\;Z#H/A_4+6T%_#,\AGA#XV#(-23Z5\38TD>#Q-I$K M*,I$UCC?[$]LFL?X@S:K%\5?"(T.&SEU$PW&Q;HD+MP!]9\0>*?".MRG4(DU%;^>VM9GARL07&,C SC-;W@7PP/"?AQ M+#[4+N625[B:<# D=SDL,?A7-_!@C^P-='<:YM2VTCXE7-M;RR>+M-C5U5W5=-!('4C]<4[XV_\ MDIU7ZQ?^C%KN['_D'VX_Z9+_ "% '%:)XCU33_'=WX7\2W,4KS1K/IMWY8C$ MZ]#& !@D<_K[4[QWXJU.QO=/\-^&U$FNZ@V5=DWK;Q#[SL/SQFK/Q$T!-3\. MRZG;GR-5TE3>V=RIP8W0;L>X(!&#Q65\+M%ENK9O&NKS"ZU?5HPPE88\J+^% M0.B_0>@H [ZRBN(+&&*ZN#<7"(!)-MV[V[G':L+QIXJ7PMI<@^GK73'I7FWBIA+\8O!EM<!^8H >FA?$G4%2 M]G\76NEW#*&-E;V"RQ*2/NDL<_CDU?\ "GBG5&UVX\,>*([:+6HH_/BDM@1% M=19QN4'G/K7:\9]Q7FOC,B/XP>!)(#MN'^U)*5_BB"@@'\XA\P*8P3T]Q_*F3Z/\44A>6/Q3I$LJJ2L9L=JL?3-9_C@ MZLGQ9\)G1$ADO4M;C"W#8C9,84MR3 MQN!. .V30!V/@+Q/+XL\,QW]U;BWO(I7M[B-3E1(AP2/8UTY("DGH.N:YWP1 MX;B\+>&H-/2Y%U(S//-<8QYLCG<6'MTK5UJ66'0M0E@7=,EM(T:^K!20/SH MX+^V_%'CG5KN#PS./ ML^L/JJ>(=* MC8&Z@EMQ%+%'T+*5^]C.:U_A%'#%\+]$$39+1.[D]2Y=BQ/ODUT^O>3_ ,(] MJ1GVF'[+*7W=,;3F@#*U'^U/$.DZ?>^&=8ALXY@)3+)#Y@=&&0,>M<1JUWX^ MTCQEH&@CQ!:3Q:F9")C:@,IC4LP/L:W_ (-- ]K* !=E@3_P!,Z -S0M*\76FL--K.OVMY8"(JL$5ML(;CDG\# M5#X:Z_J>NKXB74YQ,;'5I;6(@8PJ]J[HUXMX+T_Q5+JWBU_#6J6%E9?VW,KI M=P&5C(,;B,=N12 [?XH:SJ.@> ;W4M*G,-W"T>UP@;@N 1@^Q-1?$/6]2T;X M<2ZK87:V]Z@A/FNN1\S 'C\:XOXKV7C.+X>WC:MJ^FSVHDB+I!;F-F^8=R?6 MNC^+8=_A%,8R5($# #O@@@4P+-IH/CZ2.*9_&-MAU#;?L"D#BMKPYI7B73[R MZEUS7X]2BD51%&EN(_+/?IUK!A'Q+-E;-!_8:@0H"K[B3TR3^%=+X:7Q*+>X M_P"$E:P:;S,P_8PP 7WS2 X;3I_&?B7Q=XC@T[Q-'8V.F7I@2-[59&((SUJ7 MQ'<^._!.FG7)=;L]5L;=U\^V:T$;;&(&0P[Y-9_AQ/%3^./&[: ^GI;?VD!) M]KW$APO;%1ZFOB?Q?XB_X0OQ/?V>F6Y"3E;>//VY5.<*QZ8(&13 ]@M)UNK6 M"X0866,.!Z9 /]:GJ*"*."&.&(8CC4(H] !Q_2I: "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ JI?\ ^I'^]_2K9Z&JU[_JE_WJ M +%%%% "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110!QWQ4D:+X8Z^R[LFVQD=OF%:WA5TE\(:, M\9!4V4/(&,G8,]JV)8TEC:.1%=&&"K#((^E*B! %4 *!@ # ] * #MDUY$W MBK2/"WQF\33ZF\D4=Q:6ZH\4#.,JO.2H/J!^%>OGI4+6\+/N,,98]6*@G\Z M.4TKXG>%-;U:#2]/OII[FXU.65(9[6 MW1)%@9@&1<%>!7K2V\*$,D2 CH0H%)]FA+;S#&7[L5!/YT <,OQC\&N"5N[P MG.,?8Y?_ (FL?49-.^(_Q+M-)>%[K1M)MC=N2&5)9FP #],C]:]2\B+&/*3' M^Z*58HT'K-"W&54@_S]ZYSX=/<6]MXE\#F62"; M3)I$LY2#Q"X^4@GK@_SKU ]*9L4/O"KO;J<8.* /*_"?CUO#%@VA>.&NK:]L MW95OIHV*7"9)#;@/0@56\1:Q;_$;Q3X8M/#L5S-#8WJWEQJ(B*QI&.H!/7/] M:];FMH+E=L\,3&""$ M7([XH R?#?B;3O%-B]WIIG\J-RC":(QL#]#5CQ _E^&]4< DBTE( &2?D-7T M14SM55R>(X-J8Y(W&,C+9&#[&NS5%5-BJ O3:!BE50H"J .PXH \!O/#&H>&_ MB]X:TZ%KF308[PW%KN!9(-V2RY[%)(60&]-V!S:"T7=O:QVNL"2>18U+6#@ M D@#)["NZ50.G3L,#BE*@CD#CGD4 ><>(BY^./A,B.4QQ6=QN=4.W+!L GMT MKL/$WAZT\3Z#<:9>!E24?)(I^:-NS UK;1N!(!QTIQQ0!PGPSU^\O=+N-"U> M*6+5='D-O)O!Q*@X1P3U&./P'K5'XOQ/+9>'%BBEDD76K>0B.,MA03DDCH*] M' PV>A-!4'@CH<]* ' Y_+-# ,I4]"*0=?UI>O2@#R33=9U?X9ZEJ=IK]CJ= M_H-QPXR: .>F!0!QWC?PG=ZYH=E)ILJIK6E2+<64KD(/KS0!YWX/TC5M:\6W7C/7;3 M[&YB-K86K+\Z1=2S>A/\R:9XITW5O#GCN+QII&GSZA;R6OV;4;2 @,5'(<#N M1Q7HX/-*>1Q0!YEJ'Q62_LFL_#V@:Q=:M-&?+BDMC&(R1U9NV*V_A_X;NO"G M@=;6^EEFOI-\\^]]Q#D?=!_ 5V/!-*>G7]: /#=%FU?1O@7-80:5J!U&ZNYK M9(DB8/&'>.F.]>G^'?"NF:3X>T^P;3K9WB@02,\*DL^.23ZYKHN"/\]:7 MWH \T\6.X-M?+:0Y+6[#G< .QJKXYN;S3?B=X;UVVT: M^U"WM;.82BVBR1OR%'U&2:]5ZT@QF@#@C\2Y&=%3PCKYWNJY:W QDXSUZ5WB M'#O'ESXETW3;G6-)U"!4N[:%\R0R+G#*# MVZ=*;K?CBX\3^'KW2="\.ZLU[>0-"QGMS$L6X8.2>O&:]0/2D P: /-?$OA> M\L_@7)XOM7I-)@>E ')Z!XQN->UF2PD\-:OIR+"S_ &F[B"J2"!@'/7G-<]/::SX! M\6ZIJVGZ3)J6AZO(DD\-M_K;>3&"V.X->FX&+=4\96$_A_P MSH.J(]VOES7EW$8$A7.#@D]:ZP^#X#\/'\*;_P!VUF;EWT8DM[B,HP(Z'LP]P>:T>]+0!POPU MGURUTN;0->M+A;K2W\B.[=3LN8Q]TJ>_&*@^$EGJ%EH.KKJ-E:6%?+@C+M@.I)P!G Q M7:V"LNGVRL"K")0P/8XJQD>U+QB@#*\4123^$M9AA1I)9+&=41!EF8H0 .I MS69\.K:XL_AYH-O=P2P7$=HBO%*A5E([$'D&NHI 1@<\4 +7'^/?"]]KMC9W MVC21Q:WIDWVBS>3[K'NI]C789I#S0!Y[;?$:_AB%MJO@[7HM20;2D-MYD4C@ M#)5P>A.<4GA+2=?UKQ=-XP\369T]D@^S:=8%@S11D_,S8_B->A8!/KBEZ4 < M#K=A>2?&;PU?Q6=P]K%8W$S#W!P:TN,@G'M1GW&: .'^&4FMVNBRZ'KUK10\;*1D$8(]1Z4H SG'-+0!Y;IT.N_#*XN[.'2;G5_#I$CIF@? M3'M0!2TC3+?1='L],M5Q;VD20IQV QG^OXUQWB32]1N?BMX1OK>SD>RM(YQ/ M,%RJ97 R>U=_28&?>@!#7!_#'2;[2D\1B\M)[9;G5YKB)9A]X,!\P]N*[ZC\ M* .'^+>F7VK_ ZU"RTVUENKEVC*Q1#+$!@3C\*@^)>D:GJOPS;3M-LY+B\8 MP#RHP,_*03_*N_-% 'G\/C;Q'!&D)\ :NQC10665,' QQ6OX<\3ZKK5_);W_ M (5U#2$6/>LURRLK\]..]=31B@#@/A]INI67B'QE/?V,MM#>:F9;=G 'F)R, MC'T%6?B-X8N-;TB'4-,5AK.ER"YLV3AF(Y*'U!KMOPHH R] U"XU31K6[O+. M6TN63]Y#,N&5AP?UK4I,4M !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 'H:K7O^J'^]_2K)Z56O/]4/][^E %BBBB@!:*** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH *#THI&^Z?I0!F)KVFR:_)H:W2G48XA,\ M'.0GK5'5O&_AO0M2_L_4]6AM;K9O\MPV=OX"N7LE_P",A-4.1@Z)'_Z&*8(+ M>[^/5W%<6\,RC2%8"10<'HP.:P]=\&Z+K>C76GRZ;:)YT;*DJ0A6C8CA@0,Y!P?PKF_AS MK%SJOPZO;6_G\^[TQY["61ARP0'!_P"^<4 :!^*_@D1>8==A"@[QL/YU0^#\,4_@JZ6:)'#:IMBU\2:9>>(;K0X)RVH6L8D MFCVGY5.,<_C5R/3K*)E:*SMT88(980"*X30CO^.GBDG/RZ=; >_3F@#&=&U9],OM0\J[0 LGEL>O3H*I_\+8\'?:XK0:H3/*P1$\IQDDX'45@6L^EV M7QR\1?VK/:1J]A;M&;DJ,GVS7<1:GX8NM02SBNM+FO&)VQH49\CD\#F@!]MX MITBY\0R:&MSMU)$WF%T*DKZ@G@_A6Q(Z1QL[L H&23Z5POQ&\,W%];6_B'1D MV:YI3>=$5X,R#EHSZY&:YSQ!X\?QOIEEX:\+M*NIZHH6\91_QYQ])-Q_,9H M[W1_&>BZ[IU_J.GS22VED6\V7RB <#)QZ]*O:/X@T_7M#CUBQE9[.12RLRD' M Z\5130;/P]X>FQCVV\%E(B\8+'8L7X7+GX1:0"WWK5^G;EJ .A\.> M*]&\5V\\VCW?GK!)Y<@*E2K>X-+KWB?3/#:V3:C(Z"\G%O#L0MER>!7A/@V> M^\"M:>+V8R:'J5V]O=J.!&-Q"O\ @>]>@_%J5)[;PE-&ZM#)K%NP<<@KD$4 M>ERS101/)+(J1H,L[' ]:X>Y^+/AA+AX[7^T;]8R0TUE9O+&".OS ?RJI\3 MY9-3U'P[X1!*V^KW6;IE;!,48W%?QKN[#3[/2K.*SL;:*UMHAA(XU 51Z4 9 M_AKQ=HOBRV>?2+M9?+.)(R-KQG_:4\BMP]*Y*+P5!:?$ ^*+.[^S>=;^3<6J M( LS=F.,<_GTKK30!SFL^-=$T#7;'2-2N&@N+U=T+%?D/.,$_6MVYN([.SFN M921'"AD0_%3P])XM\>Z-H]K<+;WHL9IXI6[%6.!^)KH?!GB>?7/ M!6HZ?JFV+7-+ADM[V%OO#"D*_N"!UH Z?1O%6G:YX7_X2&T\TV6R23YDPQ"9 MSQ^%3>'/$-CXHT2#5].,AMI\A"Z[3P<'BN,^&BL/@E;[F5BUK<-QT&6?BKOP M;&SX7:0/^NO_ *,:@#>\1>*['PW<:9#>I,S:A<"VB\M@\5?$G1=&G.%GTRX*G M_:4G'ZT >KQ2I/"DJ_ZN10Z_0C-D>-)&8OJ&O+;P!ATA1M MJX_%30![;XK\8:9X.M+>YU03F.>41)Y,9<[OI7.GXP>'$!:6SUF*->6DDL'" MJ,]S5+XT2BWT?0KEV58(=6A>60C(5<]:V+_XG>!?L%QOUZQN$\MB8%;<9 !] MW'O0!U&EZK9:UIL5_I\Z7%M+RKK7'?\ "W?#QNKBWBMM6F>WE:*0Q63. P.. MHJ3X3:;/I_@S?*@BCN[F6Y@B!SLC8_**YCX<^,O#_A^WU^SUC5K:TN3K%Q(( MY#@["1CM0!U,'Q2TBZO(;:/2]9#3.$#O9,JC)QDGM6IXI\;Z7X1>S748[MVO M&*PK;PERQ';'K26/Q!\)ZKJ,.GV.MVUS=2GY(T)).!GT]JYCXG:A::7XL\#7 ME].(+:&_E:21LD*-@H O'XMZ,$,CZ5KR(O+.U@P"CU-=9H6O:;XETN+4M*N5 MN+5R0' (P1U!!Z$5B7'Q+\%QPMYFNVA4I]S));(Z8Q6/\(K>0Z=K>IK:M:V. MHZE+/9PM'LVQ],X]^M 'HYZ5S7B'QOI'ANYCM+DS7%]*NZ.TM4\R1AZX':NB ME?RXG<_P@FO-?A3:PZS;ZEXPNX@]_?WDRQ2/\QCB5L*H].P[8R3V+9P#7:2SI%:R3\NJ(7^3G( SQ5#Q#H=IXBT*[TN]B M22.>,J-X^ZV.&'T.#^% M0-+::9KMPJDKO@L&=W\N,R-+>6AB3J!C)[\U MP/PL\>^&-"\%16.K:S#;7JW,QECDW9!+G&2!C%>H:%XFT?Q(DTFCWT=VD#[) M"F?E/XT ;%E=*>E><)8P^-_'NNM>( M)=+TRW-A$",CS7&78'U X]N* /0+2ZBO;.&Z@;,,R+(A_P!DC(K)\3^+=*\) MV<=QJ+N6E;9#;PIOEE;.,*O?K6%\+[Z8Z%=:!>L?MVB7#6CJ1_RSS^[/XK5+ MQ];W^F>+-$\6Q:=+J=CI\*.^* )&^*T=H%FUCPQKFEV+$ 7 M5S HST)YR*[R.[MY+);M)4-NT8D$F>"N,YS7$Q>/O WC.SN-%N-1CC^U(89 M;:\4PN1CI\V.:UK_ ,+QQ_#^X\-Z.YC7[(8+8RR%L<<9/I0!B'XJ6EU<2+HO MA[6]8MH7*OM=-X;\4:;XJT][S3)),1N8Y8IE*R1,.H89X-<%X M0^(>E^&-(L?#7B:RNM$NK*%8#)/"?)DPO+!@._7GUKMO#NA:!:7U_K>AE6.I MD/,89=T1;&^'VX>-?'QSF/^TUZ^NTY%0_#FV@U[Q!XF M\5W<0DN7U%[2V=QDQ11\;1V% %E?BK':A9]:\+>(-(L6./M5S;?(I_VL MN\MKN"\M(KJVE26&9 \-V'((QT-9_A M+0K;PSX?@TBSO9;NWMV8(TK!F4$Y*\>F?R- %;PMXXTKQ7<7UM8":.>R;$D< MR@$]>1CMD5;\5>)[;PGI:W]W#/+$TRP@0@$[FX'7WKP_1K*^T*QN?B#I=S(R MVFI3PWEHPW P;\,>/0D'Z5WWQ2U&UU7X=:5?VKB2WNM0M)(R.<@MF@#K_%'B MFS\)Z0FJ7\%Q);F18\0IN8%LXX)]JYZ7XJ6XC\R/PQXAEC(R&6RX_G47QFE2 MW\%VEQ)_J8M2MY)"?[@)S6BGQ6\#D877X 5XV['X_ "@#2\,>*QXECN772=1 MT_R2.+V+9O'^SS7/)\6]/FN;N"ST+6[MK68PR-!;AAD?C77:%XATOQ)8M>Z3 M=+<6X>-?#_ (X] :ZH4 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% >E5KS_5#_>_I5D]*K7G^K'^]_2@" MQ1110 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%(>1B@#S:SV_\-!: MD>XT:,8_X%1;)(O[0EXV04;1EX[CYQ74P^%+:'QM<>*!/,;F>V6W,1^X%'ZU MF:[\.;'7?$;:X^I:C;7AB$2M;3; J^E '4:IJ5KI&F7%_>3)%;P(7=F..!V^ MM>>_#"RFB^'^J:E<(\3:K<7-Z%DX(5L[3[<#-:8^%FD3RQMJFHZMJ21G(BNK MHM&?JHZUV36D)L<41P>68@J#[JXQ@?A0!Y-\+? WAC6_ EM?ZCHD%Q=R2R M[Y)LECACZ&N^TGP)X8T+44O],T:VM+E 5$D8.<'ZFN=MOA!I5G;&WM-;UVWC M)+;8;PJN2<]*N6/PUBL+^UND\1Z[+]G@+9I_Q MF(/A/30!DG5[7'MR:Z;PCX4L?!ND'3-/DF:W,K2@2MG&>PI_B?PO9^*;&"TO M7F2."X2X7RSC++R* -SO7G>A@_\ "]/%/&/^)=:]OI7H8& !_/FL.R\+V=CX MKU#Q#'+.]W?1I%(&;*JJ],"@#ADT'2O$/QO\0PZKI\-W'#IMN4$HR%)Q78?#;3K2V^('CIXH$1X[U8T91T4@L1^=>H'I6%HGA6QT36M7U2UD MN&GU259)UDDW*"!VH OZX<:!J)SC%K+S_P !-:YC93SP789'YUP6LWM_H^I>'? FIQ_-IVIQO:W:YQ M)!N&T<]\<9KW3PQX:L?">B1:1IOF?9HV9AYCDG+')YJGXA\#Z-XGU+3M0U". M4W-@X>%XWVYPO!SCZ"@#E7\/:=X9^,/A>PTS4K^57CF>XAFNC*$P MIP3GIG->U=ZYCPU\/_#OA65I].L=UVV=]U.QDE;/^T:Z8B@#SG6/^2]>'B,[ MCI4XX^K52^(VEW7AF]G\::+:^:TD#6^I1 XW(1A7QW(-=W<>&K"Z\46GB"3S MA?6L+0QXD.W:W7(K2O;2"_LI[.YC#P3(8W4]P1@T <#\,K9 M5;H3N+8/MUI/@O=PMX!@TP,!=:?++#/$Q^93O8\UV'AW0+#PQH\6E:8LJVD1 M)0/(7(R<]3]:Q-8^&GAW6-4;4C%=65XXP\MA.8"_^]C@GWH POB%/#?^/O!. MDV[AKJ._^UR*.2B*.X[=*GU^55^.GA10?F^P7.1[$&NA\.^ ]"\,7#W=E!++ M>NNU[JZD,LI'7[Q_I5^[\-:7>^(+/7)[/Q- 'E/B/Q!_P MK_5?%6C06[^;K06?3A&O623Y9![8ZU:\=Z1'H/@_P+I:# MM2M4.3R6R"Q_, MFO1]7\(Z)KNJ6>I:A9+-=V?^I'#8VN.E ' M'_&!87TS0A.$:$:M#O#_ '<9Z&NJETGPLT+K)9:0L>W+?NXU'Y^E/\1^%-)\ M5VD-KJ\#30Q/O5 Y S[U@?\ "HO!>XL=*)4_\LS.Y7\B: ,SX4SI]M\46FGS MO/HEO?8LF;E1Q\P7VS5;X5V.CR:=KIO(K&68ZQ<9,Z(6QGCKVKTC2](L-%L( M['3;2*VM8^%CC7 '^)KE3\)O!SW$D[:8QDD8NY$SKDG.3@'K0!T,=GX?M;E) MHK?3(9E.%=%16'Y5Q_Q"6";QOX#MYHEF62]E!5P"#\@[&KT7PB\&1.CKIDA9 M'#@M.YY!R.]=%J/AO3-5U33M1N[V<,1M)]NAH QO&'@;3]>TAOL=I M;P:G;_O;25(E7$B\@'U!QBIO /B=O$N@_P"E1>1J=FWV>]@VXV2#T'H:ZGKS MUK'L/"^DZ=K][K=I;>7?7P N'#'#X]NE &Q(JM$RM]T@@UYA\,]0@\,S:AX' MU%UM[RSNI)+8R':)XG;<"I/4\]J]0/2L+Q#X/T/Q3$JZK8)+(HPDRDK(GT8< MB@ \4^)M/\,:-->7EPJ.5*PQKR\CG@!1W.<5@_#O1;K1/ARL5VCI=7(FNI%? MJIG65Y\.K>6ZLK:65[B?<[Q DXD->CV]I;6886]O%"'.6\M H)]\53T/0 M=.\-Z8FG:5;BWM$8LJ D\DY/6M,T 8WBO7HO#7AB_P!6D(/V>(LBDCYF_A'Y MUP7AKX'QAJUG/?L;N:&UVA%=^>,\]Q7H&N^'M,\26*66JV_GVRR"3 M86(!8=,^HK251&JHN JC [#TH \IM-.N_A[\1K":ZU:YU&Q\0 VTT]XP#K< M*"4Y''(&/QKI=1\:/HWQ!@T75%M[?3+N#-M=.<%I >4.>*W==\.:5XD@MXM4 MM?.%M,)XB&96C<=""#FG:SX>TKQ#9?9-6L(;N'L)!DK]#U'YT 8?C[1_#-]X M7O9]=M[,(D+/'._#*^/E*L.>N*YW0]<\1:1\$;'5;6V2YO;9,A;D-\\ 8@'" M\D[<&MBT^#_@JTN4F_LIY_+X1+FXDE1/HK&NV2WA2V%NL*+"%V",*-H7TQZ4 M 8NC:SHWC#0(;J&6SO8)8@94X8(2/F5E/(P?6N*^'D%EI_Q*\5Z?H3AM$1(Y M-J#KZ\>Z_LMK>23_6"UG>%6^JJ<5T^CZ!I7A^S^RZ38Q6 MD);P% 'GGPBA@G\(ZO;2 21OJMTCHW.03T_* MO.O&D&I^#Y+3P8Z*^BW&J17=A+G+(-_,9^F:][T70--\/P30Z7:BWBFF::10 MS'<[=3R:9K7AO2/$(M_[5L8[DV[B2(L#E&]C0!R7QAV_\(C8^9M,0U6V\T'I MMW,5)K?A[2O$5BMEJUFMS;JP<1L3C(Z=*Y]_A-X%UVKR5@VX&>YQ7G/PMETE;+7_ +4UEYO] ML7#!I2NXJ2,=>U=IX?\ !N@>%YKB31M-2T>X"B4HS' M"9R>GGP?^C%H K#Q]?-@KX&\3%3T)MT_J]//CS4 I/\ P@WB0GT\F/\ ^+KL MT^ZOTIU '$'QYJFT,O@/Q&3Z&.,?^STZ+QQJLJ9/@3Q I]&6(?\ L]=K10!Q M1\;ZL%R/ NO$^F(O_BJ3_A-M;+ +X#UL@]R\0Q_X]7;44 <8/&.ODD?\()J_ M'\ '*,#'@FY)_Z^XZ5/$WBAF(?P5<+Z'[9'78T4 <"G(_Z_%KMZ M* .,?Q'XP5P$\&97O_IR?X4I\1>,"N4\%X/OJ$?^%=E10!QR>(O%Y3+>"R,= MO[0C_P */^$C\6D_+X,(/'&X;?!41'?_B9H M/Z5VM% '&C7/&[_\R?;I_O:DG]!1'K7CC?B3PA:X]5U1?\*[*B@#BY-<\=C MC\&6C<=3JR?_ !-1#7_B%O ;P/9;?4:PG_Q-=S10!PXUSXADG/@S3U';.K _ M^R4]M:\?AU4?T2E_MCXBX_P"1 M3TGZ?VH?_B*[>B@#BQJWQ!\LY\+:4&[#^TSC_P! J$:M\2>_A;1OPU(__$5W M5% '$_VG\13@_P#".Z-]/M[?_$THU+XA[SGP[H^WM_IS?_$UVM% '%/??$4G MY-%T,#_:O'/_ ++0MY\1MIW:/H&>V+N3_P")KM:* .(6^^(^UMVBZ%GM_IC_ M /Q-.%[\1B@)T?00_?\ TJ0C^5=K10!Q8OOB(.NC:(3ZBZ>E:]^(7R[-(T0> MN;EZ[.B@#D#=>/\ 'RZ7H>?>XDJ$7/Q&.V9I.*[&B@#C%E^(H0;K7P^S=\22#^E/\_XA8_X\= _[ M^R5V%% ''&;XA9_X\O#_ /W]DI?M'Q!R/] T#'_7:2NPHH XXS?$(YQ9Z /K M+)33+\11@+:^'3ZYDEKLZ* .-$_Q%[VGAW/L\O\ C2&3XCXR(/#6?0M-_.NS MHH X\R_$/;Q;>'-WJ9)O\*C,GQ)"#$'AK=_O3UVE% '&[_B.5_U7AD,/5I\4 M!OB1M!,?A8-WYN*[*B@#C2_Q)R/W/A4CUWW'^%*Q^(^.(_"Y/^_/_A78T4 < M<#\19<8_E7:44 <8A^);??3PHOT:X/]*&;XE!3B+PJQ_P!^ MX_PKLZ* .+S\2F'W/"RGZSFEQ\20>OA<_A/79T4 <:J_$?;\S^&,_2>@+\1_ M+;WE2UV-% '("W\?[?FO= S[12_P"-$<'Q $A:2\T%D[ 12_XUU]% M')-;^/MORWNA Y[Q2'^M-DMO'YV^7J&A#US!)_C77T4 <@+?X@KG-]H#?]L) M1_6@6WQ )YO] '_;&4_UKKZ* .0^R^/\?\A'01_V[R?XTC6OQ!R-NI:#CWMY M/\:["B@#CQ9_$ DYU30L'H!;2?XTU;+XA!B3JVA-Z?Z+(,?K7944 I:$I[YMI#_6FBR^('&[5-"_\ 63_ !KL** ./>S\?G)35-"'I_HLG^-1 M:+J?B>#QN=%UN;3)X)+$W4;VL3(P(<+@Y-=K7'RMCXO6P]=%?_T<* .PHHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH *KW?W%^M6*KW?\ JU^M $]%%% " MT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 5QWQ-7=X&N!_TW@_]&+78UQ_Q+)'@J;WG@_]&+0!UR]OI3J1?NCZ4M ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M>EE5KS_5C_>_I5FJ]W]Q?K0!/1110 M%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %[_U8_WOZ58/2JUY_JQ_O?TH L4444 +1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7'_$K_D2 MIO\ KO!_Z,6NPKCOB7_R)EW_ M .P0W_HRNMKD)S_Q=FT'_4(?/_?V@#KZ*** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "JUY]Q?K5D]*K7G^J'^]_2@"Q1110 M%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<;\3?^1)EYQ_I,'/_ M &T6NRKD/B5C_A"9\]//A_\ 1BT =:O04ZFCK3J "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBC- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 449HH **** "BBB@ HHHH **** "BBC- !1110 5R$I)^+=J,?*-'?!_ M[:UUYKD9E)^+5J0W T9\C_MK0!UU%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% >E5KS_5#_>_I5D]#5:]_P!4/][^E %BBBB@!:*** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH #7'_$W_ )$>Y(95 MVRPG+' QYBYKL*I:KI5EK6G2V&H6ZW%K*,/&_0\Y_G0 ]-0LG;"7ENQQG E4 M_P!:5]0LH\>9>6ZYZ;I5&?UKG5^''A%2630;9"W#%2RY'X&HU^&'@H,3_P ( MW8CWV'/\Z .C.K::&VG4+0'T\Y?\:1M7TQ5W-J-H%]3.O^-<\?ACX*+[_P#A M'+(L/53_ (U(WPX\',@4^'K(J#D*8^* -S^VM*VAO[3L]IZ'SUQ_.F?V_HQ; M:-7L,^GVE/\ &LD?#SPB(A'_ ,(_9>7UV%"1^6:%^'?@]!\GAO31_P!L!0!L M'6])7KJED/K<)_C2?V]HV"?[6L,#J?M*?XUFCP'X448'A_3\?]H^SK0!H_\)!HI.T:O89]/M*?XTU_$6B1L%?5[!2>F;E!_6J0\"^% M'=.!]?LZT\^"/"[#!\/Z<1_U[K0!;/B30@NXZUI MV/7[4G^-"^(]#=MJ:Q8,WH+A2?YU1'@/PH,8\.Z=Q_TP6I4\'>&XVW)H5@C> MJP+D4 3-XH\/INW:UIPVG#?Z0G'ZTT^+/#HQG6]/&?\ IX3_ !J(>#/#0+'^ MPK ECR3 O/Z4\>#_ V/^8%I_3'_ ![K_A0 I\6^'0P!UO3R3_T\)_C3QXHT M%D+C6;#:.I\]>/UJ(^#?#1(8Z%I^1W^SK_A0/!_AL$$:'8#OQ O^% /&'AO M!(URPP.N9U_QH;Q?X;7 ;7=/&>G^D+_C2GP?X;8'.A:?SU'V=?\ "E_X1'PX M,'^P]/X&!_HZ_P"% _BWP[&5$FMV"[NF9U&?UIC>,O#*G:==L ?>X7_ !J5 M?"V@#IHMA^-NI_I2MX7T!CEM%T\G_KV3_"@"#_A,_#/3^WK#_O\ C_&@^-/# M"C)U[3P/^NX_QJ8>%/#P(8:)IX(_Z=U_PITGAK0Y5P^C6# ?].Z_X4 5O^$W M\+9 _M_3\GI_I"_XTJ^-/#+R>6->T_?_ '?M"Y_G5D>&M" &C6 &/^/=/\ M*/\ A&M#SG^Q[#/K]G7/\J *1\=>%!(8SXBTT,O!7[0N1^M./C?PL.OB#3O_ M (7_&KG_"-Z'@C^Q[#DY/\ HR<_I2+X;T-$ P4^)=+R> /M*\_K6D/#V MBC@:/88]/LJ?X4O]@:/GC2;'_P !D_PH HR^./"L'^M\0Z#%;:?$VF@_]=Q_C2M\2?!B$ ^)=.YZ?OA6U_8.D8_Y!=D/I;I_A3_[(TT# M TZUQ_UQ7_"@# _X67X*+;?^$FTTD]O.H;XF>"E^]XET\?\ ;7_ZU=!_9.G# MII]H/^V*_P"%']EZ?D'[!; ]<^2O^% '.M\3_!*$",C7+?'KM;_ KH?[/L^,6D&1T_=C_"G?8[8\?9XL>FP?X4 M L'/7]V/ M\*46-HO2UA'TC'^% '.R?$;PE&C.VM0 #T5L_P J1?B1X19=PUN#&.I5O\*Z M,V5J?^7:'_OV*/L5K_SZP_\ ?L?X4 N(Q_A2BSMATMXA_P ?X4 D+_\ Q-=/]DMQTMXO^^!_A1]E@/6"+'^Z/\* .:'Q M'\*E _\ :?RGUADX_P#'::?B9X07KJZC_MB__P 374?9;?\ YX1_]\"D^QVQ M_P"7:$_5!_A0!S4GQ(\)QQJ[ZLH!Z?N7_P#B:0?$OP?MW_VS&!W/E2$" 1K"$ M>HAD/_LM1GXH>#]VS^V &/0&"4?^RUUBQHIX11]%I3&C')13]10!RLOQ,\(0 M'Y]849[B"5A^86H_^%J>"STUG/TMI?\ XBNN$: Y"+^5+M4?PC\J ./?XI^# M4QNU9L>OV6;_ .(IK?%CP2I .M9)["VE/_LM=GBC:/[HH XX_%7P6N-VM8SZ MVTW_ ,10/BKX+8D#6E_\!I?_ (BNP*ANHS]:-BCHH_*@#C3\6/! ;:=<4'T^ MS3?_ !- ^*_@@_\ ,=3_ ,!Y?_B:[/:,DX'/M2;0.@''M0!QW_"U_!/;6@?I M;2__ !-.7XI^#''RZT#_ -NTO_Q-=A^% &.G% '&_P#"UO!G3^UV_P# 6;_X MBG#XH^#6&1K''_7M-_\ $5V&/44!0/I0!QS?%+POQ/\ "KY"WEP3Z"SE_P#B:[$4=* .,7XI>%7;:MW'/\ GI>_^ 4O^%'_ LWPWNV^;>9]/L'F.% M_M$G_KPE'_LM*?B5X?'5=2_\ 9?\*Z^C% ')#XC:$5W;-2V^IL9?_B:B/Q.\ M/ X,>J?7^SIO_B:[+'UHQ0!QK?$WP\L3/LU,@#.!ITV?_0:S]&UVS\0?%!+R MRAO1$FDM$7N+5HQN,F[ + AJM>_ZI?]ZK)Z&JU[_JE_WJ +%%%% "T444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !30O[S=D].G:G44 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% >AJK??ZI M?][^E6CTJK??ZE?][^E %FBBB@!:*** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** #M56^_U(_P![^E6NU5;[_4C_ 'OZ4 6:*** M%HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH .U M5;[_ %(_WOZ5:[55OO\ 4C_>_I0!9HHHH 6BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "D[BEI.] "T444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 @!'4TM%%( HHHI@% M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !VJK??ZD?[W]*M=JJWW^ MI'^]_2@"S1110 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%)W% "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 55OO\ 4C_>_I5JJE__ *D?[W]* +5%%% "T444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !111F@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **,T4 %%%% !1110 4444 %%&:* "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **,CUHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH ***,T %%%% !1110 4444 %%%&: "BBB@ HHHH **** "BBB@ HHHR* M "BC-% !111D4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 449 M'K10 449HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MR*,B@ HHHH **** "BBB@ HHHH ***,B@ HHS1F@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ /2JM]_J5_WOZ5:/0U6O?]4O^]0!8HHHH 6BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J>HZKI^D6GVK4KVWM M+?<%\V>0(N3T&35P]*H:GH^G:U9_9-3LH+RWW!C',@9^$6 _"2*53PUI0#=?\ 1$Y_2C_A M O"0&/\ A&=)'_;G'S^E _C[PA']_Q-I2_6[3_&HS\0_!F.?%&DX_Z^T_QJ M<>!?"2\CPQH^?>QC_P *>/!7A4?\RSH__@#%_P#$T 5W^(/@^,*7\3:6 W0_ M:5Y_6HC\2?!8//B?2\_]?"_XUH?\(CX;X_XI[2N.G^A1\?\ CM+_ ,(GX=SD M:!I6?^O./_XF@#./Q)\&!-Y\2Z:5]1,*#\1_!HQGQ+IHR,C,PK3_ .$7T#;M M_L+3-OI]DC_PIW_",Z$<9T333@8'^B1_X4 9(^)7@PG \2:WF_\ UJU/^$9T$#']AZ;C_KTC_P *4>&]##;O[%T[/_7JG^% &2_Q M)\&1L _B*P4GIF3']*#\2?!H7NCZ>?K:I_A1_PC^B MX _L>PX_Z=D_PH Q_P#A9'@W&?\ A(K$CU#_ /UJ9_PLSP6?^9DL?^^__K5N M#0=''32;$?\ ;LG^%']@Z/\ ] FQ_P# =/\ "@#$'Q+\&,P4>(K)B>@#$Y_2 MB3XE^#(7V2>(+1']&W _RK;_ +#TD'(TJQR.G^CI_A2MH>E."AU\16GXY_P *W%T+2%^[I=D,G/$"?X4\ MZ-IAZZ=:'_M@O^% &!_PLSP7M+#Q#:8'H3_A2#XF^"R@?_A(;7![_-_A6^-& MTP#']FV?_?A?\*4:/IG3^S;0#_K@M '/'XG^"@?^1BM?_'O\*;_PM/P/O"_\ M)%:Y/3AO\*Z/^Q],_P"@=:?]^5_PI?[)TT_\P^T_[\+_ (4 <>6__P 3 M72C2]/ P+&V'&/\ 4K_A2C3K($?Z%!GIGRE_PH Y8_%GP,"!_P )!!D_],Y/ M_B:8?B]X$!Y\00_A%(?_ &6NN_L^S[VD!_[9K_A0-.L@.H%O+_\ $TP_&7P&O77 /3'Q_LB@#A9/C-X'BD"2:I< M*QZ?Z%-S_P".4\?&+P2<;=3F?/;[)+_\37<+&B\! ,]<"G;%_NC\J .#E^,/ M@Z$;GO+K'J+.4_TJ-?C1X*?[E[>-["QF_P#B:] VCTI< =.* .$C^+WA*7E9 M[W\;&4?TI@^,?@\D@7-[D'&/L,O^%=]2;1TP* .%/Q?\) 9\Z_\ PL9?\*3_ M (7!X3\O?YFH8'_3A+_A7>8^E% ' CXQ>%& PVI$GL-/E_PIZ_%[PJS%=VH@ M@9YL9 /Y5WE% ' K\7_"S$A1JAQZ:?)_A4G_ M?PSQQJ73/_'A)_A7J$GC']GR9_E0GQ;\.2.RK!JV1W.GR<_I7=XQ10!PW_ M? MP_Q_H^K<_P#3A)Q^E#?%;P^K8^SZLWTL)/\ "NZYI.: .&?XJ^'XU8_9M7./ M[NGN<_I31\6M *!A9ZU@]O[.DS7=T4 <&WQ9T!%#-9:U@_\ 4.>GCXJZ&0"+ M'6L'O_9[UW/UH_.@#AO^%JZ$#_QXZU]?[/>FGXLZ"#C[!K9^FG/7=XHH X0? M%C0BC"7RQIFN.WJFGL:8/BOI!D9/['\197 MJ3ICUW>/>DQ@Y Y[G% '"?\ "V-(\PJ-&\1'W&FOBF?\+U+B@#AG^*FB(NX:?K;_ .YI[G%1#XN:&V<:7K_'_4,>N^Q1@T <$GQ; MT-\_\2S7QCUTUQ0GQ;T*1MJZ;KQ_[AKUWN*,4 <"?BWH0SNTW7EP<9.FR8H/ MQ=T 2!1I^NG/0C39,5WV*,4 <)_PM?0]^P:;KK'VTYZ%^+&B,*,4 <&WQ8T16 73->8^VG/3C\5M( S_9.O'V^P-_C7=8HQ]: .#D^*^D1K MDZ1KY'MI[4B_%C2I(V:/1M?8C^'[ PS7>XHP/>@#A_\ A:&FK$KOHVO*&&(O_ %J[X8(X/%'!]* .$'Q1LRF3X>\0#V-DU-C^*=J[[3X=\0#T_T(UWI MHX[D4 <,_P 3;='5?^$<\0'/<61H;XG6ZOM/AOQ 1ZK9$UW1]3VHH X$?%.V M,C+_ ,(QXDX[_8#S^M+_ ,+2@P3_ ,(OXD_\ 3_C7>]>]'XT <%_PM* _P#, MK>)!_P!N!_QI&^** KX3\2MDXXL3G^==]_*C/..* . 'Q1!DV_\(?XG^OV MX_G2-\4@G3P?XG/_ &X'_&N_W#U'YTI./2@#S[_A:L>/^10\59]!IQ/]:>WQ M3MU3=_PB7BS'?.F'_P"*KOLT>W'YT < /BK 1D>$O%9'_8-/_P 537^*\,9 M;P?XL /?^S3_ /%5Z#GC((_.@GZ4 >?K\5[1NOA7Q4/KII_^*IK?%NP4X/A; MQ7^&F$_^S5Z#^-'!]* //S\6M/R!_P (SXJ.?^H6>/\ QZD;XMV:D?\ %*^* MV'J-,/\ \57H0QVHXSCB@#@#\6+)*^?\ J&'_ .*H7XJV; '_ (1? MQ2/KIQ_^*KOZ* . _P"%JVVXC_A%/%>.Q_LT_P#Q5'_"TXRI9?"7B< ?WK#' M_LU=_P!>])D=,CZ9H X/_A9Z%%9?"GB,Y[?8^GZTC?$Y@I(\(>)#S_SY_P#U MZ[[.*,_2@#@4^)S../!_B0'T-IC^M/'Q)D+$?\(AXB SDVO_P!>N[S1GWH MX,_$Q@N3X1\0CV-K_P#7IP^)$A&3X1\0JOJ;;_Z]=U29[Y'YT %M? ]1:Y_K7>9'J.*/;- '!-\3E'3PKKY_P"W7_Z]-/Q10>CXJ R%?^$1\18]?LAJ;_ (6:!CS/"GB%0>_V3_Z] M=Y10!P/_ M*W!*GPSXCR/2Q.#^M._X6C;?Q>&?$@'M8$_UKO._7FC\: .!/ MQ3LPQ_XIKQ'@=SIY_P :;_PMG3 P5O#_ (E!]M,8_P!:] I,#/7F@#@3\6=+ M!(_X1_Q/@?\ 4+;_ !I[?%;2D0.^A^(P#_U#6_QKNR!WQ1CGZ4 <&WQ9T5,; MM+\0#(SSIKTDGQ'N=-DQ3F^+OAU6VO:: MR/\ N&R5WU'UQ0!Y^?B]X>4X-EKGM_Q+9!_2D_X7%X= R;+7 /?3I*]!S2=\ M#'% 'G__ N+P]DA;#768?PC37S2_P#"X-!QG^R]?'UTYA7?Y!Q@Y^E+0!P4 MGQ:T1$4G2]=;=V73V/\ 6F#XMZ-DXT;Q#QW_ +.;_&O0,X[T?C0!P ^+FD,# MC1/$7_@N:E_X6QIA("Z'XA)/8:>W^-=]CWI.V<_K0!PC?%73@^/[ \1X]?[. M/^--;XJV ?:OA[Q$WO\ 8#_C7>\8SV/.:#@=Z .#_P"%J660!X=\1$G_ *<# M_C1_PM6PW8/A_P 1 ^GV!J[S@=QFE(H X0_%*P'_ # /$/\ X '_ !H'Q3T[ M:"=!\1 G_J'M_C7=?CS2T <&?BG9+)AO#_B +V;["U#?%735(']A^(,=S]@; MBN\QGC.:3CL10!PJ?%32G&5T?7MN<9_L]J1/BOH\CLBZ1X@##CG3F&:[L8]> M/:CCUH X9_BEIJG"Z'X@8^@T]J1?BGI[?\P'Q"#Z?V>U=UQU)'N:, 'K0!PC M_%2P1PH\/^(VS_=T]C2-\5+%3_R+GB7'K_9S?XUWAP.21Z\TI /I0!P3?%.S M!&/#7B-L]_[//^--/Q4MAT\+>)3]-//^-=^>!DX %% 'GX^*D3 [?"7B+B>V-,/_P 57?<#VI.!@GZ"@#SYOBFP8 >!O&!^FFG_ .*I M3\4)=P \">+SGTT[_P"RKT'BC(/I0!P"?$VX8MGP)XN7'=M/X/T^:HS\5756 MW>!/&((_ZAG!_P#'J]#R,9%'% '"1_$II(@X\&>*UR,D-IX'_LU0/\50C8;P M3XN _O?V=Q^>ZO0L48 ]L4 < ?BK;KP?"GBG\-._^RJ1/BC:./\ D6?$ZGWT M[_[*N[R/4?G29'K0!PA^*-NC$/X8\2J.Q%@3G]:5OBC:*N3X;\1X_P"O _XU MW?6B@#@A\4[)@/\ BG/$>3V-@?\ &GQ_%"P=BK:!XA3'K8'G]:[K'O2<=(C@XQ_9Y_QKN>!WI#C')&* .$' MQ3LB(\>O]GG_&GK\4=.(.=#\0J?0Z>?\ &NYI..>1Q0!PA^*NF@X& MA>(2?^P>U'_"U=.+JHT'Q%DG_H'M7=X'?%! '.: .%;XIZ:C$'0_$/!QG^SV MH7XJZ6YQ_8GB$?\ <.:NZQS^M&!0!PI^*NF*?FT/Q$/3_B6O2GXJ:4J@G1?$ M1)[?V:]=R0.]+C- '!CXJZ8TFP:#XES_ -@QZD_X6?IW7^P?$G_@L:NW [TI MZ4 <$/BQI1)#:'XD4^^F/3D^*FE/)Y8T7Q%G&O]F/BN]*^HS2XZ>U 'G_ /PMW13P-'\1$^G]F/4C?%?1 MT17.C^(0#_U#7XKO",TF/:@#@3\7M#60*VEZ^N>YTY@*63XNZ#&X7^S]<<^J M:>S?RKOL4?\ _"W]!_Z!>OC_ +ACT[_A;OA_;DV6MK]=.DKOL48H X(_ M%[PRH!:/5EXSSI\G'Z4/\8/"R*I;^T\-Z6$AQ^E=[2T <"/C!X4V[MVH@>]A M+_A3XOBWX5G4E'U#CUL91_2N[I,4 <')\7O"L?WAJ1^EA)_A1#\7O"TSE5;4 M5P,_-8R#/Z5WM(1F@#AV^*_A@'!;4/PL9/\ "F'XN>&%8#;J?U^P2?X5W>/: M@T <2?BIX;";L:B1[63_ .%1'XN>%PV"-2W>G]GR?X5W6/:C'.<#/TH X?\ MX6QX9W*-NIC/K82?X4DGQ;\+HV"=1+9QM%C*3_*NZ_"DVC.=HSZXH X\P)LU(Y[BR? _ M2G-\4?#B-@C4!CO]BD_PKL]H'04NT9SB@#A)/BYX6CSEM1X]+&3_ ID?Q@\ M+RG"KJF?^O"3_"N]*@_PC\J H'10/PH X@?%?PT2!MU(9[FQ$8GV/+?@XSG[#)C^5=[@4$ ]10!P)^,?A =)[XD^EE+_A3T^,'A%R0;B]0# MNUE*/Z5WE% '!'XO^#Q)L^V7G'<6,V/_ $&@?&'P:S[1>W?XV,W_ ,37>8%& M .U '!R?&#P9$Q#7]S]?L4N/_0:$^,'@J2,NFI3\=1]CES_Z#7>$ ]0#^%-\ MM/[B_E0!Q)^+7@]8O,^WSE?06DI/_H-11_&/P1(X1=3F#8S@VDH_]EKNA&J] M$ ]P!088RVE']*0_%WP?G'VVY^HM)#F<*+^<$^MK(/Z4]OBOX2 )-],0. MZVTA_D*[(P1'K$G_ 'R*!;Q8P(DQZ;10!R"?%3PA)&7_ +2=0.NZWD']*5OB MGX/55/\ :I.>P@D_^)KJS96IZVT)S_TS'^%'V&TX_P!%A..!^['^% '*Q_%# MPA(X4:H1GU@D_P *8WQ7\%I*8WUI58>L+C/_ ([76_8;7M:P#Z1C_"D.GV;$ MEK2 GWC'^% '+'XI^# ,C6D;V$3Y_P#0:%^*/@]H_,_M8 >\3_X5U']GV1'_ M !YV_P#WZ'^%*-/LP !9V_'_ $S7_"@#E_\ A:/@[< =84$],Q./_9:>WQ+\ M)+&9!JJE1Z1/_A73?8+,G)M(#_VS'^%!L+-A@VD!'IY8_P * .77XG^$F0-_ M:H"GN8F_PH'Q0\'%]O\ ;29_ZY/_ /$UTXT^R7&VSMQ](E_PI?L-IDG[+!D_ M],Q_A0!RS_%'P;&,MK48YQ_JG_\ B:4?%'P5C)UV$#WC6O\ A2?V=9#_ )<[?/\ UR7_ M H Y4_%CP.)"G_"00Y'_3*3_P")J.3XO^ X_O:_'^$,O_Q-=?\ 8+0'(M(, M^OEC_"E^Q6O_ #ZP_P#?L?X4 <;_ ,+B\ [ UQGQ';_@DG_Q-.'Q9\"-T\26OXAQ_P"RUU']E:>?^7"U MS_UQ7_"F/HNEN/FTVS/U@0_TH P1\3/!9C$@\06FP_Q?-_A3?^%H>",X/B6Q M!]V(_I6[_P (_HW?2+ _]NR?X4UO#FAMUT73C];5/\* ,A?B5X,D4E?$FG$# MKB7FMS2=8T[7;%;[2[N*ZMF)42QG(R.HS58^%O#_ "?["TSGK_HD?^%7[*PM M=.MUM[*UAMH!DB.&,(H)]A0!9HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH #T-5KW_5+_ +U63T-5KW_5+_O4 M 6**** %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!#P":X/7-5O-5;7UTZZGM M;/1+64-+ V&DN1&6V_11C\37>GI7FOA<*OP;U&XP[W%Q%?23L0=S2%I!S[XP M/PH =HOAZ]O_ II^HW'CC6%DN+5)VF\]0JL4!/7L"?TK/L?$6K7FG>"#<7C M/+-JTEO<3)PMPB!P&]P0 >*V?#'P_P##4OA/2C/IAD=[6)W$TKYW%0>1G'6C MQP+306\+3QVK1V=EJ0)6WCSL3RV'0<]2*0'>:?XXT/5-2AT^VEN#<3@E-ULZ#IG!)&,X%<) MX;UGPC8P:C!K%@9+QM3N9&>;33(6S(<$';Z8I@=SX0L].M+2[DT[7;C589)2 M3)-<>=Y9 Y (KG=(UG6#XSAUFXN-WAW6V:ULX0#^Z=.8W)[;]K_F*CO_ !;H MLOA^XTOPE;RPWE]*+9!'9/&(RYPTARN!M&3GVINI_#2\MO":6MCXEU61].19 MK2%RNPR)R.@SZBD!M^/-1O+'^R;:&\GT^QNIS'=W\*;C;@+E>>V3QDU1TG1[ MZWU73[WP]XMGU;3]X6]MKRY68,ASEU('# XXJ:^\3:F^EZ)KMOIKW>DSHPU& MT6+,L9.!D*>N&!!'H:YZ^ET?6-8TAO!VB7,>HQ7\4L]Q';O;)%$#\^_( .02 M,<\T 6=4FLKKXAZY!J_BZ[TN.UAMA;6\5YY(.Y,EOS_G70>%++1EUA[C3/%E MYJ\@@(,,U^)U",P(;'X8_&N=N=1T/1OB?XE?7M-DG6ZCM6@G-B9E 6/##(![ MXKI_#VN^%[K5A;:/8F"Y=#\PLFB!4)MK* MK2*#SVX-<_K_ (;M=#\-WNIVOC/58+JWB:6&:2^#HSCD H>&STQ[UN?$ZV%[ MX)FLV@>>.:>!)(T!R5\U<].GUJQ!\/?"4$D4R:':[XP-A?+X_,TP.8UJYGUG M5?!T6HZQ<:7;7MA--=+!<>0SR!(R 3V')/X8JEKD-IX:;3+O0?&.I75W)>PQ M+9M??:1<(6PPVCT!/-='XETFTU7XA>&X;ZP2ZM4M[DE7BW(K84#/8<9_*JFJ M^';+P9XCM/$VC:/"+69Q!J,<$/S(K<"5 !P0< X[&D!I:==7$GQ1URS>YF-N MFG6[)&'&R,DL#CW[YKG/AKXBU:T<:?XBE>2#5)I9M+O'T$?V>XV/#^ZW$(>P)ZUEKX1>3Q M[+HZ^+O$R6Z:3CD8%7_ (:S:OU6![Y S6K;H_\ PMZ\D\MO+_L6-?,Q\I/FDXSZXH Z#2=._LG3(++[5=W8 MB7'G7MW^DZ':W#V\$5EA)+DH<-(TG4+N! &.U M>A'H:\WLM9;X=S7>EZ[:W1TM[F2>QU"WMVD0+(V2C["/$ MFF65WK%[J^CZK(UNDE\0\MM*%+*-_P#$&P1SWK,M]-3Q!XI\1C4?&.M6*VM^ M(X+2UU,0JJ[ >GU)_*M)=0D\>^(-(ET^PN8M$TRX^UR7=Y;M$9I0I"")6Y.- MQ))&./6H])\(Z+XAU[Q5<:SHL%TS:AY:2SQ')01J!MSV!SR.OX4 +X=>;2OB M*^C6GB*[UC36L3-(ES+Y[6\F\8^<=,C/!KK-?\/KK]O#&VI:G8^4^_=87/DL MWLV.HKF?"6GVW@CQ#<^&TL4BM+O-Q972)DN/XHY&QU&,C/:N_P"G>@#RK0/" M5QJNK:]!<>+?$Q@T^]$%N(]0*G;M5SGCKSBM>[>;P%KD5Y/>7EQX=OL0W!N9 MFF^QR]%DRQ)"-G#=LD5;\#QNFN^,2RN%?5RR%A@,/+3D>HR#6OXTC27P3KB/ M$)0;&;Y-NGOZ4 8NC7=UXM\2OJT-Q-#H.GEHK14;:MY)T:0XZH.@_.L# MPMX+/ BQNLND, B[B/[(8].P(7K2 M[NQBBBTZWBAF>:)8P%D9]S,,=2>YKS?4-;)/X*]A#_Z@ MNHPX'H,9/UKTC3;NWO\ 3;:[M@RP2QAHPZ[2%[9!Z5R^BV8N/&/C.*ZMV:VN M#;*-Z?*X\H@X]:8":Y>2GQYX-6"[(MKA;MG"'Y90(E*GWY/'UJOXYEUO4[R' M1_#MY]FO+6%M1E8#._:<)'_P(Y%8::;JVA?$KP]83(\V@V,=U):7&TDQAHS\ MCM[8P,_TK1\/Z%>>([N_\52ZKJFGS7TAB@MT(14@0D)D=R1S]: .EGU@7_@2 MYU>"3RF?3Y)8G"$D?4'(_"N9^$>H:H=(N=*URYDGU"(I=J\K[F>&50RG\ M\BH+.SE\/Z'XL\)R/=74,.GRW-G*Z%FD1T;FW$04[@VT;&QZ@EJ )_#VK:SJGQADN9KN0:+=6D_V. 2':1&X3=C MIRPTAM'\9^%[2.*0PV MFBRQ/(!QNRA.3TR2"?SK!\):WX7T;PS;66JZ'<"[C>3S=^F-(23(2"3CZ4 = M]X/MM,M=&;^RM6GU.T>9B)YKCS3GN U5_&UY>FQM-$TF:%]EOV+:CI\K6=TQXWNH'S?1@5;\ M:Y#X;^)-8MC%IWB20M#JE %:^U6]M[CXE/]MEVV5I&]L%;_ %1-N6X]\\T[2/!=_=Z!87B>,]?CO)K6 M.4L;@,F2H/W,=.:Q='35KO2?B4VMV+17LJF';$I(DQ 54KZYX/'K6YH_Q&T* MR\)V".;U[J"TB5K9;.0NSA0"H&/4?K0!M^"-8O=3TRZM-4D234],NGL[EXUP MKLN"&_$$58\7:CBBWL6*ZA?R+:6S#^!WSE_HH!/X5G_#^QOX=,U#5M3MW MMKS5KQ[QK=CDQ*0 JG\ *H:Q8W/B[QS]EM=3N].@T.(.9K<#,D\G;D8("@?F M: -;P-J-]<:/+IFK2^9J^ER?9KI\_P"L/57_ !4BN55CC56X*Y&>]3VFG7G@[Q]!)'[W6=&\37WAK6=1;45 M%E]ML+QU"RL@.UU?'!()'-87@_0-?\3^$;'6YO'&N6\]VC2>7&8]B?.<<$<] M!WK8T:X;Q5XVN_$-O;2PZ3;Z<;&WGF4IY[,P=F"D9VCIDUD^!?B#X6T3P+I> MG:AJOV>ZMXS&\;029!WGL%^E %^'7-?LO#/B[3=5N5DU31K;?#?1KM,L;HS( MY'9AM.?>FZ?X6U"_T"RO&^(6MB:6!)2Z31; 2NY^#VL:@=91KNUN6MH=4A 7S(UE1?,'&,X)JX=(M%@\R? MXJ:F/DR7%_;J/K@K_6JNJ:O87WP>U.WBL8;-[(Q6EY8JGRQ.)$#* !R.X/<4 M2:E\&X%_>VVADKW;3R__ +(: -;QEJUWH6CZ%90ZV]M;73^3A>-UZ$9^[WJSK'B&*WT MW2KZPT]-1\*S*RW:PVQ=HTQ\A")Y_#EM;^6+.*!Q"]WN'^L\QNV MRO),>;S]Y6QUP<8-8&K^(K?3M3U"P\?Z M9!)IKR;M.NA8F:)X^ZL1NVMGZ5'X%^QMXNU6]\/VEW:^''M$&9%=(I9@?O1H MW(PN1Q0!Z8?3-WFUR[&UP01]W:RGMCL:SO"MOK9^(VJ:;K:F:. MTT=+2*Y5,">,OD,?]K!&10!:T"QUKQSIB^(-0UZ^L+6\W-9V5@?*$<6?E+-U M8G&>:O0V_B71O"'B6WU?4/M?V>VF:PO)M"\37#Z?)::4UJ\.GI-&4GE/EMN M8CT)(P* .@\(7$MSX-T6>XD>262RB=W8Y+$J.367:W5T_P 6-0M6GD0N ML6[Y-S2-E@/7 K#\._$CP_I?A33+6]DO$N+:UCBE7['(=K!0,=*NZA>)H7CJ M/Q*UK>3:;J6G) \T,1<1,K;E+#J 0U &CXRO+NUU7PHMM<21)/JRQ3*O\:E& M.#^58=EIM]XE\:^*5G\0ZM;P6-S%%;P6LVQ%!B#9]^2:EN-5B\:^*_#Z:5%< MM::9=/=W-Q+"T:Y"%5 R.3EJBT[Q)IWAWQCXKBU$7,33W4(M8@^'WABWM9OM.LZNYB6XF&0@^9GD([[0.E;'C72; MZ#/BC0%']K6ML\;QX^6YB/.T^N#R*PM,TG4Y?A]X/U:PMG;4M(7SOLDGRF12 M"KKS_%CD4 ;=QX*U1K0RP>+M8&JJI*3&4>46/8Q8QM)Q72:$VJ-HEF=:2)-2 M\H"X$)RF[V^O6N$UGQ!X7\2+ ;ZRU[[;$K*EO%#-&ZD]0<8!/'7I72_#RPO- M-\%V5M?07$,ZEVV7,F^0*7)7<133Z[Y#W,4VUUC-P5/S>F*T_$&@Q>'-$N=4T[QGJ ML5[ \0N;X2I.PY$93N6Z?C63-8R7?PJL[)[*:59=?\ WL3(2?+^T,22/3'? MWKT*T\!^%K"[2YMM$M$E4[E:RO;:!I5*NV=C!02&!)[4 ;&AV.M^'#JBZOJQO]&B4RVM MQ.Q:X10,LKG !QV-8VEZ)JGCC3(]:UC7M1M+:]3S;:PTR?R4CB)RNYAR[$8/ MM6KHVJ:AXNNM3,VG36GAY[\16 M%ZIL8Q%;W5K:O-#<1CA<;02&Q@8-("WI,VI>&_$DGAW4-1GO[*YLY+FQN)_] M;'L(#QEAUX((-8O@WP8FO^#+'4KOQ)XF%Q=H9"R:HZ[/F(&T#@<#N*V=-34/ M$WB:?Q!/87%GIMG:26NGQ7 V23,YR\I7JHP H!]S6-X,\=:9HGA.PTBZTW7% MNK.,QO&NFRR-BI8C^ M)2",U@:3_P (9<:#8M>?$C55N?(5IA_;94JQ7YN#R*W;>SU#4M#\9^(KNPGM M)-5L6@L[60$RB)(F5=R8X8LQ.*HZ%XK\#0^'-/M+O195EM[:-)EDT5CA@H#< M[,'GTH ]"\,PV4&@6B:?J4VHVFW,=U--YK2#UW=ZUSR".]-F:WE5=P4O_$" M>M5]-U<_#]'T;6K6Z;3TEDDM+VVMVD0H[%MK!02&!)^M2VMS+XV\6Z7J,%C< MV^CZ09)EGN(S&;F9UV+M4\X +'- &!:/IU_KGB,:OX]U&PG@U*2..U345@$: M _+@'J.$;"QM;*:XT[7+S5[>>3/G7-R)MN.H5@*Q?!FC:;>7'B:>]T MJUEF?6[@AYK=6+)\NW!(Y'6NUM;*VL81#:6\4$0S\D2!5Y]A0!S?C=]2O+&W MT+1KP6FHZBSJ)_\ GE&@W.?SVC_@57O"&K7&L>'+>>\&V^B+070QC$J':W'O MC-:NNK:AI\.GC[%:"WPI?@&1CD8.3@?A3M!T^Y\*^-KK2GO;J M[M=6A-TD\X!VW"\,.!CE>??!H Q],NCXBN+Q=9\6:AI&II6;B%2X$>_ EV]V"IXX\%P?:)(4F- MV9XHY"%D*Q X([@&N6\1:EX:U_1KJ+3_ ]>?\)%)$8X4CLFBFBE/1B^.@/. MQ^)/ 8NEWW$2SK<2!<@/Y !Y'3D'ZXI@,MYM5\;ZC>S6NJW&F:+ M97+VJ?9@!)=.G#-N/1<\ =\5[LKV"-I H<99'V\@AL\]\UB:79V=WXUT.?PN MFL2V<,\LMY<3R2"':588P_.7(^*]A:K<.+.32))#"#\K.)5 ;'T_G5'P[IJ:EJ'CFQU&V M,EK=:B1AU(WJ84'!_#K63X=@UFR^*-OINIIYT&G:9)#;784_O(RRD;CTW<#C MV- %+P])!K&FW4^K^/;ZSN1>3QM"+](]@60@#';@5M7)ATKX;>(+K2/%-WJ> MR*1DNVN%F:)P.@(%87A'4O!=II5U;:Y8VRWR7UP9&GL"Y;YR0<[2>E;&MZKX M?O\ X:^);?PO"I2*$[XH+9H\NV.0I )I 5K:TT.32X7N/B9J!D>)=S_VHBC. M,\ =*VKHR>%UT358-7N+[3)/+M+EKJ7S-ZO_ *N8-Z@G!/0AO:LRU\2?#=;& MU,UG:H6B3(DTUBPX[_(:N^-+ZPU;X;B'36PE_-#;68$94A_,7&!@8 "D].U M'?@\TM-7TIU, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ /0U6O?]4/\ >_I5 MD]#5:]_U0_WJ +%%%% "T444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 &L;0-"&A MVMW;+,TT$]U+.B,O^K5SG9[CDULT4 -5=HP /RH*@D$CITSVIU% #2N>2 2. MG%($"G@8'H!BGT4 )CV]Z3VYIU% #%154!5 'H!BE"@=LTZB@!N.?TS2XI:* M $90PY /X4?YYI:* &A &!P,C@&E8 J01D'K2T4 -VCKCD]Q2!0H "@#V%/H MH 9M&2=O)Z\=32A1N#;0#C!-.HH *:5!&,4ZB@!N..G3VZ4*,'@8]\=:=10 MTJ&()7)'3(I3T-+10 T#!_&E8 J01D'J*6B@!F.*4#!X&!3J* "FGIWIU% # M=O&* H!) )ZG'6G44 -*@]LCTH"X7"@#TXP!3J* &;1GD9XQS2X_P ^].HH M 9CG@_2E [TZB@!I4''&2#D>U 4 <#CZ4ZB@!@49R M5P3UQUS]:7&!P/RIU% #><=#2! &+!?F)Y..:?10 PHIP64$CD''3WIGD1[M MWE)GO\HZ^N<5-10 T# P!C'M31$@4!8PN.F .*DHH :RAD*LH*D8(QGBD"X M ' Z#TI]% $0@C&[]TGSG+':/F/O2&WAVE?(C(/4;1@U-10 Q4"*%50 .@ X M%+] 3]*=10 W'MG-)MP..,=A3Z* *6F:=!I-A'9VRL(D)(SUR3G^M6MH)R5Y MQC..QZBGT4 1J@&<+@DY.!C)IV._>G44 -P:"#CN:=10 PJ"I7''<4H'3VIU M% #2,D'F@CGI^E.HH ;@!< ?04T1KMV%!M'08&/6I** &D9&",T!0@PJX'H M!3J* &[?R^E+^%+10 W'-!'?'-.HH 8$'3;QG/0=?6G"EHH #TIOX&G44 -P M?QH(/!IU% "8I-OKS^ IU% "$<8Z4'-+10!5O;&&_@\B=2T>]7P#CE6##]0* ML =/_P!=.HH :1_.C':G44 - P:<>E%% #0H'08_"@J"02!QTR*=10 W!_R: M,9[#-.HH ;C%& 2#CH?2G44 -(^OK]*",#IQZ4ZB@!@4 D[<$]3CKVI=O.[; M\W3-.HH B,*#[L:\GT _'I3@@!) Y/4XZT^B@",Q1G&8UX_V:R[C0H;S7+._ MN"'2S5C;0;/E1SP7^N.!]36Q10 @I:** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "JUY]Q?K5FJ]Y]Q?K0!/1110 M%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !5>\^XOUJQ5>[^XOUH GHHHH 6BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JO=_<7ZU8J MO=_<7ZT 3T444 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 57N_]6OUJP>E5KS_ %0_WOZ4 6**** %HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBC- !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%&: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHS0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11D4 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%&: "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **,T4 M %%%% !1110 4444 %%%% !1110 4444 %%&:* "BBB@ HHHH **** "BBB@ M HHS10 4444 %%%% !111F@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M ***,T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%&:* M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH ***,B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH #T-5[O\ MU8_WOZ58/0U7N_\ 5C_>_I0!/1110 M%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %4]1U2PTBW^TZA=Q6T.<>9*VT9 M]*MD9&*I:CI-AK%M]GU*R@NH=V[RYXPXS]* ,4_$7P<#@^)=,'_;=?\ &D;X MD>#%Z^)M,'UG'^-64\#^%$7"^&]) _Z\X_\ "IAX/\,@<>'=)_\ */_ .)H M H'XD>"QC_BI]+Y_Z>%_QH_X6-X.)('B3321U F%:'_")>&^_A[2C_VY1_\ MQ-*OA3PZC%ET#2PQ[BSC!_E0!E'XF^"ESN\26 Q_M_\ UJ1/B=X)D.$\1V!/ MLY_PK8'AG0?^@)IO_@(G^%*/#6A+]W1=.'_;JG^% &2WQ*\&I]_Q%9#ZL?\ M"F_\+-\$A=W_ DECCUWG_"MG_A'-$+ G1M/R._V5/\ "G?\(]HH'&CV''_3 MLG^% &"WQ1\$ X/B.R_[Z/\ A3G^)W@E$5V\1V6P]&R2/Y5N_P!@:.?^818? M^ R?X4?V#H^W;_9-C@=OLZ8'Z4 8'_"TO W&/$=GD]/O?X4[_A9W@O>5_P"$ MAM,CDYW?X5N_V%I'_0*L?_ =/\*7^Q-*SG^S++/K]G3_ H YU?BIX'8D#Q# M:$CV;_"E;XI^!T56;Q#: -TX;_"NA&AZ4#D:79 ^UNG^%+_8VE\?\2RSXZ?N M%X_2@#GQ\4/!3)N77[ZHQ_I73?V98<_Z!;<]?W2_X4#2[!>EC;?A"O\ A0!RS_%7P9&K M$ZU'\O4>6_\ \32?\+9\$E59=_=/\ X5U_V&T_ MY]H?^_8_PI/L%GS_ *)!SU_=#_"@#CS\7/!GF^7_ &H2V,X$3?X4]_BQX.B M,FJ%0?\ IB_^%=9_9]GG/V.#/KY8_P *=]BM?^?:'_OV/\* .0'Q:\&$@+JQ M)/\ T[R?_$T2?%OP5&Y1M8P1U_<2?_$UV!M+WD2'^E=F;:!NL"?]\BE^SQ M?\\H_P %% '$#XQ>!R#C5V_\!I/_ (FA_B_X,3'_ !,9R#Z6LI_I7;^1$!Q$ MG_?-.$:#HH'X4 <#_P +G\$?]!*?_P !)?\ XFI$^,7@QU+#4+C ];24?TKN M]B?W5_*C8O\ <'Y4 <"_QE\&H,_:KQO]VSD/]*%^,GA%QF.74)/9;&0_TKO] MH'0 ?2C% ' R_&+PG"<.VHCZ6$G^%'_"X?"GEK)G4MK=/] D_P *[['^31CV MXH X)?B_X5;H=1_&QD_PIO\ PN'PONP%U3VS82#/TXYKT"DQQ_C0!PTGQ7\/ M)M/V?5FSTVV$A_I3!\6_#Y; L]:_\%[UWGX4?+\8O#C?=L];)]!ISU*?BWX>"Y^RZQ]/[/?-=Y]! MBC% ' K\7?#SG L=<_'3G%2?\+7T/MI^MG_N'O7=X_ZASU*/BIH[(6&EZY]/[/;_&NYQ1B@#@9?BUH\<:M_9.O$GL-/?BFK\7=# M=OETS7CZ_P#$O?BO0,?6B@#AA\5M%*Y_LS7/73&']:[K'XT4 <&GQ4T^1@%\/\ B;'JVFL/ZTDGQ6TV-L'P]XG/ MN-,8C^==[CC HQ0!P9^*VE!?#_ (F'UTMA_6N_ MQCIQ28YH X0?%336BWC0/$A]AIK9_G40^+>F$X/AWQ0/?^S&_P :]!QCI28] MJ .$7XJZ:REAX?\ $V!ZZ:W^-*/BEIQ&?[ \2@?]@QO\:[O'']*,<=!B@#A1 M\4=/9BJZ!XE) S_R#6&?UII^*5F,?\4WXEY&>=/Z?^/5WF*,4 >?K\5[1FVG MPSXE7W-@0/YU*GQ0MG.#X;\0K[M98S^M=WCVHQ0!P0^*=GCGPYXD!]!8$_UI MR_$Z"0'R_#'B+_@5B1_6N[Q10!PZ_$F)NOAG7UQ_TZ?_ %ZB/Q0B#8_X1?Q$ M??['_P#7KO:,'UH X3_A9L8&1X8\0'V^R?\ UZ5/B6CC/_"+Z^#Z?9?_ *]= MUS1]: .&'Q';DGPGX@ ]3; ?UIG_ LJ4X*>$-?/KFW _K7>G_P!>E'Q)G)_Y$WQ' M_P" G_UZ[NC ]* .&;XBW28W>"_$?/3%KG^M._X6%<%-W_"'>(P/>U_^O7;_ M *T4 <1)\0KA54KX0\0R,?X5M>::_P 0[Q0I'@CQ(V>H%L./UKN<4M '!O\ M$>[49_X0?Q2?I9C_ !IH^)%R?^9'\4 _]>/_ ->N^I* .!?XDW:J2/ ?BEOI M9C/\Z"?%(QW-CC/ZU MW_X48H \^;XGW"A2/ GBIE)X/V+_ .O3G^)=TJAE\"^*7^EF,C]:[_'M10!P M*_$F[<<>!?%.?0V8_P :G'Q ORN[_A!_$H]OLR_XUV]+0!P$?Q'OV/B+>\Y\#^)% [FW7_&N\Q28H X,_$>\[>"/$1_[8#_&GGXA7ZA2 MW@CQ%\WI"#C]:[G%% '"M\1+Q25_X0KQ$2/^F _QI!\1;PG_ )$GQ$/K"/\ M&N[]\4M '!K\1;ML_P#%%>(ACU@'^-+_ ,+&NP?^1+\0?]^!_C7=8HP/2@#A M5^(UVQQ_PA?B$?6 ?XTO_"P[O!_XHSQ!_P!^1_C7'&?!7 MB$?]L!_C3A\1+LL0?!?B$ =_('^-=SBB@#A8_B/.X;/@[Q$".WV7K^M,?XE7 M2G \%>)#_P!NO_UZ[W [#%&* .%/Q)D1-S^$/$0^EIG^M5S\50O+>#_$^")X_6O0L>U'- '"-\3HEVD^%_$?/866?ZTW_A:=F#\WAKQ./^X:3_6N]HY] M* .";XJZ>O7P[XHQZ_V6W^--7XL:8W_,O^)Q]=+;_&N_Q1B@#@?^%KZ;@$>' M_$YSV&EM_C2_\+7TL==!\3#ZZ6U=Y@TN* //_P#A;6E?] 'Q-_X*VI5^+6DG M[VA^)4'JVF-BN_VT;: .!'Q:T=SA=%\1L?;3'H/Q8TD,%&A>)<_P#H5/C^)D$F3_PBWB=0.YT__P"RKN,>PHH MX5OB=;+$7'AOQ"Q'\/V+YORS4,7Q4BD'_(J>)5/^U8D?UKT#%'- '!_\+/C_ M .A6\1?^ ?\ ]>E'Q++("GA/Q"Q]!:<_SKN^:,&@#@T^)4CN$_X0_P 1 GUM M?_KT]OB043)\*^(-V<;?LH_QKN>:.: .$'Q*=C@>$O$!_P"W7_Z]*_Q)*(6; MPIXAX[?9?_KUW5'- ' #XH# +^$_$(!_Z=<_UIT?Q.24L/\ A%O$"@=VM.WY MUWM&/>@#@5^*EF[LJ^'?$!VG!Q9&K ^),!7(\/Z[CT^R'/\ .NVQ1B@#@XOB M='(6'_",>((R?3[%_\ 7KO** .#7XEEC@^$?$2G MMFTQ_6C_ (64V[:?"7B('U^RG%=Y1S0!P8^)3[L?\(CXB/TM2:5?B3,[;1X. M\29][/\ ^O7=T8]J .!/Q*NQ(%_X0CQ&1_>%L/\ &IF^(5QMR/!WB%F_NBUY M_G7<8HQ0!PZ_$.\(/_%$^)0?>U_^O3/^%D7>\(?!'B7)_P"G3_Z]=Y24 <&_ MQ&OE&5\">)F^EJ/\:1_B-J"1AQX!\3L3V%J,_P Z[ZB@#S[_ (63J7'_ !;_ M ,4X/3_11_C3E^(^I-U^'_B@#WME_P :[^B@#@G^(VH(N?\ A ?$[>PM1_C4 M2_$O4CG_ (M[XJ _Z]1_C7H5% '!I\1KQE);P)XI4@=[,?XTS_A9ET&13X#\ M6\CD_8>!_P"/5W]% ' O\2+I2,>!O%1![_8QQ_X]3D^),C'YO!GB8?\ ;F"? MYUWF*3'M0!PK?$EQT\'>*#_VXC_XJE7XD2,I/_"'>)P?0V0'_LU=SBC\* .# M3XELS[6\'^)4/J;,8_G4K_$?:1CPKXB/TL__ *]=O1S0!PK?$K'W?"7B1O7% MG_\ 7I?^%D';N;PIXA4'IFTY_G7<\T8Z>U '"GXEJ"/^*6\0X]K3_P"O33\3 M".!X2\1'ZVF/ZUWE'- '#K\2X/++/X<\0(P_A^Q'^>:8/B="4W?\(UK^?0VA MKN\>PHH X'_A:,.<'POXA_"S-._X6?%M+?\ "+^(N/\ IR/^-=YBCF@#A(_B MA:/P?#WB!7[*;%OYT'XG0J0/^$:\0L>^+(_XUW>/844 <(OQ-4\GPKXC"^OV M+_Z]/'Q+M#U\.>(=WI]@)/\ .NXHQ0!PI^)D"_?\,>(U'8_8"?ZTA^*%F/\ MF7/$A/MIQ/\ 6N[YHQ0!PB_%"U?_ )EGQ,!ZMIK ?SIB_%2R.1_PC/B@8_ZA MC?#/BD>W]F'/Y;J[VB@# M@!\5[ _\RSXJ_P#!4W_Q5!^+%@#C_A&?%7_@K;_&N_HQ0!P#?%G34(!\.>*" M3T']F-_C3G^*NG1[=_A[Q)SZ:<6_DQQ7>XHQ0!P*_%K23G=H?B2/'][3&']: M&^+FBKTTCQ"Q]!IKUWVVC'U_.@#@1\6]$QE]+U]!_M:HV^+?AU&(-KK''?^SI/\*[WFC!]J M .(_X6IH'E[Q;ZL1_P!>$F?Y4R/XK^'Y"0+;6!]=/D']*[JC&* .$/Q8\/#/ M^C:QD>FGR?X4+\6O#LCE/LVL#ZZ=(/Z5W>,44 <*?BMX>4$_9=8X&?\ D'O_ M (4H^*WA\QHXM=7(;I_Q+W_PKN:,4 <*_P 5] 0?-::P1[:>YI5^*OA\KN%K MK'T_L]_\*[FB@#@O^%N>'LG-EK8(_P"H=)3E^+/A]A_QZ:RH]6T^2N[Q[44 M<*?BOH.PL++66QZ6#TUOBUX>6-7-IK//\/\ 9\F1]:[RC% '!R?%OPW$FY[? M5A];!Q4@^*WAYD5_(U3:PS_QY-7;D9[ _A2^U ' I\7?#?A1S0!P ^,/A=F"B/5B3V_L^3_"GR_%OPU" 98]34 MGI_H$A_D*[RB@#@E^+_A4OM/]I)WRUA(!_*C_A;_ (2\HR>;?E0><6$H(_2N M]P*6@#S]?C+X08X$NH_C82_X4X_&/PBHR9;_ /"QE/\ 2N^HH \_7XR^#W)' MVB^!'4&PE_PIQ^,/@X+N-W>\?].,W_Q-=[CG/?O00,4 <(/B]X1:/>MS>'V% ME+G^5"?%WPDQ8":^&.N;&4?TKN@HSD 4N!SQUH X8_%WPD!S$00#>7&3_ -.DG^%=L(D#;@@!^E#1(X^9%/U&: .+_P"%L^$\C_2;LY[B MTD_PH;XM>$4(#7LX)];9_P#"NS$$0&/*3_OD?X4TVL#'YH(C]5!_I0!R!^*_ MA+>$%]*6/_3N_P#A3X_BCX4D9E6]ER.N;=_\*ZS[';9S]GBS_N#_ I1:6^< M_9X@?9!0!QI^+/A'S"GV^;<.WV9_\*?'\5?"38'I;O\ X4P?%KP@RDK?RG'8 M6[_X5V/V2 =((Q]$%(+*U!S]FASZ^6/\* .2'Q4\)&,O]OD 'K;N#_*D/Q8\ M'KC?J3IG^] X_I77_8[;_GVB^NP?X4&RMF^];Q'ZQC_"@#D/^%L>#/\ H+C_ M +\O_P#$U(?BEX/\LR?VNNT=_*?_ .)KJOL5K_SZP_\ ?L4?8K4'(MH<^H09 MH XY?BYX-89&J-^-O)_\33?^%O>##)Y:ZG(7]/L\G^%=J+: ?\L8_P#OD4?9 M8,Y\B//^Z* .,/Q<\%A23JK9';[/(?\ V6G-\6?!@A63^U7(;H!;R9_]!KL1 M;PJ,"% #U^44OV>+(_5'C 1/Q6FFV@/_ "QC_%!0!QK?%_P*B!GUY%SZ MV\N?_0:5/B]X#D("^(H23V\F4'_T&NO:SMF/S6\1QTR@I#I]FPP;.W(]#$O^ M% '+-\5O ZC+>(+=?]Z.0?\ LM-'Q8\"-Q_PDMI^(?\ PKJ#I6GM]ZPM3]85 M_P *0Z/IG_0.M/\ OPO^% '-CXI>!FX7Q+9$_4_X5TFF:I9:Q8QWNGW"7%M) M]V1.AICZ'I+@A]*LF!Z@P*1_*K5O:P6<2PVT$4,0Z)&H4#\ * )J*** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M ]*K7G^J'^]_2K)Z56O/]4/][^E %BBBB@!:*** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** ]#5>[_U8_WOZ58/2JUY_JA_O?TH M L4444 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 'I5:\_U0_WOZ59/0U6O?]4O^]0!8HHHH 6BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ /0U7N_\ 5C_>_I5@]*K7G^J' M^]_2@"Q1110 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% >AJM>_ZI?]ZK)Z&JU[_JE_WJ +%%%% "T444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !0>E%% **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ]#56^_U*_[W]*M=JJW MW^I'^]_2@"S1110 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%&0>] !1110 4444 %%%&: "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHR** M "BC(]:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBC(]: "BC-% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !111F@ HHS10 449'K1F@ HHH MH **** "BBB@ HHHH ***,T %%%% !1110 4444 %%%% !1110 4444 %%%% M !11D>M% !111GG% !11FB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHS10 4444 %%%% !1110 4444 %%%% !1110 449HS0 444 M4 %%%% !1110 4449'K0 4444 %%%% !1110 4444 %%%% !1110 449HH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MS10 4444 %%%% !1110 449HH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH ***,CUH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** #M56^_P!2/][^ ME6NU5;[_ %(_WOZ4 6:*** %HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ -8OB/^WUTT'PW'9-?;P,7I8)MQS]WFMJ MB@#SZ.3XLNHWVWA.,]\/.333_P +;X 'A7'?F8UZ'10!YTX^+S<(?"0]V$U* M(/B[N^:Y\([>^$G_ ,*]$HH \]6V^+3-\U]X55?:.;_"@6GQ9,C?\3/PN%[' MR9C7H5% ' _8OBELYU3PUOR.1!+BD^P_%0S$_P!K^&A%V MY:_H6W'\-HV: M[VB@#@VTKXF%R5\2:*%]/L1H72OB6),MXDT8IZ"R-=Y10!PATKXD?-CQ)I S MT_T(G%.&E?$8P!6\2:3YH_B%D#2#0_B,IS_PENFM['3@*[RB@#A7 MT?XC$?+XITM3Z_V?G^M1R:%\2'A"KXOTU7[D::/\:[ZB@#@7\/?$0Q@+XTLP M_<_VRYZ_\2M?\:=_PC_Q M$P0/&EGCL?[-7-=[10!YZ?#7Q(,A(\=V@7T.E(?ZU*/#?Q!\L@^-[;?V8::@ MQ^&:[VB@#@#X:^(@8,/'5MQV.F)_C2?\(W\1FX;QW:@'NNEIG^=>@44 >?'P MK\0=PV^/TQWSIB?XTY_"OC]E 'CY%/\ >_LQ#^F:[^B@#SV/P=X\$SO+\179 M2,!!I<8 /_?51)X(\=[1O^)$^[.3C38\8_%J]'HH \]D\%>-G=2/B/T4 <(G@ M?Q*KY/Q!U0KZ&WCH?P/XE;I\0=4'_;!*[NB@#@U\#>)@P)^(.JD#J/(2E;P/ MXC//_"?ZL/I#'7=T4 <)_P (+XA)!/Q UC'_ %RCI6\"Z^5 _P"$^UH8ZX1. M:[JB@#BI/!6MN%"^.-60#J51,FJX\!:^LRR?\+ UH@'.PHF#^E=[10!Q+>"] M<9Y"/'&KJ'Z (GRGVJ/_ (077C'M/C_6\^H2/_"NZHH X5? >MJ!GQ]KI([X MC_PIK> =<8_\E UX?01C^E=Y10!P9^'^M%0#\0/$''7!3G]*=)X#UF1 H\=Z M]%CNC+S]F8_P#"N\HH M X$?#W6=Q)^(/B(^V]/\*67X>ZM)C'C_ ,1KCTD3_"N]HH X*7X>:JZ!4\>> M(8R.I65>:B/PXUK((^(GB3_OXM>A44 >?I\/=<4<_$'Q P]RF:E/@'6?-##Q MYKY3!!1F3!X]@#7=T4 <$WP^U@GZX'W?\+#\0 M8]/D_P *] HH X%?A[K*OO/Q \0L?=DQ^6*D_P"$"UK/_(^ZYCZK7=44 <$? MA]K)Q_Q7^OCZ,M"?#W5T#?\ %?>(6)Z$R+Q7>T4 <%_PK_6"Q)\>^("/3:C"6(\;Z^^>FZ M4$"N[HH X0?#R]R2WC7Q"<_W9P/Z4W_A75_O++XW\0#/8S UWM% ' I\.+]5 M8-XX\0L#ZS"G2?#B[DQ_Q6>OC'I,.:[RB@#@G^'%R^W/C'7\+V\\4( M5_X2W7LG^(7&"*[NB@#A!\.)T''C#Q!^-QG^E(/AO<8.?%^OY/<3@?TKO** M.$;X;S,P/_"8>(>/2Y_^M43?#"1RK-XR\2ET^ZPNA_\ $UZ!10!PB?#B8(5; MQAXC8'@_Z2/_ (FHXOAE+&-I\8^(V&]&/_ $&F MM\,$<'_BK/$H9OO%;P8/_CM=[10!P+O$I'_7X/\ XFD'PRVR;U\8 M^*0?:_Q_[+7>T4 >?I\+MK,Q\8>)G)[M> D?CMII^%>7#CQEXH!'I>C_ .)K MT*B@#@I/AG,^W;XW\51X[I? '_T&FK\,KA3G_A._%['T:_!'_H-=_10!P$?P MQ=)5F/C3Q8SC^$ZA\G_?.VB3X97$A(_X3GQ6H]5OOF/U..:[^B@#S]/AA,C! MO^$[\8-CL=0'_P 33F^&)*DCQIXLW$=3J&1^6VN^HH \]A^%KPIC_A-/%+'/ M4WW_ -C4H^&(P0WB[Q0X/7.H'_"N]HH X$_# D?-XP\3'T_T[I^E1M\*8F:[RB@#A!\,H@/^1FU_=Z_:S2#X9@#GQ3K^?7 M[57>44 <.?API4K_ ,)/K^#_ -/?2HT^&:*A4^)_$)SU/VRN\HH X%?A?&N1 M_P )3XA*GL;LTY/AE'&V^/Q-KX8=";O-=Y10!P4GPTD=@P\7>($/^S>) W]\3)G^5 M=W10!P2?#K4U&&\?>)6]_/7_ IO_"NM6V;1\0?$HQT/G)_\37?T4 >?-\.M M9*C;\0O$8(&.70_TI4^'VO*I!^(>O-[D)_A7H%% ' #X?:]C!^(>O9^D?^%* M/A_KGRY^(.OD#K@H,_I7?44 <%_P@7B /Q\0M;V>A2,G\\9J3_A ]:Q_R/FN M;O7Y?\*[FB@#@?\ A7VN9)_X6%X@Y[9CQ_*F#X=ZV, ?$/Q#CZI_A7H-% '! M+\/=6#!CX]\0G'_31?\ "AOAYJ;D[O'?B3!_NSJ,?I7>T4 <"?AUJ9&!XZ\0 M_P"\95+?G2M\.[^1PS^-_$>!V$X']*[VB@#A6^'5TT>S_A-/$7/(2<8'^E8Q0GPXN$A$0\8>(,#O]IYK MO** .#7X;SJP)\8>(6 [-HN!FG)\.+E$"#QEXA*CH#<9Q7=T4 <$WP\U(IL7QUXA5>X$J_X4_\ MX5Y>[8Q_PFWB+*=_.7G_ ,=KNJ* .#/PZO6!W>-O$7X3+_\ $T[_ (5U=[-H M\:^(Q[BX7/\ Z#7=44 <2/A_<)#L'C#Q#D]6-R"3_P".U7'PSD$;+_PF'B/Y MN3FZ'7_OFN^HH X%OAI(SEF\9>)B2,$F['/_ ([Q3F^&>Y K>+?$N1T(O /_ M &6N\HH X0_#4M"(V\7^)CCN+T?_ !-0M\*87V[O%GB;(ZG[<,_^@UZ#10!P M,?PLMHR"/%/B@D>NH?\ V-.E^&22L"?%GB?CC_C^'_Q-=Y10!P0^%MOY:QMX MK\4%5[_;P"?Q"4C_ KM7_YFKQ6![:D?_B:[ZB@#ST_":S(P?%GBTC_L)_\ MV-(/A)8C&?%7BTX]=4//_CM>AT4 <"OPJL5Z>)O%(]_[3/\ \335^%%FC[AX MI\5D_P"UJ>1^6VO0** .%F^&%I-MSXF\3J1T*:AC_P!EJ-?A=&@.WQ?XK![' M^T<_^RUWU% '!Q_#(0H GB_Q22#SOU#<#_X[1_PK:3SC(/&7B@#L%OL?TKO* M* .'G^'DMPZ,_B[Q$"G0K>8_/BFR_#9IO\ ZU=O10!P@^&\HD#CQ?XC!'_3W_\ M6IW_ KF;S-Q\7^(3[&ZX_E7-/$2D]Q<#_"I5^'UT(RA\8^(6)_B^T#/\J[ M>B@#A%^'-TK[O^$T\1Y][A2/_0:F'@.]4\>,M?/_ &V7_"NUHH XEO FH%LC MQIX@5<$$"9?\*8?A]?DY_P"$X\2 XV@BX7_XFNYHH X9OA[?/U\<^)?PN%_^ M)I&^'E^T83_A.?$H [K)1ZXN5Y_\=H;X>W[; MO^*Y\2C/I/\ Q3^- MRO\ \37?T4 <,/A]?A"H\<^)>?XC<+D?^.T@^'FH@Y_X3SQ.?;[0G_Q-=U10 M!P@^'>HC'_%>^)R?>Y7_ .)J,_#C4B23X_\ $XSZ7"__ !-=_10!P ^'.J+_ M ,U \3G_ +>%_P#B:>/A]JHBV#Q[XB^]N#&5"?I]VN\HH X(?#W5]Q;_ (6! MXDR>WF)C_P!!IW_" :R.5\?^(,^YC(_E7=T4 <"OP_UY0V/B%KN3ZK'_ (4^ M7P+X@<+L\?ZS&1_TS0YKNZ* . _X0/Q+_P!%&UC\8(O\*7_A!/$N.?B)JY_[ M=XO\*[ZB@#AF\$^(R%_XK_51C_IA'S^E1R>!?$;R%Q\0M84'^%88\"N]HH X M/_A!O$@;(^(.KCZP1FG/X)\1L!_Q<#5@P[B"+_"NZHH XH>#O$>T ^.M2.._ MV>/-1_\ "$>(!O$**1_P )_K#9 M]8H_\*[JB@#A#X&\0G_F?]8'TBCH_P"$%\1J(?+"'X@ZP?4^3%_A7=T4 <-_P@VOF/;_PGVL?411?X4S_ (03Q%O)'Q"U MG;Z&*+_"N\HH X-_ OB1GR/B%JZCT\B(_P!*7_A"/$WE!#\0=5X_B%M%D_I7 M=T4 <&? WB0]/B'J_P",$?\ A49\!^*#D#XC:L,_].T=>@44 <#'X&\4(,?\ M+$U4^YMHJ='X'\41OG_A86IN/1K6(BN\HH X'_A"?%HDW#XBZB!_=^Q18J23 MP9XJ<@I\0;^,CK_H41S7=44 <'_PAGBX$8^(M]_X 1&G?\(=XM)8_P#"PKWG MI_Q+X>*[JB@#@G\%^,3]WXCWJ^W]G0_XT/X,\8-C;\1;Y<=?^)?#S^M=[10! MPH\'^, '!^(=T0W0_P!G19'ZU&/!7C#G?\1KYO0C3XAC]:[ZB@#@QX.\7@8' MQ"NS[G3X\_SJ4^$?%F!CQ]=G'8V$7/ZUV]% '"IX.\7QDG_A8-VX/9["+C]: M?'X6\8HZY\=2LHSG-A'Z?6NWHH X4^$_&)5?^*\F!!Y_T"/_ !J3_A&/&"X M\;R'W-A'_C7;44 <5-X;\8L 8/&/ED=0UFK _P"%1CPSXU(^;QL<^UBE=S10 M!PO_ BOC,@Y\_^A(- MH[=XYA(/3.FI_C7?T4 < M*WAGQT!N3QTH?T.FQD?SH3PWX\0QD^.87P?F4Z7&,_K7=44 (?UJ(^'/B4#E?'EF?9M M)3_&O0:* //O^$?^)@"_\5MI[$'D'2U&?UJ4Z+\2"X*^+-,5>X_LT'/ZUWE% M ' MI/Q,7[OB;1W]VL2/T'^-=3H,.LPZ:B:[H L4444 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 'H:K7O^J7_ 'JLGH:K7O\ JE_WJ +%%%% "T444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 !Z&JU[_JE_WJLGI5:\ M_P!4/][^E %BBBB@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBC(H **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ /2JUY_JA_O?TJR>AJO=_ZL?[W]* )Z*** %HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JO?7<-A8S MWEPX2&%#(['L!R:L5C>+-.N-7\)ZG86C!;B>!EC)]>H% ' 6OC/QSXT3[5X2 MTBTM--\PJEU?-\TB@]0*?>^+O'G@_-QXCT:UO],!^:YL&PR#U(_^M1\-O'VD M6VBVGAK5YH]-U>P!@DAF^4,0>H)KT?4K&WUC2;BQFPT%S&4)&",$=10 NEZE M;ZQI=KJ-JQ,%R@D0X['L:Y.W\5ZE=_%N?PW (?[-M;/SYFV_-N(&!GZFMGPA MX:7PEX<@T9+V>\2 MMEE S@G./;%>5>%O$M[)\0/&,VD:5-J&I7$ZQ0L<+%! M$"1ECZ9YH ]TR,XS2Y'K7D/B+Q)\0_!$5KJNKOI-YIC3JD\<$94Q!CQS7J%W MJ5K8:3)J5S((;:*+S'9N-JXS_P#6H O49%>3:=XE\>>/9I;OPQ]@TG0E)6*Y MNXM\DV.X!!P/P%31^+_%OA+Q)I^F>,([*ZM-0E\F"]LP5^;W' ]* /4Z*YCQ M[XAD\,>#;[58&C6>)0(C(,C<3WQ7'Z=XN\<^,-!AE\,Z?:V[",>=?7R%!(^. M1&G<>] 'JV0>A%+UKSO7_'E[X0T#3;34H(]1\572 ?9;484MGD^P%44G^,"V MK:B\.A% I<:>-WFXZX!Z9_$T >I9%%)5\->%]&34-2,/FRR3R;(H0>A/K0!WM%>4WWB?XF>%K :GKFCZ M1?6,6#<-8LP=%SR<$\UZ)H6M6GB'1;35;)F-O=)O3<.1[&@#2HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH #T MJM>?ZH?[W]*LGH:KW?\ JQ_O?TH GHHHH 6BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBC- !11FB@ HHHH **** M "BBB@ HHHH **,XHH **** "BBB@ HHS10 4444 %%&110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%&:* "BBB@ HHHH ** M** "BBB@ HHHH ***,T %%%% !111F@ HHS10 4444 %%%% !111F@ HHHH M***,T %%%% !1110 4444 %%%% !1110 4449H ***,T %%%% !1110 4444 M %%%% !1110 4444 %%%&: "BBC- !1110 4444 %%%% !1110 4444 %%&: M* "BBB@ HHHH **** "BBB@ HHS10 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%&:* "BC-% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !111G% !1110 4444 %%% M&: "BBB@ HHHS0 4444 %%%% !1110 4444 %%%% !11G-% !1110 449HH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHS10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%&: "BBB@ HHHH * MK/?VD=ZED]U$+IQN6$N-Y [XZU9->8_$33M5T?Q'IOC;1K-KR2S0PW5N@)9H MSW4?C0!U/B7P-X>\5PE=4T^-Y<';.@VR+]".M>=:E:>*?A''%?6>K2ZMX<25 M5EM[GEXD)Z@^@KI;3XS>#YHE^U7DEE-T>&>(C8>M<_XJ\52?$N!?"_A.WEFM M;IU-U?R(5B5 1D#WXH ].O\ 58X_"MQJT+[4%FUQ&S?[NY?Z5Q?P3TD6O@@: MK-"JWFJS27,C]2REOE__ %5)\5KI=!^%%Q91'YY(X[*(+U/0<#\/UKK_ O8 M1Z9X4TNSA&$AM8U ]]HS^M ' _&J5KZW\/>'(\LVI:@@95Z[5(_QKNO$>KZ3 MX:\.2W6KE39QJ(]C(&,AZ!0#U)]*X/5@==_:"TFUY,.CV;7!(Y&\\ ?7FKWQ M?L[A]-T?4TLY+JUTV]6XN(T7)"C'.!UQS^= $&G^._$]W#:KH'PUG33G'[II MKI+<;?7;MPM<[KM[XH\0?$WPGI/B#1K:PBCN/M21P7'FD@9R20<<8]*[*/XQ M>#)K19;?47EG*92SCAR@ 8SVKD/".I7NO_'6YU#5M-ETZ9-/(M;:7 8) MGJP]: -[XU-+?:9H?AZ+).JWZHV.H5<'I^->CV%E!INGP6=NH2&% B@#' '6 MO-M6ECUOX_:/9*=R:19/.XQD"1LX_'D?E7J6.M '@D>L:W/\8=8\06/A:XUR M&S4V<060)Y7N"5;NWO$C8HCG@JQQUK6\3_%G2/[/DL/"UY_:FLW"E+=+2,R!2>Y[?K0!7 M^%=MK2>(O%%[JF@SZ0E_*D\<4BD*"0<@'N?7%3>,O"7B6V\7CQEX3N(I+P0" M&>SN,E9%'I71:!8>)HO 8@U34I)M>D@9O-=4!C<@[5X&#CCDUQW@+XCP:59/ MH7C?49;36K>9\S7W"RJ3D8;IW_2@"YIGQ4LKR<:#XST>;1KZY4QM'*I,4JGC MKU /O7HVG:?9Z39166GVT5O:Q#;''$N% KR#XJ>(O#GB[2X-#T.2'5=9FF1H M7M06,(!R26'L.E>QV43064$4AR\<:JQ]2!S0!8HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH #T-5[O_5C_>JQ M5>[^XOUH GHHHH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** \@BL3Q+=Z]9V"2>']+@U"Z+X,4TWE +ZYK;HH \] M&N?$\XSX.TL?]Q(4IUKXG[\#PCI.WU_M&O0:* //VU?XH'[GA;1%^NH$_P!* M?_:GQ-V?\BYH8?WO6(KO:* //1J7Q5).?#_AX>G^EO3QJ/Q2_BT#P]^%V]=_ M10!Y[]O^*QY_L3PV/;[5(:E2]^*3!]^D>'%(^Y_I$GZUWM% '!B[^*)CS_9? MAH/_ -=Y34?VKXJD\Z;X:Q[32_XUZ!10!P,HR]=_10!P!?XI= MHO#_ /WT]2 ?$UAR= 0^GSFN[HH \_3_ (6GO82?V!CL5+U.J_$DC#/H@]\- M7<2/H?U :NZHH X,Q_$TQ<3:"),]U?%,>#X MI,%"W7AT$_>)20UW]% '""+XF'@SZ",=]KG-,,/Q0P0MWH ]"8WKOJ* .!2W M^)^T"2]T'.>6$;4L]E\3R08=6\/@=PUN]=Z:* .$%I\2]GS:CH1;U\I\4?8_ MB=L&-4\/AN_[AZ[NB@#A19?$PJ,ZMH /?$#TCV/Q-*MY>L: &[;K=\5W=% ' MGO\ 9_Q6S_R&O#>/^O:2I9-/^*!0>7K7AY6]3;25WM% 'GZ:;\4@Q\S7O#Y' M^S:O2C3/BB6Y\0:"![6;5W]% 'GO]D?%,DD^)]#'H/L)IXTCXH'KXGT0>XL" M:[^B@#@#HWQ.(_Y&O1A]-./^--_L3XG[2#XNTC/K_9U>@T4 <&=$^(YCP/%^ MG!_7^S1BF#0_B4% ;Q=II]3_ &#_ ,5A9 ^U@*:WA_XACB+Q?9C/4M8@ MUWU% '#IX?\ '8@82>,+'O'3R;CXOMU&.BV0ZUW%% '!?\ "->/69BWC.$ ] +) M>*:GA?QX 0WC:,@^EBH-=_10!P[>&_&S0A1XQ17'\0LUJ!?#'CY7&?&L17WL MAFN_HH X9/#?C<2,9/&$;(1T%F*A;POX]!^3QO& #P&LE-=_10!P;^&O'K ; M?&L((_Z<%%!\->.RRD>-8QC_ *<5-=Y10!P2^%_'9#!_'*D'TT]!_6E_X1?Q MP%(7QLH/K]@0_P!:[RB@#S\>$O'F!GQ_^']G)_C3D\*>.U<$^/,CT.GH?ZUW MU% ' -X2\=&0,/B P'H--3'\Z1O"7CQN/^%@L/IIL?\ C7H&:* .!/A7QXRX M/CY5(Z%=*CY^O- \*>.^-WQ R >@TN,9_P#'J[ZB@#@KGPIXYE?-OX^,"X^[ M_9L9Q^M(GA3QZHPWQ#!]SI,1_F:[ZB@#@9/"OCYY0?\ A805?;28A^F::WA+ MX@;\K\1_E]#H\7^->@44 < GA3Q\3^\^(7_?.EQ?XT'PCX[VL!\0W!/0_P!E MQ?XUW]% 'G[>#O'151_PL:;(ZXTR(9_6I&\)^-64C_A/)@<<.+*/(_#%=Y10 M!P"^#?&N!GXB7.1U_P")?'_C4I\(^,-N/^$_N,^OV"/_ !KNJ* .!_X0WQGR M3\1;O\-/B_QJ2+P=XM16\SX@7CD@X_T&+_&NZHH X%O!?B\NK#XAWHPN"/L, M7)_.I6\'^+"BC_A/[S(ZG[#%S^M=S10!PL?@[Q8C9;Q]>./3[%&/ZTO_ B' MBLL0WCJ\"GNMJF17)2Q/_"P-4'MY"4H\$^)=H!\?ZIGU\B.NZS1D4 <-'X)\1QN M2WCW59 >QA08IC>"?$K @>/M34'TA3BN\HH \_C\">)XV#?\+"U9L#&#!'BI M3X'\1D8_X3_5>>N(8Q7=T4 <(O@7Q /O>/\ 63_VSC_PIP\#Z\,?\5[K!_X ME=S10!Q/_"$Z[@C_ (3K5^>^Q*@'@/Q"'S_PL'6B/3RTKO:* .";P%X@(X^( M.M@_[B&F+X"\2J<_\+%U@CT,$=>@44 <$/ OB8 C_A86JGZP)3O^$(\1^7M_ MX3W5-W][R4_QKNZ* .!;P+XHVC;\1-4##N;:,C\J)/ _BM@ GQ%U%/7%G'S7 M?44 <%'X(\5HHS\1-19AW:TCQ0_@GQ5)'L/Q#U%?=;2,&N]HH X!/ WBQ5P? MB-J)'O9QD_G2GP/XI* 'XB:IGU%I%7?9HR/6@#@?^$&\4X(_X6-JO_@+%_A3 M1X$\5!L_\+'U0CT^RQUZ!FC- ' -X$\4L?\ DHVJ@=P+6,?K2Q^ _$L;9/Q$ MUA_8P1UWU& _$8Z_$+63_V MRCI6\">(V(_XN%K ["&.N]HH X0^!O$)//Q U@?2*.FCP)XB _Y*%K.?>*/ M_"N]R/6B@#@QX%\1A@3\0=7(]/)2G?\ "#>( #CQ_J_/K$E=U10!PH\#^(<\ M^/\ 5R/^N24X^"-?VX'CW5P?7RDKN** .&;P1XB(X^(&K_\ ?F/_ IL7@?Q M%'G?X^U:7/K#&,5W=% '"2^"/$KN#'\0-40#J/L\9I'\%>*C&%3X@Z@#ZFTC MKO** .!'@SQD!_R4*[SVS8QFA?!WC0-D_$.X(]/[/C_QKOJ* . _X0_QLI^7 MXA38]].C_P :7_A$O'/E[1\07#?WO[-C/]:[ZB@#SUO"'C[<"OQ%;CUTN+_& MFMX1^(9=BOQ' !Z?\2F(X_6O1*,CUH X"/PI\0%C*O\ $4$GN-'B_P ::_A3 MXALA1?B*BCLW]CQ;OYUZ#10!P$?A;XA;<2?$1..A71HAGZ\TH\*^/<_\E Q_ MW"XF_F>*[ZB@#SX>#O'C1%7^)$P;.#/';<)\29Q]=+B_QKT*B@ M#S^+P7XU0?/\1[ECW_XED7^-/'@WQEGGXB76/^P=%_C7>T4 <"_@WQER4^(E MW[ V$7^-//@WQ:4 _P"%A7P;N18Q?XUW=&: . 7P/XM#9;XCZB1Z?8HA4@\% M^*O+*-\0+_G^(6D>17=Y![T4 <$? _B?R]J_$/5-W]XVT= \#^)MJAOB%JA( MZG[+%_A7>T4 <,?!?B8C!^(&I^V+6+_"F-X*\5;5"_$+4LCKFTBY_2N\HH X M/_A"?%.01\0M2/J/LD=$G@GQ2Q4K\0=1&.WV6.N\HH X5_"'BW ">/+O'V0TJ>#?%*Y#^/;YE/\ MTZQ@UW5% '"/X*\4-&%3Q_J*?[0MD)I[>#/$C"/_ (KS4P5Z_P"CQ_-7<44 M<,/!7B0LQ/CW4^?2"/BD_P"$'\1'[WQ U?\ "&,?TKNJ* .)F\%:]+&%_P"$ MYU9#_>CC0']:B_X07Q!D@^/]8VGMY,>?Y5W=)D>M '"?\(+XB(7_ (N#K!*] M/W,?^%#>!?$;# ^(.KK[B&.N\HH X'_A O$F?^2BZU_WYB_PIQ\!^(#G/Q!U MOGN(XN/TKO** . _X0#Q <_\7$UW_OB/_"C_ (5_K_'_ !<37>G]R/\ PKOZ M* .!/@+Q$1@?$36\?]??\ " >)N?\ MBXVL_P#?F.GKX%\3JNT?$35C[FWC)KOJ* .#'@?Q.K97XB:K_P "M8B/Y4/X M)\5L,#XBZB/<64-=Y10!P*]V?^%A7WT^PQ4B^#/%BMD_$*^;V-C%_C7=T4 <)_PAGBO> M&/Q!U#Z"RBQ_.I6\(>*&3 \>WRGU^QQ5VU% '"#P5XIV;3\0M1SZ_9(ZM(Z[FB@#@V\&^+2#?%:*0?'UZV?6TCKNZ* . M&'@_Q4(PO_"=WF1_%]E0T/X1\6Y!3QY=<=C9I@UW-% '##PIXOQ@^-IO_ 1* M3_A$O%Y!'_"=W"Y]+-#BNZHH X$>#/&'RAOB%>8!SQ91Y-3GPEXL(('CNY&3 MP?L4>17;T4 <$/!GC 9Q\0[OGUL(^/UI1X.\8*G'Q NB_#_&0"_\7#N< MCM_9L6/YTV7PAXW89C^(4H)ZYTV+_&N^HH X4>%O' BQ_P )[\_9CID9'Y9J M%/"/CW<"_P 1V('55TF$9_6O0** .#/A?QX"2GC]>?[VDQ''ZTV3PMX_(!C^ M(BJ??1XB/YUWU% ' CPQ\0MN'^(41^FCQ#^M \+_ ! \HJ?'Z;^S?V5'_C7? M4 @]#0!Y_P#\(U\1U7"^/;4^[:3'G^=//A[XB*GR>-[-F_VM*0#]#7>YHS0! MY^-!^)G0^,]-Q_V#!4T>A?$+;B3QC8GW&FK_ (UW5% '"C0_B)DY\76'L?[/ M'\J0:%\1.=_C"Q/H!IRBN[HH X9M$^()B14\5Z>&'WF.G#]*&T'Q^R_\CA: M^VGJ!7*M-W'HPL*[FB@#A/[$^(@B"KXMT_=_>-@#2 M#0_B.''_ !5^FE>__$M%=Y10!PL>A_$,,Q?Q=IY!Z8TX<4QM!^(V,)XPT_ZG M3A7>T4 <-%HOQ$&/-\6::?==.'^-.DT?X@G_ %7BG3D^NG@Y_6NWHH X0Z)\ M1B/^1NTP'U&FC_&EAT3XB)GS?%FG2?\ <. KNJ* .&?1/B(9"4\6ZFOHGQ))^3Q M?IB#T_LT'^M=[10!P<>B?$D??\7Z:WTTP?XT\:'\0\'=XPT_Z?V6/_BJ[FB@ M#@3H7Q)"C;XRTUCGOI8'_LU$FA_$ICE?%^F+[?V8/\:[ZB@#@3HGQ+ ^7Q=I M1/OIHI_]C_$@)@>*-)+'N=/X'X9KNZ* .#&C_$M03_PE.C.>P.G$#\\TR+3/ MB@%Q)K^@DYZBT:N_HH X%M,^)^T8\0:$#G_GT:FC3?BD)@4 M4 <&=-^)NTXU[0<]O]$>FKIGQ/\ XO$&@CZ6;&N^HH X4Z;\2\\:_H1'I]B8 M?UH?3?B5G*:]H>/1K1J[JB@#@1IWQ1')UOP\3V'V5Z<]A\4& "ZSX=7W^RR? MXUWE&: .%^Q?$W?SJWATK_U[2#^M(;/XF@#;J?A[_OQ)7=T4 <#':?%'S'\S M4O#VWMB"3_&EFL_B>9"8M5\/A<=#;R?XUWM% '!?9?B?N_X__#V,=?)DJ:&W M^(XC<37NA%_X2(GQ7;T4 <+]D^)A5O\ B9^'U./E_<2=?SJYHD/CR/5HSK5W MI$NGA/G%O&RN6QVS[XKKJ* "@]*** *$VC:9.^Z73;.1O5X%;^E6H+>&VC\N M"%(4'\,:A1^0J6B@"&:V@N5"SP1RJ#D!U#8/KS4@& !C&..*=10!$L$2S&98 MD61AAG"C"#2T4 4H]*T^*Y^T1V%LD__ #T6%0WYXJ?R(O/6 M8Q)YH&T2;?FQZ9]*FHH B6WA6E%% $%S;0W!>GG1!L?G6E10!G:?H>E:4/^)=IEG:?]<(%3(_ 5H 4M% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 'H:KW?^K'^]_2K!Z&J]W_JQ_O4 3T444 +1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 44U=V3NQ[4Z@ HHHH ***#P* #-&:R=? M\1Z3X9T\WNL7L=I!G"EN2Q] .I-<=:_&GPC.P.[4([=CQ MLS7=Z'XACT_2+8WDL,-^&O L! **>P/WA0!WGAOXM>'?%6N1:7IL.HF:56 M97EMPJ;5ZG.3Q7>BN<\)Z[HWB&R,NCV[);VS>2C-"$'3HO)KHS0!7O[ZVTVQ MFO+R9(K>%"[NQP !4>F:C;ZOIT&H6I8P3J'C9AC0#W..U=UX&\6Z5XBL&M=*@NXX["..)C-#Y8^[C S]/UH N6_ MC#3;CQC-X8@2=KVWB\V9A'B-![FNBR*\:\(Z]IMAXL\9^)M7O5MQ+>+:0Q'E MW"]E4"^U2^A_P!;%80^;Y?U/:@#O**Y#PI\0]'\4W+6<2W-C?(- MQM+U/+D(]1D\BNOH ***P?$GBW2/"ELDVISE3*2(XHUW.Y]@* -ZD[5YF/C% M90P+O':N]L-7L]3TE-3LIA/;.GF*R\DCTQZT 1ZKKV MGZ/):Q7GO7LNE:_;:EX?369(I;.W92Y%TNQE&>I]* -BBO.+CXP:9++*FBZ/JFL M)$2'DMX2$R.N">M;GA'Q]HWC#S8[)I8+R ?OK6X79(GX4 =714-U=V]E:RW- MS,D4,2EG=C@**\ZG^,5A*^=&T+5M7MU8JT]M =F1[GK0!Z7FLW7];MO#NA7> MKW89H+9-[A.21G''YUD>$/'6D^,HIOL)EBN;10!W.AZK'KFC6>IPPR0QW,?F(DBX8 ],UI5F"6U\/Z C74 ML<-M90*KN>B@ "L7PGXXMO&-Q*^F:?>#3XLA;R5 J.V>B]Z .MHHJAK>K0:' MHMWJEP&:&VC,CA,9(% %_-%>=3_%G3GTJ"XTS2[[4KR:'SVM+5=S1K_M$9Q6 MXOC:QMO!T'B'7(7TR*1M>7)\7[BZB:ZL/!&OW-@AR M;H187;Z@8YKMO#7BC3/%FDIJ.ES%XR=KJW#1MZ$>M &W17*^,_'6G>"+>SFU M".1TN9?+&P\KZDCTK N_BP9%:;0O"FLZQ9(-WVR*$I$?]TDDT9KG?"/B M_3_&.C_VA8AXRC&.:"48>)QU!J/QIXQM?!FF07UU"\L/-)\(1PI=F2>^G.(+ M. ;I)#]/3WH ZJBO,O\ A:&KV<'VS5_!.J65AGF=F#;1ZD=17H&FZC:ZMIL& MH69=ZVEJO(7L6-84GQ3U; M1HHY_$_@Z^T^V=PIN$<,L8)ZMF@#U&BJMG>6U_9Q7=I*LL$R;XW4\,/6N'UC MXI0Q:O+I'AW2+O7=0B;;(+? C0]P6H ]"HKSS3_B;)#JUKIGB;0+K1+BZ.V% MY6#QN3VW#BO0>M+7GEO\5;&75M6T^2QF^T64OE0Q1?.]P?]D"J=Y\4 M]3T;4;4:[X0O=/T^ZD$:7+R!L,3_ !8Z4 >G'!!'Z5@IXJL9O%__ CEOF6Z M2$S3LOW8AV!]35_5=0DT_2I;V"SFO710RP0_>?Z5X?X,\8ZO+XMUW7K/PA>W MAOIEA+H0#!@X*O\ 2@#Z R/6BL/Q#XGT_P +Z*VIZK)Y48P @P6=C_"OK7&C MXC^*+N$WUCX$OI-/QO1Y'"NR]R!0!Z=D>M%<[X1\8Z=XQTU[NP\Q'B?RYX)5 MP\3^A%6?$?B73O"^EM?ZA*50':D:\M(V< =^30!LGI7)>*O&;>'M:T72H+ MW=QJDWEJH<#:.YQ[5SZ_$7Q,L:ZC)X'O%TD\L^_$J+_>*]ZQXM8LO''QNT>X ML9_-L=,LWE1L8RY!XQ[4 >QCL"@;' [=: /4:,U TNZV,T 64E-R#. W&1 MS7.>!O%__"8Z7<79L_LCV]P]N\>_<"5/4'% '545@^+O$UMX2\/SZG\U"816]O%U;GDD]@!6^Y(0D*6(&0!WKP;7/%>IZA\5K"ZB\)WM MS^J.NGFUM[*Z:V20R[O-(ZD# M P*F&OW9\"7&MZE82Z7<+;2.UO*&_$FAMI.HSJSPJ)0Z,!Z-WSSTKN MKR\MM/LY;NZF2*WB4N[NV * +%%>71_$_7-?G9O!_A&XU"Q3(= M4URRGLUMI-+N?(.V0MNXSDY Q57XA>/4\"V%G.;473W$A0)NP1CO]* .UH/( MJII]W]NTRVNP-OG1+)@=LC.*Y_0?%S^(/%.LZ;;60^PZ8XA>ZW@[Y>NT#T% M#O$?B+5M*UW2;#3M$EOH;Q\37 )VPC/>M#Q+XBLO"^@W.K7S'RH%Z#JS=A^- M8]MXSGO/B3=>%H;!6@M8!-+=>9G&>V/K7!?&'6]=NKZQ\-P: \MG/=(T+E_^ M/EDYV@4 >PZ9=O?Z7:W:-7,9_AR,@5SUMXPFNOB-<^%X+$-!;6XFFNM M_0D<#'Y5:\)ZKK&IVLYU;1&THP,J0HS[MZXY/X8KS3PUXLLK7Q_XNO8K:YOM M4NIA%;VENFXLJ^IZ >YH ]OI#TXZUY;<_$;Q5H%]9'Q)X4BL]/NY%C$T%QYA MC)X ;M7J 8,NX'CK^% ',1>(=9E\?2Z(-"E72HH=YU%B0I; .!^/%=3D=?2N M/\$^,;GQ;&?%]AHT]MOAN$WR3 \IZ# M [GC\Z .\HKSC5?&OC&*WEU'3?!I;38E9V>ZN DCJ/X@@Y''K75>$/$<7BSP MU::Q%"T0G',;<[3W% &[0>E%4M8U*#1]'O-1N#B&UA:5OH!G% '-^,/B#IOA M-XK0Q2WVIS_ZJSM^6/\ /'Y5S9\:_$MH_M,?@)%M^JJ9\R%?IZX]JO?#+P]# MUET[5H/\ M66*+.]6RDM0?/18@QGY]>U;/BKQ;I?A#2VOM M3FQQ^ZA'+R-Z 4 ;^:*\MC\:_$:]MFO[/P'&+,@-&DUV%E9",YQ76>#?&-KX MPTZ6>."6UNK=_+N;:88:)^X^E '34&N4\=^,8O!6BQ:A) )VDF6$(6P.>IK! MN_'GB;5(UE\(>%?[0MU +W5S-Y:;NZJIP6QZT =AXF\1V7A70I]6U N88\!5 M09+L3A5'U)J[I]RU[IMO=RPF%YHQ)Y9.2N>0#[UXG\3O$7BK4)]*T2?PO+!' M+=JD X_.O4O"&L:YJUI*VM:$=*=-H1"^=PQ_]:@"*#Q#K4OC MR716T&5-*CB+_P!HMD*Q[ =C2^._%Z^#-"2]6T-WE5O!'C*Y M\8?VQ+]A2&WLKMK>$A\F7;UKS3QGXC\5ZYXRT72)?"XCEM9S>16XD\PRA>A; M'0#&?PH [FR\3?$)6EFU+P; +<6[2QK;W2LY;@A,9ZUTWA'5M5UO0HK[5],_ MLZY=B/LYSN4>^>AKE]8\?:]H/@237=3\.I;7S7:V\5HTW4'@,3]>U=S:W9;2 M8KR]V0DPK++S\J?+D\GL* +V1ZTF1ZUYHWQ$UW7M2N+7P7X=34+6#AKVYF\N M)SW"TNC_ !'U:W\4P>'_ !=H(TNXN3MM989"\:/X4LX[!\F-KVX*.Z_0^M 'I]1S MRI!!)+(VU$4LQ] .2:XGPAX]FUG69M US3/[+UN)#(;?>75TSU!J+XH^(]3T M+P_<+:6.^VFMW2:Z)^6'(P* -_PGXH@\6:?/J%G"Z6BSM%&S=7V]3705Y;\+ M[OQ/:Z?INDWGAL6NF) 7^V,_S.3R#M]3Q6OXK^(L>CZQ%H&C:>^KZY*-WV>( MX5!ZL?SH [O(HSGI7F%SX^\7^'Q'>>*/"L,.EE@'GL[CS&BSQE@?+?B&NB:M%H.C:;)K&MRC<;>)L" M,>KGZ9H [JBO+K_QUXW\/V@U#6?!T0L%YE:TN [1KGDD5Z#HVKVFNZ1;:I8R M;[:Y0.A]O0T :%%<)XD^)%IX;\96>AW4&8IH#,\H.64]E"]R?ZUFZK\1O$MG M;MJ-KX'O&TB-2S3S2!7VCJ2G44 >FT5D>&]?M?$WA^UU>T#"&X3=M;J#W%87 MBGX@6F@ZBFC6-G-JFLR*66SMCRH[;O2@#LS@C%IT45'//%;P/--(L<:#M>&]5GUOP_8ZG/:?9'N8EE,!; M<4!&1V^E:]48O(TC1HA/(D4%I"JL[' 4*,?TKSX?%#4]GT5P&@?$G[9X@7P_K^CW.C:JXS&LIW1R_[K5WPZ^] "UROC MSQ:?!^@Q7Z6HNIY9XX(XB^W)8XKJ3TKR3XP:G80^(/"%GJ,PBM!>FYF)Z;5Z M<=^: /5;61Y;:&29!'*R!F3.=I(Y%3UYQJ/CKQ3- U[X=\'3WFGJNX2W4GDL MXZ[E7J1BNB\$>+8?&7AZ/4XX6@DWF*6$G.QQU% '2T5RWB_QQIWA&.".:*2[ MO[DXM[.#F23G^5M&: M\Y7QMXJU+48&T?PF[:1-.JK>SOM+1]WV]A]:N^*OB-:Z#JL6B:?8S:KKK:)/;?\)=X(+ M;POX?NM6NN5A7(3F: -HUS MGC'6M5T+11ED^,-#T"TT]9VU++22L MV/+0=>* .JM7>2UBDFC\N5D#.G]UB.14V:YGQSXH/A#PU+JJVXN'1U18R<9S M7,3?$3Q!K5J)?!OA=[^)4!ENKE_+C#\911P6(]J /3&/"Q?1VD51>WL@C>12>61#S@> MIH ](R#T-%<7XM\?0>&I[?3K>U.HZU<']W9PMTXSD^E<_<>-_B#HMM_:FM># M(!IBG,HM;G?-$OJ1DYH ]4HSFL[1=9L]?T>VU.PDWVUPH93W'L?>N=\.>,[G M5_'.O^'+JRCA.F;6CE1R?,4^H- '9T9%17$T=O;R32L%CC4N['H .37+>!_% MMSXQMKJ_^Q10V"S-';R!V8RX.,X('% '745Y[K?Q,,>MR:)X8T>?7=2B8";R MFVQ1?5NE4KCXEZYX;E@/B[PP;"UF?8+FWF$B(2?XC0!Z?1D>M1PS1W$$MZ'J5 MK;^,/"[:;;W4@BBN89Q*@<^I%>B7NH6NGZ=-?7,RQVT2;VD8X&.M %JBO,+? MXD>(O$ ,_A7P?-=6 )"W-U*(EE_W?;WK9\(>/GUW5[C0M8TN32=;MUWM;NVY M9%]4/<4 =C*[GQAI,^HS64=M"L[Q0[)-^]5.,FK MGCG4AI/@C6+PL 4MF"^Y(P/YUYA\//%^HP^ --T[PMX7N-0F@4_:II#Y40,N\01-(5!QG SBN1\'_$ ^(-7N=!U33)-*UJV3 M>UN[;@R^JGO3_BMJ?]F?#?6) Q666(0QD?WF( _K0!I>!_$<_BSPO;:S<6/V M/[06,<>[.5!P#^-='7+:0DGA;X;6@A@-Q)8:>K>4.-Y"Y(_G5SPCXB3Q7X7L MM:CB\D7*$^7N#;2"1C/X4 ;N:*YGQEXN@\*6$#F$W-W=2B&WMU/,C&MZREFF MLX9;B$0S.@+1YSL..F: +%&117%^)_B#;:'J*:1I]C-JNL28(M;U M':9%%>77/Q+\0:"Z3^)O",UEIQ?#7,,OF!/\L8KV"16MY4$BR9X M*XZT 6:,UYO??%&>[UB?2_">@7.N36[;9IHVV1(?0L>*2R^*-S::U!I/BSP] MOK@\9KSFQ^+ME?27]M!I=UM%>8Q_$W6+#7+:S\2>$+G2;6[D$=O.TXD&3T!(XSTKT MJ1UCC:1SA$!)^G6@"3(]:*\P?XI:MJEQ.OA/P=?:O;PN4-V\@AB8CK@D8-:? MA_XBF^\0)H&NZ+<:-JCH&CCD8.DA]%8"@#M[F>*UMI)YG5(HU+.S= ,D_E6 M/X7\2VGBO23JEC'(MH962)W&/,"G&X#L#7)_%GQ9>Z'H-W8VVAW=S%=VS(]Z MO$,);CYCCKC-1_"S6=371M+T&?PO?V-O;V>3>3_*KGV&!G- '1^)?%LV@ZOI M6G6^CW-_)?R!"\7"Q#/)/ZUKZ[K=CX=T>XU34)EBMX%RS'N>P^I-8L?C/SOB M+-X3BTYW,-N)Y+LRX5(+.8W&@WFD"V*QJMSCY^.W MM4?A;QI%XIU36;2#3YH8M,G,)G=P5D8$C@=NE '59'K02/6N;\:>+8_!VCQW M\EI+=F298%BC8*2S'BI]=\0R:'X>&J'3+JZD(4M;P#+*2._L* 'V?B:QO_$U MUH5INEGLXP]PZCY(R>BY]?:MNO!_AGXOO%OM3NX_#&I73:O?[VN4'R1C.,$X M[5Z_XB\2Z;X6TIM0U.?RX@0J@8+.2<8 ^IH V:*\U'Q-UB5#=P>!M6?3A\WG MY )7^\!BNQ\-^)-.\4Z6NH:;+NB)VNI7#(PZ@T ;-%%(3@4 +17":]\2K;3M M9;1M(TJ\UO44SYL5H.(S_M-TJI'\4Q8:G:V'B7P]?Z*UQ@)/-AHLGH,CI0!Z M-1D>M,!!7(/!Z$=*XE?BAH@UC5=.F65)+"3RQM&]IV[A%'/&: .YHKS6Y^*[ M:9>6XUCPOJFG65Q((XKJ?&TYZ$@=,^]>CHZR1JZG*L 1^- #ZCFE6&%Y6Y"* M6('M7#ZY\3+6PUA]&T;2[O7-1B.)8[,?+&?0MT!]JI:A\286\.:U%J.GW.CZ MK#;,4M+OK)D8!0]#R>U '1^"_%R>,M-N+^&S>WACN&A0LV?,V]2,5TU<1\)- M-_LOX;:3$6W/*C3N<=V.:[>@ S161XA\1Z9X8TM]0U2X$4*G"@HS6;7\/@/77L0-PFV@%E]0".E 'I=%<]X2\7Z9XQTHWVG%U"-LEAE&UXF M'8BJOC7QWI_@>&QEU"&62.[F\L&/'RX&22* .KHKSJ_^*$HC^TZ-X5UC5K%5 MW/=1Q[5QWQD?-72>$?%VF^,='74-.$JJK;)(I5VO&W<'M^5 '0T5S'C'QQIG M@F"SGU-93'=3>4I1<[?4GV%<]>?%96>230_"VM:Q8QKN>]@@*1$=]I89:@#T MC(SC-%8'A/Q5IWB[2!?Z>)(]IV2PRC#Q-Z,*D\2>*-(\)Z=]MU:Y6&,G:B@9 M=SZ =Z -ND/0XKS3_A;9$/VMO!OB!--Z_:C -NWUQZ5VOA[Q%I?BC24U/2KC MS;>3C/(*GN"#T- %/QCXLM_!VB'4I[6:Y D$8CA&2+K31-=T;1Y;.6ZN-5D*1JFW"XZL0?2M;6]6AT+1+O5+A))(;6 M,R.J8W$>W:@#2S17!CXGZ;<:3;76G:;J-_>W";UT^VBWR1@?W\$A:D\*?$BR M\3ZS-HT^FWFEZI"GF&UO%PQ'?% ';.P5"S$ S206\ MQ@,N/E=AUV_2L'XB^,8O"NA2JUI<327,3HC(F4CXZL>PKE_@YXDLX]!TOP]; MZ7J*R-'),]T\.(G.-E4^A(Q0!Y1X:TZ'XC^,=4\0ZTB M7.F:=.;73[20[D##JY'0GTKTV^TBQU/39-.N[:)[5T*;"HPHQV&.*X'X)30Q M>$+K3#(IO;._F6X3^($MP376^,O$]KX4\-7>HW#KYBHP@C)YDD[ ?C0!Q?P1 MFD31]=TCS"T&FZE)# &.2J\\474<&I_'^ULUMD,&G::TLFU1C>W3/X'O6K\( M]!NM&\&BXOT5;O4IFO)5 Y!;IFLKX:9U;X@>--?8EE:Y6UB;MM3@@#MTH ]0 MAAB@&V*-(P>2$4 $U(>E+B@]* /+O&K#4?BOX1T>*".3RR]YFE>%=*L%Z0VJ+S]!G^=<#KC'7?CW MHFF@9BTFU:ZWT;;9B@BB(_A9N ?PKDO /BKP+ MX:\+6J2Z]9)J$Z>;=R.QWR2'DDG^E:7QFMC+X+BN&4-#;7D4LRL.J9YKHK#0 M_"NI:9:7]MI&F/ T0>*3R$("D>I'^<4 >;^-_%7AO4O%'AK4_#^IVTVJPW:K M(\1P?*/&&]>M>V @GBO-M+U/P]K7C>XT32O"^G3VEF TNH0QHH1QR!D#GG'0 MUZ2..,4 *>E>5_$VWU73O$^B>*+/39-3LK$,MS;*,[>?O ?C7J4A(C8J,D#@ M>M<3X$\=MXLGU:SO;>&TO+&Z:$6X?)9!WP: #1?B%X5\9VLVG_:EAFD4QO:W M8"/R.P/7%;/A;PO:^$],>QLYI9(BY<"0_=]A7(_%?PCX=G\*WNL2Q0V6HVT9 M>"YBPC%\\#CK71^#[^\'PXTV^U%BUTMCYDA/!. 3SGV% '.^#&?5?BKXPU0; M&MK7RK*$J.X&3C^50_$^:YUCQ!X>\%VLS1)?2F:[*$Y\I3TXZ=*L_!B#_BD; MK4Y#F;4KZ69CZ_-@54\53IH/QH\/ZW?LL=A-:26JRNZM[>TDN9I MD2!$+-(6&-O7.:\H\-W4GQ ^*4OB.(2#1M)B:*SKSQ:-\?=.O MK]S%;7=@8(9&.$#\\9]37I.JZI9Z-ILU_?3I%!$I9BQZ^P]Z .4LUOY4MHJ *Y_O5RGQ(U&QC^)'A2'4KI(K.T9[F0/R-PZQMHK6UA2&&)0D<: M@ *H["O,/B/&/"?B?P_XOM$$44F=_&C4);/X?SVUN3]HO94MT4=6R><5Z)7E?Q%']K_ !%\&:#P8Q,]Y(0, M\#@9_6@#K?!/A:Q\+>'+6SMK?9*T:M.[#YF,OBMX?\/RC=;6<#7ERN<;AG@?C7JT,$=M MD$,82%%VJJC@#TQ7C.E^);"'X^:O/?7D<:F,6<)E2 M:AJ%S''$J[E7<-TA]%'>O'K5;XL0CQ M'XM\+^$R 8[B0W,K<\*#S^@K5^$^E7GV34O$VIQR1WNLSF81R=4BS\H_*JND MM_;?Q\U:ZX\O2;!;<9Y^9CS].M 'HUM;6VDZ:D$"+%;6T6T*. HKP/PYXW\ M+KX_USQ%XDBN#=^>4L2L1FCBC&5^7'0G^M?0-W"9[*>(=7C9>?<8KR[X/:AI MMIIU_P"&[GR(=3LKN0R(P"M(I/#>] %K4/B_X.N]-N(98]2>*5"NUK%\/D>I M%.^"-W)<^")(RLJI%=R")9.H0G(%:7CGQQ#XGS:)='R)[@>3+878V/GT!Z'I4WPW\6JZQ"[):Y3XR0Z&1IK6 B7Q$UTA@^R[?,/(Y;'.,9H Z3QQ M-:?#_P"%=Q!I9:!(T$%OD[B"QY_K7+^!OB!X.\+>&+6V^S7\5W( ]RZV+DR2 M'J<@"YF3&=RJ?F&._6NH\/^)=$US0[>_L[JT$ M$D8++O4;#CD$=L4 >4_$SQ_H/B;PVD&EVE]-J<%S'+ TEHZ>7@\G./2O8UU# MR/#:ZA.WS+:"9BW&3LS_ #KC!XXEUWQ_!H?ARUM;S3X0QU&\9#@@L<<"@#&^#>A6XT:Z\331;KW4[F24,XSM3)QBG_ M !FD-QIF@Z-$I:>^U.(*!R<*Z8]O,/3\: /0=1N1INB75SQ_HUN[\]]JDUQ'P7M98?AW M!>3J/.OYY;ICCJ"W'\JM?%_4FTSX9:NZ@EID6 $=MS8S6YX/CLK3PII=E9W$ M4B0VD8Q&P./E'I[T >3>/?$FF7'QALK35K:[O=+TF(.\5JADQ*>064>G%=F/ MC'X87:BVNL*.V-/?"CZ5D6=_;^$_C7K2:SL@M]8C1[2X@4>6?NM,W25@%8@=,T@/5R%*E2 5Z$ M8X/M7E'PXT>U@^*'C2\M?):&*584V#A">2!78>*_'6C>&=+FN9+N&>Y6,M%! M$0[,>QP.@KG/@E"\GA6]U:90)]2OI)G/KZ?SI@>FU'<3+;VTLS_=C0N?H!FI M*YWQYJG]C^!=9O05WI;.JACU9A@?SH X?X-Z5%?'6O%=PBR3WM_*MN[#)6,' MMZ5TWQ6$!^&>N/,J,4M\QEL<-D8(]ZP/@YXATN+P7:Z-/<6]I?VREF@D_=LR MDY#X;J#D\U!\0]3'C/4;+P/H3QW!DFCFOY5;*Q1*XL.?NBN.^%Z_V?XH\;:2IY MSGTH \MUIQJWQZT*RC)7^S+*2XE;;]XG.!FJGQSUPV]EI&B1B1_MEP))XXN7 M>)3R .]7?AXW]N?$+QAXB?E4F6Q@R.BKUQ^(IOQ,8Z'XQ\+>*K@;K"T=H+C M)*!S][VYQ0 67Q9\*Z1I\%A9Z-K<=O"@14CT\@+@=.HYK!N?%%KXF^+GA74= M)L=1MD4/%<33V[1[U(. >WXYKU9_%>@Q:7_:4FL6:VNSS/,,R]/IGK7/>"/% M6L^+]5U"_$$$7AQ3LLW*D2RD?Q'/&* .Z'!IQI!Q2GI0!YCX,:2V^+_C:R8; M5D\JY';.>,UG:UIL?CE/&.JRA3!9V[V5@YY 9!EV'OGBJ?C/79/"'Q/U2\@B M>6YU;2X[:V51]V7. 37?V&@#1OAK)I 8F46$GFNW!:1D)8GWR: ,FU\41Z-\ M&K+6(MKR&Q1+=2?ORD;5'YUJ_#SP\WAWPI;IRML2"W=\],84X_I M0!Y]\+?^)IXN\9Z^Y!,E[]F0]<*M3>(636/C9X=TS+!=-MGO6(_O'(%6?@M8 MM:_#FUN9%/FWTLERS$&-/32O#&F6,?W8;9!^@S0!Q'QBF-S:^']#B($M M_J49]\(C^&KRZDDVK;6K'?[A>M<'K(77/CMH]DW,.D63W+#J-[=/ MZ5I?&*]DMOAU?6\)'G7CI;*,XSN8 T 1_!FQ-K\/K6Y=<27\LETQ[D,W&:QM M$LX?%/QPU[4KB,-!H\:VL:$95G/?\A7?:+;1:!X*LX L=I8@G)X&%R:Y'X* MV^_PQ?ZP[EY]3OY)G;U /'\Z .N\9:BFD^#-7O6 *Q6K\'IR,?UK$^$.G2Z9 M\,])CF8EY4,^#V#'(%9OQINF?PC;:-%*8YM5O(X%(_NY&:]!TZU6PTZTLU M@A6,8''R@"@"T>E<1\6YGA^&6M&,D%H<''ID9KMZR?$FCIK_ (;O]*?:/M,) M0%N@;M^N* &^%HXH?"FD)#CRQ90XQ[J#6QFO+/!/C[3-'L(/"WB:X33=6TT> M0WFD^7*!P&5C[>M;7B#XI^&-$A807R:A?,,0VUI^\:1NW3B@#LA>VK7;6BW, M)N5&XPB0;P/4CKBO#O&?B.VN_C%!#=:1?:K8:-%DV]M )")#SN(/4?6NP^&G MAG4DN=0\6^((FCUG56XB<$&"+LN.U9BZI!X)^,NJ2:N'AL-;B0P7;K\BNHY4 MGMTH O\ _"X;)I'4/BOXAO[?2=0T^QOK='"7410 M,X."V,8!/UKMO$/Q \/Z)I,MRFI6UU/MQ!!;2B1I'/087WH\ W7B:_\ #HO? M%,445[,Y:.-$"E(^P.#UH Y+XI(GB#Q;X6\*LC.DTWVJ;;_='KZ=*]2M[:*T MMT@MXQ'%&NU548 %>:Z6?[:^/>JW ?=#I5@L*J1T=NO\Z]0.<4 >9ZW)_;'Q MRT+3OG\G2[.2[D!Z%VX6NZ\07JZ;X>U&]8X\FW=\^X!Q^M><>$=1TW_A:WC+ M4[W4(('$D=K#'.X4X'4C/O6K\9]0-I\.+N&"4+->21P1@=7R0<"@"7X-V1M? MAQ97##$M\\ERQQ_>8@?RK,T4#6?CWK=\S#9I-FML@']YNO\ 6N\T2WBT?PK8 MPJNV.VLTR![+DUQ7PAMI9;37]ZEJ+N"1SL7@"@"#XK!M5\0>#_#RN5% MSJ FEXR"J?\ ZZN_&'4);;P?#I5LWERZKKOQ>LKN31M-U2UMFN/[,O4N)%7.0G<\4 =GH.D6^@:)9Z9:HJ1 MPQ!?E'4XY)]:I^(O"6E^)KC3I]1$I>PG$\)C;;\P]3Z>U5K7XA>%;K11J@UV MQ6 ('<-*-R>H*]>6'PN@V6\3I_KF_O GM0!L^/[_PC M9:9;KXK\N2(2AX+?EG9QTVJ.365:_$Y[N%AI7@SQ!YZ5C>)[ MFPT?XW:;JGB%]FFO8F.VDE3]W')SWZ9KM=6^(/AK2[4.NIVUU,X_7UTF@>%YKAN196N>F>57 _4"O$?AMXRMM'CO;^Z\-:Q= MWM],TQO4@+[@3]U?:O:-8CMO$GA._AM94N(KJW=$:-@0QP<8_&N.^&?B_28O M#\?A^_NH+'4=,!ADAF81Y _B&>M %76/B7;ZUHE_IO\ PB>NLUQ R 369V9/ M Y]C73?"Y;B+X=Z1!=PS0S0Q&,QS+AA@FL/Q/\1)[O5K/P]X'FAOM4ED!GE5 M?,C@C[DG&*]$$AM+ 2WDJ@Q1[II,87@98_2@"S16=HNMZ?X@T];_ $NY6YM6 M8JLB@@$CKC-:- "'I7FE_P",O!GA[Q7J$VGZ;? M?%OQ[IFKZ3%X=TB[\_[5=1I=3Q+1_#@<,OE6EID-D8PJ?_ M %J /-O#EA#XI^-'B+7+F)9;?2@EK;MG*[L<_P!:[;X@:D-(\ ZW=G!*VKJ% M]=PVX_6N:^"EGM\&W&J.N)]3O9;AR?XAGBH_C3.)_#^EZ NYI=5U"*/:O78" M"WX=* -CP!'+H'PGTU[I%]$N8[J\OY%@F:(;D121\NX<9)[5ZQHMFNG:)8 M6:H$$%ND>T=L*,T 7STKS'XMW=S>C0_"5I+Y;:S=;)SG!\I>6_/^E>G'@5Y5 M\3Y5T3QEX1\2W(_T"TN&AG?&=F[C/ZT >CZ9IMIH^FV^GV4*16]N@1$4<# _ MG7EWC_2(+_XO^"XQ'&6?S))MJX+*O(8UZ/<>)=$M=)&JSZI:)9,NY9C*,,/; MGDUYEX1UX^./C/=:LEOLM=+LC!"=P)(8\,?K0!K_ !?O)[NVT;PK:2,DNM7B MQN5.#Y:GD?C7H.F:;:Z1ID.GV48CMX$"1IZ >M>>?%%?[*UWPUXI:&22'3K@ MB4J,A%;C)_.NXM_$VAW.F?VC#JUDUH4W>9YZD >_/7VH X?XOXB?PO<0A1># M5HTBDQR%/W@#],UZ>.@]Z\?ANS\4OB/9W-F';PWH;&03$8$\V>WJ*]@'6@!: M\@N-/MO%_P ?)8[R-+BTT.S5O+;E1(>F1]2#^%>O$X&:\O\ A3']NU_QCX@E MBQ)=:AY*/G(*(/\ ]5 'H>J7J:;I%W>,!L@A:3!Z<#I7"?!."0?#];V4;6OK MJ:XV8XP6XQ5WXOZH=-^&NI!/]==!;9!G!RYQQ70>$],32/".DZDZAJ"0,;:T:WMS)Y!!P1QQ7:K\8;%P5?PSX@7.1A MK,X/U]*S/A_K5OX1\1Z]X6UV2.PGEOI+FTDD 19D;GANAKH_&OQ%L-#TU[?2 M+F"_UR;Y+6U@82'<>Y [=Z ,/X*SRNGB,O9WEG#+?FXAAN8RI4,.0/Q]*KZ[ M:1^+?CQI^G2QB:STBT\Z96'R[B>,_I7I'AI]8D\/64-2= TZPKA03VKA M/AAC5?&WC7Q!SB6\%K&M7LSJ&C7MFIPT\#Q@^Y!%>?? M"CQ%80>&T\-7LD=GJ6DLT$L4IV;AN)##/6@#$\=?$;1_$/@O4-+BT36I9YXP ML8DLF4*W9MW;'6O0O!UU+'\/M+N;SS-\5DK2[Q\WRCG/OQ7-ZYX^O[WQ?8>' M?"'D7E=-\4DA?X::ZTP'[NV+(W&0W&,>]<]\) MO$>F6O@ZTT:]GAL;ZW3O6JOC[6D\<7MOX-\/3+@ZUR/PZ\K3?B%XVT:)'1! MS#_&O2;:W2UM8K>, 1Q(J*!Q@ 8KQ;QQX@O/ OQ3N[[3[%)Y=8T]8E&<,'!P M"/7F@#9U_P WQ_\ $FV\.PC=HVCC[1?.?NR2=D]^U>J1QK$BQHH5%&%4# ' M05R/PX\,OX;\,I]J._4;US=7ILP52S$ 9)/:O+?A,1JFN^,?$3J-UYJ)BC8'^! 1C^5 $7QD1]9 MO?#'AB-L-?WVZ0 ]47K7IUC90:?9PVMM&$AA0(J@=A_7BO.9BNL_M VZ9$D6 MDZ:6P.0KN:].(X_2@#R+QS9)XK^,?AK0&;=!90M>7"$9!YR/Y8KU=S%96;N% M"10H6PJX 4#/2O./!!&K_%?QEK/RR);M'8Q2=< #) _$5Z3=PFXLIX!C,D;) MR<=1B@#Y^\&^-H+?Q+KGB6[\.:WJTU[-BWNK2T,L:(N1A6-S9-'>2%8;B-D*J3D 9'(]ZJ&1]-_:*VL-D.I:7@,QX9E[#\J]&TF.^CTF MV34Y5EOO+'GNBA07QS@"O,OBM=Q>'_&7A+Q*ZLXMWEC9$."XVYQ0!H_$O4;C M5KFQ\$::Y^TZFX-VR'F&#N?QQ6QXGFB\#_#"]^P(J_8K/RH W&6/R@_7)S6/ M\,='N+ZYO_&NK))_:.J,1%'*/]3"#PJ_XUN_$O1IM>^'NL6-NA>748GNG)R7=AGK^/2I_B1!;3?#O7?M2*T:VCL MPSAAR,?CBJ_@GQCI6K^&++S+F.UNH81%-!/(%9&4 'KU'O7(>.O$\?CG48?! M'ALM>+-(K7]S V8TC!Y&1]* -*VU^30/@'::I<2%;A=.5$8@Y+-PH_6M_P"& MNA1Z%X+L 8]MW=1BXN7;EF=N>3WJG\0_#C2_"F[TC3H#(;6!/*C5E &EXI\,6'B[1&TO4?,6 MNLFZ,X92IR,'MTJGXL'ANP\)_9O$LRKI:*J8EBM^72J/Q,^RP?$3PI7SV%Q8_V=I_DO!< MJ!("Q&"<''0UZ%=^+/#FE:^>_ H L?&RZD;PM8Z)"<2ZO>QVP^F037=:%I%IH.C6FF6<2Q MPP1JF$&,G&"3]:\L^*6M-'\1/"\%M;M=?V8_VVXB0?<7."<=^.:]''C'P[_8 MYU4:Q9FS )+^:HQ[8SG/M0!Q7B2-8OCOX6EM1B>6SE%P4[H,\FIOBRW]HW7A M?PV'P=0U)&=2.JH<_P!:@\!QW'B[QUJ/CR>(QV/E?9-/5@??!:41^!9[5V"BR MO[B+G^%0V>?3J:]'Z9-?.EQK&H:-K_BKP-HEJ!/J>I9697R8D< MQ],T =QX M>C?Q]\0[KQ'=0[M&TDFVTX$<.X^\_O7JF.:Q_"WAZV\+^';/2+4?) @W,>KO MW)K9H IZO?II>CWE_(0%MX6E.>G S7"?"'3WE\-OX@O);!M4\,ZE8H,O/;NB@=SCBN-^%?B;2G\%6>E37*6E]IJ_9Y[>X<(X()]> MHH [/Q!HMOXBT&\TFZ9TANHS&S)CVT M9FDTVZCN711@NJD9P!^= '5>#_#UKX8\,6.G6T6PI$#*3U:0C+$GZURGQPBB M/PYGG9?](AGB,#@?,'W #%=3H'C'1-?T>+4+34;;:ZY=6D"E6[@@]*\\\3Z@ MGQ.\8Z;X:T:1IM)T^<3ZC=1 ^7\O1,]#S0!Z)?ZD-.\!S:CG>8[D\Y\ MOK^=E^!K74I45KW4?9/A\VG6\JQ2ZA/%:(O M7()&1^0KNM'M$L-%L;-%"K# D> ,#A10!YO\6'&H>)?!>BPD_:9M0$^,=$7& M?Y5Z5JEH;_2[RRW!3/ \>?3XS6E\2_ M$NN>%AI-[IHSIIN0M]MA\Q@F1S[4 )- EN='@8K#J=E\P M"DYY'^/-=O;'P9\29K#6+:X2]GT\^;$%D*/$?]I>H_&NDL=:TK5].%W:7MM/ M;2+DG>,8/9A^G->7>&+;3/\ A>M^_A@1+ID5G_IGV?!B,I].P/TH V/C&YNM M,T30T+9U+4XHRJGDJ.3QZ5Z1%$L,*11CY$4*H] .*\P\3S0WWQQ\-65Q,(HK M"TDNLR'"L^>,9[UZ'J^HP66@WNHM*GDQ0/)O!R. : /.OAJW]L?$'QKX@RS1 M&X%G&S>B]?Y5:\4-)JWQE\*:8CYBLHI+Z51CY3@@9J;X*V36_P /8KJ3&^^N M);DG'9FXS5+PU/'?_&KQ3J%Q*B_8[>.TA#''&021F@#T;4[Z/2]+N[Z4@);Q M/(<^P)K@O@I9RKX+EU:Y5UGU:[ENCN[KG Q^M:GQ7N)X/AMJ_P!F 9YHQ'R< M8#$#/Y5>\+7&F:/X&TN/[?;I;V]H@:1I #MRWZT ,O!GA[#'S+P MW4A'0*O'(KM?&>IC1_!>KZ@2!Y-JY'U(P/YUYYX9U!?%OQVU?4D+_9=)LQ# M&!P=V/FYZ9Y-;OQFN?+\!O9^:J&]N8H,OP-I(SF@#1^%FGG3OAMHL+JRR20^ MV?AWXM^*=&U-(+>749%NK.63 \Q<W#H5&3P>".*[;Q9XKT;PKH\MU> MR6YE"GR;?@M(W8 ?7%/\$ZAJVK>'X-1UC3;?3IYQO2"+.0G;=GO0!TE1S;#! M)O?:FT[FW8P/7/:I#7#_ !:EOXOASJ?]GLR2L%1V7J$) - &+I7BWX=^"WNK M33M0DN9YIF>9H8WN&+>A(!KGOB?XWTKQ/H%EHUC97XFNKZ)8YI[9HE7#=02. M:]%\$V_AO3_"=A)I'V%+=85WRJ1G=CYB6ZYZUPWB?Q%8^+?BEX6T:REBN;&T MN/.D=2-K28/"GN * /6LKIVE9D;*VT'S'U"KS_*O,_@SH=O=:;>>*KJ)9;S4 M+J1XG<FZ9''OFO]1BCCP,XP&(O#7A.U4J#>W8^T74IY9W89Y-<_\ ''3+6^\%1S.H M6[6[BB@D'WOG."HKLO#/B+3=:\-6FH6EW"\)B4/\P&U@ "#Z.1X.BN]/OO%6H"$VS[X86E;#D="4'6JJ?&/PG+$SVSZC< ' $-C(V M<>AQBL71;?2M0^-'B+^W/+GOK=4%BET!A8\?P ]?K78>,?%ND>#-#N'FF@2Y M:)OL]JI :1L*B\:V$7B_XN:! MX?FP]G80->W*'H3GY1Q]*V/@U:?9_AQ9SLP,MW))<.1ZLV>?I7-Z)XCME^/& MO7%\1#!)$MC!.W";EYP3T!.#Q0![#'$L4:QQH$15PJ+P,?2O+OA\$M?BKXYL M[10EDLD/6N\\2>)=-\+Z--J.H3HB*#L3/,C]E4=S]*Y7X3:->VN MD7^N:G&T=[K-R;DHXY1/X1^O\J ,OQQ8KXM^*V@>'7=C:V<+7EP@/'7(_E7J MD<20QK&BA44;0HX 'TKQO1_$MDGQ[UV2[DV(8ELHI7^XK#D#/O7J/B#Q!8>& M])FU"^E551QM@(K<>7*84&$#GJWUHTRP3QA\ M7M:O]1 FL]!*VMK"W*>81EF(]1FKWPITF[&GZAXCU.!H[_6KAIMC@AEBS\H. M?:H/!-]:Z7\1/&.BWK=PA^/,0H.GK@T >D,BLA0J-AX*XX/MCTKS' MX9B'3_''C;2;-0EG#>+(J#^%B.0!Z5V7B[Q5I_A'0I]0O95#*I\J+J9&Z = M>N*YKX1Z)A7FMWZN+W6[@W3J_55).T?D: *=Z5UOX_6,#@[=\:3M?2XYX0<9H ['PAX8L_"GAVTTVUA0.L:^?(!S(^.6/XUQM MJ3J/[0]U+"5:+3]*$)95.;N^:" M(]+P+]@B_P!?J5S%:+QDC_I0!/1110 M%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %(>E+10!P>M?#&SO-6EU?1=1 MN]#U&;_72VC$+*?4KDWL8B82$%4 M4<_+QQ7144 5[NTM[^SEM;J%)H)5*O&ZY# ]J\^G^#VGN6MH-=UJVTLMD:?# M?;W^TV5^!C[39R&-C]<=:[.B@#@[#X5Z3!(KZA?ZCJFW&%NYRR_E7:O: MPO:FU:)?(9/+* 8&W&,?E4]% '">'_A=I?AK71J&GW^H+ I8QV32YA0G.<#\ M:Z;7O#NF>)=.:QU6U6XA)R >"I]0>QK5HH \Y'P=T1U%O<:AJ]Q8JV4M9+H[ M1['U%=UINF66D6$5EI]M';6T0PD<:X JY10!B^(_#&E>*=.-CJMMYL0.Y2I* MNC9ZAAR*Y6/X->&AW>O1** ((+6&UM5MK>)8HE&U M4C&T 5E^'_#%AX:%W]B,S-=2F65I7W')M&FTO4XFDMI@ M-P4X(([@]JFTC3(=&TRWTZV:5H+= B&5BS #H,]ZOT4 %83^$],D\6Q^)9$D M?48X/(5BWRA?I6[10 A%8'B3P;H?BVV2'6+$3%#E)0Q21#ZAAS7044 >?Z=\ M'?"EA?+>317E_(A!1;VX,BICI@8'ZYKMKJ6.RT^>XR",_A0!YG\,="L_$GA#4[[5[6&>+5KV24( MP!(7/!W="VN+IXSF)+J;>D?^Z,#]& 8$DI!9OPK'T;PMI>A:CJ%_90N+F_D\R> M1W))/I]*VZ* $/2N4\1?#KPUXHN1=ZCI^+L&O#ETUW8::OVIAS-*2[_F>E=110 QT61"CJ&5A@JPR#7#ZA\(?! MNI3M,^F-"7;>ZP2LBL?0@5W=% &9H^A:9H%DMII5C%:P@8VQC^9/)IFN>'=+ M\1P10:I;">..02*#G[PK6HH :JA5 P.P'85F0>'].MM=N-9BM\7\Z"-Y""6,38W;Y"_ [# M/2NCHH RM:\.Z3XBLQ::M80W<(.0LB_=/J#VK"TSX7>$=*O$NX-)1YH_N-.Q MDV?3/2NRHH 8 % & ..!6-XA\):'XI@6'6-/CN OW'/#+]".16Y10!R^E_# M[PQI%I+;6VD0E9DV2/)\[L#V+'FMG2=(L-$T^*PTVU2VM8\[(TZ#\ZOT4 !Y M&*S]6TBQURP:RU&W$]LQ!9"2 <>N*T** .:UOP)X9\0VT$&HZ1#*D"A8F7*, MJCL".<5ZG8:V]MN^[YLH M4M],GFO,-(M4\>_%27Q&;9ETK28OL]L[C_CXDSRP]0*[CQ'X*T3Q7-:RZO;/ M,]L28RLA7\\5JZ9I=EH]E'8Z?:I;6T?W8T&!]?\ ]= %P=>?K2T44 -=5>-D M90RL,$'N*Y73/AOX6T;7QK6GZ8+>]&<%)&V@GJ=N<=ZZRB@#(E\-:1<:]#KD MUBCZG I6*=B.60R2 M$DLYZDY-7;FU@O(&@N84FA?ADD4,#^%3T4 <6OPH\%?;3=-H4+R$YP[$J/PS MBNNM[:&TA2&WB2*%!M5$&U0/8"IJ* "BBB@#*O?#>CZCJ<&HW>GPS7/^35S4-/M=4L) MK&^@6>VF7;)&_1A5FB@"K8Z?:Z98Q65E D%M"NR.-!@**QM4\"^&]9U'^T+_ M $F&6ZR&,G()(Z$XKHZ* ,S5-!TS6;6&WU&SCN(H6#QHV<*1T-:"H(T"(N%4 M #L*?10!0BTC3X-3FU**TB6\F7;). =S#TIFJZ'IVN10QZG9I<)%()463^% MAWXK2HH @N+6&ZM7M9H@\#KL9#T(]*CL-.M-+LDL[&W2"WC^ZB# %6Z* ,Z^ MT33=2NK6[O;**>>U;?"[C)0^HK0[TM% !0:** ,/6O"'A_Q$0VK:/:W3CH[Q MC=_WT.:CTGP/X9T.42Z;HEG;RCHXCR1^)KH** $QCZU4U'2K#5[5K?4+2&YB M/\,J!JN44 _;+#0K6.XSN$C;G(/MN)Q^%=1CC';TI:* ,S3] MTO2[ZZO;*RCAN;LYGD7.7^M:1Z&EHH Y[4?!/A_5-0%_=Z;&]R'#^8"5)/OB MK^IZ%I>LI FHV,5RMNXDB$@SL8="*TJ* ()K:*XMGMI8PT+KM*GICIBHM.TV MTTJS2SL;=(($^ZB]![U&U@2&WB2*)!A41 M0 !]*FHH H:KHNFZY:&VU2QANH3_ RINK.TGP3X:T*4RZ9HEI;2'^-8\D?G MTKH** ,^QT?3M,N+F>QLXH)+I]\[(N-[>IJOKOAC1O$L"0ZQI\5VB'*[\Y7Z M$5L44 4M-TRTT>PAL+"!8+:$;4C7. *S]7\&^'M=D$FI:1;3R9SO*8;\2.M; MM% &5HWAW1_#\)BTG3;>S0]?*0 GZGO3?$=[#8:).TUA-?K(/+^S1Q[S(6., M'T'/)K7-)CCZ4 <_X+T-O#WA6QTYXU22-2SHAX5B2<#Z XKH:0=:6@!#T-:Z>B@#$E\)Z!+I<>FOH]I]CC8.D(B 5 M6!R",?2M&ZT^VO;"2QN(5DM9%V-&>A7TJU10!4T_3K32;"*RL8%AMH5PD:#@ M"JNH>'M+U/4K/4+RU66YLF+0.<_(36K10 A&>MU.HH M 0\@U4U'3;/5K)[2_M8[BWD^]%*NX&KE% '%:9\*?!>E:A]NMM$C:8'Y?.=Y M57Z*Q('Y5O:=X:TC2=4N]2L;&."[O,?:)$)^?'3@\#\,5KT4 0W%M#=P/!<0 MI+$XPR2+N!KBY/A!X'>^^U_V%$KYR461@A_X"#7=44 5;&QM=-M8[6RM8[>W M3A8XE"J/PJU110 C ,I!&01@BJ&EZ/8:+;-;:=:I;PLY=E0=6/4FM"B@#.U7 M1=.UN%(=1M([F-&WJL@. PZ&KP7: JC '0>E/HH Q];\+Z+XCA$>L:;!=J.G MF+\P_$?&/, +-^9Z5TE% #64.I5AE6&#[U1TC1- M-T.W>#3+..VCDV#EOJ>IJQJND6.N6#V6I6RW%LY#-&_0D=* MOT4 <]J_@KP[KMO%#J&D6\RPJ%C.W#*!T&1VJWHOAK1O#D;II&G06@?&_P M M>6^IK6HH I7^JZ?IBJU]>06P;.TRR!$-$\5K -8L_M @;<@+%DV<=I8VT<$"#Y40 M8H M4M%% #9(UEB:-UW(XVL#W!ZU0TG1=.T.T^R:9916L!8N4B7 +'O]:T:* M ,ZUT/3;/5;G4[>RBCO;H 33J/FD'H:T3THHH S]-T33='>X;3[**V-Q(99C M&N-['N:OGI2T4 8FM>%-"\1(HU?2;6\*\AI8P6'T83^-;5% "8]/K5#4]%TW6$C34;*&Y6,[D$BYVGVK0HH CABC@B2 M*) D:#:J@< 4\]*6B@#E]7^'OA77+A9M0T6VE=:!:O,3EF4%-WU (KK: M* *6FZ78Z1:+:Z?:16L"]$B0**35-)L-9LFL]1M([FW;JD@R.N:O44 V>A6L=POW7(+8_ GBM73]!TS2KR\NK"RB@FO'#SL@^^1W(K3HH S M!X?TH:S)J_V&(ZC)'Y37!R6*>GTK%F^&OA"XO#=2:%;>86W, "%8^N :ZVB@ M"&""*U@2&"-8HD&%1%P /852M]"TRUUFXUB&SC34+A DL_.YE'8UITAZ4 9N MK:]I6BP22:C?00!$+E7=?#?2CXC\6:Q\0+NV,<=Y+Y=@KC_ )9@ M ;_QKL-;^'WAOQ%JZ:IJNGBZN40(-\C!2!Z@5T5M;0V=O';V\2101KM1$& H M]!0!*,]Z6BB@!",BN4UWX<>%?$EX;S4](C>Y/WI48HS?7%=910!D:'X9T?PW M!Y&DZ?%:J1AB@R3]2>36LRAE*L 5(P01G(I:* .-O?A;X-O[UKJ;1(1(YRXB M)16^J@XKH=(T/3-!LA9Z58PVEN#G9$N 3[]S6C10!E:OX7K W$Q=G9\=,[B<#Z8J_=6 MD%[;/;W4$B@#@[CX/>";B[:X.DF,L>4BF=$_('%=3H^@:7 MX?M?L^E6,5K'WV+R?J>IK3HH YCQ3X"\.^,?+;6;'S98AM25'*NH],CM5U/# M&E)X87P[]G9M,$0A,1D;)7W8'/ZUM44 4M*TNTT?3;;3K&$0VMLFR*,$G:/3 M)Y-6LJ7>X,S0RE ^.1D#K79T4 4[W3K2_TV6PNH%EM)(] MCQ-R&7TKC;#X.^#=/ODNETV28QL3''-.SQISV4G'YUWU% &1I_AS2]+U>^U2 MTLTBO+[;Y\JD_/M&!QT%+X@\.Z;XGTM].U6V$T#D-CH01W!K6HH Y[PKX-TK MP=;3V^E"?9.X=_.E,ASC'&>@J;7?"NC>(U3^TK)99$XCF!*NGT81Z>]S.G*/=2F7:?49KM54+T&!Z"G44 %1SP17,+PSQK)&XPRL, M@BI** .!3X/>#X[N69+.X"2L6>%9V$9]MM;2>!?#D6HZ??6^F1VUQIXVP-"- MGR^AQU_&NDHH R-?\.:;XFL5L]4A:6!7$FP-C)'2M..-8HU1%VJH 51V [5) M10!D0>&M,@\23:^L!.I2Q>2TI8GY,YP!6I+&DT31R(KHPPRL,@CTI]% '!'X M1>$UU)KV&WN[?<^]H(;EUB8_[H[5MQ^"= AURUUB+3TCN[5-D)0D*H^G3/O7 M144 (!S2GI110!R?BGX=^'_%UY!>:E#,MU",+/;R>6^/<]Z@T_X7>$]/CN,: MFWN;V2+!A% M[.TJQ8Z8!KM+F9;2TFN'^Y#&SGMP!FIZJ:G8KJ>EW-A)))&EQ&8V>,@, >#C M(/\ *@#RWX7>'M/\3>!]5N]7M1<+J]_+(P?(; ;Y<$'/#]IX7T.VTFQ,C6\ PK2$%C[G %:U # J@ M!0!Z8KF_%'@'0/%SQ3:G:N+F+A+B"0QR+^(KIZ* ."TKX2>&=-U&"_E6^U&Y MAY1]0N#+M_#&*[ED#(4Y4,,?+QBI** ,+PUX5T[PK:3VVFK-MN)FGD:60L2Q MH_X133#XN_X29EF;41#Y"LTAV*GLM;M% $-U;K=6DUN[.J2H4)0X(!&.#69X M9\,Z=X2T9-*TM9%MU,'MIK_ .TQ7-L3Y,]O M*4=<]LUJZ#H\>@:-;:9#-/.D"X\V=RSM[DUIT4 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 'H M:K7O^J7_ 'JLGH:KW?\ JA_O?TH GHHHH 6BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***,4 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% >AJM>_ZI?\ >JR>E5KS_5#_ 'OZ M4 6**** %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH #T-5KW_5+_ +W]*LGH:K7O^J7_ 'OZ4 6**** %HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH #T-5KW_5#_ 'OZ59[5 M5OO]2/\ >_I0!9HHHH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ [55OO\ 4C_>_I5KM56^_P!2/][^E %FBBB@!:*** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** #M56^_U(_W MOZ5:[55OO]2/][^E %FBBB@!:*** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** #M56^_U(_WOZ5:/2JM]_J1_O?TH LT444 +1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%'2L[7=9M M- T6ZU.]E2.&W0L=QQD]A^>* -&BO-OAOX^U3Q9KFJ6.J6<5H]M$DL4:@Y9& MZ,37I!Z4 +D45RMUXOC'CRR\*VD_AC_ XX]SZ5V?CGQ5#X.\*W>JR -*HV0(?XY#P!_GTK MRGX>?$#P[X9\/3W.I6^HMK%U(9KR06[,78Y*@$]@,_E0!U7S:1^T-$!A;?5] M(V*,D7SW$=C.]I$LUR$)BC9L!F[ GL*\.UOQ_HNO_ !(\&:EI MZ7BFVN'AEDGB,8VR +^/)->Y7-PEI:RW#\1Q1M(Q]@,T >"^';[QYJ'Q(\1Z MU8Z3IUQ>PJ+*=)I<)$ W"J1U/R_I6I\7M6\5?V'9Z/K7-AX&T:&YM;=BDFI7M2:'\-]3G@+"6<"W4@X(WG!/Y9 MK9\%Z'%X;\(:9I<:@/% IE/=G(RQ/XYH XZZ\;>+_"$\$OB_2[%],FD6+[59 M.>OF;AC' MO5+6]0GT7X"I-=L1=#288FYY+,JJ>?<$T 8OAGXJ>)O%EC);:/H4-SJHG96E M.Y+:&+ (+-GECZ"MV_\ $GBKPK\/+O5O$8L'U:.X"1+"#Y; D >A]>:T_A=X M<'AKP!IELT/E74T0GN,CYM[\X/T&!7-_&G.JOX8\,IN8ZEJ*F1%/\"\'_P!" M)_"@"QIOBGQYXIT*TOM"T:PMX6B#- /&.K: MWJFKZ!K]A%;ZKIA7S&@.8W5OZUVMK;0V5K%;01K'!$H5$ P% %>8?"A9-5\6 M^-/$I)$-U??9HAVPA/0_0B@#J?&WCZR\'101>1)?ZG?%K7?$,/A:\UZ*R#6 M4'V?G[.5/7H02>:[+_A:.M@Y?X;^),=,K"6S_P".T =3X.\6VOC'0AJ-I%); MLDC1302'+1.O53Z]:SM)\7WUS\3M7\*WEO D5K;"XMY4W;G4E?O$\9PW;T-< M]\)$U0:YXMN+W1KS2;>\NDN(+>XB*;=V[. 1CTS4FJ*FF_M"Z+E7MY;V%E-=W,JQPPH7=V. *Y;X?>+[WQKIMUJDNG+9V7GM':MN M):51CYB.W7'X5@?%"_N=E3,MSJ;;KN1.?*@')SZ9 /Z>M>B:7IUOI M.FV]A:H$@MXPB@#'3O\ C0!V+MS3DO_ (F[OWFB>'\8[73T =W17!?VA\4"Q']A^'@O M8_:GJ0WGQ+**5TOP_N[@SR4 =S17GZW7Q3:2/=IGAQ%YW$3R'Z5,MQ\3%5MV MG^'F;L?.DH [JBN!6Z^*/\6G>'0?^NTE/>X^)VT%;'P]GN/-DH [NBN%67XD M8YM-$WG_ &VP/ZTF_P")N[_4>'\>F]Z .[HKA#)\3@#O**X63_A917]W_ &(I]]U-3_A9N/G&A$^OS4 =Y1D>M<)CXEY_Y@(_ M[[IB)\43(=\GA\+V&'H [ZBN"=/BASMD\/\ XAZ<$^)@MQ^]T(S=\J^V@#NZ M*X'R?BB4_P"/GPZK?[LAIXB^)WEC=<^'RW49!K@QHGQ&8Y?Q5IJ^BQV/ M%-DT3XDMMV^+=,4]_P#B7T =]17!_P!A_$;G/BW3N1Q_Q+Q4<6A?$E,A_%VF ML/\ KPH ] HK@1H7Q&SSXMT_'M8BGKH?Q%3('BS3F![M8,+8,O<6"\TB^'_'O.[QA;>W^@B@#NJ*X1 M?#WCX9_XK"USVS8@_P!:2W\.>/H9&>7QG;REN@_L\ +^M '>45PK>'O'SOD^ M,K4+GHNGK_C2?\(]X_);=XTMMI.0!IR]* .[HKA9/#GCQE^3QG;J?4Z>IIJ> M'/'_ /RT\;6['MC34']: .\HKA/^$<\>YX\;PCV_LU/\:&O'[#'_">0K]-*C_ ,:1O"_CWRP!X_7>._\ 94>/YT =Y17! M)X8^(&#YGCZ,M[:3'C^= \-_$':,^.X,YY_XE4?^- '>T5P9\-?$ EO^*\@& M<8QI4?'ZT/X<^(?/E^.[;VW:3&?ZT =Y17!KX:^(+##^/H%]UTB(_H30OAKX M@!\-X]A91T/]D1@_SH [RBN!/A?Q_P _\5_&/^X5'_C3T\-^/E&#X[B;W_LJ M/_&@#NZ*X4>&O'A3#>.X\^HTN/\ QIK^%_';' \>A1[:;'_C0!WF:*X1/"WC M=!@^/&?/,?+Q_PGUQNSU^PQ_XTK>$O&3'(\=S MICTLD.: .[HKAD\*^,@/G\#O& M&[Y?B!=X]#91T\>#?%6P[O'U_N]1:QXH [JBN&'A'Q8H_P"1YNF/O:1T?\(A MXL)S_P )W=CV%I'0!W-%<+_PA_BS!QX\O,Y_Y](Z5O!WBDD'_A/+WCK_ **E M '(MN&\?ZJ?0B!*%\#>(U7 M!^(&KGW\F.@#O**X3_A"O%.PHOQ"U':1QNLXB?SZT_\ X0SQ+A"?'FH;E3;_ M ,>L?/O]: .XS17!#P-XF!!_X6%JW_@/'_6E3P1XG1B3\0]4;T!M8L?RH [R MBN"E\%^+G8&/XA7D7J%L(CG\ZAT^ M+_&D?P9XP/W?B'>+ZXL(^?UH [ZBN&D\'^+'0!?']XA'<649_K33X,\6D?\ M)0[[\+"+_&@#NZ*X'_A"/%9.3\1=2Q[6<0J3_A"?$VTC_A8&IY]?LT= '=9H MKA(_!7BE -WQ!U)C[VL=/?P7XC?'_%>:FI]5MXQ0!W%%<$? OB;G_BX>K#_M MA'3SX(\28'_%P-5R/^F$= '=9HKA_P#A"_$FS \>ZEN/?[.E-_X0OQ."#_PG MVHGGH;=* .ZS17%R^$/$GV> M.GOX*\2D#9X_U,>_V>.@#N:*X<>#/$V!GQ[J)(_Z=HQFA_!WB=I0Z^.[Y?\ M9^S(10!W%&:X5_!_BTOE?'ET!_UYI2-X0\8X^7Q_<@^IL8S0!W=%<$?"7C=4 M C\?.3W+Z?'_ (TYO#'CH,-GCI<=]VFQG^M '=T5P3>&/'SN2?'D('8#2H_\ M:<_ASQ^RC'CN -_V"8\?SH [NBN ?PU\1BWR^/[8#_L#Q_XTJ>&_B+C]YX\M M3Z$:1'_C0!WU%< WASXCE?E\>V@/;_B31_\ Q5(?#?Q)VC'C^TS_ -@>/_&@ M#T"BN 'ASXD]_'EG_P""B/\ QIX\/?$/<,^-[4COC2HQ0!WE%<0/#_CW&#XV MA!SU&F1FJ[>%_B%OR/B%&5/8Z1$,?K0!W]%< OA7Q^S R>/DP/[NEQ_XT]O" M_CMD*_\ ">A3G@C3(O\ &@#O**\_C\)>/%;+_$$L/3^S(Q_6K!\*^,BCC_A. MI%)'!&GQG^M '<45P8\'^,]F#\0KC=CJ-/C_ ,::G@WQF(2K_$.Z+?WA81?X MT =]17#+X/\ %8P6^(%Z3C'%C$/ZU&G@WQC$#_Q<&ZER?X[&,8_6@#O:,UQ+ M>$_%;*/^*ZNE;U%G'BHW\(>+SC'CVYQ_UYH* .ZHKA1X1\6JN%\"_&"C;_P +!O"/4V4> M:D'@[Q;M(/CZ\SZ_8XZ .ZHK@D\%>*P3O^(-^?I:1U-%X/\ $\<>UO'E](<_ M>:TCR* .WHKB!X.\4;& \>WP)/!^QQG%,3P9XJ4Y;X@7S#T%E$/ZT =U1GG% M<3_PB'B;SE?_ (3N]PO\/V./!^M1S^#/%,S%E\?W\1SD!+./'X@T =U17 ?\ M(/XMP0?B/J/_ (!15)%X)\4(#O\ B'J3Y_Z=8Z .[HKA/^$*\4+&57X@ZEG^ M\;2(FF1^!_%:-EOB+J3#'0V45 '?45P;>"O%A.1\1=07_MQA/]*9_P (3XPY MQ\2+_P#\%\- '?T5P'_"%>,MH'_"R+TGWTZ'_&I&\'>,&V_\7$NAC_J'1<_K M0!W>117!-X-\9&;>OQ%N@F/N_P!FQ?XU)'X3\7Q,I_X3RYE&>0UA&/ZT =S1 M7#2>$_&).8_'LZY;.#81GC\Z1O"7C,X(\?3<=O[/CY_6@#NJ*XE_"WB\@;?' M$JD#G_04YIA\*>,3&JCQS*KCJ_V%#N_"@#N:,UPX\)^, I!\=3$^OV&,?UIK M^$_&9"[?'-U MQZ&Q6G-X9\=,,?\ ":QCZ6"T =W1FN%'AOQT$V_\)I%]?L"T/X;\/$)QSG34_\ BJ .^HK@QX=^(2R@ MGQQ;&/T.EIG^=)-X=^(9EW0^.K54_NMI,9_K0!WM%<&?#GQ"8#/CJW^@TF/' M\Z1_#OQ%/W?'=J/^X1'_ (T =[17GA\-_$O:!_PGEF>>O]DQ_P"-2?\ "/?$ MC/\ R/-D1_V"4']: ._HK@SH'Q%P-OC:RS_M:4A_K3?[ ^)(/'C73F'OI2C_ M -FH [ZBO/O[ ^)H.?\ A-=-(]#I:_XTO]B_$U2"/%FD-]=.Q0!Z!17GQTCX MHF3(\3:($]!8GFIIM+^)+8\GQ#HJ<+?XT =U17"'2_B3V\1:-_X!'%)_9?Q,"_\C#HA;_KS84 M=Y17!#2?B9G_ )&/1>?^G-C0-*^)H89\2Z+CT^PF@#O:*X5M+^)1)QXBT7'H M;(U$FE?$\$E_$FAD=@+)J ._HK@_[,^)F_\ Y&+1 O\ UYMFGII?Q(&=_B/1 MS]+(T =S17$#3/B+MP=?T8MZ_8S4;:5\2MWR^(M%QWS9&@#NZ*X3^ROB3L(_ MX2+1=Y.0?L3<"D;2OB61@>)-&'O]B- '>9HKBCIOQ!$*J->THR?Q-]D.*C.E M_$C=\OB#12/>S:@#N:*X==,^(PSN\0:+GVLFJ,:7\3 23XCT0CL/L+?XT =Y M17!1Z9\3@3YFOZ$P[#[(U-.F?%$G/_"0: !V'V1Z ._HK@/[,^*/_0PZ#_X! MO0=+^*7;Q%H/XV;T =_D>M%<'_9WQ.!3_B>Z >,-_H;]?7K3CI_Q*5 %UK0& M(_O6L@S^1H [JBN#6S^*&T;M4\-;L<_Z/-_C339_%-@/^)KX84]\6\W^- '? M45P)L_BH",:IX8(Q@_Z/-U_.@VGQ5V #4_"^[W@F_P : .^HK@4M/BJOW]1\ M+-](9Z<;7XI]1J/A?Z>1-0!WE%<";7XJ9&W4?"^.^8IO\*>;;XH;.;_PUN]H MIO\ "@#NZ*X1+?XG(P+7?AN0>@CE%*\/Q-(8I=^'0G[R@#O:*X3_ (N:6)_XD &.G[RE4?$Q0-QT M!L=OGYH [JBN%\WXED\V^@ =B'?BD=OB8!\D>@D^[/0!W>:1CA3SCCK7*:2W MC@ZQ"-5BTA=/V-YIMV??NQQC/OBNK(R"",YH \E>7_A8OQ2C@$?FZ#X?8NY) M^26?H.._?\*]2^QVQZVL) '>,?X46EC:V09;6WCA#MN<(N-Q]3ZU9- 'F7QH MM$B\"I?6\,:365Y#.KA<$ -ST[=8;D\L;CAQCCUP# M747%M#=P-#<0I+$_#(ZY!I4@BCMU@2-5A"[ @'&WIC% '!?"C6M"F\':3HVF MW\$MW;VBM/ O#*?XBP^IKG9-?TJQ^/NH7NMW(LX[;3EMK1I^%9B06VGIW->G MZ?X=T?2KN2ZL-+M;6>08>2*(*S#ZBEU/P]I&LLK:CIMK=,O0S1AB* .=^)FC MS>*/AQ?P:>/,F9$N(0!]_!SC\15'PQ\5/#EYHT":K?QZ7J,*!)[6Z)1@P'., M]17H"QB.-8XU"JH 50, =JSK_P[HVIRB:^TFRN95.0\T"N1^8H \KUZ\G^+ MOB*TT32(I#X7LIQ+>WQ4A)R/X5SU]*T_C+<1?V3X?\-1A0NI:E#"4'\*!A^G M.*]0M[:"TB$5O#'#&/X(U"@?A236=M<2Q2S6\4DD1W1LR E#ZCTH D10J*B\ M #T%>67Q&O?M":= 59H=%L'F)QQYC=/Q^;]*]4Q[$X]:ACL[:*Z>Y2WC6= MQAY0@W,/0F@#,\6ZJ-$\(ZKJ6,M;VKNH]6P8$8]SCCCDX]J[Z^T^TU*U>UOK6&Y@<8:.9 ZD?0U2TWPUH>C$/INC M6-HRC :&W56Q]0* (/",&LV_ART77[QKK46!>5FB6,KGHN%XXK@/C-=-X>U# MPQXKMH4EN=/N'3:YX9&7I_.O3M4U;3]%L6O-3NX[6V4X,DAP!FO)O$6IVOQ6 M\::5X:T:47&D:?)]KO[I!E3@?*%/<'I^- &]\+-#N)C?>+]7#-J>J2%H]Z8\ MN(XP #TS@?E7I51PQ)!$D4:!$0!54= !TJ2@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH #T-5;[_5+_ +W] M*M'I56^_U*_[W]* +-%%% "T444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 444$X&: "BJ&JZQ8:-:K<:A<)#&SK&NX\ MLS' 'F* '449HH ***#SQ0 9HK+M=>T^\UVYT>WN%FO+2, M27"IR(LG !/8GGCVK4S0 449'K10 449'K10 449'K1F@ HHHH **0USOC#Q MCI_@S2UO;]9',C>7%%$,L[>@H Z.BN)\&?$(>+]0N+0:#J6G>3&)/,NDPK9. M.*[:@ HHHR* "BC(]:* "BL[6]:L?#^E3ZEJ,XBMX1EFS^0'N:L65T+ZQAND M1D69!(H<8(!&1D4 6)[_5K>S@E$>FS^0\SD8=^^!724 %%%% M!1110 4444 %%&:* "BBDR* %R/6C-E '744 M49% !11D>M(<8Z]: %HKGG\66 \81>&H=TM\83/-M'$*@<;CZFN@S0 M%%% M!111D4 %%(3A2:Y/PQXS_P"$D\2Z[ID5D4@TN01?:0V1(3G_ S0!UM%%% ! M1110 4444 %%&1ZT4 %%'2FNZHA9B ,G/84 +D>HI<@]ZY[PMXJM?%EM>7= MA')]C@N#;QS,,"4J!N..PSQ52+Q;--\2)O"T.G[H;>U%Q/=F7[I/1=OXT =9 M11D>M% !11FC- !112'H: %S17(3>,94^)4'A.&R213:FXEG,V"G' V_E^== M?WH **,YHR/6@ HHR/6C- !111F@ HK/US4TT70K[4G *VL#2X/0X'2L[P5K M]SXG\*V6LW5JEJUTN]8T8D;>QH Z&BC(QG-&: "BC-% !111F@ HHSQFD)XH M 6BO-/$7C_Q ?%T_A[PEH4>HW%G&'N9)F*JN3TSD<_C78^%[W6K_ $2&XU[3 MX["_9FW01MD*.W/- &U1D'H:S]/H]'CT)CHWD&234F)QNP>!VZX%=3D9H M6BBB@ HHHH **,C.** "BBC/.* "BBC(]: "BC-% !111D4 %%&:,B@ HHS2 M,< \^] "T5R?@OQD_C!]3D33C;6MGH4=Z\IE^* MNN:$3)XJ\&W=C:[P!/ QD51GJ>*](TK5;+6=.@U#3[A)[2==R2*>#_\ 7]J M+U%&:,T %%%&: "BC-% !11FB@ HHHS0 449'K1F@ HHS1D>M !1D8SGBH+R MZALK.:ZG;;%"A=SZ #)K(\*>)(O%6D?VK;P/%:R2NL)<8+H#@-CWH WLBBN8 MOM?UB#QK9:/;:')-ITL1DEOR2%C//'IZ5TW>@!:*3(]:7- !111D>M !11D4 M4 %%&1ZT4 %%("#T.:">,T +1GFN6TK7MXC6*:6)7=%.0I(R1GVH MT49HH **:S*J%F.% MR3[5Y.?BEXEUC4;Y?"OA#^TK"TE,+7+S;=S#K0!ZU15:REGFLK>6ZA\B=XU, MD8.=C$WB(?=Y M@7@F@#J\T5R?AKQ=-X@\3:]I@LA';Z5*(1.'SYC?TKK* "BBB@ HHS1F@ HH MHH ***,CUH **,BC(H **,T9H **3('<4N1ZT %%&1G&>:* "BBB@ HJKJ6H M6^E:=<7UTX2"!#(Y]A7FNC?%37->O;:2P\%7[Z3<2A$O23C;G!8\<"@#U2BD M'7V]:4D#K0 449HH **,CUHH **I:MJ46D:/>:C."8K:)I6 ZD 9Q6?X2\0G MQ1X*_^$5M;65;"XO)+F;RE2%22..IQ0!TU%9FK:U9Z M)HLVJ:@X@@B3>V_UQ]WZ]JLZ?="^L+>[\MHQ-&'"OU //- %JBBC(]: "C-- MD=8XV=V"HHRS$X ', M5A\=P>%UTR[>22+S3=D8B48)QGU_QKJ!@'% "T49HR* "BC(/>B@ HHI&Z4 M+17+>*O&EOX5N]-MI;&ZNY+^81(( /DR<9-=.#SW^E #J*,T4 %%!Z,K3Q5>: MI#:6T\::?.;=Y9< ,XZ[1UH Z:BC-% !1110 4444 %%&:* "BBC- !1110 M4444 %%&1G&>:* "BDSGI69XAUJW\/:'=:I=12RQ6Z;F2)=S'D8P/QH U**R M_#NLQ^(=!L]6AAFABN4WJDP 8#WQ6I0 449HS0 4'I110!0U72+#6[-K/4K. M*ZMF8-Y//#V MK_$#P_:>9-<66E7+3W11,J7'0 =\8/YUZ[H?B/3_ !#H2ZU:-)'9MD[YTV'" MGDX/;_"N+TDPZO\ '77)5"O%IEC%#RN0'/)QQUZU#\1Y;CQ!XMT'P);2M%:W M8-Q?M$Q!\M?X<#L<&@"[<_&GPRET\.GVNK:HL6?,EL;3>BX]R1D?2NF\,^-- M#\6P^;I=T3(A(>&6,QR*1U&#Z>U:FFZ99Z38QV=A:Q6UO'PL<2!5^N*\UURV M31?CGX>NK%$C;4K:1+D@?>QGD_7^E 'J^1CKUK'\1^([/PQI,FHWRSM$G&V& M,NQ_ 5L8YS6#XTU%=)\%:Q?N,B*T<@>Y&!^IH \A^%GCC3+/5M5>2RU*>[UO M42\L:WXTTKP_KMAI%Z91/>J75P!LC49R6)/ X-9_PMTTZ= M\.='1@/-EA\]CM ^]\P^O45Q&L:1;^.OCP;&Y1Y=/TBU5IEZ*&Z@'ZDT =C; M_$W3M1UVTT_3M-U.[@N9C$MXEN1#D=2">J]>>E+KOQ0T+2-5;2+>&[U;4D^_ M;V$7F[#Z$] ?:NP%M!!9>1$JV\*Q[0$ 4(,=1Z5YIH?B#X;^ #!D5.<':Q SUKK_B M_?-IOPTFLX26DNVCM$ ZG)'/Z4 6XOBEH5UHL%[:1W=U-,N5M+>+?*HSC+#M M^-/\,?$O3_$6O/HLFGWVG:@%+I#=1[2RCJ16CX+\)Z?X1\/VUG9VX6;RP9I" M/G9NIR?KVKDI76^_:*MTC3*V&E-YC#^\W3/YT >@Z[KNG>'-,?4-4G$-NA ) MQDDDX [FN&;XM.\+W4/@SQ!-8*?^/D0 ;AZ[3S5SXK^'M4UW0+.;2$$]UI] MTMT+?0]0 "F*[3"DX['TS0!TFB>.-'\1>'I] M7TV229+="TL 7]ZA SM(]3BO*?$WCJUU[Q]HTHT?4Y;?2_WTEJ8/G8GD-M/I M7JV@>$=$T?5+_6M+WE]3_>.0^8R#R"H[?_7KE?!3R:S\6/&.L$AK>V\NQA(] M1UQ^5 '5V_C'3_\ A%$\1:C'-I5J?X+M=KCG ^7U/I^-ZTSPGK5 M]9KSY\<0 *]R,]>.:Y?XF:_I5Q\3=)TG797.BZ?&;F6*$%BTF/E# ?2NJ3XR M^!X8Q"EU/&@&$7[(P&/;BD!U'A;Q;I?BW3FN]-D?Y&V2Q2KMDC;N&':J?B;Q MWI?A;5[#3K\.&O 7W\;8U'4M[=:XCP#KFFW_ ,8O$/\ 8J2+IUY:)/S'M!E& M,MCMG--UG38O&7QYBLID$MCI%FLDPSP23G'YFF!U4'Q%_M#4K6#3=!U&YM)W M51>-'L3!S\P]O>NX'!_F:;'$D4:QQQJJ( %4#@#VIYH \3^,?BA+J2S\+_V5 M=R W22LP4A90I^ZH[^E=[IGB[[;X:U6^?2;O3(K"(A%N5VD@)D8_2N=UYO[5 M^._AZP 5ETZRDNV7/.3D#^=;'Q^1LG@M_=X'4UUVA?$AK_P 00Z'K'AV_T:\G4M"+ M@@J^/0^M:7P^\,6WA?PAI]K%"@N&A5YW Y=B,G_]5WMOI]I+=74JQ0Q+N=F["O/1\4[K5)&;PYX0U75[16*_:E MC1B/3-8WQI\1Q6][H^@7#2?8)Y1/>"+DL@;[M:-I\8_ FE6J65HE[!! NT1) M9, F/44 =/X1\=Z=XLEN;1(9K'4[0XN;&Y7;)&?ZBNKS7B&F>+=(\0?'#3-2 MT1+A(Y;)X+EY(B@E."P_+'6O;@,4 1W,\=M;23S/LBC4N[>@')KST?$V\U)W M;P[X/U34[4$A;LD1QR$?W>N?TKL_$>G-K'AR_P!/B?:]Q"R*V>]>2>'O'^J? M#RTA\/>,-!N(;:T41Q7UNNY67GKT!/T.: .W\*_$FQ\1:O+HUU8W.E:M&,FU MNL98=]IK2\7^--,\'V,$?&>J6/BNS>.[N[ M5?W,T4K*4_WEXSW'(K(\9ZEX T'Q19ZQX@E:36;=?]'B4O(RCUV#@>V: (&^ M(_BP0F[_ .%<:B++;OW_ &E2^W']W&175^$/%^F^,]'_ +0T_1$V MXQ@ $?@: .LM?%3W7Q O_#$5B2EE;I/+=%^/GY Q^/Z5!XN\?6'A>6*RCMIM M2U:89BL;4;I"/4^@K$\#M'-XC\=>)G+,K7A@0_[$*]OQJK\([ :L^K>,[T": M[O[N1;>1SEDB!Q@>V<]/2@"[8_$36+.;S/%GAB;1K!QE+KS/,"GT;^[6;\&Y M$UC6/%OB,-N-Y>B,''\*C(_G7H'BI+63PIJJWH5K?[+(6#].%./QSBN5^"NG M"P^&]E(% -T[S[@,;@3Q_*@#T0]*Y?Q=XUM/"GV2%K.ZO[Z\;;;VEJN7<_T% M=.>E>I45TMAXRM-<\('7]$@EO\K@6T9Q('X&T^A&:Y?1OB[IMW*=, M\3Z9<:+>$^6R7"?NFSQP3ZYKL]+T?1?">BW+:1:106N&N76,Y#';G(/T% 'C MOACQ7X@N?&_B#Q#8>$;N^N+G9;-&) /LX7'RD]#V_*O5?$WC?3_">G6TVH1R MR7UR!Y=E;C?([8Z >F>]8/P8MR_@J;4I%/F:C>S3$GNNX@?RJAX+A3Q?\2_$ M'B>\C#II[_8+)6Y"@=6P>YH NMXX\;1P?;I/ DRV0Y9/M&9@O7./8=JZKPEX MLT_QCHPU&P#J%(RI!__77DW@)UTWXB_$$1;A80R"7 ^ZK8 M)(% '6>*O'UCX;O(M-AM;C4M6F7,=E:C+8]6_NCW-^'UUJU?S+5X//4CNN,XKA/@E 3X+N=9F.)M4O9;A MBW]T':/RP:L^+K&S\$_!W4=-L)IHX$MC#$S-N8;CS^F:\\N?&DP^'&BZ9HEG M>6FA)Y5O?ZD$V@9QY@7\SDT >E/\09]3\3-HWAS2O[16)L3W9;$4?KSW_P : M[Q-VT;\;L'-&TK0]'M[71X5BM2@=2O5\C[Q/>M8]* *6KZO9:'I?VOQ!\7:\IN/#W@N1[')"S7DWE[QZJ#VJ'Q_%_PD_Q M\.^$79FL3NN[M <;@G(!_2O3XHTCB6.- L:C"J!@ >E '%^%/B%_;6N3Z#JV MES:3K<*;S;RMD2+ZH>XK4\<^*?\ A#O"USK'DK.T3*JQLVT,3VS7)^-PB?%S MP1)$0+AI)%DV#!,>#U]14?Q>5M9U#PQX6C<;=0O?,G0_Q(F#_C0!J'Q]J^L6 MD#^%/#4NHLZ!I9IY1%#&V!E0Q^\?<5=\$>-I_$EU?:9J>FG3M7L3^_MP^\ ' M@$&NKM+.WL;:.VM8EBAC7:JH, #I7F_PZ']I_$?QMKT?_'NTR6L8QU*YR?Y? MG0!ZB:X?XF^)-4\.>&+B;3M':]C>%UFF$FT6X(QN/KUKN*\Z^-%W(G@![&$X MFU*YAM5'<[F&<#\* ,CX27WB*STC2]'G\(RVNG.CS-J#SC$F[Y@VWJ"<@55T M_P 6VVG_ !0\8W7V6YO]2D:*UM+2SC9VD6,Y]*]7M$BTO18(VR([6 MV .!_"J@?TK@_@W907'AV\\1E%>ZU:]FD:;;R45RJC]#0!7N?B1XHT&ZM)_% M'A)=/TNZE$2S1W E:(GIOQP*].:>)+E $Q^)>JZ[J M$UIX,\,R:I#;R^7+>3S"*'/MZU>T/X@7K>)(_#WB?1)-(U&<$VS+)YD4^.RG MUX-Y]_>@]#2+@ 8'%17MPMI87%RWW8HFD/T )H M\4LO%?V7XP^*+BTTR[U;4F1+2V@MQ@!5ZDMV' .:Z&X^)/B+P[J%O_PEGA7[ M!I]Q(L:W$%P)%C8_WB.*7X-:.JZ)>>([@;[O5;J24.PY6// K2^,?V?_ (5A MJWGA6?:@BSU#EAC'O0!VMQ=V]K9O=W$RQV\:;VD8\!?7->>P_$77?$=W*O@_ MPT;VQB)7[==R^5%(?]C'6LWQ]=WC>$/"/AV/SEGU=H(I2 <@!!N!/X]/:O4- M,TZWTK3;>PM(U2&! BJHQTXS0!P^E_$74;?Q-;Z!XLT%M+NKGBWN(I/,AE.. M@-=OJVJV.B:;/J&H7"06T2Y9V; ^GUKSSXTB+^R]!96*WG]J0K RCG.<$5'\ M1P_B/QQX4\(-DVD[M>70SC^,/$.ZX\->#0UA_!VLK5$8L<=_&G6;6RUKPK:WL32VT=V+F1(R/HD=AHN2(9IG)EE'8@=A5&^\>ZSJ>NW>D^#M &HM92^5=7EQ-Y<*-C[H]37 M?HB11JB*$1!@*!P .P%>02Z+XU^'NNZIJ6AVL.L:1?7!FEM1Q(I/<4 :TGQ" M\0^&-0LH/&F@VUI:74GEK>V<^^-6[;L]*],1E=596#*1D$=Q7G6D^,_"WQ%) MT#5M/:*^!#FPOD(.1W4^U>B(BQHJ( JJ OH* '$@ DD#'->=:A\2+[4-:ET M?P7HXUB> XN+F239!$?3<.IK:^)&KOHOP_UB[B?;.8#'$?\ :;Y1_.D^'?AZ M'PYX*TZV6-5N981-.W\3NPR23^- '/7GCOQ7X6EBN/%OAZV33)'"&ZL)]XB) M.,MGH.:Z[7]8U*UT2._T*P34"Z[R"X4!,9W>]5?B,(3\/-;,Y&P6Q.<=#VQ^ M-86GZI+I?P(AU&Z),T>E$GS>Y(P,_F* .,\!:OXVN=1U/7-+\.V][;:I>#SK MF:8)Y8'#!1G.!R:]X7.!D8.!FN.^%6F?V5\.-&A9=DDL1F<8(Y<[OY$5V9Z4 M >1?&C5];32?[%M]'633[]HXEN?.&YWR#L"]1]:ZWP5>>)YK0VWB#1+?3(;: M&-(=DHD+X'/?C&!6#\0R-6\?^"] V%E%RU]*0>B)T_6NV\3ZFNB^%M3U!AN% MO [8!QSCB@#R/P'XI:+6_%5Q8Z3-JFLW^H-L2+ "JH(&]S]T9/Z5T_\ M!.W)PA'_P!>@#TK4=2L](T^6]O)UBMXERS, M?\\UYS:?$#QCXH9KGPGX3B?3 Q"W5_<>7YN.ZCCBJ7QQU5BFBZ#':SW@NYQ+ M+:P EY54C@ M?B5J%G"EI!\-O$L4,"JH1+<_*,< #'- &MX7\>7UYXB;P MSXFTD:7K80RQB-P\,R>JMGK7>?2O%KW7-6\3_$+PM?KX1UO3(K*Y*237=H5W M*W!YQP.WACF>UB\SRY&(!Y'<5-X>U;^W?#F MGZKM53=P++M4Y )';-1^+K3[=X/UBVVAB]I)A3W.TD?J*XOPYXA_LGX%6&H# M'VB.S\B)5(YE)*+C\<4 3VGQ.%[\4&\*V]K";1-RM=;SN9P,X4=#76>*?$$/ MAGPS?:Q,%=;=-RINQO/8#ZUYI<:!#X;\0?#>22-5O)97CN2O&Z5EW$GN>6(K M:\:Y\5>.M'\'QN1:VX_M"_(_NJ1L4_7% &C?>--2TCX8-XHU/3X(;XQ+*MH) M"5^8C:"?7!JMXD\6>(;3X=6VLV^AQ///;>9=*9L"V5AU'X,5FF/\>XS(0PSNV^YXJ'7_$5I#\=;9KF&>Y&GV)2WBMXB[M(^>W;J>:] M6T:T%AHEE9XV^1;QQD8QC"@&O-/AA%#K_C?Q=XHGC5I4O/LL!/.P*.&+)-*@5G:W>X/GE/4@="/2N^\/ZNFO>'K'58XRBW4(DV9 MSM)ZC\ZYWXKZD-,^&FLR$D/+%Y"'W<@5+X=C;PQ\)[0SR?/::9YI)XYV;L?F M: (_!7C"]\5:KK\4MI%#::==FVAD5B3)C.?;L/SK-U7XFMI'Q&F\-2V*SP1V MZNC0Y::21@,*%Z=^OUI?@K:/#\/TO)1F:_N9;IF(Y;+8'\JS?AK:VNO^-O%/ MBUHW<_:S:VAD'W57J1^@H N:]XQ\=:/I<^LOX7M$T^'YWC>YW3!,]<#^5=WH M6J1ZYHEEJD*E8[J%95!Z@$5R?QAU1M+^&NILB@R7 6W7/JQ__771^$]/_LKP MGI-CSF"UC0Y]=O- &U7!>.?B%_PAVM:-9FUCF2^?]ZY)W(H[@5WIX&:\E>T@ M\4?'V7S4$]KHMB,HX^42,>#^&?TH V;OQ'XZO ;O1O#5I'IX!8?;YRLLBCN$ M'3(]:V_ WBL>,O#<>J_9C;N)'ADC))PRG!Q6IKEZNF:!J%ZQ $%N\F?<+7&? M!FWEL_AG;7-TP7[3++=9/ "ENOTP* )]<\?WAUQ]#\)Z0-8OXA_I#^:%A@]F M/K69J'CWQAX66.\\5>';%-*+A);FQN"YBSQR#UZ]JB@^('AG3=8O(O"7AF^U M2YGE/VJ>PM\(6[[G/:L3XI>+-=U7P?\ V8_A2]T]+^6.(SW3*<$L,* .1^AKS?3OBR-0OM3L+;29;N_MYO*@MK;+,^#@ER>% M ]:[&]G7P]X(FF9BGV*P/.>A5,#]0*Y?X.:#'IW@J'5)(U-_JK-=32XY^8Y4 M?3'- %";XE>(_#FLV,/C+P_;:?IUVY1+N"?S A]&Q^M:EUXYU[5!]8_Q2BAU[QOX.\,2#*27#74W&?D7U]N*]1 AL;3"J M(H(4X & H _^M0!RW@'QL?&%A>?:+ V%_8S>3=6Y.=C>WY5'XP^(ECX6N[?2 MXK:?4-8N1^ZLK?EOJ?2N<^#Q,UAXF\43EB+Z_D=6Z HE<;X"\9V=IXAUWQ#? M^'M7U"]O9SY-S:VIE"KR-H/\)Z4 =[<>.O&NBP2:EKO@I(M)3!D>VO%>2(=V M9>XKO]*U*TUG2[;4;"42VUP@D1AZ&O.;SXN65U87%O+X1\2$2QLGEO8Y#9&/ M6LKPAJ]WX6^ NH7TEK-:7%M)/Y$4R%2-S#;P>WS?I0!T^L_$>?\ MB71/"6B M2Z]J$'^O:.01PPGT9SQ5*Z^)=[I&F:C%XMT.31+Q(&:W82>=%,Q& %=>,Y[5 MN?#/P]'H'@NRW)B\O%%U=.W)>1QGDUG_ !H6 _#2_:9%=Q)&(@V/O%@/ZF@! M_P &K)K3X;V$K@"2\>2Z;;_M,?\ "N_/2LKPQ8)I7A?2[&-=HAM8UQ[[1G]< MUK'I0!Y/\1;F[\5^+],\ V%Q)%!*IGU.2%L$18X4^Q'\Q7H^C:-8Z!I<&G:; M;K!;0KM50.ON3W-<%X419?C5XOG=MTD=O"B9'W03V_(5Z=D>M %:^L;?4;*: MSNXEE@F0JZ.H((-/Y@6;Y1R/K0!DZI\2[B?7IM#\ M):))K=Y!Q+,) L$9]"U0O\0]?\.W$(\9>&X[&VF<(ES9S^:BD_WO05N?#?P] M'X;\$:;;&,+=2Q">X;J6=ADY/?K2?%".W?X;:V;A8RJVY9=XSALC!_.@#I;J M\2'2YKY2'CCA,P]P%S7FOA[XL7OBS3?*TC0Q69\ #\JZ3X9^&8O#'@;3K;R52YEA66Y;')=AD@ MGT&: ,#7OB)X@\&^&[2_U_0X3>3W;0^5#+D!.Q&.]66\9>-M7L$OM \'*MH4 MWYU"X".XZ_*HYYJEXYM!XD^*_A3095$EG!&]]<1GIQT_7%>HJJHH55 48 "C M&!Z4 *[O=(4NS9VF M\<(B]2M %V7Q1\2K:UDOI/!=BUJ@#&".\_?;>_'KBNJ\(>++'QCH2:G9*\6& M,7_ N7R_&/CR*W(%FFI#RPO3)SG _*@#1U?XEP MZ-XVO/#\]A+-Y%LDD1A):25VYV!?ZUW3]:R/!.GQ:M\0O%?B>9$D1+@65JQY 5!AB#ZYKKO%U[H%EX=N3XE>(: M8XVR++DA_; Y/T% '(V7Q \2>)P]QX6\,A[$.5CN;Z0QI*!_$*M:/\0M07Q3 M;^&_%.B#2[ZY4FWDCE\R*7V!JAIOQ-L8H8;'P_X/UN:PA0"%HK;8@3MC=VK% MOM:O?%7QA\+VEQHEQISV2O<%+AAOQCKQVH Z#XO>(=8T?P]/;V>E>=8W4)AG MNM^#$6., ?0T_P"&USXHMK33]&U#PXEEI5M:#R[LS99SVX]P:C^,,DES8Z!H ML?+:CJD2LOTA;/P9'JLR W^K.UW<2$?,=QX'TQ_.@"A? M^.?'/AA!?>)?#%E_9>?GEL;DNT0]2":]%T[4+?5=.M[^SD\RWN$$D;=.#_6J M_B-8'\-:F+C;Y7V63=O' ^4UQ7PBO39_"&UO+EY&A@6>3<_78K,?Y"@"*V^* MKS>+M:T*+3/MPR=N2!@]@>M+\8YWGTW0]%C M(\S4M1C4+C).T@_UH ])BD$L:2+G# ,,C!P>:JWPMD:PN?&L-P4AAM-5=R#QM&WDGVXKG=?M3XB^%_B; MQ=>1 3W4PFM21]VWC8*F/J,F@#VQ'5HED)7:0&SVQBN-\*>,+_Q,^MWK6=O! MI-C*\-O(6;?,4^\Q/3'N*K^-M?FT_P !6%MIQ8ZCJZQ6=H%!)RX +?@#3M;M MX/ 7P>O+>UVC[)8E,G^.1A@D^I))H /"GC+6O%'@_4=<@TBWDFCF=+*WCG(\ M[;QRS=.:\^\,:[XXU#QKXA\06?A6&>[(2RE22Y"BW*X^4'OZ\5Z1\.K0:#\+ M-+$B;"MJ;B13P 6RU9GP7@!\'7.JLA$VIW\]RYS]X%L#'Y4 9/QAU2&-?"EA MJG[M)+U+BZ2-=^ @Y"]^M;<_BSQE?C[3X:\(%M/4<2:C,(9)<=U0'./0FLO7 M+-?$_P <]-T^=%>STFR-PZCNQ/&?TKU"ZG6TLIKA\;(8VD/;@#- '.^!/%W_ M F&BO=RVAM+NWF:"XM]V=C"NJ/2O,_@HC7'AG4-78;1J6H2S*OL"17IAZ4 M<-\1O$FK^']$NYK+25N;;R2))V?&S=\N?UKG/A0_BK3M-TW3)O#T,.E2F2XD MOFF(8[N1A/Q YK3^-EU.O@9-.M6VS:C=Q6PP,GEA7?HB<_R MH Y_P[XPNM?\8:]I*:>J66E.(C<[R2\A[8JUX[\5?\(=X4NM96!;AHF54C9M MH8DXZUROP1MY)?#&H:[,6,FKW\L_S=< X'\C2_%V7^T6\.^%X\-)JFH(7C/_ M #S7DT =-JFN3V_PYN=9O(E@G^P&5XU;(1F7CD_6LWX7V2:%\+["68MEXGO) MBW^V2_\ +%4/C/,(/ ,>FP-Y9O;N"U55[J3R/R K5\=7(\,_"G4!$P0P62VR M$>I 2@#&^"<#/X;U/5G +:EJ4TP;N0#@?UKTZN:\ Z6-'\":+9X 9;5'?CJS M#BQ1V\((X60]3]>M>J2*C1L' M 9""&#=".] &5X8\16?BOP_;:Q99$4X^ZQY4CJ#[UA>*?B##H>H)I&EZ=/K& ML./^/6V/^KX_C/:N<^$]XEAX5\4WD?RV=OJ%Q)"6/RD*,Y'MQ5OX.:9YNB77 MBF\!?4-7N'E+OU$88A0/2@!;CQSXUT6W^W:]X+5+%!ND>TN1(T0]Q75R>*8+ MGP1+XDTI1-&.-V!R#^1K;NX8;BSFAG"F*1"K[NFW'->6?"BW:[^%6J M6)B9X#/=10J3GG?:-R$\_*QX]J MYK4]'ET[P]X3\3:BACU&[UF*XOF(^;$IR$/T&* /:]1U"'2]-NK^Y8)#;Q-( MY)P, $]:PO"WBJ75_"*^(=5M8]-MY-\B R;OW0/#$]B?2L+XF3RZQ=Z/X)M2 MPEU>4OPZ7X8T7PW:12F.>9!Y%NIW-&F/E '4GF@#5@^ M)'B#Q)<2'P=X4:]L8V*F\O)O*20C^YFMGPKX\FU76I/#^NZ6^DZY&A?R"^Y9 M%_O*>X]ZP]*^*&EZ9IL-E:^$O$4-O!&J(HL#CIT^M8.K^+4\2?$'PG=V&A:W M:&VN=DUQ<6AC&QN,<=1]: /2O'/BV/P9X9;5W@$[;TC6,N%R6/K7,3?$?7M8 MLDF\&^%9=4 4>;2]A$-RT8:6,'(1B.1GFH] M7UBQT/2Y]1U"X6&VA7I-73TKROQ\K>)_B/X:\)%&-C$3?W>#PP7[J MD>F1^M $EO\ $CQ7KX^T^%_ D]UIQ&Y;B\NE@,@_V5;^A-;GA7X@1Z_J\^B: MEI5SI&M6Z;WM9\,&7N48=17811QPQK%$BI&H 55& ![5Y=XQ"VWQM\%SVI"W M$Z21S8_CCYZT 4_BQXQU2+3;OPZGAV[C@O7%NE\Q^27H3MQW-=9X"U/5);2# M2+WPQ=:7!8VR(L\SC$A Q@#'X]:Y_P")OV?BKP3X[U#Q5I.F M_P!L:;?QJMQ#&?WL>/0>GTH OP?%&^TN[@B\8>&;C1+>X;9'=%]\0;'0GM7: M^(-=AT#PW>:TR^=%;Q>9A6 #CC'/XURUCXA\)_%/37TB\BD2=6$DNGW/R2H5 M/IW%4/C-.MMX(LM M@RMJ5S%9Q\]L@8/^>U '=>&]7?7O#UEJDEJ;8W48D$3 M')4'I65XA\8G1?%.C:'%8_:9M2/42A2@'4X].#6_IUJ+#3+2SR#Y,*19' ^4 M 5YU%C6_C],X421:+IX&3_"[<8^OS&@#6^+VH_V?\-]2&[#7 6$1^0K M"T?QQ>P>&-,M_"/A*^U6VM[98FG+>6F5 ! )Y;GO[TGQ?$FM:SX6\*1MC^T+ MHO)[HO7\<9KT^SL[?3[**TM8UB@B4(JJ .* .=\%^.++QC'=1I;366H6;[ M+JSG^_&W]14GBWQM:>%6M;=K2YOK^[)$%I;+EW]_8>]!=0ALQRS)*':,>K =JZ9O&%O<^$1X@T>VFU*-U'EQ0#YB?0_3O7/:1 M\4O#_B'S=&UF"?1[R53&]K?)MWYXP#6\FE:7X'\%W\6EQ&&U@@DF +EN<$]_ M>@#RKX>^*=4/B?Q#J]IX1O+S^U+Y$:>-@JPC."#Z@=:].U+QFMGX[T_PLFGO M-+=QF9IE<8B7!R2.M4_A%9O:?#737D4B2Y#W# ]?F8G^6*Q-!"ZO\??$%_N+ M+I=FEJI[ GJ/YT 8WQC\27M[-;>'!HEUY'VV-][#(NMO.U,5Z+X?\3W.HZ5? M7=YH5WI:62DB.*O^$R\.1ZRMC):1R.ZQQR')(4XS]*A\ M;>,D\(6^GM]D:YEO[I;6)!)MY/>K?@G2_P"Q?!&CZ><;H;5-Q [D9/\ .N,\ M7@ZW\9/"6CC#06*R7\RD9&1T_D* -;XG>+;GPWXE:/QHN/^*(CTY7*RZC> M0VZJ.^3D_P!*[2J9^4+GH* &2?%+5- M&*2^)_!VHZ992,%%UO614_WL=!7HUK=P7UI%=VTBR0S('C93D$'I6?XHM;:[ M\+:K!=HCPM:R%@PX'RG!^N:XGX::M);?!6._G=F%K!-L+<':NUN/L\45OB9YV[E5';WJM-\4[_ $C4;=/$7A*^TRRNIA%#=,ZL MHSTW =*K?!7P];Q>&CXFN+<'4=2DDE\QQDA-Q _+K3_ (TS/+8^'M(BB:26 M^U.,<=@I!/'^>E 'J0P<$'/%*>E,3@!?04XG S0!RTWB^+_A/XO"D>GRRS>1 M]H>XW*%C7'OSGI4&L?$/2]"\80>'[Z-HC- 9Q<%@5[_+MZECCI7.^! =5^*G MC/76_>1PLEE$_7@=TU[1K35+%BUKM8G MQ(U)=*^'FM7)(W_9RB XY+<#^?Z4[X<6LMC\/-"M[A"DRVBEU/4$\_UH ZH] M*\-^+/B:2]U[2]%.BZC(EG>I/A8R?M8'9!CD9'->XDX4GK7F=R[ZK\?;2)23 M#I6G,[XZ!GZ9_.@#?TWQ:^J^%M2U:YTF[TI;99 J7@P6PN%+*VMH$6:2)9)G"X+L1D\T 9V@?$@ZEXAAT+5]!O=&OID9X5N M2,/CT/K78ZCJ-II6GS7U[,L-O"NYW;L*\U\3E=3^.?A>RA4,]E;R7,IZ$*<] MZR?B[XALY?&&A>'=2DGCTO<)KWR026]%P.2#0!OQ?%J2_,TVD>#]:O[./G[5 M&@567U&:ZOPKXPTWQ9;2/9"6*> A9[>9=LD9/8BN>M/BGX&L;:"TM;IX8$S& MD:6K@+CMC'M7.>'/$.FZO\;H*N^%OB-8^(]5FTFXL+O2M4CZVMVN"1['\*T/!/AJV\+^&+ M2R@0"9D#SN!R\A'-66!>2WIC=$&"Z>_KU- 'H'B/7+?PYH M%WJUVCO!;)O=4&21D#^MQJM\:[ MQU\'V^DP$_:M4NT@C [^OX=*Z[PMX8L?"NAP:?9P*@51YC@I/M0!0N/' MNFZ7X6L];UM)--:ZC#):2\RY(Z8]:Y^#XNB3;-+X2UV"P;_E[DBP@'KZXKC# MXM\+:K\4M1U+Q).[V>FMY5FA4F-74XR5'TKT&7XL^ [BUD675T:)E(=#&QXQ M["@#L=,U.SUBPBOK"X6>VE&5=#Q_^NL*_P#'>E:;XO7P]=AXY?LQN6N7P(T7 ML,YZ_P"-0K><%@BCX #$C&!5WX>^$K+PI MX5LK>&!%NWB#W$NWYW$9CTW3#'*X[NV.#^=2>/ M'76?BCX+T/RS+%#,U]+CH-H) /Y"@#N]I2>1:Q87A,GGHH KB M_P#A;%U*#<6W@C7YK #=]J$6 5]0"*N_%?P_JNO>&[?^QXA<75G=)<>03CS M#G'OTJEH7QAT>:9=.\16\^A:DIV-'=H51C['L* .P\+^)].\7:(FJ:8S&)F* MO&X =&!P0P[&LGQ!\1M)T2_;38(KG4]23[UI9+O93Z'W]NM4=5M]+\$>$O$N MOZ1*"^H!I^)=T9D((&P#COV]*XCX<>,_ 7A30OM>HZM_Q.[QO,O)I+>1G)/. M!@'Y1[4 =QI?Q2L;C4H;#6=*U/0IYR!"=0BV)(3V!.#G\*[S< I8D #DD'C' MK7BOQ)^(G@?Q)X,N8;+5O/U*-EDM L,JE9!R#DJ.,9KTC39+C6_A[;,CXN;K M3@ P)'S%,9SUZT 8&H?V2STNRU36IX7V2BPM6=4/^\>OX5H>%?B5HGB MG49-.ACN[&^CZVU[$(W;Z8-<)X/\>Q?#^QC\-^,-%N=)EC=MEXD1:*7)R"2. M_7IFNYO/"^@^,M:TGQ18ZD_G61!2:PD4"0=<,<$X]NM ';9'K12"EH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** ]#5:]_U2_[U63T-5KW_ %2_[U %BBBB@!:*** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0\"EI& 92I&0>* /- M/A0C7MYXMUZ6$*U[JKHC[PV43@<_4U3U6[@T/X_V-WJ#B&"^TUH()&Z;\],F MM?3_ (4:;I'B4:O8ZKJL,0G,[623?N68YSD=^:Z3Q)X2T?Q78K::M:^:J$M& MZL5>-O56'2@#7GGBMH))YY4CBC&YW=L #U)KR;PQ*?''QCO?$MOYG]E:7;_9 MK=V7Y97/4@_0D_A6I'\%]'W[+O6M?OK+ M+F\W)^@']*[W2])L=&L8K'3K6 M.VM8ONQQC '^- %WO7G7QIN2O@"2Q1B)+^YBMEP>N6&:]&/2L3Q1X6TOQ=I# M:=JL;M%NW*T9VNC#N#0!?L;>.QTV"V4A8[>%8P!V 4#^E>=_"C_B9ZQXN\0. M#F\U'RHV_P!A/Z9)KJ?#O@NR\-Z5>Z?!=W]S'=,6>2XFW.O&,*<<<5=\,^&= M.\):0-,TM9!;AVD_>.68D\GF@#G/B_/=P_#J^^RNT9D9$E<$J5C)^8Y[5?\ M"7A[PMIWARQDTJSL&@\I7^T;5=BVT$DN>&(K@R)+JJPDY:V6[(B/MM Z4 O3M6M\1@NL_$+P5X?>-GB^T&]E _NKZCZK75)\/O#4.KZ=JEKIJ MVMU8 K";<[ 001A@.O7O5UO"VG2^+8_$L@F:_C@,"9?Y%4]<+V- &SG ))QC MDUYA\,U?5?&?C#Q'(A"2W0MH=W78OI^GY5Z=-$L\,D39VNI4X.#@UFZ#H%AX M;T[[#I\;+$7,AWL222>YH Y6P\?2+\2=3\.:R+>Q@C0-9,YV^<>YR>.G:MOQ M?H_AS5/#]VVNPVQM_)8F9\!EXZJWKZ5-XC\&Z%XJB"ZM8I*ZCY)1\KI]"*P+ M;X0^&+9T+#4+E5/$=Q=LZ_D: ,_X07MS;_#2>ZNS*;6WEF>U>8\F$DMI3Q%+-D\ORXOE 7T&*31=%L MM TJ#3-.A,-K"#L3)..?6@#S2!K'0_CCJ_\ ;*1F/4[2,VD\R90$=5R>*[O7 MM1\/>'M)FOKY;&-(TW*K*N6/8 =\G%6M=\-Z3XDMA;ZK91W" Y4G@J?4&N=L MOA/X5LYA(UM&W!;J=I%4^P- $_P /-6O-?T+^UK[1;;2_-'_#> MF>&+%K+2X&BA:0R-N8L68\DDT :](>E+0>E 'EOA+R[WXQ>+M5N)8PULB6<( M)P0G<\^X%.^+9;4+GPQH".V+_44,BKW52#_C6_JWPQ\,ZSK@UBXM)8[S(+-# M,R!R#D;@.M;-SX:TN\UBSU6>W+7=G_J&W'"<8Z4 :J*(T5%Z* !FO+O"*?VW M\:/%>LR!66PC2QA8'(]_Y5ZD5RI![C!K*T7PYIF@-='3K?>,[NW\-?%W0/$&I!1IL]L]H\SC(C<],^GUKT"[U_0M/T]]2GU*RCMB-Q MF\U<,/;UJWJ>DV&L63VFHV<5U;MUCE4,*Y&V^$/@NVNS/'I1*-SY#S.8OKM) MH / ?B?4O%]YJ-_-ID$.D1R;;"?80\OJW/M7=$IVDEI?6L=Q XPTF6<5K;(.(XDP,^OJ:R/$7@#PQXJG$^KZ3%<3 M8\P,R-CZJ10!@_$;XB:3X?\ #U_;6UY'2MTY())_2MK3_ #X7TK3IK"ST2T2WG7;,"N3(/0DY)_.M!/# MVEQ:$=$CLU332GE_9P3MVGL.ZD#'J=[, 3^&*H_ M"/Q!ING:'/X7O;I+6_TV=U,4S;,HQR"">O4UZ3I6EV6BZ=#I^G6XM[6$8CB4 MDA1U[GWK'U_P!X8\37"SZKI$,\P_Y:#*,?J1UH X?XL?$&R'A^[T+1IXKV[N M%\J5X6WK$"1W'&>U>C>%=/CTGPKI-C'PL5K&H'OMR:JCP/X:72XM-71K5;2- M@Z(J]"#G.>IK?1%10J#"@8 QV% #FSM..O;)KS'P=\0W_MW6-%\6WD5IJ$5R M?LRRIY2F+ P3P>A->GGI6-K/A70_$"@:MI=O=8Z,Z_-^8H XOXM:GX5G\%W M5O>W-I<7TR;;)(F#R>82,%=O-1ZM/?:%\ =MT9#?)IZPG@Y!) R?PKJ-,^'? MA+2+H75EH5I'..CE2Q'TSTKH;JSM[ZUDM;J%);>1=KQN,@CZ4 <]X"?3+?PA MI.FV-[!.T-G&6$;@MDCDD#ISFN(\$ZQ9^!_%WB#PWKDXM3XT;3(K.6==LAC).1G..:M:QX*/'VCZ%IDC6]W!=WSKM@@MW#EF/3IVK+^'7A*^TOPAJ+ZIQJN MM.\]R"<[=P( _(UT.E>!O#.B7 GT[1;6"7IN";C^O2N@(XQDT >4?"?7K#0M M%E\*ZQ<1V&IV-Q+^[N6";T+9!4GK5SQEXWO+J_L_#_@VY2;4II@)IXEWI"F> M'_$,BR:MI%M=R*,!W7YA^-3Z1X=TG0(6BTK3X;16Z^6O)^IH M\]^+3O?R>%O"I M0-#VL?'[8X62#2-.)0'JKOCG]:]+1%C0)&@1% M& %& /P]*IVNCZ=9:C=:A;6,,-W=8\^94PTF.F30 FM:@FD:)?:@[!5MH'ER M?4#/\ZXSX,:>]MX$CU"@% $YZ5Y9\3KFVD\:>";&_E2&S%Z;B225@J M97[H)/'6O4ZR]9\/Z3XAMA;:O80WD(.0LJYP?:@#!\>>([.R^'.L:E:WD+J8 M&BBD1P07;*@ CZ_I5KX=Z:ND?#W1+)<92U#GZL2Q_4U=7PGH:Z)#HQTNV?38 M6W1VLB;T4Y)SSWYK7CC6*-(XT"H@"J ,!0. !0!YAK*KK7Q^T2TP6CTFQ>X< M8R QSM/ZC\JO?%JTN5TS2=:MXFE72;U9Y$5]=O%I&GPZI)J4=E"M[ M*NQ[@(-Y'H35QU#HRLH8$8((R#0!S-E\0/"E_I@OTUVRCB W,LLH1E[\JV#G MZ5S_ (8\8:SXS\9SS:2H7PI;H4\Z:$9FD_V#UQFNAF^'GA&XOVOIO#UB]RQY MI0&"]MHYX20Q21%M/\/ZQ<1:9J5I# MM\JY/EB13R&!/!JGXFU*+XGZ_:>&M#8SZ79W FOKR,_NR5/W >AKT;5O"VA: M['%'J>E6MTL(VQ^;&"4'H#Z5:TS2-/T:V%MIME#:P _"",@USD_@'PI&20$"XDSP0/RJ[\0VE\,>.?#_ (S,4TUC K6ET(EW%%;/S?3FO3;>VAM( M%AMX4AB7A4C4*!^ I9H(IXS'-$DD9ZJZY!H YEOB+X1CTO[?_;UD8=NX 2#< M?;;Z]JY/PM;7GCSQ]_PFE];2P:78Q^5ID4JX+DYR^*[,> O"BW)N%\/V'FDY M+^2.M= D211B.- B*,!5 ]A0!Y3:P0>)_CUJ,DRI<6VC6:($<9"R'KQ6M\ M7]*EG\*1:S:96^T:X2[B9>. 1N_"NXM=+L;*ZGN;:TABGN#F:1$ +X]35B>& M*X@>&:-9(W&&1AD$4 <-XAUS5=<^%8UOPK,RWW4"?(5_NEAQFO8! MGBJFG:3I^D0^3IUE#;1_W8D"_G5V@#D?B3H-QXC\!ZE86H)N2@DC7U93G'Z5 MD^$/B;X?N_#EJFIZA#I^H6T0BN;>Y/ELK*,'&?I7HE8NH>$] U9Q)?Z-97#C M/S/",YH \T\5:^WQ/U&'PKX9\R?3/,#ZC?HI$1 /W0W?_&M'XPM;Z9\/;/P_ M:/Y)N[B*UAC]4!Y'\J]*L=/M--MUM[*VBMX$^['$@51^ HN].L[[R_M5K%-Y M3[T\Q<[6]10 NGVXM-/MK88 AB6, >RBK)Z4@ZT'I0!Y3J6MZ1IOQU>XUG4( M+..VTM4@:=MJY8\\GO5OXR:O&/A\MI!,-^K3101 -]]&()-=MJWAK1-=,9U7 M2;2\*?=:>$.5^A/-3W&CZ;=QV\=QI]M*MOCR0\0/EXZ;>./PH 72;5;#1K&T M50JPP)'M';"@5YPLG_"0?M!A0%DM]#T\C*C[LC'O[_,:]3Y X']*JV^F6-I= MS75M900SS?ZV6.,*S_4@>_$N270/$OA[Q=]EDGM+!GCN2BEBB-QG]:WQ M\3/![:<+Q->M)%*[Q$C[Y<=?]6,L,>XKK)$21"DB!U(Y5AD5@GP3X8^VF\'A M_3OM!QE_LR\_ATH Y[P'K?B3Q7K%_K5R#:^&V^6PM9(E#R?[9.,_K7H5,1 @ M"J % P !@ >E/H ANX?M-G-!N*^8C)D=LC&:\%^'CGQ'=:;X32"1+#0[V6]N MW=LBU>_G..*I6FDZ?I\LDEE8VUN\O^L:&%4+?4@<]: . ^+M_ M_82^'/$#0":+3;XR/&.&.5P /UK2^'5BUS;7?BR]C9+_ %MO-*N<^5",[4'L M,G]*["]T^SU&'RKRUAN8P=P69 PSZX-3QHL2+&B!$7 55 ] !T% 'F/BV8 MZK\9O"6BJRO%9H][*OHW.,_@*/BQ=6_]L^$++4',.G'4!-@/XBO1E MTRR74#?BS@^V%=IG\L;\>F>M+?:;9:G (;ZUBN(P<[95WZ MU9W\4]I%"Y$T+[EW#MGZD5S?P9TXV7P]@GD4>=>S2W+MW?E7(+>*U@C@MXDBBC&$C0;54>F!0!YI\8'>_D\->'XR6 M^W:BC31CNBX/^-:7Q=U)-&^&6H0H0C7"+:Q#OS@[MC;7$$17U>7?"'.IZAXL\1 M2 ,][J1CCE]8U[?F:]2=0R%6 (/4$9S5>SL;73X!!9V\<$62=L2A1D\YH X7 MXRZBUI\/+FUB;$VH2QVJJ.I#$9Q6E?Z'/8_"F;1-*W">/3?)BV]<[>"['3)K^VTZ]M$V7-O<,( MWWCJ3GKFN>\8>+++QE\0/"6D6I=])%X)?M6S"RN/[I/4#'6O5[WP?X=U&\6\ MN]$L)KA3D.\"DY_K5]M)T]EMU-E;D6Y'D@Q B/\ W?2@#A?C;J367PZN;6%@ M+B^F2VC0=7R>0/PKM]$LTTW0=/LD4(D%O'&%^B@5)?:58:FT+7MG#<&%M\9E M3=L/J/2K>.,8H \MTACKOQ[U:]$A:WTBQ%L@!! =CS_6NM^(&J#1O 6LWF_8 MZVSJAQD[F&T?SK9LM(T_3KBYGL[*"WFN6WS/%&%,A]3ZT[4M,LM6LWM-0M8K MFW<@M'*NX''/(_"@#E?A[H:VGPLTS363RVGLR90/60$D_K7-?"OQ-9Z'IUQX M1UN>.RU#3[F1$:=M@E0L2#D\>OZ5ZO%$D,211($C0!551@* . /:LG6_"NA^ M(U0:OI5O=F,Y1I%^8?0CF@#B_&GQ-CB\K1O!L\.I:_=.%3R%\U(AGDL0"#WK M5\=:3JFJ?"J^LYA'/J7V8/,L8P'<8)Q^5=#HOAC1/#L7E:3I5M:*>K1QC%K1Y]4M+.>VA2.YAN)EC:-E&#G<1D<5PGC_Q M?9^-O%'AOPSI!\^R>]CEEN<[8I@#RJY^]CKD5Z?>?#WPG?ZB]_=>'K&6Y9@Q M/J1TK5_L#23<6D_]G6PELQBW81@>5_N^E &BH PJXP. /2E/2D P:=0! MY-XO^W>"/B+%XSA@EFT>[@6WU!85R5(( 8C\JZK3_B7X-U&T%S!X@LT&,^7- M)LD'U5N?RKK)(DF0I*BNA'*L,@URUS\-O!]W>"\F\.V)GSG4]3ZD9KL[&PM=/A$-G;1P1?W8T"C\?>K5 '"^$OB%X>U30(!<7]O875M$(Y M[:ZE$;QE1@]<''%"O M#6M3>=J.B65Q)_>>(9_''6M+3]+L-*@$&GV<-M$/X8D"_P#ZZ /-OBO'$;7P MKX4M_+\N[OHE,9//EIBO4T4(H1>% P /:JUQIEE=W4%U<6L4MQ;\Q2.N2A]J MGGDCM[>6:4XC12S'T Y- 'B%SXC-I\=]1UR2VN9M)TZ 6%S-&GRP,P')[XS7 MH6M?$WPMI&E_:UU:WNI)!^X@MVWR2MV 4<]:Y_X-VXO]"US5YQYJZKJ4DA21 M>JC@9!^M=I9^#/#=A?/>VVBV4=RYY<1Y/X9Z?A0!S7PPT'4;:TU/Q#KD1CU3 M6I_.>,_>BC_A7\JPO ^JVWP_U_7?#.NRBUA>[:[M+N0;8W5STSV/2O7\8%9^ MJ:'IFMV_D:I8P7<7]V9 0/I0!R'BOXG:3IUBUKHL\>IZO<*4@M[5]Q!/0DCM MWIW@309O!7@*YNM3"+J4PDO;Q\YR^"0#]*Z32_"F@Z(0=-TBTMB.ACB&1^)Y MK5F@BN8'AG0212 JZL,AA0!POP=)E^'=M=N 'N[B>=OF,CO7H]G96VGVL=K9VZ00(,*B* !1=V=O?6SV]U D MT+\-&Z@@_G0!SEUX^\*Z?I:78U6U:$@>7% 0S'M@*._(&*X3P%JS>+/C%K>L M7,$MO]ELUCMHI%*D*3@D@^PKT73O!'AC2KDW-CH=E#,3G>L7?\>E:<>E6,.H M2:A'9Q)=R+M>51AF'H: /-O&&J6$'QC\.C5;J*TL[*VDG$DQPOF\5#E1,F=OTISZ M!I4FCQZ3)I\#Z?& JV[)E !TXH Y#0O##2_!.#08P(Y)]..,G:IIZ"!X[EMF\#^(5Z1%$D$,<,2!(T4*JJ,8 Z8K,U7PQH MFMNKZGI-I=.O1Y8@6'X]: /-_&_C)O&G_%'>#6^VS7AV7MW&I\N&///S>M:W MCR*W\%_!JXTNS81!8%M8SG&2QY/\_P Z[O3M'T[2(3%IVGV]I&>HAC"Y^N.M M27VFV>IP>3?6D-S%NW;)4##/KS0!F^#M,_L?P;I&GG&8+5%./7&?ZUQ>MQR: M_P#'#0[12H@T:W:Z10!X%K\UW8>/_$_AG2[=VE\1O"CRL_\ JU.? M,8?\!)KTSQ?HT%O\+-2TBW7;##8>6B@<84#'YXKIO[+L#>B]-C;&['2#],TC2M5MKF:UM%:6.-_G3/)+#MR37;21)-&T<;02"?RKK?B$UPOP M]UTVVX3-:.J[!D\\?UK;;3+)]134&M(C>(I19R@W*I[ U:90ZE6 *D8(/<4 M>;> /&/A;2_AOH\;ZQ:QF"W5)(RXW^9U(VCD\FL>UU&;Q3\>[1WMIHK+3K%I M8$F7:XH \Y\?O%J_P 1O!_A]P'5)VO90#R N<9'X?K2?&JX,^C:+H*XSJFI M11.!UV Y->B-I5BVIIJ1M(3>HFQ9]OS*I[ TMSIEE>7,%Q<6<,LT#;HI'0$H MWJ#0!/#$L$21)PB*%4>@'^13I9%BB>1R B LQ/8#K3N]8'CC55T;P1K%^>L= MLX49ZDC''YT >5?#'Q;;Z9K>O7>LA[>TU:^8P:A)_JG9"P*D_P /'K7<>,?' M=I!I?K6_I/A;0M"9CI>DVMJ6.XM'&-V?J: ,7PMX/.B?#=?#\A_TF6" M03L.\C@D\_CC\*YSX6^*;#2] 'A76)H]/U+2G>)EG.S>I8D,"?K7JOX5D:MX M7T37.=3TNVNCW+IS^8ZT <+X]^(5O/83>'?"DIU'6KQ3$OV0[A"#U)(]LUUW M@GPRGA/PC9:.IS(B[IFZYD;EC^=7M(\-Z-H2LNEZ;;6H/4QI@G\:U2..] 'S M_P"'4DU2\O/AQ'%(L$6L275Y)NX> ,&V_B0*[[XN".T\$V]SL7R;&^MIRG^R MC=!_*NRM="TNQOYKZUL+>&ZFSYDJ)AFSSR:GOK"UU*U:VO;:.X@;&8Y%# _@ M: .!^'PD\3:QJ/CN[MWB^UJ+:PB?DI"HY(XX+&H/BE')I6K^&_%OD2SV^EW0 M%RJ*3M1N-V!Z9KTBUM8+*VCM[:%(88QA8T7:%'TJ26))HS')&LB,,%7&01]* M .;7Q]X5?2$U-M=LEMG7(+3+NZ9^[UR*P_!'BG7/&/B#4=21$3PJAV61>';) M,W][GFMO_A7GA(7ANQX>L?.)R3Y?&?7;TKHXHDAC$<4:QHO"J@P!^% 'FL[+ MK'Q\LX0#U-:- M "-]TUY3XSOQX1^*ND>);Y'&E3V[6LLX!*Q-V)]!TKU[MXYX M6X*2*&!_.@##N_'7A>RTIM1DUW3S;A=RE+A6+>P .2:X;P3%=^._'T_CF\M' MM].MHOL^F)(/O#N_ZUUT7PO\%077VF/P[9^8&W#_->I]ZS+#P_I6F:G>:C9V,<- MY>D&XF&2TF/6M2@#-\0W%[:>'[ZXTV-9+V.(M"K#(+#VKD_A_P#$"R\1:%#% MJE_;1ZU&"+JWD(B(.>RFN^/(KF-;^'OA7Q%)YNI:-;RRG_EHN4;_ ,=Q0!P7 MBX:==_%WPI_8 1M268_;);8?((L9PQ'&<9ZU<^(5Q ?BGX.BOKF.&QA=IF\S MA?,&=O/K7>Z#X3T/PQ#Y6CZ=%; \,P&6/U)YJ76_#FD>(;46^JV,=RB_=W Y M7Z$(O$=RX>;4+S 8 M+C"@?=KMM(\%>'M!CG73-*A@-PNR5E!W,IX.2:T-'T:PT*Q6RTRV6VMU8L$3 M.,GJ>: /(_%>OI;?'.PNYXA)IVDVNVXE*EEBWYRW'<9'TKTC5/&_AS2M%?59 MM7M&MPH=?+E5FD] #U-7X_#NDQ7=Y=+80^=>#;<,1N\P>AS6*GPP\&1WWVT M:!;&;(8;LD ]N,XH YOX:Z;?WUUKWC:[MFAN=6)^QPO_ Q#[O7WQ5OP)X_D MO;C4-*\4WEM:ZS;W# 0M^[!3MC/%>BHBHH5%"JHP !C ]*PM>\%>'?$I#:KI M4,\@_P"6F-K?F.M '%?&.7PQ<^#)VFDMI=5?_CQ,+!I3("",;>2*3QW>7UA\ M"$BO2([R>W@MY#GH6VY_PKJ]&^&_A+0;D7%AHL"3@DB5R7;D8[\=ZW=5TFQU MG3Y+'4;9+BVD^]&XR,]J */AZ?3K;PW:6]G=6\D-G:HK^5(&V@+WQTZ5Q7P8 MC^VVGB#Q"Y#OJ6I2%6_V5.!_.NNT/P-X?\.VUY;Z;8"**\XG4NS;AC&.:TM' MT73] TY-/TNT2UM48E8TZ GJ?K0!Y]X6O;2X^+OBR_NKN%'A$5G LI"G'?!/ MTJ+XWSI_9WARWN)EBLIM3C-PS?=VKSS^===JWP]\-:UJ@U*\TX&[#B3S(W*$ MD="<=:V=4T73M:T]K#4;.*YMB,>7(N0/I0!3O/$^A:=;(7U&W?<,111.'=^G M"J.37G?PTOG\5_$GQ+XDGB91"BVL2/UBYZ?D.17 MYD+L -P' Y^E=!\1M:BLOAOJ]Y;3H[20F*)T8$,S''!'7@FM?Q#X1T/Q5#'' MK6GI=",DHQ)#)]".:A;P3H$N@6NAS6 DTZUP88G9CM([YSS0!@Z=X8D_X4K' MH4 19Y=-_ NPW&H/A1XGTRY\(6>C27$=OJ6FQ_9[BVD8*X*DC.#U%>AQ1K#& ML<:[410JCT Z"N:USX=^%/$,_P!HU'1H'G)R98P8V/U(ZT /-6-:\.Z9XAB@BU2T%PD$@D168X#>OO0 >&].BTC MPSI>GQ*$2WM8TQ] ,_KFN!UH?VY\>=#M!(#'I-H]RZ@Y <\#(]>:]1"@8P,8 MZ8X_STK-LO#FDV&LW6KVUFB7]V,33

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�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

  • #CZXS6;-X;TSPQ\:?"MEI%S.J/%-)-#)<-)@A M6QP>F:VQIMAJ/Q^O?M=I#D8Q^'I7D7A#Q5H7AWQAXYM]6U*"SDDU9I563/*XQFO7:\Q^'NGV5W MXK\>&YM()W76& ,L88[2#QSVXH 3X@^.O"^J?#S6[6RUJVGFEMBL:IGELC Z M5K7BN_P0=3MWG0@ OYT?$O2=-@^&FO/%86L3+:DJR0J"#D>@IUX$?X M)OF3:IT$?-C_ *8?XT 9'@7X@^$K'P'HMM>:[9Q7$-JB2(_!#@[N4C,A5,Y"YQGD>M9/P\TC39_AYH,DVFVCR/9QL[-;J23CJ> M.M=5;:7I]K.9K>RMX9"N-\<2J2#VX% %SM7F'BR_LM,^-7A:ZU&>.& 6%RGF M2' 5CG'^%>G'A2*\P\7VEAJ?QF\)V5]:)./"D5 MI--)K=@T2*6<+*&)'?@=:Y?X-Q.=(UR^B@DM].OM4EGL8W7&(SC! ]#_ $J; MQK\/M,?16U+0M$L4U>RD6YB5(0JRE3DJP'7(S71^#/$MKXK\.6]_;QK"XS%- M ,?N9%X(H X/PUXIT'PWX_\ '0UG4+>S>6^C>,RD\K@C@_CTKKE^*/@B66.* M/Q%:.\CA%5=Q))X':L'P18:?>?$'Q[)/:P3R"^C4&5 QQL]#[UWW]B:4"&&F M62D'((@48(H X?XRL1X3TO8NY6UBU'L!\U>D>]>>?&+YO"FG8Y_XF]J>/]XU MZ'D8SD8- $%[=Q6%C/=SL!%#&TCG/\*C)KQR#PL_B;X>Z[XF> +KU]BV>IVOS0W40E3V)'3Z@\5Q?Q)D M,?B7P)P>=94=^F!Q_GTJ+X627>D3ZSX-U*X$MUI-QOA;&-\$@# @>F3VZ9Q4 MOQ,(7Q)X"+$ ?VTO7Z4 >B8Q],8KS;X51LM]XV22-5SKLVY>HY S]17I5><_ M"XDZKXX.P'+6\G M#9QU _K5;2;J+QQ\5I-4MITN=&T&W$5NZY*/<2 %F7MP,"@"K\4M-M?#WPOT MFPML)9V%[:H6(S\JYR3[D\FNF/Q3\#A Q\16FTG ^\?;TK*^,RK)X,LT9 ZO MJEL"#T(W(]'\20RW&CWL5W%&VQWCSC. M,_CUK6/2J]K96MD"MK;0P*QR1%&%R?PJP>AYQ[T >3>'/$&E:'\4/'(U?4K: MT\V:W:'SB%R I#$'ZD5J^._''A6;P9J5F+Z"_FNX)(8+:W/F/(Y&!@#T.#6= MX4TC3-5^)WCPWUA;W+17$ C,R!P 4)/!]\4[Q?H,/@C5+3QIHNE6[06P\C4+ M98_^6+')D4=F!Q^% '3^$;.\T_X8:=:W@87<6GX96.2IVD@9]A@5R_PVU7^Q M?@3_ &K+@&UCN9>/4.V/UKT$:C;:GX>;4;.426T]LTD;@]5*]37G?PST]M8^ M S:?C+W,=W$!_M%W _7% &[\*-&BL_!=KJZ1J%Q;F&=&B?=(NY#Z^Q!P:Y[X6ZQ'<>$++1[EA#JFFQBVN+63B1 M=O ./2G:_P" ?!I34=6U&PB2657DDFDE(&<9SC.!TH T%TR#2/AQ=:9:7KW4 M-O831).[AB<(W4^W]*X_XTO-7C@GMX?+D1U8$'<>>!TH^'&Y M/@%<'+$BUO"-PP2/GQ^F*Z'X8:=I\GPUT%C9P,6M07+QJ23DYS0!R?CKQAH7 MB/5O!L&DZ@ETXUJ)VV*PP <=Q7L9X_"O,OB=9V]MJ/@I[>VBB8Z["#Y: $@Y M]/PKT[(YH \ZT)BWQS\5(,;$T^UR/0D#I^%=W?VINM.NK:-@CS1,@;T)!&?U MKA-!X^.OBO X;3K4Y]\ 5V7B._O-*\/7U_I]H+NZMX3)'"6P'QUY^F30!YGX M)\96?@71(?#7BBPNM+N+1F5KHQ%H9\L3OW =3D5V5K8>&/%7B&R\4Z??I M&/BKX3F\/0QVEU?R21W=M!\JO$%^\5'N3S[4 >M\9ZTM-'4\TZ@#S7XG3P6G MB3P+=7,J101:H2[N0 !M[YKJM4\8>&=/T^:>]UG3S $.]/.5RX] H.3Z5RGQ M1M+6_P#$G@:RO(%G@FU-E>-NA&T=:Z:V\!>$[6=9X?#VGK,.0Q@!(_.@#COA MG;7"?"S6)VC>)+N6[FMD=-N(ROR_+V[U)\,O&GANP^'&C6U[K-E:W$4162.6 M4(0=Q['K7?ZX!%XRD>:(EVDA5V M8[CGG% &7XXUS2O%OB7POI/AZ5+[4;?4HKJ2XMCE;>)<[MS#U]#6Q\:9/(\! M),[$)'?0-(1_=!)-9^A11_#7QR^@FUABT'69&FLK@* T4N!F)CZ<!%B4_\)%:J".%VL"/8\5N:%XGT7Q*L[Z-J M$5XL#!9&CSP>U65T?2_+7;IUEC''[A2,?E4]M8VED'%I;0VXD.6$<87<<=\4 M >4Z!XLT#PS\2?'":QJ$-F9KF%HO,!YPA!&0/4BNZTKQ[X6U[4H].TS6(+J[ M=2RQHK=AG.2,#I7+>"[.RN_B3X^>:U@G*W<&UY%#,/D.1@]!D=:]!@TG3K:X M%Q!86T4P! DCA56P?<#- 'G7C;7+'P_\7/"U_JEV+:R%G?&OPI%=01SQ_8KDA9,%5.#@X/4UW1T; M2^3_ &;9\\']PO\ A0!3N-1M-8\'W5[8S">UN+.4QR+P&&TUQ'PN\9^&[7X= M:)97>MV-O=)$RO%-,%8'>W'/M7?ZNL-MX;U".)8XTCM)<*N JC8>WXUPWPR\ M+:#J/POTA[S1K*9YX6,K20*68[SWQF@#,\;ZU8>*O%GA72_#DXOK^UU%+F6> MV.4AA7[V6'&,5L_&R58/A^)W+[(KZW=MO7 :J>A+#\./&_\ PCC6L::/JSM+ M87 !CDZF(GTX./PJW\:Q&W@>!9 &C;4K<.&Z8W'.?:@#63XI>"SM UVW#;= MVW:V1QT.![UKZ!XIT;Q.)WT>]6Z6W;9(RJ0 3]:MKI6E%%VV%IMVX4^2IXZ= M<58M[6UM-PMX(8=QW.(U"Y/OB@#PR[\/ZAJ7C+QEXATB=UUC1+R-K>)3@2IM MW%3[G!XKO[GQ+;^*?A%JNJVZE3+ITZR1L.4D"$,/S-5/ &/^$\^(()R/M\/_ M * :Y?QRFH_#QM?DL[87&@:[#)NCS_Q[3E3D@=@>?TH VAJDV@?LZ6]W"Q6= M=,2-&!QAF(7.?QKL_!6B6_A_PGI]G#'A_(629CDEY6&78D\G)/Y5QYT:;6_V M>H-.@1GN#IJ/&@X)92& _2NO\%:_:>(O"]EZ=+OCE@P"P/\+>HKF/BC?6VF:YX)OKN=8;>'5-TC'L"O M7Z5L^,_&C^';[2--L+:.]U/4;D1);[N53N_X#-9'Q)ACN/$W@1)HXI(SJI62 M-\$([?X=7 M^K:/XGL[FV\[4))H=3\@F.:-VXW,.F#Z^M=G>Z?X;\?S:7J%KJ8DFTZ<7$,E MI, W!&01Z'C\ZL>#O$]IXY\-BZ>VC24.T-W9N0QB<'&T@_G7$_$3P]IOA2ZT M/7?#D$=AJSZG%#Y4'RK#9;>QPVH:E(M MC;*3U=^#^F:[''!'4=*\I\10ZIXU^)RV.D7T=K%X;C$QF9-ZFX?^$CV&/UH M;J6@V?PZUWPCK&GVRP6BJ-+U!D'W@X 1V/<[P>?>O2-?;9X;U1L_=M)3G&<$ M(:X/Q'X,\=:[H-[87?B:RG1U#QI'9"(EU^9>1[@5>T#Q"WB7X07EW-(&O8;" M>WNE;JLJ(0<_7K^- 'G7P_-Y\.++1-=GN3+X?UV)5N@>EM+G"-[#L3[UW7Q3 M_?:AX%>%@5.NP$-[= MWCE4K)&C C;@J""/3D5Y_P#%)?,U3P4N/^8Y$:\PTV<>(?CQ=ZA8R)-9:1IGV. M25GGI0!YOJJI_PO[P^2?F_LB?'YM7I%>;ZL%'Q]\/-USI$ M_P"'+5Z10!YCXU('Q?\ BG.6,^./1:K?$[1K?Q/XY\)Z%=$)!=)=$R 98$1 MY 'MD"I_&^!\8? !SSNN1CT^45)XP)'QG\"G*[=EUP3_ +!H V_AIJ4U[X*M MX+M=EWITCV,Z]P8VVC\Q@UY5XY@B\02WOBIOF\G7X--M&SQY2$AB/JU=;J&M MVWP_\4^,'N;E4BU"V6_M(W/+3X*E5'N<5F^*]&;1/@UX;LI#NF34+6:=SP=[ ML68G\6Q^% '1_&@;O">FJ0"&U>U!S]37HC("V[8I8 @$_P OI7G?QG8+X8T@ M>NLVW\S7H] 'FD#9_:%N%P %T,=0.O0YI(K."6YDPD<2%G;_94'J:\ MZ@ /[1MVOSBK_ ,5-3N4\/V^@::G:LH!,\0+@C[LB_ M*P/N&!KF+'PUX_TG2K?3M/\ $6D+!;H(X_,LB2% QV[U4^&PO/"OB75?!FJ7 M23N?].LY%7:&1OO #V/7ZT 2?&!Q''X4PJ%FURW4DKDE>>/SQ7I)53U XY&> MU>;?&"/S$\),.VN6_/XUZ7D T >9^#/&/W2ML!GV6F^%K:/Q;\2O$.O MWXCN(-*F%AIT;#B,@?.^#W/]3Z4>"MR_&/QZ&Y!^SL#_ ,!I_@-H_#?CSQ3X M:NI-CW-R-0L_,89ECAR.L<;.[A5499B< >IKSCX51M>W/BCQ( M(FCM=7U%GM@QY:-,C=^))H \Z\.QZIX4EU#Q_9R-/8'4Y[;4;8#)2(.0K<=< M9'YUZ!\7[V+5/@U>7MDRR6\ZP2HW^P74TOPCMX=0\#:M#<(DD-SJ=T'0C(() M (KS_P 9W.H>"?!FK^!=0\R>UNIP^E7)YVPEPQ5O<8_G[4 >M^,M.O-6^%M[ M9:;G[3)9(8T4X+8 .W\0"*SO!OQ&\*W.DVNG-<1:5>6\:QR6=TODF-@,'K@8 M]ZUM<\5Q>$?"FFZE-:236K&&*5D./)5@!N/L*T-0\.^'O$UFK7VG65]#(!(K MM&#D$<,&Z\T 5-&\)6.F^+M1\1Z?=/MU*(++;K@Q[AC##'L/UKJ#TKRCPM:C MPG\7;OPQI5S-)I,UB;MK:20M]GDR,8],CM7JS=* /,M1M%\7?&0:=?HKZ=X? MM$N5B8<22R8P2.^!FO2=JF,KM 3&,=L?ETKSC[1_PC/QLNI[XA+/7K-$@G9@ M )8_X3]1G%>E-T]^E 'F&GP_\(E\:WTRTV1Z;KUH]UY"9 6=.IQTY /YU%)K M.E>'_CIJLVK7\%E%-I401[A@H9\@<$]\"K%MH!^M '7VGC;PMJ5VEE:: M]I\]Q*=JQ1SJ68_3-;XQ61;>$_#UG=1W5MH6FP7$1RDL-JB,I]B!FM?&!QF@ M#D?B5K";W[-N-_>8L[4(,MYLGR@CZS&@(+QYY4$JB9N%4KZX['U M-6]<\&^/M>\/76E7WB?2Y8YDPP%@5+8.1\V>,$#MVH ] U0!]%O0#PUNX&#C M^$U\_P#@Y[WP%I6C>,\^9H^J,T&HHH.8AYA4-WS@J>1CJ*]2\%^(9-;^'8W(QZ<'Z MT .^,$RR^#-+FB=7C;5;1@PY# D__6KK_%'ARR\5:!D6'P\UE'>XMM3@>RN\_++;AL@GWYQ7T9T&!VXH \JTKXCKX< M\-7NF^)#LUS2I/LL4#N>.:W?AWX8GTZWGU_6/G\0:N?.N7)SY:'E M(QZ #'Y5C>+["QF^-7@YIK=':2.8MG'S%02N1WP<5ZB!SUS0 IZ5YEX,A'BG MQSXC\0ZBGG"RNOL.GQRC(AC4?,RCIEC@Y^M>FGI7F_P[EBT?Q/XH\.7#B.Y% MZU["C\%XFXW#UH ['Q+X>M/$OA^\TJZ50D\957V@F-NS#W!P:@T;29]"\'QZ M7->O>26MNT?GNNTL,'&1^0K5U'4+?2].N;ZZD5(+>,R.S'' &:P_#GB0>*_" M']L_8Y;.*99"B2\DH,C=^- &!\$B6^&=F6')GGZ?]=#7HIKSKX(J%^&5EA@5 M,\Y4^WF-7=ZC?V^F:;<7UTX2"",R.V>@% 'G-Y86WQ ^)]Y97T*W&C:%;>65 M)X-S)_55S6E\+KF:VTG4/#=VS&YT*[>U#,N,9H O?%$+::_P"%M6U*W:?0+2X<7BA2PC8CY68=P*ZN&_\ #/C'1I;& MSN[&[MKB(J8TVG ((SM/>)M/C\70^%[ZU=6NH#+#+*!Y4N#RHSWK.UK MX7>%]6:2>.R.GWIZ7-DYB8'L3C@T :'ACPW<>%_!XT2*^:Z>%7$$LGRE0G>(/M4AN/M@V-,Q;A@Q[8Q^M;/@'Q->Q_#.ZU'5C M+?R:9--!OC7+S)&V ??CO[5N6]MX8^(GAZVU*?3K6\M[E-P\Q%+H>F"1T(H M9>^$H-0\9:3XJTZ]2WDM5>.80HI%RC=0Q'\ZZSH/3^E>37FDQ_#WQYX;_ !$5O$/BKP[X-+,+2\9[J]"M M@O$G\/T)%=W9:1I^G6J6MI9000(NT(B #']:X/QC=?V#\5?"^NW2,-/EMY;" M27^&-V.5SZ9)Q7I(.[H<_2@#R[7K2W\#?$G0M:TZ-;>SUJ;^S[V%>%+-@HP4 M<9R*F\:0Q2_%SP1]H2!X=MRK>;CKMXZ_04WXB,FM>-_!OAZV.^YAOQ?SJG/E M1)W/IFJ_Q%TFPUOXF^"]/OO,:.87!9%H% 'HL^GZ.MM(9[2Q6 K MABT:A7^SV ^4KWVGN.E5O&GPITV/1GU#14NC<6C M+-):MTN=!MX[:Q(VB!% \IAPR'W!H Z-L M[3CK7D6J7NC:5\;Y[GQ4J):RV44>F3W*YA1OX^O /N:]=;I7)VFK>'_&UYJ^ MBW-@LTVG2>3<07D2Y(/<#KCWH /%?AC3?''AM[:VEM%N/E>UO8U63R7!!!!' M;C'XUD?$F&ZM/@SJ5O=21W=S';1I)+MVAB'4%\5E>*?AGI7AO1;W7O"MQ=Z+ M?6<;3A8KAC$^!G:58G^E6_%NK2ZS\ KG5+H!9KG3XWDV^I*YQ]: .ET2Q\,K MH.G&.WTK8;>,*VR/GY1WQZYK4L;70UN3-IT&GB95P7MU3<%/^[7):3\)_!+: M592R:%$TS6Z%G,LF3E?]['>N@T#P3X?\+W&?RKH/%'A[PJOAC4GO\ 3=,MX/(Y'-4_&?@33?"=S8 M:W-#J>K>'H9-M_93W+S+$#TDPQY /6@#JOAM-=3_ ?LS?*Q=;694+YR\8+; M3_WSBF_!6/9\+M/)P!)+,_'8&1JZZ(VU)@$(&TJ5XQCCN*Y'X M)!A\+=-#;A^]FQGT\QJ ,GX2^'-#OO"=T][I.GW4PU&<,T\*.V W&VU2QCO5N+JLRZ')J M*B^*DC( RH(],]?I72ZGX1\,>)=!N+6/3M->.:)D2:WC4;6QP0R^AP:GU36M M#FUZ#PKJ<8EN;R%I8XYH=T;@9R,GC/%XO/#.IZEH=XVZ1%M[@ MF'?CNA[4 =1X-TO4=$\+6.F:I=QW=S;(8_.3.&4'Y>OM@5OUQ_PT\07WB/P? M#=:F ;V*:2WF8#&\H<;OQKL* $/2O'? 2:+/XO\ %#>)/(;Q"+]U3[?C/DCA M=@/&.3TKU^XF6WMI9GW;(U+MM&3@#/ KC4TGP;\2]+CU=M-CN5=BHF9/+E5E M..2.(-,U3X6P6.K:+KEY/"HXVVH_'::]+Z\UYMX*4R?%CQY/<#_ !!3F@".>U7Q_P#$;4-.O6:30=""*UMG"RW##/S>H SQ71Z]X"T' M6-"ET]-*M+=PA-O)#$(S&XZ$$<]0*Q/!#?8/B7XWTV?Y9[B>&]BSQOC9<<>N M#7HDC*L3,S * 26/0#UH YGP_9:W:>#/L.NR02W\,#Q>9$Y;>N" 3GO6'\$T M\KX86";LXEF!P\"6VH7%SJ22SS2D^3=-&O#D# ''04 =/\9U#>$+$$@?\36V_P#0C7HHXX Q MCM7BGQ*\$:9X?T"PO+2ZU O_ &G K">Z:16#-D\'OD"O:QUH X[XK*I^&&O; MAD?9QQ_P):@TGX>>$)=!TUY] L9'-O&Q:2/<22HSWYJ?XKMM^%WB XZVV.F> MK 5AZ;\.;G_A'+9['QAKMM-):QLNVX^0'8.WI0!273K#PC\:=%L-"B:"VU&T MG:[M(SF-" 2KXSQDC]:L>.='L]<^+GA*QU"UBN+22VN6DCEZ-M!(''O_ "H^ M%5CIL%YJ"Z@LLGBZT8PW0IGY2A/\)]JC^(&DPZ]\5O"&FS7%S KPW#[ M[=RC\#)^8=!QB@#K?^%<>#01M\-:<,'/$(&?\:M20Z/X(\+7T]C9QVME:QO. MT<0QSC-8$OPDT257']J:^I*?#IM_A5JFB6$MQ-Y=BZQM-)OD;'S8 M+'J2 : ,/P5X-M_$EC#XM\5(NJ:E?@RQPW S#;QD_*JJ>.F.HJ?QOX&LK'2+ MGQ#X7M(],UJP7[2K6:^4LRIRR,HP#D ]JZ/X?7\&H^ ="N+=@5%G'$P!!VLJ MA2#[Y!JYX@UC3[7PIJE_)8VL>!UB =SK:'9CD@=3^%0_&&T&HCPG9 MF:2'S]8C3S(OO+D=0>WUH V1\*/ J+A?#EO@\'YG_P#BO:MK2/#VE>%-+N+; M0[%;:(LTQA1F.Y]H]2?0<5S*_"FU69I%\6>+=QX(.I_4?W<_K70V=O9^"/"F M+S4[J>TLE9Y;J\8R28SDY('O0!YW\,_#N@^++&\U_7X(M2UZ6[E6<7)W>0%; M"J$SP,5OKX$N/#OC[3=7\+1K;:9-NCU.T\TA-IZ.H/?IQ4MW\/O"OBM!KVE/ M-8W-XF];[3Y3&Q!_BQTS64;KQ+\/O$VBV>H:ZVLZ)JEP+1&NT G@; Q\P^]T MQ^- '6ZG\/?"NM:E)J.HZ-!<74N"\C%@3@8'0CM7G_@GP%X7U+Q'XPMKG24D MBL]3\J!3(V$4+TX([^M>S]Z\[^&P_P"*M\??]A@_RH [#0O#FE>&K1[72+-; M6"20RNBDG+'J>3[5S7Q?*K\,=58NR$! K*<,1H3(1]6(_*@#8^$ZD?##0=V68PDL2$X+SO]Q??@#\ZV?AYJ%MI'P9TN_N' M[6S>5F/HK,:YOP#KNK6 M-C?ZM=>$=6NKK5KLW+W,**=T9 V \\#MZT =KX!U=/%'@&R>Z_>3>4;6[1N M"'7*MGT]?QKG/#?G?#_QO)X8N))9-%U1C-ILLC;C$_>,GT]/H/6HO!6L36'Q M(UG3+O2KG2;?60+RSBN !F55 DQC@9ZXKK/'^@6NO>$[U;AC%+:QM5[G5-6B$UQ<2G+8R<*#Z"O0Z /.?C29 M5\#1>5++$3J$"LT;E&"DE3R.>]6S\*/#GRE9=5#*<@_;I"0?7DU2^-ZF3X?; M S*7OH%#+U7YC@_G5M? >NB(J?'NM E,=%PIQVH K?"^]OQ<^)-#O+V6^BTF M^\JWNGY+(1D GN1@5BZ7X4T_Q5X_\9KJ4NH".WNHXXTCNF1>5SD8/MTK4^'$ MDGA_6M4\#WT<;7EH/MBWB#FZ1S]]_P#:Y K(TC0=2UOXE^-9+'Q)=Z4(;F)7 M2U0'=E>"<\9X- '1-\&_"C+S_:9.,9^WR'^9KN;.TCL;*&TAW>5"@1-QR<#U M-<9_P@NO^?%(?'^LLJNK,ACC 8 YQP*[E?E !.<8&: .,^*SK%\-]6F9G4QJ MA5D;:10!!\7Y+[4;6Q\.Z6 MV+N:.:\,M98; MK;3[0Z5:GW"EY2/^!%1^%3_#"]@T[X,Z3>W4@2"WMI))&]%#N?SH Q_']EJ' MCKQ@GA?2M0>S_LJU-Y/*N0#*^/+0^W>N\\)ZS'XA\+V&J1LK-+$!)@8Q(O## M_OH&O,?!'BFYL)=5UBY\'^(KNYUB[,YNK2RWH8NB@'=D87M6K\+M7>T\0ZYX M\ M@[?FQ]3^0K7NOA4MM"\V@>)==T^]5#L9[PR1MQP&4]LTQP3^T/$Q' T)O_1@ MKTDD 4 ?%VFZAJF MH>(?$$;'49HDBM[YD551L#''O70?#0QW'BCQW?0IBWEU78C9R'90=Q'XD'\: MYSX>Z'XFU32]5O-'\8-I=G)JEP$MQ8I-@[N3ECD?2@#K8OA9:V]S!<0^)_$Q M>*59-LFH%U8 ]"".17?#K7%:=X:\:6NJ6L]]XZ^VVD;YFMO[-CC\U?3<#D5V MB]: '4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %9]]_K1]*T*S[_ /UB_2@"_1110 M%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(P)4[< ]LC/-+ M10!Y?I'PW\5Z#'-#IGCEK:WEFDF\H:>KJK.<\;F-:%I\-);G6K75?$_B*]UR M6V.^*"2-8H5;L=B\<5Z!29 [B@#G/&GAAO%WAJ71UO&L_,='\U8]^-ISC'X5 M@KX'\91(J0_$B\5%& K:;"V/3J:]"HR/6@#C] \->)],UI;K5/&4VK6@1@;9 M[)(AN/0Y4]JZ;4;4WVF75H'\LSQ-'OQG&1C-6J* ,'PAX>_X1;PM9:+YYN!: M*RB4KM)RQ/\ 6L[QOX)/C(:;LU2?3I-/G\^*2*,,=V, \UU^:,T >??\(+XL MVC'Q'U/<",'[''T^E;7AGP_K.C7-W)J?B:ZUA9@HC6:!8_*QG)XZYR/RKIZ, MT Z$]U)<[VC"8W8XX^E6?%OABS\7>'Y]+O"T8'AYKG4I//T>YCN3)Y8_?.N.3Z4GCKP)9^.M/MK6 MZG>W^SREU=$!)&,$?2NM%+G- ',^(_",.N^"Y/#<\*+KW@I_#DEV\2/ D)F5 3\N.Q^E=)D>M&: ,#4_#2ZGX)D\-O=.J26@M3/ MM&[ &<=.U7=$TI=$T.QTM':5+2!85<@ G:,9K2S10!QNK_#VPU3QMIWBG[1 M-#>66,H@&V0CN:D\8^!D\7W6FSG5+NPDT]V>-K; .2/?Z5UU)D'N* .!7X>Z MPI;/C[Q 0> "R\5O^&O#UUH"W N=@Q709![T4 @I^110!SGC#PM#XLTA+& M6ZFM6AG2XBGB W(Z],9[57U#P9#J'BS0_$$U]/Y^E1-&J*HQ+D$$M^==4<$< MTAP1CI0!%-%'=VSPRINCE7:ZD9&#UKF_!W@>S\%+J"V%Q<2I>S"8I*1B,^@K MJ5QGBG9'K0!Y^?A@(]5O]0LO$^MV,E].9YEMY54%C_P&IX?AG82WT5WK&JZM MK#Q,&CCO+C,8_P" @"NYHS0 Q%VX QC &,>E./2EHH X;4?AO VM2ZOH6K MW^AWM3^%?"MEX1TQK"QDFE1Y6F=YB"Q9NIR!6]1D4 - M=0R,I&01@CUKB'^&6F/X&/A)KZ^>Q$WG+([@N#NW8X XS7M $<(;*UV[1"MUN"K_=4GE17H-)@9S0 M!ROAKX?Z%X8F:[MH9KC4'&'O+N0RS'_@1Z?A4.M_#K3-M '!M\+[1T*2>(O$3(3G'V]A72^'-"3P[I,>G1W=U=*C, MWFW,F]SGMFM>C- >E8/B3PK8>*/[/\ MQE7[#/RJ%_#MI)X57P\[2FS%LMKG=\Q0 #K]!6Q29'J* //[7X1Z-9 M6RV]KJFN0Q 8")?, !Z8[5=L/AMINGZC:WJ:GK$KV[;E2:]9T;C'([UVF1ZT M9% "?7ZU@7_A*QU#Q7IOB*629;O3XGBB4-\I# @Y_.N@R,XS1D>M "$5SVC^ M#]-T#6[_ %/33/";X[Y[:K#=7DG MF3&VNS&">W2HW^$VDN'']L^( '&,?V@QQ7?T9H YC5_ ^F:YX;LM!OI+I[.T M*,I$Q#L4! );N:QF^$FCD%8]7\0Q(>BIJ3@"O0,CUHR* .1TWX>Z7I^NVFKM M M01MA)E[;AWQ3M=\+6>O:AI=[=R7 ?2Y_M$*Q, "X]>.:WZ* &]_\*Q?#WA>R M\-RZE)9M,S:C=-=3>8V?F/I6Y1D>M %34].M]6TRYT^[3?;W$9C< X.#69X6 M\*:9X.TDZ=I,M[-&: ,+Q1X6T_Q=I2Z=J8G^SK()?W,FP[ MATYKG_\ A5&D9PNK>(4'3"ZFX':N]S1F@#F?#G@C3_#-]-=VEYJ<\DJ;&%W= MM*N,]<'O73'I1D8SGBC(]: ,/2?"VGZ1K^JZS;>=]KU-E:?>^1\HP,#M6K>6 ML-]9S6EQ&)(9D*.I[J>#4]&1ZT 8'A_PG8^&]!DT:REN6LVW!5FDWE PP0/; MK4OAGPW9^%=#CTBP,AMXW=P93DY9BQ_4UM49H Y?Q!X#T3Q%>I?7,4L%^@PM MW;2F.3'H2.HK-3X6:-)*LFIW>I:H%.5BNKDLGXKWKNJ* ,^;1[.719=)2$06 MM &)KWAC3_$ M4NFRWRR,VG72W<&QL?..F?:MGGGK3LT9H QK/PS86/B:_P!?B$OVV^C2.8ER M5PO3 K7=0R%64,#P01D&G49'K0!P\_PMT#[9-=Z=)?Z7+-)YDGV&X,2L?]WI MU]*TM!\#:+X=OI-0MHYI]0D&UKJZD,LA'< GH/I72Y![TN: .5N=+N)?B3I^ MII#.+>+3Y(Y9<_(6W?*N/7YF_(5U)Y7%+1F@#$UGPQIVNZCIE]>I*TVFS>=; ME7P WN._2MH=:6DR,9R/6@"&]M([^PN+.;=Y4\;1/M.#AA@X/XU1\/Z%9^&M M$MM(T]91;6RD()&W'DD\GOR:UN@S10!Y^/A'H*)A+W7 !T5=2 M<9]JU_#_ ($TSPWJ#7MG=:G+*8S%BZO'E7!(/0G]:ZC(]11D>HH Q-'\+:?H MNL:IJEKYWVG4Y1+<;WR,C/0?C6X:*,CUH Y3Q-\/]%\6W]K>ZG]K$ULACC-O M<-'M!/M6&>]FMKTN93< M3EW^==IPQZ<"KN@:':^&]$MM)L3-]FME(C\UMS $D]>_6M3(]12YH P_$GA7 M3/%5C'::E'(5BE$T3QL5>-P^174T4 8FC^&+#1-4U;4+42>?JDPFN-S9&[GI^=3Z_H&G^)=(FTS4X3);2C MG:<,#[&M2C(SC/- %#2-*MM#TFUTRR5EMK9!'&&;)"_6N;U3X;:/?ZI+J=M/ M?:;>2_ZR2RG,88^I'K799&<9&:7(- '*:%\/]$T#4FU1$N+O4BNW[7>2F63& M.WI4_BCP5I/BX6?]JK<'[$Y>$PS%""<E:A(69LEF/]*WLT4 (>AKEK7P-IUD/$"6T MUU%#K>YIX@PVHS @LGIG-=529'/(XZT 97A_1(?#N@6ND6KRR0VJ;$:8Y8C) M/)%9'B/P!I/B;7-+UBZ,T5WI\@=&BPN_!# -ZX(KK6OV2?SXWM6"MN^IK'_X5@7!BN/&/BF>W;AHGO^&'IPO%=_D>M&: ,CP[ MX;TOPOIHL-)M1!!N+,YXS10!S6J^# M[75_%&BZ]+=7*3Z3N\J-<;7W#'/&:EU/PI;:IXFTC79;FXCGTO>(HXR-CAA@ MYXKH*,@]#0!RGBKP'IGB^_TV\OWF1[&0.HC( 89SAO:KOBGPO;>*]+AL+N:> M&*.X2<&$@'*G@?2MZDR/44 8'BGPI9^++"UM+V69$MKE+E3&>2RYQG\ZW@,8 M'7ZTZB@#GH_"=K'XWE\5">6XAO=.#+&8FP&5NH;UKH: M,T 8'B7PI9>*/[.^VR2J+&Z6ZC$9P&9>F:W>>.*=10!@:9X4L=)\1ZKKENTO MVK4]GG!CE?EX&*/$/A#2?$RH;^%UGB.8KF%BDJ'V8=O:M^C- '!2_#/[8IAU M+Q/K=[9XVBW:?:N/0XZUV5A86VF64-E9PK#;0H$CC0<*!Z5;HR/6@#G_ GX M5M_".FSV-K>)DFG-Y=6ZV[H2-@ M4'/ QG/%;U% !2,,J>2/<4N:,T 8'AOPE8>&)=0FM'N)9M0G,]Q+.X9F;VXX M'M6\"M-L;_ %R\@ENU.LJ12WM]Q5IV#-\S%CR .Y-;5% ',>*O VD>+I+*;4%F2XLI!)#- M"P5ASG!]1Q72 8&.3COZT^C- '.ZEX1L]4\6:3XBGFG%UIBNL2*1L.X$'/&> M]="*7(-% >EB@#SR3X8/ MJBQP>)/$^JZS91G<+:4B-&8)]>LX 2WE13@+N.!SZ>H%=WGG'>C- $<<:Q1K&B[4084#L!VK$\7>%;/Q?H;Z9>221+YBRI M+%]^-EY!%;V1ZTN1ZT )488R01ZXK'F\ : MQ=0_9;GQOJ\EBPVO"$0,P]"XYKO:* ,[2]&L='T>+2K.W5;6--FS'#9ZD^N> M]WAQ)%N/<*>E=_G-% '':+X"BL-<77-5U2[U MC4XTV12W. (AWVJ.,^]=?BG49'K0!FZWHFG^(=*FT[4[99[>7JI'0CH1Z&N0 MC^'VN6%N++3/&^J6]D,A5DC65XU/96/0"O0%_!.G>&9I[M);B\U* MY \^]NGWR/CL/0>PI^K>$+?5?%NC>(7NIHYM,#JD*8V/O&#G\ZZ3-&1ZT -/ M(.1D8Z5S6@^#HO#OB'4]0L;N5;34&,LED5&Q)/[R^F:Z?-&: ]*XWQ#X!AU M;53K&FZI>:-JQ&&NK7D. , ,IX-=E1F@#SIOAWKNK*L'B?QI>:GI^1OM(;9+ M=9@.<.5Y-=%XB\*0:YX0E\,P3-86CQI$#$@.Q%(PHS_NBNCS10!P$?@'7X85 M@A\?:O'"BA400Q?* ,#J/ZU=T?PEX@TW6(;R[\:ZAJ%LF=UK-;H%?@@<@]C@ M].U=E10!S6G^%?L/CG4_$8O&87\"1&W*<)M[[OZ5O7EM%>V4]K.@DBF0QNA_ MB!&"*GQ10!ROA/PG<>%]!FT7^U9+JT!?[+OCVM"K9^7.3D#-2^"_"[>$?"<. MB"\:Z,1D83,N/O,3_6NEHH \QTSX;^*=%AEBTKQU)9PR3/+Y L$D0%CDX+'- M:#>%_'Q9#_PGR%5() TN,%AGD9SWKOJ* .8\5^#+7Q3;6IEGFMM0LV#VUY#P MR-QV[@XZ>]8K^&_B!>V[6-[XLL8[61=LD]K98F8?CP,CBO0:* ,'3?#4.@^% MCHFC2-:E8F6.<_,1(1]\Y[YYK1TJWNK32[:WOKHW=U'&%EN"H7S&]<=JNT4 M(>E>?M\/M3T75;K4/".O'3UNY?-GL[B+S868]6 Z@YKT&B@#A!X*U?6KVSN/ M%NL1WT-I*LL5G:P^7$9!G#-GD]>E;WBKPS9^+=#?3;QI8EW"2*:+AXG'1E]^ MM;M% '!0Z+\1(+;[(/$>ER( %2XDM290H[GL36SX0\)0>$["XC6YENKR[E,] MU=2##2R'O@=O:NDHH Y3Q7X0?798-0TV^?3-9MN(KR-);2"S?"RR6,!261</J:I>!_#4WA/PI;:-/<))/".I:-!,D,MW%Y8D=1VK M0TRT:PTBSLW8.T$"1%@,!BJX_I5RB@#C];\(W,_B^P\3:/<16U_$AAN1(I*S MQ9Z$#N/6JWBGPAK>K>*])U[1]6M[&>Q@DBQ+ 9-Q?KWKN:* .!ET7XDNV8_% M6EJ.FTV&0:Z+P[9:[;6-Q'XBU&WOYWE8HT,.Q1&1PN._>MRB@#SU_ ^N>'M1 MEN?!>JVUK:SN7FL+Z-GAW$Y)3'*USMS\*_$E_/>ZAESZ2\A>.UU6-\PYZA73DCZUZ-10!P&G>#-=U+Q-8>(?%VIVUQ/ M8;C:V=E&4BB9N-VX_,W'K5OQ]X6U?Q*-);2;RVMIK&Y^T[KE2P)&-O _&NTH MH X!=/\ BEE,ZSX=X&&!MI.:W="LO$,FEW5MXLFT^[>4E%%HC*I0C&"#7144 M >9:?X1\:>#?,M/"^I:??:.)#)%:ZH'\R+/55=>WI]:NV/A3Q%K>O6&L>,;F MRQI\C2VMA8AC&K]F8MU->@44 -P>M"2+5+TW,2Q@@J# MG@Y_"NMHH *Y;X@>'[OQ/X1N=)L_+\Z9T.9&*C 8$\CZ5U-% ')>,/"]QK_@ MY-.MG"W]OY;P2%B KKQUZ],TF@^%I]%^'[:&626ZDMY1*V3AY'!SD_CUKKJ* M /+Y? WB*3X:Z)X2CFMH@CA-0DW$@Q!R0H'?((S]*]*M[>.UMHK>)=L<2!$ M'0 8J:B@#B_'OAG4]971]0T1HTU32KQ9XO-. 4QAES[C%=)J]K-?:!?6D07S MY[:2)=W3\%Z7I5Z4-S;0['V'(ZGI70GI2T4 <=\2? M#VJ>*/"G]GZ1Y2W?VF*4-,Q50%)/:JAN_B:%"C2_#['H7\^08]\5WE% '&^$ MO"%_I&M:GKVLWZ7FJ:@%4F-<)%&/X!GMFL*'0?'&A>,/$&JZ/:Z3*]/HH X1KWXFL&4:-X>7CY2;F0\UV&G->OI]NVHI''>%!YRQ'*! MO8U;HH Y3XBZ%>^(_!5YIFGHC74I0H'; X8$_H*@\9^%[SQ#X%33K;8NIP"* M2!RY0)*N!D,.G>NRHH XWPQX5N?#_P .VT=L2:E)#*9WW9$DS@\DGZ@9KFAX M,\5#X3Z)X5B-O#.)-NH$/TA\PMM4]\\"O5Z* (+6V2SM8K:%0L42!$ [ "N/ M\8^'-5O/$?A_Q!H8C^VZ?,R3AVVB6%@-RG\,UV]% 'FWB#1_%T7Q)'B/0M+L M;F*.Q%J%N;@IYF3DD?W2.GO4]U+\3M6MI;6'3M$T=I$VF[-TTK)GKM '7T/K M7H5% &!X3\,6OA'04TZU,DS[C--,YRTTK?>8Y]<5Y_X1M?B)X4L+JTB\*V=U M#->RW*EK](V4.>^,@UZ_10!P$GB3XAQ[<>!;=@6 8KJ:$@9Y/2N]0D@%EVDC MD>GM3J* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ K/O_\ 6+]*T*S[_P#UJ_2@"_1110 M%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4]6^WC2K MDZ6(3?;/W(GSLW>^*N4=J /)_$/BGXE>%M#;5-3L?#DD:2)&1 \N[+'&><>M M;,4_Q/N);.7R?#D=JY1Y0#+O"'J!GC-1?&L _#2\R<8N(3_X^*[RTYL;?'_/ M)?Y"@#D/%?C2]T_5[;PYX>T]-1U^YB\W8[[8X$SC>YZXZUGO8_%B" W8U70+ MR;AC8_9F1/=5<\_B:;X"BCN?B/X[U"4[KF.[CM4R<[(@N0!Z FO2"1ZT CZ%>ZA/>^'91;1&4(D4@8 MA><>F<4W2KOXH:_H-IJEE>^';>.[A$J1R0R%UR/4$C\JZ[Q[QX!UWG'^AR=\ M=JK?#7GX:^'N_P#H4??VH SK_P 0:Y9?$;PUH+S6XM;NRDEN\1Y+2J"/E/89 MP?I7=DX%>4^.Y=5MOBYX6GT:QBO;W['.OE2R;%"YY.>W&:VTU7XD%FW>&='5 M,G'_ !,#G^5 $OP_\1:EK]SXDBU":*5;#5'MH=BXP@]?6L.TUCQWK_BWQ+I^ MDZGI-O;:7=+"GVF LQR,\8I_P<>YD7Q5)>+&MTVKR-*B'(1B!D9K*T6Z\56W MQ!\:KX;TVQO(#?+YINI?+VOM[=S0!U":;\35FC,FOZ$T8==X%HP)7/./?%=R MH(')!8#DXQ7'Z?J/Q DU"W34-"TJ&U9_WLD5T695]@:[+H10!RGC[Q7/X6TB MW:QMUN-1OIUM;1'.%\QNA..PZ_A63_8/Q&:%;D^+;$7>-WV868$0/<9')Y[U MN^,_"4/B[2HK9KAK:YMIEN+>=>=D@Z<>E8"7OQ)T"-1=Z?I^OPH.9+:0PS$# M_9/!- &IX \6W'BK3+I=0MOL^I:?.;:Z0#Y68?Q+GL:Y[3]3\=^(?$?B.TTO M5]+MK73+TVR">U+,1C(Z5UGA#Q5IWBJTN;BSMI+6Z@D\N[MY4VR1R>C>OUK@ M/#MSXJ@\;^-3X M\3>)4\(^&!J%\#<7 V0JD8QYLS< #'3FLM+[XC//!YVC:*D!D7SBMRQ(7/)& M?:L_XBK]H\5^";.F>M 'G.J:IXNO_BA>^']$U:WL[>"S2Y/GVPD'/''?J:FOK#X MFZ?:R75OX@TJ^,(+M;-9[#(!U /;BLK4;K6;'XVW[Z)IL=]<2:7&KI+)L51G MCGZT_6O&?CC[;#X>_P"$?L],O=0_=07DMSOB (YQCJWH* .O\(>*!XO\&P:S M'$89I$=7CQ]R13@@?C7$>#[KXC>+-#74X?$NG6L'G21!)+(.YVL1R:[GPAX6 M3P?X-BT=;AI9$#O+-G[SMDDC/O7F?PTG\>1^%F30++1Y;#[9-MDNY65R=YSP M*0'<+HGQ"^UV[2>+-/\ (613*BV(!=<\C/;-6]MM=TC3KR3Q/K5O?[6,J3)#Y2QH! MSG':N7\$*T?Q9\=@])&MW_)2*M?%[7(]*\'&P-TMO)JLRV?F8)V1G[YX]%S^ M=,#%\*>//$5YXDL[C6(A'H&M23+IC;5& I^0'^+) /7U%>KW#,+>0HVU@IPQ M' XZUX_XOUOP;)\/8-.T?7[(7FE+'+8;&Y,D>./Q[_C7I.B:Q!XC\)VVIQL# M'=6P9P.S%?F'X&@#SKP=+\0O%^@?VI;^,;2T@:66-5.GI*XVL1R35S5M7\;> M Y["^UG5K36])FN$MYMEH(9(MW 88Z\_RK(^&VH^-K?PEY.D>'].NK&.XG$< MLMUY;,=YXQ]<\U,C^(OBIJITO5$M]%LM*NUDN[($M-,PP5.3_#GO0!UOCS4M M?\/PVWB+29O.TZW8&]LFB!W1'JRGJ",UU&GZK9:KI,.JVTP-M-'YBN3T'O[B MKC1I)%Y;KN1AM*L.",=Q7AVKZ+K^D>*_^%?Z1J7D:)K9-RC/S)#&#^\1#VZ? MD* .P\+:YK?C;Q5=:K:WCVWABS^(/$OC+Q#?:1X1O+6PTVQ8176 MJ.GF/YG=$7U'J:34M(\=>%-.EU/3/$DNN) F^:ROH%#2 ?>*,.AQGBI/@LD? M_"%W,^T"XFU&X,S=RP*?#-OJTGC22V:5G"JMFC9"L1FI_A62O@_Q-".+6+4; MM80/NA?;VK*^'%OX]D\&VSZ+?:%%8-++Y2W,/Z5V$RL\3JC%&*D!L=#ZUA>&8O%,1N1XFN- M.F)8& V2,H [YW5T% 'FNI^'O&>E:'J.H?\ "=3R/!%),B-9IMP 3M]>U4/# MNC^./%'A:PU>3QQ-:R7<8E$<5LA"CZUWWC)@O@K6R>GV*7_T$UF?# Y^&7AX M_P#3FO\ 6@#,\4ZEJ^C:[X(TV'47(N[LPW3;!B4!0>?Q-=_CG/>O,?BK]O/B M/P4NE201WYU"00O.,H#L&<_AFM%K+XHM*N-4\/*F>4MO"1@)N&36'"WBGQ)\1?$NF67B:XTZST]H]BB,-RP]^U3_#E= M1C^(?C!=4E@DO T0=X%VJ>.H!K.T^W\33_%GQC_PCE]8VX7R?.^UQEPQ(XP! MTQS0!TG_ A7C QR@_$"\!9<*1:IP:[BQAFMK*""XG:XFCC"O*PP7(')P*XU M+#XE+(ADUK1&0.I8+;,"5R,C\LUW*YVKN()P.G3- &1XI\0VWA?P[=:M=*76 M%?EC'5V/ 4?4URMIX=\6^(K*/4-7\37>D331@K::> HB!YY)ZGI4?QD)_P"$ M=TD-DV[:O;"8=BN[O7HOIC'3@>W^<4 ><^']8\1>'O&:>%/$$TNJVUQ'YEEJ M8B.>_P DF. <#K6GXR\4ZC8ZC8^'_#\4%)$5WC6 M1ON[B,GZ5YU8K"W[0.J-.J^:NCQBWR><%OFQ0!83P+XI*F>7Q_J:W9&XK'"G MDJWH%/)%3>$_$^K1^*+WPEXF>%M1@C$UM=1KL6ZC[D#U'>N[.#W]J\U\9(%^ M+?@B6W&+AS.LC+U,>WO[9H C\13^(;[XJV^A:;X@DTVVDL#<%%C#\J<=#ZYJ M]<^$/&D=LTMKX[N9+E#O2.2T38^/X36-XI?6$^-NEMX?BM)+T:5)YJW3%5,9 M?U'?.*7Q)XD^(FG2VMC>6VAZ?#?R_9TU*%W=8">[;NGM[F@#J_A[XEN_%/A5 M;N^1(M0AFDM[E4''F*<9%<7X,@\9>+=-N[__ (32>RCCO)84B2T1^%8CJ:[_ M ,'>&(?"GA]+!9S,;/3M4MM!\/V=Y8+J4Y M6>>[\HEBW(QZ4 :VH3>+?A[>:9=WOB!M=T>ZNH[:X6>!4DC+Y *D5U'CCQ5< M^'K>QL]+@BN=9U&7R;6"0\<#+,<,?&.JV!\2K9:9I-C,MPMK M:2&1II%Y7<>P!J?6P&^.7AOSTS$-.N/*+'C?G^>* ')X'\67L?VG4O'FHP7S M#)CL45($;_=/44OAW7]OA/Q3/#=O/#YNGZBB;#< =58=-WTKT 'C@]J M\Y^):;?$O@B>($7"ZKC*#+%,?,/IB@"OXEG\2:E\4H/#^D^))](MVL#&X[*6^_ MLIC(M\6$>S=CY2O(/2IM?\1_$2R%K8WEMHFE1W[^0NHK(\B0DCOD\'TS0!U/ MP^\47'BGPS]KO8A%>P3/;W 48!=#@D>U4?B+J^MI_9^@^&)1'K5_(65R0 D2 M EB<],]*V_!OAJ/PKX>BT])S<2%C+-.1CS)&.2V.U>>:9XV\-#XDZ[K^L:JD M"0H+&P#QN5V*?G<$#NW% '<> -?N-?\ #8.H?+JEG*]I>*<;EE3@G&.,\&LV MZ\+>+XA>W,?CZX48=TB:PC94'4#)K!\.>*M#3XN7D.D7HN+/7(%D;8&55N$' M7YNI*Y_2O4M1_P"07=C_ *8O_P"@F@#RKP79^,O&/AB/5I?'=Q;/(TD82WLX MRORL5SD@>G;%:_B"XUC0M<\!::-8GE6>Y:&[(0#[1A0=QQ^-3_!8;?AG8C_I MM/\ ^C&J+Q_A?'7P_8G_ )B$H(_[9B@#=\;>*)?#6EP"SA6YU6]F6WL[=C@. MY/4X[ =:Q8/!'BC4(C=:QXVU&"ZD&?L]@!'%"3V']['O4?B]O^+M^"TF*FVQ M.5#'@R;3C'O7HH([<_2@#S?3=9\0>$O%MGX?\3:@FI6&H[EL-1,6Q_,'\#@< M5%\7]?U?P\FB7&D7$Z3/<.K0QC/F '&/P-3?%U(WT_PZ /]*_MFW$++U'/S M8_2I/'K ^/? 49(*F^FW*1D$%,?XT =5X8\167B?0;;4[.1625/G7'*,/O C MMS7->$=5U2Z^)OC'3KR\FEM+0PFVB@/]:M^"B&^*GCAPP;BF@#T<\@YZ5Y[XCU[7=9\6'PGX6N(K62 M&(2ZC?LN[R >BJ/4BO0S7G?P^$9\;>.V?FZ_M(9)ZA-O ^E $G_"OM9MU-Q; M>-=6>_ XDGPRL?<#M5KP'XHOM6DU#1-<$2:]I4@CN1$/ED4_=<>QKM<@C@UY MOI[,OQ[U@0 ;#I,1G('&<\'ZT 9NAVGB+Q3XE\5(GB_4+*VL-0-O#'&JM@8] MZM^(M+\7>$M!N=>L_%UQ?M8IYLEK>0KLD0=0,=#BLSP\WBYO&WC,^'/[,^Q+ MJ1\P7F_<9-O;':DU&7QAXHU[_A#/$=W9:-:SV^]VMAN-XN1E48]/>@#U31]0 M75=&LK^, "XA64 '@9 .*J^(]'O-:TY;>RUBZTJ4.'\^VQN(]#FM"QM8;&TM M[2V7;!#&(T&G0^-]3FCU6Z:WD>9%RF!G(Q M77Z-X,U;3-5M[VZ\8ZMJ*19+6\^W8^1CG'YUE_$=L>,? ./^@HW_ *"*] NU M9[.=$)#M&P7'7..* /.)=2\0>/\ Q#J%AH6JMI&B:=+Y,MY N9II.I5<\ #U MJU=>!O$6E6SW6@>+]4EO(UW"'49!+'*1S@^F>F:3X*A!X P1,+VX68DY)?? MW/TQ7HAZ<=: .:\$>*!XL\/B\>-8;N&5K>ZA!_U'TJ]XATF]UG3A;66K M7.ER^8KFXMP"V!U7FN0^&01?$7CE80! -7.P@\'Y>9Z'9^*[SQ_XY/AS5;&PC M6^19!<0>;N;:>0*U/$^E_$"+P?J[W^OZ3H2?! M:'5'O93?G3/--UNRY;&<\5C>&/#_ (RU_P -:=JC_$2]B-U")-B649P#TY[\ M5I6#*OP#B:0?+_8I+!!VV5B>"-.^(LG@C1FL->T:&S:T1K=);5G=$(^4$C@X MZ4 =?I7A3Q#8:O;W=SXUO;ZWC_UEK+;HJR<$-;;5FD M\0:MIEU8>4P6.UMC&P$?$ESJMS=P>.+ZVMY6)CM4MD*H M/3)YKC_!=CXS\7Z5=7TGCN[M5BNY+=8XK5'/R'&26KV6O./@Q_R*FI_]A>Y_ M]"% %+QNWB'P[X5T#3K;Q)=/J%SJ"V\E_P"6JLZNQ/(]LC\JU#X'\4;E9_P :#)$NYE@,F4')NFX#O71>+ MM=3PUX5U#5F*[K>(F,'^)SPH]^2*Y_P!X>E@DN_%-_JD>H:CJZ(S/"/W4:@< M*OTK#^*>N:5_PD?A[0M5G9+%9A>W8C4MD+G:" #QNP?PH F^'^K^)+#Q$=$\ M67@N)]0M1?638Z#^)!] ?TKN/%EQ-:^$]5GMIFAGBMG=)%."I SG]*\V\<>. M?#EY!INLZ3=O+?Z5=I(N('7]VW#@Y7IBNW\974-_\--7NH'+PSZ>\B,AZ@KD M8H Y/X/>/;K7K1]&UZ9VUB%3*CRC#31'N/7'J*V?B!J6IV'B#P?#8WLEO%=Z MD(;A$'^L3@X_G7,#0;FZ^%_A?Q-I 8:UIEG'*ICX,Z8&Y&QUX_E5KQ/KUIXC MF^'>IV2Q M]\"JR>!O$*0F<>.=5>^P3\P7R2V.!M],UT'BKPUI_BS3/[.O79&#B6&2-L/& MXZ,*Y;^S/B/X=8"PU6RUZRC^['>)Y<^ .F\<9H V? &O:IKNA2C6K9H-2M9F MMYF$>Q7P>&4'M7&^#;#Q7XOT^_U!_&VH6D:7\T$<:0(6?C&XTG4I-#U33K73SJ=QY<=Q 78'=SR* M.TTOPAK^GZK;W5SXUU*^@C;+V\T2!9!CH<(M3^+G_ CNG^(9=,LS MIHNAY<8NN\.VGBJWGE/B#4K&[B*#RUMH#'L/?.:X+7H=;N?CLJ: M!=VUK=KI/[R2XB+KLW=,?7% '3CP?XJ\PD^/;[:!\O\ HD=6M375_#OPWOVG MUA[K4K6VDD%Z\8!+#D<#CVJC)IGQ,,3^7KVAA\';FT;DUH>+UN5^%^K+J+)+ M=#3G\XQC"EMO.!0!BZ;X9\9WVE6EY+X[N(Y)H5D*I9HP&0#C)^M-TS6/$7AO MQW9^'?$.I0ZG:ZG')):7"P^6Z%.JD#VJ#1M2^)-KX2L9UT?2+L):JR1B9E=U M"C:!CC.*/!EAJ7C'7+/QKKEU:J;9)(K;3K=5>/->T67XD:#H^L:E':V%@/M\ROP MK2#[@/Y"@#4^'GB'Q!+J>H^'?%VP:S;(ES&5 P\+#&1CT/%=CK^MVGA[0[O5 M;U]L%LA<^I/8#W)KR[Q;XS\-0^,O#/B32M;@N)DE-G=) ^=\+]S[ \\UM_&1 M]WA/3X22;>?5;9)CG@IN[GTZ4 ,TV+Q]XRMXM3EU>+PU82C?#:P6WFSE>QD+ MXP?:J^I:SXN^'EU9SZQJ,>N:#/,(9)_)$)P-\L2[.N ^>: /2]? MN)[;PYJ=S:RK'/%:2R1N1N (4D''X5ROA^X\3>)OACI5[9ZS#:ZOG3%9'A?6[M_!WB+PIK+L=7T>UGA+.>9H=AV./7C )_P :Z+X5#'PQ MT >EL!^IH Y7Q9??$+PRVDHOB73[C[?>):@M8JFPGO[UU&FZ-XZCU2VFU+Q1 M9SV:-F6&*R$9;@\9K&^+X4R>$-W7^VX> :],% "$'K^E>._\+-U#1OB]?Z'J M\J?V*T@CCD90ODDCY>?*!KR:1X1,1GL[1K^^+'H@/"_4C./6NU\+:]%XD\- M6.KPG'VB,,ZYSM8<%?8YKS;P#XR\*M-K?B#5M;M(M0U6Z8&*9L%($X10#VQS M5_X6ZYIL?B3Q)X+::1*386]H MEU<0^7G]WNPQS7KUI=17EG#=1-F*>-9%(YR" 1_.O-[J-+OX[7FGS?ZJZ\/& M,C&>"^#4GA;Q ='^$E\;EF^TZ"L]I)N;YLH2$)_ K0!A7/C_ ,27'Q8L].M) MT30)]0-HC"($.4^_AJZKXB:IKMEJ_AC3]#U&.SEU*Z>!VDCWC 4'I7+3:5_8 MP^%UK(#]I?4&GF)')=UW-G\ZV_BM]O\ ^$@\%?V6$-]]OE\GS!\N=@ZT :#^ M&O'A)*^,X0Y P#9#&:VK:/7=+\)7IU;48+S4HH99%N(HO+7A21D5B&3XGE&V M0: 'VY!+ORV.AQ6_=MJ3^![PZHD*7YL9?.6#)0-L/3- '$^%A\0_%'ANTUH> M*[&V6[4R)&M@K;1G&"3]*M_\))XI\'Z]9VOBR2UOM+OI/)AO[:/RS&_& XZ# MOS6O\)SGX6Z!@_\ +N?_ $-JS_C4XB^&UW( ?,6>(Q;>2'WC!H ]"Y[UB^+/ M$EOX4\.76K3J9/* $<0ZR.>%4>Y-:5@SMIUL92=YB3?NZYQS7 _%,K)J7@ZU MGR;.;6$\].S8&0#^- "6FA^/_$")?ZGXF.BK)\R65G;J3&.H5V;J:0>(/$G@ MG6]/LO$]W;ZCI-_-Y$6HI'Y;Q.>@<=/3FO2>,XR,^E>?_&:-6^&M^P"^=$\; MPD]0P8E,C_';667YA_8L&&[$;LYKT6@#SZ?PY\0(IKJXC\=0"'YFCA?3$8*. MH&^E\E5%P.# MG;SM_ UZ*PR,?I[5YE\7/[2_M'P>=&$']I?VF1;F?[FXIW]JO"/XM%5)E\(@ MXRP(G.#QQT^M $GA_6=7NOBMXGTFZNV>QM(('M8-H 0,.3TS2VVMZJ_QHO-$ M:[?^RX],6=;?8N-Y8#=G&:Q/A_%K$?Q7\6G7)+:2]-M;EC:L3$H.< 9Y'XUH M6F3^T!J((^4:)'CW^<4 3^)]>U^^\:VWA'PW<06,K6INKJ]FCWF-$M'GUFT\6-K)M5\R6RN;%%$J9YV[.=U;OBGP3)K.JV^N:1J)_B'X2MVG\2:#8ZMIT63+=Z9)MD1?[Y0]?H * .^T M'5DUW0['5$1HAX[&N=^*TLD/PPUUXBX;[/@E.H!8 _H: ,?3KWQAX^ MMAJ6G7Z^'=%D.;8B!9KB9.S$-PH--?Q#XD\$>)+#3_$=Y'JVD:E((+>]CA\N M:)S_ 'U'!'3FNV\,Q06WA;28;8 0K:1; /3:*TGCCDVEU5BIR"0.#ZC- '!_ M$S7M>T4Z#!H%Q;PW&H7_ -E8SQ[U^8<''MBI3H_Q%8+M\6:8#_$?[/'-9'QD M%X(_"LFGI')=IJ\9A61@%+X.,YK5;4/B6,[=#T(COB[?- &YXH M /6@#:UC7?&_@E;74M;NM,U32I+E8;C[/ T4D2N)+7Q-=_9F\- MZK9V6TDS"ZMS)O'&,>G>O/;F[\1?%.]ET&6PBT;3K&=&U!)GW32,#D!1V!QU MKV%46- JC P![4 >4W&J_$:U\:Z?X9?5-%DENK5[@3BU8!0N0>,^O\ *NMT M^'Q=I]KJ-QK6J6%TJ6SM MO;[,.!G)S6/J?/QZT'T&CSG_Q\UV^L_P#(#U#_ M *]I/_030!S?PZUO4O$7P_LM6U%XWOIED)=4 '#,!Q^%S!9IKLQN3O.[(]C0!WNEZ?X^AU>VDU36])GT]2?.B@M2KMP<8)ZEQ&@C^8.3@\^E:7AJ]\47;3CQ%I5G8A0OE&VG, MF[USZ5S%HZG]H#45VX<:/'R#_M4 :_B7Q;=VNMP>'/#]K'=ZY/'YK"5BL=O' M_?;W]!WK)OM.^)NFVLFH0^(=,OGC7?)9/9[$8#J%8-H(X]W\,94GC\:])/(QUH Y_P '>*K7Q?H$6J6R&-LF.:%NL;CJ/I6=\0/$ M^HZ#8V=IHD"7&LZA+Y5M$W3 &2Q]@*ZN&WAMD*P0QQ DL0B[03Z\5YG::OIN MK_&34;N_O[>WBT*W%K;1SRJFZ1OOL,GG'3\: .J\#>))O$OAWS;I5CU*VD:W MNXL8V2KP>/2L6[MOB;:1W-T-7T&2&+>ZQ-;."4&2!GUJGH^IZ=HGQ@U"PM;R M*6UUZ!;I!%*K*LZ\$<'^(<>'M2^)?BC08=7 MM;_P_:Q3AMB/"[G@XY(XJ]XV\1^*M TGP];6(TZ;6-0G%M*TH/E>9@'@>F)I=+D.X>0;!7 Q_M;N]<^OB+XC[V#>! M;4KV(U2,9_6NG\,ZAK&I:2MQKFD?V5>;V!M_/$O Z'(H VJ*** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH *S[[_7#Z5H'H:S[W_7K_NT 7Z*** %HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ I#]TYZ8I:0\B@#SOXVRA/AO< M@$;VN80HQG)WCBN[L6WZ?;.0OS1*3CIT%236\-PNR:))%SG:ZAAGL>:D &! MP!0!Y?KBWG@#Q]<^*8;&XN]$U6)4U!;=2[12KT?:.V.M:S?%WP4UF9K?5C%L;SBPN =JG SGK7 MH]-V*7#%02!@-W^E//2@#S;X4/(]UXO,@8%M9D8$K@'([>O2L#1?&VE^$O'? MC'^TX[_;=7P>-X;9I$;"XXP*]E$:IG:H&XY.T8R?6G =J ."_X7#X7*KM&I M%F. OV%\Y_*NZBE6>&.5!\KJ&&1S@C-/=5==K*&![$9I0,8 [<4 G2N_/0 MU";6!GW-#&6SP2@S0!P?PWTZ]EU/Q#XINK)[%-:G22WMY/OJB@C+#L3UKG/# MGC'3_"OBWQC%J-MJ!%UJ9GC:WM'D4C&.H%>R="../K2!54_* ,]<<9H \_;X MP^&U5BMKK#8'_0/<#\\5;\9Z+)XQ\+V6H:2S1W]JZWUD77!+#G:?J.*[8@$8 M*]?UHP .G_UJ /.;/XN:/%"8M=M+[3M0A'[Z%[5B"P_N$=:A\*Q:MXM\>3>+ M;VVNK'2+> P6$$K$&;/60IVX->D-!$YWM&C-ZE1FI,8[8]J /.K&&4?'O59E MC=(CI$0+E3M<[NF>F:Z'QOX4A\6>&Y[)F:.ZC_>VLR'#1R#D$'ZUT@4!MV & MQ@GO2GI0!Q7@/Q+MF:.[F8/'8LRLK.2.:]JV@9P!SU]Z4*%X4 = !0!PQ^*FCF:*$:9K M>Z5@H)L& &3W-=PK"2,,,_, 1D.3 MUIP% &:V@:.W)TFQ/_;LG^%<%X"\WPYJ?BKPG+;S+9VLTEW8LR?*8G&=H.,' M'^->H'I3<H'4BO25]*4]* *FG7L.I6$%[;AA#.@=0Z%6&?4'I M7!^((9V^-GA:58I?(CLYU:78=@;!XW=,XKT;TP#1^ Q0 HI3T]:*,T >6-!J MOPT\2ZG>VFE7.H>&M2D^T2+: O+;2G[QVC^&I=1^)$^OV4NG>#]$U2[OIU*> M?/;M#%;YXWL2.<5Z:>E(!S0!RWA[PQ'X2\!'2(V>>1()'F<\F21@2Q_.L_X0 MV\MK\.[*&>*6%Q)*?+E3:5RY/2NZ-(.&H =1110!B>,(Y)O!NL1Q1/+(]I(J MH@RS$J>!6?\ #:":U^'&A07$$D$T=J%:.52K*>>H/2NJ/(I , #VQ0!Y]X M]M[F7QQX'E@MI)(X;]VE=5)" KU)[5Z$>1C_ "*0@$\CIR,BES0!YQX-@NXO MBGXUFEMI4MYFA,,K A7P#G%9,&I7_A?XG>*;[_A&=3N[:]\H)+;1[@2HQG]: M]< YSW]Q2XY_SS0!Y[-\47A''@[Q$Q]%M0?ZUVVEWK:CIMM>-;36QF0,89AA MT]B.QJY1^- &!XQ\-1^+/#%UI+R&)Y &BDQG8ZG*G\ZY#3/B-=Z):IIGBG0= M42]MQY9N+2V,R3XX##'3.*]//2FDD'U^M 'F6FV>L^./'5GX@U+3)],T72U8 M6D,[X>X<_P ;*.@^M:7CGP]JIUC3?%GAZ,3:IIP:.2V8[1?0_%*%H&2?PSX@CU",?-:BS9AGT#C@CWH\*Z'J^J^+KGQAXBM3:RB(06 M%H7!,4?=FQQDUZ!@=?Z4O44 >=36MVWQYM;K[)XQ_G MK0.V.E >AKB?B!X6U#6?[,UC1&C76=(G\Z 2':)5/WD)P>H%=O29% 'GL?Q M1^RJ8-8\*^(+34%R&ABM#,CM_L.O!!JOH&EZQXL\+M=TR33K&RA\O3;.= MOWH+=7<=CCBO23SQ_P#7H_G0!YT]M='X^0W(M+G[*NCM&UQY;>66+ XW8QGC MI77>)O#MGXGT&XTJ]5C'(N493@HX^ZP/L:U^,Y/YT[(H \DL_%'B#2/ =_H] M]HVI3Z]9;K2W=8'=9P>%D# 8P ?TKM?"7ABTTCPKI]G/:P23K$#,SQAB7/+< MGW-=)@#G'/K2T E=9%=R M:CX<%R;>2*6>U+&%U(96*\J1ZYK4ZTF,=OPH X?X2VMU9_#ZT@O+:6WG66;= M'*I5AF0D<&J_CNTN[CQOX)FM[:>6*VOG>9HT+",%0,L1T'UKT# ' '%'7M^= M '(_$#PM<>)-'@ETTQQZQ83+5)'8]*R;7XE75K#]G\0>%=:M=14 M$%+>V,TW/C?P3-;VDTT-K>R23RHA*QJ5QSZ5W]! )YYH RO$.AVWB+ M0KK3+M3LGC*JPZHW9@>Q!KS;X.>'M8T'7_$::I:3QAFC5)YO M4# /O0 'I7GOB#0=8T/QB?%WART%V)X?*U"Q!PTN#PR^X_I7H=!Z4 <#+\1; MF:W:*P\):Y+J(4_N)(-JJ?=B<&I_A_X:U+3!J6N:]M_MK5IO-G52"(D'W8QC MT%=L,9I: . ^'UG?6NO>,IKNTEACN=3\Z%F4@2*5ZCU%7?B'X8EU_0UN]/RF MLZ*VU%I)Y$4E8UP!ECV%=\>0>M+QTX/UI: M/,QI6M_#W7=1OM%TN35= OY/.DLK3N4!Z@^E37OCS6M7LY+3PSX3U?[ M9(A7SKZ'[/' 3QDDGG'M7HU( !T _"@#F? GA1/"/AR*R9A)>2L9[N4?\M)6 M^\:Z>B@T XCMM3\R=HT+"-<8RV.@]S7?=O2EHH X#P M%:7UOXO\:SW5G<0076H+) \L942*%(R"1R/I70^-H)KGP1K4%O$\LTEI(J(@ MR6;' K>H/2@#S_3+.\_X4C%8RV=P+PZ5Y)M_*/F!RI&-N,YK'\)^-=0T/PI MIFDR^!?%3S6=ND3,MCPV!U&2/RQ7JX^G%+0!P^G_ !"N;_4[>S;P9XFM5E;: M9[FSV1I[DY/%=N.U! ]*.] 3A2:\_\ A%97EAX9OX+VTN+65M3N) LZ%"5) M&#@]CZUZ#2?3]* /._BO97E]'X96RM)KAH]7AD<1(6V(#RQQT'O7H,D:2Q/& MZ!T==K*><@]*,NL)QED M..G/2K/@#3+N_P!6\0>(]:L'BN+VZ\JV2X3YE@3IP1QDFO0SCO0,#';VH HW MNCV-_87%G-:P^5/&8WP@Z$5YOH%OKL7PLU_P]>Z;=_:;".:VM6=>;B,@["OK M7J^1ZTG49]: .:\ 6LUI\/\ 0[2Z@>*:.S1)(Y!@@XY!!KS3Q#X%U/3/BAHE MSI5E//HYO!=%$R4A;/.1VS7N'?CZ4=Z .$\=:#J[ZKI?B70(S/?Z>626V+8$ MT1Z@#.,\]:A/Q4MPI@E\->($U +G[+]C)^;T#=/QKT$]*3'- '$?#[1-3L&U MO6]6@^SW>LW(N?L@QF%0, ''&?4U!\(K&\T[PK=VU]:36TPU&=]LJ;=P9L@C M/:N^I1UQ0 IZ5Y1KD^IZ'\9&UR/0M0U"Q.FBW+VT8;#YS7JYZ4F._>@#AA\1 MI6^4^$?$ /I]G'^-/UO4[CQ)\+M8N+?2;^WGFM98TM9HMLI.,#"UVU';'Z4 M9GA^-HO#>F1NC(Z6D2LK#D$*,YKA+NRN_ GQ%CU'3+&XGT+6AY=Y#;QEE@FS MQ)@= <\UZ=CI[4A /O0!%??#O1VU:'5/$NNZ M7MO-4NV9(KR'YXX5X1<,/2O1NU [8^E ',^)O!FE:QX:U"PAT^U@FE@81210 MJK*_4$$#U KF='L9_B'\(_[%U9)K34H5^S2--&05ECQM< ]00!S]:]-/2DQ_ MDT >:Z;\0I?#=FFF>,]+O;*ZM0(_M4-NTL$RC@."H."?2L[Q9XNE\?:!/X>\ M(Z1J%Z;TB.2[F@,4$:Y!R2PR>E>MX[8X^M 7A0 /:@#SGXHV\]O\+DMD@DF MEC:W4QVT98_*1G ]./U%2P?%C0X[>)&TW7 X4 J-.D.WCUQ7H/!I>_\ ]>@# MDM ^(6D^(M7&G6=KJ<4K(7W7-FT:\=LFL+P3'(OQ5\<.\4J!WAVLR$*PQV/> MO2<=_P#ZU '.: /+OB]X3N[S3O\ A(]%,\>JVL312B 12 8Z=* /-_BY%-,?"HAMYYMFLPNWE(6"J.I M..@KTGO32H;&0#@Y&1G!]:<./\: %KS3P+!-%\3O'DLEM,DE'I2#CD\4 >6_%_P )W=WI,WB#1#.FIP0F&9(!_KXCU! Y)':L^[FU M6+X)^'="L+2Y74-3CCM'*0L?(4GYV;^[QZ^]>R'D4W XSS]: ,>Q\+Z-96-O M:KI=DX@C$89H%R<#KTKC/&^E#PYXA\/^+-$TT;X)_LEY%;1 ;H).-Q '4'^= M>F4$<4 >;FWN'^/L=S]GE^SC13'YVT[S@>U'&<]Z ///'\,G_"6^ Q#:RO%!J#.[1H2L:[0. M2.GX^E0_$ZXDL?$?@_4%L;N\CM+V225+>(N5&T 'C_/%>DD=.*.OYT <(WQ4 MTD M_8_B @=_[-;C.*U(_$-MXG\'ZI]6]6.K?$O4M-L8M)O-/\.V] MPMU555ZXS7J9ST[4N* /.?BU;S2:7X? M2UMIYO+U>WD*PH6VJIZD#M7::[HMGXAT2YTJ^0/;W$>PYZJ>S#W'6M'&>HZ< MTH'UH \;^%6B:SHOQ"U^+5H[R1$MD@@NIT.UU4C 5NAXKV6DQ@Y_6ES0!4U0 M$Z3> DF!\8&3]TUQ7P+_ OEV\TD4>I-)*T:$A % R2.G?\ *O0J0J...ASTH_/K^= 'G7A> MVNH_C'XQN)+:X2WE@MQ%*\9".0.<'H<9HMK:Z;X\WMU]DNEM?[)6,3F(B-GW M#@,>.E>B\9R.]+WS^M 'F.KR:YX'\E:MIEQI_A^PU+4]2N8VACM_L;HJLPQEV88 '>O2SR*0 8QCB@#G? MFA3^&_!NF:5=;?M$,7[P*EPZWH=[I<_^JNH6B8^F1UJ]2GI M0!Y5H/C;_A!K*+PUXOM;NWDLAY5M>Q0O+%<1?PME0<$#M3-9UJ^^(VJ:=I/A MO^T;;28YA-?:FJ/"&4?P)G!YKU;&2/2C&,>WI0!YC\7':S_X12X%M<7"6NII M-)Y49D<*HZ\ FM9OBKX?3I;:LS8)XL)/\*[C XXZ>U*>E '->&_&VE^*;FX@ ML(;Y7MT#N;FV:+KQ@9'-<_\ "M&6Y\6DV\L0?6)&4NI&\8ZCVKT3&><$8]Z% M4*> !DY^OO0!YQX_TR]T+4K;QOH<,SW5L!%?PQ\_:(,]2!U(SG\*[S2]1AU; M3+74+?>(;A ZAEVD9[$&KC#((IN !Z4 >?ZD)#\=]#=8W,0TB92X4[0=Q M.,UV>N?\B_J6<_\ 'K+T'/W35W:N_=@;L8SWQZ4YL$$'GVH X3X7$P_"?3!B M2-HX),AUP0=S&J_P661/ "K,CK(+VXR'7!Y?.<5Z"J+&NU5"J.@48%"JJ8"@ M 9SP,4 /KS6T20_M :A+Y;^7_9"+OV\$[NF?6O22?>FB-0Y<* QX+8&?SH \ MX\0I?>#/':A6TMHFWI!$K_ -Y4 - 'G&@7NL^%? 6I:]XE MEN#?7F M* .&^#CJWPPTK!8D>9G(P0?,:LWXM7MKIVJ^#KVZF:**VU3S9&5"Q5<#)X!X MKTQ%"*%5< =AP!2/%'(5WQHY7IE0<4 <0GQ>\$.P5=7?GD?Z)*/YK6OX>\;^ M'_%,MQ'HU]]H:V ,H\ITV_FHS6_Y$0_Y91Y_W12K&B?=4+[#C^76@#-T+Q#I MOB.U>ZTRX\Z%)6B8E"I#*<$8-:U1QQI$-L:*BDYPHP/_ -=24 %%%&10 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111D M4 %%%% !1110 4444 %%%% !11D>M% !1110 4444 %%%% !1110 4444 %% M%% !1110 449%&1ZT %%%% !1110 4444 %%%% !1110 4444 %%%% !111D M>M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 5GWW^M'TK0K/O\ _6+]* +]%%% "T444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5S7C3Q'>^&-#74+ M+2I-2D\Q4:&/.X ]^ :Z6D(R* /(6^,6OK!YG_"OM58?WEW$?^@4D7QCU^5P M$^'NK-D9PJO_ /$5Z_CI1C'2@#R3_A;GB-G*K\.]5&!_&S#_ -EI@^*_C%F^ M3X;:D1_P/^>RO7NE&.>] 'DJ_%/Q>PPWPZU%#[EC_P"RTUOB=XX6(.?A[=DE ML;/$*A?AY)(0OP\NG'J"W^% ^(OQ"RH/4R&O6J3\* /*E^('CXI_R($I/IN:A_'?Q$&TKX M ;GK\YR*]5I: /*6\>?$53C_ (0!S]&:HO\ A/?B49<#X=$KZF4UZW1B@#RE M/'7Q'+$-\/V4#TD)J,^/?B0&8?\ "O)"!T.XC^M>M44 >21>/OB3)NW^ ?+Q MT#,W^-+_ ,)W\3MF1\.P3VQ/_P#7KUG ]*6@#R5O'7Q.&TK\/!COF8G^M/?Q MQ\2%.5\!@X'*[FR?UKU>C% 'D?$]9%5O "L M#V5V./UKUVCOTH \GG\-?BD(<_\ "!QE]V,;SC'YTP>.?BKG'_"O8S_VT(_K7K]% 'D0\;_% M0G'_ KZ)??S"?\ V:GOXU^*6PE/ D6_MDG_ .*KUJB@#R&/QQ\5F!W^ 8E( M'!W''_H5.A\:?%8JYF\#6Z'&5QN.?R:O7** /(4\:?%ADW'P-:+ST)?/_H5# M^,_BS_RS\#6A^I;_ .*KUZB@#R!/&7Q<+ -X&M/<[R/_ &>I8O%7Q7$.Z3PC M9^823LPWRCMSOKUJB@#R!/%/Q<9_WOA.SC7&1M!/_LU./BKXNA@#X/L2OKD_ M_%5Z[10!Y+%XC^+;3DOX9L%B[#G/\Z9_PDOQ<(ROA>R')Z@_XUZ[10!Y%_PD M?Q>8J5\,V(&/F!R/ZT#Q-\7@26\)V# >C$'^=>NT4 >1CQ'\7#ACX8LE![;B MOT4 >0KXE^+P(!\+6//?<>/UIS^(/B^I!7PU MIY'^^3_6O7** /(D\1?%]B0WAFQ4>N?_ *]-_MSXQ;?^1=T_/KN%>OT4 >0- MK?QB5E)T&PV]]K TLOB#XO$CRO#EF/4DBO7J* /(H]>^,)8AO#E@<>K@5(=; M^+CQ;ET*Q1AVSFO6:* /(CKOQ@"G'AZQ8^NX"D;7?C",8\/6/3^^#7KU% 'D M4>M_&$H&;0;$_P"SN /\Z/[<^,!1T/ARRWY^4[UQ_P"A5Z[10!X^-6^,R,%E MT:PY'#(4;'Y&I4U;XQE64^']/R.0YF09_#->MT4 >.MK7QH& /#^GD^N]?\ MXJI5U[XPC /ANP+=_F 'Y[J]=HH \B_MGXS&7 \/Z8 ?608_]"IIUSXRK(X_ MX1[3VQTPXP?QW5Z_10!X_)KWQE3:1X:L.1SAU./_ !ZD76OC2#EM TP@_P"T M./\ QZO8:* /(6U[XR11G/AO39F[;6QC_P >I!X@^,S.?^*6TX#CK(O_ ,77 MK]% 'DBZ]\8P2TGAG3,=@'!_D](NN?&9@1_PCFE ]CO_ /LZ]EX'^U_]E7KM% 'DG]K_&,D,-#TO!.-I;_[*FKJGQH61PVC M:2XSQ\P&/_'J]=HH \C75/C.LS;]%TDH>@#C_P"*IR7_ ,9G8[M-TE3Z9&,? M]]5ZU10!Y)+JOQB+'R-)TXJ.[@#^M1?VQ\92FW^Q=.#GC=D8%>P44 >22ZC\ M8]B&+3=,WCALX_2A;WXTEEL/4,M>NT4 >0F^^-.W TS2R?=U_QJ1+_ M .,IC.[2M-W]L.F/YUZU10!X^M]\;')']EZ6H]6=,?SJ9+KXS!@LECIASW5D M_P :]:HH \D-Q\:?-PMGI6SU+)_C3I;[XQQOB+3-/E3')WH#G\Z]9HH \>_M M+XUNNY='TQ?JZ9_G3AJ/QK R=&TP_P#;6/\ QKU^B@#Q]K[XV;MRZ3I)C_NE MDS_Z%2?VO\:VX&@::,=S)'C_ -"KV&B@#R ZE\:P@/\ 8VF9]-\?_P 540U? MXW;N="TW'^^G_P 57LE% 'CS:M\:W(VZ%IB?\#0Y_P#'J?\ VQ\:D//A_2W_ M .VB_P#Q5>O44 >0+JOQK,GS:+I(7T!&1^.^AM6^,IEVQ:+IQ4=Y<#\B&KU^ MB@#R5-4^,CAPVCZ5&P'RX((/_CU(NJ?&) IFTG36/<)@_P#LU>MT4 >2+J?Q MAD#$:5IT?/ ('/\ X]43ZC\:]XQIFDA?8@_UKV"B@#R-]2^,BL%73-,<]R< M4_[=\95?+:;I&S'9@3_.O6:* /(#J?QFZC2M,//3BI9=6^,*!=FCZ'].([E7SFO6Z* /)1X@^*[;@?#MLH' MW2.M0C7OC%W\.V7/0[AQ7L%% 'D)UGXR%AMT+3\?[PI#X@^,"RA?^$;LV4=] MPYKU^B@#R8^(/BV6&WPS9X[YD'^-1-XE^+PD^7PM9E1UR_\ ]>O7J* /)V\3 M_%98@P\)6S/_ '=V/ZU7_P"$N^+C#:/!4 ([F4?XU[!10!Y%'XO^+"Q_O/!$ M#$>DO_UZ/^$U^*H.3X#BP>WF$_UKUVB@#Q]/'GQ3#_O/ "$>Q;_&AO'_ ,4, M';\/N>WW_P#&O8** /'E^(/Q0!4/\.R?4@M_C3_^%@?$S>V?AXX7^$Y8_GS7 MKU% 'D"_$+XEE#N^'A?%-_X6+\2U&X_#F4CT&_->PT4 >/I\1_B.V=WP MWG![1RC?#N6,XR"2Y!_2O7:* /(&^(OQ'"G'PZN"W;AP*.[-4/_"POB<1Q\.''U=J M]AHH \A'C[XG"/>?A\/]T%R:5OB!\3-@V_#UBQ[988_6O7:* /)1XX^)V#GP M'&"%SC>YR?3K42^.?BHS(W_" IM/4%R,?K7K]% 'DK>-_B>C-GP(A!^[AF./ MUI/^$W^*(PH\!(V?XO,(Q^M>MT4 >1'QK\4T?9_P@T;+_P ]-S?RS2S>.?B@ MK#R_ <=SYA_QKURB@#R'_A-OBIC=_P@2E_P#:LXH_.@#R;_A._B4957_A M7QVGJ2Q_QI9_''Q-BFPG@)9(ST(=LC]:]9HH \C/COXH8S_PK]?^^V_QI\7C MKXE21%F\ E&_N[FY_6O6:* /(U\I[^-_B:NX?\ M"!@D#J"<'_QZO6:* /(?^$Y^*/7_ (5^B@C.-Q/]:6/QS\4"C%_ 2J0.!EN? M_'J]=HH \=7QY\5C@CX?)CT+,#^K5(?''Q5(R/ 4* HH \?7QW M\4I5S'X!10.T@8'_ -"I!X[^*P.&^'\9]P6_^*KV&B@#QUO'?Q6#[4\ QOC^ M(AAG_P >I#X]^+ '/P^C_ M_\57L=% 'CB^/_BIU;X>+CV+_ .-2GQ_\3%&X M_#\O[+OKUZB@#R+_ (6'\1\@'XOT8 H \A;XE^/U0-_PKJX [Y<_X4C?% M'QLH'_%O;G/U;_"O7^.@HS0!X]_PM+QP3Q\/;G_OIO\ "I5^)_C9L8^'UT3_ M +Q_PKUS-% 'D1^*'C=%+2?#VZ4!L$DGI^5.?XK>)P1L\#7;^N" * /(W^+'BGI'X U#/JV) M,8/@+40WT./Y4D?Q=\22.J'P)?@D]PV/Y5Z_@TGXT >22_%_7HGV+X#U1L'J M%;'\J3_A<.MO&YA\":KO7LZL!_*O7._;ZTOZ4 >0_P#"X=>\O>? >I>X&<_R MIC?&C6(_E?P%JX;_ &48_P!*]@X]11@'D_RH \CE^,NJQQ*Z^"-58'MY;9'Z M5%_PNO5CC;X"UD^N8F'_ ++7L.T>GZ4 #M0!Y _QIU6/&_P#K S_ ++?_$TS M_A>%^#SX"UC'LK?_ !->Q8&>N32X]Z /'?\ A>-Z&Y\!ZR%]2&_^(J;_ (7? M)E0/!NKDGJ,'/_H->N8HH \>?XXWHR4\!ZR0#U(/_P 30GQTDVMO\%:PC8X' M)S_X[7L/XT=/_KT >00_'1W;$G@K6$&.N/\ [&G-\=%5F4^#=:8CKL 8?H*] M=_&CWQ0!Y(GQTMVC+2>%=60C^ J,FF#X\6@*A_"VLH2>Z 5Z]CO@4A4,1N / MU% 'DK_'C3T?:?#6L'W" XI[_'C250%=!UAS_=\G!KU8HO)VK^5(8HV!#1H1 MZ$"@#RJ'X[:9(^#X>UA,]VC%$OQWTF.0H=#U8D>D=>I?9K?_ )XQ?]\BC[+; M@Y\B+/KL'^% 'EB?'C2Y&PN@:P?^V5+_ ,+WTP/M/A_6![^57J?V>$?\LHP/ M]T?X4&VM^\,7_?(H \N?XZ:6(_,70=59>Q\OK2+\=M+;DZ#JRC_KG7J/V6W* MX,$6/38,?RH^R6W_ #[P_P#? _PH \OC^/&AR$C^R-5!'4"'-/3X[:%),L8T MO5;/\ ''14D=?[)U3Y._D] M:KCX^:"9-@TK4\_]:R_'30X MBN_2]2"GN(LT]?CGX?9-XL-0V_\ 7*O2#I]B>#9VY_[9+0--L0,"RML?]EC3[)?NV=N/I&H_I0=/LCUL M[?/_ %S'^% 'FG_"^O"_'^BZEN]/LYI#\>?#0&6LM3"^I@.*]+.G6+?\N=O_ M -^E_P *!IUD,?Z';\?],E_PH \U7X]^$V _?"?E!O)U'.?F7R G_\^%L/^V*_ MX4#2].'2PM1_VQ7_ H \[D^//@R(X;^T#&5"JZBQ?L+GDY-A:Y]?)7_ H_LO3L8^P6I [>4O\ A0!YX_QX\'1L!(-20GLU MN/\ XJF_\+]\$%MHDU G_KU_^O7H;:5IK8W:?:$GIF%?\*:VC:4^"VFV3>F8 M%_PH X%?CQX+9P@?4 ?>V_\ KTK?'?P2IV^??$^@MB?ZUWAT+2.^E6/_ (#I M_A2?V#HP)/\ 9-AS_P!.R?X4 <(_QX\$(0#"Y"P^TWB;1DE[8X M_.E3XX^!WSMO;C@9/^CM7:GP[HF<_P!CZ?G_ *]D_P *4>'M%'(TC3Q_V[)_ MA0!Q(^.7@=@=M[5]#;)_A1 M_P (_H@7:-'L-OH+9/\ "@#B8_CIX&D)'VVY4#H6MV /TJ1OC=X(7@W\^?3[ M.U=@WAO0F4*=&T_ _P"G9/\ "D;PQH1;/]C6&>G%NG^% '(K\;? [+N&I2X] MX33O^%U>!P0#J;KGN8C74'PEX>(Q_8MC_P!^5IS>%M ==K:+IY [>0O^% ', M#XS^!BA;^UP/^V;4+\9O [$@:OT&<^6U=$?!_APC!T.PP.PA7_"E'@_PV%P- M$L-I[>0IH YS_A%<$-H-C@^L8H R!\7O Y./[^#QD?\(YIXSUS"*4?#WP@.GAW3Q](0 M* *;_%7P0@YU^W_[Y;_"HQ\6_ Q./^$AMOR;_"M'_A ?"0.?[ L2?>/-)_PK MSPANW?\ ".:=G_KB* *)^*W@@==?MP/]UO\ "D_X6UX%SC_A(K7/T;_"KY^' MOA$CGP[8'V\H4P?#CP8KA_\ A&M-S[P T 4A\6_ QD*?V_!Q_LM_A2GXM>!5 MZ^(K8?\ 6_PJ^?AYX/.?^*;TS)[BW44S_A6_@S_ *%O3C]80: *@^+/@1NG MB.U_[Y?_ .)IH^+?@,_\S):_]\O_ /$UH'X>^#\$?\(UI@SZ6ZBH_P#A6W@O M&/\ A&M.Q_UQ% %# M6 (\1V&#T)DQFH&^%?@=F!/AJRZ=@P_K3#\)? C$$^'+;CMN?_&@"Y_PL3P> M.XMY%DAD&Y'4\,/45Q[_"+P&X(_P"$=MU)[AGX M_6NMT^PM],L8+*U0I!"NR-,^U '$:A\1[2/6Y MM*T;2=1UNYMCBY:RC!2(^A8\9]A6AX4\;Z;XL^UQ6\V;;;BTN5VR1^Y' MI7/_ <>,^&]3B.!>QZI<+<9'SY+97/X5MWMSHKQ>)8]%:T_MN*UD^T^4H$@ M;8=NXX]<4 9LGQ.CNKZYM] \/ZKK:6S^7-<6L8$8;T#'@UL>'_&NG^(+*]D@ M@N+>ZL@?M%G<)LDC.,X_'UK/^$S6K_#71S;%2?+(F(&"9T9=G]C*;L1G@R9_B]\4 =?X,\4)XP\.1ZO':/;(\CH(W8,?E.,Y%-\6>*T M\+'3#)9RW"W]XEJ"AP$+=S6#\%B@^&MGL!5?/FP&X/WS4/Q=7-IX<((&W68, MDG&.: .F\7>*8_">G6MY-:27"3W4=MA& VES@'FLGQ9\2K#PAX@T[2;VQN&- M]M*S*RA5R=O/TJI\8,-X;TD$_P#,:M/E]?FJCXV\/VOB;Q\MC, TO]A2O;X' M*R>9PGSVRZUX;UC2X+B584GN(AL#'U(/%;FH^+H-/\ M7Z3X>-I-+-J43RI,OW4"CG(_SUKS_P ?6_C"/1;6[\2/IESHUK>13W45B&5R MJG@DM[\GZ5NZNT\(7$ .UK"X*\X^4KGD?E0!L^-_'VF^!X;1KV*6>2Y8 MJD<1YP._TKI+"]AU&QM[R!@8IXUD3GL1FO)[SQ#X=OOBEK0UB0R6UI9"RC'D MEUW-]\\9P>PK>^$&J0W7A:?2HYGD.EW#VZ[U*L(\Y3(/M0!T?BWQ5;^$-&CU M&YMY[A7F2!8XA\Q9NE89^)MK9W-HFLZ'JFDP73A$N;F+]WD],D=,U5^,\LD7 M@ZR>%/,E75;8I'G&]@V0*SM?M?&OCNSMM&N_#T&E6;7$@Y MKD/#>GKX:TO1O&FGP$">ZDM]656)!B9RH?\ X/XT >EIXUBEB\021:9?2MH ML_D/'$H9ICQ]P=^M8+_&'38[H65/?&E:5/HVJ6 M5QJ4;21_:8@FT+G.03D=*LV'CW2=0\9WOA6,2QW]J"277"M@9./P-8?B(@?& MSPGE2<65Q@CMGBN:GT0W6O\ B_Q/I:/_ &]I&I(8B&)\R-5!9-OH1Q^% 'IY M\36P\8CPWY$_VC[-]I\T ; N<8]AJO\)XH4T/7]46-KG5I=1N#. MI8>9E3\J9/3VH ZCPMX_T+Q7/+;64LUO?1?ZRRNT\J91Z[>_7L:Z#4K^UTO3 MI[Z\F6&V@0O)(QX %>=Z)K\&H_$NV74O!,^D:W/:.RW<\P9C&N. !Q^-=CXP MT^QU;PK?Z?J-^EC;7,?EM<,P79R,'GCKB@#FX?C#X9DDC,L6J6T$K!4NKFR9 M(6ST._ICWK=\4^-M(\(6%I>ZB9W@NY/+B-M'YFXD9'3UK@=0/C+P_P"&1:^( MM*TCQ-X;@C19)(&*RB)<8"<8Z59^)=V9O#OA*\T:V#,^H0O:0N=@Z?*K> MV* -R#XLZ%<7=O;+I^N1M/(L:M)I[JN2<#)JWKWQ+T#P]KK:->_;6O1&LNRW MMFDRI!.1@>U5[#5OB%-J-O%?>%M-M[,R#S9DO0Y5>Y ]:Y_5]0UFR^--W_8V MDP:C+_9<9=7E",BY/3/<]/QH ZW1?B+X=UZ\DM+2XF6[CC,I@N(&CD*CK@'K M6UH6M6?B#2(-2L79H)LXW#!!!P01VQBO-?"<^H>-_B,=?U&WM]+DT1'MCIZM MNG8L#\SD@<"I]$U<^$-"\;6%W( ^FW,L]OR 76493 ^M '4Q?$/1+C0M6UF+ M[2UGI'H->W&BOX? M_9WU&&4$W4]DUS<'U>0@G^8IU]##<^,_A[I]W&LFGKI_G(A/R&4(-O'>@#JM M)^)OA?5]22P@O)89Y1F(7,+1"7V4MP34OB'XB:#X8U>+2]1:[-U*GF*L%NTF M1^%7_$&@:%K4=G_;$4)%O*KV\C-L*MV /'Y5PGBF;6+/XSZ3-H6G0WUX=)D4 MQ3R>6-N[D[O7I^= '6:%\0]$\1:JNG6*7PG9"^9K5XUX[9(J+4_B?X5TK47L M)KV66>-MLOV>%I1&?1BH(%6= U3Q5>ZF\>M>'H-/MEBRLL=T)26STX%E:7JMCK-A%?:=TU[2;;5+%BUM<)OC9A@D?2C6-;TW0;% MKS5+R*VMU.-\C8R?0>I]JY_X7G'PR\/8'/V11C\36)XKMH-6^+WAK2]2P]@E MI-H;;AQF-)T,9D_P!W/6NLR/6N>USP MIH&KR6,U_;1QR6DPD@>,B,[AVR.OTK>=A&A&M7U(Z;I^KV]Q>.O:N=^+VCM>^%8M M4A4&YTFXCND..=H8;A0!UNL>(M(T VXU2_AM#< ^O:KUQKMG\0-4 M\$Z!;J\HMY%N=04C@>6H^4_B* /5]%\3:+XB\XZ/J$-V(3ME,>?E/H&M+O9K.^UBW@N8 #+ M&Q.4STSCI6BNLZ1?V?L\S[06PFWUSZ5YIX$T>V\53>--=NK9735;I MK>W>1<_NU& 1Z/!#.6UC[=_9K0%2"(RV0: /=-.US2]8TUM1 ML+V&XLUSF9#E1MZ_E2:-KNF>(+5[K2;Q+J!7,;2)G&X=1S7BFFZZOP_\#^)/ M"6HW:0ZC;Y^QIU:82#^'UKU;X?Z(F@>!]*L BI((%DF [NPR2?SH OZ[XHT/ MPU&DFL:G;V:O]WS&^8_0#D_E4>B>+_#WB1V31M7M;N11EHT;# >NT\UPWC_P MKK+>,[+Q1I^B6_B"&& Q/I]P5PIS]Y=W?\*J^'-6\+7'Q$MFOO"MYX>\3/%L MB23B.3CH I /'^S0!J'XH69^)9T=M0L8]'BMSF?>#OF+ !@:'XLT'Q&6&D:M:WC)RR1/\P^H MJSK&N:7H-H+K5=0@LX"9_$'2-/\+>)O"^O:1;I9WDNH):S+ M -B2QGL5''%2ZC8V7B7XZ'3]7ABNK2QT\/!;2C*ECC+%3P<4 >@Z+XFT3Q$C M/I&IVUV$Z^6V2/PZUR6GZKK!^-FHZ1)>ROIB6"SI;G 523C([UL0>!-!L?%R M>(+)7L[SRC'Y%NX2*08QR@%>:>.]=UO1/B]66V+@G(QZ4 M>RP>(-)NM4?2X-1MY;Y!EX(WW,H]P.E%3?6H,NJ32'[?/-S*9,]#Z#VJI\/8DA^)WCM40(HN4QCO MG)H [Y_$>BQPSRR:I9JD!Q*3*/D/OS4FFZWIFM6K7.FWT%S O#/&X(7ZUY)\ M/_!N@ZWXN\8WU_8I=+#?&"..3E<'DG&>N:T/ FE6ND_%CQCI5K;>18&WC=8 M?EP2 <#\: *=[XVU_7OB/>Z+HGB/2]/L;;:(GF4,)FST![_A7J]WJMGH]E%+ MJU_;P9 4R2,%#-WQFO)?#W@;0%^,VO6E6OC?XN M^(1KA^UVFCA(K>S;[@)&=Q'0T >G:7K>EZU$9=,O[>[13AC%(&Q^522ZI807 M+6TU[;I.J;VC:0!@OKC/2O*?%6CVG@7QYX5U308?L5O>W1L[JW@R$?=T)%1> M*O#]IXF^.^GZ?]AU.T>U1MC2B5=JG MT)SBEFU_2+>ZAM9-1M5GFQY=?$CPUI'AKX4:G9:7:BWMWG23R MU)/)('%8OC/P)X>T?X31ZK;V3?VA!#%(MTTC&3<0.X/O0!Z]<^(-'L[X65SJ M=I%YH Z"#Q+H=S*(H=7LI') MVA5G4Y/YUD>/_&4?@OPW-?*L<]WPL4#. 6).-V/0&O%/%@\'6GA6T/A72+]; MJWEC;^TF@>/<,CDNW!S[5VWQGTG3KOX;0:W,@JS8Z MC Z5YOXN\,Z5H/P0U*ST^W81R1).0[[B'.WG)^E0^-M4NK7X9>%M-LYGMAJK M6UK++']Y$91G% 'ID/B31+B^-E%J]B]T#M\D3KN)] ,YJ]<7=M:1>; M0NZ1PHR>@R:\XU?X0>$X/"=Q':67D7UO TD=\CL)?,5<@DY]>M8=_J]SKW[. M4E]K7FOZ/ITL,=YJ=G!)-_JUDF52WTR:T4='171@R M$9# Y!%>03?#3PPOPG>X>S,EW]@^U"[=RTBN5W<<\"NQ^%TLDWPTT"25][FV M W'J0": .O) !R1CWK.L_$&C:A=/;6>JV4]Q&Q5HHYU9P1U& 2&97(^H!KS?XG&;6?$GACP8]Q- M'9ZB[27;Q-M+HO8_4_SJCXX^&N@^&O"\NN^&X9=-U/2T$R2P2MF0 C(8$G- M'L#21H5#NJECA-WY=:\<^)FH'7_AYX7NC- M)!)?74&7C&"&(Y.:SOB-\/K+PQ8:/JVBW%_%J1O(K:>]^TNTCAN,\DC/TH ] MS%W;&?R!<0F7IY>\;ORJ:O#O'?@K3O!_]@ZSIC7(U ZC#'<7,ERQ,F2,LP)Q MDC(_&O< E+10!Q^I?#S3KO5KC5;"^U'2+ZX&V>33[@Q MB3W9>F?>K_AGP=I?A6.X^Q)-+>Z?\+WTBS:UTSQ5K5K$22$20%5).20#6L? ]O?>%&T'7+^[U5#(9%N;@@2H M,S^ M=YY)Y8P&8L+/ M"Z>*M/M;.6ZDMUM[J.X#(,Y*'(K? .!W[$GO3J* .=N?"XN/&UIXF%W()+:V M>W%OL&U@W/7J.:AUSP@-4\3:7KUIJ$UC>V.49D4$31D\HPKJ** .;MO"BV_B M[5O$ NY"^H6R6YB*#$>WH0>])H7A/";^'YIFN87\P-(5 .'S_ "S72T4 M<=X#\!V_@*RO;2VO9[M+J;SLRJ 5P,=1UJW-X2\SX@V_BK[8V8;1K7[/Y8P0 M><[NM=-10!S&I>$_[1\;:3XC-Z\9T^%XQ L8(DW?[7:I]"\-?V)JFMW@N#,- M3NA<%"N/+.,8SWKH** .&\,?#BV\,>+M1UVVO7<7H):!HP-N3G&?2DU/XU_0K+Q'HMQI6H1F2WG7! Z@YR"/<$ _A6G10!YA)\+]=GL!H M]SX\U";1 AM#:IO*#^$R9R16UXI\!MKFCZ/8Z;?_P!FG3)5DAD,(E(VK@<' M@UVM% '!'PUX_66+/CN*2)&!=3I:*7&>F0>*T[?PI<1?$2?Q.;U#%+9+:F 1 M8(*GKFNJHH Y"]\(7*^/K?Q1IEXENS1>1>P,A(G3MT[CU]JS/&'PT_X2GQ-; M:H-0,$*A%N;<+Q.%.1FO0J* ,/Q3H/\ PD'A34-%BE%O]J@,*OMR$'';\*R] M6\"Q:OHFCVQOIK2_TH1_9[Z!?G4J #P>QQ7844 >#];OO&<'B+2-:CL98K4V^R2'S!R>>*[FB@#CM/T M?QK'JL3ZEXBLKK3\$30+9A6<8/&>U9=KX UWP]/>)X6\1"TT^ZD:7[)?P?X%UF*RU&1]2F26Y:\,?)EQD$**W_"%-,DU61 MI+YK=6F)H_F&1R,5;HH \]^&OPY ME\#PZ@+JY@N9+K: 8XR,*,Y!SUSQ5?P+\,9O"?BK4M9NK^.Z,ZLMNJQD% 6R M6=I'!XKJ** .%\3>"=8O->37_#GB M.?3-05/+:&5/-@D'NO0?4 U#IG@76;KQ39^(/%6L0W]Q8H5M8;> 1HA/4],] MZ] HH \Y\2^!O$-SXZ3Q1X=UN&SG: 6\L=Q%N&T>GYU=U_P+>:AK5GX@TO5C M8:W!"(99A$-DX']X?YXKN:* /.K'P'KNI:_::OXQUJ*_:P8M:VMK'Y<0;^\> M,DU=\5^!KO5-?M_$>@ZF-.UJ",Q;WCW)*OHW>NXHH \YTCP+XAN?%=OXB\6: M['=SVJD06MDK1Q*<=2.]:-GX5U*#XJ7_ (EDGB:QGM%MUCY+@C'Z=:[6B@#B M=)\):AH'CN^U+39(!HVHC?<6[$[TE_O+VYH\*^%=3TCQCXDU>]>W,&I2AH5B M)R /7WKMJ* .)\!^%=0\-:AXBFO#$8]0O3/#L8G"X[T:%X6U#3_B1KOB"X,9 MMKZ)8XL-R #GI7;44 <5HWAS5+3XFZYKUP(A8WMK'#%M;+94]Q4/B'PCK:^( MG\0^%=0@L[V6,)<0S1YCF(Z$UW=% 'GFF>#?$.J>)+76O&&HP3?86+6=I:+M MC5B,%FSU-79/"^H/\6H?$P$(L8[$VYY^?VT<'/6JGC/PUJVM?#$:%:)$U^884<,^%^7&<'\*[JB@#B/&GAK4]:^ M&;Z#8)$;TPQ1X=L+\H&>?PJ/Q1X)O/$W@"PT83Q6M];+"V6&Y"R <'U'%=W1 M0!Y#XA\(?$+Q/X5&F7=QH]N(64K#$N?-V].?X:Z?Q;X5U#Q1\-O[$#1VU^8H MCC.4#ICC/IQ7;T4 >87^@^.-9^&FJ:)JEOIKWSB.&U6*0A3&,9+$]^*VM3\$ M_P#"1?#ZRT*\")Q\*)/"OA] TB1(B>8P&[!!)SZFO0:* .=GTR^;P M$VE*J&]_L_[/C/&_9MZUDZ/HWB+0_A;!I=@8H]O21PZNR+)))$,JLRDD$8[5S5_X=^)WB6TAT?4[[2]-L M8W4O=V+OYT@7W['Z 5ZS10!Q/C'P1<:U9Z=@KUFB@#SGX@^$M0U'0?#^ MG:+9"9;"[B=AE%"(G&<$\_A4OQ4T/6=?TG2K;2;,W+1:A'/, RKM53U^:O0: M* //OBIHFL:[H^E6^E64MR\>H133*KJ JJ?PKOU!P#C![TZB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH *S[_ /UB_2M"J%[_ *U/]V@"]1110 M%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !5"]_UR_2K]4;S_CX3_<_K0!=HHHH M 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J MA><3K_N_UJ_6??\ ^M7Z4 7Z*** %HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH *S[[_7#Z5H'I6=?_ZX?2@#0HHHH 6BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ /2LZ_P#] MAK/O1^_7_=K0/2J-W_KQ_NT 7:*** %HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *J729D!QVJW2 M$ ]10 4444 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% #=HW9P,^M.HHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 3 **** "BBB@ HHHH **** /_V0$! end EX-101.SCH 14 xtnt-20211231.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Deficit) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Deficit) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - Consolidated Statements of Cash Flow link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Business Description and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Receivables link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Property and Equipment, Net link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Goodwill and Intangible Assets link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Accrued Liabilities link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Equity link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Warrants link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Employee Benefit Plans link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Supplemental Disclosure of Cash Flow Information link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Segment and Geographic Information link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Business Description and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Business Description and Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Receivables (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Property and Equipment, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Goodwill and Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Accrued Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Warrants (Tables) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Supplemental Disclosure of Cash Flow Information (Tables) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Segment and Geographic Information (Tables) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Summary of Revenues from Product Lines (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Business Description and Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Schedule of Allowance for Credit Losses (Details) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Schedule of Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Schedule of Property and Equipment, Net (Details) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Property and Equipment, Net (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Schedule of Goodwill and Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - Summary of Future Amortization Expense for Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - Goodwill and Intangible Assets (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - Schedule of Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - Schedule of Long-term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - Debt (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000051 - Disclosure - Schedule of Share-based Compensation, Stock Options, Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000052 - Disclosure - Schedule of Assumptions of Stock Option Granted (Details) link:presentationLink link:calculationLink link:definitionLink 00000053 - Disclosure - Schedule of Restricted Stock Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000054 - Disclosure - Stock-Based Compensation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000055 - Disclosure - Schedule of Warrant Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000056 - Disclosure - Warrants (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000057 - Disclosure - Schedule of Future Minimum Rental Payments for Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 00000058 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000059 - Disclosure - Schedule of Components of Income Loss Before Provision for Income Tax (Details) link:presentationLink link:calculationLink link:definitionLink 00000060 - Disclosure - Schedule of Components of Income Tax Provision (Details) link:presentationLink link:calculationLink link:definitionLink 00000061 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 00000062 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00000063 - Disclosure - Income Taxes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000064 - Disclosure - Employee Benefit Plans (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000065 - Disclosure - Schedule of Supplemental Cash Flow Information (Details) link:presentationLink link:calculationLink link:definitionLink 00000066 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000067 - Disclosure - Schedule of Revenues by Geographic Region (Details) link:presentationLink link:calculationLink link:definitionLink 00000068 - Disclosure - Segment and Geographic Information (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 15 xtnt-20211231_cal.xml XBRL CALCULATION FILE EX-101.DEF 16 xtnt-20211231_def.xml XBRL DEFINITION FILE EX-101.LAB 17 xtnt-20211231_lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Investor Rights Agreement [Member] Concentration Risk Benchmark [Axis] Revenue Benchmark [Member] Customer [Axis] No Customer [Member] Concentration Risk Type [Axis] Concentration Credit Risk [Member] Accounting Standards Update [Axis] Accounting Standards Update 2016-13 [Member] Long-Lived Tangible Asset [Axis] Computers and Equipment [Member] Surgical Instruments [Member] Product and Service [Axis] Orthobiologics [Member] Spinal Implant [Member] Other Revenue [Member] Equipment [Member] Computer Equipment [Member] Computer Softwares [Member] Furniture and Fixtures [Member] Leasehold Improvements [Member] Other Properties [Member] Term Loan Commitment [Member] Title of Individual [Axis] Agent and Lenders [Member] Revolving Loan Commitment [Member] Second A&R Credit Agreement [Member] Variable Rate [Axis] London Interbank Offered Rate (LIBOR) [Member] Credit Facility [Axis] Revolving Credit Facility [Member] Credit Agreements [Member] Second A And R Credit Agreements [Member] 2020 Warrants [Member] Related Party [Axis] ROS and Royalty Opportunities [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Restructuring Agreement [Member] Royalty Opportunities and ROS [Member] Investor [Member] Sale of Stock [Axis] Private Placement [Member] Investor Warrant [Member] Placement Agent Agreement [Member] Private Placement Warrant [Member] Plan Name [Axis] 2018 Equity Incentive Plan [Member] Employees And Directors [Member] Award Type [Axis] Share-based Payment Arrangement, Option [Member] Restricted Stock [Member] Class of Stock [Axis] Equity Option [Member] Restricted Stock Units (RSUs) [Member] Measurement Input Type [Axis] Measurement Input, Expected Term [Member] Measurement Input, Price Volatility [Member] 2020 Warrant [Member] Settlement Agreement [Member] Geographical [Axis] UNITED STATES Soleholders [Member] Sublease Agreement [Member] Legal Entity [Axis] Cardialen, Inc., [Member] One Customer [Member] Two Customer [Member] Rest of World [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated By Reference ICFR Auditor Attestation Flag Auditor Firm ID Auditor Name Auditor Location Income Statement [Abstract] Revenue Orthopedic product sales Other revenue Total Revenue Cost of Sales Gross Profit Operating Expenses General and administrative Sales and marketing Research and development Total Operating Expenses Loss from Operations Other Expense Interest expense Total Other Expense Net Loss from Operations Before Provision for Income Taxes Provision for Income Taxes Current and Deferred Net Loss Net loss per share: Basic Dilutive Shares used in the computation: Basic Dilutive Statement of Financial Position [Abstract] ASSETS Current Assets: Cash and cash-equivalents Restricted cash Trade accounts receivable, net of allowance for credit losses of $552 and $653, respectively Inventories Prepaid and other current assets Total current assets Property and equipment, net Right of use asset, net Other assets Intangible assets, net Goodwill Total Assets LIABILITIES & STOCKHOLDERS’ EQUITY Current Liabilities: Accounts payable Accrued liabilities Current portion of lease liability Current portion of finance lease obligations Line of credit Current portion of long-term debt Total current liabilities Long-term Liabilities: Lease liability, net Financing lease obligations, net Long-term debt, plus premium and less issuance costs Total Liabilities Commitments and Contingencies (note 11) Stockholders’ Equity: Preferred stock, $0.000001 par value; 10,000,000 shares authorized; no shares issued and outstanding Common stock, $0.000001 par value; 300,000,000 shares authorized; 87,068,980 share issued and outstanding as of December 31, 2021 and 300,000,000 shares authorized; 77,573,680 shares issued and outstanding as of December 31, 2020 Additional paid-in capital Accumulated deficit Total Stockholders’ Equity Total Liabilities & Stockholders’ Equity Allowance of accounts receivable, net Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common Stock, shares outstanding Statement [Table] Statement [Line Items] Beginning balance, value Beginning balance, shares ASU 2016-13 cumulative effect adjustment Stock-based compensation Common stock issued on vesting of restricted stock units Common stock issued on vesting of restricted stock units, shares Issuance of warrant Debt exchange, net of exchange costs of $1,058 Debt exchange, net of exchange costs of $1,058, shares Issuance of common shares, net of issuance costs of $143 Issuance of common shares, net of issuance costs of $143, shares Exercise of warrants Exercise of warrants adjusting to additional paid in capital, shares Private placement of common stock, net of issuance costs of $1,926 Private placement of common stock, net of issuance costs of $1,926, shares Warrants issued in connection with the private placement Warrants issued in connection with the private placement, shares Warrants issued in connection with the private placement to placement agents Warrants issued in connection with the private placement to placement agents, shares Gain on debt extinguishment Gain on debt extinguishment, shares Withholding of common stock upon vesting of restricted stock units Withholding of common stock upon vesting of restricted stock units, shares Net loss Ending balance, value Ending balance, shares Statement of Stockholders' Equity [Abstract] Debt, exchange costs Share issuance costs Payments of stock issuance costs Statement of Cash Flows [Abstract] Operating activities: Adjustments to reconcile net loss to net cash provided by (used in) operating activities: Depreciation and amortization Non-cash interest Non-cash rent Gain on sale of fixed assets Stock-based compensation Provision for reserve on accounts receivable Provision for excess and obsolete inventory Changes in operating assets and liabilities: Trade accounts receivable Inventories Prepaid and other assets Accounts payable Accrued liabilities Net cash provided by (used in) operating activities Investing activities: Purchases of property and equipment Proceeds from sale of fixed assets Net cash used in investing activities Financing activities: Payment of taxes from withholding of common stock on vesting of restricted stock units Payments on financing leases Costs associated with refinancing Payments on long-term debt Borrowings on line of credit Repayments on line of credit Proceeds from issuance of common stock, net of issuance costs Proceeds from exercise of common stock warrants Net cash provided by (used in) financing activities Net change in cash and cash equivalents and restricted cash Cash and cash equivalents and restricted cash at beginning of year Cash and cash equivalents and restricted cash at end of year Reconciliation of cash and cash equivalents and restricted cash reported in the consolidated balance sheets Cash and cash equivalents Restricted cash Total cash and cash equivalents and restricted cash reported in the consolidated balance sheets Organization, Consolidation and Presentation of Financial Statements [Abstract] Business Description and Summary of Significant Accounting Policies Credit Loss [Abstract] Receivables Inventory Disclosure [Abstract] Inventories Property, Plant and Equipment [Abstract] Property and Equipment, Net Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Payables and Accruals [Abstract] Accrued Liabilities Debt Disclosure [Abstract] Debt Equity [Abstract] Equity Share-based Payment Arrangement [Abstract] Stock-Based Compensation Warrants Warrants Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Income Tax Disclosure [Abstract] Income Taxes Retirement Benefits [Abstract] Employee Benefit Plans Supplemental Cash Flow Elements [Abstract] Supplemental Disclosure of Cash Flow Information Related Party Transactions [Abstract] Related Party Transactions Segment Reporting [Abstract] Segment and Geographic Information Business Description Investor Rights Agreement Concentrations and Credit Risk Use of Estimates Cash, Cash Equivalents, and Restricted Cash Trade Accounts Receivable Inventories Property and Equipment Intangible Assets Other Assets Long-Lived Asset Impairment Goodwill Revenue Recognition Research and Development Net Loss Per Share Fair Value of Financial Instruments Reclassification Summary of Revenues from Product Lines Schedule of Allowance for Credit Losses Schedule of Inventories Schedule of Property and Equipment, Net Schedule of Goodwill and Intangible Assets Summary of Future Amortization Expense for Intangible Assets Schedule of Accrued Liabilities Schedule of Long-term Debt Schedule of Share-based Compensation, Stock Options, Activity Schedule of Assumptions of Stock Option Granted Schedule of Restricted Stock Activity Schedule of Warrant Activity Schedule of Future Minimum Rental Payments for Operating Leases Schedule of Components of Income Loss Before Provision for Income Tax Schedule of Components of Income Tax Provision Schedule of Effective Income Tax Rate Reconciliation Schedule of Deferred Tax Assets and Liabilities Schedule of Supplemental Cash Flow Information Schedule of Revenues by Geographic Region Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Total revenue Percentage of total revenue Schedule of Product Information [Table] Product Information [Line Items] Cash and Cash Equivalents, at Carrying Value Retained Earnings (Accumulated Deficit) Cash and cash equivalents Invester rights agreement, description Concentration risk, percentage Cumulative effect adjustment Property and equipment, estimated useful lives Antidilutive securities excluded from computation of earnings per share, amount Beginning balance Provision for expected credit losses Write-offs against allowance Ending balance Raw materials Work in process Finished goods  Total Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Total cost Less: accumulated depreciation  Total Depreciation expenses Patents Accumulated amortization Net carrying value 2022 2023 2024 2025 2026 Thereafter Total Amortization of intangible assets Wages/commissions payable Other accrued liabilities Accrued liabilities Amounts due under the Term Facility Accrued end-of-term payments Amounts due under the Second A&R Credit Agreement Premium related to Second Amendment Less: unamortized debt issuance costs Less: current maturities Long-term debt, less issuance costs Schedule of Long-term Debt Instruments [Table] Debt Instrument [Line Items] Line of credit facility, maximum borrowing capacity Line of credit Line of credit facility expiration date Gain on extinguishment Reacquisition price Debt instrument, interest rate Line of credit, interest rate Line of credit New effective interest rate Line of credit, description Increase in liquidity amount Line of credit facility maximum amount outstanding Issuance of warrants to purchase a common stock Exercise price of warrants Warrants expiration date Debt conversion converted instrument Debt conversion converted instrument, shares Values issued prepayment fees Shares issued prepayment fees Debt instrument face amount Line of credit facility interest rate at period Gain on restructuring Conversion of convertible securities Conversion of convertible securities, shares Conversion of convertible securities, shares Undiscontinued future cash payments Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary, Sale of Stock [Line Items] Shares issued in exchange of loans outstanding Stock issued during period, shares, new issues Shares issued, price per share Share price Right offering expired date Proceeds from common stock Proceeds from warrant exercise Warrants to purchase common stock Proceeds from private placement Warrant exercise price Warrants exercise price percentage Warrant term description Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Shares, Outstanding, Beginning Balance Weighted Average Exercise Price, Outstanding Beginning Balance Weighted Average Fair Value at Grant Date, Outstanding Beginning Balance Shares, Granted Weighted Average Exercise Price, Granted Weighted Average Fair Value at Grant Date, Granted Shares, Cancelled or expired Weighted Average Exercise Price, Cancelled or expired Weighted Average Fair Value at Grant Date, Cancelled or expired Shares, Outstanding, Ending Balance Weighted Average Exercise Price, Outstanding Ending Balance Weighted Average Fair Value at Grant Date, Outstanding Ending Balance Shares, Exercisable, Ending Balance Weighted Average Exercise Price, Exercisable Ending Balance Weighted Average Fair Value at Grant Date, Exercisable, Ending Balance Risk free interest rate Dividend yield Expected term Expected volatility Shares Outstanding, Beginning Balance Weighted Average Fair Value at Grant Date, Outstanding Beginning Balance Shares Granted Weighted Average Fair Value at Grant Date, Granted Shares Vested Weighted Average Fair Value at Grant Date, Vested Shares Outstanding, Ending Balance Weighted Average Fair Value at Grant Date, Outstanding Ending Balance Number of shares available for issuance Term of plan, description Number of common stock shares remaining available Share based compensation Unvested employee stock options not yet recognized Stock option vested weighted average period Schedule Of Warrant Activity Common Stock Warrants Outstanding, Beginning Balance Weighted Average Exercise Price Outstanding Beginning Balance Common Stock Warrants, Issued Weighted Average Exercise Price, Issued Common Stock Warrants, Exercised Weighted Average Exercise Price, Exercised Common Stock Warrants, Expired Weighted Average Exercise Price, Expired Common Stock Warrants Outstanding, Ending Balance Weighted Average Exercise Price Outstanding Ending Balance Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Warrants contractual term Warrants and rights outstanding, measurement input Issuance of warrants to purchase a common stock Fair value of warrants 2022 2023 2024 2025 Total future minimum lease payments Less amount representing interest Present value of obligations under operating leases Less current portion Long-term operating lease obligations Operating lease expiration description Operating lease weighted-average remaining lease term Lease expense related to operating leases Operating lease weighted-average discount rate Reserve for one-time lump sum amount Total Federal State Total current Federal State Total deferred Total provision for income taxes Statutory Federal tax rate Valuation allowance State income taxes, net of Federal benefit Attribute reduction related to Sec. 382 Change in state income tax rate Gain on extinguishment of debt Stock compensation adjustment and other reconciling items Nondeductible executive compensation Nondeductible meals and entertainment expense Accrued liability for vacation Accrued commissions and bonuses / compensation Accrued contingencies Amortization Bad debt reserve Charitable contributions carryforward Lease liability Interest expense Inventory reserve Net operating loss carryovers Stock option compensation Other Total deferred tax assets Right of use asset Prepaids Depreciation Total deferred tax liabilities Valuation allowance Net deferred tax assets Valuation allowance deferred tax asset change in amou Operating loss carryforwards Operating loss carryforwards expiration period Indefinite carryforward available to offset taxable income percentage Discretionary match Contribution limit, description Employer contributed amount Interest Gain on extinguishment of Second A&R Credit Agreement Extinguishment of Second A&R Credit Agreement financed by line of credit Prepaid debt issuance costs Fixed assets acquired under finance lease Warrants issued in connection with the Private Placement to placement agents ASU 2016-13 cumulative effect adjustment Recognition of 2020 Warrants Partial extinguishment of Second Amended and Restated Credit Agreement (including debt issuance costs) Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table] Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items] Equity Method Investment, Ownership Percentage Rent expense Schedule of Revenues from External Customers and Long-Lived Assets [Table] Revenues from External Customers and Long-Lived Assets [Line Items] Schedule of Revenue by Major Customers, by Reporting Segments [Table] Revenue, Major Customer [Line Items] Restructuring Agreement [Member] Royal opportunities and ROS. Right offering expired date. ROS and royalty opportunities. Investor Warrant [Member] Warrants exercise price percentage. Placement Agent Agreement [Member] Private Placement Warrant [Member] 2018 Equity Incentive Plan [Member] Number of common stock shares remaining available. The weighted average grant-date fair value of options outstanding during the reporting period as calculated by applying the disclosed option pricing methodology. during the reporting period as calculated by applying the disclosed option pricing methodology. The weighted average grant-date fair value of options exercisable during the reporting period as calculated by applying the disclosed option pricing methodology. Proceeds from exercise of common stock warrants. Other Equity Transactions [TextBlock] Accounting standard two thousand and sixteen thirteen cumulative effect adjustment. Two Thousand Twenty Warrant [Member] Share issuance costs. Adjustmentst to additional paid in warrants issued in connection with the private placement. Adjustmentst to additional paid in warrants issued in connection with the private placement to placement agents. Adjustment to additional paid in capital debt extinguishment. Withholding of common stock upon vesting of restricted stock units. Share-based compensation arrangement by share-based payment award, non-options, outstanding, weighted average exercise price Share-based compensation arrangements by share-based payment award, non-options, grants in period, weighted average exercise price. Orthopedic product sales. Non cash interest. Provision for excess and obsolete inventory. Payment of taxes from with holding of common stock on vesting of restricted stock units. Exercise of warrants adjusting to additional paid in capital. Debt exchange net of exchange costs adjustments to additional paid in capital. Weighted average exercise price exercised. Share based compensation arrangements by share based payment award non options expirations in period weighted average exercise price. Withholding of common stock upon vesting of restricted stock units shares. Exercise of warrants adjusting to additional paid in capital shares. Debt exchange net of exchange costs adjustments to additional paid in capital shares Settlement Agreement [Member] Employees And Directors [Member] Schedule of income loss before provision for income taxes [TableTextBlock] Adjustment to additional paid in capital debt extinguishment shares. Adjustments to additional paid in capital warrant issued in connection with private placement agents shares. Adjustments to additional paid in capital share based compensation requisiteSservice period recognition shares. Adjustments to additional paid in capital warrant issued in connection with private placement shares. Nondeductible executive compensation. Deferred tax assets tax deferred expense amortization. Deferred tax assets tax deferred expense lease liability. Deferred tax assets tax deferred expense interest expense. Deferred tax liability right use of asset. Deferred tax liabilities depreciation. Indefinite carryforward available to offset taxable income percentage. Operating loss carryforwards expiration period. Investor Rights Agreement [PolicyTextBlock] Contribution Limit, description. Gains losses on extinguishment of line of credit. Prepaid deb issuance costs. Fixed assets acquired under finance lease. Warrants issued in connection with the Private Placement to placement agents. ASU 2016-13 cumulative effect adjustment. Recognition of warrants. Partial extinguishment of second amended and restated credit agreement including debt issuance costs. Soleholders [Member] Sublease Agreement [Member] Cardialen, Inc., [Member] Rest of World [Member] Invester rights agreement, description. Investor Rights Agreement [Member] Gain on extinguishment of Second A&R Credit Agreement. Computers and Equipment [Member] Surgical Instruments [Member] Other Assets [PolicyTextBlock] Computer Softwares [Member] Other Properties [Member] Orthobiologics [Member] Percentage of total revenue. Spinal Implant [Member] Other Revenue [Member] Debt Exchange Net Of Exchange Costs Adjustments To Additional Paid In Capita Shares. Stock issued during period value new issues. Stock issued during period shares new issues. Debt exchange net of exchange costs adjustments to additional paid in capital shares. Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer). Loans payable two. Term Loan Commitment [Member] Agent and Lenders [Member] Revolving Loan Commitment [Member] Second A&amp;R Credit Agreement [Member] Reacquisition price. Loans payable three. Capitalized debt issuance costs. Credit Agreements [Member] Second A And R Credit Agreements [Member] Percentage of debt payment. Increase in liquidity amount. Values issued prepayment fees. Shares issued prepayment fees. Undiscounted future cashn payments. Stock Issued During Period Shares Conversion Of Convertible Securities One. Concentration Credit Risk [Member] One Customer [Member] Two Customer [Member] No Customer [Member] Current and deferred income tax expense benefit. Warrant term description. Cumulative effect adjustment to retained earnings and accounts receivable. 2020 Warrants [Member] Term of plan description. Income tax reconciliation gains losses on extinguishment of debt. Gross Profit Operating Expenses [Default Label] Operating Income (Loss) Interest Expense Nonoperating Income (Expense) Income Tax Expense (Benefit) Weighted Average Number of Shares Outstanding, Basic Weighted Average Number of Shares Outstanding, Diluted Assets, Current Assets Liabilities, Current Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Shares, Outstanding Gain (Loss) on Disposition of Assets Increase (Decrease) in Accounts Receivable Increase (Decrease) in Inventories Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Accounts Payable Increase (Decrease) in Accrued Liabilities Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities PaymentOfTaxesFromWithholdingOfCommonStockOnVestingOfRestrictedStockUnits Finance Lease, Principal Payments Payments of Financing Costs Repayments of Long-term Debt Repayments of Lines of Credit Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Restricted Cash and Cash Equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Inventory Disclosure [Text Block] OtherEquityTransactionsTextBlock Inventory, Policy [Policy Text Block] Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Accounts Receivable, Allowance for Credit Loss Accounts Receivable, Allowance for Credit Loss, Writeoff Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Finite-Lived Intangible Assets, Accumulated Amortization Finite-Lived Intangible Assets, Net CapitalizedDebtIssuanceCosts LongTermDebtsCurrent Long-term Debt Long-term Line of Credit PercentageOfDebtPayment StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesOne Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations Lessee, Operating Lease, Liability, to be Paid, Year One Lessee, Operating Lease, Liability, to be Paid, Year Two Lessee, Operating Lease, Liability, to be Paid, Year Three Lessee, Operating Lease, Liability, to be Paid, Year Four Lessee, Operating Lease, Liability, to be Paid Lessee, Operating Lease, Liability, Undiscounted Excess Amount Operating Lease, Liability Current Income Tax Expense (Benefit) Deferred Federal Income Tax Expense (Benefit) Deferred State and Local Income Tax Expense (Benefit) Deferred Income Tax Expense (Benefit) IncomeTaxReconciliationDeduction Deferred Tax Assets, Gross Right of use asset Deferred Tax Liabilities, Prepaid Expenses DeferredTaxLiabilitiesDepreciation Deferred Tax Liabilities, Gross Deferred Tax Assets, Valuation Allowance Deferred Tax Assets, Net Asu201613CumulativeEffectAdjustment EX-101.PRE 18 xtnt-20211231_pre.xml XBRL PRESENTATION FILE XML 19 R1.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Cover - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2021
    Mar. 08, 2022
    Jun. 30, 2021
    Cover [Abstract]      
    Document Type 10-K    
    Amendment Flag false    
    Document Annual Report true    
    Document Transition Report false    
    Document Period End Date Dec. 31, 2021    
    Document Fiscal Period Focus FY    
    Document Fiscal Year Focus 2021    
    Current Fiscal Year End Date --12-31    
    Entity File Number 001-34951    
    Entity Registrant Name Xtant Medical Holdings, Inc.    
    Entity Central Index Key 0001453593    
    Entity Tax Identification Number 20-5313323    
    Entity Incorporation, State or Country Code DE    
    Entity Address, Address Line One 664 Cruiser Lane    
    Entity Address, City or Town Belgrade    
    Entity Address, State or Province MT    
    Entity Address, Postal Zip Code 59714    
    City Area Code (406)    
    Local Phone Number 388-0480    
    Title of 12(b) Security Common stock, par value $.000001 per share    
    Trading Symbol XTNT    
    Security Exchange Name NYSE    
    Entity Well-known Seasoned Issuer No    
    Entity Voluntary Filers No    
    Entity Current Reporting Status Yes    
    Entity Interactive Data Current Yes    
    Entity Filer Category Non-accelerated Filer    
    Entity Small Business true    
    Entity Emerging Growth Company false    
    Entity Shell Company false    
    Entity Public Float     $ 22.0
    Entity Common Stock, Shares Outstanding   87,313,701  
    Documents Incorporated By Reference None    
    ICFR Auditor Attestation Flag false    
    Auditor Firm ID 166    
    Auditor Name Plante & Moran, PLLC    
    Auditor Location Denver, Colorado    
    XML 20 R2.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Consolidated Statements of Operations - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Revenue    
    Orthopedic product sales $ 55,146 $ 53,188
    Other revenue 117 149
    Total Revenue 55,263 53,337
    Cost of Sales 22,773 18,945
    Gross Profit 32,490 34,392
    Operating Expenses    
    General and administrative 14,449 13,503
    Sales and marketing 21,025 20,983
    Research and development 870 657
    Total Operating Expenses 36,344 35,143
    Loss from Operations (3,854) (751)
    Other Expense    
    Interest expense (995) (5,976)
    Total Other Expense (995) (5,976)
    Net Loss from Operations Before Provision for Income Taxes (4,849) (6,727)
    Provision for Income Taxes Current and Deferred (296)
    Net Loss $ (4,849) $ (7,023)
    Net loss per share:    
    Basic $ (0.06) $ (0.25)
    Dilutive $ (0.06) $ (0.25)
    Shares used in the computation:    
    Basic 85,456,175 28,499,847
    Dilutive 85,456,175 28,499,847
    XML 21 R3.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Consolidated Balance Sheets - USD ($)
    $ in Thousands
    Dec. 31, 2021
    Dec. 31, 2020
    Current Assets:    
    Cash and cash-equivalents $ 18,243 $ 2,341
    Restricted cash 144
    Trade accounts receivable, net of allowance for credit losses of $552 and $653, respectively 7,154 6,880
    Inventories 17,945 21,408
    Prepaid and other current assets 844 736
    Total current assets 44,330 31,365
    Property and equipment, net 5,212 4,347
    Right of use asset, net 1,258 1,690
    Other assets 287 402
    Intangible assets, net 400 457
    Goodwill 3,205 3,205
    Total Assets 54,692 41,466
    Current Liabilities:    
    Accounts payable 2,615 2,947
    Accrued liabilities 4,349 5,462
    Current portion of lease liability 462 423
    Current portion of finance lease obligations 31 20
    Line of credit 3,620
    Current portion of long-term debt 16,797
    Total current liabilities 11,077 25,649
    Long-term Liabilities:    
    Lease liability, net 842 1,303
    Financing lease obligations, net 103
    Long-term debt, plus premium and less issuance costs 11,787
    Total Liabilities 23,809 26,952
    Commitments and Contingencies (note 11)
    Stockholders’ Equity:    
    Preferred stock, $0.000001 par value; 10,000,000 shares authorized; no shares issued and outstanding
    Common stock, $0.000001 par value; 300,000,000 shares authorized; 87,068,980 share issued and outstanding as of December 31, 2021 and 300,000,000 shares authorized; 77,573,680 shares issued and outstanding as of December 31, 2020
    Additional paid-in capital 266,068 244,850
    Accumulated deficit (235,185) (230,336)
    Total Stockholders’ Equity 30,883 14,514
    Total Liabilities & Stockholders’ Equity $ 54,692 $ 41,466
    XML 22 R4.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Consolidated Balance Sheets (Parenthetical) - USD ($)
    $ in Thousands
    Dec. 31, 2021
    Dec. 31, 2020
    Statement of Financial Position [Abstract]    
    Allowance of accounts receivable, net $ 552 $ 653
    Preferred stock, par value $ 0.000001 $ 0.000001
    Preferred stock, shares authorized 10,000,000 10,000,000
    Preferred stock, shares issued 0 0
    Preferred stock, shares outstanding 0 0
    Common stock, par value $ 0.000001 $ 0.000001
    Common stock, shares authorized 300,000,000 300,000,000
    Common stock, shares issued 87,068,980 77,573,680
    Common Stock, shares outstanding 87,068,980 77,573,680
    XML 23 R5.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Consolidated Statements of Changes in Stockholders' Equity (Deficit) - USD ($)
    $ in Thousands
    Common Stock [Member]
    Additional Paid-in Capital [Member]
    Retained Earnings [Member]
    Total
    Beginning balance, value at Dec. 31, 2019 $ 179,061 $ (223,266) $ (44,205)
    Beginning balance, shares at Dec. 31, 2019 13,161,762      
    ASU 2016-13 cumulative effect adjustment (47) (47)
    Stock-based compensation 1,084 1,084
    Common stock issued on vesting of restricted stock units
    Common stock issued on vesting of restricted stock units, shares 144,878      
    Issuance of warrant 1,862 1,862
    Debt exchange, net of exchange costs of $1,058 62,175 62,175
    Debt exchange, net of exchange costs of $1,058, shares 58,754,394      
    Issuance of common shares, net of issuance costs of $143 620 620
    Issuance of common shares, net of issuance costs of $143, shares 712,646      
    Exercise of warrants 48 48
    Exercise of warrants adjusting to additional paid in capital, shares 4,800,000      
    Net loss (7,023) (7,023)
    Ending balance, value at Dec. 31, 2020 244,850 (230,336) 14,514
    Ending balance, shares at Dec. 31, 2020 77,573,680      
    Stock-based compensation 2,209 2,209
    Common stock issued on vesting of restricted stock units
    Common stock issued on vesting of restricted stock units, shares 782,596      
    Private placement of common stock, net of issuance costs of $1,926 12,831 12,831
    Private placement of common stock, net of issuance costs of $1,926, shares 8,888,890      
    Warrants issued in connection with the private placement 5,243 5,243
    Warrants issued in connection with the private placement to placement agents 351 351
    Gain on debt extinguishment 785 785
    Withholding of common stock upon vesting of restricted stock units (201) (201)
    Withholding of common stock upon vesting of restricted stock units, shares (176,186)      
    Net loss (4,849) (4,849)
    Ending balance, value at Dec. 31, 2021 $ 266,068 $ (235,185) $ 30,883
    Ending balance, shares at Dec. 31, 2021 87,068,980      
    XML 24 R6.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Consolidated Statements of Changes in Stockholders' Equity (Deficit) (Parenthetical) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Statement of Stockholders' Equity [Abstract]    
    Debt, exchange costs   $ 1,058
    Share issuance costs   $ 143
    Payments of stock issuance costs $ 1,926  
    XML 25 R7.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Consolidated Statements of Cash Flow - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Operating activities:    
    Net loss $ (4,849) $ (7,023)
    Adjustments to reconcile net loss to net cash provided by (used in) operating activities:    
    Depreciation and amortization 1,332 2,079
    Non-cash interest 147 5,963
    Non-cash rent 9 16
    Gain on sale of fixed assets (86) (369)
    Stock-based compensation 2,209 1,084
    Provision for reserve on accounts receivable 45 307
    Provision for excess and obsolete inventory 839 485
    Changes in operating assets and liabilities:    
    Trade accounts receivable (319) 2,890
    Inventories 2,624 (5,792)
    Prepaid and other assets (67) 40
    Accounts payable (332) 101
    Accrued liabilities (1,113) (512)
    Net cash provided by (used in) operating activities 439 (731)
    Investing activities:    
    Purchases of property and equipment (2,115) (1,545)
    Proceeds from sale of fixed assets 225 241
    Net cash used in investing activities (1,890) (1,304)
    Financing activities:    
    Payment of taxes from withholding of common stock on vesting of restricted stock units (201)
    Payments on financing leases (50) (156)
    Costs associated with refinancing (136) (1,058)
    Payments on long-term debt (411) (315)
    Borrowings on line of credit 36,361
    Repayments on line of credit (36,492)
    Proceeds from issuance of common stock, net of issuance costs 18,426 620
    Proceeds from exercise of common stock warrants 48
    Net cash provided by (used in) financing activities 17,497 (861)
    Net change in cash and cash equivalents and restricted cash 16,046 (2,896)
    Cash and cash equivalents and restricted cash at beginning of year 2,341 5,237
    Cash and cash equivalents and restricted cash at end of year 18,387 2,341
    Reconciliation of cash and cash equivalents and restricted cash reported in the consolidated balance sheets    
    Cash and cash equivalents 18,243 2,341
    Restricted cash 144
    Total cash and cash equivalents and restricted cash reported in the consolidated balance sheets $ 18,387 $ 2,341
    XML 26 R8.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Business Description and Summary of Significant Accounting Policies
    		 12 Months Ended
    Dec. 31, 2021
    Organization, Consolidation and Presentation of Financial Statements [Abstract]  
    Business Description and Summary of Significant Accounting Policies

    (1) Business Description and Summary of Significant Accounting Policies

     

    Business Description

     

    The accompanying consolidated financial statements include the accounts of Xtant Medical Holdings, Inc., formerly known as Bacterin International Holdings, Inc., a Delaware corporation, and its wholly owned subsidiaries, Xtant Medical, Inc., a Delaware corporation, Bacterin International, Inc., (“Bacterin”) a Nevada corporation, and X-Spine Systems, Inc. (“X-spine”), an Ohio corporation (Xtant Medical Inc., Bacterin and X-spine are jointly referred to herein as “Xtant” or the “Company”). The terms “we,” “us” and “our” also refer to Xtant.

     

    All intercompany balances and transactions have been eliminated in consolidation.

     

    Xtant products serve the combined specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders to promote healing following spine, cranial and foot surgeries and the development, manufacturing and sale of medical devices for use in orthopedic spinal surgeries.

     

    Since March 2020, the COVID-19 pandemic has caused business closures, severe travel restrictions and implementation of social distancing measures. At the onset of the COVID-19 pandemic, hospitals and other medical facilities cancelled or deferred elective procedures, diverted resources to patients suffering from infections and limited access for non-patients, including our direct and indirect sales representatives. Because of the COVID-19 pandemic, surgeons and their patients have been, and may continue to be, required, or are choosing, to defer procedures in which our products otherwise would be used, and many facilities that specialize in the procedures in which our products otherwise would be used have experienced temporary closures or reduced operating hours. These circumstances have negatively impacted, and may continue to negatively impact, the ability of our employees, independent sales representatives and distributors to effectively market and sell our products, which has had and will likely continue to have a material adverse effect on our revenues.

     

    At December 31, 2021, the Company had cash and cash equivalents of $18.2 million, and an accumulated deficit of $235.2 million and has incurred significant losses in the current and prior periods.

     

    Management’s evaluation of going concern was conducted as part of its discussions with the Xtant Board of Directors’ review of the 2022 Annual Operating Plan. Management believes that our $18.2 million of cash and cash equivalents as of December 31, 2021, together with amounts available under our line of credit, will be sufficient to meet our anticipated cash requirements through at least March 2023.

     

    Investor Rights Agreement

     

    We are party to an Investor Rights Agreement with ROS Acquisition Offshore (“ROS”) and OrbiMed Royalty Opportunities II, LP (“Royalty Opportunities”), which are funds affiliated with OrbiMed Advisors LLC (“OrbiMed”). Under the Investor Rights Agreement, Royalty Opportunities and ROS are permitted to nominate a majority of the directors and designate the chairperson of our Board of Directors at subsequent annual meetings, as long as they maintain an ownership threshold in our Company of at least 40% of our then outstanding common stock (the “Ownership Threshold”). If Royalty Opportunities and ROS are unable to maintain the Ownership Threshold, the Investor Rights Agreement contemplates a reduction of nomination rights commensurate with our ownership interests. In addition, for so long as the Ownership Threshold is met, we must obtain the approval of a majority of our common stock held by Royalty Opportunities and ROS to proceed with the following actions: (i) issue new securities; (ii) incur over $250,000 of debt in a fiscal year; (iii) sell or transfer over $250,000 of our assets or businesses or our subsidiaries in a fiscal year; (iv) acquire over $250,000 of assets or properties in a fiscal year; (v) make capital expenditures over $125,000 individually, or $1.5 million in the aggregate during a fiscal year; (vi) approve our annual budget; (vii) hire or terminate our chief executive officer; (viii) appoint or remove the chairperson of our Board of Directors; and (ix) make, loans to, investments in, or purchase, or permit any subsidiary to purchase, any stock or other securities in another entity in excess of $250,000 in a fiscal year. As long as the Ownership Threshold is met, we may not increase the size of our Board or Directors beyond seven directors without the approval of a majority of the directors nominated by Royalty Opportunities and ROS.

     

     

    The Investor Rights Agreement grants Royalty Opportunities and ROS the right to purchase from us a pro rata amount of any new securities that we may propose to issue and sell. The Investor Rights Agreement may be terminated (a) upon the mutual written agreement of all the parties, (b) upon our written notice, ROS or Royalty Opportunities if the ownership percentage of our then outstanding common stock of ROS and Royalty Opportunities is less than 10%, or (c) upon written notice of ROS and Royalty Opportunities.

     

    Concentrations and Credit Risk

     

    The Company’s accounts receivables are from a variety of health care organizations and distributors throughout the world. No single customer accounted for more than 10% of our revenue or accounts receivable in the fiscal years 2021 or 2020. Management believes that all significant credit risks have been identified at December 31, 2021.

     

    Use of Estimates

     

    The preparation of the financial statements requires management of the Company to make a number of estimates and assumptions relating to the reported amount of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the period. Significant estimates include the carrying amount of property and equipment, goodwill, and intangible assets and liabilities; valuation allowances for trade receivables, inventory and deferred income tax assets and liabilities; current and long-term lease obligations and corresponding right-of-use asset; and estimates for the fair value of long-term debt, stock option grants and other equity awards upon which the Company determines stock-based compensation expense. Actual results could differ from those estimates.

     

    Cash, Cash Equivalents, and Restricted Cash

     

    The Company considers all highly liquid investments purchased with an original maturity date of three months or less to be cash equivalents. Cash equivalents are recorded at cost, which approximates market value. At times, the Company maintains deposits in financial institutions in excess of federally insured limits.

     

    Cash and cash equivalents classified as restricted cash on our condensed consolidated balance sheets are restricted as to withdrawal or use under the terms of certain credit agreements. The December 31, 2021 balance included lockbox deposits that are temporarily restricted due to timing at the period end. The lockbox deposits are applied against our line of credit the next business day.

     

    Trade Accounts Receivable

     

    Accounts receivable represents amounts due from customers for which revenue has been recognized. Normal terms on trade accounts receivable are net 30 days, and some customers are offered discounts for early pay. The Company performs credit evaluations when considered necessary, but generally does not require collateral to extend credit.

     

    In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments–Credit Losses: Measurement of Credit Losses on Financial Instruments to change the impairment model for most financial assets and certain other instruments. For trade and other receivables, held to maturity debt securities, loans, and other instruments, entities are required to use a new forward-looking “expected loss” model that generally will result in the earlier recognition of allowances for losses. The Company adopted the guidance on January 1, 2020 and recognized a cumulative effect adjustment of $47,000 to retained earnings and accounts receivable, net as a result of adoption. The Company has included the additional disclosures required by ASU 2016-13 in Note 2, “Receivables.”

     

     

    The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing receivables. The Company determines the allowance based on factors such as historical collection experience, customers’ current creditworthiness, customer concentration, age of accounts receivable balance, general economic conditions that may affect a customer’s ability to pay, and management judgment. In addition, we include provision for current expected credit loss based on historical collection experience adjusted for current economic conditions affecting collectability. Actual customer collections could differ from estimates. Account balances are charged to the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. Provisions to the allowance for doubtful accounts are charged to expense. The Company does not have any off-balance sheet credit exposure related to its customers.

     

    Inventories

     

    Inventories are stated at the lower of cost or net realizable value. Cost is determined using the specific identification method and includes materials, labor and overhead. The Company calculates an inventory reserve for estimated obsolescence and excess inventory based on historical usage and sales, as well as assumptions about future demand for its products. These estimates for excess and obsolete inventory are reviewed and updated on a quarterly basis. Increases in the inventory reserves result in a corresponding expense, which is recorded to cost of sales.

     

    Property and Equipment

     

    Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally three to seven years for computers and equipment and five years for surgical instruments. Leasehold improvements are depreciated over the shorter of their estimated useful life or the remaining term of the lease. Repairs and maintenance are expensed as incurred.

     

    Intangible Assets

     

    Intangible assets with estimable useful lives are amortized over their respective estimated useful lives to their estimated residual values and reviewed for impairment whenever events or circumstances indicate their carrying amount may not be recoverable. Intangible assets include trademarks and patents and include costs to acquire and protect Company patents. Intangible assets are carried at cost less accumulated amortization. The Company amortizes these assets on a straight-line basis over their estimated useful lives.

     

    Other Assets

     

    Other assets consist of the short-term and the long-term portion of prepaid expenses and security deposits.

     

    Long-Lived Asset Impairment

     

    Long-lived assets, including property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the estimated fair value of the assets.

     

    Goodwill

     

    Goodwill represents the excess of costs over fair value of assets of businesses acquired. Goodwill and intangible assets acquired in a business combination and determined to have indefinite useful lives are not amortized, instead they are tested for impairment at least annually and whenever events or circumstances indicate the carrying amount of the asset may not be recoverable. The Company conducts its impairment test on an annual basis and reviews the assumptions on a quarterly basis. We test goodwill for impairment at the reporting unit level, which is an operating segment or one level below an operating segment, referred to as a component. A component of an operating segment is a reporting unit if the component constitutes a business for which discrete financial information is available and segment management regularly reviews the operating results of that component.

     

     

    Revenue Recognition

     

    In the United States, we generate most of our revenue from independent commissioned sales agents. We consign our orthobiologics products to hospitals and consign or loan our spinal implant sets to the independent sales agents. The spinal implant sets typically contain the instruments, disposables, and spinal implants required to complete a surgery. Consigned sets are managed by the sales agent to service hospitals that are high volume users for multiple procedures. We ship replacement inventory to independent sales agents to replace the consigned inventory used in surgeries. Loaned sets are returned to the Company’s distribution center, replenished, and made available to sales agents for the next surgical procedure.

     

    For each surgical procedure, the sales agent reports use of the product by the hospital and, as soon as practicable thereafter, ensures that the hospital provides a purchase order to the Company. Upon receipt of the hospital purchase order, the Company invoices the hospital, and revenue is recognized in the proper period.

     

    Additionally, the Company sells product directly to domestic and international stocking resellers, original equipment manufacturer resellers and private label resellers. Upon receipt and acceptance of a purchase order from a stocking reseller, the Company ships product and invoices the reseller. The Company recognizes revenue when the products are shipped, and the transfer of title and risk of loss occurs. There is generally no customer acceptance or other condition that prevents the Company from recognizing revenue in accordance with the delivery terms for these sales transactions. In the normal course of business, the Company accepts returns of product that have not been implanted. Product returns are not material to the Company’s consolidated statements of operations. The Company accounts for shipping and handling activities as a fulfillment cost rather than a separate performance obligation. The Company’s policy is to record revenue net of any applicable sales, use, or excise taxes. Payment terms are generally net 30 days from invoice date and some customers are offered discounts for early pay.

     

    Disaggregation of revenue

     

    The Company operates in one reportable segment with its net revenue derived primarily from the sale of orthobiologics and spinal implant products across North America. Sales are reported net of returns. No rebates, group purchasing organization fees or other customer allowances are present, and so are not relevant to net revenue determination. The following table presents revenues from these product lines for the years ended December 31, 2021 and 2020 (dollars in thousands):

     

     Summary of Revenues from Product Lines

      

    Year Ended

    December 31, 2021

    		  

    Percentage of

    Total Revenue

    		  

    Year Ended

    December 31, 2020

    		  

    Percentage of

    Total Revenue

    		 
    Orthobiologics  $42,259    77%  $39,308    74%
    Spinal implant   12,887    23%   13,880    26%
    Other revenue   117    0%   149    0%
    Total revenue  $55,263    100%  $53,337    100%

     

    Research and Development

     

    Research and development costs, which are principally related to internal costs for the development of new products, are expensed as incurred.

     

    Net Loss Per Share

     

    Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding. Shares issued during the period and shares reacquired during the period are weighted for the portion of the period that they were outstanding. Diluted net loss per share is computed in a manner consistent with that of basic earnings per share while giving effect to all potentially dilutive shares of common stock outstanding during the period, which include the assumed exercise of stock options and warrants using the treasury stock method. Diluted net loss per share was the same as basic net loss per share for the years ended December 31, 2021 and 2020, as shares issuable upon the exercise of stock options and warrants and settlement of restricted stock units were anti-dilutive as a result of the net losses incurred for those periods. Diluted net loss per share is not reported as the effects of including 13,282,882 and 5,115,868 outstanding stock options, warrants and restricted stock units for the years ended December 31, 2021 and 2020, respectively, are anti-dilutive.

     

     

    Fair Value of Financial Instruments

     

    The carrying values of financial instruments, including trade accounts receivable, accounts payable, accrued liabilities and long-term debt, approximate their fair values based on terms and related interest rates.

     

    The Company follows a framework for measuring fair value. The framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:

     

    Level 1: Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets.

     

    Level 2: Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.

     

    Level 3: Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

     

    A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. During the years ended December 31, 2021 and 2020, there was no reclassification in financial assets or liabilities between Level 1, 2 or 3 categories.

     

    Reclassification

     

    Certain prior year amounts have been reclassified to conform with current year presentation.

     
    XML 27 R9.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Receivables
    		 12 Months Ended
    Dec. 31, 2021
    Credit Loss [Abstract]  
    Receivables

    (2) Receivables

     

    Concurrent with the adoption of ASU 2016-13, the Company’s allowance for doubtful accounts was expanded to include provision for current expected credit loss (“CECL”). The Company’s provision for CECL is determined based on historical collection experience adjusted for current economic conditions affecting collectability. Actual customer collections could differ from estimates. Account balances are charged to the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. Provisions to the allowance for credit losses are charged to expense. Activity within the allowance for credit losses was as follows for years ended December 31, 2021 and 2020 (in thousands):

     

      

    December 31,

    2021

    		  

    December 31,

    2020

    		 
             
    Balance at January 1  $653   $547 
    Provision for current expected credit losses   45    307 
    Write-offs against allowance   (146)   (201)
       $552   $653 

     

     
    XML 28 R10.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Inventories
    		 12 Months Ended
    Dec. 31, 2021
    Inventory Disclosure [Abstract]  
    Inventories

    (3) Inventories

     

    Inventories consist of the following (in thousands):

     

      

    December 31,

    2021

    		  

    December 31,

    2020

    		 
    Raw materials  $5,613   $3,757 
    Work in process   571    1,733 
    Finished goods   11,761    15,918 
     Total  $17,945   $21,408 

     
    XML 29 R11.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Property and Equipment, Net
    		 12 Months Ended
    Dec. 31, 2021
    Property, Plant and Equipment [Abstract]  
    Property and Equipment, Net

    (4) Property and Equipment, Net

     

    Property and equipment, net are as follows (in thousands):

     

      

    December 31,

    2021

    		  

    December 31,

    2020

    		 
    Equipment  $5,541   $4,807 
    Computer equipment   828    649 
    Computer software   490    570 
    Furniture and fixtures   94    133 
    Leasehold improvements   3,994    3,987 
    Other   10    10 
    Surgical instruments   11,424    11,291 
    Total cost   22,381    21,447 
    Less: accumulated depreciation   (17,169)   (17,100)
     Total  $5,212   $4,347 

     

    Depreciation expense related to property and equipment, including property under capital lease, for the years ended December 31, 2021 and 2020 was $1.3 million and $2.0 million, respectively.

     
    XML 30 R12.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Goodwill and Intangible Assets
    		 12 Months Ended
    Dec. 31, 2021
    Goodwill and Intangible Assets Disclosure [Abstract]  
    Goodwill and Intangible Assets

    (5) Goodwill and Intangible Assets

     

    The results of the Company’s annual goodwill impairment tests for the years ended December 31, 2021 and 2020 indicated that no goodwill impairment existed as of the test date.

     

    The following table sets forth information regarding intangible assets (in thousands):

     

      

    December 31,

    2021

    		  

    December 31,

    2020

    		 
    Patents  $847   $847 
    Accumulated amortization   (447)   (390)
    Net carrying value  $400   $457 

     

     

    Amortization expense was $0.1 million for both of the years ended December 31, 2021 and 2020. The following is a summary of estimated future amortization expense for intangible assets as of December 31, 2021 (in thousands):

     

          
    2022  $54 
    2023   53 
    2024   52 
    2025   52 
    2026   49 
    Thereafter   140 
    Total  $400 

     
    XML 31 R13.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Accrued Liabilities
    		 12 Months Ended
    Dec. 31, 2021
    Payables and Accruals [Abstract]  
    Accrued Liabilities

    (6) Accrued Liabilities

     

    Accrued liabilities consist of the following (in thousands):

     

      

    December 31,

    2021

    		  

    December 31,

    2020

    		 
    Wages/commissions payable  $3,184   $4,057 
    Other accrued liabilities   1,165    1,405 
    Accrued liabilities  $4,349   $5,462 

     
    XML 32 R14.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Debt
    		 12 Months Ended
    Dec. 31, 2021
    Debt Disclosure [Abstract]  
    Debt

    (7) Debt

     

    Long-term debt consists of the following (in thousands):

     

      

    December 31,

    2021

    		  

    December 31,

    2020

    		 
    Amounts due under the Term Facility  $12,000   $— 
    Accrued end-of-term payments   83    — 
    Amounts due under the Second A&R Credit Agreement   —    15,556 
    Premium related to Second Amendment   —    1,241 
    Less: unamortized debt issuance costs   (296)   — 
    Less: current maturities   —    (16,797)
    Long-term debt, less issuance costs  $11,787   $— 

     

    Current Credit Facilities

     

    On May 6, 2021 (the “Closing Date”), the Company, as guarantor, and its subsidiaries, as borrowers (collectively, the “Borrowers”), entered into a (i) Credit, Security and Guaranty Agreement (Term Loan) (the “Term Credit Agreement”) with MidCap Financial Trust, in its capacity as agent (the “Agent”), and a lender and the additional lenders from time to time party thereto and (ii) Credit, Security and Guaranty Agreement (Revolving Loan) (the “Revolving Credit Agreement,” and, together with the Term Credit Agreement, the “Credit Agreements”), with the Agent and the lenders from time to time party thereto. Contemporaneously with the execution and delivery of the Credit Agreements, that certain Second Amended and Restated Credit Agreement, dated March 29, 2019, among the Company, the Borrowers, OrbiMed Royalty Opportunities II, LP (“Royalty Opportunities”) and ROS Acquisition Offshore LP (“ROS”), as subsequently amended (the “Second A&R Credit Agreement”), which was scheduled to mature on December 31, 2021, was terminated in accordance with the terms thereof and all outstanding amounts were repaid by the Borrowers to Royalty Opportunities in its role as sole lender thereunder.

     

    The Term Credit Agreement provides for a secured term loan facility (the “Term Facility”) in an aggregate principal amount of $12.0 million (the “Term Loan Commitment”), which was funded to the Borrowers on the Closing Date, and an additional $5.0 million tranche available solely at the discretion of the Agent and the lenders, for the purposes agreed to between the Company, the Borrowers and the lenders in advance of the making of loans under such additional tranche. The Revolving Credit Agreement provides for a secured revolving credit facility (the “Revolving Facility,” and, together with the Term Facility, the “Facilities”) under which the Borrowers may borrow up to $8,000,000 (such amount, the “Revolving Loan Commitment”) at any one time, the availability of which is determined based on a borrowing base equal to percentages of certain accounts receivable and inventory of the Borrowers in accordance with a formula set forth in the Revolving Credit Agreement. As of December 31, 2021, the Company had $3.2 million available under the Revolving Credit Agreement. All borrowings under the Revolving Facility are subject to the satisfaction of customary conditions, including the absence of default, the accuracy of representations and warranties in all material respects and the delivery of an updated borrowing base certificate.

     

     

    The Facilities have a maturity date of May 1, 2026. The proceeds of the Term Facility were used to pay transaction fees in connection with the Facilities and to pay in full all outstanding indebtedness and accrued interest under the Second A&R Credit Agreement. The proceeds of the Revolving Facility were used to pay transaction fees in connection with the Facilities, to pay in full all outstanding indebtedness and accrued interest under the Second A&R Credit Agreement, and for working capital and general corporate purposes. As a result of the refinancing, we recorded a gain on extinguishment totaling $0.8 million. The gain represents the difference between the carrying value of our outstanding loans under the Second A&R Credit Agreement prior to the extinguishment and $15.6 million, the reacquisition price. Because of the related party affiliation between the Company and ROS, this debt extinguishment resulted in an increase in additional paid-in capital rather than flowing through our consolidated statements of operations as a gain on extinguishment.

     

    The loans and other obligations pursuant to the Credit Agreements bear interest at a per annum rate equal to the sum of the LIBOR rate, as such term is defined in the Credit Agreements, plus the applicable margin of 7.00% in the case of the Term Credit Agreement, and 4.50% in the case of the Revolving Credit Agreement, subject in each case to a LIBOR floor of 1.00%. The Company is also required to make a final payment in an amount equal to 3.75% of the principal amount borrowed under the Term Facility. The final payment is being accreted to interest expense over the term of the Term Facility using the effective interest method. The effective rate of the Term Facility, inclusive of amortization of debt issuance costs and accretion of the final payment, was 9.87% as of December 31, 2021. In addition to paying interest on the outstanding loans under the Facilities, the Borrowers are also required to pay an unused line fee equal to 0.50% per annum in respect of unutilized commitments under the Revolving Facility, a fee for failure to maintain a minimum balance under the Revolving Facility, a collateral management fee under the Revolving Facility equal to 0.50% of the amount outstanding under the Revolving Facility, an origination fee equal to 0.50% of the Revolving Loan Commitment and 0.50% of the Term Loan Commitment, and if activated, of any additional term loan tranche, and certain other customary fees related to the Agent’s administration of the Facilities.

     

    The Credit Agreements contain affirmative and negative covenants customarily applicable to senior secured credit facilities, including covenants that, among other things, limit or restrict the ability of the Borrowers, subject to negotiated exceptions, to incur additional indebtedness and additional liens on their assets, engage in mergers or acquisitions or dispose of assets, pay dividends or make other distributions, voluntarily prepay other indebtedness, enter into transactions with affiliated persons, make investments, and change the nature of their businesses. In addition, the Credit Agreements require the Borrowers and the Company to maintain net product revenue at or above minimum levels and to maintain a minimum adjusted EBITDA and a minimum liquidity, in each case at levels specified in the Credit Agreements.

     

    On March 7, 2022, the Credit Agreements were amended to, among other things, (i) provide for a waiver of compliance with respect to the Company’s minimum adjusted EBITDA requirement if and so long as the Company’s liquidity (as specifically defined in the Credit Agreements) is in excess of $14 million and there is not otherwise an event of default under the Credit Agreements, commencing with the next delivery of the compliance certificate required under the Credit Agreements, and (ii) re-set the date certain fees payable in connection with optional prepayments are determined to the date the amendment was executed and consequently extend such fees’ original expiration. In addition, the exit fees were increased by 25 basis points.

     

    Prior Credit Facilities

     

    Under the Second A&R Credit Agreement, we could make requests for term loans from ROS and Royalty Opportunities in their sole discretion in amounts equal to the remaining commitment for additional delayed draw loans, which was approximately $2.2 million as of the date of the Second A&R Credit Agreement, and could request additional term loans with ROS and Royalty Opportunities in their sole discretion in an aggregate amount of up to $10.0 million. No interest was scheduled to accrue on the Second A&R Credit Agreement through March 31, 2020.

     

     

    On May 6, 2020, we entered into a First Amendment to the Second A&R Credit Agreement (the “First Amendment”) with ROS and Royalty Opportunities which, among other things, provided that:

     

    ●No interest would accrue on the Loans from and after March 31, 2020 until September 30, 2020;

     

    ●Beginning October 1, 2020 through the maturity date of the Second A&R Credit Agreement, interest payable in cash would accrue on the Loans under the Second A&R Credit Agreement at a rate per annum equal to the sum of (i) 10.00% plus (ii) the higher of (x) the LIBO Rate (as such term is defined in the Second A&R Credit Agreement) and (y) 2.3125%;

     

    ●The maturity date of the Loans was December 31, 2021.

     

    On May 6, 2020, we issued warrants to purchase an aggregate of 2.4 million shares of our common stock to ROS and Royalty Opportunities, with an exercise price of $0.01 per share and an expiration date of May 6, 2030 (collectively, the “2020 Warrants”). The issuance of the 2020 Warrants was a condition to the effectiveness of the First Amendment. The First Amendment was accounted for as a debt modification whereby the recorded debt balance was discounted for the fair value of the 2020 Warrants issued and interest expense is accrued through the maturity date of the Loans at the post-amendment effective interest rate of 10.02%. These 2020 Warrants were exercised in full in November 2020.

     

    On October 1, 2020, we entered into a Second Amendment to the Second A&R Credit Agreement (the “Second Amendment”) with ROS and Royalty Opportunities, which among other things, provided for:

     

    ●Extinguishment by ROS and Royalty Opportunities of approximately $61.9 million of principal and paid-in-kind interest outstanding on the Loans in exchange for approximately 57.8 million shares of our common stock and the addition of a principal amount equal to prepayment fees associated with the Loans not paid in cash or exchanged for shares of our common stock;

     

    ●Exchange of approximately $0.9 million of prepayment fees associated with the Loans for approximately 0.9 million shares of our common stock (the “Prepayment Fee Shares”);

     

    ●Elimination of the availability of additional draw loan advances and reduction of available additional term loans to $5.0 million, the availability of which is in the sole and absolute discretion of the lender;

     

    ●Accrual of interest payable in cash for the remaining term of the Second A&R Credit Agreement at a rate per annum equal to the sum of (i) 7.00% plus (ii) the higher of (x) the LIBO Rate (as such term is defined in the Second A&R Credit Agreement) and (y) 1.00%; and

     

    ●Elimination of certain financial covenants.

     

    As a result of the debt restructuring, as previously described, we recorded a gain on restructuring totaling $15.1 million during the year ended December 31, 2020. The gain represents the excess of the carrying value of our outstanding loans under the Second A&R Credit Agreement prior to the extinguishment of such debt in the debt restructuring transaction, $80.3 million, over the sum of the fair value of the 57.8 million shares issued therewith, $48.2 million based on the closing price of our common stock on October 1, 2020, and $17.1 million of undiscounted future cash payments associated with the Second Amendment. Because of the related party affiliation between the Company and ROS and Royalty Opportunities, this debt extinguishment resulted in an increase in additional paid-in capital rather than flowing through our consolidated statements of operations as a gain on extinguishment.

     

    The carrying value of loans outstanding under the Second A&R Credit Agreement was equal to the undiscounted future cash payments associated with the Second Amendment and principal associated with loans thereunder. Cash interest payments in connection with the Second A&R Credit Agreement reduced the carrying value of associated loans; and accordingly, no interest expense related to cash interest payments was recorded for the remaining duration of the Second A&R Credit Agreement.

     

     
    XML 33 R15.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Equity
    		 12 Months Ended
    Dec. 31, 2021
    Equity [Abstract]  
    Equity

    (8) Equity

     

    Charter Amendments

     

    On August 7, 2020, the Company’s stockholders, upon recommendation of the Board, approved an amendment to the Company’s Charter to increase the number of authorized shares of common stock from 75 million to 300 million. This Charter amendment was effective upon the filing of a Certificate of Amendment with the Office of the Secretary of State of the State of Delaware on October 1, 2020.

     

    Debt Restructuring

     

    On October 1, 2020, we issued 58.7 million shares of our common stock in connection with our debt restructuring. See Note (7) Debt.

     

    Rights Offering

     

    On November 6, 2020, we distributed to holders of our common stock, at no charge, non-transferable subscription rights to purchase up to an aggregate of 14,018,690 shares of our common stock (the “Rights Offering”). In the Rights Offering, holders received 0.194539 subscription rights for each share of common stock held on the record date, November 5, 2020. Each whole subscription right entitled the holder to purchase one share of our common stock for $1.07 in cash. The Rights Offering was commenced on November 6, 2020 and expired on December 4, 2020, at which time the rights were no longer exercisable. We issued 712,646 shares of our common stock in the Rights Offering, resulting in $0.8 million in gross proceeds to us.

     

    Warrant Exercises

     

    On November 17, 2020, ROS and Royalty Opportunities exercised warrants representing an aggregate of 4.8 million shares of our common stock and in connection therewith we received aggregate proceeds of $48,000. See Note (10) Warrants.

     

    Private Placement

     

    On February 24, 2021, we issued in a private placement (the “Private Placement”) to a single healthcare-focused institutional accredited investor (the “Investor”) 8,888,890 shares of our common stock at a purchase price of $2.25 per share, and warrants to purchase up to 6,666,668 shares of our common stock (the “Investor Warrant”). We received net cash proceeds of approximately $18.4 million, after deducting fees and other estimated offering expenses, from the Private Placement.

     

    The Investor Warrant, described in more detail in Note (10), Warrants, has an exercise price of $2.25 per share, subject to customary anti-dilution, but not price protection, adjustments, is immediately exercisable and expires on the five-year anniversary of the date of issuance.

     

    In connection with the Private Placement, we entered into a placement agent agreement with a placement agent (the “Placement Agent”) pursuant to which the Placement Agent served as our exclusive placement agent in connection with the Private Placement (the “Placement Agent Agreement”). Pursuant to the Placement Agent Agreement, we agreed to pay the Placement Agent a fee equal to a certain percentage of the aggregate gross proceeds from the Private Placement. In addition to the cash fee, we agreed to issue to the Placement Agent a warrant to purchase up to 5.0% of the shares sold to the Investor in the Private Placement, or 444,444 shares of our common stock (the “Placement Agent Warrant”). The Placement Agent Warrant, described in more detail in Note 10, “Warrants”, has an exercise price of $2.8125 per share, subject to customary anti-dilution, but not price protection, adjustments, is immediately exercisable and expires on the five-year anniversary of the date of issuance.

     

     
    XML 34 R16.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Stock-Based Compensation
    		 12 Months Ended
    Dec. 31, 2021
    Share-based Payment Arrangement [Abstract]  
    Stock-Based Compensation

    (9) Stock-Based Compensation

     

    Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan

     

    On August 1, 2018, our stockholders approved the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan at the 2018 annual meeting of stockholders of Xtant and on October 30, 2019 at our 2019 annual meeting of stockholders, our stockholders approved an amendment to increase the number of shares of common stock available thereunder by 1,500,000 shares. On October 27, 2020, at our 2020 annual meeting of stockholders, our stockholders approved an amendment to further increase the number of shares of our common stock available for issuance under the 2018 Plan by an additional 5,550,308 shares (as amended, the “2018 Plan”). The 2018 Plan became effective immediately upon initial approval of the plan by our stockholders on August 1, 2018 and will expire on July 31, 2028, unless terminated earlier. The 2018 Plan replaced the Amended and Restated Xtant Medical Equity Incentive Plan (the “Prior Plan”) with respect to future grants of equity awards, although the Prior Plan continues to govern equity awards granted under the Prior Plan. The 2018 Plan permits the Board, or a committee thereof, to grant to eligible employees, non-employee directors, and consultants of the Company non-statutory and incentive stock options, stock appreciation rights, restricted stock awards, restricted stock units, deferred stock units, performance awards, non-employee director awards, and other stock-based awards. The Board may select 2018 Plan participants and determine the nature and amount of awards to be granted. Subject to adjustment as provided in the 2018 Plan, the number of shares of our common stock available for issuance under the 2018 Plan is 8,358,055 shares, of which 1,246,080 shares remained available for grant as of December 31, 2021. Under the 2018 Plan, shares of our common stock related to awards granted under the plan that terminate by expiration, forfeiture, cancellation, or otherwise without the issuance of the shares become available again for grant under the plan.

     

    Stock options granted under the 2018 Plan may be either incentive stock options to employees, as defined in Section 422A of the Internal Revenue Code of 1986, or non-qualified stock options. The exercise price of all stock options granted under the 2018 Plan must be at least equal to the fair market value of the shares of common stock on the date of the grant. The 2018 Plan is administered by the Board. Stock options granted under the 2018 Plan are generally not transferable, vest in installments over the requisite service period, and are exercisable during the stated contractual term of the option only by the optionee.

     

    Stock option activity, including options granted under the 2018 Plan and the Prior Plan was as follows:

     

       2021   2020 
               Weighted           Weighted 
           Weighted   Average
    Fair    		       Weighted   Average
    Fair    		 
           Average
    Exercise    		   Value at
    Grant    		       Average
    Exercise    		   Value at
    Grant    		 
       Shares   Price   Date   Shares   Price   Date 
    Outstanding at January 1   2,190,892   $2.25   $1.65    602,966   $6.07   $3.99 
    Granted   1,012,083    1.27    1.07    1,708,743    1.24    1.01 
    Cancelled or expired   (1,309)   345.82    170.89    (120,817)   6.95    4.31 
    Outstanding at December 31   3,201,666   $1.80   $1.40    2,190,892   $2.25   $1.65 
    Exercisable at December 31   649,042   $3.36   $2.37    122,739   $14.74   $8.95 

     

    The estimated fair value of stock options granted is determined using the Black-Scholes-Merton method applied to individual grants. Key assumptions used to estimate the fair value of stock awards are as follows:

     

       Year Ended 
       December 31, 
       2021   2020 
    Risk free interest rate   0.97%   0.54%
    Dividend yield   0%   0%
    Expected term   6.3 years    6.3 years 
    Expected volatility   113%   105%

     

     

    Restricted stock unit activity for awards granted under the 2018 Plan was as follows:

     

       2021   2020 
       Shares  

    Weighted

    Average Fair

    Value at Grant

    Date Per

    Share

    		   Shares  

    Weighted

    Average Fair

    Value at Grant

    Date Per Share

    		 
    Outstanding at January 1   2,503,698   $1.54    499,914   $2.87 
    Granted   1,249,002   $1.27    2,148,662   $1.29 
    Vested   (782,596)  $1.72    (144,878)  $2.52 
    Outstanding at December 31   2,970,104   $1.39    2,503,698   $1.54 

     

    Total stock-based compensation expense recognized for employees and directors was $2.2 million and $1.1 million for the years ended December 31, 2021 and 2020, respectively, and was recognized as general and administrative expense. As of December 31, 2021, total compensation expense related to unvested employee stock options not yet recognized was $2.7 million, which is expected to be allocated to expenses over a weighted-average period of 3.1 years. Total compensation expense related to unvested restricted stock units not yet recognized was $3.4 million as of December 31, 2021, which is expected to be allocated to expenses over a weighted-average period of 2.8 years.

     
    XML 35 R17.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Warrants
    		 12 Months Ended
    Dec. 31, 2021
    Warrants  
    Warrants

    (10) Warrants

     

    2021 Warrants

     

    As noted in Note 8, “Equity,” on February 22, 2021, the Company issued the Investor Warrants and Placement Agent Warrants. The Investor and Placement Agent Warrants meet all the requirements to be classified as equity awards in accordance with Accounting Standards Codification (“ASC”) No. 815-40. The number of shares of Company common stock issuable upon exercise of the Investor Warrants and Placement Agent Warrants is subject to standard and customary anti-dilution provisions for stock splits, stock dividends, or similar transactions. In addition, the Investor Warrants include a buy-out right whereby the holders of such warrants may put the warrants back to the Company or its successor in the event of a purchase, tender or exchange offer accepted by 50% or more of the Company’s holders of common stock and not approved by the Company’s board of directors. The buy-out amount is equal to the Black-Scholes value of the warrants on the date the triggering transaction is consummated based on certain inputs as defined in the Investor Warrant agreement. The consideration to be paid if the buy-out provision is triggered shall be in the same type or form of consideration that is being offered and paid to the holders of Company common stock in connection with the triggering transaction.

     

    While the Investor Warrants are classified as a component of equity, we were required to allocate the proceeds of the Private Placement between the shares of common stock and Investor Warrants issued based on their relative fair values. We utilized a lattice valuation model to determine the fair value of the Investor Warrants. The fair value of the Placement Agent Warrants issued in connection with the Private Placement was determined using a Black Scholes model. Significant assumptions in both models included contractual term (5 years) and the estimated volatility factor based on a weighted average of comparable published betas of peer companies (61%).

     

    2020 Warrants

     

    As noted in Note 7, “Debt,” on May 6, 2020, we issued warrants to purchase an aggregate 2.4 million shares of our common stock to ROS and Royalty Opportunities with an exercise price of $0.01 per share and an expiration date of May 6, 2030. The issuance of the 2020 Warrants was a condition to the effectiveness of the First Amendment. The fair value of the 2020 Warrants upon issuance was determined to be $1.9 million. The 2020 Warrants met all the requirements to be classified as equity awards in accordance with ASC No. 815-40. The number of shares of our common stock issuable upon exercise of the 2020 Warrants was subject to standard and customary anti-dilution provisions for stock splits, stock dividends, or similar transactions. The 2020 Warrants were exercised in full on November 17, 2020.

     

     

    The following table summarizes our warrant activities for the years ended December 31, 2021 and 2020:

     

           Weighted 
       Common   Average 
       Stock   Exercise 
       Warrants   Price 
    Outstanding as of January 1, 2020   2,908,874   $4.16 
    Issued   2,400,000    0.01 
    Exercised   (4,800,000)   0.01 
    Expired   (87,596)   85.92 
    Outstanding as of December 31, 2020   421,278   $10.80 
    Issued   7,111,112    2.29 
    Expired   (421,278)   10.80 
    Outstanding at December 31, 2021   7,111,112   $2.29 

     
    XML 36 R18.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Commitments and Contingencies
    		 12 Months Ended
    Dec. 31, 2021
    Commitments and Contingencies Disclosure [Abstract]  
    Commitments and Contingencies

    (11) Commitments and Contingencies

     

    Operating Leases

     

    We currently lease four office facilities. These leases are under non-cancelable operating lease agreements with expiration dates between 2023 and 2025. We have the option to extend certain leases to five or ten-year term(s) and we have the right of first refusal on any sale.

     

    The Company records lease liabilities within current liabilities or long-term liabilities based upon the length of time associated with the lease payments. The Company records its long-term operating leases as right-of-use assets. Upon initial adoption, using the modified retrospective transition approach, no leases with terms less than 12 months have been capitalized to the consolidated balance sheet consistent with ASC 842. Instead, these leases are recognized in the consolidated statement of operations on a straight-line expense throughout the lives of the leases. No Company leases contain common area maintenance or security agreements.

     

    We have made certain assumptions and judgments when applying ASC 842, the most significant of which is that we elected the package of practical expedients available for transition, which allow us to not reassess whether expired or existing contracts contain leases under the new definition of a lease, lease classification for expired or existing leases, and whether previously capitalized initial direct costs would qualify for capitalization under ASC 842. Additionally, we did not elect to use hindsight when considering judgments and estimates such as assessments of lessee options to extend or terminate a lease or purchase the underlying asset.

     

    As of December 31, 2021, the weighted-average remaining lease term was 3 years. Lease expense related to operating leases was $0.6 million for both of the years ended December 31, 2021 and 2020. The Company’s lease agreements do not provide a readily determinable implicit rate nor is it available to the Company from its lessors. Instead, as of December 31, 2021, the Company estimates the weighted-average discount rate for its operating leases to be 5.2% to present value based on the incremental borrowing rate.

     

     

    Future minimum payments as of December 31, 2021 under these long-term operating leases are as follows (in thousands):

     

          
    2022  $521 
    2023   489 
    2024   224 
    2025   180 
    Total future minimum lease payments   1,414 
    Less amount representing interest   (110)
    Present value of obligations under operating leases   1,304 
    Less current portion   (462)
    Long-term operating lease obligations  $842 

     

    Litigation

     

    In November 2020, we received a letter from a third party’s legal counsel alleging that some of our hardware products allegedly infringe an expired patent and offering to discuss settlement terms. Without admitting any liability, in July 2021, we entered into a confidential settlement agreement and release that included, among other things, a full release of all asserted patent claims from the third party and otherwise settled the dispute in exchange for a one-time lump sum payment of $550,000, which was recorded as a special charge in general and administrative expense.

     

    In addition, we may be subject to potential liabilities under government regulations and various claims and legal actions that are pending but we believe are immaterial at this time or may be asserted in the future from time to time.

     

    These matters arise in the ordinary course and conduct of our business and may include, for example, commercial, product liability, intellectual property, and employment matters. We intend to continue to defend the Company vigorously in such matters and when warranted, take legal action against others. Furthermore, we regularly assess contingencies to determine the degree of probability and range of possible loss for potential accrual in our financial statements. An estimated loss contingency is accrued in our financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Based on our assessment, we have adequately accrued an amount for contingent liabilities currently in existence. We do not accrue amounts for liabilities that we do not believe are probable or that we consider immaterial to our overall financial position. Litigation is inherently unpredictable, and unfavorable resolutions could occur. As a result, assessing contingencies is highly subjective and requires judgment about future events. The amount of ultimate loss may exceed the Company’s current accruals, and it is possible that its cash flows or results of operations could be materially affected in any particular period by the unfavorable resolution of one or more of these contingencies.

     

    Indemnifications

     

    Our arrangements generally include limited warranties and certain provisions for indemnifying customers against liabilities if our products or services infringe a third-party’s intellectual property rights. To date, we have not incurred any material costs as a result of such warranties or indemnification provisions and have not accrued any liabilities related to such obligations in the accompanying consolidated financial statements.

     

    We have also agreed to indemnify our directors and executive officers for costs associated with any fees, expenses, judgments, fines and settlement amounts incurred by any of these persons in any action or proceeding to which any of those persons is, or is threatened to be, made a party by reason of the person’s service as a director or officer, including any action by us, arising out of that person’s services as our director or officer or that person’s services provided to any other company or enterprise at our request.

     

     
    XML 37 R19.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Income Taxes
    		 12 Months Ended
    Dec. 31, 2021
    Income Tax Disclosure [Abstract]  
    Income Taxes

    (12) Income Taxes

     

    The Company’s provision for income taxes differs from applying the statutory U.S. Federal income tax rate to income before taxes. The primary difference results from providing for state income taxes and from deducting certain expenses for financial statement purposes but not for federal income tax purposes.

     

    The components of income (loss) before provision for income taxes consist of the following (in thousands):

     

             
       Year Ended December 31, 
       2021   2020 
    United States  $(4,849)  $(6,727)
               
    Total  $(4,849)  $(6,727)

     

    The components of the income tax provision are as follows (in thousands):

     

             
       Year Ended December 31, 
       2021   2020 
    Current:          
    Federal  $(51)  $51 
    State   51    245 
    Total current   —    296 
               
    Deferred:          
    Federal   —    — 
    State   —    — 
    Total deferred   —    — 
               
    Total provision for income taxes  $—   $296 

     

    The reconciliation of income tax attributable to operations computed at the U.S. Federal statutory income tax rate of 21% to income tax expense is as follows (in thousands):

     

             
       Year Ended December 31, 
       2021   2020 
    Statutory Federal tax rate  $(1,018)  $(1,413)
    Valuation allowance   315    (10,968)
    State income taxes, net of Federal benefit   (110)   619 
    Attribute reduction related to Sec. 382   —    8,607 
    Change in state income tax rate   (33)   (61)
    Gain on extinguishment of debt   165    3,488 
    Stock compensation adjustment and other reconciling items   557    14 
    Nondeductible executive compensation   124    — 
    Nondeductible meals and entertainment expense   —    10 
               
    Total provision for income taxes  $—   $296 

     

     

    Deferred tax components are as follows (in thousands):

     

             
       At December 31, 
       2021   2020 
    Deferred tax assets:          
    Accrued liability for vacation  $130   $123 
    Accrued commissions and bonuses / compensation   284    565 
    Accrued contingencies   52    42 
    Amortization   27    32 
    Bad debt reserve   148    174 
    Charitable contributions carryforward   15    — 
    Lease liability   350    459 
    Interest expense   1,968    2,342 
    Inventory reserve   2,777    2,975 
    Net operating loss carryovers   13,164    12,114 
    Stock option compensation   783    653 
    Other   113    109 
    Total deferred tax assets   19,811    19,588 
               
    Deferred tax liabilities:          
    Right of use asset   (338)   (450)
    Prepaids   (83)   (73)
    Depreciation   (111)   (100)
    Total deferred tax liabilities   (532)   (623)
               
    Valuation allowance   (19,279)   (18,965)
               
    Net deferred tax assets  $—   $— 

     

    The ultimate realization of deferred tax assets is dependent upon the existence, or generation, of taxable income in the periods when those temporary differences and net operating loss carryovers are deductible. Management considers the scheduled reversal of deferred tax liabilities, taxes paid in carryover years, projected future taxable income, available tax planning strategies, and other factors in making this assessment. Based on available evidence, management does not believe it is more likely than not that all of the deferred tax assets will be realized. Accordingly, the Company has established a valuation allowance equal to the net deferred tax assets. The valuation allowance increased by $0.3 million in 2021 and decreased by $11.0 million in 2020.

     

    At December 31, 2021 and 2020, the Company had total domestic Federal and state net operating loss carryovers of approximately $101.8 million and $97.0 million, respectively. Federal net operating losses generated prior to 2018 and State net operating loss carryovers expire at various dates between 2024 and 2040. Federal net operating losses generated after 2017 have an indefinite carryforward and are only available to offset 80% of taxable income beginning in 2021.

     

    On March 27, 2020 the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) was signed into law. The CARES Act provided for an increased interest deduction for tax years 2019 and 2020, as well as the deferral of the employer portion of social security taxes.

     

    The Company has completed a study to assess whether an ownership change, as defined by Section 382 of the Internal Revenue Code, had occurred from the Company’s formation through December 31, 2019. Based upon this study, the Company determined that an ownership change occurred during 2018. Accordingly, the Company reduced its deferred tax assets related to the federal net operating loss carryforwards that are anticipated to expire unused as a result of these ownership changes. These tax attributes were excluded from deferred tax assets with a corresponding reduction of the valuation allowance with no net effect on income tax expense or the effective tax rate. Future ownership changes may further limit the Company’s ability to utilize its remaining tax attributes.

     

    The 2018 through 2020 tax years remain open to examination by the Internal Revenue Service and various other state tax agencies. These taxing authorities have the authority to examine those tax years until the applicable statute of limitations expire.

     

    The Company did not recognize any material interest or penalties related to income taxes for the years ended December 31, 2021 and 2020.

     

     
    XML 38 R20.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Employee Benefit Plans
    		 12 Months Ended
    Dec. 31, 2021
    Retirement Benefits [Abstract]  
    Employee Benefit Plans

    (13) Employee Benefit Plans

     

    We have a 401(k) plan for our employees. The 401(k) plan is a defined contribution plan covering substantially all of our employees. Employees are eligible to participate in the plan on the first day of any month after starting employment. Employees are allowed to contribute a percentage of their wages to the 401(k) plan, subject to statutorily prescribed limits and are subject to a discretionary employer match of 100% of their wage deferrals not in excess of 4% of their wages. The 401(k) plan matching contributions by the Company were temporarily suspended at the onset of the COVID-19 pandemic, but future plan matching contributions were subsequently restored effective July 1, 2020. The Company contributed $0.3 million and $0.2 million as part of the employer match program for the years ended December 31, 2021 and 2020, respectively.

     
    XML 39 R21.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Supplemental Disclosure of Cash Flow Information
    		 12 Months Ended
    Dec. 31, 2021
    Supplemental Cash Flow Elements [Abstract]  
    Supplemental Disclosure of Cash Flow Information

    (14) Supplemental Disclosure of Cash Flow Information

     

    Supplemental cash flow information is as follows (in thousands):

     

             
       Year Ended 
       December 31, 
       2021   2020 
    Cash paid during the period for:          
    Interest  $846   $13 
    Non-cash activities:          
    Gain on extinguishment of Second A&R Credit Agreement  $785   $— 
    Extinguishment of Second A&R Credit Agreement financed by line of credit  $3,755   $— 
    Prepaid debt issuance costs  $75   $— 
    Fixed assets acquired under finance lease  $163   $— 
    Warrants issued in connection with the Private Placement to placement agents  $351   $— 
    ASU 2016-13 cumulative effect adjustment  $—   $47 
    Recognition of 2020 Warrants  $—   $1,862 
    Partial extinguishment of Second Amended and Restated Credit Agreement (including debt issuance costs)  $—   $63,233 

     
    XML 40 R22.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Related Party Transactions
    		 12 Months Ended
    Dec. 31, 2021
    Related Party Transactions [Abstract]  
    Related Party Transactions

    (15) Related Party Transactions

     

    Royalty Opportunities, which owns approximately 20% of the Company’s outstanding common stock, was the sole holder of our outstanding long-term debt and a party to the Second A&R Credit Agreement, which was terminated in connection with our debt refinancing described under Note 8, “Debt”. In addition, as described in more detail under Note 1, “Business Description and Summary of Significant Accounting Policies,” we are party to an Investor Rights Agreement and Registration Rights Agreement with Royalty Opportunities and ROS. Transactions between the Company and Royalty Opportunities and ROS are conducted under the provisions of the Second A&R Credit Agreement, the Prior Credit Agreement, the Investor Rights Agreement, and the Registration Rights Agreement, as noted above.

     

    The Company was party to a Sublease Agreement wherein the Company leased from Cardialen, Inc., a portion of Cardialen’s office space on a month-to-month. The rent was approximately $1,000 per month. The agreement was terminated effective September 30, 2021. Because Jeffrey Peters is both a member of our Board of Directors and the Chief Executive Officer, President, and a director of Cardialen, this transaction qualified as a related party transaction.

     

    All related party transactions are reviewed and approved by the Audit Committee or the disinterested members of the full Board.

     
    XML 41 R23.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Segment and Geographic Information
    		 12 Months Ended
    Dec. 31, 2021
    Segment Reporting [Abstract]  
    Segment and Geographic Information

    (16) Segment and Geographic Information

     

    The Company’s management reviews our financial results and manages the business on an aggregate basis. Therefore, financial results are reported in a single operating segment: the development, manufacture and marketing of orthopedic medical products and devices.

     

    The Company attributes revenues to geographic areas based on the location of the customer. Approximately 99% and 98% of revenue was in the United States for the years ended December 31, 2021 and 2020, respectively. Total revenue by major geographic area is as follows (in thousands):

     

       Year Ended
    December 31,    		 
       2021   2020 
    United States  $54,570   $52,147 
    Rest of World   693    1,190 
    Total  $55,263   $53,337 

     
    XML 42 R24.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Business Description and Summary of Significant Accounting Policies (Policies)
    		 12 Months Ended
    Dec. 31, 2021
    Organization, Consolidation and Presentation of Financial Statements [Abstract]  
    Business Description

    Business Description

     

    The accompanying consolidated financial statements include the accounts of Xtant Medical Holdings, Inc., formerly known as Bacterin International Holdings, Inc., a Delaware corporation, and its wholly owned subsidiaries, Xtant Medical, Inc., a Delaware corporation, Bacterin International, Inc., (“Bacterin”) a Nevada corporation, and X-Spine Systems, Inc. (“X-spine”), an Ohio corporation (Xtant Medical Inc., Bacterin and X-spine are jointly referred to herein as “Xtant” or the “Company”). The terms “we,” “us” and “our” also refer to Xtant.

     

    All intercompany balances and transactions have been eliminated in consolidation.

     

    Xtant products serve the combined specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders to promote healing following spine, cranial and foot surgeries and the development, manufacturing and sale of medical devices for use in orthopedic spinal surgeries.

     

    Since March 2020, the COVID-19 pandemic has caused business closures, severe travel restrictions and implementation of social distancing measures. At the onset of the COVID-19 pandemic, hospitals and other medical facilities cancelled or deferred elective procedures, diverted resources to patients suffering from infections and limited access for non-patients, including our direct and indirect sales representatives. Because of the COVID-19 pandemic, surgeons and their patients have been, and may continue to be, required, or are choosing, to defer procedures in which our products otherwise would be used, and many facilities that specialize in the procedures in which our products otherwise would be used have experienced temporary closures or reduced operating hours. These circumstances have negatively impacted, and may continue to negatively impact, the ability of our employees, independent sales representatives and distributors to effectively market and sell our products, which has had and will likely continue to have a material adverse effect on our revenues.

     

    At December 31, 2021, the Company had cash and cash equivalents of $18.2 million, and an accumulated deficit of $235.2 million and has incurred significant losses in the current and prior periods.

     

    Management’s evaluation of going concern was conducted as part of its discussions with the Xtant Board of Directors’ review of the 2022 Annual Operating Plan. Management believes that our $18.2 million of cash and cash equivalents as of December 31, 2021, together with amounts available under our line of credit, will be sufficient to meet our anticipated cash requirements through at least March 2023.

     
    Investor Rights Agreement

    Investor Rights Agreement

     

    We are party to an Investor Rights Agreement with ROS Acquisition Offshore (“ROS”) and OrbiMed Royalty Opportunities II, LP (“Royalty Opportunities”), which are funds affiliated with OrbiMed Advisors LLC (“OrbiMed”). Under the Investor Rights Agreement, Royalty Opportunities and ROS are permitted to nominate a majority of the directors and designate the chairperson of our Board of Directors at subsequent annual meetings, as long as they maintain an ownership threshold in our Company of at least 40% of our then outstanding common stock (the “Ownership Threshold”). If Royalty Opportunities and ROS are unable to maintain the Ownership Threshold, the Investor Rights Agreement contemplates a reduction of nomination rights commensurate with our ownership interests. In addition, for so long as the Ownership Threshold is met, we must obtain the approval of a majority of our common stock held by Royalty Opportunities and ROS to proceed with the following actions: (i) issue new securities; (ii) incur over $250,000 of debt in a fiscal year; (iii) sell or transfer over $250,000 of our assets or businesses or our subsidiaries in a fiscal year; (iv) acquire over $250,000 of assets or properties in a fiscal year; (v) make capital expenditures over $125,000 individually, or $1.5 million in the aggregate during a fiscal year; (vi) approve our annual budget; (vii) hire or terminate our chief executive officer; (viii) appoint or remove the chairperson of our Board of Directors; and (ix) make, loans to, investments in, or purchase, or permit any subsidiary to purchase, any stock or other securities in another entity in excess of $250,000 in a fiscal year. As long as the Ownership Threshold is met, we may not increase the size of our Board or Directors beyond seven directors without the approval of a majority of the directors nominated by Royalty Opportunities and ROS.

     

     

    The Investor Rights Agreement grants Royalty Opportunities and ROS the right to purchase from us a pro rata amount of any new securities that we may propose to issue and sell. The Investor Rights Agreement may be terminated (a) upon the mutual written agreement of all the parties, (b) upon our written notice, ROS or Royalty Opportunities if the ownership percentage of our then outstanding common stock of ROS and Royalty Opportunities is less than 10%, or (c) upon written notice of ROS and Royalty Opportunities.

     
    Concentrations and Credit Risk

    Concentrations and Credit Risk

     

    The Company’s accounts receivables are from a variety of health care organizations and distributors throughout the world. No single customer accounted for more than 10% of our revenue or accounts receivable in the fiscal years 2021 or 2020. Management believes that all significant credit risks have been identified at December 31, 2021.

     
    Use of Estimates

    Use of Estimates

     

    The preparation of the financial statements requires management of the Company to make a number of estimates and assumptions relating to the reported amount of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the period. Significant estimates include the carrying amount of property and equipment, goodwill, and intangible assets and liabilities; valuation allowances for trade receivables, inventory and deferred income tax assets and liabilities; current and long-term lease obligations and corresponding right-of-use asset; and estimates for the fair value of long-term debt, stock option grants and other equity awards upon which the Company determines stock-based compensation expense. Actual results could differ from those estimates.

     
    Cash, Cash Equivalents, and Restricted Cash

    Cash, Cash Equivalents, and Restricted Cash

     

    The Company considers all highly liquid investments purchased with an original maturity date of three months or less to be cash equivalents. Cash equivalents are recorded at cost, which approximates market value. At times, the Company maintains deposits in financial institutions in excess of federally insured limits.

     

    Cash and cash equivalents classified as restricted cash on our condensed consolidated balance sheets are restricted as to withdrawal or use under the terms of certain credit agreements. The December 31, 2021 balance included lockbox deposits that are temporarily restricted due to timing at the period end. The lockbox deposits are applied against our line of credit the next business day.

     
    Trade Accounts Receivable

    Trade Accounts Receivable

     

    Accounts receivable represents amounts due from customers for which revenue has been recognized. Normal terms on trade accounts receivable are net 30 days, and some customers are offered discounts for early pay. The Company performs credit evaluations when considered necessary, but generally does not require collateral to extend credit.

     

    In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments–Credit Losses: Measurement of Credit Losses on Financial Instruments to change the impairment model for most financial assets and certain other instruments. For trade and other receivables, held to maturity debt securities, loans, and other instruments, entities are required to use a new forward-looking “expected loss” model that generally will result in the earlier recognition of allowances for losses. The Company adopted the guidance on January 1, 2020 and recognized a cumulative effect adjustment of $47,000 to retained earnings and accounts receivable, net as a result of adoption. The Company has included the additional disclosures required by ASU 2016-13 in Note 2, “Receivables.”

     

     

    The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing receivables. The Company determines the allowance based on factors such as historical collection experience, customers’ current creditworthiness, customer concentration, age of accounts receivable balance, general economic conditions that may affect a customer’s ability to pay, and management judgment. In addition, we include provision for current expected credit loss based on historical collection experience adjusted for current economic conditions affecting collectability. Actual customer collections could differ from estimates. Account balances are charged to the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. Provisions to the allowance for doubtful accounts are charged to expense. The Company does not have any off-balance sheet credit exposure related to its customers.

     
    Inventories

    Inventories

     

    Inventories are stated at the lower of cost or net realizable value. Cost is determined using the specific identification method and includes materials, labor and overhead. The Company calculates an inventory reserve for estimated obsolescence and excess inventory based on historical usage and sales, as well as assumptions about future demand for its products. These estimates for excess and obsolete inventory are reviewed and updated on a quarterly basis. Increases in the inventory reserves result in a corresponding expense, which is recorded to cost of sales.

     
    Property and Equipment

    Property and Equipment

     

    Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally three to seven years for computers and equipment and five years for surgical instruments. Leasehold improvements are depreciated over the shorter of their estimated useful life or the remaining term of the lease. Repairs and maintenance are expensed as incurred.

     
    Intangible Assets

    Intangible Assets

     

    Intangible assets with estimable useful lives are amortized over their respective estimated useful lives to their estimated residual values and reviewed for impairment whenever events or circumstances indicate their carrying amount may not be recoverable. Intangible assets include trademarks and patents and include costs to acquire and protect Company patents. Intangible assets are carried at cost less accumulated amortization. The Company amortizes these assets on a straight-line basis over their estimated useful lives.

     
    Other Assets

    Other Assets

     

    Other assets consist of the short-term and the long-term portion of prepaid expenses and security deposits.

     
    Long-Lived Asset Impairment

    Long-Lived Asset Impairment

     

    Long-lived assets, including property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the estimated fair value of the assets.

     
    Goodwill

    Goodwill

     

    Goodwill represents the excess of costs over fair value of assets of businesses acquired. Goodwill and intangible assets acquired in a business combination and determined to have indefinite useful lives are not amortized, instead they are tested for impairment at least annually and whenever events or circumstances indicate the carrying amount of the asset may not be recoverable. The Company conducts its impairment test on an annual basis and reviews the assumptions on a quarterly basis. We test goodwill for impairment at the reporting unit level, which is an operating segment or one level below an operating segment, referred to as a component. A component of an operating segment is a reporting unit if the component constitutes a business for which discrete financial information is available and segment management regularly reviews the operating results of that component.

     

     
    Revenue Recognition

    Revenue Recognition

     

    In the United States, we generate most of our revenue from independent commissioned sales agents. We consign our orthobiologics products to hospitals and consign or loan our spinal implant sets to the independent sales agents. The spinal implant sets typically contain the instruments, disposables, and spinal implants required to complete a surgery. Consigned sets are managed by the sales agent to service hospitals that are high volume users for multiple procedures. We ship replacement inventory to independent sales agents to replace the consigned inventory used in surgeries. Loaned sets are returned to the Company’s distribution center, replenished, and made available to sales agents for the next surgical procedure.

     

    For each surgical procedure, the sales agent reports use of the product by the hospital and, as soon as practicable thereafter, ensures that the hospital provides a purchase order to the Company. Upon receipt of the hospital purchase order, the Company invoices the hospital, and revenue is recognized in the proper period.

     

    Additionally, the Company sells product directly to domestic and international stocking resellers, original equipment manufacturer resellers and private label resellers. Upon receipt and acceptance of a purchase order from a stocking reseller, the Company ships product and invoices the reseller. The Company recognizes revenue when the products are shipped, and the transfer of title and risk of loss occurs. There is generally no customer acceptance or other condition that prevents the Company from recognizing revenue in accordance with the delivery terms for these sales transactions. In the normal course of business, the Company accepts returns of product that have not been implanted. Product returns are not material to the Company’s consolidated statements of operations. The Company accounts for shipping and handling activities as a fulfillment cost rather than a separate performance obligation. The Company’s policy is to record revenue net of any applicable sales, use, or excise taxes. Payment terms are generally net 30 days from invoice date and some customers are offered discounts for early pay.

     

    Disaggregation of revenue

     

    The Company operates in one reportable segment with its net revenue derived primarily from the sale of orthobiologics and spinal implant products across North America. Sales are reported net of returns. No rebates, group purchasing organization fees or other customer allowances are present, and so are not relevant to net revenue determination. The following table presents revenues from these product lines for the years ended December 31, 2021 and 2020 (dollars in thousands):

     

     Summary of Revenues from Product Lines

      

    Year Ended

    December 31, 2021

    		  

    Percentage of

    Total Revenue

    		  

    Year Ended

    December 31, 2020

    		  

    Percentage of

    Total Revenue

    		 
    Orthobiologics  $42,259    77%  $39,308    74%
    Spinal implant   12,887    23%   13,880    26%
    Other revenue   117    0%   149    0%
    Total revenue  $55,263    100%  $53,337    100%

     
    Research and Development

    Research and Development

     

    Research and development costs, which are principally related to internal costs for the development of new products, are expensed as incurred.

     
    Net Loss Per Share

    Net Loss Per Share

     

    Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding. Shares issued during the period and shares reacquired during the period are weighted for the portion of the period that they were outstanding. Diluted net loss per share is computed in a manner consistent with that of basic earnings per share while giving effect to all potentially dilutive shares of common stock outstanding during the period, which include the assumed exercise of stock options and warrants using the treasury stock method. Diluted net loss per share was the same as basic net loss per share for the years ended December 31, 2021 and 2020, as shares issuable upon the exercise of stock options and warrants and settlement of restricted stock units were anti-dilutive as a result of the net losses incurred for those periods. Diluted net loss per share is not reported as the effects of including 13,282,882 and 5,115,868 outstanding stock options, warrants and restricted stock units for the years ended December 31, 2021 and 2020, respectively, are anti-dilutive.

     

     
    Fair Value of Financial Instruments

    Fair Value of Financial Instruments

     

    The carrying values of financial instruments, including trade accounts receivable, accounts payable, accrued liabilities and long-term debt, approximate their fair values based on terms and related interest rates.

     

    The Company follows a framework for measuring fair value. The framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:

     

    Level 1: Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets.

     

    Level 2: Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.

     

    Level 3: Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

     

    A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. During the years ended December 31, 2021 and 2020, there was no reclassification in financial assets or liabilities between Level 1, 2 or 3 categories.

     
    Reclassification

    Reclassification

     

    Certain prior year amounts have been reclassified to conform with current year presentation.
    XML 43 R25.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Business Description and Summary of Significant Accounting Policies (Tables)
    		 12 Months Ended
    Dec. 31, 2021
    Organization, Consolidation and Presentation of Financial Statements [Abstract]  
    Summary of Revenues from Product Lines

    The Company operates in one reportable segment with its net revenue derived primarily from the sale of orthobiologics and spinal implant products across North America. Sales are reported net of returns. No rebates, group purchasing organization fees or other customer allowances are present, and so are not relevant to net revenue determination. The following table presents revenues from these product lines for the years ended December 31, 2021 and 2020 (dollars in thousands):

     

     Summary of Revenues from Product Lines

      

    Year Ended

    December 31, 2021

    		  

    Percentage of

    Total Revenue

    		  

    Year Ended

    December 31, 2020

    		  

    Percentage of

    Total Revenue

    		 
    Orthobiologics  $42,259    77%  $39,308    74%
    Spinal implant   12,887    23%   13,880    26%
    Other revenue   117    0%   149    0%
    Total revenue  $55,263    100%  $53,337    100%
    XML 44 R26.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Receivables (Tables)
    		 12 Months Ended
    Dec. 31, 2021
    Credit Loss [Abstract]  
    Schedule of Allowance for Credit Losses

     

      

    December 31,

    2021

    		  

    December 31,

    2020

    		 
             
    Balance at January 1  $653   $547 
    Provision for current expected credit losses   45    307 
    Write-offs against allowance   (146)   (201)
       $552   $653 
    XML 45 R27.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Inventories (Tables)
    		 12 Months Ended
    Dec. 31, 2021
    Inventory Disclosure [Abstract]  
    Schedule of Inventories

    Inventories consist of the following (in thousands):

     

      

    December 31,

    2021

    		  

    December 31,

    2020

    		 
    Raw materials  $5,613   $3,757 
    Work in process   571    1,733 
    Finished goods   11,761    15,918 
     Total  $17,945   $21,408 
    XML 46 R28.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Property and Equipment, Net (Tables)
    		 12 Months Ended
    Dec. 31, 2021
    Property, Plant and Equipment [Abstract]  
    Schedule of Property and Equipment, Net

    Property and equipment, net are as follows (in thousands):

     

      

    December 31,

    2021

    		  

    December 31,

    2020

    		 
    Equipment  $5,541   $4,807 
    Computer equipment   828    649 
    Computer software   490    570 
    Furniture and fixtures   94    133 
    Leasehold improvements   3,994    3,987 
    Other   10    10 
    Surgical instruments   11,424    11,291 
    Total cost   22,381    21,447 
    Less: accumulated depreciation   (17,169)   (17,100)
     Total  $5,212   $4,347 
    XML 47 R29.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Goodwill and Intangible Assets (Tables)
    		 12 Months Ended
    Dec. 31, 2021
    Goodwill and Intangible Assets Disclosure [Abstract]  
    Schedule of Goodwill and Intangible Assets

    The following table sets forth information regarding intangible assets (in thousands):

     

      

    December 31,

    2021

    		  

    December 31,

    2020

    		 
    Patents  $847   $847 
    Accumulated amortization   (447)   (390)
    Net carrying value  $400   $457 
    Summary of Future Amortization Expense for Intangible Assets

     

          
    2022  $54 
    2023   53 
    2024   52 
    2025   52 
    2026   49 
    Thereafter   140 
    Total  $400 
    XML 48 R30.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Accrued Liabilities (Tables)
    		 12 Months Ended
    Dec. 31, 2021
    Payables and Accruals [Abstract]  
    Schedule of Accrued Liabilities

    Accrued liabilities consist of the following (in thousands):

     

      

    December 31,

    2021

    		  

    December 31,

    2020

    		 
    Wages/commissions payable  $3,184   $4,057 
    Other accrued liabilities   1,165    1,405 
    Accrued liabilities  $4,349   $5,462 
    XML 49 R31.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Debt (Tables)
    		 12 Months Ended
    Dec. 31, 2021
    Debt Disclosure [Abstract]  
    Schedule of Long-term Debt

    Long-term debt consists of the following (in thousands):

     

      

    December 31,

    2021

    		  

    December 31,

    2020

    		 
    Amounts due under the Term Facility  $12,000   $— 
    Accrued end-of-term payments   83    — 
    Amounts due under the Second A&R Credit Agreement   —    15,556 
    Premium related to Second Amendment   —    1,241 
    Less: unamortized debt issuance costs   (296)   — 
    Less: current maturities   —    (16,797)
    Long-term debt, less issuance costs  $11,787   $— 
    XML 50 R32.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Stock-Based Compensation (Tables)
    		 12 Months Ended
    Dec. 31, 2021
    Share-based Payment Arrangement [Abstract]  
    Schedule of Share-based Compensation, Stock Options, Activity

    Stock option activity, including options granted under the 2018 Plan and the Prior Plan was as follows:

     

       2021   2020 
               Weighted           Weighted 
           Weighted   Average
    Fair    		       Weighted   Average
    Fair    		 
           Average
    Exercise    		   Value at
    Grant    		       Average
    Exercise    		   Value at
    Grant    		 
       Shares   Price   Date   Shares   Price   Date 
    Outstanding at January 1   2,190,892   $2.25   $1.65    602,966   $6.07   $3.99 
    Granted   1,012,083    1.27    1.07    1,708,743    1.24    1.01 
    Cancelled or expired   (1,309)   345.82    170.89    (120,817)   6.95    4.31 
    Outstanding at December 31   3,201,666   $1.80   $1.40    2,190,892   $2.25   $1.65 
    Exercisable at December 31   649,042   $3.36   $2.37    122,739   $14.74   $8.95 
    Schedule of Assumptions of Stock Option Granted

    The estimated fair value of stock options granted is determined using the Black-Scholes-Merton method applied to individual grants. Key assumptions used to estimate the fair value of stock awards are as follows:

     

       Year Ended 
       December 31, 
       2021   2020 
    Risk free interest rate   0.97%   0.54%
    Dividend yield   0%   0%
    Expected term   6.3 years    6.3 years 
    Expected volatility   113%   105%
    Schedule of Restricted Stock Activity

    Restricted stock unit activity for awards granted under the 2018 Plan was as follows:

     

       2021   2020 
       Shares  

    Weighted

    Average Fair

    Value at Grant

    Date Per

    Share

    		   Shares  

    Weighted

    Average Fair

    Value at Grant

    Date Per Share

    		 
    Outstanding at January 1   2,503,698   $1.54    499,914   $2.87 
    Granted   1,249,002   $1.27    2,148,662   $1.29 
    Vested   (782,596)  $1.72    (144,878)  $2.52 
    Outstanding at December 31   2,970,104   $1.39    2,503,698   $1.54 
    XML 51 R33.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Warrants (Tables)
    		 12 Months Ended
    Dec. 31, 2021
    Warrants  
    Schedule of Warrant Activity

    The following table summarizes our warrant activities for the years ended December 31, 2021 and 2020:

     

           Weighted 
       Common   Average 
       Stock   Exercise 
       Warrants   Price 
    Outstanding as of January 1, 2020   2,908,874   $4.16 
    Issued   2,400,000    0.01 
    Exercised   (4,800,000)   0.01 
    Expired   (87,596)   85.92 
    Outstanding as of December 31, 2020   421,278   $10.80 
    Issued   7,111,112    2.29 
    Expired   (421,278)   10.80 
    Outstanding at December 31, 2021   7,111,112   $2.29 
    XML 52 R34.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Commitments and Contingencies (Tables)
    		 12 Months Ended
    Dec. 31, 2021
    Commitments and Contingencies Disclosure [Abstract]  
    Schedule of Future Minimum Rental Payments for Operating Leases

    Future minimum payments as of December 31, 2021 under these long-term operating leases are as follows (in thousands):

     

          
    2022  $521 
    2023   489 
    2024   224 
    2025   180 
    Total future minimum lease payments   1,414 
    Less amount representing interest   (110)
    Present value of obligations under operating leases   1,304 
    Less current portion   (462)
    Long-term operating lease obligations  $842 
    XML 53 R35.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Income Taxes (Tables)
    		 12 Months Ended
    Dec. 31, 2021
    Income Tax Disclosure [Abstract]  
    Schedule of Components of Income Loss Before Provision for Income Tax

    The components of income (loss) before provision for income taxes consist of the following (in thousands):

     

             
       Year Ended December 31, 
       2021   2020 
    United States  $(4,849)  $(6,727)
               
    Total  $(4,849)  $(6,727)
    Schedule of Components of Income Tax Provision

    The components of the income tax provision are as follows (in thousands):

     

             
       Year Ended December 31, 
       2021   2020 
    Current:          
    Federal  $(51)  $51 
    State   51    245 
    Total current   —    296 
               
    Deferred:          
    Federal   —    — 
    State   —    — 
    Total deferred   —    — 
               
    Total provision for income taxes  $—   $296 
    Schedule of Effective Income Tax Rate Reconciliation

    The reconciliation of income tax attributable to operations computed at the U.S. Federal statutory income tax rate of 21% to income tax expense is as follows (in thousands):

     

             
       Year Ended December 31, 
       2021   2020 
    Statutory Federal tax rate  $(1,018)  $(1,413)
    Valuation allowance   315    (10,968)
    State income taxes, net of Federal benefit   (110)   619 
    Attribute reduction related to Sec. 382   —    8,607 
    Change in state income tax rate   (33)   (61)
    Gain on extinguishment of debt   165    3,488 
    Stock compensation adjustment and other reconciling items   557    14 
    Nondeductible executive compensation   124    — 
    Nondeductible meals and entertainment expense   —    10 
               
    Total provision for income taxes  $—   $296 
    Schedule of Deferred Tax Assets and Liabilities

    Deferred tax components are as follows (in thousands):

     

             
       At December 31, 
       2021   2020 
    Deferred tax assets:          
    Accrued liability for vacation  $130   $123 
    Accrued commissions and bonuses / compensation   284    565 
    Accrued contingencies   52    42 
    Amortization   27    32 
    Bad debt reserve   148    174 
    Charitable contributions carryforward   15    — 
    Lease liability   350    459 
    Interest expense   1,968    2,342 
    Inventory reserve   2,777    2,975 
    Net operating loss carryovers   13,164    12,114 
    Stock option compensation   783    653 
    Other   113    109 
    Total deferred tax assets   19,811    19,588 
               
    Deferred tax liabilities:          
    Right of use asset   (338)   (450)
    Prepaids   (83)   (73)
    Depreciation   (111)   (100)
    Total deferred tax liabilities   (532)   (623)
               
    Valuation allowance   (19,279)   (18,965)
               
    Net deferred tax assets  $—   $— 
    XML 54 R36.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Supplemental Disclosure of Cash Flow Information (Tables)
    		 12 Months Ended
    Dec. 31, 2021
    Supplemental Cash Flow Elements [Abstract]  
    Schedule of Supplemental Cash Flow Information

    Supplemental cash flow information is as follows (in thousands):

     

             
       Year Ended 
       December 31, 
       2021   2020 
    Cash paid during the period for:          
    Interest  $846   $13 
    Non-cash activities:          
    Gain on extinguishment of Second A&R Credit Agreement  $785   $— 
    Extinguishment of Second A&R Credit Agreement financed by line of credit  $3,755   $— 
    Prepaid debt issuance costs  $75   $— 
    Fixed assets acquired under finance lease  $163   $— 
    Warrants issued in connection with the Private Placement to placement agents  $351   $— 
    ASU 2016-13 cumulative effect adjustment  $—   $47 
    Recognition of 2020 Warrants  $—   $1,862 
    Partial extinguishment of Second Amended and Restated Credit Agreement (including debt issuance costs)  $—   $63,233 
    XML 55 R37.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Segment and Geographic Information (Tables)
    		 12 Months Ended
    Dec. 31, 2021
    Segment Reporting [Abstract]  
    Schedule of Revenues by Geographic Region

     

       Year Ended
    December 31,    		 
       2021   2020 
    United States  $54,570   $52,147 
    Rest of World   693    1,190 
    Total  $55,263   $53,337 
    XML 56 R38.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Summary of Revenues from Product Lines (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
    Total revenue $ 55,263 $ 53,337
    Percentage of total revenue 100.00% 100.00%
    Orthobiologics [Member]    
    Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
    Total revenue $ 42,259 $ 39,308
    Percentage of total revenue 77.00% 74.00%
    Spinal Implant [Member]    
    Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
    Total revenue $ 12,887 $ 13,880
    Percentage of total revenue 23.00% 26.00%
    Other Revenue [Member]    
    Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
    Total revenue $ 117 $ 149
    Percentage of total revenue 0.00% 0.00%
    XML 57 R39.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Business Description and Summary of Significant Accounting Policies (Details Narrative) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Jan. 02, 2020
    Dec. 31, 2021
    Dec. 31, 2020
    Product Information [Line Items]      
    Cash and Cash Equivalents, at Carrying Value   $ 18,243 $ 2,341
    Retained Earnings (Accumulated Deficit)   235,185 $ 230,336
    Cash and cash equivalents   $ 18,200  
    Antidilutive securities excluded from computation of earnings per share, amount   13,282,882 5,115,868
    Computers and Equipment [Member]      
    Product Information [Line Items]      
    Property and equipment, estimated useful lives   three to seven years  
    Surgical Instruments [Member]      
    Product Information [Line Items]      
    Property and equipment, estimated useful lives   five years  
    Accounting Standards Update 2016-13 [Member]      
    Product Information [Line Items]      
    Cumulative effect adjustment $ 47,000    
    Revenue Benchmark [Member] | No Customer [Member] | Concentration Credit Risk [Member]      
    Product Information [Line Items]      
    Concentration risk, percentage   10.00% 10.00%
    Investor Rights Agreement [Member]      
    Product Information [Line Items]      
    Invester rights agreement, description   In addition, for so long as the Ownership Threshold is met, we must obtain the approval of a majority of our common stock held by Royalty Opportunities and ROS to proceed with the following actions: (i) issue new securities; (ii) incur over $250,000 of debt in a fiscal year; (iii) sell or transfer over $250,000 of our assets or businesses or our subsidiaries in a fiscal year; (iv) acquire over $250,000 of assets or properties in a fiscal year; (v) make capital expenditures over $125,000 individually, or $1.5 million in the aggregate during a fiscal year; (vi) approve our annual budget; (vii) hire or terminate our chief executive officer; (viii) appoint or remove the chairperson of our Board of Directors; and (ix) make, loans to, investments in, or purchase, or permit any subsidiary to purchase, any stock or other securities in another entity in excess of $250,000 in a fiscal year. As long as the Ownership Threshold is met, we may not increase the size of our Board or Directors beyond seven directors without the approval of a majority of the directors nominated by Royalty Opportunities and ROS.  
    XML 58 R40.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Schedule of Allowance for Credit Losses (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Credit Loss [Abstract]    
    Beginning balance $ 653 $ 547
    Provision for expected credit losses 45 307
    Write-offs against allowance (146) (201)
    Ending balance $ 552 $ 653
    XML 59 R41.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Schedule of Inventories (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2021
    Dec. 31, 2020
    Inventory Disclosure [Abstract]    
    Raw materials $ 5,613 $ 3,757
    Work in process 571 1,733
    Finished goods 11,761 15,918
     Total $ 17,945 $ 21,408
    XML 60 R42.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Schedule of Property and Equipment, Net (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2021
    Dec. 31, 2020
    Property, Plant and Equipment [Line Items]    
    Total cost $ 22,381 $ 21,447
    Less: accumulated depreciation (17,169) (17,100)
     Total 5,212 4,347
    Equipment [Member]    
    Property, Plant and Equipment [Line Items]    
    Total cost 5,541 4,807
    Computer Equipment [Member]    
    Property, Plant and Equipment [Line Items]    
    Total cost 828 649
    Computer Softwares [Member]    
    Property, Plant and Equipment [Line Items]    
    Total cost 490 570
    Furniture and Fixtures [Member]    
    Property, Plant and Equipment [Line Items]    
    Total cost 94 133
    Leasehold Improvements [Member]    
    Property, Plant and Equipment [Line Items]    
    Total cost 3,994 3,987
    Other Properties [Member]    
    Property, Plant and Equipment [Line Items]    
    Total cost 10 10
    Surgical Instruments [Member]    
    Property, Plant and Equipment [Line Items]    
    Total cost $ 11,424 $ 11,291
    XML 61 R43.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Property and Equipment, Net (Details Narrative) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Property, Plant and Equipment [Abstract]    
    Depreciation expenses $ 1.3 $ 2.0
    XML 62 R44.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Schedule of Goodwill and Intangible Assets (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2021
    Dec. 31, 2020
    Goodwill and Intangible Assets Disclosure [Abstract]    
    Patents $ 847 $ 847
    Accumulated amortization (447) (390)
    Net carrying value $ 400 $ 457
    XML 63 R45.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Summary of Future Amortization Expense for Intangible Assets (Details)
    $ in Thousands
    Dec. 31, 2021
    USD ($)
    Goodwill and Intangible Assets Disclosure [Abstract]  
    2022 $ 54
    2023 53
    2024 52
    2025 52
    2026 49
    Thereafter 140
    Total $ 400
    XML 64 R46.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Goodwill and Intangible Assets (Details Narrative) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Goodwill and Intangible Assets Disclosure [Abstract]    
    Amortization of intangible assets $ 0.1 $ 0.1
    XML 65 R47.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Schedule of Accrued Liabilities (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2021
    Dec. 31, 2020
    Payables and Accruals [Abstract]    
    Wages/commissions payable $ 3,184 $ 4,057
    Other accrued liabilities 1,165 1,405
    Accrued liabilities $ 4,349 $ 5,462
    XML 66 R48.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Schedule of Long-term Debt (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2021
    Dec. 31, 2020
    Debt Disclosure [Abstract]    
    Amounts due under the Term Facility $ 12,000
    Accrued end-of-term payments 83
    Amounts due under the Second A&R Credit Agreement 15,556
    Premium related to Second Amendment 1,241
    Less: unamortized debt issuance costs (296)
    Less: current maturities (16,797)
    Long-term debt, less issuance costs $ 11,787
    XML 67 R49.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Debt (Details Narrative) - USD ($)
    $ / shares in Units, shares in Millions
    		 12 Months Ended
    Mar. 07, 2022
    May 06, 2021
    Oct. 02, 2020
    Dec. 31, 2021
    Dec. 31, 2020
    May 06, 2020
    Debt Instrument [Line Items]            
    Line of credit facility expiration date   May 01, 2026   Dec. 31, 2021    
    Increase in liquidity amount $ 14          
    Debt conversion converted instrument     $ 61,900,000      
    Debt conversion converted instrument, shares     57.8      
    Values issued prepayment fees     $ 900,000      
    Shares issued prepayment fees     0.9      
    Debt instrument face amount     $ 5,000.0      
    Line of credit facility interest rate at period     7.00%      
    Gain on restructuring         $ 15,100,000  
    Conversion of convertible securities     $ 80,300,000      
    Conversion of convertible securities, shares     57.8      
    Conversion of convertible securities, shares     $ 48,200,000      
    Undiscontinued future cash payments     $ 17,100,000      
    2020 Warrants [Member] | ROS and Royalty Opportunities [Member]            
    Debt Instrument [Line Items]            
    New effective interest rate           10.02%
    Issuance of warrants to purchase a common stock           2.4
    Exercise price of warrants           $ 0.01
    Warrants expiration date           May 06, 2030
    Revolving Credit Facility [Member]            
    Debt Instrument [Line Items]            
    Line of credit, interest rate   4.50%        
    London Interbank Offered Rate (LIBOR) [Member]            
    Debt Instrument [Line Items]            
    Debt instrument, interest rate   7.00%        
    Line of credit facility interest rate at period     1.00%      
    Term Loan Commitment [Member]            
    Debt Instrument [Line Items]            
    Line of credit facility, maximum borrowing capacity   $ 12,000,000.0        
    Term Loan Commitment [Member] | Agent and Lenders [Member]            
    Debt Instrument [Line Items]            
    Line of credit facility, maximum borrowing capacity   5,000,000.0        
    Line of credit       $ 3,200,000    
    Revolving Loan Commitment [Member]            
    Debt Instrument [Line Items]            
    Line of credit facility, maximum borrowing capacity   $ 8,000,000        
    Revolving Loan Commitment [Member] | London Interbank Offered Rate (LIBOR) [Member]            
    Debt Instrument [Line Items]            
    Line of credit, interest rate   1.00%        
    Second A&R Credit Agreement [Member]            
    Debt Instrument [Line Items]            
    Gain on extinguishment   $ 800,000        
    Reacquisition price   $ 15,600,000        
    Credit Agreements [Member]            
    Debt Instrument [Line Items]            
    Line of credit       3.75%    
    New effective interest rate       9.87%    
    Line of credit, description   In addition to paying interest on the outstanding loans under the Facilities, the Borrowers are also required to pay an unused line fee equal to 0.50% per annum in respect of unutilized commitments under the Revolving Facility, a fee for failure to maintain a minimum balance under the Revolving Facility, a collateral management fee under the Revolving Facility equal to 0.50% of the amount outstanding under the Revolving Facility, an origination fee equal to 0.50% of the Revolving Loan Commitment and 0.50% of the Term Loan Commitment, and if activated, of any additional term loan tranche, and certain other customary fees related to the Agent’s administration of the Facilities        
    Second A And R Credit Agreements [Member]            
    Debt Instrument [Line Items]            
    Line of credit       $ 2,200,000    
    Line of credit, description       Beginning October 1, 2020 through the maturity date of the Second A&R Credit Agreement, interest payable in cash would accrue on the Loans under the Second A&R Credit Agreement at a rate per annum equal to the sum of (i) 10.00% plus (ii) the higher of (x) the LIBO Rate (as such term is defined in the Second A&R Credit Agreement) and (y) 2.3125%    
    Line of credit facility maximum amount outstanding       $ 10,000,000.0    
    XML 68 R50.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Equity (Details Narrative) - USD ($)
    		 12 Months Ended
    Feb. 24, 2021
    Nov. 17, 2020
    Nov. 06, 2020
    Oct. 02, 2020
    Dec. 31, 2021
    Dec. 31, 2020
    Aug. 07, 2020
    Subsidiary, Sale of Stock [Line Items]              
    Common stock, shares authorized         300,000,000 300,000,000  
    Shares issued in exchange of loans outstanding       57,800,000      
    Stock issued during period, shares, new issues     712,646        
    Shares issued, price per share     $ 0.194539        
    Share price     $ 1.07        
    Right offering expired date     Nov. 06, 2020        
    Proceeds from common stock     $ 800,000   $ 18,426,000 $ 620,000  
    Investor [Member] | Private Placement [Member]              
    Subsidiary, Sale of Stock [Line Items]              
    Stock issued during period, shares, new issues 8,888,890            
    Shares issued, price per share $ 2.25            
    Proceeds from private placement $ 18,400,000            
    Investor Warrant [Member] | Private Placement [Member]              
    Subsidiary, Sale of Stock [Line Items]              
    Warrants to purchase common stock 6,666,668            
    Warrant exercise price $ 2.25            
    ROS and Royalty Opportunities [Member]              
    Subsidiary, Sale of Stock [Line Items]              
    Proceeds from warrant exercise   $ 48,000          
    Restructuring Agreement [Member] | Royalty Opportunities and ROS [Member]              
    Subsidiary, Sale of Stock [Line Items]              
    Shares issued in exchange of loans outstanding       58,700,000      
    Placement Agent Agreement [Member] | Investor [Member] | Private Placement [Member]              
    Subsidiary, Sale of Stock [Line Items]              
    Stock issued during period, shares, new issues 444,444            
    Warrants exercise price percentage 5.00%            
    Placement Agent Agreement [Member] | Investor [Member] | Private Placement Warrant [Member]              
    Subsidiary, Sale of Stock [Line Items]              
    Warrant exercise price $ 2.8125            
    Warrant term description five-year            
    Minimum [Member]              
    Subsidiary, Sale of Stock [Line Items]              
    Common stock, shares authorized             75,000,000
    Maximum [Member]              
    Subsidiary, Sale of Stock [Line Items]              
    Common stock, shares authorized             300,000,000
    Stock issued during period, shares, new issues     14,018,690        
    XML 69 R51.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Schedule of Share-based Compensation, Stock Options, Activity (Details) - Equity Option [Member] - 2018 Equity Incentive Plan [Member] - $ / shares
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
    Shares, Outstanding, Beginning Balance 2,190,892 602,966
    Weighted Average Exercise Price, Outstanding Beginning Balance $ 2.25 $ 6.07
    Weighted Average Fair Value at Grant Date, Outstanding Beginning Balance $ 1.65 $ 3.99
    Shares, Granted 1,012,083 1,708,743
    Weighted Average Exercise Price, Granted $ 1.27 $ 1.24
    Weighted Average Fair Value at Grant Date, Granted $ 1.07 $ 1.01
    Shares, Cancelled or expired (1,309) (120,817)
    Weighted Average Exercise Price, Cancelled or expired $ 345.82 $ 6.95
    Weighted Average Fair Value at Grant Date, Cancelled or expired $ 170.89 $ 4.31
    Shares, Outstanding, Ending Balance 3,201,666 2,190,892
    Weighted Average Exercise Price, Outstanding Ending Balance $ 1.80 $ 2.25
    Weighted Average Fair Value at Grant Date, Outstanding Ending Balance $ 1.40 $ 1.65
    Shares, Exercisable, Ending Balance 649,042 122,739
    Weighted Average Exercise Price, Exercisable Ending Balance $ 3.36 $ 14.74
    Weighted Average Fair Value at Grant Date, Exercisable, Ending Balance $ 2.37 $ 8.95
    XML 70 R52.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Schedule of Assumptions of Stock Option Granted (Details)
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Share-based Payment Arrangement [Abstract]    
    Risk free interest rate 0.97% 0.54%
    Dividend yield 0.00% 0.00%
    Expected term 6 years 3 months 18 days 6 years 3 months 18 days
    Expected volatility 113.00% 105.00%
    XML 71 R53.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Schedule of Restricted Stock Activity (Details) - Restricted Stock Units (RSUs) [Member] - 2018 Equity Incentive Plan [Member] - $ / shares
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
    Shares Outstanding, Beginning Balance 2,503,698 499,914
    Weighted Average Fair Value at Grant Date, Outstanding Beginning Balance $ 1.54 $ 2.87
    Shares Granted 1,249,002 2,148,662
    Weighted Average Fair Value at Grant Date, Granted $ 1.27 $ 1.29
    Shares Vested (782,596) (144,878)
    Weighted Average Fair Value at Grant Date, Vested $ 1.72 $ 2.52
    Shares Outstanding, Ending Balance 2,970,104 2,503,698
    Weighted Average Fair Value at Grant Date, Outstanding Ending Balance $ 1.39 $ 1.54
    XML 72 R54.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Stock-Based Compensation (Details Narrative) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Aug. 01, 2018
    Dec. 31, 2021
    Dec. 31, 2020
    Oct. 27, 2018
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
    Share based compensation   $ 2,209 $ 1,084  
    Share-based Payment Arrangement, Option [Member]        
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
    Unvested employee stock options not yet recognized   $ 2,700    
    Stock option vested weighted average period   3 years 1 month 6 days    
    Restricted Stock [Member]        
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
    Unvested employee stock options not yet recognized   $ 3,400    
    Stock option vested weighted average period   2 years 9 months 18 days    
    Employees And Directors [Member]        
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
    Share based compensation   $ 2,200 $ 1,100  
    2018 Equity Incentive Plan [Member]        
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
    Number of shares available for issuance   8,358,055    
    Term of plan, description The 2018 Plan became effective immediately upon initial approval of the plan by our stockholders on August 1, 2018 and will expire on July 31, 2028, unless terminated earlier.      
    Number of common stock shares remaining available   1,246,080    
    2018 Equity Incentive Plan [Member] | Maximum [Member]        
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
    Number of shares available for issuance 1,500,000     5,550,308
    XML 73 R55.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Schedule of Warrant Activity (Details) - $ / shares
    shares in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Warrants    
    Common Stock Warrants Outstanding, Beginning Balance 421,278 2,908,874
    Weighted Average Exercise Price Outstanding Beginning Balance $ 10.80 $ 4.16
    Common Stock Warrants, Issued 7,111,112 2,400,000
    Weighted Average Exercise Price, Issued $ 2.29 $ 0.01
    Common Stock Warrants, Exercised   (4,800,000)
    Weighted Average Exercise Price, Exercised   $ 0.01
    Common Stock Warrants, Expired (421,278) (87,596)
    Weighted Average Exercise Price, Expired $ 10.80 $ 85.92
    Common Stock Warrants Outstanding, Ending Balance 7,111,112 421,278
    Weighted Average Exercise Price Outstanding Ending Balance $ 2.29 $ 10.80
    XML 74 R56.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Warrants (Details Narrative)
    $ / shares in Units, shares in Millions, $ in Millions
    May 06, 2020
    USD ($)
    $ / shares
    shares
    Dec. 31, 2021
    2020 Warrant [Member]    
    Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
    Issuance of warrants to purchase a common stock | shares 2.4  
    Exercise price of warrants | $ / shares $ 0.01  
    Warrants expiration date May 06, 2030  
    Fair value of warrants | $ $ 1.9  
    Measurement Input, Expected Term [Member]    
    Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
    Warrants contractual term   5 years
    Measurement Input, Price Volatility [Member]    
    Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
    Warrants and rights outstanding, measurement input   0.61
    XML 75 R57.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Schedule of Future Minimum Rental Payments for Operating Leases (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2021
    Dec. 31, 2020
    Commitments and Contingencies Disclosure [Abstract]    
    2022 $ 521  
    2023 489  
    2024 224  
    2025 180  
    Total future minimum lease payments 1,414  
    Less amount representing interest (110)  
    Present value of obligations under operating leases 1,304  
    Less current portion (462) $ (423)
    Long-term operating lease obligations $ 842 $ 1,303
    XML 76 R58.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Commitments and Contingencies (Details Narrative) - USD ($)
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Jul. 02, 2021
    Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
    Operating lease expiration description operating lease agreements with expiration dates between 2023 and 2025. We have the option to extend certain leases to five or ten-year term(s) and we have the right of first refusal on any sale    
    Operating lease weighted-average remaining lease term 3 years    
    Lease expense related to operating leases $ 600,000 $ 600,000  
    Operating lease weighted-average discount rate 5.20%    
    Settlement Agreement [Member]      
    Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
    Reserve for one-time lump sum amount     $ 550,000
    XML 77 R59.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Schedule of Components of Income Loss Before Provision for Income Tax (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Total $ (4,849) $ (6,727)
    UNITED STATES    
    Total $ (4,849) $ (6,727)
    XML 78 R60.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Schedule of Components of Income Tax Provision (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Income Tax Disclosure [Abstract]    
    Federal $ (51) $ 51
    State 51 245
    Total current 296
    Federal
    State
    Total deferred
    Total provision for income taxes $ 296
    XML 79 R61.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Income Tax Disclosure [Abstract]    
    Statutory Federal tax rate $ (1,018) $ (1,413)
    Valuation allowance 315 (10,968)
    State income taxes, net of Federal benefit (110) 619
    Attribute reduction related to Sec. 382 8,607
    Change in state income tax rate (33) (61)
    Gain on extinguishment of debt 165 3,488
    Stock compensation adjustment and other reconciling items 557 14
    Nondeductible executive compensation 124
    Nondeductible meals and entertainment expense 10
    Total provision for income taxes $ 296
    XML 80 R62.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2021
    Dec. 31, 2020
    Income Tax Disclosure [Abstract]    
    Accrued liability for vacation $ 130 $ 123
    Accrued commissions and bonuses / compensation 284 565
    Accrued contingencies 52 42
    Amortization 27 32
    Bad debt reserve 148 174
    Charitable contributions carryforward 15
    Lease liability 350 459
    Interest expense 1,968 2,342
    Inventory reserve 2,777 2,975
    Net operating loss carryovers 13,164 12,114
    Stock option compensation 783 653
    Other 113 109
    Total deferred tax assets 19,811 19,588
    Right of use asset (338) (450)
    Prepaids (83) (73)
    Depreciation (111) (100)
    Total deferred tax liabilities (532) (623)
    Valuation allowance (19,279) (18,965)
    Net deferred tax assets
    XML 81 R63.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Income Taxes (Details Narrative) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Income Tax Disclosure [Abstract]    
    Valuation allowance deferred tax asset change in amou $ 0.3 $ 11.0
    Operating loss carryforwards $ 101.8 $ 97.0
    Operating loss carryforwards expiration period Federal net operating losses generated prior to 2018 and State net operating loss carryovers expire at various dates between 2024 and 2040  
    Indefinite carryforward available to offset taxable income percentage 80.00%  
    XML 82 R64.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Employee Benefit Plans (Details Narrative) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Retirement Benefits [Abstract]    
    Discretionary match 100.00%  
    Contribution limit, description wage deferrals not in excess of 4% of their wages  
    Employer contributed amount $ 0.3 $ 0.2
    XML 83 R65.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Schedule of Supplemental Cash Flow Information (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Supplemental Cash Flow Elements [Abstract]    
    Interest $ 846 $ 13
    Gain on extinguishment of Second A&R Credit Agreement 785
    Extinguishment of Second A&R Credit Agreement financed by line of credit 3,755
    Prepaid debt issuance costs 75
    Fixed assets acquired under finance lease 163
    Warrants issued in connection with the Private Placement to placement agents 351
    ASU 2016-13 cumulative effect adjustment 47
    Recognition of 2020 Warrants 1,862
    Partial extinguishment of Second Amended and Restated Credit Agreement (including debt issuance costs) $ 63,233
    XML 84 R66.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Related Party Transactions (Details Narrative)
    		 12 Months Ended
    Dec. 31, 2021
    USD ($)
    Sublease Agreement [Member] | Cardialen, Inc., [Member]  
    Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]  
    Rent expense $ 1,000
    Soleholders [Member]  
    Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]  
    Equity Method Investment, Ownership Percentage 20.00%
    XML 85 R67.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Schedule of Revenues by Geographic Region (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Revenues from External Customers and Long-Lived Assets [Line Items]    
    Total revenue $ 55,263 $ 53,337
    UNITED STATES    
    Revenues from External Customers and Long-Lived Assets [Line Items]    
    Total revenue 54,570 52,147
    Rest of World [Member]    
    Revenues from External Customers and Long-Lived Assets [Line Items]    
    Total revenue $ 693 $ 1,190
    XML 86 R68.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Segment and Geographic Information (Details Narrative) - Concentration Credit Risk [Member] - Revenue Benchmark [Member]
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    One Customer [Member]    
    Revenue, Major Customer [Line Items]    
    Concentration risk, percentage 99.00%  
    Two Customer [Member]    
    Revenue, Major Customer [Line Items]    
    Concentration risk, percentage   98.00%
    XML 87 form10-k_htm.xml IDEA: XBRL DOCUMENT 0001453593 2021-01-01 2021-12-31 0001453593 2021-06-30 0001453593 2022-03-08 0001453593 2020-01-01 2020-12-31 0001453593 2021-12-31 0001453593 2020-12-31 0001453593 us-gaap:CommonStockMember 2019-12-31 0001453593 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001453593 us-gaap:RetainedEarningsMember 2019-12-31 0001453593 2019-12-31 0001453593 us-gaap:CommonStockMember 2020-12-31 0001453593 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001453593 us-gaap:RetainedEarningsMember 2020-12-31 0001453593 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001453593 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001453593 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001453593 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001453593 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001453593 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001453593 us-gaap:CommonStockMember 2021-12-31 0001453593 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001453593 us-gaap:RetainedEarningsMember 2021-12-31 0001453593 XTNT:InvestorRightsAgreementMember 2021-01-01 2021-12-31 0001453593 XTNT:NoCustomerMember us-gaap:SalesRevenueNetMember XTNT:ConcentrationCreditRiskMember 2020-01-01 2020-12-31 0001453593 XTNT:NoCustomerMember us-gaap:SalesRevenueNetMember XTNT:ConcentrationCreditRiskMember 2021-01-01 2021-12-31 0001453593 us-gaap:AccountingStandardsUpdate201613Member 2019-12-30 2020-01-02 0001453593 XTNT:ComputersAndEquipmentMember 2021-01-01 2021-12-31 0001453593 XTNT:SurgicalInstrumentsMember 2021-01-01 2021-12-31 0001453593 XTNT:OrthobiologicsMember 2021-01-01 2021-12-31 0001453593 XTNT:OrthobiologicsMember 2020-01-01 2020-12-31 0001453593 XTNT:SpinalImplantMember 2021-01-01 2021-12-31 0001453593 XTNT:SpinalImplantMember 2020-01-01 2020-12-31 0001453593 XTNT:OtherRevenueMember 2021-01-01 2021-12-31 0001453593 XTNT:OtherRevenueMember 2020-01-01 2020-12-31 0001453593 us-gaap:EquipmentMember 2021-12-31 0001453593 us-gaap:EquipmentMember 2020-12-31 0001453593 us-gaap:ComputerEquipmentMember 2021-12-31 0001453593 us-gaap:ComputerEquipmentMember 2020-12-31 0001453593 XTNT:ComputerSoftwaresMember 2021-12-31 0001453593 XTNT:ComputerSoftwaresMember 2020-12-31 0001453593 us-gaap:FurnitureAndFixturesMember 2021-12-31 0001453593 us-gaap:FurnitureAndFixturesMember 2020-12-31 0001453593 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001453593 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001453593 XTNT:OtherPropertiesMember 2021-12-31 0001453593 XTNT:OtherPropertiesMember 2020-12-31 0001453593 XTNT:SurgicalInstrumentsMember 2021-12-31 0001453593 XTNT:SurgicalInstrumentsMember 2020-12-31 0001453593 XTNT:TermLoanCommitmentMember 2021-05-06 0001453593 XTNT:AgentAndLendersMember XTNT:TermLoanCommitmentMember 2021-05-06 0001453593 XTNT:RevolvingLoanCommitmentMember 2021-05-06 0001453593 XTNT:AgentAndLendersMember XTNT:TermLoanCommitmentMember 2021-12-31 0001453593 2021-05-05 2021-05-06 0001453593 XTNT:SecondAAndRCreditAgreementMember 2021-05-05 2021-05-06 0001453593 us-gaap:LondonInterbankOfferedRateLIBORMember 2021-05-06 0001453593 us-gaap:RevolvingCreditFacilityMember 2021-05-05 2021-05-06 0001453593 XTNT:RevolvingLoanCommitmentMember us-gaap:LondonInterbankOfferedRateLIBORMember 2021-05-05 2021-05-06 0001453593 XTNT:CreditAgreementsMember 2021-01-01 2021-12-31 0001453593 XTNT:CreditAgreementsMember 2021-12-31 0001453593 XTNT:CreditAgreementsMember 2021-05-05 2021-05-06 0001453593 2022-03-06 2022-03-07 0001453593 XTNT:SecondAAndRCreditAgreementsMember 2021-12-31 0001453593 XTNT:SecondAAndRCreditAgreementsMember 2021-01-01 2021-12-31 0001453593 XTNT:ROSAndRoyaltyOpportunitiesMember XTNT:TwoThousandTwentyWarrantsMember 2020-05-06 0001453593 2020-10-01 2020-10-02 0001453593 2020-10-02 0001453593 us-gaap:LondonInterbankOfferedRateLIBORMember 2020-10-02 0001453593 srt:MinimumMember 2020-08-07 0001453593 srt:MaximumMember 2020-08-07 0001453593 XTNT:RoyaltyOpportunitiesandROSMember XTNT:RestructuringAgreementMember 2020-10-01 2020-10-02 0001453593 srt:MaximumMember 2020-11-05 2020-11-06 0001453593 2020-11-06 0001453593 2020-11-05 2020-11-06 0001453593 XTNT:ROSAndRoyaltyOpportunitiesMember 2020-11-15 2020-11-17 0001453593 us-gaap:InvestorMember us-gaap:PrivatePlacementMember 2021-02-23 2021-02-24 0001453593 us-gaap:InvestorMember us-gaap:PrivatePlacementMember 2021-02-24 0001453593 XTNT:InvestorWarrantMember us-gaap:PrivatePlacementMember 2021-02-24 0001453593 us-gaap:InvestorMember us-gaap:PrivatePlacementMember XTNT:PlacementAgentAgreementMember 2021-02-24 0001453593 us-gaap:InvestorMember us-gaap:PrivatePlacementMember XTNT:PlacementAgentAgreementMember 2021-02-23 2021-02-24 0001453593 us-gaap:InvestorMember XTNT:PrivatePlacementWarrantMember XTNT:PlacementAgentAgreementMember 2021-02-24 0001453593 us-gaap:InvestorMember XTNT:PrivatePlacementWarrantMember XTNT:PlacementAgentAgreementMember 2021-02-23 2021-02-24 0001453593 srt:MaximumMember XTNT:TwoThousandAndEighteenEquityIncentivePlanMember 2018-08-01 0001453593 srt:MaximumMember XTNT:TwoThousandAndEighteenEquityIncentivePlanMember 2018-10-27 0001453593 XTNT:TwoThousandAndEighteenEquityIncentivePlanMember 2018-07-28 2018-08-01 0001453593 XTNT:TwoThousandAndEighteenEquityIncentivePlanMember 2021-12-31 0001453593 XTNT:EmployeesAndDirectorsMember 2021-01-01 2021-12-31 0001453593 XTNT:EmployeesAndDirectorsMember 2020-01-01 2020-12-31 0001453593 us-gaap:EmployeeStockOptionMember 2021-12-31 0001453593 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001453593 us-gaap:RestrictedStockMember 2021-12-31 0001453593 us-gaap:RestrictedStockMember 2021-01-01 2021-12-31 0001453593 XTNT:TwoThousandAndEighteenEquityIncentivePlanMember us-gaap:StockOptionMember 2020-12-31 0001453593 XTNT:TwoThousandAndEighteenEquityIncentivePlanMember us-gaap:StockOptionMember 2019-12-31 0001453593 XTNT:TwoThousandAndEighteenEquityIncentivePlanMember us-gaap:StockOptionMember 2021-01-01 2021-12-31 0001453593 XTNT:TwoThousandAndEighteenEquityIncentivePlanMember us-gaap:StockOptionMember 2020-01-01 2020-12-31 0001453593 XTNT:TwoThousandAndEighteenEquityIncentivePlanMember us-gaap:StockOptionMember 2021-12-31 0001453593 us-gaap:RestrictedStockUnitsRSUMember XTNT:TwoThousandAndEighteenEquityIncentivePlanMember 2020-12-31 0001453593 us-gaap:RestrictedStockUnitsRSUMember XTNT:TwoThousandAndEighteenEquityIncentivePlanMember 2019-12-31 0001453593 us-gaap:RestrictedStockUnitsRSUMember XTNT:TwoThousandAndEighteenEquityIncentivePlanMember 2021-01-01 2021-12-31 0001453593 us-gaap:RestrictedStockUnitsRSUMember XTNT:TwoThousandAndEighteenEquityIncentivePlanMember 2020-01-01 2020-12-31 0001453593 us-gaap:RestrictedStockUnitsRSUMember XTNT:TwoThousandAndEighteenEquityIncentivePlanMember 2021-12-31 0001453593 us-gaap:MeasurementInputExpectedTermMember 2021-12-31 0001453593 us-gaap:MeasurementInputPriceVolatilityMember 2021-12-31 0001453593 XTNT:TwoThousandTwentyWarrantMember 2020-05-06 0001453593 XTNT:TwoThousandTwentyWarrantMember 2020-05-05 2020-05-06 0001453593 XTNT:SettlementAgreementMember 2021-07-02 0001453593 country:US 2021-01-01 2021-12-31 0001453593 country:US 2020-01-01 2020-12-31 0001453593 XTNT:SoleholdersMember 2021-12-31 0001453593 XTNT:SubleaseAgreementMember XTNT:CardialenIncMember 2021-01-01 2021-12-31 0001453593 XTNT:OneCustomerMember us-gaap:SalesRevenueNetMember XTNT:ConcentrationCreditRiskMember 2021-01-01 2021-12-31 0001453593 XTNT:TwoCustomerMember us-gaap:SalesRevenueNetMember XTNT:ConcentrationCreditRiskMember 2020-01-01 2020-12-31 0001453593 XTNT:RestOfWorldMember 2021-01-01 2021-12-31 0001453593 XTNT:RestOfWorldMember 2020-01-01 2020-12-31 iso4217:USD shares iso4217:USD shares pure 0001453593 false FY 10-K true 2021-12-31 --12-31 2021 false 001-34951 Xtant Medical Holdings, Inc. DE 20-5313323 664 Cruiser Lane Belgrade MT 59714 (406) 388-0480 Common stock, par value $.000001 per share XTNT NYSE No No Yes Yes Non-accelerated Filer true false false false 22000000.0 87313701 None 166 Plante & Moran, PLLC Denver, Colorado 55146000 53188000 117000 149000 55263000 53337000 22773000 18945000 32490000 34392000 14449000 13503000 21025000 20983000 870000 657000 36344000 35143000 -3854000 -751000 995000 5976000 -995000 -5976000 -4849000 -6727000 296000 -4849000 -7023000 -0.06 -0.25 -0.06 -0.25 85456175 28499847 85456175 28499847 18243000 2341000 144000 552000 653000 7154000 6880000 17945000 21408000 844000 736000 44330000 31365000 5212000 4347000 1258000 1690000 287000 402000 400000 457000 3205000 3205000 54692000 41466000 2615000 2947000 4349000 5462000 462000 423000 31000 20000 3620000 16797000 11077000 25649000 842000 1303000 103000 11787000 23809000 26952000 0.000001 0.000001 10000000 10000000 0 0 0 0 0.000001 0.000001 300000000 87068980 87068980 300000000 77573680 77573680 266068000 244850000 -235185000 -230336000 30883000 14514000 54692000 41466000 13161762 179061000 -223266000 -44205000 -47000 -47000 1084000 1084000 144878 1862000 1862000 1058000 58754394 62175000 62175000 143000 712646 620000 620000 4800000 48000 48000 -7023000 -7023000 77573680 244850000 -230336000 14514000 1926000 8888890 12831000 12831000 5243000 5243000 351000 351000 782596 785000 785000 -176186 -201000 -201000 2209000 2209000 -4849000 -4849000 87068980 266068000 -235185000 30883000 -4849000 -7023000 1332000 2079000 147000 5963000 9000 16000 86000 369000 2209000 1084000 45000 307000 839000 485000 319000 -2890000 -2624000 5792000 67000 -40000 -332000 101000 -1113000 -512000 439000 -731000 2115000 1545000 225000 241000 -1890000 -1304000 201000 50000 156000 136000 1058000 411000 315000 36361000 36492000 18426000 620000 48000 17497000 -861000 16046000 -2896000 2341000 5237000 18387000 2341000 18243000 2341000 144000 18387000 2341000 <p id="xdx_808_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_zIOjrEs1Rach" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1) <span id="xdx_82D_zwCBrJxlRds3">Business Description and Summary of Significant Accounting Policies</span></span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z8pwxPN3vRU" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_861_zqDVot1ZpXd6">Business Description</span></span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying consolidated financial statements include the accounts of Xtant Medical Holdings, Inc., formerly known as Bacterin International Holdings, Inc., a Delaware corporation, and its wholly owned subsidiaries, Xtant Medical, Inc., a Delaware corporation, Bacterin International, Inc., (“Bacterin”) a Nevada corporation, and X-Spine Systems, Inc. (“X-spine”), an Ohio corporation (Xtant Medical Inc., Bacterin and X-spine are jointly referred to herein as “Xtant” or the “Company”). The terms “we,” “us” and “our” also refer to Xtant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All intercompany balances and transactions have been eliminated in consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Xtant products serve the combined specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders to promote healing following spine, cranial and foot surgeries and the development, manufacturing and sale of medical devices for use in orthopedic spinal surgeries.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Since March 2020, the COVID-19 pandemic has caused business closures, severe travel restrictions and implementation of social distancing measures. At the onset of the COVID-19 pandemic, hospitals and other medical facilities cancelled or deferred elective procedures, diverted resources to patients suffering from infections and limited access for non-patients, including our direct and indirect sales representatives. Because of the COVID-19 pandemic, surgeons and their patients have been, and may continue to be, required, or are choosing, to defer procedures in which our products otherwise would be used, and many facilities that specialize in the procedures in which our products otherwise would be used have experienced temporary closures or reduced operating hours. These circumstances have negatively impacted, and may continue to negatively impact, the ability of our employees, independent sales representatives and distributors to effectively market and sell our products, which has had and will likely continue to have a material adverse effect on our revenues.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At December 31, 2021, the Company had cash and cash equivalents of $<span id="xdx_90E_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20211231_zFTW5X8r9sf9">18.2 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, and an accumulated deficit of $<span id="xdx_90A_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20211231_zserxO37hwHl">235.2 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and has incurred significant losses in the current and prior periods.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management’s evaluation of going concern was conducted as part of its discussions with the Xtant Board of Directors’ review of the 2022 Annual Operating Plan. Management believes that our $<span id="xdx_90A_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20211231_zNjCKfUtHeC8" title="Cash and cash equivalents">18.2</span> million of cash and cash equivalents as of December 31, 2021, together with amounts available under our line of credit, will be sufficient to meet our anticipated cash requirements through at least March 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_ecustom--InvestorRightsAgreementPolicyTextBlock_zKvwRxmxUJdb" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_865_zj28JRrwdCWb">Investor Rights Agreement</span></span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are party to an Investor Rights Agreement with ROS Acquisition Offshore (“ROS”) and OrbiMed Royalty Opportunities II, LP (“Royalty Opportunities”), which are funds affiliated with OrbiMed Advisors LLC (“OrbiMed”). Under the Investor Rights Agreement, Royalty Opportunities and ROS are permitted to nominate a majority of the directors and designate the chairperson of our Board of Directors at subsequent annual meetings, as long as they maintain an ownership threshold in our Company of at least 40% of our then outstanding common stock (the “Ownership Threshold”). If Royalty Opportunities and ROS are unable to maintain the Ownership Threshold, the Investor Rights Agreement contemplates a reduction of nomination rights commensurate with our ownership interests. <span id="xdx_907_ecustom--InvesterRightsAgreementDescription_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--InvestorRightsAgreementMember_z28F6xZOqNy7" title="Invester rights agreement, description">In addition, for so long as the Ownership Threshold is met, we must obtain the approval of a majority of our common stock held by Royalty Opportunities and ROS to proceed with the following actions: (i) issue new securities; (ii) incur over $250,000 of debt in a fiscal year; (iii) sell or transfer over $250,000 of our assets or businesses or our subsidiaries in a fiscal year; (iv) acquire over $250,000 of assets or properties in a fiscal year; (v) make capital expenditures over $125,000 individually, or $1.5 million in the aggregate during a fiscal year; (vi) approve our annual budget; (vii) hire or terminate our chief executive officer; (viii) appoint or remove the chairperson of our Board of Directors; and (ix) make, loans to, investments in, or purchase, or permit any subsidiary to purchase, any stock or other securities in another entity in excess of $250,000 in a fiscal year. As long as the Ownership Threshold is met, we may not increase the size of our Board or Directors beyond seven directors without the approval of a majority of the directors nominated by Royalty Opportunities and ROS.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Investor Rights Agreement grants Royalty Opportunities and ROS the right to purchase from us a pro rata amount of any new securities that we may propose to issue and sell. The Investor Rights Agreement may be terminated (a) upon the mutual written agreement of all the parties, (b) upon our written notice, ROS or Royalty Opportunities if the ownership percentage of our then outstanding common stock of ROS and Royalty Opportunities is less than 10%, or (c) upon written notice of ROS and Royalty Opportunities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--ConcentrationRiskCreditRisk_znyO6dTjlHed" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_867_zDjGHBOgPlCe">Concentrations and Credit Risk</span></span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s accounts receivables are from a variety of health care organizations and distributors throughout the world. No single customer accounted for more than <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20200101__20201231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--NoCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__custom--ConcentrationCreditRiskMember_zUDLFahUfWK2" title="Concentration risk, percentage"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--NoCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__custom--ConcentrationCreditRiskMember_z2ma6PrYyVg5" title="Concentration risk, percentage">10</span></span>% of our revenue or accounts receivable in the fiscal years 2021 or 2020. Management believes that all significant credit risks have been identified at December 31, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--UseOfEstimates_zaAVzdsrQ1p8" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_866_zyY9LZK2TK2">Use of Estimates</span></span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the financial statements requires management of the Company to make a number of estimates and assumptions relating to the reported amount of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the period. Significant estimates include the carrying amount of property and equipment, goodwill, and intangible assets and liabilities; valuation allowances for trade receivables, inventory and deferred income tax assets and liabilities; current and long-term lease obligations and corresponding right-of-use asset; and estimates for the fair value of long-term debt, stock option grants and other equity awards upon which the Company determines stock-based compensation expense. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zm1Omxk3EAi" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_865_zc99QYe0uBVc">Cash, Cash Equivalents, and Restricted Cash</span></span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company considers all highly liquid investments purchased with an original maturity date of three months or less to be cash equivalents. Cash equivalents are recorded at cost, which approximates market value. At times, the Company maintains deposits in financial institutions in excess of federally insured limits.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents classified as restricted cash on our condensed consolidated balance sheets are restricted as to withdrawal or use under the terms of certain credit agreements. The December 31, 2021 balance included lockbox deposits that are temporarily restricted due to timing at the period end. The lockbox deposits are applied against our line of credit the next business day.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--TradeAndOtherAccountsReceivablePolicy_z787hnjnBQod" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_860_zPEv33JMw3hg">Trade Accounts Receivable</span></span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts receivable represents amounts due from customers for which revenue has been recognized. Normal terms on trade accounts receivable are net 30 days, and some customers are offered discounts for early pay. The Company performs credit evaluations when considered necessary, but generally does not require collateral to extend credit.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Financial Instruments–Credit Losses: Measurement of Credit Losses on Financial Instruments </i><span style="background-color: white">to change the impairment model for most financial assets and certain other instruments. For trade and other receivables, held to maturity debt securities, loans, and other instruments, entities are required to use a new forward-looking “expected loss” model that generally will result in the earlier recognition of allowances for losses. The Company adopted the guidance on January 1, 2020 and recognized a cumulative effect adjustment of $<span id="xdx_902_ecustom--CumulativeEffectAdjustmentToRetainedEarningsAndAccountsREceivable_pn3n3_c20191230__20200102__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201613Member_zctS0jMCu37d" title="Cumulative effect adjustment">47,000</span> to retained earnings and accounts receivable, net as a result of adoption. The Company has included the additional disclosures required by ASU 2016-13 in Note 2, “</span><i>Receivables</i><span style="background-color: white">.”</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing receivables. The Company determines the allowance based on factors such as historical collection experience, customers’ current creditworthiness, customer concentration, age of accounts receivable balance, general economic conditions that may affect a customer’s ability to pay, and management judgment. In addition, we include provision for current expected credit loss based on historical collection experience adjusted for current economic conditions affecting collectability. Actual customer collections could differ from estimates. Account balances are charged to the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. Provisions to the allowance for doubtful accounts are charged to expense. The Company does not have any off-balance sheet credit exposure related to its customers.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_eus-gaap--InventoryPolicyTextBlock_zjusn6qvKDuk" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86B_zZ35Jk0aDj9i">Inventories</span></span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories are stated at the lower of cost or net realizable value. Cost is determined using the specific identification method and includes materials, labor and overhead. The Company calculates an inventory reserve for estimated obsolescence and excess inventory based on historical usage and sales, as well as assumptions about future demand for its products. These estimates for excess and obsolete inventory are reviewed and updated on a quarterly basis. Increases in the inventory reserves result in a corresponding expense, which is recorded to cost of sales.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zRCzgvdpiORa" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86C_zjLDMQs8svC3">Property and Equipment</span></span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally <span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputersAndEquipmentMember_zNZV8ltLf6rc" title="Property and equipment, estimated useful lives">three to seven years</span> for computers and equipment and <span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--SurgicalInstrumentsMember_zinEWSMlybzd" title="Property and equipment, estimated useful lives">five years</span> for surgical instruments. Leasehold improvements are depreciated over the shorter of their estimated useful life or the remaining term of the lease. Repairs and maintenance are expensed as incurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zKrF9hKfoKR6" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_861_zMQJNDEcK3jg">Intangible Assets</span></span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible assets with estimable useful lives are amortized over their respective estimated useful lives to their estimated residual values and reviewed for impairment whenever events or circumstances indicate their carrying amount may not be recoverable. Intangible assets include trademarks and patents and include costs to acquire and protect Company patents. Intangible assets are carried at cost less accumulated amortization. The Company amortizes these assets on a straight-line basis over their estimated useful lives.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_ecustom--OtherAssetsPolicyTextBlock_zxtrKLtCLPuc" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_866_zmWlStkXKtA">Other Assets</span></span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other assets consist of the short-term and the long-term portion of prepaid expenses and security deposits.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_zi4G8X3r3EH8" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-Lived Asset Impairment</span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-lived assets, including property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the estimated fair value of the assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--GoodwillAndIntangibleAssetsGoodwillPolicy_zqfAPhZ5Him9" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_869_zlvCGLLAe2vb">Goodwill</span></span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill represents the excess of costs over fair value of assets of businesses acquired. Goodwill and intangible assets acquired in a business combination and determined to have indefinite useful lives are not amortized, instead they are tested for impairment at least annually and whenever events or circumstances indicate the carrying amount of the asset may not be recoverable. The Company conducts its impairment test on an annual basis and reviews the assumptions on a quarterly basis. We test goodwill for impairment at the reporting unit level, which is an operating segment or one level below an operating segment, referred to as a component. A component of an operating segment is a reporting unit if the component constitutes a business for which discrete financial information is available and segment management regularly reviews the operating results of that component.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zHIZpyRJXhL6" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86E_zxtWIuyVGS8g">Revenue Recognition</span></span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the United States, we generate most of our revenue from independent commissioned sales agents. We consign our orthobiologics products to hospitals and consign or loan our spinal implant sets to the independent sales agents. The spinal implant sets typically contain the instruments, disposables, and spinal implants required to complete a surgery. Consigned sets are managed by the sales agent to service hospitals that are high volume users for multiple procedures. We ship replacement inventory to independent sales agents to replace the consigned inventory used in surgeries. Loaned sets are returned to the Company’s distribution center, replenished, and made available to sales agents for the next surgical procedure.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For each surgical procedure, the sales agent reports use of the product by the hospital and, as soon as practicable thereafter, ensures that the hospital provides a purchase order to the Company. Upon receipt of the hospital purchase order, the Company invoices the hospital, and revenue is recognized in the proper period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally, the Company sells product directly to domestic and international stocking resellers, original equipment manufacturer resellers and private label resellers. Upon receipt and acceptance of a purchase order from a stocking reseller, the Company ships product and invoices the reseller. The Company recognizes revenue when the products are shipped, and the transfer of title and risk of loss occurs. There is generally no customer acceptance or other condition that prevents the Company from recognizing revenue in accordance with the delivery terms for these sales transactions. In the normal course of business, the Company accepts returns of product that have not been implanted. Product returns are not material to the Company’s consolidated statements of operations. The Company accounts for shipping and handling activities as a fulfillment cost rather than a separate performance obligation. The Company’s policy is to record revenue net of any applicable sales, use, or excise taxes. Payment terms are generally net 30 days from invoice date and some customers are offered discounts for early pay.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disaggregation of revenue</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--DisaggregationOfRevenueTableTextBlock_z0y4l9052eu3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company operates in one reportable segment with its net revenue derived primarily from the sale of orthobiologics and spinal implant products across North America. Sales are reported net of returns. No rebates, group purchasing organization fees or other customer allowances are present, and so are not relevant to net revenue determination. The following table presents revenues from these product lines for the years ended December 31, 2021 and 2020 (dollars in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B5_z1NvRR0wqAQ5">Summary of Revenues from Product Lines</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2021</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Percentage of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total Revenue</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2020</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Percentage of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total Revenue</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Orthobiologics</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20211231__srt--ProductOrServiceAxis__custom--OrthobiologicsMember_zRKHCSk8f4z8" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42,259</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_ecustom--PercentageOfNetRevenue_pid_dp_uPure_c20210101__20211231__srt--ProductOrServiceAxis__custom--OrthobiologicsMember_zhy8iayxpsH2" title="Percentage of total revenue">77</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20201231__srt--ProductOrServiceAxis__custom--OrthobiologicsMember_zT2v5qgHA6nb" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39,308</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--PercentageOfNetRevenue_pid_dp_uPure_c20200101__20201231__srt--ProductOrServiceAxis__custom--OrthobiologicsMember_zEdiWaxVrG9i" title="Percentage of total revenue">74</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Spinal implant</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20211231__srt--ProductOrServiceAxis__custom--SpinalImplantMember_zq8y5FC9kFC4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,887</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_ecustom--PercentageOfNetRevenue_pid_dp_uPure_c20210101__20211231__srt--ProductOrServiceAxis__custom--SpinalImplantMember_zbqxRrwdqAyi" title="Percentage of total revenue">23</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20201231__srt--ProductOrServiceAxis__custom--SpinalImplantMember_zhBdN6LwqBX7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13,880</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_ecustom--PercentageOfNetRevenue_pid_dp_uPure_c20200101__20201231__srt--ProductOrServiceAxis__custom--SpinalImplantMember_zMkQLc7gPSbj" title="Percentage of total revenue">26</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other revenue</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20211231__srt--ProductOrServiceAxis__custom--OtherRevenueMember_z5043v1SZkxh" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">117</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_ecustom--PercentageOfNetRevenue_pid_dp_uPure_c20210101__20211231__srt--ProductOrServiceAxis__custom--OtherRevenueMember_zCZKYt62XMB" title="Percentage of total revenue">0</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20201231__srt--ProductOrServiceAxis__custom--OtherRevenueMember_z39PbFre20vc" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">149</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_ecustom--PercentageOfNetRevenue_pid_dp_uPure_c20200101__20201231__srt--ProductOrServiceAxis__custom--OtherRevenueMember_zM1yLkeCXxy7" title="Percentage of total revenue">0</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total revenue</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20211231_zIcI8kL4cYF2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55,263</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_ecustom--PercentageOfNetRevenue_pid_dp_uPure_c20210101__20211231_z8oTjvwNV9a1" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Percentage of total revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20201231_zS8Xy32WAg9h" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53,337</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_ecustom--PercentageOfNetRevenue_pid_dp_uPure_c20200101__20201231_zGoyrjmcpG4j" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Percentage of total revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> </table> <p id="xdx_8AB_z6V5Lki2BGm5" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--ResearchAndDevelopmentExpensePolicy_zN34x2OMHc73" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_862_zrdOxS3NSoq4">Research and Development</span></span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development costs, which are principally related to internal costs for the development of new products, are expensed as incurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--EarningsPerSharePolicyTextBlock_zkfi6wESfwsg" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_861_z8YuZ0TsHZLg">Net Loss Per Share</span></span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding. Shares issued during the period and shares reacquired during the period are weighted for the portion of the period that they were outstanding. Diluted net loss per share is computed in a manner consistent with that of basic earnings per share while giving effect to all potentially dilutive shares of common stock outstanding during the period, which include the assumed exercise of stock options and warrants using the treasury stock method. Diluted net loss per share was the same as basic net loss per share for the years ended December 31, 2021 and 2020, as shares issuable upon the exercise of stock options and warrants and settlement of restricted stock units were anti-dilutive as a result of the net losses incurred for those periods. Diluted net loss per share is not reported as the effects of including <span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231_zCFTuOFyp3Be" title="Antidilutive securities excluded from computation of earnings per share, amount">13,282,882</span> and <span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231_zScBDLYbWJrb" title="Antidilutive securities excluded from computation of earnings per share, amount">5,115,868</span> outstanding stock options, warrants and restricted stock units for the years ended December 31, 2021 and 2020, respectively, are anti-dilutive.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z0zk7lMSjO7f" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86F_zw3siTW7pMJ2">Fair Value of Financial Instruments</span></span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The carrying values of financial instruments, including trade accounts receivable, accounts payable, accrued liabilities and long-term debt, approximate their fair values based on terms and related interest rates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company follows a framework for measuring fair value. The framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1: Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2: Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3: Inputs to the valuation methodology are unobservable and significant to the fair value measurement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. During the years ended December 31, 2021 and 2020, there was no reclassification in financial assets or liabilities between Level 1, 2 or 3 categories.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zIlp1vxWeRJf" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_866_zLVhDDGl0ve9">Reclassification</span></span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior year amounts have been reclassified to conform with current year presentation.</span></p> <p id="xdx_858_zhjHJFCsZNHf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z8pwxPN3vRU" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_861_zqDVot1ZpXd6">Business Description</span></span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying consolidated financial statements include the accounts of Xtant Medical Holdings, Inc., formerly known as Bacterin International Holdings, Inc., a Delaware corporation, and its wholly owned subsidiaries, Xtant Medical, Inc., a Delaware corporation, Bacterin International, Inc., (“Bacterin”) a Nevada corporation, and X-Spine Systems, Inc. (“X-spine”), an Ohio corporation (Xtant Medical Inc., Bacterin and X-spine are jointly referred to herein as “Xtant” or the “Company”). The terms “we,” “us” and “our” also refer to Xtant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All intercompany balances and transactions have been eliminated in consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Xtant products serve the combined specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders to promote healing following spine, cranial and foot surgeries and the development, manufacturing and sale of medical devices for use in orthopedic spinal surgeries.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Since March 2020, the COVID-19 pandemic has caused business closures, severe travel restrictions and implementation of social distancing measures. At the onset of the COVID-19 pandemic, hospitals and other medical facilities cancelled or deferred elective procedures, diverted resources to patients suffering from infections and limited access for non-patients, including our direct and indirect sales representatives. Because of the COVID-19 pandemic, surgeons and their patients have been, and may continue to be, required, or are choosing, to defer procedures in which our products otherwise would be used, and many facilities that specialize in the procedures in which our products otherwise would be used have experienced temporary closures or reduced operating hours. These circumstances have negatively impacted, and may continue to negatively impact, the ability of our employees, independent sales representatives and distributors to effectively market and sell our products, which has had and will likely continue to have a material adverse effect on our revenues.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At December 31, 2021, the Company had cash and cash equivalents of $<span id="xdx_90E_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20211231_zFTW5X8r9sf9">18.2 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, and an accumulated deficit of $<span id="xdx_90A_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20211231_zserxO37hwHl">235.2 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and has incurred significant losses in the current and prior periods.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management’s evaluation of going concern was conducted as part of its discussions with the Xtant Board of Directors’ review of the 2022 Annual Operating Plan. Management believes that our $<span id="xdx_90A_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20211231_zNjCKfUtHeC8" title="Cash and cash equivalents">18.2</span> million of cash and cash equivalents as of December 31, 2021, together with amounts available under our line of credit, will be sufficient to meet our anticipated cash requirements through at least March 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 18200000 -235200000 18200000 <p id="xdx_848_ecustom--InvestorRightsAgreementPolicyTextBlock_zKvwRxmxUJdb" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_865_zj28JRrwdCWb">Investor Rights Agreement</span></span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are party to an Investor Rights Agreement with ROS Acquisition Offshore (“ROS”) and OrbiMed Royalty Opportunities II, LP (“Royalty Opportunities”), which are funds affiliated with OrbiMed Advisors LLC (“OrbiMed”). Under the Investor Rights Agreement, Royalty Opportunities and ROS are permitted to nominate a majority of the directors and designate the chairperson of our Board of Directors at subsequent annual meetings, as long as they maintain an ownership threshold in our Company of at least 40% of our then outstanding common stock (the “Ownership Threshold”). If Royalty Opportunities and ROS are unable to maintain the Ownership Threshold, the Investor Rights Agreement contemplates a reduction of nomination rights commensurate with our ownership interests. <span id="xdx_907_ecustom--InvesterRightsAgreementDescription_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--InvestorRightsAgreementMember_z28F6xZOqNy7" title="Invester rights agreement, description">In addition, for so long as the Ownership Threshold is met, we must obtain the approval of a majority of our common stock held by Royalty Opportunities and ROS to proceed with the following actions: (i) issue new securities; (ii) incur over $250,000 of debt in a fiscal year; (iii) sell or transfer over $250,000 of our assets or businesses or our subsidiaries in a fiscal year; (iv) acquire over $250,000 of assets or properties in a fiscal year; (v) make capital expenditures over $125,000 individually, or $1.5 million in the aggregate during a fiscal year; (vi) approve our annual budget; (vii) hire or terminate our chief executive officer; (viii) appoint or remove the chairperson of our Board of Directors; and (ix) make, loans to, investments in, or purchase, or permit any subsidiary to purchase, any stock or other securities in another entity in excess of $250,000 in a fiscal year. As long as the Ownership Threshold is met, we may not increase the size of our Board or Directors beyond seven directors without the approval of a majority of the directors nominated by Royalty Opportunities and ROS.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Investor Rights Agreement grants Royalty Opportunities and ROS the right to purchase from us a pro rata amount of any new securities that we may propose to issue and sell. The Investor Rights Agreement may be terminated (a) upon the mutual written agreement of all the parties, (b) upon our written notice, ROS or Royalty Opportunities if the ownership percentage of our then outstanding common stock of ROS and Royalty Opportunities is less than 10%, or (c) upon written notice of ROS and Royalty Opportunities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> In addition, for so long as the Ownership Threshold is met, we must obtain the approval of a majority of our common stock held by Royalty Opportunities and ROS to proceed with the following actions: (i) issue new securities; (ii) incur over $250,000 of debt in a fiscal year; (iii) sell or transfer over $250,000 of our assets or businesses or our subsidiaries in a fiscal year; (iv) acquire over $250,000 of assets or properties in a fiscal year; (v) make capital expenditures over $125,000 individually, or $1.5 million in the aggregate during a fiscal year; (vi) approve our annual budget; (vii) hire or terminate our chief executive officer; (viii) appoint or remove the chairperson of our Board of Directors; and (ix) make, loans to, investments in, or purchase, or permit any subsidiary to purchase, any stock or other securities in another entity in excess of $250,000 in a fiscal year. As long as the Ownership Threshold is met, we may not increase the size of our Board or Directors beyond seven directors without the approval of a majority of the directors nominated by Royalty Opportunities and ROS. <p id="xdx_845_eus-gaap--ConcentrationRiskCreditRisk_znyO6dTjlHed" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_867_zDjGHBOgPlCe">Concentrations and Credit Risk</span></span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s accounts receivables are from a variety of health care organizations and distributors throughout the world. No single customer accounted for more than <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20200101__20201231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--NoCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__custom--ConcentrationCreditRiskMember_zUDLFahUfWK2" title="Concentration risk, percentage"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--NoCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__custom--ConcentrationCreditRiskMember_z2ma6PrYyVg5" title="Concentration risk, percentage">10</span></span>% of our revenue or accounts receivable in the fiscal years 2021 or 2020. Management believes that all significant credit risks have been identified at December 31, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0.10 0.10 <p id="xdx_842_eus-gaap--UseOfEstimates_zaAVzdsrQ1p8" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_866_zyY9LZK2TK2">Use of Estimates</span></span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the financial statements requires management of the Company to make a number of estimates and assumptions relating to the reported amount of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the period. Significant estimates include the carrying amount of property and equipment, goodwill, and intangible assets and liabilities; valuation allowances for trade receivables, inventory and deferred income tax assets and liabilities; current and long-term lease obligations and corresponding right-of-use asset; and estimates for the fair value of long-term debt, stock option grants and other equity awards upon which the Company determines stock-based compensation expense. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zm1Omxk3EAi" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_865_zc99QYe0uBVc">Cash, Cash Equivalents, and Restricted Cash</span></span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company considers all highly liquid investments purchased with an original maturity date of three months or less to be cash equivalents. Cash equivalents are recorded at cost, which approximates market value. At times, the Company maintains deposits in financial institutions in excess of federally insured limits.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents classified as restricted cash on our condensed consolidated balance sheets are restricted as to withdrawal or use under the terms of certain credit agreements. The December 31, 2021 balance included lockbox deposits that are temporarily restricted due to timing at the period end. The lockbox deposits are applied against our line of credit the next business day.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--TradeAndOtherAccountsReceivablePolicy_z787hnjnBQod" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_860_zPEv33JMw3hg">Trade Accounts Receivable</span></span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts receivable represents amounts due from customers for which revenue has been recognized. Normal terms on trade accounts receivable are net 30 days, and some customers are offered discounts for early pay. The Company performs credit evaluations when considered necessary, but generally does not require collateral to extend credit.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Financial Instruments–Credit Losses: Measurement of Credit Losses on Financial Instruments </i><span style="background-color: white">to change the impairment model for most financial assets and certain other instruments. For trade and other receivables, held to maturity debt securities, loans, and other instruments, entities are required to use a new forward-looking “expected loss” model that generally will result in the earlier recognition of allowances for losses. The Company adopted the guidance on January 1, 2020 and recognized a cumulative effect adjustment of $<span id="xdx_902_ecustom--CumulativeEffectAdjustmentToRetainedEarningsAndAccountsREceivable_pn3n3_c20191230__20200102__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201613Member_zctS0jMCu37d" title="Cumulative effect adjustment">47,000</span> to retained earnings and accounts receivable, net as a result of adoption. The Company has included the additional disclosures required by ASU 2016-13 in Note 2, “</span><i>Receivables</i><span style="background-color: white">.”</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing receivables. The Company determines the allowance based on factors such as historical collection experience, customers’ current creditworthiness, customer concentration, age of accounts receivable balance, general economic conditions that may affect a customer’s ability to pay, and management judgment. In addition, we include provision for current expected credit loss based on historical collection experience adjusted for current economic conditions affecting collectability. Actual customer collections could differ from estimates. Account balances are charged to the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. Provisions to the allowance for doubtful accounts are charged to expense. The Company does not have any off-balance sheet credit exposure related to its customers.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 47000000 <p id="xdx_84D_eus-gaap--InventoryPolicyTextBlock_zjusn6qvKDuk" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86B_zZ35Jk0aDj9i">Inventories</span></span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories are stated at the lower of cost or net realizable value. Cost is determined using the specific identification method and includes materials, labor and overhead. The Company calculates an inventory reserve for estimated obsolescence and excess inventory based on historical usage and sales, as well as assumptions about future demand for its products. These estimates for excess and obsolete inventory are reviewed and updated on a quarterly basis. Increases in the inventory reserves result in a corresponding expense, which is recorded to cost of sales.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zRCzgvdpiORa" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86C_zjLDMQs8svC3">Property and Equipment</span></span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally <span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputersAndEquipmentMember_zNZV8ltLf6rc" title="Property and equipment, estimated useful lives">three to seven years</span> for computers and equipment and <span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--SurgicalInstrumentsMember_zinEWSMlybzd" title="Property and equipment, estimated useful lives">five years</span> for surgical instruments. Leasehold improvements are depreciated over the shorter of their estimated useful life or the remaining term of the lease. Repairs and maintenance are expensed as incurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> three to seven years five years <p id="xdx_845_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zKrF9hKfoKR6" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_861_zMQJNDEcK3jg">Intangible Assets</span></span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible assets with estimable useful lives are amortized over their respective estimated useful lives to their estimated residual values and reviewed for impairment whenever events or circumstances indicate their carrying amount may not be recoverable. Intangible assets include trademarks and patents and include costs to acquire and protect Company patents. Intangible assets are carried at cost less accumulated amortization. The Company amortizes these assets on a straight-line basis over their estimated useful lives.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_ecustom--OtherAssetsPolicyTextBlock_zxtrKLtCLPuc" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_866_zmWlStkXKtA">Other Assets</span></span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other assets consist of the short-term and the long-term portion of prepaid expenses and security deposits.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_zi4G8X3r3EH8" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-Lived Asset Impairment</span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-lived assets, including property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the estimated fair value of the assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--GoodwillAndIntangibleAssetsGoodwillPolicy_zqfAPhZ5Him9" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_869_zlvCGLLAe2vb">Goodwill</span></span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill represents the excess of costs over fair value of assets of businesses acquired. Goodwill and intangible assets acquired in a business combination and determined to have indefinite useful lives are not amortized, instead they are tested for impairment at least annually and whenever events or circumstances indicate the carrying amount of the asset may not be recoverable. The Company conducts its impairment test on an annual basis and reviews the assumptions on a quarterly basis. We test goodwill for impairment at the reporting unit level, which is an operating segment or one level below an operating segment, referred to as a component. A component of an operating segment is a reporting unit if the component constitutes a business for which discrete financial information is available and segment management regularly reviews the operating results of that component.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zHIZpyRJXhL6" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86E_zxtWIuyVGS8g">Revenue Recognition</span></span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the United States, we generate most of our revenue from independent commissioned sales agents. We consign our orthobiologics products to hospitals and consign or loan our spinal implant sets to the independent sales agents. The spinal implant sets typically contain the instruments, disposables, and spinal implants required to complete a surgery. Consigned sets are managed by the sales agent to service hospitals that are high volume users for multiple procedures. We ship replacement inventory to independent sales agents to replace the consigned inventory used in surgeries. Loaned sets are returned to the Company’s distribution center, replenished, and made available to sales agents for the next surgical procedure.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For each surgical procedure, the sales agent reports use of the product by the hospital and, as soon as practicable thereafter, ensures that the hospital provides a purchase order to the Company. Upon receipt of the hospital purchase order, the Company invoices the hospital, and revenue is recognized in the proper period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally, the Company sells product directly to domestic and international stocking resellers, original equipment manufacturer resellers and private label resellers. Upon receipt and acceptance of a purchase order from a stocking reseller, the Company ships product and invoices the reseller. The Company recognizes revenue when the products are shipped, and the transfer of title and risk of loss occurs. There is generally no customer acceptance or other condition that prevents the Company from recognizing revenue in accordance with the delivery terms for these sales transactions. In the normal course of business, the Company accepts returns of product that have not been implanted. Product returns are not material to the Company’s consolidated statements of operations. The Company accounts for shipping and handling activities as a fulfillment cost rather than a separate performance obligation. The Company’s policy is to record revenue net of any applicable sales, use, or excise taxes. Payment terms are generally net 30 days from invoice date and some customers are offered discounts for early pay.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disaggregation of revenue</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--DisaggregationOfRevenueTableTextBlock_z0y4l9052eu3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company operates in one reportable segment with its net revenue derived primarily from the sale of orthobiologics and spinal implant products across North America. Sales are reported net of returns. No rebates, group purchasing organization fees or other customer allowances are present, and so are not relevant to net revenue determination. The following table presents revenues from these product lines for the years ended December 31, 2021 and 2020 (dollars in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B5_z1NvRR0wqAQ5">Summary of Revenues from Product Lines</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2021</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Percentage of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total Revenue</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2020</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Percentage of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total Revenue</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Orthobiologics</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20211231__srt--ProductOrServiceAxis__custom--OrthobiologicsMember_zRKHCSk8f4z8" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42,259</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_ecustom--PercentageOfNetRevenue_pid_dp_uPure_c20210101__20211231__srt--ProductOrServiceAxis__custom--OrthobiologicsMember_zhy8iayxpsH2" title="Percentage of total revenue">77</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20201231__srt--ProductOrServiceAxis__custom--OrthobiologicsMember_zT2v5qgHA6nb" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39,308</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--PercentageOfNetRevenue_pid_dp_uPure_c20200101__20201231__srt--ProductOrServiceAxis__custom--OrthobiologicsMember_zEdiWaxVrG9i" title="Percentage of total revenue">74</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Spinal implant</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20211231__srt--ProductOrServiceAxis__custom--SpinalImplantMember_zq8y5FC9kFC4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,887</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_ecustom--PercentageOfNetRevenue_pid_dp_uPure_c20210101__20211231__srt--ProductOrServiceAxis__custom--SpinalImplantMember_zbqxRrwdqAyi" title="Percentage of total revenue">23</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20201231__srt--ProductOrServiceAxis__custom--SpinalImplantMember_zhBdN6LwqBX7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13,880</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_ecustom--PercentageOfNetRevenue_pid_dp_uPure_c20200101__20201231__srt--ProductOrServiceAxis__custom--SpinalImplantMember_zMkQLc7gPSbj" title="Percentage of total revenue">26</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other revenue</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20211231__srt--ProductOrServiceAxis__custom--OtherRevenueMember_z5043v1SZkxh" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">117</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_ecustom--PercentageOfNetRevenue_pid_dp_uPure_c20210101__20211231__srt--ProductOrServiceAxis__custom--OtherRevenueMember_zCZKYt62XMB" title="Percentage of total revenue">0</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20201231__srt--ProductOrServiceAxis__custom--OtherRevenueMember_z39PbFre20vc" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">149</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_ecustom--PercentageOfNetRevenue_pid_dp_uPure_c20200101__20201231__srt--ProductOrServiceAxis__custom--OtherRevenueMember_zM1yLkeCXxy7" title="Percentage of total revenue">0</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total revenue</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20211231_zIcI8kL4cYF2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55,263</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_ecustom--PercentageOfNetRevenue_pid_dp_uPure_c20210101__20211231_z8oTjvwNV9a1" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Percentage of total revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20201231_zS8Xy32WAg9h" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53,337</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_ecustom--PercentageOfNetRevenue_pid_dp_uPure_c20200101__20201231_zGoyrjmcpG4j" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Percentage of total revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> </table> <p id="xdx_8AB_z6V5Lki2BGm5" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--DisaggregationOfRevenueTableTextBlock_z0y4l9052eu3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company operates in one reportable segment with its net revenue derived primarily from the sale of orthobiologics and spinal implant products across North America. Sales are reported net of returns. No rebates, group purchasing organization fees or other customer allowances are present, and so are not relevant to net revenue determination. The following table presents revenues from these product lines for the years ended December 31, 2021 and 2020 (dollars in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B5_z1NvRR0wqAQ5">Summary of Revenues from Product Lines</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2021</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Percentage of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total Revenue</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2020</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Percentage of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total Revenue</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Orthobiologics</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20211231__srt--ProductOrServiceAxis__custom--OrthobiologicsMember_zRKHCSk8f4z8" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42,259</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_ecustom--PercentageOfNetRevenue_pid_dp_uPure_c20210101__20211231__srt--ProductOrServiceAxis__custom--OrthobiologicsMember_zhy8iayxpsH2" title="Percentage of total revenue">77</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20201231__srt--ProductOrServiceAxis__custom--OrthobiologicsMember_zT2v5qgHA6nb" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39,308</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--PercentageOfNetRevenue_pid_dp_uPure_c20200101__20201231__srt--ProductOrServiceAxis__custom--OrthobiologicsMember_zEdiWaxVrG9i" title="Percentage of total revenue">74</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Spinal implant</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20211231__srt--ProductOrServiceAxis__custom--SpinalImplantMember_zq8y5FC9kFC4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,887</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_ecustom--PercentageOfNetRevenue_pid_dp_uPure_c20210101__20211231__srt--ProductOrServiceAxis__custom--SpinalImplantMember_zbqxRrwdqAyi" title="Percentage of total revenue">23</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20201231__srt--ProductOrServiceAxis__custom--SpinalImplantMember_zhBdN6LwqBX7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13,880</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_ecustom--PercentageOfNetRevenue_pid_dp_uPure_c20200101__20201231__srt--ProductOrServiceAxis__custom--SpinalImplantMember_zMkQLc7gPSbj" title="Percentage of total revenue">26</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other revenue</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20211231__srt--ProductOrServiceAxis__custom--OtherRevenueMember_z5043v1SZkxh" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">117</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_ecustom--PercentageOfNetRevenue_pid_dp_uPure_c20210101__20211231__srt--ProductOrServiceAxis__custom--OtherRevenueMember_zCZKYt62XMB" title="Percentage of total revenue">0</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20201231__srt--ProductOrServiceAxis__custom--OtherRevenueMember_z39PbFre20vc" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">149</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_ecustom--PercentageOfNetRevenue_pid_dp_uPure_c20200101__20201231__srt--ProductOrServiceAxis__custom--OtherRevenueMember_zM1yLkeCXxy7" title="Percentage of total revenue">0</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total revenue</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20211231_zIcI8kL4cYF2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55,263</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_ecustom--PercentageOfNetRevenue_pid_dp_uPure_c20210101__20211231_z8oTjvwNV9a1" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Percentage of total revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20201231_zS8Xy32WAg9h" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53,337</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_ecustom--PercentageOfNetRevenue_pid_dp_uPure_c20200101__20201231_zGoyrjmcpG4j" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Percentage of total revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> </table> 42259000 0.77 39308000 0.74 12887000 0.23 13880000 0.26 117000 0 149000 0 55263000 1 53337000 1 <p id="xdx_841_eus-gaap--ResearchAndDevelopmentExpensePolicy_zN34x2OMHc73" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_862_zrdOxS3NSoq4">Research and Development</span></span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development costs, which are principally related to internal costs for the development of new products, are expensed as incurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--EarningsPerSharePolicyTextBlock_zkfi6wESfwsg" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_861_z8YuZ0TsHZLg">Net Loss Per Share</span></span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding. Shares issued during the period and shares reacquired during the period are weighted for the portion of the period that they were outstanding. Diluted net loss per share is computed in a manner consistent with that of basic earnings per share while giving effect to all potentially dilutive shares of common stock outstanding during the period, which include the assumed exercise of stock options and warrants using the treasury stock method. Diluted net loss per share was the same as basic net loss per share for the years ended December 31, 2021 and 2020, as shares issuable upon the exercise of stock options and warrants and settlement of restricted stock units were anti-dilutive as a result of the net losses incurred for those periods. Diluted net loss per share is not reported as the effects of including <span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231_zCFTuOFyp3Be" title="Antidilutive securities excluded from computation of earnings per share, amount">13,282,882</span> and <span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231_zScBDLYbWJrb" title="Antidilutive securities excluded from computation of earnings per share, amount">5,115,868</span> outstanding stock options, warrants and restricted stock units for the years ended December 31, 2021 and 2020, respectively, are anti-dilutive.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 13282882 5115868 <p id="xdx_841_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z0zk7lMSjO7f" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86F_zw3siTW7pMJ2">Fair Value of Financial Instruments</span></span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The carrying values of financial instruments, including trade accounts receivable, accounts payable, accrued liabilities and long-term debt, approximate their fair values based on terms and related interest rates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company follows a framework for measuring fair value. The framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1: Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2: Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3: Inputs to the valuation methodology are unobservable and significant to the fair value measurement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. During the years ended December 31, 2021 and 2020, there was no reclassification in financial assets or liabilities between Level 1, 2 or 3 categories.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zIlp1vxWeRJf" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_866_zLVhDDGl0ve9">Reclassification</span></span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior year amounts have been reclassified to conform with current year presentation.</span></p> <p id="xdx_809_eus-gaap--AccountsAndNontradeReceivableTextBlock_zQH3QM4stSPf" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2) <span id="xdx_829_zuEVQmroOwZa">Receivables</span></span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Concurrent with the adoption of ASU 2016-13, the Company’s allowance for doubtful accounts was expanded to include provision for current expected credit loss (“CECL”). The Company’s provision for CECL is determined based on historical collection experience adjusted for current economic conditions affecting collectability. Actual customer collections could differ from estimates. Account balances are charged to the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. Provisions to the allowance for credit losses are charged to expense. Activity within the allowance for credit losses was as follows for years ended December 31, 2021 and 2020 (in thousands):</span></p> <p id="xdx_89D_eus-gaap--AccountsReceivableAllowanceForCreditLossTableTextBlock_zW8lMQDYVHM8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"> <span id="xdx_8BC_zdYQWBAKQQyf" style="display: none">Schedule of Allowance for Credit Losses</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2020</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance at January 1</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_983_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iS_pn3n3_c20210101__20211231_zSPzPJGAiOoc" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">653</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iS_pn3n3_c20200101__20201231_z3BUUvB6UjZ7" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">547</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provision for current expected credit losses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--ProvisionForDoubtfulAccounts_pn3n3_c20210101__20211231_z4Axkbb99qMg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Provision for expected credit losses"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--ProvisionForDoubtfulAccounts_pn3n3_c20200101__20201231_z5GQPyCWhCve" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">307</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Write-offs against allowance</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_eus-gaap--AllowanceForDoubtfulAccountsReceivableWriteOffs_iN_pn3n3_di_c20210101__20211231_zAEDJCch2sVj" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Write-offs against allowance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(146</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--AllowanceForDoubtfulAccountsReceivableWriteOffs_iN_pn3n3_di_c20200101__20201231_zARBInxNnVE1" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Write-offs against allowance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(201</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_986_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iE_pn3n3_c20210101__20211231_zVSx5QUwoxl2" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">552</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iE_pn3n3_c20200101__20201231_z3Z32JFTLs07" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">653</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A8_z7qf40qf29Ok" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_89D_eus-gaap--AccountsReceivableAllowanceForCreditLossTableTextBlock_zW8lMQDYVHM8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"> <span id="xdx_8BC_zdYQWBAKQQyf" style="display: none">Schedule of Allowance for Credit Losses</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2020</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance at January 1</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_983_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iS_pn3n3_c20210101__20211231_zSPzPJGAiOoc" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">653</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iS_pn3n3_c20200101__20201231_z3BUUvB6UjZ7" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">547</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provision for current expected credit losses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--ProvisionForDoubtfulAccounts_pn3n3_c20210101__20211231_z4Axkbb99qMg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Provision for expected credit losses"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--ProvisionForDoubtfulAccounts_pn3n3_c20200101__20201231_z5GQPyCWhCve" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">307</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Write-offs against allowance</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_eus-gaap--AllowanceForDoubtfulAccountsReceivableWriteOffs_iN_pn3n3_di_c20210101__20211231_zAEDJCch2sVj" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Write-offs against allowance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(146</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--AllowanceForDoubtfulAccountsReceivableWriteOffs_iN_pn3n3_di_c20200101__20201231_zARBInxNnVE1" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Write-offs against allowance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(201</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_986_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iE_pn3n3_c20210101__20211231_zVSx5QUwoxl2" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">552</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iE_pn3n3_c20200101__20201231_z3Z32JFTLs07" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">653</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 653000 547000 45000 307000 146000 201000 552000 653000 <p id="xdx_80D_eus-gaap--InventoryDisclosureTextBlock_zXkVQLQBCwj9" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3) <span id="xdx_827_zK9le1u1thwb">Inventories</span></span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_ziq7lHvUNfv6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories consist of the following (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BF_zoKBZG8P7hBl" style="display: none">Schedule of Inventories</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49C_20211231_zPEtyg9fncJ" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49F_20201231_zY6Z9JWRlHdj" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2020</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_407_eus-gaap--InventoryRawMaterialsAndSupplies_iI_maINz0Il_zYjoKr5V8Uva" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Raw materials</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,613</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,757</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--InventoryWorkInProcess_iI_maINz0Il_zUTolkoVTdOj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Work in process</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">571</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,733</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_405_eus-gaap--InventoryFinishedGoods_iI_maINz0Il_zGt9LYOo37S3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finished goods</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,761</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,918</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--InventoryNet_iI_mtINz0Il_zqnHKSvLVsqc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"> Total</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17,945</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21,408</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A6_zPBqflWNiagj" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_ziq7lHvUNfv6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories consist of the following (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BF_zoKBZG8P7hBl" style="display: none">Schedule of Inventories</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49C_20211231_zPEtyg9fncJ" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49F_20201231_zY6Z9JWRlHdj" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2020</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_407_eus-gaap--InventoryRawMaterialsAndSupplies_iI_maINz0Il_zYjoKr5V8Uva" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Raw materials</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,613</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,757</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--InventoryWorkInProcess_iI_maINz0Il_zUTolkoVTdOj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Work in process</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">571</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,733</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_405_eus-gaap--InventoryFinishedGoods_iI_maINz0Il_zGt9LYOo37S3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finished goods</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,761</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,918</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--InventoryNet_iI_mtINz0Il_zqnHKSvLVsqc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"> Total</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17,945</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21,408</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 5613000 3757000 571000 1733000 11761000 15918000 17945000 21408000 <p id="xdx_800_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zDtsMDMgN7S2" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4) <span id="xdx_823_zbLRqamncLM4">Property and Equipment, Net</span></span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_eus-gaap--PropertyPlantAndEquipmentTextBlock_z8qGBjlvuvn3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, net are as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B3_zogVbMVxAhT8" style="display: none">Schedule of Property and Equipment, Net</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_494_20211231_zO5Ukey5398c" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_499_20201231_zPmZL9pUTYm5" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2020</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zaixNkEsAog4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equipment</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,541</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,807</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zsG1GEO8HOZ9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer equipment</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">828</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">649</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerSoftwaresMember_zj4jCbzwKcd2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer software</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">490</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">570</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zGf2USTSDes6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture and fixtures</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">94</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">133</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zstCWA8PT9Ud" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold improvements</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,994</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,987</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OtherPropertiesMember_z7o4ODjiXOkg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--SurgicalInstrumentsMember_zdcqZO339oib" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Surgical instruments</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,424</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,291</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total cost</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22,381</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21,447</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_zAzFM0lRK991" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: accumulated depreciation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(17,169</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(17,100</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_zlBkKh0k9wB2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"> Total</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,212</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,347</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8AB_z9U4a2SnrHtg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation expense related to property and equipment, including property under capital lease, for the years ended December 31, 2021 and 2020 was $<span id="xdx_900_eus-gaap--Depreciation_pn5n6_c20210101__20211231_zu1XzTPvKiw1" title="Depreciation expenses">1.3</span> million and $<span id="xdx_907_eus-gaap--Depreciation_pn5n6_c20200101__20201231_zo06doFA4OOd">2.0</span> million, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_eus-gaap--PropertyPlantAndEquipmentTextBlock_z8qGBjlvuvn3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, net are as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B3_zogVbMVxAhT8" style="display: none">Schedule of Property and Equipment, Net</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_494_20211231_zO5Ukey5398c" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_499_20201231_zPmZL9pUTYm5" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2020</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zaixNkEsAog4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equipment</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,541</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,807</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zsG1GEO8HOZ9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer equipment</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">828</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">649</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerSoftwaresMember_zj4jCbzwKcd2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer software</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">490</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">570</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zGf2USTSDes6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture and fixtures</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">94</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">133</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zstCWA8PT9Ud" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold improvements</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,994</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,987</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OtherPropertiesMember_z7o4ODjiXOkg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--SurgicalInstrumentsMember_zdcqZO339oib" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Surgical instruments</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,424</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,291</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total cost</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22,381</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21,447</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_zAzFM0lRK991" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: accumulated depreciation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(17,169</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(17,100</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_zlBkKh0k9wB2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"> Total</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,212</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,347</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 5541000 4807000 828000 649000 490000 570000 94000 133000 3994000 3987000 10000 10000 11424000 11291000 22381000 21447000 17169000 17100000 5212000 4347000 1300000 2000000.0 <p id="xdx_809_eus-gaap--GoodwillAndIntangibleAssetsDisclosureTextBlock_ztK54hr6N0B2" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5) <span id="xdx_82E_zIhjdc1kJfa7">Goodwill and Intangible Assets</span></span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The results of the Company’s annual goodwill impairment tests for the years ended December 31, 2021 and 2020 indicated that no goodwill impairment existed as of the test date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_897_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zYx753GFSka" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table sets forth information regarding intangible assets (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B7_zGwqCPxmYU2l" style="display: none">Schedule of Goodwill and Intangible Assets</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49F_20211231_zD9DV465tZtb" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_496_20201231_zisOE9VcjN9j" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2020</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_maIANEGzgp3_zFSpudpPG8e6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patents</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">847</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">847</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_msIANEGzgp3_z7Q1ak92jqri" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated amortization</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(447</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(390</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_40D_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_mtIANEGzgp3_zVlMeXtKnlGc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net carrying value</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">400</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">457</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A9_zEB92xxwWjLa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization expense was $<span id="xdx_902_eus-gaap--AmortizationOfIntangibleAssets_pn5n6_c20210101__20211231_zJyQQA4rhKne" title="Amortization of intangible assets"><span id="xdx_907_eus-gaap--AmortizationOfIntangibleAssets_pn5n6_c20200101__20201231_zveRGerF7GEg" title="Amortization of intangible assets">0.1</span></span> million for both of the years ended December 31, 2021 and 2020. The following is a summary of estimated future amortization expense for intangible assets as of December 31, 2021 (in thousands):</span></p> <p id="xdx_89A_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zTnQFy2d9Iqc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_zrFAqNRNnnA9" style="display: none">Summary of Future Amortization Expense for Intangible Assets</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_498_20211231_zTaCfPCSZLJk" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANzqWk_zEacInCRPVNi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANzqWk_zctGib5cYAA3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maFLIANzqWk_zAUPAWh9gsi8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_maFLIANzqWk_z9rtGe026wI4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pn3n3_maFLIANzqWk_zLMfNPsr7GUk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2026</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_pn3n3_maFLIANzqWk_zqqwJcTs5cHa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thereafter</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">140</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANzqWk_zU9YzdupxZVf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">400</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8AD_zwvLPF5ZNFml" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_897_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zYx753GFSka" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table sets forth information regarding intangible assets (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B7_zGwqCPxmYU2l" style="display: none">Schedule of Goodwill and Intangible Assets</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49F_20211231_zD9DV465tZtb" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_496_20201231_zisOE9VcjN9j" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2020</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_maIANEGzgp3_zFSpudpPG8e6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patents</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">847</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">847</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_msIANEGzgp3_z7Q1ak92jqri" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated amortization</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(447</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(390</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_40D_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_mtIANEGzgp3_zVlMeXtKnlGc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net carrying value</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">400</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">457</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 847000 847000 447000 390000 400000 457000 100000 100000 <p id="xdx_89A_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zTnQFy2d9Iqc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_zrFAqNRNnnA9" style="display: none">Summary of Future Amortization Expense for Intangible Assets</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_498_20211231_zTaCfPCSZLJk" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANzqWk_zEacInCRPVNi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANzqWk_zctGib5cYAA3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maFLIANzqWk_zAUPAWh9gsi8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_maFLIANzqWk_z9rtGe026wI4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pn3n3_maFLIANzqWk_zLMfNPsr7GUk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2026</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_pn3n3_maFLIANzqWk_zqqwJcTs5cHa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thereafter</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">140</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANzqWk_zU9YzdupxZVf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">400</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 54000 53000 52000 52000 49000 140000 400000 <p id="xdx_80F_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zKiBzcefokCf" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6) <span id="xdx_829_zdQBniDs8Jfi">Accrued Liabilities</span></span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zZUq7F4lhazg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued liabilities consist of the following (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B2_zHhAyCBGphAc" style="display: none">Schedule of Accrued Liabilities</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_498_20211231_z4yIvoUEFffk" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_498_20201231_zwSBRxovxAY9" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2020</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--WorkersCompensationLiabilityCurrent_iI_pn3n3_maALCzGtq_zXretVd883rk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wages/commissions payable</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,184</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,057</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_407_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maALCzGtq_zkqzrOCAn8Kb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other accrued liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,165</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,405</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCzGtq_zmFVhnhY8JD2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,349</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,462</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A7_zVqNjJYfVPpg" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zZUq7F4lhazg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued liabilities consist of the following (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B2_zHhAyCBGphAc" style="display: none">Schedule of Accrued Liabilities</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_498_20211231_z4yIvoUEFffk" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_498_20201231_zwSBRxovxAY9" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2020</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--WorkersCompensationLiabilityCurrent_iI_pn3n3_maALCzGtq_zXretVd883rk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wages/commissions payable</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,184</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,057</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_407_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maALCzGtq_zkqzrOCAn8Kb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other accrued liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,165</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,405</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCzGtq_zmFVhnhY8JD2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,349</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,462</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 3184000 4057000 1165000 1405000 4349000 5462000 <p id="xdx_801_eus-gaap--DebtDisclosureTextBlock_z2Os7Muu9jc7" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7) <span id="xdx_829_zAVAJ0ZfAMbk">Debt</span></span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfDebtTableTextBlock_z6IeE8x5ImK" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-term debt consists of the following (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BC_zCtnTVDyDnld" style="display: none">Schedule of Long-term Debt</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_493_20211231_zoyxjj0kPOmc" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_496_20201231_zDdiiQHXRSb" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2020</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_404_ecustom--LoansPayable1_iI_pn3n3_maLTDzAov_zwidA0HH7971" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amounts due under the Term Facility</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0761">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_404_ecustom--LoansPayableTwo_iI_pn3n3_maLTDzAov_zZJ1Ioj3pKPf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued end-of-term payments</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">83</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0764">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_ecustom--LoansPayableThree_iI_pn3n3_maLTDzAov_zeKtWrbAptic" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amounts due under the Second A&amp;R Credit Agreement</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0766">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,556</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_402_eus-gaap--DebtInstrumentUnamortizedPremium_iI_pn3n3_maLTDzAov_zIMmUMrpIoL" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Premium related to Second Amendment</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0769">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,241</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_ecustom--CapitalizedDebtIssuanceCosts_iNI_pn3n3_di_msLTDzAov_zrYnhGAHAko2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: unamortized debt issuance costs</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(296</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0773">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_404_ecustom--LongTermDebtsCurrent_iNI_pn3n3_di_msLTDzAov_zT1ChdlV5joc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: current maturities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0775">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(16,797</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_40E_eus-gaap--LongTermDebt_iTI_pn3n3_mtLTDzAov_zZSUzn9dxw0i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-term debt, less issuance costs</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,787</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0779">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A1_zMgsHD5YV2a" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current Credit Facilities</span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 6, 2021 (the “Closing Date”), the Company, as guarantor, and its subsidiaries, as borrowers (collectively, the “Borrowers”), entered into a (i) Credit, Security and Guaranty Agreement (Term Loan) (the “Term Credit Agreement”) with MidCap Financial Trust, in its capacity as agent (the “Agent”), and a lender and the additional lenders from time to time party thereto and (ii) Credit, Security and Guaranty Agreement (Revolving Loan) (the “Revolving Credit Agreement,” and, together with the Term Credit Agreement, the “Credit Agreements”), with the Agent and the lenders from time to time party thereto. Contemporaneously with the execution and delivery of the Credit Agreements, that certain Second Amended and Restated Credit Agreement, dated March 29, 2019, among the Company, the Borrowers, OrbiMed Royalty Opportunities II, LP (“Royalty Opportunities”) and ROS Acquisition Offshore LP (“ROS”), as subsequently amended (the “Second A&amp;R Credit Agreement”), which was scheduled to mature on December 31, 2021, was terminated in accordance with the terms thereof and all outstanding amounts were repaid by the Borrowers to Royalty Opportunities in its role as sole lender thereunder.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Term Credit Agreement provides for a secured term loan facility (the “Term Facility”) in an aggregate principal amount of $<span id="xdx_905_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn5n6_c20210506__us-gaap--TypeOfArrangementAxis__custom--TermLoanCommitmentMember_zZeolQBArJy7" title="Line of credit facility, maximum borrowing capacity">12.0 </span>million (the “Term Loan Commitment”), which was funded to the Borrowers on the Closing Date, and an additional $<span id="xdx_905_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn6n6_c20210506__us-gaap--TypeOfArrangementAxis__custom--TermLoanCommitmentMember__srt--TitleOfIndividualAxis__custom--AgentAndLendersMember_zi5u2rm8Q1Yl" title="Line of credit facility, maximum borrowing capacity">5.0</span> million tranche available solely at the discretion of the Agent and the lenders, for the purposes agreed to between the Company, the Borrowers and the lenders in advance of the making of loans under such additional tranche. The Revolving Credit Agreement provides for a secured revolving credit facility (the “Revolving Facility,” and, together with the Term Facility, the “Facilities”) under which the Borrowers may borrow up to $<span id="xdx_90E_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20210506__us-gaap--TypeOfArrangementAxis__custom--RevolvingLoanCommitmentMember_zdK3b77OxyAe" title="Line of credit facility, maximum borrowing capacity">8,000,000</span> (such amount, the “Revolving Loan Commitment”) at any one time, the availability of which is determined based on a borrowing base equal to percentages of certain accounts receivable and inventory of the Borrowers in accordance with a formula set forth in the Revolving Credit Agreement. As of December 31, 2021, the Company had $<span id="xdx_904_eus-gaap--LineOfCredit_iI_pn5n6_c20211231__us-gaap--TypeOfArrangementAxis__custom--TermLoanCommitmentMember__srt--TitleOfIndividualAxis__custom--AgentAndLendersMember_zDmQjTLf49k3" title="Line of credit">3.2</span> million available under the Revolving Credit Agreement. All borrowings under the Revolving Facility are subject to the satisfaction of customary conditions, including the absence of default, the accuracy of representations and warranties in all material respects and the delivery of an updated borrowing base certificate.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Facilities have a maturity date of <span id="xdx_90D_eus-gaap--LineOfCreditFacilityExpirationDate1_dd_c20210505__20210506_zFkI2iK5H331" title="Line of credit facility, maturity date">May 1, 2026</span>. The proceeds of the Term Facility were used to pay transaction fees in connection with the Facilities and to pay in full all outstanding indebtedness and accrued interest under the Second A&amp;R Credit Agreement. The proceeds of the Revolving Facility were used to pay transaction fees in connection with the Facilities, to pay in full all outstanding indebtedness and accrued interest under the Second A&amp;R Credit Agreement, and for working capital and general corporate purposes. As a result of the refinancing, we recorded a gain on extinguishment totaling $<span id="xdx_901_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pn5n6_c20210505__20210506__us-gaap--TypeOfArrangementAxis__custom--SecondAAndRCreditAgreementMember_zLa8zLHGgU2l" title="Gain on extinguishment">0.8</span> million. The gain represents the difference between the carrying value of our outstanding loans under the Second A&amp;R Credit Agreement prior to the extinguishment and $<span id="xdx_90B_ecustom--ReacquisitionPrice_pn5n6_c20210505__20210506__us-gaap--TypeOfArrangementAxis__custom--SecondAAndRCreditAgreementMember_z15P3BIbLrha" title="Reacquisition price">15.6</span> million, the reacquisition price. Because of the related party affiliation between the Company and ROS, this debt extinguishment resulted in an increase in additional paid-in capital rather than flowing through our consolidated statements of operations as a gain on extinguishment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The loans and other obligations pursuant to the Credit Agreements bear interest at a per annum rate equal to the sum of the LIBOR rate, as such term is defined in the Credit Agreements, plus the applicable margin of <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210506__us-gaap--VariableRateAxis__us-gaap--LondonInterbankOfferedRateLIBORMember_zKsOQRiL0kg2" title="Debt instrument, interest rate">7.00</span>% in the case of the Term Credit Agreement, and <span id="xdx_901_eus-gaap--LineOfCreditFacilityInterestRateDuringPeriod_pid_dp_uPure_c20210505__20210506__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zg79vZ9OxnC5" title="Line of credit, interest rate">4.50</span>% in the case of the Revolving Credit Agreement, subject in each case to a LIBOR floor of <span id="xdx_903_eus-gaap--LineOfCreditFacilityInterestRateDuringPeriod_pid_dp_uPure_c20210505__20210506__us-gaap--TypeOfArrangementAxis__custom--RevolvingLoanCommitmentMember__us-gaap--VariableRateAxis__us-gaap--LondonInterbankOfferedRateLIBORMember_zmxwCQsCjCS8" title="Line of credit, interest rate">1.00</span>%. The Company is also required to make a final payment in an amount equal to <span id="xdx_909_ecustom--PercentageOfDebtPayment_pid_dp_uPure_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--CreditAgreementsMember_zr7Rd01mt4Sa" title="Line of credit">3.75</span>% of the principal amount borrowed under the Term Facility. The final payment is being accreted to interest expense over the term of the Term Facility using the effective interest method. The effective rate of the Term Facility, inclusive of amortization of debt issuance costs and accretion of the final payment, was <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20211231__us-gaap--TypeOfArrangementAxis__custom--CreditAgreementsMember_z6JE0Y5AX1Z" title="Debt instrument interest rate">9.87</span>% as of December 31, 2021. <span id="xdx_90E_eus-gaap--LineOfCreditFacilityDescription_c20210505__20210506__us-gaap--TypeOfArrangementAxis__custom--CreditAgreementsMember_zYCYVG0PfFn9" title="Line of credit, description">In addition to paying interest on the outstanding loans under the Facilities, the Borrowers are also required to pay an unused line fee equal to 0.50% per annum in respect of unutilized commitments under the Revolving Facility, a fee for failure to maintain a minimum balance under the Revolving Facility, a collateral management fee under the Revolving Facility equal to 0.50% of the amount outstanding under the Revolving Facility, an origination fee equal to 0.50% of the Revolving Loan Commitment and 0.50% of the Term Loan Commitment, and if activated, of any additional term loan tranche, and certain other customary fees related to the Agent’s administration of the Facilities</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Credit Agreements contain affirmative and negative covenants customarily applicable to senior secured credit facilities, including covenants that, among other things, limit or restrict the ability of the Borrowers, subject to negotiated exceptions, to incur additional indebtedness and additional liens on their assets, engage in mergers or acquisitions or dispose of assets, pay dividends or make other distributions, voluntarily prepay other indebtedness, enter into transactions with affiliated persons, make investments, and change the nature of their businesses. In addition, the Credit Agreements require the Borrowers and the Company to maintain net product revenue at or above minimum levels and to maintain a minimum adjusted EBITDA and a minimum liquidity, in each case at levels specified in the Credit Agreements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 7, 2022, the Credit Agreements were amended to, among other things, (i) provide for a waiver of compliance with respect to the Company’s minimum adjusted EBITDA requirement if and so long as the Company’s liquidity (as specifically defined in the Credit Agreements) is in excess of $<span id="xdx_903_ecustom--IncreaseInLiquidityAmount_c20220306__20220307_z0C2o3lvL9z2" title="Increase in liquidity amount">14</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and there is not otherwise an event of default under the Credit Agreements, commencing with the next delivery of the compliance certificate required under the Credit Agreements, and (ii) re-set the date certain fees payable in connection with optional prepayments are determined to the date the amendment was executed and consequently extend such fees’ original expiration. In addition, the exit fees were increased by 25 basis points.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior Credit Facilities</span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the Second A&amp;R Credit Agreement, we could make requests for term loans from ROS and Royalty Opportunities in their sole discretion in amounts equal to the remaining commitment for additional delayed draw loans, which was approximately $<span id="xdx_900_eus-gaap--LineOfCredit_iI_pn5n6_c20211231__us-gaap--TypeOfArrangementAxis__custom--SecondAAndRCreditAgreementsMember_zAdA0waXXHJ1" title="Line of credit">2.2</span> million as of the date of the Second A&amp;R Credit Agreement, and could request additional term loans with ROS and Royalty Opportunities in their sole discretion in an aggregate amount of up to $<span id="xdx_908_eus-gaap--LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_pn6n6_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--SecondAAndRCreditAgreementsMember_z7zIHKbGK6T3" title="Line of credit facility maximum amount outstanding">10.0</span> million. No interest was scheduled to accrue on the Second A&amp;R Credit Agreement through March 31, 2020.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 6, 2020, we entered into a First Amendment to the Second A&amp;R Credit Agreement (the “First Amendment”) with ROS and Royalty Opportunities which, among other things, provided that:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No interest would accrue on the Loans from and after March 31, 2020 until September 30, 2020;</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--LineOfCreditFacilityDescription_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--SecondAAndRCreditAgreementsMember_zX53QSs80de8">Beginning October 1, 2020 through the maturity date of the Second A&amp;R Credit Agreement, interest payable in cash would accrue on the Loans under the Second A&amp;R Credit Agreement at a rate per annum equal to the sum of (i) 10.00% plus (ii) the higher of (x) the LIBO Rate (as such term is defined in the Second A&amp;R Credit Agreement) and (y) 2.3125%</span>;</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The maturity date of the Loans was <span id="xdx_903_eus-gaap--LineOfCreditFacilityExpirationDate1_c20210101__20211231_zXD3Ulje2lgg" title="Line of credit facility expiration date">December 31, 2021</span>.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On May 6, 2020, we issued warrants to purchase an aggregate of <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pn5n6_c20200506__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentyWarrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ROSAndRoyaltyOpportunitiesMember_znqxA3Eswt11" title="Issuance of warrants to purchase a common stock">2.4</span> million shares of our common stock to ROS and Royalty Opportunities, with an exercise price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20200506__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentyWarrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ROSAndRoyaltyOpportunitiesMember_zKWz3ccyTzpf" title="Exercise price of warrants">0.01</span> per share and an expiration date of <span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20200506__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentyWarrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ROSAndRoyaltyOpportunitiesMember_zzIiB1aUQcD2" title="Warrants expiration date">May 6, 2030</span> (collectively, the “2020 Warrants”). The issuance of the 2020 Warrants was a condition to the effectiveness of the First Amendment. The First Amendment was accounted for as a debt modification whereby the recorded debt balance was discounted for the fair value of the 2020 Warrants issued and interest expense is accrued through the maturity date of the Loans at the post-amendment effective interest rate of <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20200506__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentyWarrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ROSAndRoyaltyOpportunitiesMember_ztVVjZAim7bi" title="New effective interest rate">10.02</span>%. These 2020 Warrants were exercised in full in November 2020.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 1, 2020, we entered into a Second Amendment to the Second A&amp;R Credit Agreement (the “Second Amendment”) with ROS and Royalty Opportunities, which among other things, provided for:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Extinguishment by ROS and Royalty Opportunities of approximately $<span id="xdx_906_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn5n6_c20201001__20201002_zZiDhiQgY6h3" title="Debt conversion converted instrument">61.9</span> million of principal and paid-in-kind interest outstanding on the Loans in exchange for approximately<span id="xdx_904_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pn5n6_c20201001__20201002_zaAij5Qsmjre" title="Debt conversion converted instrument, shares"> 57.8</span> million shares of our common stock and the addition of a principal amount equal to prepayment fees associated with the Loans not paid in cash or exchanged for shares of our common stock;</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exchange of approximately $<span id="xdx_908_ecustom--ValuesIssuedPrepaymentFees_pn5n6_c20201001__20201002_zEdAgqAGcWl9" title="Values issued prepayment fees">0.9</span> million of prepayment fees associated with the Loans for approximately <span id="xdx_905_ecustom--SharesIssuedPrepaymentFees_pn5n6_c20201001__20201002_zityQZysdm1i" title="Shares issued prepayment fees">0.9</span> million shares of our common stock (the “Prepayment Fee Shares”);</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Elimination of the availability of additional draw loan advances and reduction of available additional term loans to $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_c20201002_zwl9D5xxcazl" title="Debt instrument face amount">5.0</span> million, the availability of which is in the sole and absolute discretion of the lender;</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrual of interest payable in cash for the remaining term of the Second A&amp;R Credit Agreement at a rate per annum equal to the sum of (i) <span id="xdx_90C_eus-gaap--LineOfCreditFacilityInterestRateAtPeriodEnd_iI_pid_dp_uPure_c20201002_zc8tLAsJ34Id" title="Line of credit facility interest rate at period">7.00</span>% plus (ii) the higher of (x) the LIBO Rate (as such term is defined in the Second A&amp;R Credit Agreement) and (y) <span id="xdx_905_eus-gaap--LineOfCreditFacilityInterestRateAtPeriodEnd_iI_pid_dp_uPure_c20201002__us-gaap--VariableRateAxis__us-gaap--LondonInterbankOfferedRateLIBORMember_zBAW287di3Ud" title="Line of credit facility interest rate at period">1.00</span>%; and</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Elimination of certain financial covenants.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a result of the debt restructuring, as previously described, we recorded a gain on restructuring totaling $<span id="xdx_900_eus-gaap--GainsLossesOnRestructuringOfDebt_pn5n6_c20200101__20201231_zNM4xxs7a1Rh" title="Gain on restructuring">15.1</span> million during the year ended December 31, 2020. The gain represents the excess of the carrying value of our outstanding loans under the Second A&amp;R Credit Agreement prior to the extinguishment of such debt in the debt restructuring transaction, $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_pn5n6_c20201001__20201002_zO1LElkoCHJ4" title="Conversion of convertible securities">80.3</span> million, over the sum of the fair value of the <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pn5n6_c20201001__20201002_zgWo8S73hrf7" title="Conversion of convertible securities, shares">57.8</span> million shares issued therewith, $<span id="xdx_90C_ecustom--StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesOne_pn5n6_c20201001__20201002_z6pKh73ndlN2" title="Conversion of convertible securities, shares">48.2</span> million based on the closing price of our common stock on October 1, 2020, and $<span id="xdx_90C_ecustom--UndiscountedFutureCashPayments_pn5n6_c20201001__20201002_z74fChlq01ke" title="Undiscontinued future cash payments">17.1</span> million of undiscounted future cash payments associated with the Second Amendment. Because of the related party affiliation between the Company and ROS and Royalty Opportunities, this debt extinguishment resulted in an increase in additional paid-in capital rather than flowing through our consolidated statements of operations as a gain on extinguishment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The carrying value of loans outstanding under the Second A&amp;R Credit Agreement was equal to the undiscounted future cash payments associated with the Second Amendment and principal associated with loans thereunder. Cash interest payments in connection with the Second A&amp;R Credit Agreement reduced the carrying value of associated loans; and accordingly, no interest expense related to cash interest payments was recorded for the remaining duration of the Second A&amp;R Credit Agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfDebtTableTextBlock_z6IeE8x5ImK" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-term debt consists of the following (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BC_zCtnTVDyDnld" style="display: none">Schedule of Long-term Debt</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_493_20211231_zoyxjj0kPOmc" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_496_20201231_zDdiiQHXRSb" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2020</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_404_ecustom--LoansPayable1_iI_pn3n3_maLTDzAov_zwidA0HH7971" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amounts due under the Term Facility</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0761">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_404_ecustom--LoansPayableTwo_iI_pn3n3_maLTDzAov_zZJ1Ioj3pKPf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued end-of-term payments</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">83</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0764">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_ecustom--LoansPayableThree_iI_pn3n3_maLTDzAov_zeKtWrbAptic" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amounts due under the Second A&amp;R Credit Agreement</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0766">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,556</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_402_eus-gaap--DebtInstrumentUnamortizedPremium_iI_pn3n3_maLTDzAov_zIMmUMrpIoL" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Premium related to Second Amendment</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0769">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,241</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_ecustom--CapitalizedDebtIssuanceCosts_iNI_pn3n3_di_msLTDzAov_zrYnhGAHAko2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: unamortized debt issuance costs</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(296</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0773">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_404_ecustom--LongTermDebtsCurrent_iNI_pn3n3_di_msLTDzAov_zT1ChdlV5joc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: current maturities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0775">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(16,797</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_40E_eus-gaap--LongTermDebt_iTI_pn3n3_mtLTDzAov_zZSUzn9dxw0i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-term debt, less issuance costs</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,787</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0779">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 12000000 83000 15556000 1241000 296000 16797000 11787000 12000000.0 5000000.0 8000000 3200000 2026-05-01 800000 15600000 0.0700 0.0450 0.0100 0.0375 0.0987 In addition to paying interest on the outstanding loans under the Facilities, the Borrowers are also required to pay an unused line fee equal to 0.50% per annum in respect of unutilized commitments under the Revolving Facility, a fee for failure to maintain a minimum balance under the Revolving Facility, a collateral management fee under the Revolving Facility equal to 0.50% of the amount outstanding under the Revolving Facility, an origination fee equal to 0.50% of the Revolving Loan Commitment and 0.50% of the Term Loan Commitment, and if activated, of any additional term loan tranche, and certain other customary fees related to the Agent’s administration of the Facilities 14 2200000 10000000.0 Beginning October 1, 2020 through the maturity date of the Second A&R Credit Agreement, interest payable in cash would accrue on the Loans under the Second A&R Credit Agreement at a rate per annum equal to the sum of (i) 10.00% plus (ii) the higher of (x) the LIBO Rate (as such term is defined in the Second A&R Credit Agreement) and (y) 2.3125% 2021-12-31 2400000 0.01 2030-05-06 0.1002 61900000 57800000 900000 900000 5000.0 0.0700 0.0100 15100000 80300000 57800000 48200000 17100000 <p id="xdx_80A_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zb3wElQL9u4" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8) <span id="xdx_825_zKbtJY36Uaz1">Equity</span></span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Charter Amendments</span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 7, 2020, the Company’s stockholders, upon recommendation of the Board, approved an amendment to the Company’s Charter to increase the number of authorized shares of common stock from <span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_iI_pn6n6_c20200807__srt--RangeAxis__srt--MinimumMember_z1jeVoJMuxlj" title="Common stock, shares authorized">75</span> million to <span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_iI_pn6n6_c20200807__srt--RangeAxis__srt--MaximumMember_zDbVJ49NM5Ei" title="Common stock, shares authorized">300</span> million. This Charter amendment was effective upon the filing of a Certificate of Amendment with the Office of the Secretary of State of the State of Delaware on October 1, 2020.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt Restructuring</span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 1, 2020, we issued <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pn5n6_c20201001__20201002__us-gaap--TypeOfArrangementAxis__custom--RestructuringAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RoyaltyOpportunitiesandROSMember_zLXSTKIqoAV9" title="Shares issued in exchange of loans outstanding">58.7</span> million shares of our common stock in connection with our debt restructuring. See <i>Note (7) Debt</i>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rights Offering</span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 6, 2020, we distributed to holders of our common stock, at no charge, non-transferable subscription rights to purchase up to an aggregate of <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20201105__20201106__srt--RangeAxis__srt--MaximumMember_zMKsAd66f01h" title="Stock issued during period, shares, new issues">14,018,690</span> shares of our common stock (the “Rights Offering”). In the Rights Offering, holders received <span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_c20201106_zh3cYbXy0SH3" title="Shares issued, price per share">0.194539</span> subscription rights for each share of common stock held on the record date, November 5, 2020. Each whole subscription right entitled the holder to purchase one share of our common stock for $<span id="xdx_90B_eus-gaap--SharePrice_iI_c20201106_zeO0UEia4E7" title="Share price">1.07</span> in cash. The Rights Offering was commenced on <span id="xdx_90C_ecustom--RightOfferingExpiredDate_c20201105__20201106_zy9GqUZZRGOi" title="Right offering expired date">November 6, 2020</span> and expired on December 4, 2020, at which time the rights were no longer exercisable. We issued <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20201105__20201106_znvJ3EsGeAl4" title="Stock issued during period, shares, new issues">712,646</span> shares of our common stock in the Rights Offering, resulting in $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20201105__20201106_zYPu6DO4O148" title="Proceeds from common stock">0.8</span> million in gross proceeds to us.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant Exercises</span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 17, 2020, ROS and Royalty Opportunities exercised warrants representing an aggregate of 4.8 million shares of our common stock and in connection therewith we received aggregate proceeds of $<span id="xdx_901_eus-gaap--ProceedsFromWarrantExercises_pp0p0_c20201115__20201117__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ROSAndRoyaltyOpportunitiesMember_zRfvdePmmGdj" title="Proceeds from warrant exercise">48,000</span>. See <i>Note (10) Warrants</i>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Private Placement</span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 24, 2021, we issued in a private placement (the “Private Placement”) to a single healthcare-focused institutional accredited investor (the “Investor”) <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210223__20210224__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zMWz8NT4rAS7" title="Stock issued during period, shares, new issues">8,888,890</span> shares of our common stock at a purchase price of $<span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_c20210224__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zmG414wmyJSd">2.25</span> per share, and warrants to purchase up to <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20210224__srt--TitleOfIndividualAxis__custom--InvestorWarrantMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zHyJmYn0RNMg" title="Warrants to purchase common stock">6,666,668</span> shares of our common stock (the “Investor Warrant”). We received net cash proceeds of approximately $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn5n6_c20210223__20210224__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zZuDi51ZpGya" title="Proceeds from private placement">18.4</span> million, after deducting fees and other estimated offering expenses, from the Private Placement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Investor Warrant, described in more detail in <i>Note (10), Warrants,</i> has an exercise price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210224__srt--TitleOfIndividualAxis__custom--InvestorWarrantMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zibIYiXRF0bc" title="Warrant exercise price">2.25</span> per share, subject to customary anti-dilution, but not price protection, adjustments, is immediately exercisable and expires on the five-year anniversary of the date of issuance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the Private Placement, we entered into a placement agent agreement with a placement agent (the “Placement Agent”) pursuant to which the Placement Agent served as our exclusive placement agent in connection with the Private Placement (the “Placement Agent Agreement”). Pursuant to the Placement Agent Agreement, we agreed to pay the Placement Agent a fee equal to a certain percentage of the aggregate gross proceeds from the Private Placement. In addition to the cash fee, we agreed to issue to the Placement Agent a warrant to purchase up to <span id="xdx_90C_ecustom--WarrantsExercisePricePercentage_iI_pid_dp_uPure_c20210224__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--PlacementAgentAgreementMember_z8xsufp2ALo2" title="Warrants exercise price percentage">5.0</span>% of the shares sold to the Investor in the Private Placement, or <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210223__20210224__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--PlacementAgentAgreementMember_zEwwCvTBSan5" title="Stock issued during period, shares, new issues">444,444</span> shares of our common stock (the “Placement Agent Warrant”). The Placement Agent Warrant, described in more detail in <i>Note 10, “Warrants”, </i>has an exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210224__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PlacementAgentAgreementMember_zoAFpb4zeUZ8" title="Warrant exercise price">2.8125</span> per share, subject to customary anti-dilution, but not price protection, adjustments, is immediately exercisable and expires on the <span id="xdx_907_ecustom--WarrantsAndRightsOutstandingTermDescription_c20210223__20210224__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PlacementAgentAgreementMember_zY57jSdXiYd4" title="Warrant term description">five-year</span> anniversary of the date of issuance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 75000000 300000000 58700000 14018690 0.194539 1.07 2020-11-06 712646 800000 48000 8888890 2.25 6666668 18400000 2.25 0.050 444444 2.8125 five-year <p id="xdx_80C_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zgtYae7isAme" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9) <span id="xdx_82C_z9A9iEb87hlj">Stock-Based Compensation</span></span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan</span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 1, 2018, our stockholders approved the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan at the 2018 annual meeting of stockholders of Xtant and on October 30, 2019 at our 2019 annual meeting of stockholders, our stockholders approved an amendment to increase the number of shares of common stock available thereunder by <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20180801__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_zpmAQchOOWh9" title="Number of shares available for issuance">1,500,000</span> shares. <span style="background-color: white">On October 27, 2020, at our 2020 annual meeting of stockholders, our stockholders approved an amendment to further increase the number of shares of our common stock available for issuance under the 2018 Plan by an additional <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20181027__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_zBB0gXAjsb9i" title="Number of shares available for issuance">5,550,308</span> shares</span> (as amended, the “2018 Plan”). <span id="xdx_908_ecustom--TermOfPlanDescription_c20180728__20180801__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zNy4fodQucik" title="Term of plan, description">The 2018 Plan became effective immediately upon initial approval of the plan by our stockholders on August 1, 2018 and will expire on July 31, 2028, unless terminated earlier.</span> The 2018 Plan replaced the Amended and Restated Xtant Medical Equity Incentive Plan (the “Prior Plan”) with respect to future grants of equity awards, although the Prior Plan continues to govern equity awards granted under the Prior Plan. The 2018 Plan permits the Board, or a committee thereof, to grant to eligible employees, non-employee directors, and consultants of the Company non-statutory and incentive stock options, stock appreciation rights, restricted stock awards, restricted stock units, deferred stock units, performance awards, non-employee director awards, and other stock-based awards. The Board may select 2018 Plan participants and determine the nature and amount of awards to be granted. Subject to adjustment as provided in the 2018 Plan, the number of shares of our common stock available for issuance under the 2018 Plan is <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20211231__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zm2iR5DpTky1" title="Number of shares available for issuance">8,358,055</span> shares, of which <span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRemainingSharesAvailable_iI_c20211231__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zJGnNAaiOCP5" title="Number of common stock shares remaining available">1,246,080</span> shares remained available for grant as of December 31, 2021. Under the 2018 Plan, shares of our common stock related to awards granted under the plan that terminate by expiration, forfeiture, cancellation, or otherwise without the issuance of the shares become available again for grant under the plan.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock options granted under the 2018 Plan may be either incentive stock options to employees, as defined in Section 422A of the Internal Revenue Code of 1986, or non-qualified stock options. The exercise price of all stock options granted under the 2018 Plan must be at least equal to the fair market value of the shares of common stock on the date of the grant. The 2018 Plan is administered by the Board. Stock options granted under the 2018 Plan are generally not transferable, vest in installments over the requisite service period, and are exercisable during the stated contractual term of the option only by the optionee.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zTYBBauP0i42" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock option activity, including options granted under the 2018 Plan and the Prior Plan was as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BE_zoD5bpo0kHka" style="display: none">Schedule of Share-based Compensation, Stock Options, Activity</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Average<br/> Fair</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Average<br/> Fair</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Average<br/> Exercise</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Value at<br/> Grant</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Average<br/> Exercise</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Value at<br/> Grant</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Price</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Price</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 28%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at January 1</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zJlPZbHNqeyb" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Shares, Outstanding, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,190,892</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_z1DMgSiTcqc5" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.25</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_iS_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zED0MEt5ZRdk" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Weighted Average Fair Value at Grant Date, Outstanding Beginning Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.65</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20200101__20201231__us-gaap--StatementClassOfStockAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zJhEzGcFsw82" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Shares, Outstanding, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">602,966</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20200101__20201231__us-gaap--StatementClassOfStockAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zJY6oy585hR3" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.07</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_iS_pid_c20200101__20201231__us-gaap--StatementClassOfStockAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zld8SypJM8Pl" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Weighted Average Fair Value at Grant Date, Outstanding Beginning Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.99</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zULR2MWSKy0g" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Shares, Granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,012,083</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zLVCnjCxNgTl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Cancelled or expired"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.27</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zKQVwz3CVYb6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Fair Value at Grant Date, Granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.07</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20200101__20201231__us-gaap--StatementClassOfStockAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_z3tpznJKk9ee" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Shares, Granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,708,743</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20200101__20201231__us-gaap--StatementClassOfStockAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zvC1oedb1Zj3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.24</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20200101__20201231__us-gaap--StatementClassOfStockAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zFrezBdtt7r8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Fair Value at Grant Date, Granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.01</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cancelled or expired</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_z73Ijc0cpPqd" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Shares, Cancelled or expired"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,309</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zr7Q1DD1VVMk" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Cancelled or expired"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">345.82</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardCancelledOrExpiredOutstandingWeightedAverageGrantDateFairValue_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zyIHSOkOBRq6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Fair Value at Grant Date, Cancelled or expired"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">170.89</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20200101__20201231__us-gaap--StatementClassOfStockAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zIa6bQkKihO7" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Shares, Cancelled or expired"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(120,817</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20200101__20201231__us-gaap--StatementClassOfStockAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zEsWezV5hVR9" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Cancelled or expired"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.95</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardCancelledOrExpiredOutstandingWeightedAverageGrantDateFairValue_pid_c20200101__20201231__us-gaap--StatementClassOfStockAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zmNrFPZWmIYk" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Fair Value at Grant Date, Cancelled or expired"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.31</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at December 31</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zuxEd8lgbU75" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Shares, Outstanding, Ending Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,201,666</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zauN7Cy3cIla" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Outstanding Ending Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.80</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_iE_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zr0ikP8Bns9l" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Fair Value at Grant Date, Outstanding Ending Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.40</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20200101__20201231__us-gaap--StatementClassOfStockAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zZciON6jdUH9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Shares, Outstanding, Ending Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,190,892</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20200101__20201231__us-gaap--StatementClassOfStockAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zj4227QsBSxb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Outstanding Ending Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.25</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_iE_pid_c20200101__20201231__us-gaap--StatementClassOfStockAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zAzx10ULxlEk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Fair Value at Grant Date, Outstanding Ending Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.65</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable at December 31</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zCO5HBnzqmTe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Shares, Exercisable, Ending Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">649,042</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zJHawkSprhN8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercisable Ending Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.36</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_iE_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zy8GgheDimKc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Fair Value at Grant Date, Exercisable, Ending Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.37</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20200101__20201231__us-gaap--StatementClassOfStockAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zzuCQ582qnFb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Shares, Exercisable, Ending Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">122,739</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20200101__20201231__us-gaap--StatementClassOfStockAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_z2OrV6wZgbCa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercisable Ending Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.74</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_iE_pid_c20200101__20201231__us-gaap--StatementClassOfStockAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zeSyKgLwCzv9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Fair Value at Grant Date, Exercisable, Ending Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.95</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8AE_zPU3NUOwPW4j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zz23E3uRORbd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The estimated fair value of stock options granted is determined using the Black-Scholes-Merton method applied to individual grants. Key assumptions used to estimate the fair value of stock awards are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BF_zBz7H9mlbqC" style="display: none">Schedule of Assumptions of Stock Option Granted</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year Ended</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk free interest rate</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231_zF9QhnOawQF5" title="Risk free interest rate">0.97</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20200101__20201231_zX5FT1LBiXP8" title="Risk free interest rate">0.54</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend yield</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20210101__20211231_ziXyAI7rdPsb" title="Dividend yield">0</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20200101__20201231_zJB7HRulft" title="Dividend yield">0</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected term</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231_zy8kuqUZHi54" title="Expected term">6.3</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231_z1imKDFAisnb" title="Expected term">6.3</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected volatility</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231_zHGlvIHOVxx6" title="Expected volatility">113</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20200101__20201231_z16IGGNO8GOa" title="Expected volatility">105</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> </table> <p id="xdx_8AB_z1pU91C3Qz6g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zKk0o7uheYu6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted stock unit activity for awards granted under the 2018 Plan was as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BF_zXtxMSUZjOj4" style="display: none">Schedule of Restricted Stock Activity</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Average Fair</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value at Grant</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date Per</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Share</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average Fair</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value at Grant</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date Per Share</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 36%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at January 1</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zwldUZXH8cXj" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Shares Outstanding, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,503,698</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_z62kqQCj4Azf" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted Average Fair Value at Grant Date, Outstanding Beginning Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.54</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zj1s9VJd5gVl" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Shares Outstanding, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">499,914</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zl7hDPgzwDP2" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted Average Fair Value at Grant Date, Outstanding Beginning Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.87</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zslxNWHnOPt2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Shares Granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,249,002</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zCcXQHIDIICa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Fair Value at Grant Date, Granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.27</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_z8SYwZzWOuc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Shares Granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,148,662</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_z2XB345bFRbd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Fair Value at Grant Date, Granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.29</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vested</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zcjWFsVB6mXc" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Shares Vested"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(782,596</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zm3WQebCk8c9" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Fair Value at Grant Date, Vested"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.72</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zO5yEYtulKah" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Shares Vested"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(144,878</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zBBMCc98sWY3" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Fair Value at Grant Date, Vested"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.52</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at December 31</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zbUmRPT9jx05" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Shares Outstanding, Ending Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,970,104</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zLsHDYndqI1k" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Fair Value at Grant Date, Outstanding Ending Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.39</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zYiDdxRnVZx" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Shares Outstanding, Ending Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,503,698</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zf8YXKTXWwb2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Fair Value at Grant Date, Outstanding Ending Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.54</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A3_zdpVJAiuVIpg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total stock-based compensation expense recognized for employees and directors was $<span id="xdx_907_eus-gaap--ShareBasedCompensation_pn5n6_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zxktij66PoP6" title="Share based compensation">2.2</span> million and $<span id="xdx_905_eus-gaap--ShareBasedCompensation_pn5n6_c20200101__20201231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zhUWLd1qlru1" title="Share based compensation">1.1</span> million for the years ended December 31, 2021 and 2020, respectively, and was recognized as general and administrative expense. As of December 31, 2021, total compensation expense related to unvested employee stock options not yet recognized was $<span id="xdx_90F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zc5QYTLDSZCf" title="Unvested employee stock options not yet recognized">2.7</span> million, which is expected to be allocated to expenses over a weighted-average period of <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zTbZDVfaJPU4" title="Stock option vested weighted average period">3.1</span> years. Total compensation expense related to unvested restricted stock units not yet recognized was $<span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zy6g1EBxDn22" title="Unvested employee stock options not yet recognized">3.4</span> million as of December 31, 2021, which is expected to be allocated to expenses over a weighted-average period of <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zYOvPmjtnNRe" title="Stock option vested weighted average period">2.8</span> years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 1500000 5550308 The 2018 Plan became effective immediately upon initial approval of the plan by our stockholders on August 1, 2018 and will expire on July 31, 2028, unless terminated earlier. 8358055 1246080 <p id="xdx_89F_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zTYBBauP0i42" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock option activity, including options granted under the 2018 Plan and the Prior Plan was as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BE_zoD5bpo0kHka" style="display: none">Schedule of Share-based Compensation, Stock Options, Activity</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Average<br/> Fair</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Average<br/> Fair</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Average<br/> Exercise</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Value at<br/> Grant</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Average<br/> Exercise</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Value at<br/> Grant</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Price</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Price</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 28%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at January 1</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zJlPZbHNqeyb" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Shares, Outstanding, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,190,892</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_z1DMgSiTcqc5" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.25</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_iS_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zED0MEt5ZRdk" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Weighted Average Fair Value at Grant Date, Outstanding Beginning Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.65</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20200101__20201231__us-gaap--StatementClassOfStockAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zJhEzGcFsw82" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Shares, Outstanding, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">602,966</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20200101__20201231__us-gaap--StatementClassOfStockAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zJY6oy585hR3" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.07</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_iS_pid_c20200101__20201231__us-gaap--StatementClassOfStockAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zld8SypJM8Pl" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Weighted Average Fair Value at Grant Date, Outstanding Beginning Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.99</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zULR2MWSKy0g" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Shares, Granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,012,083</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zLVCnjCxNgTl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Cancelled or expired"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.27</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zKQVwz3CVYb6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Fair Value at Grant Date, Granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.07</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20200101__20201231__us-gaap--StatementClassOfStockAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_z3tpznJKk9ee" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Shares, Granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,708,743</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20200101__20201231__us-gaap--StatementClassOfStockAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zvC1oedb1Zj3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.24</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20200101__20201231__us-gaap--StatementClassOfStockAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zFrezBdtt7r8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Fair Value at Grant Date, Granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.01</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cancelled or expired</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_z73Ijc0cpPqd" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Shares, Cancelled or expired"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,309</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zr7Q1DD1VVMk" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Cancelled or expired"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">345.82</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardCancelledOrExpiredOutstandingWeightedAverageGrantDateFairValue_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zyIHSOkOBRq6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Fair Value at Grant Date, Cancelled or expired"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">170.89</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20200101__20201231__us-gaap--StatementClassOfStockAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zIa6bQkKihO7" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Shares, Cancelled or expired"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(120,817</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20200101__20201231__us-gaap--StatementClassOfStockAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zEsWezV5hVR9" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Cancelled or expired"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.95</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardCancelledOrExpiredOutstandingWeightedAverageGrantDateFairValue_pid_c20200101__20201231__us-gaap--StatementClassOfStockAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zmNrFPZWmIYk" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Fair Value at Grant Date, Cancelled or expired"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.31</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at December 31</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zuxEd8lgbU75" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Shares, Outstanding, Ending Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,201,666</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zauN7Cy3cIla" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Outstanding Ending Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.80</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_iE_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zr0ikP8Bns9l" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Fair Value at Grant Date, Outstanding Ending Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.40</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20200101__20201231__us-gaap--StatementClassOfStockAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zZciON6jdUH9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Shares, Outstanding, Ending Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,190,892</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20200101__20201231__us-gaap--StatementClassOfStockAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zj4227QsBSxb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Outstanding Ending Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.25</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_iE_pid_c20200101__20201231__us-gaap--StatementClassOfStockAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zAzx10ULxlEk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Fair Value at Grant Date, Outstanding Ending Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.65</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable at December 31</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zCO5HBnzqmTe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Shares, Exercisable, Ending Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">649,042</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zJHawkSprhN8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercisable Ending Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.36</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_iE_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zy8GgheDimKc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Fair Value at Grant Date, Exercisable, Ending Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.37</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20200101__20201231__us-gaap--StatementClassOfStockAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zzuCQ582qnFb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Shares, Exercisable, Ending Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">122,739</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20200101__20201231__us-gaap--StatementClassOfStockAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_z2OrV6wZgbCa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercisable Ending Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.74</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_iE_pid_c20200101__20201231__us-gaap--StatementClassOfStockAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zeSyKgLwCzv9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Fair Value at Grant Date, Exercisable, Ending Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.95</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 2190892 2.25 1.65 602966 6.07 3.99 1012083 1.27 1.07 1708743 1.24 1.01 1309 345.82 170.89 120817 6.95 4.31 3201666 1.80 1.40 2190892 2.25 1.65 649042 3.36 2.37 122739 14.74 8.95 <p id="xdx_896_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zz23E3uRORbd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The estimated fair value of stock options granted is determined using the Black-Scholes-Merton method applied to individual grants. Key assumptions used to estimate the fair value of stock awards are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BF_zBz7H9mlbqC" style="display: none">Schedule of Assumptions of Stock Option Granted</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year Ended</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk free interest rate</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231_zF9QhnOawQF5" title="Risk free interest rate">0.97</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20200101__20201231_zX5FT1LBiXP8" title="Risk free interest rate">0.54</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend yield</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20210101__20211231_ziXyAI7rdPsb" title="Dividend yield">0</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20200101__20201231_zJB7HRulft" title="Dividend yield">0</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected term</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231_zy8kuqUZHi54" title="Expected term">6.3</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231_z1imKDFAisnb" title="Expected term">6.3</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected volatility</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231_zHGlvIHOVxx6" title="Expected volatility">113</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20200101__20201231_z16IGGNO8GOa" title="Expected volatility">105</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> </table> 0.0097 0.0054 0 0 P6Y3M18D P6Y3M18D 1.13 1.05 <p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zKk0o7uheYu6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted stock unit activity for awards granted under the 2018 Plan was as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BF_zXtxMSUZjOj4" style="display: none">Schedule of Restricted Stock Activity</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Average Fair</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value at Grant</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date Per</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Share</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average Fair</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value at Grant</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date Per Share</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 36%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at January 1</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zwldUZXH8cXj" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Shares Outstanding, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,503,698</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_z62kqQCj4Azf" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted Average Fair Value at Grant Date, Outstanding Beginning Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.54</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zj1s9VJd5gVl" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Shares Outstanding, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">499,914</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zl7hDPgzwDP2" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted Average Fair Value at Grant Date, Outstanding Beginning Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.87</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zslxNWHnOPt2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Shares Granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,249,002</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zCcXQHIDIICa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Fair Value at Grant Date, Granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.27</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_z8SYwZzWOuc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Shares Granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,148,662</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_z2XB345bFRbd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Fair Value at Grant Date, Granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.29</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vested</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zcjWFsVB6mXc" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Shares Vested"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(782,596</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zm3WQebCk8c9" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Fair Value at Grant Date, Vested"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.72</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zO5yEYtulKah" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Shares Vested"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(144,878</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zBBMCc98sWY3" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Fair Value at Grant Date, Vested"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.52</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at December 31</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zbUmRPT9jx05" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Shares Outstanding, Ending Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,970,104</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zLsHDYndqI1k" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Fair Value at Grant Date, Outstanding Ending Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.39</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zYiDdxRnVZx" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Shares Outstanding, Ending Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,503,698</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenEquityIncentivePlanMember_zf8YXKTXWwb2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Fair Value at Grant Date, Outstanding Ending Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.54</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 2503698 1.54 499914 2.87 1249002 1.27 2148662 1.29 782596 1.72 144878 2.52 2970104 1.39 2503698 1.54 2200000 1100000 2700000 P3Y1M6D 3400000 P2Y9M18D <p id="xdx_800_ecustom--OtherEquityTransactionsTextBlock_zdytb4CvqpVa" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10) <span id="xdx_825_znVJ2Yp02X5c">Warrants</span></span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"><i>2021 Warrants</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As noted in Note 8, “<i>Equity</i>,” on February 22, 2021, the Company issued the Investor Warrants and Placement Agent Warrants. The Investor and Placement Agent Warrants meet all the requirements to be classified as equity awards in accordance with Accounting Standards Codification (“ASC”) No. 815-40. The number of shares of Company common stock issuable upon exercise of the Investor Warrants and Placement Agent Warrants is subject to standard and customary anti-dilution provisions for stock splits, stock dividends, or similar transactions. In addition, the Investor Warrants include a buy-out right whereby the holders of such warrants may put the warrants back to the Company or its successor in the event of a purchase, tender or exchange offer accepted by 50% or more of the Company’s holders of common stock and not approved by the Company’s board of directors. The buy-out amount is equal to the Black-Scholes value of the warrants on the date the triggering transaction is consummated based on certain inputs as defined in the Investor Warrant agreement. The consideration to be paid if the buy-out provision is triggered shall be in the same type or form of consideration that is being offered and paid to the holders of Company common stock in connection with the triggering transaction.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While the Investor Warrants are classified as a component of equity, we were required to allocate the proceeds of the Private Placement between the shares of common stock and Investor Warrants issued based on their relative fair values. We utilized a lattice valuation model to determine the fair value of the Investor Warrants. The fair value of the Placement Agent Warrants issued in connection with the Private Placement was determined using a Black Scholes model. Significant assumptions in both models included contractual term (<span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zCO9EedwDAul" title="Warrants contractual term">5</span> years) and the estimated volatility factor based on a weighted average of comparable published betas of peer companies (<span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dp_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zXAfGc10sEOe" title="Warrants and rights outstanding, measurement input">61</span>%).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020 Warrants</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As noted in Note 7, “<i>Debt</i>,” on May 6, 2020, we issued warrants to purchase an aggregate <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pn5n6_c20200506__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentyWarrantMember_zPnF4dwHSKx4" title="Issuance of warrants to purchase a common stock">2.4</span> million shares of our common stock to ROS and Royalty Opportunities with an exercise price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20200506__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentyWarrantMember_zX7OvT9Wj8E6" title="Exercise price of warrants">0.01</span> per share and an expiration date of <span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20200506__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentyWarrantMember_zjM4V3p8Z2lb" title="Warrants expiration date">May 6, 2030</span>. The issuance of the 2020 Warrants was a condition to the effectiveness of the First Amendment. The fair value of the 2020 Warrants upon issuance was determined to be $<span id="xdx_906_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20200505__20200506__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentyWarrantMember_zx3ZLkHfVz7e" title="Fair value of warrants">1.9</span> million. The 2020 Warrants met all the requirements to be classified as equity awards in accordance with ASC No. 815-40. The number of shares of our common stock issuable upon exercise of the 2020 Warrants was subject to standard and customary anti-dilution provisions for stock splits, stock dividends, or similar transactions. The 2020 Warrants were exercised in full on November 17, 2020.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zlcTqh1sSC2g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes our warrant activities for the years ended December 31, 2021 and 2020:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BF_zDl767Kua5Xa" style="display: none">Schedule of Warrant Activity</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Average</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Price</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding as of January 1, 2020</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20200101__20201231_zoV05VVY844k" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Common Stock Warrants Outstanding, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,908,874</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20200101__20201231_zExNgQzNIAYh" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Weighted Average Exercise Price Outstanding Beginning Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.16</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20200101__20201231_zkhU4HYAynob" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Common Stock Warrants, Issued"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,400,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20200101__20201231_z1VkuyS35W6k" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Issued"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.01</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20200101__20201231_zHNEyKKBp5ul" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Common Stock Warrants, Exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,800,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_987_ecustom--WeightedAverageExercisePriceExercised_pid_c20200101__20201231_z8juZPruESxj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.01</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expired</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20200101__20201231_zc19p3SuNdd3" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Common Stock Warrants, Expired"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(87,596</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20200101__20201231_zVMOp1Z8at91" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Expired"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">85.92</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding as of December 31, 2020</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20211231_zYzIrkWFaxx5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Common Stock Warrants Outstanding, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">421,278</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20210101__20211231_zQVot2UT7m01" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Outstanding Beginning Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.80</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231_zNveoxJsSKYg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Common Stock Warrants, Issued"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,111,112</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_zhn8Y4IiP1y" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Issued"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.29</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expired</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20210101__20211231_zSkBE1c4AnUj" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Common Stock Warrants, Expired"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(421,278</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_zjTQV5WVbjPd" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Expired"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.80</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at December 31, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20211231_z28mHWXEk6c1" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Common Stock Warrants Outstanding, Ending Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,111,112</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20210101__20211231_z7WjTPj1YJF9" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Outstanding Ending Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.29</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A7_zBnjVO3ms0G4" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> P5Y 0.61 2400000 0.01 2030-05-06 1900000 <p id="xdx_899_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zlcTqh1sSC2g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes our warrant activities for the years ended December 31, 2021 and 2020:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BF_zDl767Kua5Xa" style="display: none">Schedule of Warrant Activity</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Average</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Price</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding as of January 1, 2020</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20200101__20201231_zoV05VVY844k" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Common Stock Warrants Outstanding, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,908,874</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20200101__20201231_zExNgQzNIAYh" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Weighted Average Exercise Price Outstanding Beginning Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.16</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20200101__20201231_zkhU4HYAynob" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Common Stock Warrants, Issued"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,400,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20200101__20201231_z1VkuyS35W6k" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Issued"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.01</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20200101__20201231_zHNEyKKBp5ul" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Common Stock Warrants, Exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,800,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_987_ecustom--WeightedAverageExercisePriceExercised_pid_c20200101__20201231_z8juZPruESxj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.01</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expired</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20200101__20201231_zc19p3SuNdd3" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Common Stock Warrants, Expired"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(87,596</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20200101__20201231_zVMOp1Z8at91" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Expired"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">85.92</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding as of December 31, 2020</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20211231_zYzIrkWFaxx5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Common Stock Warrants Outstanding, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">421,278</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20210101__20211231_zQVot2UT7m01" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Outstanding Beginning Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.80</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231_zNveoxJsSKYg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Common Stock Warrants, Issued"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,111,112</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_zhn8Y4IiP1y" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Issued"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.29</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expired</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20210101__20211231_zSkBE1c4AnUj" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Common Stock Warrants, Expired"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(421,278</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_zjTQV5WVbjPd" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Expired"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.80</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at December 31, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20211231_z28mHWXEk6c1" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Common Stock Warrants Outstanding, Ending Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,111,112</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20210101__20211231_z7WjTPj1YJF9" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Outstanding Ending Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.29</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 2908874000 4.16 2400000000 0.01 4800000000 0.01 87596000 85.92 421278000 10.80 7111112000 2.29 421278000 10.80 7111112000 2.29 <p id="xdx_80C_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zvxXeZ40PDq2" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11) <span id="xdx_82D_zgIlDDwAR2Tb">Commitments and Contingencies</span></span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating Leases</span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We currently lease four office facilities. These leases are under non-cancelable <span id="xdx_907_eus-gaap--LesseeOperatingLeaseDescription_c20210101__20211231_zTX9ydJ56Kg4" title="Operating lease expiration description">operating lease agreements with expiration dates between 2023 and 2025. We have the option to extend certain leases to five or ten-year term(s) and we have the right of first refusal on any sale</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company records lease liabilities within current liabilities or long-term liabilities based upon the length of time associated with the lease payments. The Company records its long-term operating leases as right-of-use assets. Upon initial adoption, using the modified retrospective transition approach, no leases with terms less than 12 months have been capitalized to the consolidated balance sheet consistent with ASC 842. Instead, these leases are recognized in the consolidated statement of operations on a straight-line expense throughout the lives of the leases. No Company leases contain common area maintenance or security agreements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have made certain assumptions and judgments when applying ASC 842, the most significant of which is that we elected the package of practical expedients available for transition, which allow us to not reassess whether expired or existing contracts contain leases under the new definition of a lease, lease classification for expired or existing leases, and whether previously capitalized initial direct costs would qualify for capitalization under ASC 842. Additionally, we did not elect to use hindsight when considering judgments and estimates such as assessments of lessee options to extend or terminate a lease or purchase the underlying asset.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2021, the weighted-average remaining lease term was <span id="xdx_902_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20211231_zpVjPIu4EiP1" title="Operating lease weighted-average remaining lease term">3</span> years. Lease expense related to operating leases was $<span id="xdx_906_eus-gaap--OperatingLeaseExpense_pn5n6_c20210101__20211231_zmnGQCzAXobk" title="Lease expense related to operating leases"><span id="xdx_903_eus-gaap--OperatingLeaseExpense_pn5n6_c20200101__20201231_zdpXpLIwd3zd" title="Lease expense related to operating leases">0.6</span></span> million for both of the years ended December 31, 2021 and 2020. The Company’s lease agreements do not provide a readily determinable implicit rate nor is it available to the Company from its lessors. Instead, as of December 31, 2021, the Company estimates the weighted-average discount rate for its operating leases to be <span id="xdx_904_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20211231_zt9zkzGTUhf3" title="Operating lease weighted-average discount rate">5.2</span>% to present value based on the incremental borrowing rate.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zLjTMpoKHeSb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future minimum payments as of December 31, 2021 under these long-term operating leases are as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B3_zhvoM035h385" style="display: none">Schedule of Future Minimum Rental Payments for Operating Leases</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_49D_20211231_zaOrZD0xFXM6" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzNEN_zrBi1QTaosel" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">521</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPzNEN_zf9XCHlFGSMb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">489</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maLOLLPzNEN_zAR7viNqTCMf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">224</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maLOLLPzNEN_zIPseq10mKef" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">180</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzNEN_zWNZRhzY0bjl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total future minimum lease payments</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,414</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_z04rKQflRlS4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less amount representing interest</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(110</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_403_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_zZI92GfCIevj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Present value of obligations under operating leases</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,304</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_402_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pn3n3_di_zLzkQW6Z8NLg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less current portion</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(462</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_40A_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_zPPDdEqINlq4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-term operating lease obligations</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">842</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A2_zMVQghmAoPi4" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Litigation</span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2020, we received a letter from a third party’s legal counsel alleging that some of our hardware products allegedly infringe an expired patent and offering to discuss settlement terms. Without admitting any liability, in July 2021, we entered into a confidential settlement agreement and release that included, among other things, a full release of all asserted patent claims from the third party and otherwise settled the dispute in exchange for a one-time lump sum payment of $<span id="xdx_90A_eus-gaap--LitigationReserve_iI_c20210702__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember_zzDGaBKyNy14" title="Reserve for one-time lump sum amount">550,000</span>, which was recorded as a special charge in general and administrative expense.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, we may be subject to potential liabilities under government regulations and various claims and legal actions that are pending but we believe are immaterial at this time or may be asserted in the future from time to time.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These matters arise in the ordinary course and conduct of our business and may include, for example, commercial, product liability, intellectual property, and employment matters. We intend to continue to defend the Company vigorously in such matters and when warranted, take legal action against others. Furthermore, we regularly assess contingencies to determine the degree of probability and range of possible loss for potential accrual in our financial statements. An estimated loss contingency is accrued in our financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Based on our assessment, we have adequately accrued an amount for contingent liabilities currently in existence. We do not accrue amounts for liabilities that we do not believe are probable or that we consider immaterial to our overall financial position. Litigation is inherently unpredictable, and unfavorable resolutions could occur. As a result, assessing contingencies is highly subjective and requires judgment about future events. The amount of ultimate loss may exceed the Company’s current accruals, and it is possible that its cash flows or results of operations could be materially affected in any particular period by the unfavorable resolution of one or more of these contingencies.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indemnifications</span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our arrangements generally include limited warranties and certain provisions for indemnifying customers against liabilities if our products or services infringe a third-party’s intellectual property rights. To date, we have not incurred any material costs as a result of such warranties or indemnification provisions and have not accrued any liabilities related to such obligations in the accompanying consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have also agreed to indemnify our directors and executive officers for costs associated with any fees, expenses, judgments, fines and settlement amounts incurred by any of these persons in any action or proceeding to which any of those persons is, or is threatened to be, made a party by reason of the person’s service as a director or officer, including any action by us, arising out of that person’s services as our director or officer or that person’s services provided to any other company or enterprise at our request.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> operating lease agreements with expiration dates between 2023 and 2025. We have the option to extend certain leases to five or ten-year term(s) and we have the right of first refusal on any sale P3Y 600000 600000 0.052 <p id="xdx_89F_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zLjTMpoKHeSb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future minimum payments as of December 31, 2021 under these long-term operating leases are as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B3_zhvoM035h385" style="display: none">Schedule of Future Minimum Rental Payments for Operating Leases</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_49D_20211231_zaOrZD0xFXM6" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzNEN_zrBi1QTaosel" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">521</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPzNEN_zf9XCHlFGSMb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">489</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maLOLLPzNEN_zAR7viNqTCMf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">224</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maLOLLPzNEN_zIPseq10mKef" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">180</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzNEN_zWNZRhzY0bjl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total future minimum lease payments</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,414</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_z04rKQflRlS4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less amount representing interest</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(110</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_403_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_zZI92GfCIevj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Present value of obligations under operating leases</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,304</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_402_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pn3n3_di_zLzkQW6Z8NLg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less current portion</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(462</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_40A_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_zPPDdEqINlq4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-term operating lease obligations</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">842</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 521000 489000 224000 180000 1414000 110000 1304000 462000 842000 550000 <p id="xdx_80E_eus-gaap--IncomeTaxDisclosureTextBlock_zmFTgxe9xqJf" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12) <span id="xdx_82A_zsxy3gJAVznl">Income Taxes</span></span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s provision for income taxes differs from applying the statutory U.S. Federal income tax rate to income before taxes. The primary difference results from providing for state income taxes and from deducting certain expenses for financial statement purposes but not for federal income tax purposes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_ecustom--ScheduleOfIncomeLossBeforeProvisionForIncomeTaxesTableTextBlock_zDq7ejTOXTRg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The components of income (loss) before provision for income taxes consist of the following (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B0_z0fDE2oPKCPi" style="display: none">Schedule of Components of Income Loss Before Provision for Income Tax</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_491_20210101__20211231_zbD6I0AgiGK7" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_493_20200101__20201231_zNyK1A3xO7nb" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year Ended December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_400_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_hsrt--StatementGeographicalAxis__country--US_ztErrevCGlV8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United States</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,849</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6,727</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_zjz0vRrIrdW3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,849</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6,727</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> </table> <p id="xdx_8A9_zG5HHHFwhvRh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zDzbz5lYXXFj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The components of the income tax provision are as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B9_z2jczw6in5b2" style="display: none">Schedule of Components of Income Tax Provision</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_49B_20210101__20211231_zFMJwlwcp7j6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_49D_20200101__20201231_zz43INiZ06n5" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year Ended December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--CurrentFederalTaxExpenseBenefit_pn3n3_maCITEBza89_zXwntHCAyRl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(51</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_409_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_pn3n3_maCITEBza89_zL85P8EZ3uN6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">245</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--CurrentIncomeTaxExpenseBenefit_iT_pn3n3_mtCITEBza89_maITEBzj8s_zVapRKHjEr02" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total current</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1125">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">296</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_400_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_pn3n3_maDITEBzdSv_zoDk8qwhrmHc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1128">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1129">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_409_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_pn3n3_maDITEBzdSv_z0rrzvaO43Ih" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1131">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1132">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_eus-gaap--DeferredIncomeTaxExpenseBenefit_iT_pn3n3_mtDITEBzdSv_maITEBzj8s_zcSR6RRnsW56" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total deferred</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1134">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1135">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_407_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtITEBzj8s_zs3cWIZyzfM8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total provision for income taxes</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1137">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">296</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8AF_zDJkdyBMrit7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zdWQeYJ4sWZ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The reconciliation of income tax attributable to operations computed at the U.S. Federal statutory income tax rate of <span id="xdx_906_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_uPure_c20210101__20211231_zQbdc0an4pmi" title="Federal statutory income tax rate">21</span>% to income tax expense is as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B1_zTbid2ngVSZ1" style="display: none">Schedule of Effective Income Tax Rate Reconciliation</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_499_20210101__20211231_ziPZLksNDhAk" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_499_20200101__20201231_zLlcHdra1O01" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year Ended December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_maITEBzELO_zCaPhsSyH6Ef" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statutory Federal tax rate</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,018</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,413</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_409_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_maITEBzELO_zdoEc2AquqL7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuation allowance</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">315</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10,968</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_407_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_pn3n3_maITEBzELO_zAK28xkxIhT1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State income taxes, net of Federal benefit</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(110</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">619</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_ecustom--IncomeTaxReconciliationDeduction_iN_pn3n3_di_maITEBzELO_z0jTbH5JO5If" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attribute reduction related to Sec. 382</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1151">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,607</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationChangeInEnactedTaxRate_pn3n3_maITEBzELO_zvkX6uJ4NqZe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in state income tax rate</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(33</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(61</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_409_ecustom--IncomeTaxReconciliationGainsLossesOnExtinguishmentOfDebt_pn3n3_maITEBzELO_zuID17VFUGx7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gain on extinguishment of debt</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">165</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,488</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_404_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_pn3n3_maITEBzELO_zh2o8yMqajO6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock compensation adjustment and other reconciling items</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">557</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_ecustom--NondeductibleExecutiveCompensation_pn3n3_maITEBzELO_zX677F8q5Um6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nondeductible executive compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">124</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1164">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_pn3n3_maITEBzELO_zu1XoTHlMPzg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nondeductible meals and entertainment expense</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1166">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtITEBzELO_zrk1HDR7WDUh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total provision for income taxes</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1169">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">296</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A9_zrSdzcv6RRTj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_897_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zrSFcdjN9bqb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred tax components are as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B3_zOIv3lzj96Hk" style="display: none">Schedule of Deferred Tax Assets and Liabilities</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_49F_20211231_zP5RdveD5Kv7" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_49D_20201231_zu1H5hh0qLHb" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred tax assets:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_iI_pn3n3_maDTAGzCY6_zMXxSgJOFPmh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued liability for vacation</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">130</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">123</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses_iI_pn3n3_maDTAGzCY6_z3hhmz4Xj2B8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued commissions and bonuses / compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">284</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">565</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies_iI_pn3n3_maDTAGzCY6_zga4hibVxho5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued contingencies</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_404_ecustom--DeferredTaxAssetsTaxDeferredExpenseAmortization_iI_pn3n3_maDTAGzCY6_zzlJqYOtczKc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_405_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_iI_pn3n3_maDTAGzCY6_zCslOdP8ZR2h" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bad debt reserve</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">148</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">174</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsCharitableContributionCarryforwards_iI_pn3n3_maDTAGzCY6_zXt3aomNpgIg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Charitable contributions carryforward</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1190">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_ecustom--DeferredTaxAssetsTaxDeferredExpenseLeaseLiability_iI_pn3n3_maDTAGzCY6_zIglZasTd2h4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease liability</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">350</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">459</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40B_ecustom--DeferredTaxAssetsTaxDeferredExpenseInterestExpense_iI_pn3n3_maDTAGzCY6_z6T0FmIcCgLl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest expense</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,968</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,342</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsInventory_iI_pn3n3_maDTAGzCY6_zkkoHWM5l7ah" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory reserve</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,777</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,975</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGzCY6_zfB7BZauOW0i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net operating loss carryovers</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13,164</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,114</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTAGzCY6_zMx5rG8ZLhO7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock option compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">783</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">653</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseOther_iI_pn3n3_maDTAGzCY6_z6MzSY3Un3S" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">113</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">109</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGzCY6_maDTALNzBLG_zm0pnMzU2e8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total deferred tax assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19,811</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19,588</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred tax liabilities:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_401_ecustom--DeferredTaxLiabilityRightUseOfAsset_iNI_pn3n3_di_maDITLzPVN_zUYULGpas4rj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right of use asset</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(338</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(450</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_405_eus-gaap--DeferredTaxLiabilitiesPrepaidExpenses_iNI_pn3n3_di_maDITLzPVN_z1kGMxDyNXIl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaids</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(83</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(73</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_403_ecustom--DeferredTaxLiabilitiesDepreciation_iNI_pn3n3_di_maDITLzPVN_z7QRD68dLbRk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(111</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(100</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_401_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_pn3n3_di_mtDITLzPVN_msDTALNzBLG_zSbbgqi7Qvzk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total deferred tax liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(532</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(623</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTALNzBLG_zIatNIBzoJt3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuation allowance</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(19,279</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(18,965</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pn3n3_mtDTALNzBLG_zILyH7ntqm8f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net deferred tax assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1228">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1229">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8AF_zU25s4eDuw3k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The ultimate realization of deferred tax assets is dependent upon the existence, or generation, of taxable income in the periods when those temporary differences and net operating loss carryovers are deductible. Management considers the scheduled reversal of deferred tax liabilities, taxes paid in carryover years, projected future taxable income, available tax planning strategies, and other factors in making this assessment. Based on available evidence, management does not believe it is more likely than not that all of the deferred tax assets will be realized. Accordingly, the Company has established a valuation allowance equal to the net deferred tax assets. The valuation allowance increased by $<span id="xdx_902_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn5n6_c20210101__20211231_zr1e8wUErnzj" title="Valuation allowance deferred tax asset change in amount">0.3</span> million in 2021 and decreased by $<span id="xdx_90A_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn5n6_c20200101__20201231_z5Boabg8o3K6" title="Valuation allowance deferred tax asset change in amou">11.0</span> million in 2020.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At December 31, 2021 and 2020, the Company had total domestic Federal and state net operating loss carryovers of approximately $<span id="xdx_902_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20211231_zaSAObP618mk" title="Operating loss carryforwards">101.8</span> million and $<span id="xdx_90D_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20201231_z4tCnpV6ZFOl" title="Operating loss carryforwards">97.0</span> million, respectively. <span id="xdx_909_ecustom--OperatingLossCarryforwardsExpirationPeriod_c20210101__20211231_zlzzdLNTx5Ji" title="Operating loss carryforwards expiration period">Federal net operating losses generated prior to 2018 and State net operating loss carryovers expire at various dates between 2024 and 2040</span>. Federal net operating losses generated after 2017 have an indefinite carryforward and are only available to offset <span id="xdx_909_ecustom--IndefiniteCarryforwardAvailableToOffsetTaxableIncomePercentage_iI_pid_dp_uPure_c20211231_zCLFVraLM4I4" title="Indefinite carryforward available to offset taxable income percentage">80</span>% of taxable income beginning in 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 27, 2020 the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) was signed into law. The CARES Act provided for an increased interest deduction for tax years 2019 and 2020, as well as the deferral of the employer portion of social security taxes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has completed a study to assess whether an ownership change, as defined by Section 382 of the Internal Revenue Code, had occurred from the Company’s formation through December 31, 2019. Based upon this study, the Company determined that an ownership change occurred during 2018. Accordingly, the Company reduced its deferred tax assets related to the federal net operating loss carryforwards that are anticipated to expire unused as a result of these ownership changes. These tax attributes were excluded from deferred tax assets with a corresponding reduction of the valuation allowance with no net effect on income tax expense or the effective tax rate. Future ownership changes may further limit the Company’s ability to utilize its remaining tax attributes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The 2018 through 2020 tax years remain open to examination by the Internal Revenue Service and various other state tax agencies. These taxing authorities have the authority to examine those tax years until the applicable statute of limitations expire.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company did not recognize any material interest or penalties related to income taxes for the years ended December 31, 2021 and 2020.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_ecustom--ScheduleOfIncomeLossBeforeProvisionForIncomeTaxesTableTextBlock_zDq7ejTOXTRg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The components of income (loss) before provision for income taxes consist of the following (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B0_z0fDE2oPKCPi" style="display: none">Schedule of Components of Income Loss Before Provision for Income Tax</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_491_20210101__20211231_zbD6I0AgiGK7" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_493_20200101__20201231_zNyK1A3xO7nb" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year Ended December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_400_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_hsrt--StatementGeographicalAxis__country--US_ztErrevCGlV8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United States</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,849</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6,727</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_zjz0vRrIrdW3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,849</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6,727</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> </table> -4849000 -6727000 -4849000 -6727000 <p id="xdx_895_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zDzbz5lYXXFj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The components of the income tax provision are as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B9_z2jczw6in5b2" style="display: none">Schedule of Components of Income Tax Provision</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_49B_20210101__20211231_zFMJwlwcp7j6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_49D_20200101__20201231_zz43INiZ06n5" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year Ended December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--CurrentFederalTaxExpenseBenefit_pn3n3_maCITEBza89_zXwntHCAyRl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(51</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_409_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_pn3n3_maCITEBza89_zL85P8EZ3uN6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">245</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--CurrentIncomeTaxExpenseBenefit_iT_pn3n3_mtCITEBza89_maITEBzj8s_zVapRKHjEr02" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total current</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1125">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">296</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_400_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_pn3n3_maDITEBzdSv_zoDk8qwhrmHc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1128">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1129">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_409_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_pn3n3_maDITEBzdSv_z0rrzvaO43Ih" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1131">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1132">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_eus-gaap--DeferredIncomeTaxExpenseBenefit_iT_pn3n3_mtDITEBzdSv_maITEBzj8s_zcSR6RRnsW56" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total deferred</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1134">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1135">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_407_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtITEBzj8s_zs3cWIZyzfM8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total provision for income taxes</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1137">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">296</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> -51000 51000 51000 245000 296000 296000 <p id="xdx_89F_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zdWQeYJ4sWZ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The reconciliation of income tax attributable to operations computed at the U.S. Federal statutory income tax rate of <span id="xdx_906_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_uPure_c20210101__20211231_zQbdc0an4pmi" title="Federal statutory income tax rate">21</span>% to income tax expense is as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B1_zTbid2ngVSZ1" style="display: none">Schedule of Effective Income Tax Rate Reconciliation</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_499_20210101__20211231_ziPZLksNDhAk" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_499_20200101__20201231_zLlcHdra1O01" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year Ended December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_maITEBzELO_zCaPhsSyH6Ef" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statutory Federal tax rate</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,018</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,413</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_409_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_maITEBzELO_zdoEc2AquqL7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuation allowance</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">315</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10,968</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_407_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_pn3n3_maITEBzELO_zAK28xkxIhT1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State income taxes, net of Federal benefit</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(110</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">619</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_ecustom--IncomeTaxReconciliationDeduction_iN_pn3n3_di_maITEBzELO_z0jTbH5JO5If" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attribute reduction related to Sec. 382</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1151">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,607</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationChangeInEnactedTaxRate_pn3n3_maITEBzELO_zvkX6uJ4NqZe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in state income tax rate</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(33</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(61</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_409_ecustom--IncomeTaxReconciliationGainsLossesOnExtinguishmentOfDebt_pn3n3_maITEBzELO_zuID17VFUGx7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gain on extinguishment of debt</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">165</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,488</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_404_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_pn3n3_maITEBzELO_zh2o8yMqajO6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock compensation adjustment and other reconciling items</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">557</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_ecustom--NondeductibleExecutiveCompensation_pn3n3_maITEBzELO_zX677F8q5Um6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nondeductible executive compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">124</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1164">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_pn3n3_maITEBzELO_zu1XoTHlMPzg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nondeductible meals and entertainment expense</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1166">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtITEBzELO_zrk1HDR7WDUh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total provision for income taxes</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1169">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">296</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> -1018000 -1413000 315000 -10968000 -110000 619000 -8607000 -33000 -61000 165000 3488000 557000 14000 124000 10000 296000 <p id="xdx_897_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zrSFcdjN9bqb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred tax components are as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B3_zOIv3lzj96Hk" style="display: none">Schedule of Deferred Tax Assets and Liabilities</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_49F_20211231_zP5RdveD5Kv7" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_49D_20201231_zu1H5hh0qLHb" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred tax assets:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_iI_pn3n3_maDTAGzCY6_zMXxSgJOFPmh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued liability for vacation</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">130</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">123</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses_iI_pn3n3_maDTAGzCY6_z3hhmz4Xj2B8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued commissions and bonuses / compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">284</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">565</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies_iI_pn3n3_maDTAGzCY6_zga4hibVxho5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued contingencies</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_404_ecustom--DeferredTaxAssetsTaxDeferredExpenseAmortization_iI_pn3n3_maDTAGzCY6_zzlJqYOtczKc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_405_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_iI_pn3n3_maDTAGzCY6_zCslOdP8ZR2h" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bad debt reserve</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">148</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">174</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsCharitableContributionCarryforwards_iI_pn3n3_maDTAGzCY6_zXt3aomNpgIg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Charitable contributions carryforward</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1190">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_ecustom--DeferredTaxAssetsTaxDeferredExpenseLeaseLiability_iI_pn3n3_maDTAGzCY6_zIglZasTd2h4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease liability</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">350</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">459</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40B_ecustom--DeferredTaxAssetsTaxDeferredExpenseInterestExpense_iI_pn3n3_maDTAGzCY6_z6T0FmIcCgLl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest expense</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,968</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,342</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsInventory_iI_pn3n3_maDTAGzCY6_zkkoHWM5l7ah" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory reserve</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,777</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,975</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGzCY6_zfB7BZauOW0i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net operating loss carryovers</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13,164</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,114</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTAGzCY6_zMx5rG8ZLhO7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock option compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">783</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">653</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseOther_iI_pn3n3_maDTAGzCY6_z6MzSY3Un3S" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">113</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">109</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGzCY6_maDTALNzBLG_zm0pnMzU2e8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total deferred tax assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19,811</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19,588</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred tax liabilities:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_401_ecustom--DeferredTaxLiabilityRightUseOfAsset_iNI_pn3n3_di_maDITLzPVN_zUYULGpas4rj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right of use asset</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(338</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(450</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_405_eus-gaap--DeferredTaxLiabilitiesPrepaidExpenses_iNI_pn3n3_di_maDITLzPVN_z1kGMxDyNXIl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaids</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(83</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(73</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_403_ecustom--DeferredTaxLiabilitiesDepreciation_iNI_pn3n3_di_maDITLzPVN_z7QRD68dLbRk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(111</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(100</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_401_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_pn3n3_di_mtDITLzPVN_msDTALNzBLG_zSbbgqi7Qvzk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total deferred tax liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(532</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(623</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTALNzBLG_zIatNIBzoJt3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuation allowance</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(19,279</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(18,965</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pn3n3_mtDTALNzBLG_zILyH7ntqm8f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net deferred tax assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1228">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1229">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 130000 123000 284000 565000 52000 42000 27000 32000 148000 174000 15000 350000 459000 1968000 2342000 2777000 2975000 13164000 12114000 783000 653000 113000 109000 19811000 19588000 338000 450000 83000 73000 111000 100000 532000 623000 19279000 18965000 300000 11000000.0 101800000 97000000.0 Federal net operating losses generated prior to 2018 and State net operating loss carryovers expire at various dates between 2024 and 2040 0.80 <p id="xdx_803_eus-gaap--CompensationAndEmployeeBenefitPlansTextBlock_z9PvewDUL9O6" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13) <span id="xdx_820_zH8EZbCo3JVa">Employee Benefit Plans</span></span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We have a 401(k) plan for our employees. The 401(k) plan is a defined contribution plan covering substantially all of our employees. Employees are eligible to participate in the plan on the first day of any month after starting employment. Employees are allowed to contribute a percentage of their wages to the 401(k) plan, subject to statutorily prescribed limits and are subject to a discretionary employer match of <span id="xdx_905_eus-gaap--DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_pid_dp_uPure_c20210101__20211231_zfFUuKFSwFWe" title="Discretionary match">100</span>% of their <span id="xdx_90C_ecustom--DefinedBenefitPlanContributionsContributionLimit_c20210101__20211231_zxM844ePilug" title="Contribution limit, description">wage deferrals not in excess of 4% of their wages</span>. The 401(k) plan matching contributions by the Company were temporarily suspended at the onset of the COVID-19 pandemic, but future plan matching contributions were subsequently restored effective July 1, 2020. The Company contributed $<span id="xdx_90A_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_pn5n6_c20210101__20211231_z281d35MOcBl" title="Employer contributed amount">0.3</span> million and $<span id="xdx_90F_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_pn5n6_c20200101__20201231_ze59Quxidbo4" title="Employer contributed amount">0.2</span> million as part of the employer match program for the years ended December 31, 2021 and 2020, respectively</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 1 wage deferrals not in excess of 4% of their wages 300000 200000 <p id="xdx_80E_eus-gaap--CashFlowSupplementalDisclosuresTextBlock_zCvRyOaCB8C5" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(14) <span><span id="xdx_822_zruV55oypeoh">Supplemental Disclosure of Cash Flow Information</span></span></span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89D_eus-gaap--ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_zcYurrrvFR33" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental cash flow information is as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BB_zUNBqMbcb5V3" style="display: none">Schedule of Supplemental Cash Flow Information</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_492_20210101__20211231_zJtZt6Gog3Qe" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_495_20200101__20201231_zKejIjjVUeW6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year Ended</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash paid during the period for:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_407_eus-gaap--InterestPaidNet_pn3n3_zFP6iJiw5eLg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">846</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-cash activities:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_ecustom--GainOnExtinguishmentOfSecondAAndRCreditAgreement_pn3n3_zFiuQUKZagHj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gain on extinguishment of Second A&amp;R Credit Agreement</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">785</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1261">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40B_ecustom--GainsLossesOnExtinguishmentOfLineOfCredit_pn3n3_zGvjsKnP8sb7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Extinguishment of Second A&amp;R Credit Agreement financed by line of credit</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,755</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1264">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_ecustom--PrepaidDebtIssuanceCosts_pn3n3_z95HZlKjnUmh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid debt issuance costs</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">75</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1267">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_405_ecustom--FixedAssetsAcquiredUnderFinanceLease_pn3n3_zLWBTQVlsX6l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fixed assets acquired under finance lease</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">163</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1270">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_ecustom--WarrantsIssuedInConnectionWithPrivatePlacementToPlacementAgents_pn3n3_z63d3OfZZGnl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants issued in connection with the Private Placement to placement agents</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">351</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1273">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40B_ecustom--Asu201613CumulativeEffectAdjustment_pn3n3_zhklmnLyLOy8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASU 2016-13 cumulative effect adjustment</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1275">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_ecustom--RecognitionOfWarrants_pn3n3_zz9qdancKU44" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recognition of 2020 Warrants</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1278">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,862</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_ecustom--PartialExtinguishmentOfSecondAmendedAndRestatedCreditAgreementIncludingDebtIssuanceCosts_pn3n3_z801UpzWxkT4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Partial extinguishment of Second Amended and Restated Credit Agreement (including debt issuance costs)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1281">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63,233</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A4_zedKTKdofh1l" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89D_eus-gaap--ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_zcYurrrvFR33" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental cash flow information is as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BB_zUNBqMbcb5V3" style="display: none">Schedule of Supplemental Cash Flow Information</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_492_20210101__20211231_zJtZt6Gog3Qe" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_495_20200101__20201231_zKejIjjVUeW6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year Ended</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash paid during the period for:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_407_eus-gaap--InterestPaidNet_pn3n3_zFP6iJiw5eLg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">846</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-cash activities:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_ecustom--GainOnExtinguishmentOfSecondAAndRCreditAgreement_pn3n3_zFiuQUKZagHj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gain on extinguishment of Second A&amp;R Credit Agreement</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">785</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1261">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40B_ecustom--GainsLossesOnExtinguishmentOfLineOfCredit_pn3n3_zGvjsKnP8sb7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Extinguishment of Second A&amp;R Credit Agreement financed by line of credit</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,755</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1264">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_ecustom--PrepaidDebtIssuanceCosts_pn3n3_z95HZlKjnUmh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid debt issuance costs</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">75</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1267">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_405_ecustom--FixedAssetsAcquiredUnderFinanceLease_pn3n3_zLWBTQVlsX6l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fixed assets acquired under finance lease</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">163</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1270">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_ecustom--WarrantsIssuedInConnectionWithPrivatePlacementToPlacementAgents_pn3n3_z63d3OfZZGnl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants issued in connection with the Private Placement to placement agents</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">351</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1273">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40B_ecustom--Asu201613CumulativeEffectAdjustment_pn3n3_zhklmnLyLOy8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASU 2016-13 cumulative effect adjustment</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1275">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_ecustom--RecognitionOfWarrants_pn3n3_zz9qdancKU44" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recognition of 2020 Warrants</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1278">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,862</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_ecustom--PartialExtinguishmentOfSecondAmendedAndRestatedCreditAgreementIncludingDebtIssuanceCosts_pn3n3_z801UpzWxkT4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Partial extinguishment of Second Amended and Restated Credit Agreement (including debt issuance costs)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1281">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63,233</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 846000 13000 785000 3755000 75000 163000 351000 47000 1862000 63233000 <p id="xdx_805_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_z0VvPnKcLMza" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(15) <span id="xdx_822_zJizHId9h7I3">Related Party Transactions</span></span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Royalty Opportunities, which owns approximately <span id="xdx_909_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20211231__srt--TitleOfIndividualAxis__custom--SoleholdersMember_z9FPSrpLiCNa">20</span>% of the Company’s outstanding common stock, was the sole holder of our outstanding long-term debt and a party to the Second A&amp;R Credit Agreement, which was terminated in connection with our debt refinancing described under Note 8, “<i>Debt</i>”.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, as described in more detail under Note 1, “<i>Business Description and Summary of Significant Accounting Policies</i>,” we are party to an Investor Rights Agreement and Registration Rights Agreement with Royalty Opportunities and ROS. Transactions between the Company and Royalty Opportunities and ROS are conducted under the provisions of the Second A&amp;R Credit Agreement, the Prior Credit Agreement, the Investor Rights Agreement, and the Registration Rights Agreement, as noted above.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company was party to a Sublease Agreement wherein the Company leased from Cardialen, Inc., a portion of Cardialen’s office space on a month-to-month. The rent was approximately $<span id="xdx_905_eus-gaap--PaymentsForRent_pp0p0_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--SubleaseAgreementMember__dei--LegalEntityAxis__custom--CardialenIncMember_z7ehzRyMCuVc" title="Rent expense">1,000</span> per month. The agreement was terminated effective September 30, 2021. Because Jeffrey Peters is both a member of our Board of Directors and the Chief Executive Officer, President, and a director of Cardialen, this transaction qualified as a related party transaction.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All related party transactions are reviewed and approved by the Audit Committee or the disinterested members of the full Board.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0.20 1000 <p id="xdx_800_eus-gaap--SegmentReportingDisclosureTextBlock_zXj2qWqo2BO1" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(16) <span id="xdx_823_zWzhlexIoZ56">Segment and Geographic Information</span></span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s management reviews our financial results and manages the business on an aggregate basis. Therefore, financial results are reported in a single operating segment: the development, manufacture and marketing of orthopedic medical products and devices.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company attributes revenues to geographic areas based on the location of the customer. Approximately <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__us-gaap--ConcentrationRiskByTypeAxis__custom--ConcentrationCreditRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--OneCustomerMember_zSc9nt5AITMi" title="Concentration risk, percentage">99</span>% and <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__custom--ConcentrationCreditRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--TwoCustomerMember_zno4P6CG2y6c" title="Concentration risk, percentage">98</span>% of revenue was in the United States for the years ended December 31, 2021 and 2020, respectively. Total revenue by major geographic area is as follows (in thousands):</span></p> <p id="xdx_89D_eus-gaap--ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_zm5s8YKaOmIb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zERQSYFIkceh" style="display: none">Schedule of Revenues by Geographic Region</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year Ended<br/> December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United States</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20211231__srt--StatementGeographicalAxis__country--US_z6zS7zCnhgNj" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Total revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54,570</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20201231__srt--StatementGeographicalAxis__country--US_zw497qlrsz2j" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Total revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52,147</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rest of World</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20211231__srt--StatementGeographicalAxis__custom--RestOfWorldMember_z4z5JcIGDz98" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">693</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20201231__srt--StatementGeographicalAxis__custom--RestOfWorldMember_zMh4sJASLBt1" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,190</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20211231_zRuaUuX0WZTc" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55,263</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20201231_z8GXWZ7gHfdl" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53,337</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A4_zewvhUt3UxT1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> 0.99 0.98 <p id="xdx_89D_eus-gaap--ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_zm5s8YKaOmIb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zERQSYFIkceh" style="display: none">Schedule of Revenues by Geographic Region</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year Ended<br/> December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United States</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20211231__srt--StatementGeographicalAxis__country--US_z6zS7zCnhgNj" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Total revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54,570</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20201231__srt--StatementGeographicalAxis__country--US_zw497qlrsz2j" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Total revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52,147</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rest of World</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20211231__srt--StatementGeographicalAxis__custom--RestOfWorldMember_z4z5JcIGDz98" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">693</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20201231__srt--StatementGeographicalAxis__custom--RestOfWorldMember_zMh4sJASLBt1" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,190</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20211231_zRuaUuX0WZTc" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55,263</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20201231_z8GXWZ7gHfdl" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53,337</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 54570000 52147000 693000 1190000 55263000 53337000 EXCEL 88 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 90 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 91 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.0.1 html 114 453 1 false 55 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://xtantmedical.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Consolidated Statements of Operations Sheet http://xtantmedical.com/role/StatementsOfOperations Consolidated Statements of Operations Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets Sheet http://xtantmedical.com/role/BalanceSheets Consolidated Balance Sheets Statements 3 false false R4.htm 00000004 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://xtantmedical.com/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Deficit) Sheet http://xtantmedical.com/role/StatementsOfChangesInStockholdersEquityDeficit Consolidated Statements of Changes in Stockholders' Equity (Deficit) Statements 5 false false R6.htm 00000006 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Deficit) (Parenthetical) Sheet http://xtantmedical.com/role/StatementsOfChangesInStockholdersEquityDeficitParenthetical Consolidated Statements of Changes in Stockholders' Equity (Deficit) (Parenthetical) Statements 6 false false R7.htm 00000007 - Statement - Consolidated Statements of Cash Flow Sheet http://xtantmedical.com/role/StatementsOfCashFlow Consolidated Statements of Cash Flow Statements 7 false false R8.htm 00000008 - Disclosure - Business Description and Summary of Significant Accounting Policies Sheet http://xtantmedical.com/role/BusinessDescriptionAndSummaryOfSignificantAccountingPolicies Business Description and Summary of Significant Accounting Policies Notes 8 false false R9.htm 00000009 - Disclosure - Receivables Sheet http://xtantmedical.com/role/Receivables Receivables Notes 9 false false R10.htm 00000010 - Disclosure - Inventories Sheet http://xtantmedical.com/role/Inventories Inventories Notes 10 false false R11.htm 00000011 - Disclosure - Property and Equipment, Net Sheet http://xtantmedical.com/role/PropertyAndEquipmentNet Property and Equipment, Net Notes 11 false false R12.htm 00000012 - Disclosure - Goodwill and Intangible Assets Sheet http://xtantmedical.com/role/GoodwillAndIntangibleAssets Goodwill and Intangible Assets Notes 12 false false R13.htm 00000013 - Disclosure - Accrued Liabilities Sheet http://xtantmedical.com/role/AccruedLiabilities Accrued Liabilities Notes 13 false false R14.htm 00000014 - Disclosure - Debt Sheet http://xtantmedical.com/role/Debt Debt Notes 14 false false R15.htm 00000015 - Disclosure - Equity Sheet http://xtantmedical.com/role/Equity Equity Notes 15 false false R16.htm 00000016 - Disclosure - Stock-Based Compensation Sheet http://xtantmedical.com/role/Stock-basedCompensation Stock-Based Compensation Notes 16 false false R17.htm 00000017 - Disclosure - Warrants Sheet http://xtantmedical.com/role/Warrants Warrants Notes 17 false false R18.htm 00000018 - Disclosure - Commitments and Contingencies Sheet http://xtantmedical.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 18 false false R19.htm 00000019 - Disclosure - Income Taxes Sheet http://xtantmedical.com/role/IncomeTaxes Income Taxes Notes 19 false false R20.htm 00000020 - Disclosure - Employee Benefit Plans Sheet http://xtantmedical.com/role/EmployeeBenefitPlans Employee Benefit Plans Notes 20 false false R21.htm 00000021 - Disclosure - Supplemental Disclosure of Cash Flow Information Sheet http://xtantmedical.com/role/SupplementalDisclosureOfCashFlowInformation Supplemental Disclosure of Cash Flow Information Notes 21 false false R22.htm 00000022 - Disclosure - Related Party Transactions Sheet http://xtantmedical.com/role/RelatedPartyTransactions Related Party Transactions Notes 22 false false R23.htm 00000023 - Disclosure - Segment and Geographic Information Sheet http://xtantmedical.com/role/SegmentAndGeographicInformation Segment and Geographic Information Notes 23 false false R24.htm 00000024 - Disclosure - Business Description and Summary of Significant Accounting Policies (Policies) Sheet http://xtantmedical.com/role/BusinessDescriptionAndSummaryOfSignificantAccountingPoliciesPolicies Business Description and Summary of Significant Accounting Policies (Policies) Policies http://xtantmedical.com/role/BusinessDescriptionAndSummaryOfSignificantAccountingPolicies 24 false false R25.htm 00000025 - Disclosure - Business Description and Summary of Significant Accounting Policies (Tables) Sheet http://xtantmedical.com/role/BusinessDescriptionAndSummaryOfSignificantAccountingPoliciesTables Business Description and Summary of Significant Accounting Policies (Tables) Tables http://xtantmedical.com/role/BusinessDescriptionAndSummaryOfSignificantAccountingPolicies 25 false false R26.htm 00000026 - Disclosure - Receivables (Tables) Sheet http://xtantmedical.com/role/ReceivablesTables Receivables (Tables) Tables http://xtantmedical.com/role/Receivables 26 false false R27.htm 00000027 - Disclosure - Inventories (Tables) Sheet http://xtantmedical.com/role/InventoriesTables Inventories (Tables) Tables http://xtantmedical.com/role/Inventories 27 false false R28.htm 00000028 - Disclosure - Property and Equipment, Net (Tables) Sheet http://xtantmedical.com/role/PropertyAndEquipmentNetTables Property and Equipment, Net (Tables) Tables http://xtantmedical.com/role/PropertyAndEquipmentNet 28 false false R29.htm 00000029 - Disclosure - Goodwill and Intangible Assets (Tables) Sheet http://xtantmedical.com/role/GoodwillAndIntangibleAssetsTables Goodwill and Intangible Assets (Tables) Tables http://xtantmedical.com/role/GoodwillAndIntangibleAssets 29 false false R30.htm 00000030 - Disclosure - Accrued Liabilities (Tables) Sheet http://xtantmedical.com/role/AccruedLiabilitiesTables Accrued Liabilities (Tables) Tables http://xtantmedical.com/role/AccruedLiabilities 30 false false R31.htm 00000031 - Disclosure - Debt (Tables) Sheet http://xtantmedical.com/role/DebtTables Debt (Tables) Tables http://xtantmedical.com/role/Debt 31 false false R32.htm 00000032 - Disclosure - Stock-Based Compensation (Tables) Sheet http://xtantmedical.com/role/Stock-basedCompensationTables Stock-Based Compensation (Tables) Tables http://xtantmedical.com/role/Stock-basedCompensation 32 false false R33.htm 00000033 - Disclosure - Warrants (Tables) Sheet http://xtantmedical.com/role/WarrantsTables Warrants (Tables) Tables http://xtantmedical.com/role/Warrants 33 false false R34.htm 00000034 - Disclosure - Commitments and Contingencies (Tables) Sheet http://xtantmedical.com/role/CommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://xtantmedical.com/role/CommitmentsAndContingencies 34 false false R35.htm 00000035 - Disclosure - Income Taxes (Tables) Sheet http://xtantmedical.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://xtantmedical.com/role/IncomeTaxes 35 false false R36.htm 00000036 - Disclosure - Supplemental Disclosure of Cash Flow Information (Tables) Sheet http://xtantmedical.com/role/SupplementalDisclosureOfCashFlowInformationTables Supplemental Disclosure of Cash Flow Information (Tables) Tables http://xtantmedical.com/role/SupplementalDisclosureOfCashFlowInformation 36 false false R37.htm 00000037 - Disclosure - Segment and Geographic Information (Tables) Sheet http://xtantmedical.com/role/SegmentAndGeographicInformationTables Segment and Geographic Information (Tables) Tables http://xtantmedical.com/role/SegmentAndGeographicInformation 37 false false R38.htm 00000038 - Disclosure - Summary of Revenues from Product Lines (Details) Sheet http://xtantmedical.com/role/SummaryOfRevenuesFromProductLinesDetails Summary of Revenues from Product Lines (Details) Details 38 false false R39.htm 00000039 - Disclosure - Business Description and Summary of Significant Accounting Policies (Details Narrative) Sheet http://xtantmedical.com/role/BusinessDescriptionAndSummaryOfSignificantAccountingPoliciesDetailsNarrative Business Description and Summary of Significant Accounting Policies (Details Narrative) Details http://xtantmedical.com/role/BusinessDescriptionAndSummaryOfSignificantAccountingPoliciesTables 39 false false R40.htm 00000040 - Disclosure - Schedule of Allowance for Credit Losses (Details) Sheet http://xtantmedical.com/role/ScheduleOfAllowanceForCreditLossesDetails Schedule of Allowance for Credit Losses (Details) Details 40 false false R41.htm 00000041 - Disclosure - Schedule of Inventories (Details) Sheet http://xtantmedical.com/role/ScheduleOfInventoriesDetails Schedule of Inventories (Details) Details 41 false false R42.htm 00000042 - Disclosure - Schedule of Property and Equipment, Net (Details) Sheet http://xtantmedical.com/role/ScheduleOfPropertyAndEquipmentNetDetails Schedule of Property and Equipment, Net (Details) Details 42 false false R43.htm 00000043 - Disclosure - Property and Equipment, Net (Details Narrative) Sheet http://xtantmedical.com/role/PropertyAndEquipmentNetDetailsNarrative Property and Equipment, Net (Details Narrative) Details http://xtantmedical.com/role/PropertyAndEquipmentNetTables 43 false false R44.htm 00000044 - Disclosure - Schedule of Goodwill and Intangible Assets (Details) Sheet http://xtantmedical.com/role/ScheduleOfGoodwillAndIntangibleAssetsDetails Schedule of Goodwill and Intangible Assets (Details) Details 44 false false R45.htm 00000045 - Disclosure - Summary of Future Amortization Expense for Intangible Assets (Details) Sheet http://xtantmedical.com/role/SummaryOfFutureAmortizationExpenseForIntangibleAssetsDetails Summary of Future Amortization Expense for Intangible Assets (Details) Details 45 false false R46.htm 00000046 - Disclosure - Goodwill and Intangible Assets (Details Narrative) Sheet http://xtantmedical.com/role/GoodwillAndIntangibleAssetsDetailsNarrative Goodwill and Intangible Assets (Details Narrative) Details http://xtantmedical.com/role/GoodwillAndIntangibleAssetsTables 46 false false R47.htm 00000047 - Disclosure - Schedule of Accrued Liabilities (Details) Sheet http://xtantmedical.com/role/ScheduleOfAccruedLiabilitiesDetails Schedule of Accrued Liabilities (Details) Details 47 false false R48.htm 00000048 - Disclosure - Schedule of Long-term Debt (Details) Sheet http://xtantmedical.com/role/ScheduleOfLong-termDebtDetails Schedule of Long-term Debt (Details) Details 48 false false R49.htm 00000049 - Disclosure - Debt (Details Narrative) Sheet http://xtantmedical.com/role/DebtDetailsNarrative Debt (Details Narrative) Details http://xtantmedical.com/role/DebtTables 49 false false R50.htm 00000050 - Disclosure - Equity (Details Narrative) Sheet http://xtantmedical.com/role/EquityDetailsNarrative Equity (Details Narrative) Details http://xtantmedical.com/role/Equity 50 false false R51.htm 00000051 - Disclosure - Schedule of Share-based Compensation, Stock Options, Activity (Details) Sheet http://xtantmedical.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails Schedule of Share-based Compensation, Stock Options, Activity (Details) Details 51 false false R52.htm 00000052 - Disclosure - Schedule of Assumptions of Stock Option Granted (Details) Sheet http://xtantmedical.com/role/ScheduleOfAssumptionsOfStockOptionGrantedDetails Schedule of Assumptions of Stock Option Granted (Details) Details 52 false false R53.htm 00000053 - Disclosure - Schedule of Restricted Stock Activity (Details) Sheet http://xtantmedical.com/role/ScheduleOfRestrictedStockActivityDetails Schedule of Restricted Stock Activity (Details) Details 53 false false R54.htm 00000054 - Disclosure - Stock-Based Compensation (Details Narrative) Sheet http://xtantmedical.com/role/Stock-basedCompensationDetailsNarrative Stock-Based Compensation (Details Narrative) Details http://xtantmedical.com/role/Stock-basedCompensationTables 54 false false R55.htm 00000055 - Disclosure - Schedule of Warrant Activity (Details) Sheet http://xtantmedical.com/role/ScheduleOfWarrantActivityDetails Schedule of Warrant Activity (Details) Details 55 false false R56.htm 00000056 - Disclosure - Warrants (Details Narrative) Sheet http://xtantmedical.com/role/WarrantsDetailsNarrative Warrants (Details Narrative) Details http://xtantmedical.com/role/WarrantsTables 56 false false R57.htm 00000057 - Disclosure - Schedule of Future Minimum Rental Payments for Operating Leases (Details) Sheet http://xtantmedical.com/role/ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails Schedule of Future Minimum Rental Payments for Operating Leases (Details) Details 57 false false R58.htm 00000058 - Disclosure - Commitments and Contingencies (Details Narrative) Sheet http://xtantmedical.com/role/CommitmentsAndContingenciesDetailsNarrative Commitments and Contingencies (Details Narrative) Details http://xtantmedical.com/role/CommitmentsAndContingenciesTables 58 false false R59.htm 00000059 - Disclosure - Schedule of Components of Income Loss Before Provision for Income Tax (Details) Sheet http://xtantmedical.com/role/ScheduleOfComponentsOfIncomeLossBeforeProvisionForIncomeTaxDetails Schedule of Components of Income Loss Before Provision for Income Tax (Details) Details 59 false false R60.htm 00000060 - Disclosure - Schedule of Components of Income Tax Provision (Details) Sheet http://xtantmedical.com/role/ScheduleOfComponentsOfIncomeTaxProvisionDetails Schedule of Components of Income Tax Provision (Details) Details 60 false false R61.htm 00000061 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details) Sheet http://xtantmedical.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails Schedule of Effective Income Tax Rate Reconciliation (Details) Details 61 false false R62.htm 00000062 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details) Sheet http://xtantmedical.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails Schedule of Deferred Tax Assets and Liabilities (Details) Details 62 false false R63.htm 00000063 - Disclosure - Income Taxes (Details Narrative) Sheet http://xtantmedical.com/role/IncomeTaxesDetailsNarrative Income Taxes (Details Narrative) Details http://xtantmedical.com/role/IncomeTaxesTables 63 false false R64.htm 00000064 - Disclosure - Employee Benefit Plans (Details Narrative) Sheet http://xtantmedical.com/role/EmployeeBenefitPlansDetailsNarrative Employee Benefit Plans (Details Narrative) Details http://xtantmedical.com/role/EmployeeBenefitPlans 64 false false R65.htm 00000065 - Disclosure - Schedule of Supplemental Cash Flow Information (Details) Sheet http://xtantmedical.com/role/ScheduleOfSupplementalCashFlowInformationDetails Schedule of Supplemental Cash Flow Information (Details) Details 65 false false R66.htm 00000066 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://xtantmedical.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://xtantmedical.com/role/RelatedPartyTransactions 66 false false R67.htm 00000067 - Disclosure - Schedule of Revenues by Geographic Region (Details) Sheet http://xtantmedical.com/role/ScheduleOfRevenuesByGeographicRegionDetails Schedule of Revenues by Geographic Region (Details) Details 67 false false R68.htm 00000068 - Disclosure - Segment and Geographic Information (Details Narrative) Sheet http://xtantmedical.com/role/SegmentAndGeographicInformationDetailsNarrative Segment and Geographic Information (Details Narrative) Details http://xtantmedical.com/role/SegmentAndGeographicInformationTables 68 false false All Reports Book All Reports form10-k.htm ex10-10.htm ex10-19.htm ex10-20.htm ex23-1.htm ex31-1.htm ex31-2.htm ex32-1.htm ex32-2.htm ex4-1.htm ex4-2.htm xtnt-20211231.xsd xtnt-20211231_cal.xml xtnt-20211231_def.xml xtnt-20211231_lab.xml xtnt-20211231_pre.xml http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 93 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form10-k.htm": { "axisCustom": 0, "axisStandard": 20, "contextCount": 114, "dts": { "calculationLink": { "local": [ "xtnt-20211231_cal.xml" ] }, "definitionLink": { "local": [ "xtnt-20211231_def.xml" ] }, "inline": { "local": [ "form10-k.htm" ] }, "labelLink": { "local": [ "xtnt-20211231_lab.xml" ] }, "presentationLink": { "local": [ "xtnt-20211231_pre.xml" ] }, "schema": { "local": [ "xtnt-20211231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 551, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 53, "http://xbrl.sec.gov/dei/2021q4": 3, "http://xtantmedical.com/20211231": 33, "total": 89 }, "keyCustom": 68, "keyStandard": 385, "memberCustom": 33, "memberStandard": 22, "nsprefix": "XTNT", "nsuri": "http://xtantmedical.com/20211231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://xtantmedical.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - Inventories", "role": "http://xtantmedical.com/role/Inventories", "shortName": "Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - Property and Equipment, Net", "role": "http://xtantmedical.com/role/PropertyAndEquipmentNet", "shortName": "Property and Equipment, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - Goodwill and Intangible Assets", "role": "http://xtantmedical.com/role/GoodwillAndIntangibleAssets", "shortName": "Goodwill and Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - Accrued Liabilities", "role": "http://xtantmedical.com/role/AccruedLiabilities", "shortName": "Accrued Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - Debt", "role": "http://xtantmedical.com/role/Debt", "shortName": "Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - Equity", "role": "http://xtantmedical.com/role/Equity", "shortName": "Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - Stock-Based Compensation", "role": "http://xtantmedical.com/role/Stock-basedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "XTNT:OtherEquityTransactionsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - Warrants", "role": "http://xtantmedical.com/role/Warrants", "shortName": "Warrants", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "XTNT:OtherEquityTransactionsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - Commitments and Contingencies", "role": "http://xtantmedical.com/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - Income Taxes", "role": "http://xtantmedical.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "XTNT:OrthopedicProductSales", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Consolidated Statements of Operations", "role": "http://xtantmedical.com/role/StatementsOfOperations", "shortName": "Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "XTNT:OrthopedicProductSales", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - Employee Benefit Plans", "role": "http://xtantmedical.com/role/EmployeeBenefitPlans", "shortName": "Employee Benefit Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - Supplemental Disclosure of Cash Flow Information", "role": "http://xtantmedical.com/role/SupplementalDisclosureOfCashFlowInformation", "shortName": "Supplemental Disclosure of Cash Flow Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - Related Party Transactions", "role": "http://xtantmedical.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - Segment and Geographic Information", "role": "http://xtantmedical.com/role/SegmentAndGeographicInformation", "shortName": "Segment and Geographic Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - Business Description and Summary of Significant Accounting Policies (Policies)", "role": "http://xtantmedical.com/role/BusinessDescriptionAndSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Business Description and Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - Business Description and Summary of Significant Accounting Policies (Tables)", "role": "http://xtantmedical.com/role/BusinessDescriptionAndSummaryOfSignificantAccountingPoliciesTables", "shortName": "Business Description and Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsAndNontradeReceivableTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - Receivables (Tables)", "role": "http://xtantmedical.com/role/ReceivablesTables", "shortName": "Receivables (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsAndNontradeReceivableTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - Inventories (Tables)", "role": "http://xtantmedical.com/role/InventoriesTables", "shortName": "Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - Property and Equipment, Net (Tables)", "role": "http://xtantmedical.com/role/PropertyAndEquipmentNetTables", "shortName": "Property and Equipment, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - Goodwill and Intangible Assets (Tables)", "role": "http://xtantmedical.com/role/GoodwillAndIntangibleAssetsTables", "shortName": "Goodwill and Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Consolidated Balance Sheets", "role": "http://xtantmedical.com/role/BalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:RestrictedCashCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - Accrued Liabilities (Tables)", "role": "http://xtantmedical.com/role/AccruedLiabilitiesTables", "shortName": "Accrued Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - Debt (Tables)", "role": "http://xtantmedical.com/role/DebtTables", "shortName": "Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - Stock-Based Compensation (Tables)", "role": "http://xtantmedical.com/role/Stock-basedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "XTNT:OtherEquityTransactionsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - Warrants (Tables)", "role": "http://xtantmedical.com/role/WarrantsTables", "shortName": "Warrants (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "XTNT:OtherEquityTransactionsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - Commitments and Contingencies (Tables)", "role": "http://xtantmedical.com/role/CommitmentsAndContingenciesTables", "shortName": "Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "XTNT:ScheduleOfIncomeLossBeforeProvisionForIncomeTaxesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - Income Taxes (Tables)", "role": "http://xtantmedical.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "XTNT:ScheduleOfIncomeLossBeforeProvisionForIncomeTaxesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000036 - Disclosure - Supplemental Disclosure of Cash Flow Information (Tables)", "role": "http://xtantmedical.com/role/SupplementalDisclosureOfCashFlowInformationTables", "shortName": "Supplemental Disclosure of Cash Flow Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000037 - Disclosure - Segment and Geographic Information (Tables)", "role": "http://xtantmedical.com/role/SegmentAndGeographicInformationTables", "shortName": "Segment and Geographic Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000038 - Disclosure - Summary of Revenues from Product Lines (Details)", "role": "http://xtantmedical.com/role/SummaryOfRevenuesFromProductLinesDetails", "shortName": "Summary of Revenues from Product Lines (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "INF", "lang": null, "name": "XTNT:PercentageOfNetRevenue", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000039 - Disclosure - Business Description and Summary of Significant Accounting Policies (Details Narrative)", "role": "http://xtantmedical.com/role/BusinessDescriptionAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "shortName": "Business Description and Summary of Significant Accounting Policies (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-5", "lang": null, "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Consolidated Balance Sheets (Parenthetical)", "role": "http://xtantmedical.com/role/BalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "us-gaap:AccountsAndNontradeReceivableTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000040 - Disclosure - Schedule of Allowance for Credit Losses (Details)", "role": "http://xtantmedical.com/role/ScheduleOfAllowanceForCreditLossesDetails", "shortName": "Schedule of Allowance for Credit Losses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "us-gaap:AccountsAndNontradeReceivableTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2019-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsAndSupplies", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000041 - Disclosure - Schedule of Inventories (Details)", "role": "http://xtantmedical.com/role/ScheduleOfInventoriesDetails", "shortName": "Schedule of Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsAndSupplies", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000042 - Disclosure - Schedule of Property and Equipment, Net (Details)", "role": "http://xtantmedical.com/role/ScheduleOfPropertyAndEquipmentNetDetails", "shortName": "Schedule of Property and Equipment, Net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000043 - Disclosure - Property and Equipment, Net (Details Narrative)", "role": "http://xtantmedical.com/role/PropertyAndEquipmentNetDetailsNarrative", "shortName": "Property and Equipment, Net (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000044 - Disclosure - Schedule of Goodwill and Intangible Assets (Details)", "role": "http://xtantmedical.com/role/ScheduleOfGoodwillAndIntangibleAssetsDetails", "shortName": "Schedule of Goodwill and Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000045 - Disclosure - Summary of Future Amortization Expense for Intangible Assets (Details)", "role": "http://xtantmedical.com/role/SummaryOfFutureAmortizationExpenseForIntangibleAssetsDetails", "shortName": "Summary of Future Amortization Expense for Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "span", "span", "p", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000046 - Disclosure - Goodwill and Intangible Assets (Details Narrative)", "role": "http://xtantmedical.com/role/GoodwillAndIntangibleAssetsDetailsNarrative", "shortName": "Goodwill and Intangible Assets (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "span", "p", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:WorkersCompensationLiabilityCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000047 - Disclosure - Schedule of Accrued Liabilities (Details)", "role": "http://xtantmedical.com/role/ScheduleOfAccruedLiabilitiesDetails", "shortName": "Schedule of Accrued Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:WorkersCompensationLiabilityCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "XTNT:LoansPayable1", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000048 - Disclosure - Schedule of Long-term Debt (Details)", "role": "http://xtantmedical.com/role/ScheduleOfLong-termDebtDetails", "shortName": "Schedule of Long-term Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "XTNT:LoansPayable1", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-05-052021-05-06", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LineOfCreditFacilityExpirationDate1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000049 - Disclosure - Debt (Details Narrative)", "role": "http://xtantmedical.com/role/DebtDetailsNarrative", "shortName": "Debt (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-05-052021-05-06", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LineOfCreditFacilityExpirationDate1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Deficit)", "role": "http://xtantmedical.com/role/StatementsOfChangesInStockholdersEquityDeficit", "shortName": "Consolidated Statements of Changes in Stockholders' Equity (Deficit)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000050 - Disclosure - Equity (Details Narrative)", "role": "http://xtantmedical.com/role/EquityDetailsNarrative", "shortName": "Equity (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-11-052020-11-06", "decimals": "INF", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31_us-gaap_StockOptionMember_custom_TwoThousandAndEighteenEquityIncentivePlanMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000051 - Disclosure - Schedule of Share-based Compensation, Stock Options, Activity (Details)", "role": "http://xtantmedical.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails", "shortName": "Schedule of Share-based Compensation, Stock Options, Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2019-12-31_us-gaap_StockOptionMember_custom_TwoThousandAndEighteenEquityIncentivePlanMember", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000052 - Disclosure - Schedule of Assumptions of Stock Option Granted (Details)", "role": "http://xtantmedical.com/role/ScheduleOfAssumptionsOfStockOptionGrantedDetails", "shortName": "Schedule of Assumptions of Stock Option Granted (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_TwoThousandAndEighteenEquityIncentivePlanMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000053 - Disclosure - Schedule of Restricted Stock Activity (Details)", "role": "http://xtantmedical.com/role/ScheduleOfRestrictedStockActivityDetails", "shortName": "Schedule of Restricted Stock Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2019-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_TwoThousandAndEighteenEquityIncentivePlanMember", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000054 - Disclosure - Stock-Based Compensation (Details Narrative)", "role": "http://xtantmedical.com/role/Stock-basedCompensationDetailsNarrative", "shortName": "Stock-Based Compensation (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31_us-gaap_EmployeeStockOptionMember", "decimals": "-5", "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "XTNT:OtherEquityTransactionsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000055 - Disclosure - Schedule of Warrant Activity (Details)", "role": "http://xtantmedical.com/role/ScheduleOfWarrantActivityDetails", "shortName": "Schedule of Warrant Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "XTNT:OtherEquityTransactionsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2019-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "span", "p", "XTNT:OtherEquityTransactionsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-05-06_custom_TwoThousandTwentyWarrantMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000056 - Disclosure - Warrants (Details Narrative)", "role": "http://xtantmedical.com/role/WarrantsDetailsNarrative", "shortName": "Warrants (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "XTNT:OtherEquityTransactionsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-05-06_custom_TwoThousandTwentyWarrantMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000057 - Disclosure - Schedule of Future Minimum Rental Payments for Operating Leases (Details)", "role": "http://xtantmedical.com/role/ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails", "shortName": "Schedule of Future Minimum Rental Payments for Operating Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000058 - Disclosure - Commitments and Contingencies (Details Narrative)", "role": "http://xtantmedical.com/role/CommitmentsAndContingenciesDetailsNarrative", "shortName": "Commitments and Contingencies (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000059 - Disclosure - Schedule of Components of Income Loss Before Provision for Income Tax (Details)", "role": "http://xtantmedical.com/role/ScheduleOfComponentsOfIncomeLossBeforeProvisionForIncomeTaxDetails", "shortName": "Schedule of Components of Income Loss Before Provision for Income Tax (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "XTNT:ScheduleOfIncomeLossBeforeProvisionForIncomeTaxesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-012021-12-31_country_US", "decimals": "-3", "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredFinanceCostsNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Deficit) (Parenthetical)", "role": "http://xtantmedical.com/role/StatementsOfChangesInStockholdersEquityDeficitParenthetical", "shortName": "Consolidated Statements of Changes in Stockholders' Equity (Deficit) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredFinanceCostsNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000060 - Disclosure - Schedule of Components of Income Tax Provision (Details)", "role": "http://xtantmedical.com/role/ScheduleOfComponentsOfIncomeTaxProvisionDetails", "shortName": "Schedule of Components of Income Tax Provision (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000061 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details)", "role": "http://xtantmedical.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails", "shortName": "Schedule of Effective Income Tax Rate Reconciliation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000062 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details)", "role": "http://xtantmedical.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails", "shortName": "Schedule of Deferred Tax Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000063 - Disclosure - Income Taxes (Details Narrative)", "role": "http://xtantmedical.com/role/IncomeTaxesDetailsNarrative", "shortName": "Income Taxes (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000064 - Disclosure - Employee Benefit Plans (Details Narrative)", "role": "http://xtantmedical.com/role/EmployeeBenefitPlansDetailsNarrative", "shortName": "Employee Benefit Plans (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InterestPaidNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000065 - Disclosure - Schedule of Supplemental Cash Flow Information (Details)", "role": "http://xtantmedical.com/role/ScheduleOfSupplementalCashFlowInformationDetails", "shortName": "Schedule of Supplemental Cash Flow Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InterestPaidNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-012021-12-31_custom_SubleaseAgreementMember_custom_CardialenIncMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PaymentsForRent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000066 - Disclosure - Related Party Transactions (Details Narrative)", "role": "http://xtantmedical.com/role/RelatedPartyTransactionsDetailsNarrative", "shortName": "Related Party Transactions (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-012021-12-31_custom_SubleaseAgreementMember_custom_CardialenIncMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PaymentsForRent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000067 - Disclosure - Schedule of Revenues by Geographic Region (Details)", "role": "http://xtantmedical.com/role/ScheduleOfRevenuesByGeographicRegionDetails", "shortName": "Schedule of Revenues by Geographic Region (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-012021-12-31_country_US", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-012021-12-31_custom_ConcentrationCreditRiskMember_us-gaap_SalesRevenueNetMember_custom_OneCustomerMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000068 - Disclosure - Segment and Geographic Information (Details Narrative)", "role": "http://xtantmedical.com/role/SegmentAndGeographicInformationDetailsNarrative", "shortName": "Segment and Geographic Information (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-012021-12-31_custom_ConcentrationCreditRiskMember_us-gaap_SalesRevenueNetMember_custom_OneCustomerMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000007 - Statement - Consolidated Statements of Cash Flow", "role": "http://xtantmedical.com/role/StatementsOfCashFlow", "shortName": "Consolidated Statements of Cash Flow", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - Business Description and Summary of Significant Accounting Policies", "role": "http://xtantmedical.com/role/BusinessDescriptionAndSummaryOfSignificantAccountingPolicies", "shortName": "Business Description and Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsAndNontradeReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - Receivables", "role": "http://xtantmedical.com/role/Receivables", "shortName": "Receivables", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsAndNontradeReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 55, "tag": { "XTNT_AccountingStandardtwoThousandAndSixteenThirteenCumulativeEffectAdjustment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accounting standard two thousand and sixteen thirteen cumulative effect adjustment.", "label": "ASU 2016-13 cumulative effect adjustment" } } }, "localname": "AccountingStandardtwoThousandAndSixteenThirteenCumulativeEffectAdjustment", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "XTNT_AdjustmentToAdditionalPaidInCapitalDebtExtinguishment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustment to additional paid in capital debt extinguishment.", "label": "Gain on debt extinguishment" } } }, "localname": "AdjustmentToAdditionalPaidInCapitalDebtExtinguishment", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "XTNT_AdjustmentToAdditionalPaidInCapitalDebtExtinguishmentShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Adjustment to additional paid in capital debt extinguishment shares.", "label": "Gain on debt extinguishment, shares" } } }, "localname": "AdjustmentToAdditionalPaidInCapitalDebtExtinguishmentShares", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "XTNT_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedInConnectionWithPrivatePlacement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustmentst to additional paid in warrants issued in connection with the private placement.", "label": "Warrants issued in connection with the private placement" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssuedInConnectionWithPrivatePlacement", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "XTNT_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedInConnectionWithPrivatePlacementAgents": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustmentst to additional paid in warrants issued in connection with the private placement to placement agents.", "label": "Warrants issued in connection with the private placement to placement agents" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssuedInConnectionWithPrivatePlacementAgents", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "XTNT_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedInConnectionWithPrivatePlacementAgentsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Adjustments to additional paid in capital warrant issued in connection with private placement agents shares.", "label": "Warrants issued in connection with the private placement to placement agents, shares" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssuedInConnectionWithPrivatePlacementAgentsShares", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "XTNT_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedInConnectionWithPrivatePlacementShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Adjustments to additional paid in capital warrant issued in connection with private placement shares.", "label": "Warrants issued in connection with the private placement, shares" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssuedInConnectionWithPrivatePlacementShares", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "XTNT_AgentAndLendersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agent and Lenders [Member]", "label": "Agent and Lenders [Member]" } } }, "localname": "AgentAndLendersMember", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/DebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "XTNT_Asu201613CumulativeEffectAdjustment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "ASU 2016-13 cumulative effect adjustment.", "label": "Asu201613CumulativeEffectAdjustment", "verboseLabel": "ASU 2016-13 cumulative effect adjustment" } } }, "localname": "Asu201613CumulativeEffectAdjustment", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/ScheduleOfSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "XTNT_CapitalizedDebtIssuanceCosts": { "auth_ref": [], "calculation": { "http://xtantmedical.com/role/ScheduleOfLong-termDebtDetails": { "order": 5.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Capitalized debt issuance costs.", "label": "CapitalizedDebtIssuanceCosts", "negatedLabel": "Less: unamortized debt issuance costs" } } }, "localname": "CapitalizedDebtIssuanceCosts", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/ScheduleOfLong-termDebtDetails" ], "xbrltype": "monetaryItemType" }, "XTNT_CardialenIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cardialen, Inc., [Member]", "label": "Cardialen, Inc., [Member]" } } }, "localname": "CardialenIncMember", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "XTNT_ComputerSoftwaresMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Computer Softwares [Member]", "label": "Computer Softwares [Member]" } } }, "localname": "ComputerSoftwaresMember", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/ScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "XTNT_ComputersAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Computers and Equipment [Member]", "label": "Computers and Equipment [Member]" } } }, "localname": "ComputersAndEquipmentMember", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/BusinessDescriptionAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "XTNT_ConcentrationCreditRiskMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Concentration Credit Risk [Member]", "label": "Concentration Credit Risk [Member]" } } }, "localname": "ConcentrationCreditRiskMember", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/BusinessDescriptionAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://xtantmedical.com/role/SegmentAndGeographicInformationDetailsNarrative" ], "xbrltype": "domainItemType" }, "XTNT_CreditAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Credit Agreements [Member]", "label": "Credit Agreements [Member]" } } }, "localname": "CreditAgreementsMember", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/DebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "XTNT_CumulativeEffectAdjustmentToRetainedEarningsAndAccountsReceivable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cumulative effect adjustment to retained earnings and accounts receivable.", "label": "Cumulative effect adjustment" } } }, "localname": "CumulativeEffectAdjustmentToRetainedEarningsAndAccountsReceivable", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/BusinessDescriptionAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "XTNT_DebtExchangeNetOfExchangeCostsAdjustmentsToAdditionalPaidInCapitaSharesl": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt exchange net of exchange costs adjustments to additional paid in capital shares.", "label": "Debt exchange, net of exchange costs of $1,058, shares" } } }, "localname": "DebtExchangeNetOfExchangeCostsAdjustmentsToAdditionalPaidInCapitaSharesl", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "XTNT_DebtExchangeNetOfExchangeCostsAdjustmentsToAdditionalPaidInCapital": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt exchange net of exchange costs adjustments to additional paid in capital.", "label": "Debt exchange, net of exchange costs of $1,058" } } }, "localname": "DebtExchangeNetOfExchangeCostsAdjustmentsToAdditionalPaidInCapital", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "XTNT_DeferredTaxAssetsTaxDeferredExpenseAmortization": { "auth_ref": [], "calculation": { "http://xtantmedical.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax assets tax deferred expense amortization.", "label": "Amortization" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseAmortization", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "XTNT_DeferredTaxAssetsTaxDeferredExpenseInterestExpense": { "auth_ref": [], "calculation": { "http://xtantmedical.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 8.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax assets tax deferred expense interest expense.", "label": "Interest expense" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseInterestExpense", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "XTNT_DeferredTaxAssetsTaxDeferredExpenseLeaseLiability": { "auth_ref": [], "calculation": { "http://xtantmedical.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 7.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax assets tax deferred expense lease liability.", "label": "Lease liability" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseLeaseLiability", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "XTNT_DeferredTaxLiabilitiesDepreciation": { "auth_ref": [], "calculation": { "http://xtantmedical.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred tax liabilities depreciation.", "label": "DeferredTaxLiabilitiesDepreciation", "negatedLabel": "Depreciation" } } }, "localname": "DeferredTaxLiabilitiesDepreciation", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "XTNT_DeferredTaxLiabilityRightUseOfAsset": { "auth_ref": [], "calculation": { "http://xtantmedical.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred tax liability right use of asset.", "label": "Right of use asset", "negatedLabel": "Right of use asset" } } }, "localname": "DeferredTaxLiabilityRightUseOfAsset", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "XTNT_DefinedBenefitPlanContributionsContributionLimit": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contribution Limit, description.", "label": "Contribution limit, description" } } }, "localname": "DefinedBenefitPlanContributionsContributionLimit", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/EmployeeBenefitPlansDetailsNarrative" ], "xbrltype": "stringItemType" }, "XTNT_DisclosureWarrantsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants", "verboseLabel": "Schedule Of Warrant Activity" } } }, "localname": "DisclosureWarrantsAbstract", "nsuri": "http://xtantmedical.com/20211231", "xbrltype": "stringItemType" }, "XTNT_EmployeesAndDirectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employees And Directors [Member]", "label": "Employees And Directors [Member]" } } }, "localname": "EmployeesAndDirectorsMember", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "XTNT_ExerciseOfWarrantsAdjustingToAdditionalPaidInCapital": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Exercise of warrants adjusting to additional paid in capital.", "label": "Exercise of warrants" } } }, "localname": "ExerciseOfWarrantsAdjustingToAdditionalPaidInCapital", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "XTNT_ExerciseOfWarrantsAdjustingToAdditionalPaidInCapitalShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise of warrants adjusting to additional paid in capital shares.", "label": "Exercise of warrants adjusting to additional paid in capital, shares" } } }, "localname": "ExerciseOfWarrantsAdjustingToAdditionalPaidInCapitalShares", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "XTNT_FixedAssetsAcquiredUnderFinanceLease": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fixed assets acquired under finance lease.", "label": "Fixed assets acquired under finance lease" } } }, "localname": "FixedAssetsAcquiredUnderFinanceLease", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/ScheduleOfSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "XTNT_GainOnExtinguishmentOfSecondAAndRCreditAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gain on extinguishment of Second A&R Credit Agreement.", "label": "Gain on extinguishment of Second A&R Credit Agreement" } } }, "localname": "GainOnExtinguishmentOfSecondAAndRCreditAgreement", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/ScheduleOfSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "XTNT_GainsLossesOnExtinguishmentOfLineOfCredit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gains losses on extinguishment of line of credit.", "label": "Extinguishment of Second A&R Credit Agreement financed by line of credit" } } }, "localname": "GainsLossesOnExtinguishmentOfLineOfCredit", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/ScheduleOfSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "XTNT_IncomeTaxReconciliationDeduction": { "auth_ref": [], "calculation": { "http://xtantmedical.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "order": 4.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "IncomeTaxReconciliationDeduction", "negatedLabel": "Attribute reduction related to Sec. 382" } } }, "localname": "IncomeTaxReconciliationDeduction", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "XTNT_IncomeTaxReconciliationGainsLossesOnExtinguishmentOfDebt": { "auth_ref": [], "calculation": { "http://xtantmedical.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "order": 6.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Income tax reconciliation gains losses on extinguishment of debt.", "label": "Gain on extinguishment of debt" } } }, "localname": "IncomeTaxReconciliationGainsLossesOnExtinguishmentOfDebt", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "XTNT_IncreaseInLiquidityAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase in liquidity amount.", "label": "Increase in liquidity amount" } } }, "localname": "IncreaseInLiquidityAmount", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/DebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "XTNT_IndefiniteCarryforwardAvailableToOffsetTaxableIncomePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indefinite carryforward available to offset taxable income percentage.", "label": "Indefinite carryforward available to offset taxable income percentage" } } }, "localname": "IndefiniteCarryforwardAvailableToOffsetTaxableIncomePercentage", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "percentItemType" }, "XTNT_InvesterRightsAgreementDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Invester rights agreement, description.", "label": "Invester rights agreement, description" } } }, "localname": "InvesterRightsAgreementDescription", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/BusinessDescriptionAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "XTNT_InvestorRightsAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Investor Rights Agreement [Member]", "label": "Investor Rights Agreement [Member]" } } }, "localname": "InvestorRightsAgreementMember", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/BusinessDescriptionAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "XTNT_InvestorRightsAgreementPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Investor Rights Agreement [PolicyTextBlock]", "label": "Investor Rights Agreement" } } }, "localname": "InvestorRightsAgreementPolicyTextBlock", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/BusinessDescriptionAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "XTNT_InvestorWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Investor Warrant [Member]", "label": "Investor Warrant [Member]" } } }, "localname": "InvestorWarrantMember", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/EquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "XTNT_LoansPayable1": { "auth_ref": [], "calculation": { "http://xtantmedical.com/role/ScheduleOfLong-termDebtDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).", "label": "Amounts due under the Term Facility" } } }, "localname": "LoansPayable1", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/ScheduleOfLong-termDebtDetails" ], "xbrltype": "monetaryItemType" }, "XTNT_LoansPayableThree": { "auth_ref": [], "calculation": { "http://xtantmedical.com/role/ScheduleOfLong-termDebtDetails": { "order": 3.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Loans payable three.", "label": "Amounts due under the Second A&R Credit Agreement" } } }, "localname": "LoansPayableThree", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/ScheduleOfLong-termDebtDetails" ], "xbrltype": "monetaryItemType" }, "XTNT_LoansPayableTwo": { "auth_ref": [], "calculation": { "http://xtantmedical.com/role/ScheduleOfLong-termDebtDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Loans payable two.", "label": "Accrued end-of-term payments" } } }, "localname": "LoansPayableTwo", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/ScheduleOfLong-termDebtDetails" ], "xbrltype": "monetaryItemType" }, "XTNT_LongTermDebtsCurrent": { "auth_ref": [], "calculation": { "http://xtantmedical.com/role/ScheduleOfLong-termDebtDetails": { "order": 6.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "LongTermDebtsCurrent", "negatedLabel": "Less: current maturities" } } }, "localname": "LongTermDebtsCurrent", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/ScheduleOfLong-termDebtDetails" ], "xbrltype": "monetaryItemType" }, "XTNT_NoCustomerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No Customer [Member]", "label": "No Customer [Member]" } } }, "localname": "NoCustomerMember", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/BusinessDescriptionAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "XTNT_NoncashInterest": { "auth_ref": [], "calculation": { "http://xtantmedical.com/role/StatementsOfCashFlow": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Non cash interest.", "label": "Non-cash interest" } } }, "localname": "NoncashInterest", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/StatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "XTNT_NondeductibleExecutiveCompensation": { "auth_ref": [], "calculation": { "http://xtantmedical.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "order": 8.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Nondeductible executive compensation.", "label": "Nondeductible executive compensation" } } }, "localname": "NondeductibleExecutiveCompensation", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "XTNT_OneCustomerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "One Customer [Member]", "label": "One Customer [Member]" } } }, "localname": "OneCustomerMember", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/SegmentAndGeographicInformationDetailsNarrative" ], "xbrltype": "domainItemType" }, "XTNT_OperatingLossCarryforwardsExpirationPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating loss carryforwards expiration period.", "label": "Operating loss carryforwards expiration period" } } }, "localname": "OperatingLossCarryforwardsExpirationPeriod", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "stringItemType" }, "XTNT_OrthobiologicsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Orthobiologics [Member]", "label": "Orthobiologics [Member]" } } }, "localname": "OrthobiologicsMember", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/SummaryOfRevenuesFromProductLinesDetails" ], "xbrltype": "domainItemType" }, "XTNT_OrthopedicProductSales": { "auth_ref": [], "calculation": { "http://xtantmedical.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Orthopedic product sales.", "label": "Orthopedic product sales" } } }, "localname": "OrthopedicProductSales", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "XTNT_OtherAssetsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Assets [PolicyTextBlock]", "label": "Other Assets" } } }, "localname": "OtherAssetsPolicyTextBlock", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/BusinessDescriptionAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "XTNT_OtherEquityTransactionsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Equity Transactions [TextBlock]", "label": "OtherEquityTransactionsTextBlock", "verboseLabel": "Warrants" } } }, "localname": "OtherEquityTransactionsTextBlock", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/Warrants" ], "xbrltype": "textBlockItemType" }, "XTNT_OtherPropertiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Properties [Member]", "label": "Other Properties [Member]" } } }, "localname": "OtherPropertiesMember", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/ScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "XTNT_OtherRevenueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Revenue [Member]", "label": "Other Revenue [Member]" } } }, "localname": "OtherRevenueMember", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/SummaryOfRevenuesFromProductLinesDetails" ], "xbrltype": "domainItemType" }, "XTNT_PartialExtinguishmentOfSecondAmendedAndRestatedCreditAgreementIncludingDebtIssuanceCosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Partial extinguishment of second amended and restated credit agreement including debt issuance costs.", "label": "Partial extinguishment of Second Amended and Restated Credit Agreement (including debt issuance costs)" } } }, "localname": "PartialExtinguishmentOfSecondAmendedAndRestatedCreditAgreementIncludingDebtIssuanceCosts", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/ScheduleOfSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "XTNT_PaymentOfTaxesFromWithholdingOfCommonStockOnVestingOfRestrictedStockUnits": { "auth_ref": [], "calculation": { "http://xtantmedical.com/role/StatementsOfCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment of taxes from with holding of common stock on vesting of restricted stock units.", "label": "PaymentOfTaxesFromWithholdingOfCommonStockOnVestingOfRestrictedStockUnits", "negatedLabel": "Payment of taxes from withholding of common stock on vesting of restricted stock units" } } }, "localname": "PaymentOfTaxesFromWithholdingOfCommonStockOnVestingOfRestrictedStockUnits", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/StatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "XTNT_PercentageOfDebtPayment": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of debt payment.", "label": "PercentageOfDebtPayment", "verboseLabel": "Line of credit" } } }, "localname": "PercentageOfDebtPayment", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/DebtDetailsNarrative" ], "xbrltype": "percentItemType" }, "XTNT_PercentageOfNetRevenue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of total revenue.", "label": "Percentage of total revenue" } } }, "localname": "PercentageOfNetRevenue", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/SummaryOfRevenuesFromProductLinesDetails" ], "xbrltype": "percentItemType" }, "XTNT_PlacementAgentAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Placement Agent Agreement [Member]", "label": "Placement Agent Agreement [Member]" } } }, "localname": "PlacementAgentAgreementMember", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/EquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "XTNT_PrepaidDebtIssuanceCosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Prepaid deb issuance costs.", "label": "Prepaid debt issuance costs" } } }, "localname": "PrepaidDebtIssuanceCosts", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/ScheduleOfSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "XTNT_PrivatePlacementWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Private Placement Warrant [Member]", "label": "Private Placement Warrant [Member]" } } }, "localname": "PrivatePlacementWarrantMember", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/EquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "XTNT_ProceedsFromExerciseOfCommonStockWarrants": { "auth_ref": [], "calculation": { "http://xtantmedical.com/role/StatementsOfCashFlow": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from exercise of common stock warrants.", "label": "Proceeds from exercise of common stock warrants" } } }, "localname": "ProceedsFromExerciseOfCommonStockWarrants", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/StatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "XTNT_ProvisionForExcessAndObsoleteInventory": { "auth_ref": [], "calculation": { "http://xtantmedical.com/role/StatementsOfCashFlow": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Provision for excess and obsolete inventory.", "label": "Provision for excess and obsolete inventory" } } }, "localname": "ProvisionForExcessAndObsoleteInventory", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/StatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "XTNT_ROSAndRoyaltyOpportunitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ROS and royalty opportunities.", "label": "ROS and Royalty Opportunities [Member]" } } }, "localname": "ROSAndRoyaltyOpportunitiesMember", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/DebtDetailsNarrative", "http://xtantmedical.com/role/EquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "XTNT_ReacquisitionPrice": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reacquisition price.", "label": "Reacquisition price" } } }, "localname": "ReacquisitionPrice", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/DebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "XTNT_RecognitionOfWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Recognition of warrants.", "label": "Recognition of 2020 Warrants" } } }, "localname": "RecognitionOfWarrants", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/ScheduleOfSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "XTNT_RestOfWorldMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Rest of World [Member]", "label": "Rest of World [Member]" } } }, "localname": "RestOfWorldMember", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/ScheduleOfRevenuesByGeographicRegionDetails" ], "xbrltype": "domainItemType" }, "XTNT_RestructuringAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restructuring Agreement [Member]", "label": "Restructuring Agreement [Member]" } } }, "localname": "RestructuringAgreementMember", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/EquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "XTNT_RevolvingLoanCommitmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revolving Loan Commitment [Member]", "label": "Revolving Loan Commitment [Member]" } } }, "localname": "RevolvingLoanCommitmentMember", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/DebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "XTNT_RightOfferingExpiredDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right offering expired date.", "label": "Right offering expired date" } } }, "localname": "RightOfferingExpiredDate", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/EquityDetailsNarrative" ], "xbrltype": "dateItemType" }, "XTNT_RoyaltyOpportunitiesandROSMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royal opportunities and ROS.", "label": "Royalty Opportunities and ROS [Member]" } } }, "localname": "RoyaltyOpportunitiesandROSMember", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/EquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "XTNT_ScheduleOfIncomeLossBeforeProvisionForIncomeTaxesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of income loss before provision for income taxes [TableTextBlock]", "label": "Schedule of Components of Income Loss Before Provision for Income Tax" } } }, "localname": "ScheduleOfIncomeLossBeforeProvisionForIncomeTaxesTableTextBlock", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "XTNT_SecondAAndRCreditAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Second A&amp;R Credit Agreement [Member]", "label": "Second A&R Credit Agreement [Member]" } } }, "localname": "SecondAAndRCreditAgreementMember", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/DebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "XTNT_SecondAAndRCreditAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Second A And R Credit Agreements [Member]", "label": "Second A And R Credit Agreements [Member]" } } }, "localname": "SecondAAndRCreditAgreementsMember", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/DebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "XTNT_SettlementAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Settlement Agreement [Member]", "label": "Settlement Agreement [Member]" } } }, "localname": "SettlementAgreementMember", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "XTNT_ShareBasedCompensationArrangementByShareBasedPaymentAwardCancelledOrExpiredOutstandingWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Weighted Average Fair Value at Grant Date, Cancelled or expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardCancelledOrExpiredOutstandingWeightedAverageGrantDateFairValue", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "XTNT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award, non-options, outstanding, weighted average exercise price", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice", "periodEndLabel": "Weighted Average Exercise Price Outstanding Ending Balance", "periodStartLabel": "Weighted Average Exercise Price Outstanding Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "XTNT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRemainingSharesAvailable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of common stock shares remaining available.", "label": "Number of common stock shares remaining available" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRemainingSharesAvailable", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "XTNT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options exercisable during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Grant Date Fair Value", "periodEndLabel": "Weighted Average Fair Value at Grant Date, Exercisable, Ending Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "XTNT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options outstanding during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Grant Date Fair Value", "periodEndLabel": "Weighted Average Fair Value at Grant Date, Outstanding Ending Balance", "periodStartLabel": "Weighted Average Fair Value at Grant Date, Outstanding Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "XTNT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangements by share based payment award non options expirations in period weighted average exercise price.", "label": "Weighted Average Exercise Price, Expired" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "XTNT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangements by share-based payment award, non-options, grants in period, weighted average exercise price.", "label": "Weighted Average Exercise Price, Issued" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "XTNT_SharesIssuanceCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Share issuance costs.", "label": "Share issuance costs" } } }, "localname": "SharesIssuanceCosts", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/StatementsOfChangesInStockholdersEquityDeficitParenthetical" ], "xbrltype": "monetaryItemType" }, "XTNT_SharesIssuedPrepaymentFees": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares issued prepayment fees.", "label": "Shares issued prepayment fees" } } }, "localname": "SharesIssuedPrepaymentFees", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/DebtDetailsNarrative" ], "xbrltype": "sharesItemType" }, "XTNT_SoleholdersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Soleholders [Member]", "label": "Soleholders [Member]" } } }, "localname": "SoleholdersMember", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "XTNT_SpinalImplantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Spinal Implant [Member]", "label": "Spinal Implant [Member]" } } }, "localname": "SpinalImplantMember", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/SummaryOfRevenuesFromProductLinesDetails" ], "xbrltype": "domainItemType" }, "XTNT_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesOne": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period Shares Conversion Of Convertible Securities One.", "label": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesOne", "verboseLabel": "Conversion of convertible securities, shares" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesOne", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/DebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "XTNT_StockIssuedDuringPeriodSharesNewIssuesOne": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period shares new issues.", "label": "Private placement of common stock, net of issuance costs of $1,926, shares" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssuesOne", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "XTNT_StockIssuedDuringPeriodValueNewIssuesOne": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock issued during period value new issues.", "label": "Private placement of common stock, net of issuance costs of $1,926" } } }, "localname": "StockIssuedDuringPeriodValueNewIssuesOne", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "XTNT_SubleaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sublease Agreement [Member]", "label": "Sublease Agreement [Member]" } } }, "localname": "SubleaseAgreementMember", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "XTNT_SurgicalInstrumentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Surgical Instruments [Member]", "label": "Surgical Instruments [Member]" } } }, "localname": "SurgicalInstrumentsMember", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/BusinessDescriptionAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://xtantmedical.com/role/ScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "XTNT_TermLoanCommitmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term Loan Commitment [Member]", "label": "Term Loan Commitment [Member]" } } }, "localname": "TermLoanCommitmentMember", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/DebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "XTNT_TermOfPlanDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term of plan description.", "label": "Term of plan, description" } } }, "localname": "TermOfPlanDescription", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "XTNT_TwoCustomerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Customer [Member]", "label": "Two Customer [Member]" } } }, "localname": "TwoCustomerMember", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/SegmentAndGeographicInformationDetailsNarrative" ], "xbrltype": "domainItemType" }, "XTNT_TwoThousandAndEighteenEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2018 Equity Incentive Plan [Member]", "label": "2018 Equity Incentive Plan [Member]" } } }, "localname": "TwoThousandAndEighteenEquityIncentivePlanMember", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/ScheduleOfRestrictedStockActivityDetails", "http://xtantmedical.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails", "http://xtantmedical.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "XTNT_TwoThousandTwentyWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Thousand Twenty Warrant [Member]", "label": "2020 Warrant [Member]" } } }, "localname": "TwoThousandTwentyWarrantMember", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/WarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "XTNT_TwoThousandTwentyWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2020 Warrants [Member]", "label": "2020 Warrants [Member]" } } }, "localname": "TwoThousandTwentyWarrantsMember", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/DebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "XTNT_UndiscountedFutureCashPayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Undiscounted future cashn payments.", "label": "Undiscontinued future cash payments" } } }, "localname": "UndiscountedFutureCashPayments", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/DebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "XTNT_ValuesIssuedPrepaymentFees": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Values issued prepayment fees.", "label": "Values issued prepayment fees" } } }, "localname": "ValuesIssuedPrepaymentFees", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/DebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "XTNT_WarrantsAndRightsOutstandingTermDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrant term description.", "label": "Warrant term description" } } }, "localname": "WarrantsAndRightsOutstandingTermDescription", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/EquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "XTNT_WarrantsExercisePricePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants exercise price percentage.", "label": "Warrants exercise price percentage" } } }, "localname": "WarrantsExercisePricePercentage", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/EquityDetailsNarrative" ], "xbrltype": "percentItemType" }, "XTNT_WarrantsIssuedInConnectionWithPrivatePlacementToPlacementAgents": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Warrants issued in connection with the Private Placement to placement agents.", "label": "Warrants issued in connection with the Private Placement to placement agents" } } }, "localname": "WarrantsIssuedInConnectionWithPrivatePlacementToPlacementAgents", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/ScheduleOfSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "XTNT_WeightedAverageExercisePriceExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price exercised.", "label": "Weighted Average Exercise Price, Exercised" } } }, "localname": "WeightedAverageExercisePriceExercised", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "XTNT_WithholdingOfCommonStockUponVestingOfRestrictedStockUnits": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Withholding of common stock upon vesting of restricted stock units.", "label": "Withholding of common stock upon vesting of restricted stock units" } } }, "localname": "WithholdingOfCommonStockUponVestingOfRestrictedStockUnits", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "XTNT_WithholdingOfCommonStockUponVestingOfRestrictedStockUnitsShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Withholding of common stock upon vesting of restricted stock units shares.", "label": "Withholding of common stock upon vesting of restricted stock units, shares" } } }, "localname": "WithholdingOfCommonStockUponVestingOfRestrictedStockUnitsShare", "nsuri": "http://xtantmedical.com/20211231", "presentation": [ "http://xtantmedical.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://xtantmedical.com/role/ScheduleOfComponentsOfIncomeLossBeforeProvisionForIncomeTaxDetails", "http://xtantmedical.com/role/ScheduleOfRevenuesByGeographicRegionDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r590" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r590" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r587", "r589", "r590" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r587", "r589", "r590" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r587", "r589", "r590" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r589" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r587", "r589", "r590" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r588" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r576" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r589" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r589" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r591" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r579" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated By Reference" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r582" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r578" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtantmedical.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r578" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r596" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r578" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r593" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r590" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r578" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r578" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r578" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r578" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r594" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r587", "r589", "r590" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtantmedical.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r589" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r583" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r584" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r577" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r581" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r580" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r585" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r586" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r595" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r183", "r324", "r327", "r543" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BusinessDescriptionAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://xtantmedical.com/role/SegmentAndGeographicInformationDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r257", "r295", "r335", "r336", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r540", "r544", "r573", "r574" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://xtantmedical.com/role/EquityDetailsNarrative", "http://xtantmedical.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r257", "r295", "r335", "r336", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r540", "r544", "r573", "r574" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://xtantmedical.com/role/EquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r183", "r324", "r327", "r543" ], "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BusinessDescriptionAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://xtantmedical.com/role/SegmentAndGeographicInformationDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r179", "r324", "r325", "r490", "r539", "r541" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://xtantmedical.com/role/SummaryOfRevenuesFromProductLinesDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r179", "r324", "r325", "r490", "r539", "r541" ], "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://xtantmedical.com/role/SummaryOfRevenuesFromProductLinesDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r257", "r295", "r333", "r335", "r336", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r540", "r544", "r573", "r574" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://xtantmedical.com/role/EquityDetailsNarrative", "http://xtantmedical.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r257", "r295", "r333", "r335", "r336", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r540", "r544", "r573", "r574" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://xtantmedical.com/role/EquityDetailsNarrative", "http://xtantmedical.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r180", "r181", "r324", "r326", "r542", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572" ], "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfComponentsOfIncomeLossBeforeProvisionForIncomeTaxDetails", "http://xtantmedical.com/role/ScheduleOfRevenuesByGeographicRegionDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r180", "r181", "r324", "r326", "r542", "r558", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfComponentsOfIncomeLossBeforeProvisionForIncomeTaxDetails", "http://xtantmedical.com/role/ScheduleOfRevenuesByGeographicRegionDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r185", "r471" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://xtantmedical.com/role/DebtDetailsNarrative", "http://xtantmedical.com/role/EquityDetailsNarrative", "http://xtantmedical.com/role/RelatedPartyTransactionsDetailsNarrative", "http://xtantmedical.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://xtantmedical.com/role/DebtDetailsNarrative", "http://xtantmedical.com/role/EquityDetailsNarrative", "http://xtantmedical.com/role/RelatedPartyTransactionsDetailsNarrative", "http://xtantmedical.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201613Member": { "auth_ref": [ "r201" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2016-13 Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.", "label": "Accounting Standards Update 2016-13 [Member]" } } }, "localname": "AccountingStandardsUpdate201613Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BusinessDescriptionAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsAndNontradeReceivableTextBlock": { "auth_ref": [ "r198", "r214" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts receivable, contract receivable, receivable held-for-sale, and nontrade receivable.", "label": "Receivables" } } }, "localname": "AccountsAndNontradeReceivableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/Receivables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r45" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accrued Liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/AccruedLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r44", "r477" ], "calculation": { "http://xtantmedical.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": { "auth_ref": [ "r213" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable.", "label": "Schedule of Allowance for Credit Losses" } } }, "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ReceivablesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r10", "r27", "r186", "r187" ], "calculation": { "http://xtantmedical.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Trade accounts receivable, net of allowance for credit losses of $552 and $653, respectively" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r49" ], "calculation": { "http://xtantmedical.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://xtantmedical.com/role/ScheduleOfAccruedLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued liabilities", "totalLabel": "Accrued liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BalanceSheets", "http://xtantmedical.com/role/ScheduleOfAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r42", "r233" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r28", "r374", "r477" ], "calculation": { "http://xtantmedical.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r112", "r113", "r114", "r371", "r372", "r373", "r424" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r115", "r116", "r117", "r118", "r127", "r196", "r197", "r202", "r203", "r204", "r205", "r206", "r207", "r241", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r396", "r397", "r398", "r399", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r466", "r492", "r493", "r494", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r597", "r598", "r599", "r600", "r601" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Accounting Standards Update [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BusinessDescriptionAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r338", "r340", "r376", "r377" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "auth_ref": [ "r253", "r307", "r312" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.", "label": "Issuance of warrant" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash provided by (used in) operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/StatementsOfCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "auth_ref": [ "r192", "r208", "r209", "r212" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable.", "label": "Accounts Receivable, Allowance for Credit Loss", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "AllowanceForDoubtfulAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfAllowanceForCreditLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r33", "r192", "r208" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Allowance of accounts receivable, net" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": { "auth_ref": [ "r211" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance.", "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff", "negatedLabel": "Write-offs against allowance" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfAllowanceForCreditLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r90", "r222", "r227" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/GoodwillAndIntangibleAssetsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r137" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive securities excluded from computation of earnings per share, amount" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BusinessDescriptionAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BusinessDescriptionAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://xtantmedical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://xtantmedical.com/role/DebtDetailsNarrative", "http://xtantmedical.com/role/EquityDetailsNarrative", "http://xtantmedical.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r106", "r165", "r169", "r175", "r200", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r411", "r413", "r433", "r475", "r477", "r511", "r527" ], "calculation": { "http://xtantmedical.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r11", "r12", "r61", "r106", "r200", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r411", "r413", "r433", "r475", "r477" ], "calculation": { "http://xtantmedical.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r341", "r366" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfRestrictedStockActivityDetails", "http://xtantmedical.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Business Description" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BusinessDescriptionAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r8", "r39", "r92" ], "calculation": { "http://xtantmedical.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash-equivalents", "periodEndLabel": "Cash and cash equivalents", "verboseLabel": "Cash and Cash Equivalents, at Carrying Value" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BalanceSheets", "http://xtantmedical.com/role/BusinessDescriptionAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://xtantmedical.com/role/StatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r17", "r93" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash, Cash Equivalents, and Restricted Cash" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BusinessDescriptionAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r85", "r92", "r97" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Total cash and cash equivalents and restricted cash reported in the consolidated balance sheets" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/StatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Reconciliation of cash and cash equivalents and restricted cash reported in the consolidated balance sheets" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/StatementsOfCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r85", "r92", "r97" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash and cash equivalents and restricted cash at end of year", "periodStartLabel": "Cash and cash equivalents and restricted cash at beginning of year" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/StatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r85", "r442" ], "calculation": { "http://xtantmedical.com/role/StatementsOfCashFlow": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net change in cash and cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/StatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r39" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BusinessDescriptionAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowSupplementalDisclosuresTextBlock": { "auth_ref": [ "r98" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Supplemental Disclosure of Cash Flow Information" } } }, "localname": "CashFlowSupplementalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/SupplementalDisclosureOfCashFlowInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r103", "r106", "r130", "r131", "r132", "r134", "r136", "r143", "r144", "r145", "r200", "r242", "r246", "r247", "r248", "r251", "r252", "r293", "r294", "r297", "r301", "r433", "r592" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r308" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Exercise price of warrants", "verboseLabel": "Warrant exercise price" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/DebtDetailsNarrative", "http://xtantmedical.com/role/EquityDetailsNarrative", "http://xtantmedical.com/role/WarrantsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.", "label": "Warrants to purchase common stock", "verboseLabel": "Issuance of warrants to purchase a common stock" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/EquityDetailsNarrative", "http://xtantmedical.com/role/WarrantsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r308" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Issuance of warrants to purchase a common stock" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/DebtDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://xtantmedical.com/role/SummaryOfRevenuesFromProductLinesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r53", "r239", "r516", "r533" ], "calculation": { "http://xtantmedical.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies (note 11)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r236", "r237", "r238", "r240", "r560" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r112", "r113", "r424" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BalanceSheetsParenthetical", "http://xtantmedical.com/role/EquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r26", "r307" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r26", "r477" ], "calculation": { "http://xtantmedical.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $0.000001 par value; 300,000,000 shares authorized; 87,068,980 share issued and outstanding as of December 31, 2021 and 300,000,000 shares authorized; 77,573,680 shares issued and outstanding as of December 31, 2020" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": { "auth_ref": [ "r331", "r332", "r337", "r378" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.", "label": "Employee Benefit Plans" } } }, "localname": "CompensationAndEmployeeBenefitPlansTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/EmployeeBenefitPlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r151", "r152", "r183", "r431", "r432", "r559" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BusinessDescriptionAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://xtantmedical.com/role/SegmentAndGeographicInformationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r151", "r152", "r183", "r431", "r432", "r557", "r559" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BusinessDescriptionAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://xtantmedical.com/role/SegmentAndGeographicInformationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r151", "r152", "r183", "r431", "r432", "r557", "r559" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BusinessDescriptionAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://xtantmedical.com/role/SegmentAndGeographicInformationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r148", "r524" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentrations and Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BusinessDescriptionAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r151", "r152", "r183", "r431", "r432" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration risk, percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BusinessDescriptionAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://xtantmedical.com/role/SegmentAndGeographicInformationDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r151", "r152", "r183", "r431", "r432", "r559" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BusinessDescriptionAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://xtantmedical.com/role/SegmentAndGeographicInformationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r75", "r490" ], "calculation": { "http://xtantmedical.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Sales" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/DebtDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/DebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CreditLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Credit Loss [Abstract]" } } }, "localname": "CreditLossAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r107", "r393", "r402" ], "calculation": { "http://xtantmedical.com/role/ScheduleOfComponentsOfIncomeTaxProvisionDetails": { "order": 1.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Federal" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfComponentsOfIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r107", "r393", "r402", "r404" ], "calculation": { "http://xtantmedical.com/role/ScheduleOfComponentsOfIncomeTaxProvisionDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "Current Income Tax Expense (Benefit)", "totalLabel": "Total current" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfComponentsOfIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r107", "r393", "r402" ], "calculation": { "http://xtantmedical.com/role/ScheduleOfComponentsOfIncomeTaxProvisionDetails": { "order": 2.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "State" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfComponentsOfIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "auth_ref": [ "r95", "r96" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt conversion converted instrument" } } }, "localname": "DebtConversionConvertedInstrumentAmount1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/DebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r95", "r96" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "Debt conversion converted instrument, shares" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/DebtDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r102", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r271", "r278", "r279", "r281", "r291" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/Debt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r254", "r284", "r285", "r451", "r453", "r454" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt instrument face amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/DebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r51", "r283", "r451", "r453" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "New effective interest rate" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/DebtDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r51", "r255" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt instrument, interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/DebtDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/DebtDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r52", "r105", "r110", "r254", "r255", "r256", "r257", "r258", "r259", "r261", "r267", "r268", "r269", "r270", "r272", "r273", "r274", "r275", "r276", "r277", "r280", "r284", "r285", "r286", "r287", "r308", "r309", "r310", "r311", "r450", "r451", "r453", "r454", "r523" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/DebtDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedPremium": { "auth_ref": [ "r267", "r450", "r454" ], "calculation": { "http://xtantmedical.com/role/ScheduleOfLong-termDebtDetails": { "order": 4.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt premium.", "label": "Premium related to Second Amendment" } } }, "localname": "DebtInstrumentUnamortizedPremium", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfLong-termDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]" } } }, "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r107", "r394", "r402" ], "calculation": { "http://xtantmedical.com/role/ScheduleOfComponentsOfIncomeTaxProvisionDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Federal Income Tax Expense (Benefit)", "verboseLabel": "Federal" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfComponentsOfIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r43", "r267", "r452" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt, exchange costs" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/StatementsOfChangesInStockholdersEquityDeficitParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r90", "r107", "r394", "r402", "r403", "r404" ], "calculation": { "http://xtantmedical.com/role/ScheduleOfComponentsOfIncomeTaxProvisionDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "totalLabel": "Total deferred" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfComponentsOfIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r22", "r23", "r385", "r513", "r525" ], "calculation": { "http://xtantmedical.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Tax Liabilities, Gross", "negatedTotalLabel": "Total deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r107", "r394", "r402" ], "calculation": { "http://xtantmedical.com/role/ScheduleOfComponentsOfIncomeTaxProvisionDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred State and Local Income Tax Expense (Benefit)", "verboseLabel": "State" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfComponentsOfIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards": { "auth_ref": [ "r391", "r392" ], "calculation": { "http://xtantmedical.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible charitable contribution carryforwards.", "label": "Charitable contributions carryforward" } } }, "localname": "DeferredTaxAssetsCharitableContributionCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r386" ], "calculation": { "http://xtantmedical.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "totalLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsInventory": { "auth_ref": [ "r391", "r392" ], "calculation": { "http://xtantmedical.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 9.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.", "label": "Inventory reserve" } } }, "localname": "DeferredTaxAssetsInventory", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r388" ], "calculation": { "http://xtantmedical.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets, Net", "totalLabel": "Net deferred tax assets" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r391", "r392" ], "calculation": { "http://xtantmedical.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 10.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Net operating loss carryovers" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses": { "auth_ref": [ "r391", "r392" ], "calculation": { "http://xtantmedical.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee bonuses.", "label": "Accrued commissions and bonuses / compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r391", "r392" ], "calculation": { "http://xtantmedical.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 11.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Stock option compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther": { "auth_ref": [ "r391", "r392" ], "calculation": { "http://xtantmedical.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 12.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from provisions, reserves, allowances, and accruals, classified as other.", "label": "Other" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": { "auth_ref": [ "r391", "r392" ], "calculation": { "http://xtantmedical.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.", "label": "Accrued liability for vacation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts": { "auth_ref": [ "r391", "r392" ], "calculation": { "http://xtantmedical.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable.", "label": "Bad debt reserve" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies": { "auth_ref": [ "r391", "r392" ], "calculation": { "http://xtantmedical.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from contingent liabilities.", "label": "Accrued contingencies" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r387" ], "calculation": { "http://xtantmedical.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": { "auth_ref": [], "calculation": { "http://xtantmedical.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.", "label": "Deferred Tax Liabilities, Prepaid Expenses", "negatedLabel": "Prepaids" } } }, "localname": "DeferredTaxLiabilitiesPrepaidExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.", "label": "Employer contributed amount" } } }, "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/EmployeeBenefitPlansDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.", "label": "Discretionary match" } } }, "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/EmployeeBenefitPlansDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r90", "r231" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation expenses" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/PropertyAndEquipmentNetDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r90", "r163" ], "calculation": { "http://xtantmedical.com/role/StatementsOfCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/StatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r324" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Summary of Revenues from Product Lines" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BusinessDescriptionAndSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r378" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/Stock-basedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net loss per share:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r71", "r119", "r120", "r121", "r122", "r123", "r128", "r130", "r134", "r135", "r136", "r139", "r140", "r425", "r426", "r519", "r535" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/StatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares used in the computation:" } } }, "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r71", "r119", "r120", "r121", "r122", "r123", "r130", "r134", "r135", "r136", "r139", "r140", "r425", "r426", "r519", "r535" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Dilutive" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/StatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r137", "r138" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Net Loss Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BusinessDescriptionAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r365" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Unvested employee stock options not yet recognized" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_EntityWideRevenueMajorCustomerLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue, Major Customer [Line Items]" } } }, "localname": "EntityWideRevenueMajorCustomerLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/SegmentAndGeographicInformationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r2", "r64", "r65", "r66", "r112", "r113", "r114", "r116", "r124", "r126", "r142", "r205", "r307", "r312", "r371", "r372", "r373", "r398", "r399", "r424", "r443", "r444", "r445", "r446", "r447", "r448", "r547", "r548", "r549", "r601" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/DebtDetailsNarrative", "http://xtantmedical.com/role/StatementsOfChangesInStockholdersEquityDeficit", "http://xtantmedical.com/role/WarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r199" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Equity Method Investment, Ownership Percentage" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r90", "r292" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Fair value of warrants" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/WarrantsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/WarrantsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/WarrantsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r429", "r430" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BusinessDescriptionAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r456" ], "calculation": { "http://xtantmedical.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Current portion of finance lease obligations" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r456" ], "calculation": { "http://xtantmedical.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Financing lease obligations, net" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r458", "r461" ], "calculation": { "http://xtantmedical.com/role/StatementsOfCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "negatedLabel": "Payments on financing leases" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/StatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r226" ], "calculation": { "http://xtantmedical.com/role/ScheduleOfGoodwillAndIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfGoodwillAndIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "auth_ref": [], "calculation": { "http://xtantmedical.com/role/SummaryOfFutureAmortizationExpenseForIntangibleAssetsDetails": { "order": 6.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Thereafter" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/SummaryOfFutureAmortizationExpenseForIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r228" ], "calculation": { "http://xtantmedical.com/role/SummaryOfFutureAmortizationExpenseForIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/SummaryOfFutureAmortizationExpenseForIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r228" ], "calculation": { "http://xtantmedical.com/role/SummaryOfFutureAmortizationExpenseForIntangibleAssetsDetails": { "order": 5.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/SummaryOfFutureAmortizationExpenseForIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r228" ], "calculation": { "http://xtantmedical.com/role/SummaryOfFutureAmortizationExpenseForIntangibleAssetsDetails": { "order": 4.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/SummaryOfFutureAmortizationExpenseForIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r228" ], "calculation": { "http://xtantmedical.com/role/SummaryOfFutureAmortizationExpenseForIntangibleAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/SummaryOfFutureAmortizationExpenseForIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r228" ], "calculation": { "http://xtantmedical.com/role/SummaryOfFutureAmortizationExpenseForIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/SummaryOfFutureAmortizationExpenseForIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r226", "r495" ], "calculation": { "http://xtantmedical.com/role/ScheduleOfGoodwillAndIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Patents" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfGoodwillAndIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r226", "r491" ], "calculation": { "http://xtantmedical.com/role/SummaryOfFutureAmortizationExpenseForIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Total" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/SummaryOfFutureAmortizationExpenseForIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnDispositionOfAssets1": { "auth_ref": [ "r90" ], "calculation": { "http://xtantmedical.com/role/StatementsOfCashFlow": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.", "label": "Gain (Loss) on Disposition of Assets", "negatedLabel": "Gain on sale of fixed assets" } } }, "localname": "GainLossOnDispositionOfAssets1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/StatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r90", "r288", "r289" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain on extinguishment" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/DebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnRestructuringOfDebt": { "auth_ref": [ "r290" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "For a debtor, the aggregate gain (loss) recognized on the restructuring of payables arises from the difference between the book value of the debt before the restructuring and the fair value of the payments on the debt after restructuring is complete.", "label": "Gain on restructuring" } } }, "localname": "GainsLossesOnRestructuringOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/DebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r76" ], "calculation": { "http://xtantmedical.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r218", "r219", "r477", "r510" ], "calculation": { "http://xtantmedical.com/role/BalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r229" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/GoodwillAndIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "auth_ref": [ "r220" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.", "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]", "verboseLabel": "Goodwill" } } }, "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BusinessDescriptionAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r74", "r106", "r165", "r168", "r171", "r174", "r177", "r200", "r242", "r243", "r244", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r433" ], "calculation": { "http://xtantmedical.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross Profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.", "label": "Long-Lived Asset Impairment" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BusinessDescriptionAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r69", "r165", "r168", "r171", "r174", "r177", "r508", "r517", "r521", "r536" ], "calculation": { "http://xtantmedical.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Total", "totalLabel": "Net Loss from Operations Before Provision for Income Taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfComponentsOfIncomeLossBeforeProvisionForIncomeTaxDetails", "http://xtantmedical.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r108", "r383", "r384", "r389", "r400", "r405", "r407", "r408", "r409" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r109", "r125", "r126", "r164", "r381", "r401", "r406", "r537" ], "calculation": { "http://xtantmedical.com/role/ScheduleOfComponentsOfIncomeTaxProvisionDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://xtantmedical.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://xtantmedical.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Provision for Income Taxes Current and Deferred", "totalLabel": "Total provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfComponentsOfIncomeTaxProvisionDetails", "http://xtantmedical.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails", "http://xtantmedical.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r382" ], "calculation": { "http://xtantmedical.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.", "label": "Valuation allowance" } } }, "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": { "auth_ref": [ "r380", "r382" ], "calculation": { "http://xtantmedical.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "order": 5.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.", "label": "Change in state income tax rate" } } }, "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r382" ], "calculation": { "http://xtantmedical.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Statutory Federal tax rate" } } }, "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment": { "auth_ref": [ "r382" ], "calculation": { "http://xtantmedical.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "order": 9.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible meals and entertainment expense.", "label": "Nondeductible meals and entertainment expense" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": { "auth_ref": [ "r382" ], "calculation": { "http://xtantmedical.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "order": 7.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.", "label": "Stock compensation adjustment and other reconciling items" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r382" ], "calculation": { "http://xtantmedical.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "order": 3.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).", "label": "State income taxes, net of Federal benefit" } } }, "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r89" ], "calculation": { "http://xtantmedical.com/role/StatementsOfCashFlow": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "verboseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/StatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r89" ], "calculation": { "http://xtantmedical.com/role/StatementsOfCashFlow": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Trade accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/StatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r89" ], "calculation": { "http://xtantmedical.com/role/StatementsOfCashFlow": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "verboseLabel": "Accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/StatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r89" ], "calculation": { "http://xtantmedical.com/role/StatementsOfCashFlow": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/StatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/StatementsOfCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r89" ], "calculation": { "http://xtantmedical.com/role/StatementsOfCashFlow": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/StatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsFiniteLivedPolicy": { "auth_ref": [ "r99", "r225", "r487", "r488", "r489", "r491" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.", "label": "Intangible Assets" } } }, "localname": "IntangibleAssetsFiniteLivedPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BusinessDescriptionAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r221", "r224" ], "calculation": { "http://xtantmedical.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://xtantmedical.com/role/ScheduleOfGoodwillAndIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible assets, net", "verboseLabel": "Net carrying value" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BalanceSheets", "http://xtantmedical.com/role/ScheduleOfGoodwillAndIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r67", "r162", "r449", "r452", "r520" ], "calculation": { "http://xtantmedical.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r84", "r86", "r94" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r217" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "verboseLabel": "Inventories" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/Inventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r56" ], "calculation": { "http://xtantmedical.com/role/ScheduleOfInventoriesDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r9", "r59", "r477" ], "calculation": { "http://xtantmedical.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://xtantmedical.com/role/ScheduleOfInventoriesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventories", "verboseLabel": "Total" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BalanceSheets", "http://xtantmedical.com/role/ScheduleOfInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r16", "r60", "r100", "r141", "r215", "r216", "r217", "r485" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "verboseLabel": "Inventories" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BusinessDescriptionAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterialsAndSupplies": { "auth_ref": [ "r58" ], "calculation": { "http://xtantmedical.com/role/ScheduleOfInventoriesDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed.", "label": "Raw materials" } } }, "localname": "InventoryRawMaterialsAndSupplies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcess": { "auth_ref": [ "r57" ], "calculation": { "http://xtantmedical.com/role/ScheduleOfInventoriesDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Work in process" } } }, "localname": "InventoryWorkInProcess", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestorMember": { "auth_ref": [ "r469", "r470" ], "lang": { "en-us": { "role": { "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value.", "label": "Investor [Member]" } } }, "localname": "InvestorMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/EquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r232" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeOperatingLeaseDescription": { "auth_ref": [ "r459" ], "lang": { "en-us": { "role": { "documentation": "Description of lessee's operating lease.", "label": "Operating lease expiration description" } } }, "localname": "LesseeOperatingLeaseDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r464" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Schedule of Future Minimum Rental Payments for Operating Leases" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/CommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r464" ], "calculation": { "http://xtantmedical.com/role/ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total future minimum lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r464" ], "calculation": { "http://xtantmedical.com/role/ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "verboseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r464" ], "calculation": { "http://xtantmedical.com/role/ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "verboseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r464" ], "calculation": { "http://xtantmedical.com/role/ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "verboseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r464" ], "calculation": { "http://xtantmedical.com/role/ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "verboseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r464" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less amount representing interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r48", "r106", "r170", "r200", "r242", "r243", "r244", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r412", "r413", "r414", "r433", "r475", "r476" ], "calculation": { "http://xtantmedical.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total Liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r32", "r106", "r200", "r433", "r477", "r515", "r531" ], "calculation": { "http://xtantmedical.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total Liabilities & Stockholders\u2019 Equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES & STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r50", "r106", "r200", "r242", "r243", "r244", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r412", "r413", "r414", "r433", "r475", "r476", "r477" ], "calculation": { "http://xtantmedical.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long-term Liabilities:" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r21", "r514", "r526" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-term Line of Credit", "verboseLabel": "Line of credit" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/DebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityDescription": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "Description of the terms of a credit facility arrangement. Terms typically include interest rate, collateral required, guarantees required, repayment requirements, and restrictions on use of assets and activities of the entity.", "label": "Line of credit, description" } } }, "localname": "LineOfCreditFacilityDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/DebtDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityExpirationDate1": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "Date the credit facility terminates, in YYYY-MM-DD format.", "label": "Line of credit facility expiration date" } } }, "localname": "LineOfCreditFacilityExpirationDate1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/DebtDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "The effective interest rate at the end of the reporting period.", "label": "Line of credit facility interest rate at period" } } }, "localname": "LineOfCreditFacilityInterestRateAtPeriodEnd", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/DebtDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityInterestRateDuringPeriod": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "The effective interest rate during the reporting period.", "label": "Line of credit, interest rate" } } }, "localname": "LineOfCreditFacilityInterestRateDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/DebtDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum amount borrowed under the credit facility at any time during the period.", "label": "Line of credit facility maximum amount outstanding" } } }, "localname": "LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/DebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r46" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of credit facility, maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/DebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LinesOfCreditCurrent": { "auth_ref": [ "r20", "r512" ], "calculation": { "http://xtantmedical.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Line of credit" } } }, "localname": "LinesOfCreditCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationReserve": { "auth_ref": [ "r53", "r239" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.", "label": "Reserve for one-time lump sum amount" } } }, "localname": "LitigationReserve", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate (LIBOR) [Member]" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/DebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r21", "r268", "r282", "r284", "r285", "r514", "r528" ], "calculation": { "http://xtantmedical.com/role/ScheduleOfLong-termDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "totalLabel": "Long-term debt, less issuance costs" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfLong-termDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r47" ], "calculation": { "http://xtantmedical.com/role/BalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Current portion of long-term debt" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r52" ], "calculation": { "http://xtantmedical.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term debt, plus premium and less issuance costs" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MeasurementInputExpectedTermMember": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Measurement Input, Expected Term [Member]" } } }, "localname": "MeasurementInputExpectedTermMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/WarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input, Price Volatility [Member]" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/WarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/WarrantsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability." } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/WarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r85" ], "calculation": { "http://xtantmedical.com/role/StatementsOfCashFlow": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by (used in) financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/StatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/StatementsOfCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r85" ], "calculation": { "http://xtantmedical.com/role/StatementsOfCashFlow": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/StatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/StatementsOfCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r85", "r88", "r91" ], "calculation": { "http://xtantmedical.com/role/StatementsOfCashFlow": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by (used in) operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/StatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/StatementsOfCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r6", "r62", "r63", "r66", "r70", "r91", "r106", "r115", "r119", "r120", "r121", "r122", "r125", "r126", "r133", "r165", "r168", "r171", "r174", "r177", "r200", "r242", "r243", "r244", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r426", "r433", "r518", "r534" ], "calculation": { "http://xtantmedical.com/role/StatementsOfCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://xtantmedical.com/role/StatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net loss", "totalLabel": "Net Loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/StatementsOfCashFlow", "http://xtantmedical.com/role/StatementsOfChangesInStockholdersEquityDeficit", "http://xtantmedical.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r77" ], "calculation": { "http://xtantmedical.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total Other Expense" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Expense" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://xtantmedical.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses [Default Label]", "totalLabel": "Total Operating Expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r165", "r168", "r171", "r174", "r177" ], "calculation": { "http://xtantmedical.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from Operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r460", "r465" ], "calculation": { "http://xtantmedical.com/role/StatementsOfCashFlow": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Non-cash rent" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/StatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r457" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Lease expense related to operating leases" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r456" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "totalLabel": "Present value of obligations under operating leases" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r456" ], "calculation": { "http://xtantmedical.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Current portion of lease liability", "negatedLabel": "Less current portion" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BalanceSheets", "http://xtantmedical.com/role/ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r456" ], "calculation": { "http://xtantmedical.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Lease liability, net", "verboseLabel": "Long-term operating lease obligations" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BalanceSheets", "http://xtantmedical.com/role/ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r455" ], "calculation": { "http://xtantmedical.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Right of use asset, net" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r463", "r465" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating lease weighted-average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r462", "r465" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating lease weighted-average remaining lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r390" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating loss carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r7", "r111", "r156", "r415" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.", "label": "Business Description and Summary of Significant Accounting Policies" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BusinessDescriptionAndSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r13", "r14", "r15", "r49" ], "calculation": { "http://xtantmedical.com/role/ScheduleOfAccruedLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other accrued liabilities" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r43" ], "calculation": { "http://xtantmedical.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIncome": { "auth_ref": [ "r538" ], "calculation": { "http://xtantmedical.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue and income classified as other.", "label": "Other revenue" } } }, "localname": "OtherIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsForRent": { "auth_ref": [ "r87" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash payments to lessor's for use of assets under operating leases.", "label": "Rent expense" } } }, "localname": "PaymentsForRent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfFinancingCosts": { "auth_ref": [ "r83" ], "calculation": { "http://xtantmedical.com/role/StatementsOfCashFlow": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for loan and debt issuance costs.", "label": "Payments of Financing Costs", "negatedLabel": "Costs associated with refinancing" } } }, "localname": "PaymentsOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/StatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r83" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of stock issuance costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/StatementsOfChangesInStockholdersEquityDeficitParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r79" ], "calculation": { "http://xtantmedical.com/role/StatementsOfCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/StatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r341", "r366" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfRestrictedStockActivityDetails", "http://xtantmedical.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails", "http://xtantmedical.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfRestrictedStockActivityDetails", "http://xtantmedical.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails", "http://xtantmedical.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r25", "r293" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r25", "r293" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r25", "r477" ], "calculation": { "http://xtantmedical.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock, $0.000001 par value; 10,000,000 shares authorized; no shares issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r11", "r37", "r38" ], "calculation": { "http://xtantmedical.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.", "label": "Reclassification" } } }, "localname": "PriorPeriodReclassificationAdjustmentDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BusinessDescriptionAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement [Member]" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/EquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r80" ], "calculation": { "http://xtantmedical.com/role/StatementsOfCashFlow": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from issuance of common stock, net of issuance costs", "verboseLabel": "Proceeds from common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/EquityDetailsNarrative", "http://xtantmedical.com/role/StatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "auth_ref": [ "r80" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.", "label": "Proceeds from private placement" } } }, "localname": "ProceedsFromIssuanceOfPrivatePlacement", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/EquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLinesOfCredit": { "auth_ref": [ "r81", "r105" ], "calculation": { "http://xtantmedical.com/role/StatementsOfCashFlow": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Borrowings on line of credit" } } }, "localname": "ProceedsFromLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/StatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "auth_ref": [ "r78" ], "calculation": { "http://xtantmedical.com/role/StatementsOfCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Proceeds from sale of fixed assets" } } }, "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/StatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromWarrantExercises": { "auth_ref": [ "r80" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.", "label": "Proceeds from warrant exercise" } } }, "localname": "ProceedsFromWarrantExercises", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/EquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Product Information [Line Items]" } } }, "localname": "ProductInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BusinessDescriptionAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r42", "r234" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BusinessDescriptionAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://xtantmedical.com/role/ScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r235", "r561", "r562", "r563" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/PropertyAndEquipmentNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": { "auth_ref": [ "r230" ], "lang": { "en-us": { "role": { "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).", "label": "Property and equipment, estimated useful lives" } } }, "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BusinessDescriptionAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r41", "r232" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Total cost" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r18", "r19", "r234", "r477", "r522", "r532" ], "calculation": { "http://xtantmedical.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, net", "totalLabel": "Total" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BalanceSheets", "http://xtantmedical.com/role/ScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r40", "r234", "r561", "r562" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BusinessDescriptionAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r18", "r234" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Schedule of Property and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/PropertyAndEquipmentNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r18", "r232" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BusinessDescriptionAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://xtantmedical.com/role/ScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r72", "r210" ], "calculation": { "http://xtantmedical.com/role/StatementsOfCashFlow": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Provision for reserve on accounts receivable", "verboseLabel": "Provision for expected credit losses" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfAllowanceForCreditLossesDetails", "http://xtantmedical.com/role/StatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r334", "r469", "r470" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/DebtDetailsNarrative", "http://xtantmedical.com/role/EquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r334", "r469", "r472", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/DebtDetailsNarrative", "http://xtantmedical.com/role/EquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r467", "r468", "r470", "r473", "r474" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfLinesOfCredit": { "auth_ref": [ "r82", "r105" ], "calculation": { "http://xtantmedical.com/role/StatementsOfCashFlow": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Repayments of Lines of Credit", "negatedLabel": "Repayments on line of credit" } } }, "localname": "RepaymentsOfLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/StatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r82" ], "calculation": { "http://xtantmedical.com/role/StatementsOfCashFlow": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-term Debt", "negatedLabel": "Payments on long-term debt" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/StatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r379", "r486", "r575" ], "calculation": { "http://xtantmedical.com/role/StatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r379" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BusinessDescriptionAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCashAndCashEquivalents": { "auth_ref": [ "r17", "r92", "r97", "r509", "r529" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents", "periodEndLabel": "Restricted cash" } } }, "localname": "RestrictedCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/StatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashCurrent": { "auth_ref": [ "r8", "r17", "r97" ], "calculation": { "http://xtantmedical.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted cash" } } }, "localname": "RestrictedCashCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r137" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfRestrictedStockActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r29", "r312", "r374", "r477", "r530", "r551", "r556" ], "calculation": { "http://xtantmedical.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit", "negatedLabel": "Retained Earnings (Accumulated Deficit)" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BalanceSheets", "http://xtantmedical.com/role/BusinessDescriptionAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r2", "r112", "r113", "r114", "r116", "r124", "r126", "r205", "r371", "r372", "r373", "r398", "r399", "r424", "r547", "r549" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r160", "r161", "r167", "r172", "r173", "r179", "r180", "r183", "r323", "r324", "r490" ], "calculation": { "http://xtantmedical.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Total revenue", "totalLabel": "Total Revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfRevenuesByGeographicRegionDetails", "http://xtantmedical.com/role/StatementsOfOperations", "http://xtantmedical.com/role/SummaryOfRevenuesFromProductLinesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r101", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r328" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BusinessDescriptionAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenues from External Customers and Long-Lived Assets [Line Items]" } } }, "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfRevenuesByGeographicRegionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/DebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/EquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r151", "r183" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BusinessDescriptionAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://xtantmedical.com/role/SegmentAndGeographicInformationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/AccruedLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.", "label": "Schedule of Supplemental Cash Flow Information" } } }, "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/SupplementalDisclosureOfCashFlowInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r410" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://xtantmedical.com/role/SummaryOfRevenuesFromProductLinesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r395" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Provision" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of Long-term Debt" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable": { "auth_ref": [ "r329", "r330" ], "lang": { "en-us": { "role": { "documentation": "Schedule, table or text reflecting arrangements that are not equity-based payments, or pension and other postretirement benefits, with individual employees. The arrangements (for example, profit sharing, deferred bonuses or certain split-dollar life insurance arrangements) are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain amounts at designated future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period and the carrying amount as of the balance sheet date of the related liability.", "label": "Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]" } } }, "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r388" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r382" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable": { "auth_ref": [ "r183" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure about the extent of the entity's reliance on its major customers.", "label": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]" } } }, "localname": "ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/SegmentAndGeographicInformationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r223", "r225" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Goodwill and Intangible Assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/GoodwillAndIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r16", "r34", "r35", "r36" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/InventoriesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfProductInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line.", "label": "Schedule of Product Information [Table]" } } }, "localname": "ScheduleOfProductInformationTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BusinessDescriptionAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r42", "r234" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": { "auth_ref": [ "r73", "r182" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenues by Geographic Region" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/SegmentAndGeographicInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "auth_ref": [ "r68", "r182" ], "lang": { "en-us": { "role": { "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfRevenuesByGeographicRegionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r341", "r366" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfRestrictedStockActivityDetails", "http://xtantmedical.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails", "http://xtantmedical.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r343" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Schedule of Restricted Stock Activity" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/Stock-basedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r343", "r355", "r357" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Schedule of Share-based Compensation, Stock Options, Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/Stock-basedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Assumptions of Stock Option Granted" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/Stock-basedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r313", "r339" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Schedule of Warrant Activity" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/WarrantsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r225" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Summary of Future Amortization Expense for Intangible Assets" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/GoodwillAndIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r157", "r158", "r159", "r165", "r166", "r171", "r175", "r176", "r177", "r178", "r179", "r182", "r183", "r184" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment and Geographic Information" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/SegmentAndGeographicInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://xtantmedical.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Sales and marketing" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r89" ], "calculation": { "http://xtantmedical.com/role/StatementsOfCashFlow": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share based compensation", "verboseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/StatementsOfCashFlow", "http://xtantmedical.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r353" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Shares Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r353" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "verboseLabel": "Weighted Average Fair Value at Grant Date, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r352" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Shares Outstanding, Ending Balance", "periodStartLabel": "Shares Outstanding, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r352" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Weighted Average Fair Value at Grant Date, Outstanding Ending Balance", "periodStartLabel": "Weighted Average Fair Value at Grant Date, Outstanding Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r354" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Shares Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r354" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Weighted Average Fair Value at Grant Date, Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfAssumptionsOfStockOptionGrantedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfAssumptionsOfStockOptionGrantedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfAssumptionsOfStockOptionGrantedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfRestrictedStockActivityDetails", "http://xtantmedical.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails", "http://xtantmedical.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "auth_ref": [ "r349" ], "lang": { "en-us": { "role": { "documentation": "Number of non-option equity instruments exercised by participants.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised", "negatedLabel": "Common Stock Warrants, Exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations", "negatedLabel": "Common Stock Warrants, Expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "auth_ref": [ "r348" ], "lang": { "en-us": { "role": { "documentation": "Net number of non-option equity instruments granted to participants.", "label": "Common Stock Warrants, Issued" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "auth_ref": [ "r344", "r346" ], "lang": { "en-us": { "role": { "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "periodEndLabel": "Common Stock Warrants Outstanding, Ending Balance", "periodStartLabel": "Common Stock Warrants Outstanding, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r366" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Number of shares available for issuance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r347" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "periodEndLabel": "Shares, Exercisable, Ending Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r347" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price, Exercisable Ending Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period", "negatedLabel": "Shares, Cancelled or expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Weighted Average Exercise Price, Cancelled or expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Shares, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r356" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Weighted Average Fair Value at Grant Date, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r345", "r366" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Shares, Outstanding, Ending Balance", "periodStartLabel": "Shares, Outstanding, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r344" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price, Outstanding Ending Balance", "periodStartLabel": "Weighted Average Exercise Price, Outstanding Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r339", "r342" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfRestrictedStockActivityDetails", "http://xtantmedical.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Weighted Average Exercise Price, Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/EquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r360", "r375" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Expected term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfAssumptionsOfStockOptionGrantedDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r358" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Stock option vested weighted average period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares issued, price per share" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/EquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance, shares", "periodStartLabel": "Beginning balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r24", "r25", "r26", "r103", "r106", "r130", "r131", "r132", "r134", "r136", "r143", "r144", "r145", "r200", "r242", "r246", "r247", "r248", "r251", "r252", "r293", "r294", "r297", "r301", "r307", "r433", "r592" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r2", "r55", "r64", "r65", "r66", "r112", "r113", "r114", "r116", "r124", "r126", "r142", "r205", "r307", "r312", "r371", "r372", "r373", "r398", "r399", "r424", "r443", "r444", "r445", "r446", "r447", "r448", "r547", "r548", "r549", "r601" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/DebtDetailsNarrative", "http://xtantmedical.com/role/StatementsOfChangesInStockholdersEquityDeficit", "http://xtantmedical.com/role/WarrantsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfComponentsOfIncomeLossBeforeProvisionForIncomeTaxDetails", "http://xtantmedical.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r112", "r113", "r114", "r142", "r490" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfComponentsOfIncomeLossBeforeProvisionForIncomeTaxDetails", "http://xtantmedical.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r54", "r272", "r307", "r308", "r312" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Conversion of convertible securities, shares", "verboseLabel": "Shares issued in exchange of loans outstanding" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/DebtDetailsNarrative", "http://xtantmedical.com/role/EquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r25", "r26", "r307", "r312" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Issuance of common shares, net of issuance costs of $143, shares", "verboseLabel": "Stock issued during period, shares, new issues" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/EquityDetailsNarrative", "http://xtantmedical.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r25", "r26", "r307", "r312" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.", "label": "Common stock issued on vesting of restricted stock units, shares" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r55", "r307", "r312" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Conversion of convertible securities" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/DebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r25", "r26", "r307", "r312" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Issuance of common shares, net of issuance costs of $143" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r307", "r312" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.", "label": "Common stock issued on vesting of restricted stock units" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).", "label": "Equity Option [Member]" } } }, "localname": "StockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r26", "r30", "r31", "r106", "r194", "r200", "r433", "r477" ], "calculation": { "http://xtantmedical.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance, value", "periodStartLabel": "Beginning balance, value", "totalLabel": "Total Stockholders\u2019 Equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BalanceSheets", "http://xtantmedical.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 Equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r104", "r294", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r312", "r314" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/Equity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Different names of stock transactions and the different attributes of each transaction.", "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]" } } }, "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/EquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/EquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Subsidiary, Sale of Stock [Line Items]" } } }, "localname": "SubsidiarySaleOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/EquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowElementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Elements [Abstract]" } } }, "localname": "SupplementalCashFlowElementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r188", "r189", "r190", "r191", "r193", "r195" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable.", "label": "Trade Accounts Receivable" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BusinessDescriptionAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r115", "r116", "r117", "r118", "r127", "r196", "r197", "r202", "r203", "r204", "r205", "r206", "r207", "r241", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r396", "r397", "r398", "r399", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r466", "r492", "r493", "r494", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r597", "r598", "r599", "r600", "r601" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards." } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BusinessDescriptionAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r410" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BusinessDescriptionAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://xtantmedical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://xtantmedical.com/role/DebtDetailsNarrative", "http://xtantmedical.com/role/EquityDetailsNarrative", "http://xtantmedical.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r146", "r147", "r149", "r150", "r153", "r154", "r155" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/BusinessDescriptionAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r388" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "Valuation allowance deferred tax asset change in amou" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/DebtDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/DebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstandingMaturityDate": { "auth_ref": [ "r428" ], "lang": { "en-us": { "role": { "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.", "label": "Warrants expiration date" } } }, "localname": "WarrantsAndRightsOutstandingMaturityDate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/DebtDetailsNarrative", "http://xtantmedical.com/role/WarrantsDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "auth_ref": [ "r428" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.", "label": "Warrants and rights outstanding, measurement input" } } }, "localname": "WarrantsAndRightsOutstandingMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/WarrantsDetailsNarrative" ], "xbrltype": "decimalItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r428" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Warrants contractual term" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/WarrantsDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r129", "r136" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "verboseLabel": "Dilutive" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/StatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r128", "r136" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "verboseLabel": "Basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/StatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WorkersCompensationLiabilityCurrent": { "auth_ref": [ "r49" ], "calculation": { "http://xtantmedical.com/role/ScheduleOfAccruedLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations and payables pertaining to claims incurred of a workers compensation nature. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Wages/commissions payable" } } }, "localname": "WorkersCompensationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://xtantmedical.com/role/ScheduleOfAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r111": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r156": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r184": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r198": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "310", "URI": "http://asc.fasb.org/topic&trid=2196771" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL82887624-210437" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r214": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "326", "URI": "http://asc.fasb.org/topic&trid=82887179" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r217": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r229": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123364984&loc=d3e1205-110223" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r235": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r238": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S65", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6402221&loc=d3e15743-112638" }, "r291": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r314": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r328": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=6409733&loc=d3e19524-108361" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363" }, "r331": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "710", "URI": "http://asc.fasb.org/topic&trid=2127225" }, "r332": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "712", "URI": "http://asc.fasb.org/topic&trid=2197446" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r337": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)-(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907" }, "r378": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32059-109318" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r409": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r415": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r474": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(b)", "Topic": "920", "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.4)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r576": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r577": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r578": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r579": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(4),(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r580": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r581": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r582": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r583": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r584": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r585": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r586": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r587": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r588": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r589": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r590": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r591": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r592": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r593": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r594": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r595": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r596": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r98": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "230", "URI": "http://asc.fasb.org/topic&trid=2134446" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" } }, "version": "2.1" } ZIP 94 0001493152-22-006240-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-22-006240-xbrl.zip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�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end